data_2cpi_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2cpi _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 19.9 tp . . . . . 0 C--O 1.231 0.095 0 CA-C-O 120.857 0.36 . . . . 0.0 110.898 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 79.5 t -92.64 110.7 23.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.187 179.804 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.417 ' CE1' ' HB2' ' A' ' 158' ' ' SER . 53.4 t80 -109.52 107.0 16.95 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.892 -179.931 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 69.4 t -108.73 142.57 20.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.149 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 22.4 m -126.43 171.74 14.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.136 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 69.54 48.37 44.19 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.493 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 30.9 mt -112.69 125.48 54.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.789 0.328 . . . . 0.0 110.916 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 117' ' ' SER . . . . . 0.423 ' O ' ' N ' ' A' ' 120' ' ' LEU . 26.9 t -71.79 141.4 49.69 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.895 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 36.5 tp60 -38.38 -32.33 0.07 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.9 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 15.7 mmt180 -70.79 -47.51 59.15 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.845 -179.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 120' ' ' LEU . . . . . 0.423 ' N ' ' O ' ' A' ' 117' ' ' SER . 58.7 mt -69.46 -32.74 71.85 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.913 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -64.46 83.79 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.14 179.779 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 122' ' ' ASP . . . . . 0.401 ' CB ' HG23 ' A' ' 125' ' ' VAL . 4.7 m-20 -148.66 144.06 17.96 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.59 0.709 . . . . 0.0 110.911 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.81 -45.55 1.52 Allowed 'Trans proline' 0 C--N 1.341 0.133 0 C-N-CA 122.684 2.256 . . . . 0.0 112.287 -179.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -71.48 -39.52 70.85 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.927 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.536 ' O ' ' CD1' ' A' ' 131' ' ' TYR . 74.6 t -63.21 -45.76 97.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.129 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . 0.488 HD21 ' CE1' ' A' ' 132' ' ' PHE . 95.6 mt -74.47 -34.91 63.26 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.889 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 53.0 mttt -64.61 -32.25 73.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.882 179.85 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 20.0 mmt180 -46.25 143.97 3.41 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.631 0.729 . . . . 0.0 110.85 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -4.21 13.56 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.665 2.243 . . . . 0.0 112.35 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 56.6 tt0 -100.67 -10.64 20.7 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.892 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 131' ' ' TYR . . . . . 0.536 ' CD1' ' O ' ' A' ' 125' ' ' VAL . 43.6 m-85 -103.17 -74.98 0.62 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.91 -179.864 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.488 ' CE1' HD21 ' A' ' 126' ' ' LEU . 28.2 m-85 -118.65 -40.62 2.87 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.898 179.988 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -47.93 -19.02 0.85 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.505 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . 0.404 ' HD2' ' CD2' ' A' ' 135' ' ' PHE . 0.0 OUTLIER -51.52 -40.31 59.37 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.822 0.344 . . . . 0.0 110.914 -179.995 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 135' ' ' PHE . . . . . 0.514 ' CD2' ' HB3' ' A' ' 172' ' ' ALA . 47.8 m-85 -67.16 -44.06 80.68 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.896 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 176.94 169.66 38.47 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.544 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -60.63 136.76 58.16 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.745 0.307 . . . . 0.0 110.922 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 61.1 mt -96.64 148.82 5.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.114 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 56.4 t60 -101.02 -48.74 4.33 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.854 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 22.6 ttmt -134.98 140.54 45.77 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.879 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 15.9 t -132.73 112.75 19.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.159 179.814 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 93.8 t -116.77 137.73 49.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.116 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 4.1 mm -114.0 123.68 69.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.106 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 8.9 t-20 -113.03 114.02 26.29 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.901 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 6.2 p-10 . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.888 -179.974 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 50.8 m . . . . . 0 C--O 1.23 0.074 0 CA-C-O 120.865 0.364 . . . . 0.0 110.894 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -114.41 166.46 11.66 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.103 179.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 158' ' ' SER . . . . . 0.417 ' HB2' ' CE1' ' A' ' 112' ' ' PHE . 4.8 p -134.93 150.99 50.48 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.865 -179.781 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -122.8 145.52 48.35 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.077 179.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 44.1 m-85 -119.42 107.16 13.0 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.945 -179.833 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.423 HG11 ' N ' ' A' ' 162' ' ' THR . 37.9 t -101.19 141.25 18.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.097 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 162' ' ' THR . . . . . 0.423 ' N ' HG11 ' A' ' 161' ' ' VAL . 63.0 m -111.22 123.33 49.98 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.093 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 30.5 m-85 -105.3 121.74 44.5 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.937 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 164' ' ' ILE . . . . . 0.412 HG23 ' NH1' ' A' ' 165' ' ' ARG . 74.2 mt -49.63 -37.14 11.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.137 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . 0.412 ' NH1' HG23 ' A' ' 164' ' ' ILE . 80.3 mmt-85 -107.11 114.75 29.0 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.898 179.93 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 69.0 m -51.68 -55.17 21.0 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.883 -179.803 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 24.8 mm-40 -42.96 -54.04 4.44 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.908 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -54.71 -46.11 74.13 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.871 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -60.84 -64.07 1.08 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.098 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 36.6 mt -38.28 -63.62 0.48 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.922 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 86.5 mtt180 -52.8 -51.85 59.19 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.873 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . 0.514 ' HB3' ' CD2' ' A' ' 135' ' ' PHE . . . -45.06 -32.88 1.88 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.096 179.904 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 82.2 mt -81.72 -35.28 13.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.091 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 33.4 mt-30 -64.69 -27.65 69.06 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.906 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 175' ' ' CYS . . . . . 0.441 ' O ' ' CG2' ' A' ' 179' ' ' VAL . 2.3 m -93.82 -34.29 13.22 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.87 -179.927 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 10.8 t -63.29 -33.74 62.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.147 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 177' ' ' ASN . . . . . 0.437 ' ND2' ' N ' ' A' ' 178' ' ' ASN . 1.1 t-20 -62.55 140.99 58.65 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.89 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 178' ' ' ASN . . . . . 0.437 ' N ' ' ND2' ' A' ' 177' ' ' ASN . 9.1 t-20 62.33 37.62 13.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.846 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 179' ' ' VAL . . . . . 0.441 ' CG2' ' O ' ' A' ' 175' ' ' CYS . 75.0 t -118.57 133.15 66.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.141 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 59.3 t -89.03 128.04 41.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.169 179.914 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 50.7 t -135.86 114.56 15.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.069 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 5.8 t70 63.5 28.53 15.34 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.901 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 89.21 -14.41 60.91 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.499 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 77.6 mtt85 -108.77 126.0 52.55 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.903 0.383 . . . . 0.0 110.805 -179.837 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 10.9 m -76.74 106.48 8.42 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.16 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 80.3 mt -70.24 157.05 38.39 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.907 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 16.2 tptm -135.65 115.01 12.53 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.939 179.82 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -110.13 142.96 40.9 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.083 179.88 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 86.1 p -156.71 165.39 36.37 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.873 -179.776 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 190' ' ' LEU . . . . . . . . . . . . . 4.3 pp -126.62 154.98 43.25 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.938 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.283 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.45 179.885 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 12.3 tp . . . . . 0 C--O 1.231 0.108 0 CA-C-O 120.836 0.351 . . . . 0.0 110.943 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 47.0 t -113.94 123.33 69.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.148 179.865 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.663 ' CZ ' ' CG1' ' A' ' 114' ' ' VAL . 37.6 t80 -111.17 106.56 15.61 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.891 -179.964 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 20.9 t -102.82 143.4 15.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.173 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . 0.663 ' CG1' ' CZ ' ' A' ' 112' ' ' PHE . 33.3 m -131.82 169.8 21.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.106 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 73.75 54.51 6.52 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.502 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 60.9 mt -117.31 129.96 56.23 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.84 0.352 . . . . 0.0 110.932 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 3.3 m -65.56 152.76 43.33 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.868 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 13.1 pt20 -50.9 -20.86 1.45 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.949 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 36.5 mtm180 -92.56 -42.75 9.51 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.88 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 62.8 mt -65.94 -34.74 78.8 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.948 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -62.54 85.29 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.075 179.842 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -148.48 144.09 18.13 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.626 0.727 . . . . 0.0 110.843 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.84 -42.17 3.55 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.677 2.251 . . . . 0.0 112.273 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -71.76 -44.4 64.12 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.9 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 28.7 t -60.86 -43.43 95.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.119 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 84.7 mt -68.39 -39.94 81.52 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.906 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.425 ' O ' ' C ' ' A' ' 128' ' ' ARG . 6.9 tmtt? -65.23 -37.92 88.76 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.841 179.866 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 128' ' ' ARG . . . . . 0.425 ' C ' ' O ' ' A' ' 127' ' ' LYS . 21.1 mmt180 -36.39 144.45 0.27 Allowed Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.628 0.728 . . . . 0.0 110.9 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.8 -5.17 15.59 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.679 2.253 . . . . 0.0 112.372 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 130' ' ' GLU . . . . . 0.415 ' O ' ' CG ' ' A' ' 130' ' ' GLU . 20.5 tt0 -100.88 10.29 41.3 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.898 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 131' ' ' TYR . . . . . . . . . . . . . 47.1 m-85 -127.54 -74.18 0.59 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.928 -179.853 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 69.7 m-85 -124.12 -11.44 7.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.862 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -71.12 -11.28 70.35 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.502 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -80.66 -30.79 36.54 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.794 0.331 . . . . 0.0 110.878 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 135' ' ' PHE . . . . . . . . . . . . . 22.9 m-85 -72.31 -26.06 61.8 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.827 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 167.41 -172.57 42.38 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.494 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 7.4 mtpm? -86.26 136.75 33.05 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.754 0.311 . . . . 0.0 110.917 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.442 ' CG2' HG22 ' A' ' 141' ' ' VAL . 82.5 mt -100.04 138.6 23.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.127 179.865 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -96.09 -46.51 6.45 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.848 179.878 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -141.04 141.05 34.34 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.916 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . 0.442 HG22 ' CG2' ' A' ' 138' ' ' ILE . 17.4 t -134.44 123.61 43.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.087 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 99.0 t -134.2 139.88 47.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.136 179.904 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 44.8 mm -96.89 140.41 17.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.146 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 3.7 m120 -129.09 115.87 18.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.89 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 2.7 m120 . . . . . 0 C--N 1.329 -0.316 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.884 -179.967 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 94.0 p . . . . . 0 C--O 1.231 0.092 0 CA-C-O 120.888 0.375 . . . . 0.0 110.852 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -98.31 145.69 26.42 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.094 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 80.5 p -115.15 173.65 6.39 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.87 -179.762 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -153.68 140.79 19.4 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.119 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 89.0 m-85 -111.38 123.47 50.28 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.933 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 9.7 t -123.53 139.05 51.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.092 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 58.0 m -108.41 128.6 54.92 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.117 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 25.3 m-85 -108.45 138.65 44.4 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.891 -179.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 50.7 mt -64.32 -38.11 81.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.123 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 32.6 mtm180 -103.85 114.14 28.17 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.889 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 46.9 m -51.9 -51.91 53.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.846 -179.762 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -50.91 -57.57 8.17 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.899 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -46.84 -45.58 20.29 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.888 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -61.18 -54.49 43.72 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.12 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 87.5 mt -44.2 -63.75 0.81 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.898 -179.915 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 10.5 mtp180 -54.09 -46.66 72.12 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.887 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -51.04 -33.26 24.59 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.121 179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 77.5 mt -78.26 -39.08 24.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.084 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 3.5 mp0 -68.47 -24.3 64.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.916 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 91.9 m -93.77 -27.89 16.23 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.862 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 10.6 t -74.23 -30.78 27.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.135 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -66.82 146.13 54.75 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.909 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 35.6 t30 57.83 46.31 17.14 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.88 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 91.5 t -124.91 133.42 69.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.117 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 88.2 t -96.52 114.55 33.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.13 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 96.4 t -123.29 106.22 17.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.188 179.885 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 23.8 t0 58.0 39.8 26.1 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.88 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 73.53 37.36 53.13 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.509 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 3.4 mmp_? -140.99 132.01 26.19 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.919 0.39 . . . . 0.0 110.821 -179.822 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 17.1 m -87.99 96.03 10.35 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.171 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 59.6 mt -69.94 124.32 23.75 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.869 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 17.3 tptp -123.53 113.11 18.29 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.851 179.845 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -111.95 148.18 34.3 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.105 179.821 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 8.6 t -150.83 170.9 18.15 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.902 -179.789 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 190' ' ' LEU . . . . . 0.415 HD21 ' N ' ' A' ' 191' ' ' GLY . 5.8 tt -131.17 141.54 50.09 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.945 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 191' ' ' GLY . . . . . 0.415 ' N ' HD21 ' A' ' 190' ' ' LEU . . . . . . . . 0 N--CA 1.451 -0.306 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.505 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 13.8 tp . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.792 0.33 . . . . 0.0 110.941 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 59.1 t -96.79 118.61 43.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.108 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.654 ' CD1' ' CE2' ' A' ' 160' ' ' TYR . 45.3 t80 -119.29 111.61 18.41 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.889 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 23.1 t -107.01 140.78 24.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.098 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 5.1 m -120.06 169.38 11.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.09 179.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 67.26 53.89 23.28 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.505 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 116' ' ' LEU . . . . . 0.406 ' CD1' ' HB2' ' A' ' 159' ' ' ALA . 38.3 mt -112.81 127.17 56.09 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.834 0.35 . . . . 0.0 110.915 -179.92 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 117' ' ' SER . . . . . 0.495 ' O ' ' N ' ' A' ' 120' ' ' LEU . 18.8 t -65.64 125.91 26.74 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.874 -179.902 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 118' ' ' GLN . . . . . 0.438 ' C ' ' O ' ' A' ' 117' ' ' SER . 8.5 mm-40 -34.93 -32.46 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.882 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.494 ' N ' ' O ' ' A' ' 117' ' ' SER . 24.7 ttm180 -72.07 -48.14 46.4 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.863 -179.916 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 120' ' ' LEU . . . . . 0.495 ' N ' ' O ' ' A' ' 117' ' ' SER . 84.1 mt -70.2 -35.56 74.0 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.951 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -61.68 87.17 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.062 179.79 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 122' ' ' ASP . . . . . 0.411 ' HB2' ' CG2' ' A' ' 125' ' ' VAL . 5.9 m-20 -147.59 152.67 42.14 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.609 0.719 . . . . 0.0 110.847 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 -50.18 0.49 Allowed 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.674 2.25 . . . . 0.0 112.376 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 25.3 mt-10 -71.49 -42.34 68.19 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.911 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.492 HG12 ' CZ ' ' A' ' 131' ' ' TYR . 48.2 t -57.08 -53.59 41.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.116 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 87.7 mt -68.25 -30.82 69.94 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.941 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 13.8 mmtt -64.95 -39.31 93.3 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.903 179.807 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 32.5 mtt180 -39.75 143.93 0.54 Allowed Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.648 0.737 . . . . 0.0 110.874 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 -1.15 7.99 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.652 2.235 . . . . 0.0 112.354 -179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -101.51 -24.54 14.14 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.864 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 131' ' ' TYR . . . . . 0.492 ' CZ ' HG12 ' A' ' 125' ' ' VAL . 43.9 m-85 -87.35 -74.67 0.43 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.933 -179.868 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 16.0 m-85 -118.81 -40.51 2.86 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.858 -179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -44.9 -20.89 0.26 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.45 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . 0.421 ' C ' ' HD3' ' A' ' 134' ' ' LYS . 0.0 OUTLIER -54.52 -37.55 65.5 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.834 0.35 . . . . 0.0 110.919 -179.988 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 135' ' ' PHE . . . . . . . . . . . . . 22.2 m-85 -66.23 -44.12 84.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.865 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -176.31 -153.55 10.71 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.447 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 38.7 mtmt -97.42 108.31 21.01 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.779 0.323 . . . . 0.0 110.937 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 91.6 mt -69.7 142.88 15.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.156 179.883 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 3.0 t-160 -102.16 -56.37 2.28 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.885 179.877 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 33.4 tttt -119.01 151.48 38.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.905 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 41.4 t -143.05 108.85 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.155 179.849 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 96.9 t -115.82 126.94 73.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.158 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 26.7 mm -106.3 109.28 27.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.111 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 3.2 t-20 -96.06 137.14 35.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.881 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 1.5 p30 . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.842 -179.994 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 23.2 m . . . . . 0 C--O 1.231 0.111 0 CA-C-O 120.856 0.36 . . . . 0.0 110.856 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -119.74 171.99 8.01 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.108 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 67.7 p -123.31 169.64 11.11 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.875 -179.796 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 159' ' ' ALA . . . . . 0.406 ' HB2' ' CD1' ' A' ' 116' ' ' LEU . . . -147.64 149.76 33.11 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.108 179.941 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 160' ' ' TYR . . . . . 0.654 ' CE2' ' CD1' ' A' ' 112' ' ' PHE . 43.4 m-85 -124.26 124.75 43.1 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.901 -179.847 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 57.4 t -120.39 125.32 74.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.174 179.883 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 48.7 m -93.47 131.28 38.84 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.143 -179.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 9.5 m-85 -107.35 147.15 30.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.892 -179.89 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 48.2 mt -75.29 -47.53 34.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.128 179.916 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 35.1 mtp180 -91.54 114.23 26.71 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.856 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 75.5 m -49.35 -59.4 3.74 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.867 -179.814 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 55.8 mt-10 -47.96 -47.44 32.71 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.908 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -55.34 -45.85 76.39 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.881 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -56.93 -56.63 19.17 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.1 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 56.0 mt -47.26 -59.86 2.88 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.891 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 1.9 mpt_? -56.68 -42.51 79.16 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.866 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . 0.48 ' O ' ' CG2' ' A' ' 176' ' ' VAL . . . -55.24 -32.09 62.02 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.101 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 76.7 mt -79.78 -37.99 18.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.112 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 8.6 mm100 -64.66 -28.67 69.77 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.862 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 19.8 t -93.74 -28.95 15.64 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.852 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 176' ' ' VAL . . . . . 0.48 ' CG2' ' O ' ' A' ' 172' ' ' ALA . 9.9 t -71.7 -28.07 29.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.124 -179.978 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 1.8 t30 -70.76 141.61 51.45 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.895 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 25.7 t-20 61.35 49.33 5.41 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.923 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 79.5 t -117.0 133.66 63.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.131 179.918 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 58.7 t -98.16 105.97 18.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.14 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 56.3 t -115.73 131.2 68.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.189 179.862 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 44.96 29.05 0.42 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.856 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 80.39 31.46 37.52 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.737 -0.745 . . . . 0.0 112.471 -179.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 13.2 ttm180 -134.9 136.14 42.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.855 0.359 . . . . 0.0 110.888 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 26.5 m -82.69 99.51 9.66 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.162 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 62.9 mt -84.29 140.48 31.61 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.942 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 9.4 ttpp -135.19 146.83 49.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.877 179.828 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -134.29 155.47 50.14 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.075 179.842 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 8.8 t -155.59 164.18 38.98 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.835 -179.807 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 190' ' ' LEU . . . . . . . . . . . . . 4.7 pp -130.07 147.57 51.83 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.956 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.356 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.533 179.953 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 15.3 tp . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.866 0.365 . . . . 0.0 110.878 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 89.6 t -95.58 114.12 31.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.112 179.819 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.638 ' CE2' ' CG1' ' A' ' 114' ' ' VAL . 61.1 t80 -106.86 99.25 8.83 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.901 179.98 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 54.3 t -98.94 125.36 52.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.149 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . 0.638 ' CG1' ' CE2' ' A' ' 112' ' ' PHE . 12.0 m -118.89 168.88 10.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.126 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 77.39 39.52 26.02 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.505 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 32.5 mt -105.92 137.9 43.02 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.822 0.344 . . . . 0.0 110.89 -179.909 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 78.6 p -76.58 148.14 37.2 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.842 -179.941 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 34.5 mm-40 -42.2 -34.96 0.84 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.898 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 33.0 mtt180 -69.01 -47.47 65.39 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.872 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 120' ' ' LEU . . . . . 0.424 ' CD2' ' OD2' ' A' ' 182' ' ' ASP . 85.0 mt -71.78 -24.68 61.79 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.928 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -71.29 83.49 0.76 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.105 179.807 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 19.6 m-20 -148.95 144.38 18.07 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.619 0.723 . . . . 0.0 110.845 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.8 -45.67 1.48 Allowed 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.662 2.242 . . . . 0.0 112.38 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 19.9 mt-10 -73.19 -42.6 62.51 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.885 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.414 ' O ' ' CD1' ' A' ' 131' ' ' TYR . 56.4 t -59.04 -46.3 91.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.157 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 74.1 mt -68.69 -37.56 79.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.959 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 12.8 ttmm -68.0 -35.77 78.87 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.9 179.804 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 66.4 mtt-85 -44.89 147.91 1.05 Allowed Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.59 0.709 . . . . 0.0 110.882 180.0 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.71 -3.19 11.49 Favored 'Trans proline' 0 N--CA 1.465 -0.163 0 C-N-CA 122.711 2.274 . . . . 0.0 112.367 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -97.93 6.39 47.77 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.897 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 131' ' ' TYR . . . . . 0.414 ' CD1' ' O ' ' A' ' 125' ' ' VAL . 63.0 m-85 -131.32 -73.84 0.53 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.938 -179.858 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 71.0 m-85 -127.06 -6.04 6.1 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.901 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -70.9 -18.92 76.57 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.515 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 11.2 ptpt -88.72 -27.25 21.33 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.857 0.36 . . . . 0.0 110.893 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 135' ' ' PHE . . . . . 0.408 ' CE2' HG23 ' A' ' 176' ' ' VAL . 27.9 m-85 -63.97 -43.65 95.11 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.85 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -177.43 167.55 38.69 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.482 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 27.1 mtmm -67.06 120.06 13.05 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.728 0.299 . . . . 0.0 110.87 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.463 HG12 ' CG1' ' A' ' 161' ' ' VAL . 83.3 mt -95.12 146.43 6.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.074 179.892 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 4.2 t60 -107.13 -59.94 1.75 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.843 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 27.5 ttpp -125.53 145.63 50.02 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.913 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 21.3 t -130.19 132.79 64.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.129 179.847 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 3.5 t -125.96 140.73 47.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.13 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 23.8 mm -119.4 121.66 67.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.162 179.907 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 7.1 m-80 -116.57 105.58 12.61 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.907 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.33 -0.279 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.878 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 19.7 m . . . . . 0 C--O 1.23 0.066 0 CA-C-O 120.92 0.391 . . . . 0.0 110.868 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -84.38 167.18 16.74 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.107 179.902 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 95.8 p -142.51 162.53 35.22 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.869 -179.765 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -145.88 141.88 28.26 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.116 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 15.2 m-85 -115.19 112.6 22.74 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.95 -179.88 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.463 ' CG1' HG12 ' A' ' 138' ' ' ILE . 94.6 t -106.64 133.69 50.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.146 179.911 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 9.1 m -102.66 125.61 49.45 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.159 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 13.8 m-85 -103.53 136.5 43.13 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.909 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 89.3 mt -63.85 -49.69 80.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.108 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 28.3 mmt180 -100.72 119.16 38.2 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.894 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 4.1 m -50.09 -57.61 7.3 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.848 -179.787 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -41.18 -61.48 1.0 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.886 -179.933 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 31.3 m-20 -46.65 -46.15 19.69 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.857 179.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -57.86 -55.48 34.41 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.059 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 71.7 mt -45.0 -59.72 2.44 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.917 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 13.9 mtm180 -53.94 -53.18 56.33 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.84 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -45.03 -34.83 2.67 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.118 179.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 96.4 mt -81.67 -32.15 11.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.122 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 73.0 mt-30 -66.76 -27.33 67.51 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.874 -179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 1.8 t -93.81 -35.88 12.53 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.867 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 176' ' ' VAL . . . . . 0.408 HG23 ' CE2' ' A' ' 135' ' ' PHE . 10.7 t -64.84 -45.84 93.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.113 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -51.79 144.98 10.27 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.895 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 41.6 m-20 57.61 53.43 7.28 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.882 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 78.6 t -134.59 138.57 49.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.168 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 66.6 t -92.49 124.18 44.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.123 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 60.0 t -135.37 126.89 45.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.103 179.933 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 182' ' ' ASP . . . . . 0.424 ' OD2' ' CD2' ' A' ' 120' ' ' LEU . 4.4 m-20 59.29 25.47 14.11 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.85 179.908 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 90.21 -18.04 50.59 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.464 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 15.3 ptm180 -117.33 129.66 56.02 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.923 0.392 . . . . 0.0 110.849 -179.861 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 51.3 m -71.48 138.89 49.33 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.154 -179.896 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 54.6 mt -105.53 143.65 33.39 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.884 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -115.11 117.14 29.72 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.905 179.841 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -114.96 127.68 55.83 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.065 179.857 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 4.3 t -136.6 173.78 11.33 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.848 -179.771 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 190' ' ' LEU . . . . . . . . . . . . . 3.6 pp -130.29 160.95 32.37 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.929 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.284 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.453 179.878 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 33.6 tp . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.83 0.348 . . . . 0.0 110.883 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 95.3 t -100.58 103.39 14.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.085 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.598 ' CD1' ' CE2' ' A' ' 160' ' ' TYR . 39.1 t80 -101.69 113.24 26.22 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.864 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 40.1 t -112.87 126.51 70.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.126 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . 0.414 ' CG1' ' CE2' ' A' ' 112' ' ' PHE . 17.3 m -111.83 166.36 6.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.16 179.924 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 78.68 43.15 12.24 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.435 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 49.4 mt -112.99 118.26 34.34 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.828 0.347 . . . . 0.0 110.889 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 2.8 p -65.53 143.36 57.69 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.835 -179.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 65.8 mm-40 -39.85 -34.82 0.29 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.917 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 59.8 ttt180 -69.02 -49.06 61.06 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.891 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 61.7 mt -72.63 -20.55 61.25 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.929 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -78.53 83.26 4.73 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.083 179.799 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 17.0 m-20 -148.54 149.24 30.78 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-O 121.572 0.701 . . . . 0.0 110.887 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 -48.59 0.69 Allowed 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.664 2.243 . . . . 0.0 112.39 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 44.7 mm-40 -67.0 -42.07 85.64 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.885 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.425 HG13 ' CZ ' ' A' ' 131' ' ' TYR . 38.1 t -59.82 -47.34 91.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.107 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 94.6 mt -71.58 -32.73 68.4 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.927 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 68.2 mttt -67.19 -30.26 70.15 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.896 179.836 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 9.9 mmp_? -50.23 144.29 11.63 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.577 0.703 . . . . 0.0 110.884 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 0.01 6.29 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.669 2.246 . . . . 0.0 112.365 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 35.3 tt0 -101.05 -7.71 22.99 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.877 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 131' ' ' TYR . . . . . 0.425 ' CZ ' HG13 ' A' ' 125' ' ' VAL . 41.5 m-85 -111.96 -72.88 0.69 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.932 -179.871 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 33.4 m-85 -124.42 -21.67 4.86 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.869 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -52.57 -24.36 17.43 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.479 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 14.6 ptpt -90.49 -16.9 28.06 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.77 0.319 . . . . 0.0 110.848 -179.932 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 135' ' ' PHE . . . . . . . . . . . . . 15.5 m-85 -79.15 -29.11 42.91 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.858 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 172.05 168.33 33.38 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.479 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 7.2 mtmp? -75.67 101.27 4.93 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.806 0.336 . . . . 0.0 110.92 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 81.7 mt -68.64 134.09 30.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.145 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 2.3 t-160 -103.68 -50.7 3.35 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.859 179.893 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 51.8 tttt -134.0 132.13 39.74 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.906 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 49.1 t -120.11 133.23 67.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.113 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 99.6 t -129.88 129.42 65.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.115 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 19.0 mm -107.31 119.36 56.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.139 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 7.7 m120 -111.33 101.34 9.82 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.859 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 9.1 p-10 . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.9 179.961 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 17.5 m . . . . . 0 C--O 1.23 0.073 0 CA-C-O 120.864 0.364 . . . . 0.0 110.859 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -123.85 169.43 11.58 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.081 179.897 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 20.3 m -137.53 164.51 28.55 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.882 -179.804 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -142.95 140.08 30.95 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.128 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 160' ' ' TYR . . . . . 0.598 ' CE2' ' CD1' ' A' ' 112' ' ' PHE . 33.6 m-85 -113.7 116.71 29.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.933 -179.842 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 98.0 t -116.58 139.62 42.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.111 179.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 29.9 m -106.03 129.12 54.2 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.126 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 3.7 m-85 -109.51 148.28 31.48 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.982 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 49.0 mt -76.45 -61.06 1.83 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.139 179.918 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 59.4 mtt180 -82.25 99.08 9.1 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.82 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 50.7 m -42.01 -53.34 3.92 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.878 -179.853 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 3.6 pt-20 -40.73 -59.34 1.42 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.906 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -56.7 -35.14 68.14 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.869 179.923 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -65.4 -60.18 3.23 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.122 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 39.6 mt -45.85 -51.76 12.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.903 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 2.2 mpt_? -61.07 -43.83 98.3 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.808 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -54.89 -31.81 60.27 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.134 179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 63.0 mt -81.16 -38.42 16.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.135 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 31.4 mm-40 -69.69 -22.09 63.45 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.935 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 3.4 t -93.8 -34.75 13.05 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.906 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 10.5 t -66.79 -38.17 80.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.081 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 1.7 t30 -63.34 140.57 58.89 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.874 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 25.5 t30 71.81 35.21 1.41 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.856 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 89.4 t -119.54 131.56 71.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.122 179.892 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 82.7 t -95.62 102.56 13.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.09 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 53.7 t -111.07 117.57 55.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.167 179.877 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 15.2 m-20 48.8 48.99 19.67 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.828 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 63.15 28.4 72.11 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.452 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 12.2 mtt85 -138.07 111.27 7.9 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.86 0.362 . . . . 0.0 110.89 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 36.5 m -70.63 101.21 1.99 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.126 -179.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 11.9 mt -68.45 129.6 40.4 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.914 179.928 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 22.9 tptm -124.85 120.55 32.03 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.932 179.816 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -119.82 151.82 38.24 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.127 179.857 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 8.6 t -158.38 164.01 36.72 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.849 -179.718 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 190' ' ' LEU . . . . . 0.455 ' O ' ' CD1' ' A' ' 190' ' ' LEU . 4.1 pp -128.18 130.3 47.83 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.897 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.333 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.478 179.879 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 11.2 tp . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.829 0.347 . . . . 0.0 110.902 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 98.8 t -94.64 130.11 43.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.116 179.85 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.403 ' CE2' ' CG1' ' A' ' 114' ' ' VAL . 40.5 t80 -128.95 98.23 4.88 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.893 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 54.0 t -92.76 135.75 26.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.177 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . 0.403 ' CG1' ' CE2' ' A' ' 112' ' ' PHE . 4.7 m -124.96 164.4 23.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.12 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 76.28 47.85 10.26 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.518 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 59.8 mt -108.3 130.87 55.17 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.812 0.339 . . . . 0.0 110.929 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 14.0 m -69.21 155.4 40.47 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.902 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 40.8 mt-30 -46.84 -38.07 9.73 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.915 -179.927 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 19.6 tpt180 -74.66 -50.74 16.55 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.869 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 37.0 mt -62.15 -19.09 62.69 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.904 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -76.68 83.9 3.32 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.098 179.782 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -148.66 144.02 17.91 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.639 0.733 . . . . 0.0 110.865 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 -50.78 0.43 Allowed 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.694 2.263 . . . . 0.0 112.341 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 22.1 pt-20 -67.35 -38.36 84.7 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.87 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.456 HG11 ' CE1' ' A' ' 131' ' ' TYR . 84.2 t -63.62 -42.85 97.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.084 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 47.9 mt -72.02 -32.82 67.52 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.899 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 25.0 tttm -74.44 -29.94 61.69 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.914 179.849 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 49.8 mtp180 -47.11 148.8 1.87 Allowed Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.571 0.7 . . . . 0.0 110.882 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 -2.1 9.61 Favored 'Trans proline' 0 C--N 1.341 0.138 0 C-N-CA 122.665 2.243 . . . . 0.0 112.308 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 4.0 tp10 -91.83 -23.53 19.65 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.834 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 131' ' ' TYR . . . . . 0.456 ' CE1' HG11 ' A' ' 125' ' ' VAL . 26.0 m-85 -103.34 -69.55 0.79 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.913 -179.826 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.434 ' O ' ' N ' ' A' ' 135' ' ' PHE . 87.8 m-85 -126.23 -27.9 3.17 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.887 -179.971 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -43.87 -22.23 0.27 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.536 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . 0.4 ' N ' ' O ' ' A' ' 132' ' ' PHE . 16.7 ptpt -85.09 -34.41 22.22 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.801 0.334 . . . . 0.0 110.865 -179.949 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 135' ' ' PHE . . . . . 0.508 ' CE2' HG23 ' A' ' 176' ' ' VAL . 12.9 m-85 -56.3 -39.26 72.42 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.857 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 178.77 -176.19 47.83 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.494 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 13.9 tttt -87.87 111.41 21.39 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.724 0.297 . . . . 0.0 110.902 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 61.5 mt -83.47 144.7 9.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.174 179.849 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 2.2 t60 -102.32 -44.27 5.45 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.851 179.915 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 24.1 ttpp -138.72 145.73 40.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.909 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 21.2 t -131.0 129.38 63.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.174 179.848 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 46.6 t -125.78 140.2 49.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.16 179.93 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 20.0 mm -121.92 126.83 75.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.176 179.883 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 19.0 m-20 -120.49 121.11 37.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.884 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 3.0 p-10 . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.875 -179.98 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 86.9 p . . . . . 0 C--O 1.231 0.103 0 CA-C-O 120.832 0.348 . . . . 0.0 110.873 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -127.61 167.74 15.96 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.13 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 83.5 p -126.13 166.08 17.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.89 -179.819 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -147.99 140.46 24.46 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.131 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 8.8 m-85 -114.71 136.37 53.13 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.917 -179.843 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 74.9 t -130.0 125.59 60.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.145 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 89.1 m -95.75 122.65 38.75 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.176 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 4.8 m-85 -108.16 141.43 39.9 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.936 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 65.3 mt -74.57 -39.52 47.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.073 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 38.4 mtm-85 -86.92 114.58 23.67 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.851 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 14.3 t -55.84 -59.66 4.56 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.845 -179.804 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 17.9 tt0 -51.68 -49.65 61.99 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.875 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 12.2 t0 -48.03 -46.25 32.97 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.886 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -61.67 -53.46 55.86 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.111 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 72.9 mt -44.68 -63.9 0.81 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.888 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 171' ' ' ARG . . . . . 0.418 ' O ' ' N ' ' A' ' 174' ' ' GLN . 14.9 mtp180 -59.59 -53.04 62.64 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.859 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -40.0 -37.73 0.63 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.081 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 67.4 mt -80.66 -36.7 15.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.133 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 174' ' ' GLN . . . . . 0.418 ' N ' ' O ' ' A' ' 171' ' ' ARG . 25.8 mm-40 -61.1 -26.88 67.97 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.9 179.905 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 2.5 t -93.75 -41.15 9.83 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.897 -179.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 176' ' ' VAL . . . . . 0.508 HG23 ' CE2' ' A' ' 135' ' ' PHE . 10.3 t -58.77 -39.44 76.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.092 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -62.43 136.43 57.9 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.896 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 14.6 t30 70.76 47.01 0.48 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.919 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 59.0 t -127.64 134.8 64.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.139 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 89.4 t -93.95 115.04 31.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.148 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 62.4 t -121.45 118.88 57.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.158 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 55.9 m-20 58.5 28.76 17.41 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.844 179.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 90.08 -19.52 42.0 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.497 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 25.4 ttm-85 -103.52 135.89 44.27 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.939 0.4 . . . . 0.0 110.851 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 71.2 m -86.8 131.83 34.01 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.186 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 25.4 mt -112.57 126.25 55.14 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.91 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 7.9 ttmt -109.48 136.64 48.56 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.87 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -125.64 149.52 48.36 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.096 179.844 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 7.3 t -159.37 167.71 28.14 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.828 -179.766 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 190' ' ' LEU . . . . . . . . . . . . . 4.2 pp -126.38 153.11 45.4 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.958 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.252 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.438 179.927 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 19.4 tp . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.807 0.337 . . . . 0.0 110.938 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 75.1 t -93.1 115.99 33.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.102 179.886 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.556 ' CE1' ' HB2' ' A' ' 158' ' ' SER . 6.6 t80 -112.49 118.47 35.22 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.895 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 25.5 t -115.0 137.53 48.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.169 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 19.9 m -123.42 168.96 15.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.161 179.908 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 75.59 48.62 10.19 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.499 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 36.4 mt -114.68 131.18 56.83 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.807 0.336 . . . . 0.0 110.884 -179.887 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 13.0 t -68.99 152.0 45.81 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.88 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 4.2 tp-100 -51.52 -23.57 4.23 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.936 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 30.3 ttt180 -84.62 -45.56 12.39 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.889 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 96.7 mt -68.06 -28.83 67.71 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.87 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -66.36 83.05 0.09 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.096 179.834 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 122' ' ' ASP . . . . . 0.432 ' CB ' HG21 ' A' ' 125' ' ' VAL . 1.2 m-20 -145.47 143.97 21.58 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.625 0.726 . . . . 0.0 110.842 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 -38.89 7.25 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.726 2.284 . . . . 0.0 112.345 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -77.51 -44.83 27.44 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.895 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.556 ' O ' ' CD1' ' A' ' 131' ' ' TYR . 62.0 t -60.6 -38.32 78.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.076 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 81.4 mt -75.08 -44.5 47.07 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.89 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 22.7 ttpp -67.87 -25.82 65.71 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.897 179.861 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 12.9 mmt180 -47.76 144.01 5.6 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.657 0.742 . . . . 0.0 110.803 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 -8.39 23.48 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.745 2.297 . . . . 0.0 112.324 179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 46.7 mt-10 -98.83 8.35 45.07 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.89 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 131' ' ' TYR . . . . . 0.556 ' CD1' ' O ' ' A' ' 125' ' ' VAL . 59.3 m-85 -126.08 -74.26 0.61 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.927 -179.828 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.444 ' O ' ' N ' ' A' ' 134' ' ' LYS . 58.5 m-85 -116.26 -36.66 3.98 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.914 -180.0 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -40.39 -25.58 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.488 -179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . 0.444 ' N ' ' O ' ' A' ' 132' ' ' PHE . 3.5 mtpp -42.7 -59.65 1.85 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.82 0.343 . . . . 0.0 110.875 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 135' ' ' PHE . . . . . 0.486 ' CD2' ' HB2' ' A' ' 172' ' ' ALA . 28.1 m-85 -50.93 -43.59 60.13 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.865 179.982 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 173.82 -172.99 45.69 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.46 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 20.9 mtpp -76.19 141.35 41.85 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.733 0.301 . . . . 0.0 110.887 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.438 HG23 ' N ' ' A' ' 139' ' ' HIS . 60.6 mt -99.52 141.26 17.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.125 179.866 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 139' ' ' HIS . . . . . 0.438 ' N ' HG23 ' A' ' 138' ' ' ILE . 11.2 t60 -84.97 -58.55 2.65 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.846 179.892 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 22.1 tttp -137.53 146.82 44.61 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.914 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 35.3 t -134.68 132.83 54.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.175 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 57.8 t -126.46 141.38 46.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.121 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 31.4 mm -119.87 132.65 69.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.095 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 5.2 t-20 -126.39 106.54 9.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.889 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 5.3 p30 . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.872 -179.999 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 93.4 p . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.894 0.378 . . . . 0.0 110.873 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -93.96 169.47 10.25 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.092 179.932 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 158' ' ' SER . . . . . 0.556 ' HB2' ' CE1' ' A' ' 112' ' ' PHE . 86.9 p -140.72 153.52 45.96 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.85 -179.775 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -137.68 150.93 47.73 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.109 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 160' ' ' TYR . . . . . 0.486 ' CD1' ' N ' ' A' ' 160' ' ' TYR . 1.3 m-85 -115.57 125.79 53.4 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.919 -179.832 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.425 HG12 ' CE1' ' A' ' 163' ' ' TYR . 43.0 t -120.83 125.74 74.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.151 179.909 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 87.9 m -107.44 123.88 49.04 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.161 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 163' ' ' TYR . . . . . 0.425 ' CE1' HG12 ' A' ' 161' ' ' VAL . 30.3 m-85 -104.06 164.3 11.8 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.906 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 42.7 mt -94.05 -39.46 10.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.153 179.891 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 30.5 mtp180 -102.12 120.36 40.31 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.911 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 16.0 m -47.78 -56.49 7.28 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.823 -179.733 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 34.8 mt-10 -46.23 -52.46 12.42 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.904 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 23.3 m-20 -50.95 -48.18 60.95 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.801 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -55.29 -62.47 1.65 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.082 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 66.0 mt -41.63 -62.77 0.82 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.9 -179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 171' ' ' ARG . . . . . 0.414 ' O ' ' N ' ' A' ' 174' ' ' GLN . 20.0 mtp85 -51.76 -60.06 3.59 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.829 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . 0.486 ' HB2' ' CD2' ' A' ' 135' ' ' PHE . . . -38.75 -36.42 0.26 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.146 179.893 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 60.9 mt -80.96 -39.89 18.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.12 179.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 174' ' ' GLN . . . . . 0.414 ' N ' ' O ' ' A' ' 171' ' ' ARG . 51.3 mt-30 -66.93 -22.1 65.96 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.92 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 1.8 t -93.77 -37.27 11.87 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.913 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 176' ' ' VAL . . . . . 0.464 ' CG1' ' HB3' ' A' ' 188' ' ' ALA . 10.3 t -64.37 -33.77 64.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.082 -179.954 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 3.8 t30 -67.95 143.5 55.61 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.866 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 22.8 t30 65.52 48.94 1.91 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.905 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 53.0 t -127.27 135.64 62.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.14 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 59.3 t -96.9 100.31 10.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.148 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 66.9 t -107.52 97.98 6.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.175 179.909 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 6.8 t0 66.73 36.58 4.6 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.862 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 77.59 32.54 46.1 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.499 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 65.6 mtt85 -141.66 136.51 30.98 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.911 0.386 . . . . 0.0 110.866 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 26.6 m -94.73 95.0 8.44 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.161 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 79.8 mt -67.74 132.73 48.0 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.901 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 25.4 tptt -111.08 116.41 31.08 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.92 179.815 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . 0.464 ' HB3' ' CG1' ' A' ' 176' ' ' VAL . . . -112.38 134.28 54.01 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.101 179.824 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 7.7 t -158.51 171.75 19.56 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.815 -179.791 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 190' ' ' LEU . . . . . 0.547 ' C ' ' CD2' ' A' ' 190' ' ' LEU . 0.0 OUTLIER -119.25 158.77 25.37 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.936 179.998 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 191' ' ' GLY . . . . . 0.442 ' N ' HD22 ' A' ' 190' ' ' LEU . . . . . . . . 0 N--CA 1.451 -0.356 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.491 179.91 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 62.1 tp . . . . . 0 C--O 1.231 0.084 0 CA-C-O 120.838 0.351 . . . . 0.0 110.92 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 86.9 t -111.13 106.64 21.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.065 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.469 ' CE2' ' CG1' ' A' ' 114' ' ' VAL . 87.7 t80 -94.48 102.21 14.15 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.905 179.967 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 20.2 t -107.23 131.73 56.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.16 179.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . 0.469 ' CG1' ' CE2' ' A' ' 112' ' ' PHE . 6.1 m -119.2 155.01 21.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.113 179.942 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 90.81 44.35 4.54 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.452 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 116' ' ' LEU . . . . . 0.419 HD22 ' CD2' ' A' ' 186' ' ' LEU . 38.5 mt -110.25 125.0 52.65 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.823 0.344 . . . . 0.0 110.913 -179.943 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 117' ' ' SER . . . . . 0.484 ' O ' ' N ' ' A' ' 120' ' ' LEU . 22.8 p -69.09 139.97 54.81 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.84 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 118' ' ' GLN . . . . . 0.42 ' C ' ' O ' ' A' ' 117' ' ' SER . 37.4 mt-30 -36.38 -41.79 0.3 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.914 -179.924 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 26.6 mtm-85 -66.31 -44.12 84.33 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.886 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 120' ' ' LEU . . . . . 0.484 ' N ' ' O ' ' A' ' 117' ' ' SER . 34.5 mt -72.42 -24.74 61.27 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.912 -179.976 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -71.23 83.25 0.74 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.132 179.811 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 122' ' ' ASP . . . . . 0.449 ' CB ' HG22 ' A' ' 125' ' ' VAL . 20.0 m-20 -148.87 144.0 17.73 Favored Pre-proline 0 C--N 1.328 -0.364 0 CA-C-O 121.648 0.737 . . . . 0.0 110.88 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.73 -46.65 1.16 Allowed 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.69 2.26 . . . . 0.0 112.347 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 48.7 mt-10 -71.36 -43.31 67.16 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.924 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.556 HG13 ' CE2' ' A' ' 131' ' ' TYR . 90.5 t -60.19 -42.2 89.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.136 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . 0.465 HD22 ' CE1' ' A' ' 132' ' ' PHE . 64.6 mt -72.96 -39.48 66.15 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.898 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 18.6 ttmt -61.44 -31.95 71.92 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.9 179.855 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 91.7 mtt180 -43.02 143.94 1.17 Allowed Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.635 0.731 . . . . 0.0 110.88 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 -2.69 10.57 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.679 2.253 . . . . 0.0 112.384 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 25.7 mt-10 -97.57 -30.26 12.96 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.905 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 131' ' ' TYR . . . . . 0.556 ' CE2' HG13 ' A' ' 125' ' ' VAL . 44.2 m-85 -87.64 -74.91 0.43 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.921 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.465 ' CE1' HD22 ' A' ' 126' ' ' LEU . 42.6 m-85 -117.08 -36.84 3.69 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.88 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -49.34 -18.42 1.43 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.518 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -52.49 -34.22 48.34 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.832 0.349 . . . . 0.0 110.916 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 135' ' ' PHE . . . . . 0.565 ' CE2' ' HA ' ' A' ' 172' ' ' ALA . 79.8 m-85 -73.35 -42.02 62.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.897 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 166.89 -178.14 41.3 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.493 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 5.2 ttmm -60.01 140.28 56.88 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.762 0.315 . . . . 0.0 110.858 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 91.3 mt -105.67 139.03 28.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.112 179.862 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 34.3 t-80 -75.61 -55.15 5.94 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.866 179.868 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 140' ' ' LYS . . . . . 0.462 ' HD3' ' CG2' ' A' ' 142' ' ' VAL . 13.4 ttmm -149.49 144.16 26.11 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.916 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 23.9 t -122.43 103.63 13.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.109 179.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.462 ' CG2' ' HD3' ' A' ' 140' ' ' LYS . 63.1 t -100.65 140.82 18.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.157 179.873 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 26.7 mm -119.24 125.47 74.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.15 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 19.6 m-20 -121.2 142.75 49.6 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.88 179.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 18.4 p30 . . . . . 0 C--N 1.329 -0.306 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.871 -179.983 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 82.0 p . . . . . 0 C--O 1.231 0.103 0 CA-C-O 120.905 0.383 . . . . 0.0 110.844 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -113.68 157.91 21.57 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.076 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 11.7 t -116.29 168.19 10.35 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.871 -179.763 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -148.48 147.29 28.95 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.058 179.893 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 160' ' ' TYR . . . . . 0.405 ' CD1' ' N ' ' A' ' 160' ' ' TYR . 4.5 m-85 -115.06 104.73 12.17 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.916 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 95.3 t -99.51 126.45 52.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.146 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 96.7 m -95.9 123.76 39.62 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.14 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 12.1 m-85 -106.13 121.99 45.27 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.949 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 46.0 mt -57.38 -51.5 68.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.097 -0.502 . . . . 0.0 111.154 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 39.7 mtp180 -85.72 118.08 25.0 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.847 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 22.6 t -48.72 -47.4 41.33 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.868 -179.82 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -54.36 -56.22 20.77 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.905 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -52.39 -31.9 36.17 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.867 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -70.49 -66.19 0.63 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.113 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . 0.409 HD21 ' CD1' ' A' ' 190' ' ' LEU . 31.1 mt -46.6 -56.17 6.5 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.894 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 84.9 mtt180 -56.59 -46.56 80.78 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.854 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . 0.565 ' HA ' ' CE2' ' A' ' 135' ' ' PHE . . . -51.88 -32.73 33.56 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.076 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 65.8 mt -79.13 -36.4 18.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.11 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 15.7 mm100 -65.84 -26.93 67.88 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.874 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 175' ' ' CYS . . . . . 0.401 ' O ' ' CG2' ' A' ' 179' ' ' VAL . 7.6 m -93.7 -36.63 12.23 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.907 -179.949 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 10.5 t -65.43 -40.11 87.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.083 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 7.4 p-10 -68.32 152.1 45.93 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.891 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 36.5 t30 57.1 48.77 14.84 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.882 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 179' ' ' VAL . . . . . 0.401 ' CG2' ' O ' ' A' ' 175' ' ' CYS . 94.3 t -133.56 140.21 47.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.113 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 87.1 t -99.08 105.35 17.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.097 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 91.8 t -112.06 98.73 7.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.133 179.901 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 30.9 t0 60.7 52.42 4.43 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.841 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 63.27 24.19 67.11 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.492 -179.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 66.3 mtp85 -131.61 111.91 12.14 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.874 0.369 . . . . 0.0 110.86 -179.826 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 28.2 m -76.09 93.19 3.28 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.127 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 186' ' ' LEU . . . . . 0.419 ' CD2' HD22 ' A' ' 116' ' ' LEU . 80.2 mt -68.54 128.99 38.61 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.931 179.916 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 2.5 mmmp? -117.6 118.29 31.73 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.877 179.847 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -107.19 145.56 32.46 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.127 179.819 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 4.5 t -143.33 169.32 17.88 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.857 -179.74 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 190' ' ' LEU . . . . . 0.409 ' CD1' HD21 ' A' ' 170' ' ' LEU . 8.6 tt -128.81 134.89 48.51 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.904 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.306 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.486 179.91 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 11.5 tp . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.84 0.352 . . . . 0.0 110.908 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 85.2 t -122.55 111.75 31.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.105 179.872 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.433 ' CE1' ' HB2' ' A' ' 158' ' ' SER . 42.1 t80 -98.46 113.34 25.3 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.889 179.991 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.431 HG21 ' CZ ' ' A' ' 132' ' ' PHE . 92.8 t -110.68 137.23 43.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.117 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 35.9 m -126.91 168.19 20.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.147 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 74.29 41.67 37.42 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.476 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 50.5 mt -103.54 130.84 51.02 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.797 0.332 . . . . 0.0 110.94 -179.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 117' ' ' SER . . . . . 0.491 ' O ' ' N ' ' A' ' 120' ' ' LEU . 89.6 p -77.37 142.65 39.2 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.85 -179.934 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 118' ' ' GLN . . . . . 0.442 ' C ' ' O ' ' A' ' 117' ' ' SER . 55.0 mm-40 -34.85 -40.36 0.11 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.892 -179.938 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 25.0 mtm-85 -63.34 -47.26 82.93 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.871 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 120' ' ' LEU . . . . . 0.491 ' N ' ' O ' ' A' ' 117' ' ' SER . 20.7 mt -72.44 -29.44 63.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.936 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -65.46 82.99 0.06 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.099 179.81 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 122' ' ' ASP . . . . . 0.403 ' HB2' ' CG2' ' A' ' 125' ' ' VAL . 19.4 m-20 -149.0 143.84 17.46 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.599 0.714 . . . . 0.0 110.863 179.985 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 -44.26 2.19 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.682 2.255 . . . . 0.0 112.389 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 66.3 mm-40 -74.2 -38.61 63.54 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.886 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.586 ' O ' ' CD1' ' A' ' 131' ' ' TYR . 68.9 t -61.0 -49.5 84.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.103 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 92.8 mt -66.33 -43.36 86.36 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.943 179.936 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.467 ' HA ' ' CD1' ' A' ' 138' ' ' ILE . 31.1 tttm -61.64 -42.71 99.27 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.878 179.849 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 128' ' ' ARG . . . . . 0.424 ' C ' ' O ' ' A' ' 127' ' ' LYS . 21.4 mmt180 -35.61 143.28 0.26 Allowed Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.643 0.735 . . . . 0.0 110.826 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.75 -1.4 8.4 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.66 2.24 . . . . 0.0 112.34 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 10.2 mp0 -103.26 -0.98 29.57 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.884 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 131' ' ' TYR . . . . . 0.586 ' CD1' ' O ' ' A' ' 125' ' ' VAL . 47.0 m-85 -117.06 -74.15 0.62 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.913 -179.879 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.431 ' CZ ' HG21 ' A' ' 113' ' ' VAL . 46.5 m-85 -121.75 -17.85 7.28 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.91 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -72.08 -1.44 48.88 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.491 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 1.3 ptpp? -78.85 -19.67 51.46 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.78 0.324 . . . . 0.0 110.894 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 135' ' ' PHE . . . . . 0.565 ' CD2' ' HB2' ' A' ' 172' ' ' ALA . 58.2 m-85 -85.62 -38.17 18.72 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.856 -179.99 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -179.72 -174.52 45.74 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.511 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 45.9 mtpt -81.49 134.62 35.55 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.779 0.323 . . . . 0.0 110.889 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.467 ' CD1' ' HA ' ' A' ' 127' ' ' LYS . 65.1 mt -94.98 147.03 6.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.155 179.861 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 4.6 t60 -99.11 -43.61 6.59 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.891 179.901 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 26.5 ttpt -148.28 143.69 27.12 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.95 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 41.3 t -127.23 121.17 56.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.208 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 72.4 t -125.71 145.27 33.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.153 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 29.1 mm -115.8 141.82 31.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.118 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 48.2 t30 -129.45 142.92 50.67 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.916 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 44.7 t-20 . . . . . 0 C--N 1.33 -0.28 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.831 -179.981 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 69.6 m . . . . . 0 C--O 1.231 0.084 0 CA-C-O 120.848 0.356 . . . . 0.0 110.868 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -103.92 149.14 25.38 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.079 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 158' ' ' SER . . . . . 0.433 ' HB2' ' CE1' ' A' ' 112' ' ' PHE . 53.1 p -117.21 171.59 7.85 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.89 -179.803 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -146.79 133.55 20.03 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.12 179.875 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 38.7 m-85 -104.48 113.75 27.53 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.905 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 98.7 t -109.13 123.93 65.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.129 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 40.4 m -98.02 123.88 42.24 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.134 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 9.8 m-85 -105.99 146.73 29.69 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.923 -179.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 86.9 mt -79.41 -36.24 17.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.133 179.883 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 31.9 mmm-85 -106.93 117.08 33.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.872 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 74.2 m -49.24 -51.11 35.39 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.846 -179.771 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 18.5 mm-40 -48.74 -51.02 31.11 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.897 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -54.26 -45.13 72.34 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.871 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -60.24 -62.61 1.74 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.094 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 50.6 mt -41.57 -66.38 0.35 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.9 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 79.2 mtp180 -48.37 -54.43 13.97 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.869 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . 0.565 ' HB2' ' CD2' ' A' ' 135' ' ' PHE . . . -43.51 -35.16 1.56 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.083 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 63.6 mt -77.92 -40.46 26.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.183 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 88.2 mm-40 -61.36 -27.57 68.61 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.914 179.918 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 175' ' ' CYS . . . . . 0.477 ' O ' ' CG2' ' A' ' 179' ' ' VAL . 1.9 m -93.82 -42.1 9.29 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.882 -179.914 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 10.3 t -58.07 -36.27 56.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.14 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 12.3 t-20 -68.41 150.83 47.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.873 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 178' ' ' ASN . . . . . 0.411 ' CG ' ' O ' ' A' ' 178' ' ' ASN . 37.4 t30 57.66 42.84 23.25 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.854 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 179' ' ' VAL . . . . . 0.477 ' CG2' ' O ' ' A' ' 175' ' ' CYS . 62.0 t -128.68 135.03 63.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.142 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 90.3 t -98.97 106.38 18.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.129 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 57.1 t -114.18 121.32 66.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.115 179.909 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 14.4 m-20 51.23 28.45 4.17 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.844 179.908 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 81.47 32.01 32.07 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.493 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 4.2 mpt_? -138.69 124.47 19.79 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.878 0.37 . . . . 0.0 110.878 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 19.4 m -76.65 93.28 3.6 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.122 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 51.0 mt -62.01 125.98 25.76 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.875 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 9.5 tptm -122.86 112.28 17.68 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.922 179.788 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -107.57 153.19 23.22 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.128 179.826 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 48.0 m -139.2 156.34 47.17 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.877 -179.765 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 190' ' ' LEU . . . . . 0.452 ' CD1' ' C ' ' A' ' 190' ' ' LEU . 1.5 tm? -120.2 102.28 8.4 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.913 179.968 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.313 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.494 179.87 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 15.8 tp . . . . . 0 C--O 1.232 0.141 0 CA-C-O 120.834 0.35 . . . . 0.0 110.938 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 99.1 t -122.47 110.97 28.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.13 179.833 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 46.4 t80 -102.83 108.03 19.1 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.853 -179.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 86.0 t -105.2 134.46 46.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.155 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 34.0 m -124.42 167.04 18.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.08 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 78.58 49.21 6.77 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.541 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 28.8 mt -113.78 139.89 48.75 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.823 0.344 . . . . 0.0 110.91 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 36.0 t -73.83 146.44 44.16 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.872 -179.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 25.4 mt-30 -42.19 -29.93 0.27 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.94 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 56.2 ttt180 -88.41 -38.23 15.23 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.872 -179.913 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 44.8 mt -65.18 -33.8 76.87 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.905 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -70.16 83.08 0.52 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.151 179.802 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 21.7 m-20 -148.93 147.1 23.07 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.605 0.717 . . . . 0.0 110.86 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 -37.24 9.53 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.708 2.272 . . . . 0.0 112.36 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 14.9 pt-20 -77.29 -44.43 29.74 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.87 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 86.1 t -61.71 -39.93 85.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.158 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 91.2 mt -74.2 -39.31 63.23 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.933 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 2.0 mmmp? -64.64 -30.81 71.83 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.86 179.867 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 14.7 mmt180 -42.44 143.93 1.03 Allowed Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.591 0.71 . . . . 0.0 110.876 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 -4.19 13.51 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.66 2.24 . . . . 0.0 112.337 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 4.8 tt0 -99.98 1.07 42.23 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.895 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 131' ' ' TYR . . . . . . . . . . . . . 30.7 m-85 -121.0 -74.93 0.6 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.888 -179.831 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 58.0 m-85 -122.99 -18.14 6.5 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.867 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -55.59 -23.03 34.41 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.499 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 12.4 ptpt -90.83 -11.36 39.58 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.796 0.331 . . . . 0.0 110.858 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 135' ' ' PHE . . . . . . . . . . . . . 22.9 m-85 -80.42 -33.23 37.12 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.925 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 173.65 -166.25 38.45 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.444 -179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 39.4 tptt -95.65 109.27 21.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.737 0.303 . . . . 0.0 110.911 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.453 HG21 ' CG2' ' A' ' 141' ' ' VAL . 86.2 mt -76.71 140.26 17.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.145 179.864 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 18.6 t60 -114.12 -51.07 2.79 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.9 179.871 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -127.28 135.63 50.84 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.868 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . 0.453 ' CG2' HG21 ' A' ' 138' ' ' ILE . 19.2 t -137.49 143.04 35.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.129 179.886 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.401 HG12 ' N ' ' A' ' 143' ' ' ILE . 74.6 t -145.34 140.18 22.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.132 179.959 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . 0.401 ' N ' HG12 ' A' ' 142' ' ' VAL . 24.6 mm -110.94 126.43 68.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.096 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 2.9 m120 -124.45 137.78 54.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.905 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 5.3 p30 . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.908 179.973 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 55.8 m . . . . . 0 C--O 1.231 0.086 0 CA-C-O 120.867 0.365 . . . . 0.0 110.861 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -112.85 149.71 32.73 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.091 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 89.9 p -113.71 158.27 21.14 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.852 -179.803 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -141.08 128.52 21.21 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.102 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 35.9 m-85 -99.91 126.56 46.06 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.932 -179.871 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 96.6 t -129.09 137.59 56.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.101 179.958 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 96.0 m -108.31 134.42 51.16 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.162 180.0 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 16.1 m-85 -111.8 129.51 56.11 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.937 -179.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 56.2 mt -61.46 -41.04 88.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.097 -0.502 . . . . 0.0 111.155 179.918 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 82.3 mtt-85 -91.66 113.78 26.14 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.895 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 23.2 t -52.16 -59.54 4.25 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.832 -179.751 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 54.1 tt0 -47.31 -49.19 24.56 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.898 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 4.9 t0 -52.48 -51.16 60.78 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.884 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -54.2 -57.74 10.0 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.078 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 42.0 mt -43.56 -61.43 1.39 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.931 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 41.9 mtt-85 -54.6 -43.51 72.24 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.85 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . 0.417 ' O ' ' CG2' ' A' ' 176' ' ' VAL . . . -54.39 -30.98 53.88 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.123 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 97.3 mt -82.54 -34.51 11.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.103 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 11.2 mm-40 -68.2 -27.82 66.72 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.911 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 175' ' ' CYS . . . . . 0.44 ' O ' ' CG2' ' A' ' 179' ' ' VAL . 2.0 m -93.75 -35.59 12.7 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.89 -179.954 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 176' ' ' VAL . . . . . 0.417 ' CG2' ' O ' ' A' ' 172' ' ' ALA . 10.5 t -66.48 -29.92 48.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.146 -179.974 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 4.3 t-20 -73.41 126.95 31.36 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.844 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 26.2 t-20 74.41 52.08 0.09 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.863 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 179' ' ' VAL . . . . . 0.44 ' CG2' ' O ' ' A' ' 175' ' ' CYS . 69.5 t -130.83 132.78 63.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.138 179.905 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 86.6 t -92.54 107.44 19.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.182 179.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 98.3 t -121.0 113.79 41.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.11 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 4.4 t70 58.78 26.51 14.82 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.905 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 81.33 26.67 51.16 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.508 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 3.1 mpt_? -136.27 123.48 21.77 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.932 0.396 . . . . 0.0 110.872 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 18.3 m -76.26 101.64 5.53 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.154 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 89.0 mt -78.18 125.21 29.03 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.957 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 38.1 mmtt -118.5 117.99 30.49 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.898 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -106.9 140.72 39.27 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.105 179.81 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 59.3 m -145.03 162.88 35.86 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.853 -179.768 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 190' ' ' LEU . . . . . 0.409 ' C ' HD11 ' A' ' 190' ' ' LEU . 3.5 pp -130.24 153.31 48.74 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.927 180.0 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.311 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.525 179.95 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 19.5 tp . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.826 0.346 . . . . 0.0 110.876 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 71.2 t -114.38 124.05 70.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.161 179.804 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.507 ' CE1' ' HB2' ' A' ' 158' ' ' SER . 65.2 t80 -106.55 108.32 19.77 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.866 -179.919 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 40.2 t -110.7 132.18 59.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.1 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 23.7 m -121.71 160.7 23.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.137 179.919 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 86.33 51.99 3.35 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.496 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 82.4 mt -116.17 134.44 54.92 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.808 0.337 . . . . 0.0 110.96 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 10.6 t -69.48 149.26 48.47 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.854 -179.92 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 1.4 pp0? -47.58 -31.9 4.92 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.96 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 17.0 ttt180 -84.47 -39.75 18.53 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.898 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 83.1 mt -66.68 -28.95 68.86 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.918 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -70.69 85.18 0.64 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.105 179.81 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -148.11 144.29 18.69 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.596 0.712 . . . . 0.0 110.855 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.76 -49.45 0.56 Allowed 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.66 2.24 . . . . 0.0 112.357 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 26.0 mt-10 -66.68 -41.88 87.39 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.806 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.596 ' O ' ' CD2' ' A' ' 131' ' ' TYR . 87.8 t -62.64 -42.97 98.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.129 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 89.1 mt -73.18 -42.59 62.56 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.948 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 4.7 mtmp? -61.43 -27.49 68.59 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.934 179.809 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 13.5 mtm180 -53.89 144.01 38.61 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.633 0.73 . . . . 0.0 110.892 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.81 1.89 4.06 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.691 2.261 . . . . 0.0 112.309 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 8.1 mp0 -101.67 -13.85 17.62 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.924 180.0 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 131' ' ' TYR . . . . . 0.596 ' CD2' ' O ' ' A' ' 125' ' ' VAL . 52.6 m-85 -109.41 -71.17 0.77 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.899 -179.82 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.457 ' O ' ' N ' ' A' ' 134' ' ' LYS . 25.1 m-85 -122.14 -40.14 2.53 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.895 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . 0.404 ' C ' ' O ' ' A' ' 132' ' ' PHE . . . -38.17 -28.57 0.05 OUTLIER Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.709 -0.757 . . . . 0.0 112.48 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . 0.457 ' N ' ' O ' ' A' ' 132' ' ' PHE . 8.8 ptmm? -52.89 -53.79 44.11 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.831 0.348 . . . . 0.0 110.873 -179.949 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 135' ' ' PHE . . . . . 0.413 ' CD1' ' HA ' ' A' ' 172' ' ' ALA . 70.3 m-85 -52.62 -40.22 62.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.909 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -177.66 178.62 48.4 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.476 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 28.2 mtpt -86.15 97.58 10.41 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.774 0.321 . . . . 0.0 110.915 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 71.7 mt -62.06 140.61 18.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.138 179.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 17.2 t-80 -97.34 -54.1 3.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.859 179.872 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 140' ' ' LYS . . . . . 0.422 ' HD2' ' C ' ' A' ' 140' ' ' LYS . 1.2 tmmt? -126.79 152.1 47.38 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.922 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 54.4 t -139.82 145.46 26.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.133 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 23.5 t -138.9 116.65 12.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.113 179.925 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 7.2 mm -101.57 127.81 54.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.157 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 34.6 m-80 -126.71 106.66 9.53 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.903 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 6.6 p30 . . . . . 0 C--N 1.329 -0.303 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.89 -179.984 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 4.2 m . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.857 0.361 . . . . 0.0 110.882 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -108.39 163.66 13.01 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.082 179.938 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 158' ' ' SER . . . . . 0.507 ' HB2' ' CE1' ' A' ' 112' ' ' PHE . 34.8 p -138.57 156.05 47.83 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.826 -179.782 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -148.9 152.15 35.9 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.083 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 19.8 m-85 -111.94 121.59 45.44 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.906 -179.852 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 61.9 t -109.43 131.62 59.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.114 -0.493 . . . . 0.0 111.079 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 20.8 m -101.26 124.4 46.89 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.116 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 9.5 m-85 -104.53 137.53 42.24 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.946 -179.911 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 68.4 mt -62.21 -49.21 84.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.123 179.934 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 34.0 mtt85 -104.11 127.35 51.69 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.889 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 75.6 m -53.65 -58.2 8.05 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.881 -179.779 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 66.0 mm-40 -43.7 -49.24 7.9 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.872 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -55.54 -49.44 72.64 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.887 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -56.44 -56.03 26.28 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.054 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 39.5 mt -45.41 -63.3 0.98 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.918 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 46.3 mtp180 -53.75 -48.12 69.98 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.86 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . 0.471 ' O ' ' CG2' ' A' ' 176' ' ' VAL . . . -48.36 -34.14 10.18 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.145 179.899 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 67.3 mt -80.68 -37.26 16.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.147 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 42.5 mt-30 -63.48 -27.79 69.52 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.952 179.875 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 2.6 t -93.81 -36.73 12.12 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.889 -179.927 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 176' ' ' VAL . . . . . 0.471 ' CG2' ' O ' ' A' ' 172' ' ' ALA . 11.3 t -58.31 -42.46 83.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.133 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 22.6 t30 -65.94 141.68 58.14 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.855 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 7.3 t30 69.37 51.33 0.5 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.884 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 96.9 t -135.13 137.87 49.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.092 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 94.7 t -98.64 109.21 23.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.125 179.889 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 84.2 t -116.58 102.44 13.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.116 179.918 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 6.9 t70 58.29 35.96 25.28 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.87 179.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 78.61 26.22 59.35 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.484 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 30.0 mtt-85 -133.8 115.6 14.7 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.917 0.389 . . . . 0.0 110.839 -179.833 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 23.5 m -79.73 92.76 5.45 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.157 -179.939 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 73.3 mt -62.95 136.46 57.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.927 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 13.6 tptp -123.81 116.43 22.96 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.886 179.8 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -112.47 140.13 47.47 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.093 179.807 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 74.5 m -140.15 157.94 44.83 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.858 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 190' ' ' LEU . . . . . . . . . . . . . 7.3 tt -131.75 122.66 26.22 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.901 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.331 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.5 179.909 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 23.3 tp . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.839 0.352 . . . . 0.0 110.888 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 45.1 t -133.07 107.7 11.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.107 179.828 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.562 ' CD1' ' CZ ' ' A' ' 160' ' ' TYR . 67.4 t80 -102.88 113.61 27.19 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.907 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 38.2 t -111.18 145.67 17.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.101 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 23.1 m -130.97 170.59 19.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.1 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 79.15 51.12 5.47 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.481 179.906 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 23.5 mt -118.03 131.03 56.5 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.829 0.347 . . . . 0.0 110.922 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 117' ' ' SER . . . . . 0.484 ' O ' ' N ' ' A' ' 119' ' ' ARG . 23.1 t -70.95 140.19 50.85 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.812 -179.868 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 118' ' ' GLN . . . . . 0.434 ' C ' ' O ' ' A' ' 117' ' ' SER . 9.5 tp-100 -35.54 -32.06 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.934 -179.979 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.484 ' N ' ' O ' ' A' ' 117' ' ' SER . 18.5 tpp180 -81.49 -47.12 13.56 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.856 -179.91 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 120' ' ' LEU . . . . . 0.453 ' N ' ' O ' ' A' ' 117' ' ' SER . 62.4 mt -61.83 -33.69 74.6 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.952 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -66.09 86.79 0.1 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.095 179.815 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 122' ' ' ASP . . . . . 0.407 ' CB ' HG21 ' A' ' 125' ' ' VAL . 0.6 OUTLIER -148.07 144.03 18.38 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.622 0.725 . . . . 0.0 110.871 179.969 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.81 -50.28 0.47 Allowed 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.649 2.232 . . . . 0.0 112.313 -179.984 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 42.7 mt-10 -68.14 -45.68 72.91 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.881 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.415 ' O ' ' CD1' ' A' ' 131' ' ' TYR . 58.4 t -60.03 -39.39 80.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.135 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 47.3 mt -74.63 -42.01 59.36 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.942 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.453 ' HA ' ' CD1' ' A' ' 138' ' ' ILE . 17.3 ttmt -59.48 -30.73 68.75 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.91 179.85 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 46.8 mtt180 -39.94 143.87 0.57 Allowed Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.583 0.706 . . . . 0.0 110.893 179.949 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 2.94 3.1 Favored 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.645 2.23 . . . . 0.0 112.319 -179.984 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -106.67 -30.09 9.2 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.879 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 131' ' ' TYR . . . . . 0.415 ' CD1' ' O ' ' A' ' 125' ' ' VAL . 43.4 m-85 -86.01 -75.05 0.39 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.933 -179.844 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 17.0 m-85 -115.32 -39.72 3.55 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.888 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -52.61 -20.55 7.81 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.488 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . 0.422 ' HD2' ' CG ' ' A' ' 135' ' ' PHE . 0.0 OUTLIER -51.2 -40.96 59.86 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.791 0.329 . . . . 0.0 110.875 -179.964 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 135' ' ' PHE . . . . . 0.422 ' CG ' ' HD2' ' A' ' 134' ' ' LYS . 83.1 m-85 -66.26 -46.38 77.27 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.882 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -173.86 -159.87 21.13 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.506 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 17.0 tptm -91.15 116.23 28.65 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.799 0.333 . . . . 0.0 110.861 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.453 ' CD1' ' HA ' ' A' ' 127' ' ' LYS . 91.0 mt -73.03 141.89 15.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.081 179.899 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 71.4 t60 -96.15 -44.08 7.45 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.894 179.852 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 15.8 tttm -139.67 142.7 36.94 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.911 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 39.2 t -134.59 110.55 13.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.143 179.864 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.422 HG11 ' N ' ' A' ' 143' ' ' ILE . 64.9 t -116.06 137.98 48.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.11 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . 0.422 ' N ' HG11 ' A' ' 142' ' ' VAL . 43.1 mm -111.82 134.7 53.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.094 179.928 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 34.0 m-20 -131.04 110.97 11.6 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.851 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 5.8 p30 . . . . . 0 C--N 1.33 -0.263 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.918 179.971 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 3.5 m . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.932 0.396 . . . . 0.0 110.878 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -117.41 164.47 14.82 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.125 179.898 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 158' ' ' SER . . . . . 0.56 ' HB2' ' CE1' ' A' ' 112' ' ' PHE . 71.5 p -140.09 154.74 47.13 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.84 -179.779 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -139.08 152.14 47.29 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.082 179.893 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 160' ' ' TYR . . . . . 0.562 ' CZ ' ' CD1' ' A' ' 112' ' ' PHE . 8.5 m-85 -114.0 115.83 28.24 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.933 -179.837 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.447 HG11 ' N ' ' A' ' 162' ' ' THR . 29.9 t -110.35 142.61 22.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.134 179.924 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 162' ' ' THR . . . . . 0.447 ' N ' HG11 ' A' ' 161' ' ' VAL . 18.7 m -120.44 115.86 24.31 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.119 -179.934 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 25.0 m-85 -90.32 135.08 33.9 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.933 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 64.1 mt -57.73 -42.73 82.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.139 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 17.7 mmm180 -98.25 125.65 43.41 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.888 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 46.6 m -55.26 -62.87 1.38 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.855 -179.781 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 5.4 tp10 -41.89 -55.84 2.95 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.856 -179.906 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 5.9 m-20 -49.59 -45.65 48.21 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.863 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -57.1 -61.78 2.22 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.135 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 53.7 mt -42.45 -61.74 1.14 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.957 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 59.1 mtp180 -55.7 -51.56 66.87 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.882 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -42.2 -36.58 1.24 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.055 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 173' ' ' ILE . . . . . 0.431 ' CD1' HD23 ' A' ' 190' ' ' LEU . 95.2 mt -80.18 -39.1 18.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.257 -0.428 . . . . 0.0 111.177 179.969 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 30.6 mt-30 -62.07 -26.18 68.12 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.92 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 2.2 m -93.76 -38.21 11.4 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.854 -179.92 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 176' ' ' VAL . . . . . 0.421 ' CG1' ' HB2' ' A' ' 188' ' ' ALA . 10.2 t -63.61 -39.74 86.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.128 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 14.1 t30 -63.83 138.66 58.57 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.885 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 49.9 t30 67.74 48.19 1.07 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.913 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 87.0 t -130.1 130.14 65.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.172 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 98.1 t -89.75 109.06 20.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.111 179.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 87.0 t -117.17 109.85 29.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.1 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 61.9 m-20 59.85 38.49 21.26 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.831 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 73.71 34.12 56.99 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.486 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 59.0 mtt-85 -143.02 123.25 13.75 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.887 0.375 . . . . 0.0 110.88 -179.867 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 37.7 m -80.39 93.61 6.01 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.153 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 45.0 mt -66.07 147.0 54.02 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.876 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 13.9 tppt? -128.0 112.35 14.55 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.913 179.838 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . 0.421 ' HB2' ' CG1' ' A' ' 176' ' ' VAL . . . -102.93 129.24 49.58 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.09 179.853 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 19.4 m -161.58 145.11 12.55 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.838 -179.775 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 190' ' ' LEU . . . . . 0.431 HD23 ' CD1' ' A' ' 173' ' ' ILE . 4.3 pp -118.31 158.65 24.82 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.918 179.987 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.305 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.481 179.884 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 8.7 tp . . . . . 0 C--O 1.231 0.127 0 CA-C-O 120.866 0.365 . . . . 0.0 110.894 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 96.0 t -97.85 131.76 44.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.138 179.847 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.641 ' CD1' ' CE2' ' A' ' 160' ' ' TYR . 34.5 t80 -130.27 117.43 19.81 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.845 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 69.1 t -114.73 135.54 54.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.143 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . 0.449 ' CG1' ' HB3' ' A' ' 158' ' ' SER . 35.2 m -124.2 168.57 16.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.123 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 81.93 47.15 6.35 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.508 179.999 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 38.0 mt -113.45 137.76 51.08 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.888 0.375 . . . . 0.0 110.931 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 117' ' ' SER . . . . . 0.406 ' O ' ' N ' ' A' ' 120' ' ' LEU . 38.4 t -63.8 141.36 58.8 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.887 -179.915 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 37.0 tt0 -39.26 -37.71 0.45 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.939 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 33.8 tpt85 -79.33 -40.82 29.37 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.874 -179.914 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 120' ' ' LEU . . . . . 0.406 ' N ' ' O ' ' A' ' 117' ' ' SER . 35.8 mt -62.27 -35.88 80.34 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.931 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -66.24 82.99 0.09 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.108 179.787 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 13.1 m-20 -148.06 148.35 29.37 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.555 0.693 . . . . 0.0 110.895 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 -44.34 2.15 Favored 'Trans proline' 0 N--CA 1.465 -0.165 0 C-N-CA 122.711 2.274 . . . . 0.0 112.353 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -71.87 -39.64 69.5 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.901 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.587 ' O ' ' CD1' ' A' ' 131' ' ' TYR . 37.9 t -62.55 -45.32 99.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.133 -179.989 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . 0.412 HD23 ' CD1' ' A' ' 132' ' ' PHE . 67.0 mt -74.43 -40.92 61.65 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.891 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 31.6 mttt -58.32 -31.83 67.92 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.904 179.828 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 15.8 mmt85 -44.24 143.5 1.9 Allowed Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.617 0.722 . . . . 0.0 110.888 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.69 -0.56 7.03 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.72 2.28 . . . . 0.0 112.375 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 25.6 mp0 -101.46 -26.99 13.38 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.892 -179.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 131' ' ' TYR . . . . . 0.587 ' CD1' ' O ' ' A' ' 125' ' ' VAL . 39.8 m-85 -88.76 -75.15 0.44 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.921 -179.852 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.412 ' CD1' HD23 ' A' ' 126' ' ' LEU . 10.8 m-85 -110.45 -46.17 3.44 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.872 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -47.7 -21.21 1.37 Allowed Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.501 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . 0.498 ' HD2' ' CD1' ' A' ' 135' ' ' PHE . 0.0 OUTLIER -53.88 -34.99 61.05 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.79 0.329 . . . . 0.0 110.884 -179.995 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 135' ' ' PHE . . . . . 0.498 ' CD1' ' HD2' ' A' ' 134' ' ' LYS . 70.8 m-85 -71.1 -46.03 62.52 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.905 179.958 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -172.6 -127.93 1.01 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.504 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -117.02 138.8 51.34 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.797 0.332 . . . . 0.0 110.938 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 82.1 mt -100.03 139.77 20.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.13 179.913 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 52.2 t60 -91.04 -54.14 4.08 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.852 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 35.9 ttpt -144.68 144.24 31.13 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.938 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 46.8 t -123.6 145.82 29.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.12 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 59.1 t -136.08 134.77 50.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.095 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 37.1 mm -110.47 132.46 58.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.092 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 43.6 t-20 -126.78 124.14 39.0 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.877 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 16.7 t-20 . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.883 -179.999 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 83.3 p . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.831 0.348 . . . . 0.0 110.917 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -114.74 156.24 25.2 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.12 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 158' ' ' SER . . . . . 0.463 ' HB2' ' CE1' ' A' ' 112' ' ' PHE . 22.0 p -128.37 174.12 9.59 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.859 -179.766 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -159.89 141.28 12.66 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.105 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 160' ' ' TYR . . . . . 0.641 ' CE2' ' CD1' ' A' ' 112' ' ' PHE . 35.5 m-85 -100.97 144.5 29.84 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.896 -179.848 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.414 HG11 ' N ' ' A' ' 162' ' ' THR . 80.2 t -132.19 135.49 58.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.156 179.879 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 162' ' ' THR . . . . . 0.414 ' N ' HG11 ' A' ' 161' ' ' VAL . 38.2 m -112.42 118.92 36.51 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.161 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 20.0 m-85 -102.44 143.89 31.6 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.953 -179.914 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 60.6 mt -68.19 -45.52 82.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.162 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 19.5 mtm180 -97.71 118.24 33.8 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.881 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 41.9 t -51.53 -58.5 6.13 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.846 -179.782 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 16.5 tt0 -42.4 -53.03 4.41 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.9 -179.938 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -51.85 -51.27 57.9 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.833 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -53.37 -63.27 1.2 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.077 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 39.5 mt -38.38 -57.83 1.08 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.905 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 171' ' ' ARG . . . . . 0.427 ' O ' ' N ' ' A' ' 174' ' ' GLN . 54.2 mtp180 -58.14 -57.97 10.5 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.873 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -37.67 -35.81 0.15 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.132 179.873 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 73.6 mt -82.47 -41.13 17.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.118 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 174' ' ' GLN . . . . . 0.427 ' N ' ' O ' ' A' ' 171' ' ' ARG . 15.0 mm100 -57.23 -28.28 62.76 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.895 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 3.4 t -93.77 -39.34 10.8 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.88 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 176' ' ' VAL . . . . . 0.455 ' O ' ' CG2' ' A' ' 179' ' ' VAL . 10.9 t -59.52 -48.51 87.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.132 -179.947 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 10.5 t-20 -59.08 139.12 57.2 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.893 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 4.7 t-20 70.25 45.91 0.63 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.876 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 179' ' ' VAL . . . . . 0.455 ' CG2' ' O ' ' A' ' 176' ' ' VAL . 84.3 t -125.18 137.72 56.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.138 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 95.6 t -96.51 98.57 7.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.155 179.922 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 47.7 t -111.11 111.82 37.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.169 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 57.12 42.81 25.15 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.88 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 67.03 35.08 88.74 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.511 -179.89 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 81.9 mtt85 -143.03 136.43 28.38 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.876 0.369 . . . . 0.0 110.906 -179.889 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 23.1 m -92.22 92.19 8.09 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.129 -179.885 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 44.8 mt -61.62 125.11 22.63 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.917 179.929 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 36.0 mmtt -103.09 114.01 27.95 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.862 179.848 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -111.35 132.52 54.35 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.109 179.837 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 16.8 m -149.81 145.28 26.51 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.843 -179.788 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 190' ' ' LEU . . . . . . . . . . . . . 1.3 pt? -123.81 151.1 43.73 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.932 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.296 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.518 179.911 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 17.1 tp . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.861 0.362 . . . . 0.0 110.93 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 87.9 t -115.6 132.62 64.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.152 179.86 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.568 ' CE2' ' CG1' ' A' ' 114' ' ' VAL . 50.3 t80 -128.65 106.68 9.12 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.871 -179.936 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 55.9 t -103.46 122.05 55.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.12 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . 0.568 ' CG1' ' CE2' ' A' ' 112' ' ' PHE . 18.7 m -110.66 152.65 12.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.111 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 94.2 37.7 5.31 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.524 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 30.0 mt -101.64 134.38 44.86 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.834 0.35 . . . . 0.0 110.889 -179.907 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 117' ' ' SER . . . . . 0.437 ' O ' ' N ' ' A' ' 120' ' ' LEU . 24.4 t -68.71 141.33 55.33 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.874 -179.932 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 43.6 tt0 -42.27 -25.7 0.08 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.881 -179.926 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 6.3 tpm_? -89.83 -36.32 15.17 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.83 -179.914 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 120' ' ' LEU . . . . . 0.437 ' N ' ' O ' ' A' ' 117' ' ' SER . 32.2 mt -70.25 -32.25 70.01 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.879 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -70.19 84.67 0.55 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.117 179.77 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -146.31 146.71 28.64 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.588 0.709 . . . . 0.0 110.838 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 -46.23 1.28 Allowed 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.666 2.244 . . . . 0.0 112.333 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -70.64 -38.13 73.85 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.875 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.484 ' O ' ' CD1' ' A' ' 131' ' ' TYR . 87.3 t -65.76 -50.84 68.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.085 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . 0.499 HD22 ' CE1' ' A' ' 132' ' ' PHE . 89.8 mt -68.41 -37.16 80.08 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.901 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 27.6 mttm -62.25 -37.46 85.53 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.863 179.874 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 2.5 mmp_? -43.29 143.88 1.32 Allowed Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.607 0.718 . . . . 0.0 110.839 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 -4.28 13.72 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.651 2.234 . . . . 0.0 112.338 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 1.3 tm-20 -94.18 -16.26 23.86 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.918 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 131' ' ' TYR . . . . . 0.484 ' CD1' ' O ' ' A' ' 125' ' ' VAL . 61.8 m-85 -102.53 -72.06 0.7 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.929 -179.857 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.499 ' CE1' HD22 ' A' ' 126' ' ' LEU . 61.1 m-85 -122.44 -39.6 2.55 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.862 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -41.24 -26.43 0.19 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.484 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . 0.406 ' N ' ' O ' ' A' ' 132' ' ' PHE . 8.5 ptmm? -47.0 -39.13 11.94 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.808 0.337 . . . . 0.0 110.946 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 135' ' ' PHE . . . . . 0.534 ' CE1' ' HA ' ' A' ' 172' ' ' ALA . 66.0 m-85 -63.18 -45.6 91.01 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.87 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 173.58 -148.19 10.03 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.483 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 16.6 tttm -95.42 115.71 27.8 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.828 0.347 . . . . 0.0 110.93 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 86.2 mt -71.63 140.09 18.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.109 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 34.3 t-80 -82.12 -59.62 2.5 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.883 179.871 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 140' ' ' LYS . . . . . 0.407 ' HG3' ' N ' ' A' ' 141' ' ' VAL . 39.9 tptt -140.13 151.22 45.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.966 179.942 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . 0.407 ' N ' ' HG3' ' A' ' 140' ' ' LYS . 88.3 t -136.97 122.42 26.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.133 179.933 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 43.7 t -125.9 120.23 56.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.132 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 18.2 mm -86.57 136.71 22.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.133 179.902 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 2.3 m-80 -128.48 134.35 48.7 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.897 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 88.5 m-20 . . . . . 0 C--N 1.329 -0.312 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.87 -179.976 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 21.1 m . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.867 0.365 . . . . 0.0 110.864 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -116.04 164.17 14.83 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.091 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 158' ' ' SER . . . . . 0.403 ' HB2' ' CE1' ' A' ' 112' ' ' PHE . 51.1 p -139.58 158.68 43.71 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.882 -179.827 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -139.71 145.0 37.8 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.081 179.878 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 160' ' ' TYR . . . . . 0.471 ' CZ ' ' CD1' ' A' ' 112' ' ' PHE . 89.1 m-85 -104.73 125.95 51.32 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.918 -179.841 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 85.7 t -122.11 130.92 74.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.133 179.895 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 20.6 m -111.53 129.79 55.94 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.122 -179.908 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 33.4 m-85 -105.27 160.0 15.44 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.918 -179.93 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 63.0 mt -84.51 -58.82 3.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.147 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 22.2 mmt180 -85.85 125.38 33.25 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.866 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 17.4 m -49.19 -60.55 2.7 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.878 -179.797 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 29.1 tt0 -40.89 -54.91 2.61 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.91 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 7.4 t70 -49.68 -49.91 45.62 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.901 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -57.67 -54.18 49.8 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.132 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 35.8 mt -44.09 -60.96 1.64 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.883 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 85.5 mtt180 -58.84 -42.99 90.6 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.892 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . 0.534 ' HA ' ' CE1' ' A' ' 135' ' ' PHE . . . -49.42 -35.24 18.55 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.096 179.939 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 82.6 mt -86.47 -40.7 14.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.153 179.97 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 77.3 mt-30 -62.39 -27.19 68.91 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.923 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 16.1 m -93.79 -42.21 9.25 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.941 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 176' ' ' VAL . . . . . 0.495 ' CG2' ' O ' ' A' ' 172' ' ' ALA . 9.9 t -59.05 -40.48 80.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.137 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 177' ' ' ASN . . . . . 0.435 ' C ' ' OD1' ' A' ' 177' ' ' ASN . 0.8 OUTLIER -66.49 145.18 55.93 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.916 179.982 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 19.1 t30 68.85 41.61 1.5 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.85 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 95.3 t -121.61 133.12 69.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.112 179.886 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 87.8 t -98.6 103.02 14.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.121 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 97.8 t -111.6 116.39 52.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.111 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER 47.4 43.09 15.13 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.911 179.947 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 71.22 31.29 66.41 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.464 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 32.0 mtp85 -137.09 109.42 7.33 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.883 0.373 . . . . 0.0 110.886 -179.884 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 29.7 m -71.78 92.35 1.21 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.163 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 62.7 mt -60.48 132.86 55.22 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.936 179.963 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -124.89 115.45 20.65 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.865 179.87 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -107.25 144.06 34.6 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.135 179.801 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 2.4 t -146.58 168.57 20.93 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.869 -179.763 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 190' ' ' LEU . . . . . 0.516 ' N ' ' CD1' ' A' ' 190' ' ' LEU . 0.0 OUTLIER -125.79 161.46 27.33 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.94 179.995 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.346 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.494 179.901 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 20.0 tp . . . . . 0 C--O 1.231 0.087 0 CA-C-O 120.903 0.382 . . . . 0.0 110.875 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 90.7 t -118.51 123.35 71.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.114 179.856 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.424 ' CD1' ' CZ ' ' A' ' 160' ' ' TYR . 39.2 t80 -113.34 126.06 54.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.853 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 55.6 t -119.74 141.07 41.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.128 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 19.8 m -119.73 171.76 7.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.134 179.889 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 73.75 53.56 7.2 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.514 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 29.7 mt -116.25 126.32 53.43 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.827 0.346 . . . . 0.0 110.9 -179.9 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 89.0 p -64.58 153.08 40.32 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.865 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 44.6 tt0 -52.6 -26.53 13.73 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.907 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -87.19 -43.29 12.34 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.88 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 51.9 mt -66.52 -21.16 66.17 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.964 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -71.68 82.99 0.87 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.123 179.755 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -148.98 144.01 17.65 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-O 121.63 0.729 . . . . 0.0 110.893 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -50.51 0.46 Allowed 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.728 2.285 . . . . 0.0 112.339 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 35.0 mt-10 -69.43 -45.39 69.27 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.859 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.592 ' O ' ' CD1' ' A' ' 131' ' ' TYR . 53.5 t -57.94 -42.33 82.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.156 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 77.0 mt -72.47 -44.73 61.91 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.87 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 12.0 ttpp -59.17 -35.13 72.99 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.881 179.853 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 38.4 mtt-85 -38.58 144.6 0.39 Allowed Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.567 0.699 . . . . 0.0 110.889 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.73 0.5 5.53 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.706 2.271 . . . . 0.0 112.329 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -104.98 -7.93 18.92 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.854 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 131' ' ' TYR . . . . . 0.592 ' CD1' ' O ' ' A' ' 125' ' ' VAL . 45.1 m-85 -111.47 -74.93 0.62 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.927 -179.861 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.435 ' O ' ' N ' ' A' ' 134' ' ' LYS . 14.2 m-85 -114.99 -36.34 4.46 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.886 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -42.56 -22.41 0.13 Allowed Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.486 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . 0.435 ' N ' ' O ' ' A' ' 132' ' ' PHE . 5.3 mtpt -49.22 -59.5 3.62 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.813 0.34 . . . . 0.0 110.896 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 135' ' ' PHE . . . . . 0.56 ' CE1' ' HA ' ' A' ' 172' ' ' ALA . 82.2 m-85 -47.89 -42.55 27.18 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.889 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 173.84 -168.31 41.12 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.487 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 13.5 tttt -82.68 117.6 22.73 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.751 0.31 . . . . 0.0 110.901 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 68.5 mt -77.0 144.88 11.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.167 179.859 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 9.8 t-80 -88.89 -57.62 2.84 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.879 179.846 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 42.4 tttt -142.13 149.24 39.54 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.894 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 59.7 t -133.67 140.74 45.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.144 179.855 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 84.3 t -134.66 129.79 52.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.154 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 51.9 mm -100.33 131.32 48.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.136 179.916 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 4.4 m-80 -128.67 117.45 21.21 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.881 179.961 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 3.0 p-10 . . . . . 0 C--N 1.329 -0.283 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.885 179.992 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 80.0 p . . . . . 0 C--O 1.23 0.064 0 CA-C-O 120.875 0.369 . . . . 0.0 110.855 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -91.3 168.56 11.49 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.081 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 7.2 m -130.63 168.14 17.61 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.872 -179.82 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -146.74 150.96 36.39 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.106 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 160' ' ' TYR . . . . . 0.424 ' CZ ' ' CD1' ' A' ' 112' ' ' PHE . 7.1 m-85 -116.48 123.01 46.42 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.949 -179.838 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.449 HG11 ' N ' ' A' ' 162' ' ' THR . 87.3 t -112.56 142.2 25.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.124 179.941 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 162' ' ' THR . . . . . 0.449 ' N ' HG11 ' A' ' 161' ' ' VAL . 32.9 m -113.36 118.3 34.2 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.141 -179.926 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 24.4 m-85 -98.57 150.19 21.98 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.907 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 57.4 mt -88.94 -42.09 14.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.158 179.905 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 75.4 mtp180 -94.67 119.31 33.11 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.895 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 29.3 m -49.2 -60.09 3.11 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.859 -179.776 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 19.5 mt-10 -42.92 -53.02 4.91 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.899 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -49.84 -49.05 50.53 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.849 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -56.62 -58.73 6.82 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.119 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 56.2 mt -41.0 -59.65 1.4 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.863 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 54.0 mtp180 -59.99 -44.23 94.65 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.91 179.948 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . 0.56 ' HA ' ' CE1' ' A' ' 135' ' ' PHE . . . -47.96 -36.12 11.98 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.11 179.937 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 64.7 mt -79.87 -42.67 22.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.085 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 40.3 mt-30 -65.26 -24.61 67.36 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.928 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 175' ' ' CYS . . . . . 0.494 ' O ' ' CG2' ' A' ' 179' ' ' VAL . 3.3 t -93.89 -38.94 10.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.849 -179.932 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 176' ' ' VAL . . . . . 0.421 ' CG2' ' O ' ' A' ' 172' ' ' ALA . 9.8 t -64.34 -26.97 41.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.139 -179.985 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 12.5 t30 -75.61 146.63 40.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.869 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 42.1 t30 59.89 41.43 17.85 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.887 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 179' ' ' VAL . . . . . 0.494 ' CG2' ' O ' ' A' ' 175' ' ' CYS . 85.9 t -121.12 135.96 59.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.133 179.917 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 180' ' ' VAL . . . . . 0.409 ' N ' HG11 ' A' ' 179' ' ' VAL . 99.7 t -104.15 122.98 57.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.147 179.895 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . 0.41 HG22 ' CD1' ' A' ' 186' ' ' LEU . 60.6 t -128.28 103.38 9.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.114 179.949 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 5.9 m-20 55.24 37.82 29.47 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.857 179.91 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 81.02 36.78 20.81 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.476 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -141.55 121.36 13.53 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.893 0.378 . . . . 0.0 110.866 -179.855 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 27.6 m -84.23 92.9 8.07 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.144 -179.891 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 186' ' ' LEU . . . . . 0.41 ' CD1' HG22 ' A' ' 181' ' ' VAL . 88.5 mt -69.59 120.74 15.83 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.893 179.991 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 14.8 mtmm -121.51 122.89 40.73 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.892 179.8 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -107.7 146.18 32.43 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.104 179.834 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 53.2 m -139.05 169.52 17.64 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.862 -179.821 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 190' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -127.8 125.73 40.38 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.942 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.283 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.493 179.915 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 26.2 tp . . . . . 0 C--O 1.231 0.106 0 CA-C-O 120.894 0.378 . . . . 0.0 110.873 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 99.5 t -106.48 109.68 28.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.213 179.775 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.483 ' CZ ' ' CG1' ' A' ' 114' ' ' VAL . 40.4 t80 -100.64 107.09 18.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.924 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 75.0 t -106.35 138.57 31.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.139 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . 0.483 ' CG1' ' CZ ' ' A' ' 112' ' ' PHE . 31.0 m -122.68 160.79 24.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.101 179.913 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 81.54 53.21 3.89 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.491 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 32.9 mt -106.17 120.74 42.61 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.778 0.323 . . . . 0.0 110.938 -179.903 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 117' ' ' SER . . . . . 0.42 ' O ' ' N ' ' A' ' 120' ' ' LEU . 26.3 t -64.65 142.82 58.29 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.883 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 118' ' ' GLN . . . . . 0.439 ' C ' ' CD ' ' A' ' 118' ' ' GLN . 0.7 OUTLIER -36.65 -43.71 0.43 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.917 -179.942 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 25.9 tpt180 -74.2 -42.32 59.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.852 -179.926 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 120' ' ' LEU . . . . . 0.42 ' N ' ' O ' ' A' ' 117' ' ' SER . 40.1 mt -61.49 -31.35 71.33 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.922 -179.987 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -68.5 83.37 0.27 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.134 179.801 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 73.1 m-20 -148.96 143.18 16.79 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.574 0.702 . . . . 0.0 110.899 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.86 -50.78 0.42 Allowed 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.67 2.247 . . . . 0.0 112.335 -179.925 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -65.46 -51.33 60.91 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.881 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.644 ' CG1' ' CZ ' ' A' ' 131' ' ' TYR . 64.3 t -54.02 -46.59 65.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.112 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . 0.444 HD23 ' CE1' ' A' ' 132' ' ' PHE . 83.0 mt -66.99 -42.79 84.44 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.895 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 20.2 tttm -58.17 -40.46 81.51 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.884 179.845 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 34.6 mtp180 -38.24 143.29 0.43 Allowed Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.598 0.713 . . . . 0.0 110.872 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 1.53 4.37 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.626 2.217 . . . . 0.0 112.321 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 35.2 mm-40 -99.68 -27.99 13.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.848 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 131' ' ' TYR . . . . . 0.644 ' CZ ' ' CG1' ' A' ' 125' ' ' VAL . 55.7 m-85 -90.54 -68.27 0.8 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.92 -179.82 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.493 ' O ' ' N ' ' A' ' 134' ' ' LYS . 12.8 m-85 -116.95 -52.5 2.52 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.894 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . 0.402 ' C ' ' O ' ' A' ' 132' ' ' PHE . . . -37.8 -27.37 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.5 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . 0.493 ' N ' ' O ' ' A' ' 132' ' ' PHE . 19.5 ptmt -43.04 -49.64 6.09 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.814 0.34 . . . . 0.0 110.851 -179.93 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 135' ' ' PHE . . . . . 0.482 ' CZ ' HG21 ' A' ' 176' ' ' VAL . 58.0 m-85 -63.3 -47.38 82.51 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.915 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -173.61 -172.26 38.85 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.755 -0.735 . . . . 0.0 112.477 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 22.8 mtmm -79.23 122.93 26.92 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.777 0.322 . . . . 0.0 110.872 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.438 HG22 ' N ' ' A' ' 139' ' ' HIS . 87.7 mt -79.92 141.64 15.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.111 179.871 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 139' ' ' HIS . . . . . 0.438 ' N ' HG22 ' A' ' 138' ' ' ILE . 61.5 t-80 -91.02 -49.07 6.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.852 179.868 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 76.8 tttt -146.28 153.47 40.61 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.897 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 42.2 t -132.4 140.24 48.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.156 179.881 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 93.3 t -133.23 131.52 58.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.143 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 43.5 mm -111.67 121.99 65.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.138 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 11.1 t30 -114.49 118.69 34.5 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.89 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 28.5 m-80 . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.869 -179.992 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 90.0 p . . . . . 0 C--O 1.23 0.076 0 CA-C-O 120.9 0.381 . . . . 0.0 110.817 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -87.57 162.61 17.09 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.05 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 94.2 p -136.36 163.2 31.0 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.845 -179.813 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -146.76 148.77 32.29 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.067 179.917 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 11.0 m-85 -112.73 139.53 48.26 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.948 -179.873 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 71.4 t -130.3 121.43 51.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.16 179.896 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 87.2 m -99.52 129.0 45.66 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.13 -179.93 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 52.7 m-85 -110.37 147.07 34.68 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.906 -179.88 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 53.1 mt -67.42 -60.62 2.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.123 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 46.9 mtp85 -82.43 112.99 19.88 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.893 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 74.0 m -52.45 -49.38 64.74 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.882 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 16.5 tt0 -44.5 -55.64 4.93 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.921 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 64.8 m-20 -55.84 -45.86 78.29 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.858 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -58.48 -59.85 4.73 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.063 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 46.1 mt -42.65 -61.56 1.21 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.892 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 1.3 mpt_? -54.93 -50.38 68.99 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.835 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . 0.495 ' O ' ' CG2' ' A' ' 176' ' ' VAL . . . -43.52 -36.73 2.15 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.091 179.933 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 73.6 mt -78.77 -40.79 23.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.142 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 33.7 mt-30 -60.01 -30.22 69.0 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.915 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 1.8 m -93.8 -39.91 10.48 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.832 -179.895 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 176' ' ' VAL . . . . . 0.495 ' CG2' ' O ' ' A' ' 172' ' ' ALA . 10.6 t -59.56 -45.43 94.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.156 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 177' ' ' ASN . . . . . 0.448 ' OD1' ' N ' ' A' ' 178' ' ' ASN . 37.0 t30 -53.92 146.17 14.79 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.909 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 178' ' ' ASN . . . . . 0.448 ' N ' ' OD1' ' A' ' 177' ' ' ASN . 10.4 m120 57.83 47.26 15.61 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.891 -180.0 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 95.3 t -132.43 139.76 49.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.145 179.893 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 95.4 t -93.97 114.02 29.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.101 179.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 96.0 t -120.86 105.87 17.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.156 179.879 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 6.5 t0 65.62 35.32 7.13 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.878 179.928 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 81.19 -14.03 29.83 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.493 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 10.6 mpt_? -102.94 112.7 25.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.867 0.365 . . . . 0.0 110.863 -179.869 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 25.3 m -70.9 93.7 1.0 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.17 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 83.3 mt -70.97 149.5 46.61 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.947 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 13.5 ttpt -136.36 126.45 26.18 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.928 179.863 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -112.38 141.91 45.54 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.139 179.801 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 8.5 t -139.86 165.56 26.99 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.868 -179.748 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 190' ' ' LEU . . . . . . . . . . . . . 38.1 tp -127.14 135.82 51.24 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.918 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.498 179.875 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 41.4 tp . . . . . 0 C--O 1.23 0.062 0 CA-C-O 120.896 0.379 . . . . 0.0 110.904 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 94.7 t -116.78 119.43 61.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.112 179.852 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.559 ' CE1' ' HB2' ' A' ' 158' ' ' SER . 48.2 t80 -113.67 109.64 18.91 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.861 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 68.1 t -106.32 146.5 12.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.121 179.932 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 32.9 m -132.03 170.69 19.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.086 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 78.29 45.49 9.95 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.455 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 32.4 mt -117.91 136.79 53.24 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.877 0.37 . . . . 0.0 110.955 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 117' ' ' SER . . . . . 0.483 ' O ' ' N ' ' A' ' 119' ' ' ARG . 15.3 p -82.33 140.51 33.51 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.862 -179.892 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 118' ' ' GLN . . . . . 0.424 ' C ' ' O ' ' A' ' 117' ' ' SER . 82.8 mm-40 -35.02 -33.02 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.878 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.483 ' N ' ' O ' ' A' ' 117' ' ' SER . 72.8 mtm-85 -68.85 -50.22 51.69 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.827 -179.869 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 120' ' ' LEU . . . . . 0.462 ' N ' ' O ' ' A' ' 117' ' ' SER . 36.0 mt -70.97 -38.96 72.77 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.927 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -60.14 83.48 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.116 179.823 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 122' ' ' ASP . . . . . 0.4 ' N ' ' O ' ' A' ' 120' ' ' LEU . 6.0 m-20 -147.18 145.82 23.37 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.623 0.725 . . . . 0.0 110.888 179.962 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.76 -40.02 5.82 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.736 2.291 . . . . 0.0 112.327 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . 0.421 ' HG3' ' N ' ' A' ' 125' ' ' VAL . 16.8 pt-20 -75.8 -50.23 15.79 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.883 -179.967 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.45 HG12 ' CE2' ' A' ' 131' ' ' TYR . 53.2 t -56.51 -41.38 72.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.101 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 71.5 mt -74.68 -37.22 62.73 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.893 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.452 ' HA ' ' CD1' ' A' ' 138' ' ' ILE . 35.2 mttm -65.39 -22.9 66.84 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.906 179.832 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 64.1 mtt180 -48.5 143.75 7.27 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.571 0.701 . . . . 0.0 110.908 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 1.35 4.5 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.708 2.272 . . . . 0.0 112.335 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 26.9 mp0 -103.95 -42.02 5.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.908 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 131' ' ' TYR . . . . . 0.45 ' CE2' HG12 ' A' ' 125' ' ' VAL . 37.5 m-85 -72.77 -75.14 0.15 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.932 -179.872 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 45.6 m-85 -116.35 -32.85 5.15 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.867 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -52.49 -15.28 2.81 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.514 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 16.8 ptmt -67.7 -42.83 81.38 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.79 0.329 . . . . 0.0 110.895 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 135' ' ' PHE . . . . . 0.553 ' CE1' ' HA ' ' A' ' 172' ' ' ALA . 29.3 m-85 -60.63 -45.69 93.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.888 179.939 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -179.24 167.54 37.7 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.518 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 8.0 tmtm? -61.03 131.91 52.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.732 0.301 . . . . 0.0 110.878 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.452 ' CD1' ' HA ' ' A' ' 127' ' ' LYS . 95.1 mt -93.0 142.28 13.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.111 179.876 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 38.4 t60 -104.9 -59.6 1.72 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.803 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -129.17 136.52 50.26 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.916 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . 0.424 ' CG2' HG22 ' A' ' 138' ' ' ILE . 47.1 t -129.36 139.76 50.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.179 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 5.4 t -132.18 140.19 48.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.117 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 42.1 mm -114.48 121.42 66.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.159 179.926 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 7.5 m-80 -115.67 113.39 23.45 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.933 179.916 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 53.6 p30 . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.879 -179.974 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 31.2 p . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.86 0.362 . . . . 0.0 110.859 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -95.03 163.4 13.32 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.059 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 158' ' ' SER . . . . . 0.559 ' HB2' ' CE1' ' A' ' 112' ' ' PHE . 58.9 p -134.46 164.83 26.58 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.813 -179.757 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -147.15 136.43 22.58 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.108 179.898 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 160' ' ' TYR . . . . . 0.479 ' CE2' ' CD1' ' A' ' 112' ' ' PHE . 11.9 m-85 -104.96 113.11 26.51 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.902 -179.812 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.429 HG12 ' N ' ' A' ' 162' ' ' THR . 50.0 t -108.16 139.48 30.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.132 179.915 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 162' ' ' THR . . . . . 0.429 ' N ' HG12 ' A' ' 161' ' ' VAL . 54.3 m -106.56 126.58 52.45 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.146 -179.992 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 15.4 m-85 -109.02 127.79 54.4 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.947 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 64.8 mt -59.48 -52.18 63.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.145 179.889 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 33.4 mtp85 -84.98 110.36 18.84 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.834 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 166' ' ' SER . . . . . 0.416 ' O ' ' C ' ' A' ' 167' ' ' GLU . 68.5 m -49.73 -64.72 0.72 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.833 -179.808 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 167' ' ' GLU . . . . . 0.416 ' C ' ' O ' ' A' ' 166' ' ' SER . 15.3 mt-10 -37.29 -57.69 0.87 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.899 -179.961 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -51.22 -47.74 62.24 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.895 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -54.77 -58.61 6.87 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.08 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 41.1 mt -46.21 -56.95 4.99 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.879 -179.924 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 6.6 mpt_? -55.19 -51.86 65.17 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.856 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . 0.553 ' HA ' ' CE1' ' A' ' 135' ' ' PHE . . . -47.52 -33.04 5.87 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.06 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 56.9 mt -79.12 -34.38 16.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.124 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 44.7 mt-30 -70.69 -26.01 63.23 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.912 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 4.0 m -93.77 -36.11 12.44 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.932 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 9.8 t -67.94 -35.81 73.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.118 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 58.4 t30 -62.97 145.26 55.73 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.921 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 35.5 t30 55.62 51.68 12.21 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.916 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 76.7 t -125.89 142.37 42.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.104 179.934 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 91.3 t -104.24 105.12 17.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.128 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 85.7 t -119.11 105.01 16.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.174 179.921 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 1.6 t70 60.01 41.23 17.73 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.901 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 71.28 24.09 77.35 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.524 -179.932 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 3.5 mmp_? -126.93 114.23 17.58 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.884 0.373 . . . . 0.0 110.875 -179.837 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 7.8 m -70.7 103.19 2.49 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.122 -179.89 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 31.1 mt -71.52 126.1 28.78 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.934 179.932 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -131.02 114.55 15.33 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.89 179.837 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -118.54 137.62 53.1 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.046 179.862 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 7.3 t -125.89 166.78 16.26 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.875 -179.785 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 190' ' ' LEU . . . . . . . . . . . . . 9.0 tp -131.8 143.41 50.19 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.897 -179.97 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.345 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.547 179.925 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 13.9 tp . . . . . 0 C--O 1.232 0.162 0 CA-C-O 120.843 0.354 . . . . 0.0 110.931 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.566 HG23 ' CD1' ' A' ' 163' ' ' TYR . 77.9 t -103.44 108.02 23.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.103 179.867 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.451 ' CD1' ' CE1' ' A' ' 160' ' ' TYR . 47.2 t80 -106.56 113.86 27.63 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.875 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 32.7 t -112.61 137.94 43.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.163 179.927 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 23.1 m -121.36 166.22 16.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.125 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 73.38 55.69 6.01 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.493 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 32.3 mt -117.81 127.76 54.2 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.813 0.339 . . . . 0.0 110.894 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 11.8 m -63.78 136.01 57.1 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.846 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 118' ' ' GLN . . . . . 0.454 ' OE1' ' ND2' ' A' ' 145' ' ' ASN . 4.8 tp-100 -41.97 -27.28 0.12 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.884 -179.974 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 1.8 mpt_? -78.4 -48.27 15.85 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.901 -179.932 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 42.8 mt -66.22 -38.7 88.56 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.932 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -60.91 88.12 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.069 179.839 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 24.9 m-20 -148.65 149.54 31.21 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.635 0.731 . . . . 0.0 110.852 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.82 -43.39 2.64 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.675 2.25 . . . . 0.0 112.325 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 27.6 mt-10 -76.39 -41.86 46.44 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.857 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.626 ' CG1' ' CZ ' ' A' ' 131' ' ' TYR . 74.3 t -60.24 -48.06 89.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.127 -179.987 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 42.3 mt -70.26 -40.25 74.49 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.886 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 32.1 mttm -61.54 -35.89 79.04 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.864 179.854 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 48.7 mtt85 -43.9 143.41 1.74 Allowed Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.592 0.711 . . . . 0.0 110.875 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 -3.54 12.19 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.707 2.272 . . . . 0.0 112.362 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -94.96 -36.13 11.71 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.944 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 131' ' ' TYR . . . . . 0.626 ' CZ ' ' CG1' ' A' ' 125' ' ' VAL . 57.1 m-85 -80.21 -74.23 0.32 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.888 -179.841 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.487 ' O ' ' N ' ' A' ' 134' ' ' LYS . 14.6 m-85 -116.9 -44.84 2.79 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.915 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . 0.439 ' C ' ' O ' ' A' ' 132' ' ' PHE . . . -35.39 -31.06 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.515 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . 0.487 ' N ' ' O ' ' A' ' 132' ' ' PHE . 16.6 ptmt -45.86 -48.77 15.89 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.812 0.339 . . . . 0.0 110.887 -179.995 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 135' ' ' PHE . . . . . 0.549 ' CD2' ' HA ' ' A' ' 172' ' ' ALA . 78.9 m-85 -61.69 -43.91 97.95 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.882 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -173.94 -174.54 40.91 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.491 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 29.5 mtmt -90.09 102.18 14.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.753 0.311 . . . . 0.0 110.845 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 58.1 mt -61.33 148.38 9.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.104 179.847 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 61.4 t60 -101.55 -57.55 2.06 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.875 179.837 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 40.2 tttm -123.17 143.8 49.77 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.904 179.916 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 58.5 t -135.91 118.45 21.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.135 179.89 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 83.9 t -117.32 134.72 60.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.128 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 3.3 mm -106.46 125.39 62.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.129 179.923 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 4.4 m-80 -117.87 104.36 10.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.947 179.87 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 145' ' ' ASN . . . . . 0.454 ' ND2' ' OE1' ' A' ' 118' ' ' GLN . 35.4 m120 . . . . . 0 C--N 1.33 -0.277 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.893 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 58.1 m . . . . . 0 C--O 1.231 0.107 0 CA-C-O 120.874 0.368 . . . . 0.0 110.848 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -106.5 165.32 11.36 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.064 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 79.0 p -130.12 167.38 18.44 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.842 -179.767 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -155.68 136.21 13.29 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.137 179.9 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 160' ' ' TYR . . . . . 0.451 ' CE1' ' CD1' ' A' ' 112' ' ' PHE . 98.3 m-85 -99.4 133.14 44.15 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.926 -179.869 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 75.2 t -125.6 122.28 62.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.179 179.893 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 87.4 m -94.97 124.18 38.87 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.197 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 163' ' ' TYR . . . . . 0.566 ' CD1' HG23 ' A' ' 111' ' ' VAL . 14.0 m-85 -100.2 147.77 25.35 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.925 -179.897 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 52.0 mt -73.5 -41.74 56.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.154 179.871 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 13.3 mmm180 -105.18 133.41 49.99 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.862 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 71.5 m -63.05 -68.18 0.36 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.834 -179.722 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 4.9 tp10 -42.93 -58.45 2.4 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.884 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -47.16 -46.48 23.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.921 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -58.98 -61.53 2.57 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.119 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . 0.434 ' CD2' HD21 ' A' ' 190' ' ' LEU . 59.0 mt -39.21 -52.75 1.94 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.914 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 171' ' ' ARG . . . . . 0.431 ' O ' ' N ' ' A' ' 174' ' ' GLN . 86.1 mtt180 -59.44 -58.61 7.83 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.898 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . 0.549 ' HA ' ' CD2' ' A' ' 135' ' ' PHE . . . -41.02 -35.59 0.56 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.098 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 173' ' ' ILE . . . . . 0.457 ' CG1' HG21 ' A' ' 111' ' ' VAL . 58.5 mt -76.89 -37.58 27.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.074 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 174' ' ' GLN . . . . . 0.431 ' N ' ' O ' ' A' ' 171' ' ' ARG . 61.5 mt-30 -64.68 -21.42 66.73 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.883 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 3.9 m -93.83 -40.39 10.2 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.873 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 9.1 t -62.45 -38.36 81.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.115 -179.984 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 5.1 t-20 -60.71 140.36 57.55 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.887 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 15.6 t-20 65.2 50.74 1.75 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.91 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 71.1 t -124.78 142.04 42.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.061 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 83.3 t -96.25 110.68 25.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.16 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 48.7 t -120.02 106.02 18.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.125 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 53.77 43.47 30.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.881 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 71.19 30.83 66.91 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.454 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 32.9 mtt-85 -138.24 122.71 18.41 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.882 0.372 . . . . 0.0 110.902 -179.874 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 17.7 m -82.47 96.91 8.15 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.143 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 95.8 mt -74.45 132.71 42.16 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.937 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 47.8 mttt -117.87 132.22 56.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.941 179.8 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -123.53 147.27 47.42 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.106 179.857 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 68.0 m -158.06 162.62 38.09 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.856 -179.806 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 190' ' ' LEU . . . . . 0.434 HD21 ' CD2' ' A' ' 170' ' ' LEU . 4.5 pp -129.77 156.33 44.49 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.894 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.337 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.507 179.867 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 14.1 tp . . . . . 0 C--O 1.23 0.059 0 CA-C-O 120.86 0.362 . . . . 0.0 110.877 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 41.4 t -95.49 104.22 15.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.15 179.815 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.579 ' CD1' ' CE2' ' A' ' 160' ' ' TYR . 39.5 t80 -94.08 122.36 36.51 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.848 -179.948 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 42.3 t -117.82 133.55 64.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.145 179.92 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . 0.429 ' CG1' ' CE2' ' A' ' 112' ' ' PHE . 11.9 m -120.4 166.64 14.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.125 179.899 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 67.0 53.53 26.24 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.506 179.983 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 34.9 mt -105.98 146.57 29.89 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.844 0.354 . . . . 0.0 110.846 -179.86 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 29.2 m -77.35 153.98 33.24 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.801 -179.908 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 84.9 mm-40 -56.55 -44.9 81.37 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.892 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 10.6 ttt180 -74.38 -44.96 49.85 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.897 -179.925 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 66.2 mt -66.89 -24.84 66.16 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.932 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -76.06 83.71 2.93 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.11 179.773 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -148.3 150.34 34.32 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-O 121.62 0.724 . . . . 0.0 110.857 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.83 -50.62 0.44 Allowed 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.668 2.245 . . . . 0.0 112.319 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 7.0 mm-40 -65.35 -41.91 93.38 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.89 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.629 ' CG1' ' CZ ' ' A' ' 131' ' ' TYR . 85.9 t -61.79 -42.68 95.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.128 179.975 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . 0.537 HD23 ' CE1' ' A' ' 132' ' ' PHE . 79.4 mt -74.33 -40.32 62.25 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.929 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.447 ' HA ' ' CD1' ' A' ' 138' ' ' ILE . 43.0 tttt -61.03 -31.25 70.89 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.873 179.837 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 72.6 mtt-85 -44.13 142.88 2.02 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.573 0.701 . . . . 0.0 110.873 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 0.8 5.14 Favored 'Trans proline' 0 C--N 1.341 0.136 0 C-N-CA 122.662 2.241 . . . . 0.0 112.375 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 5.0 tp10 -103.99 -36.01 7.9 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.915 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 131' ' ' TYR . . . . . 0.629 ' CZ ' ' CG1' ' A' ' 125' ' ' VAL . 38.8 m-85 -75.91 -75.02 0.2 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.962 -179.869 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.537 ' CE1' HD23 ' A' ' 126' ' ' LEU . 19.9 m-85 -114.86 -40.58 3.5 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.858 -179.996 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -52.23 -20.47 6.93 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.51 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . 0.423 ' C ' ' HD3' ' A' ' 134' ' ' LYS . 0.0 OUTLIER -53.54 -31.65 47.27 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.86 0.362 . . . . 0.0 110.903 -179.999 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 135' ' ' PHE . . . . . 0.537 ' CZ ' HG21 ' A' ' 176' ' ' VAL . 65.3 m-85 -73.21 -42.48 62.6 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.87 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -177.66 -163.41 29.41 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.47 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 16.9 mttp -79.58 142.14 35.95 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.774 0.321 . . . . 0.0 110.915 -179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.447 ' CD1' ' HA ' ' A' ' 127' ' ' LYS . 82.6 mt -105.25 132.19 52.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.146 179.899 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 3.8 t-160 -85.97 -59.64 2.24 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.857 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 73.6 tttt -132.72 146.1 51.58 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.936 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 24.2 t -129.38 130.08 67.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.153 179.876 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 96.1 t -134.34 147.49 30.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.133 179.879 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 15.3 mm -118.05 150.44 20.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.133 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 39.9 t30 -129.02 106.47 8.9 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.889 179.902 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 3.0 p30 . . . . . 0 C--N 1.329 -0.303 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.896 179.986 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 78.7 p . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.886 0.374 . . . . 0.0 110.825 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -112.28 164.81 12.79 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.082 179.911 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 14.8 m -133.16 164.55 26.8 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.87 -179.797 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -150.81 166.47 30.4 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.131 179.922 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 160' ' ' TYR . . . . . 0.579 ' CE2' ' CD1' ' A' ' 112' ' ' PHE . 11.6 m-85 -136.29 126.4 26.2 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.913 -179.821 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 67.0 t -126.72 146.13 33.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.09 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 82.2 m -108.35 134.16 51.55 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.192 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 7.9 m-85 -111.96 120.75 42.95 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.924 -179.867 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 88.7 mt -49.75 -50.86 17.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.102 179.918 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 24.9 mtp85 -88.1 109.72 20.09 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.883 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 5.3 t -48.85 -59.3 3.69 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.855 -179.772 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 23.8 mt-10 -47.94 -46.29 31.94 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.89 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 6.5 t0 -56.13 -45.12 79.68 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.829 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -55.75 -52.42 63.98 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.116 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 26.8 mt -51.38 -59.4 4.27 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.894 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 74.3 mtp180 -55.09 -49.23 72.22 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.903 179.909 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . 0.494 ' O ' ' CG2' ' A' ' 176' ' ' VAL . . . -50.08 -33.16 17.61 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.066 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 55.2 mt -76.65 -38.4 30.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.128 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 10.3 mm100 -65.66 -30.54 71.25 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.884 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 175' ' ' CYS . . . . . 0.444 ' O ' ' CG2' ' A' ' 179' ' ' VAL . 3.0 t -93.72 -27.33 16.58 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.85 -179.94 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 176' ' ' VAL . . . . . 0.537 HG21 ' CZ ' ' A' ' 135' ' ' PHE . 10.4 t -77.9 -26.28 14.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.181 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -79.09 154.15 29.61 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.855 -179.972 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 178' ' ' ASN . . . . . 0.438 ' O ' ' CG ' ' A' ' 178' ' ' ASN . 32.5 t30 55.23 36.27 26.67 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.881 179.978 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 179' ' ' VAL . . . . . 0.444 ' CG2' ' O ' ' A' ' 175' ' ' CYS . 92.3 t -108.84 141.98 22.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.109 179.919 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 53.7 t -106.2 97.1 5.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.121 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . 0.443 ' O ' ' CG ' ' A' ' 182' ' ' ASP . 40.0 t -102.41 118.34 49.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.143 179.941 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 182' ' ' ASP . . . . . 0.443 ' CG ' ' O ' ' A' ' 181' ' ' VAL . 2.9 p30 47.26 31.65 1.84 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.851 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 86.02 20.7 54.87 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.453 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 5.5 tpm_? -118.21 133.97 55.43 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.904 0.383 . . . . 0.0 110.882 -179.857 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 17.3 m -90.76 95.13 9.99 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.164 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 71.1 mt -74.8 128.33 35.3 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.892 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 2.8 mmmp? -128.79 121.7 28.92 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.887 179.822 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -119.4 156.52 29.98 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.087 179.859 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 8.5 t -147.76 165.28 31.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.857 -179.813 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 190' ' ' LEU . . . . . . . . . . . . . 1.6 tm? -132.2 137.58 47.65 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.877 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.299 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.441 179.83 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . 0.439 ' O ' ' CD2' ' A' ' 190' ' ' LEU . 9.4 tp . . . . . 0 C--O 1.231 0.092 0 CA-C-O 120.842 0.353 . . . . 0.0 110.941 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 69.5 t -108.95 106.67 21.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.131 179.899 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.511 ' CZ ' ' CG1' ' A' ' 114' ' ' VAL . 61.4 t80 -99.83 117.42 34.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.864 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 21.2 t -116.56 135.67 56.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.107 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . 0.511 ' CG1' ' CZ ' ' A' ' 112' ' ' PHE . 34.1 m -124.55 165.38 21.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.123 179.904 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 78.6 52.46 5.08 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.48 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 21.2 mt -109.16 133.67 52.72 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.85 0.357 . . . . 0.0 110.932 -179.917 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 40.2 t -66.53 147.83 52.74 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.853 -179.92 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.9 mt-30 -40.86 -47.3 2.91 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.917 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 39.3 mtp180 -71.47 -37.78 71.3 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.901 -179.922 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 51.7 mt -67.27 -26.7 66.68 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.943 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -74.01 83.81 1.76 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.098 179.763 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -148.99 142.99 16.56 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.592 0.711 . . . . 0.0 110.904 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.7 -49.26 0.59 Allowed 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.69 2.26 . . . . 0.0 112.359 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 51.4 mt-10 -69.48 -42.28 75.04 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.887 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.479 ' CG1' ' CZ ' ' A' ' 131' ' ' TYR . 60.3 t -59.16 -46.15 92.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.128 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 68.0 mt -69.81 -40.49 75.91 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.918 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 15.3 tttt -61.83 -27.88 69.09 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.937 179.809 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 13.8 mtp85 -45.24 143.6 2.52 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.632 0.729 . . . . 0.0 110.857 179.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 1.23 4.61 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.656 2.237 . . . . 0.0 112.347 -179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 7.1 tp10 -105.51 -35.55 7.42 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.931 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 131' ' ' TYR . . . . . 0.479 ' CZ ' ' CG1' ' A' ' 125' ' ' VAL . 38.0 m-85 -77.46 -75.11 0.22 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.911 -179.857 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 13.2 m-85 -116.23 -34.68 4.58 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.902 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -49.99 -23.9 5.93 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.527 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . 0.42 ' C ' ' HD3' ' A' ' 134' ' ' LYS . 0.0 OUTLIER -56.03 -34.07 65.51 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.788 0.328 . . . . 0.0 110.913 -179.959 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 135' ' ' PHE . . . . . 0.556 ' CE1' ' HA ' ' A' ' 172' ' ' ALA . 19.4 m-85 -69.89 -47.06 64.02 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.875 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -174.12 177.28 46.42 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.502 -179.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 5.8 mmmt -74.57 110.25 8.71 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.747 0.308 . . . . 0.0 110.893 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.403 HG22 ' CG1' ' A' ' 161' ' ' VAL . 56.8 mt -75.64 143.53 13.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.126 179.924 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 19.8 t-160 -99.2 -58.73 1.87 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.864 179.903 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -127.78 141.9 51.45 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.869 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 3.9 t -130.94 139.86 50.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.114 179.887 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 69.5 t -135.45 139.84 45.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.132 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 16.7 mm -112.13 114.71 47.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.143 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 1.6 t30 -99.94 127.46 46.13 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.897 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 2.1 p-10 . . . . . 0 C--N 1.33 -0.276 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.872 -179.987 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 53.9 p . . . . . 0 C--O 1.23 0.056 0 CA-C-O 120.874 0.369 . . . . 0.0 110.861 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -122.32 152.59 39.96 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.109 179.907 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 87.5 p -124.89 176.43 6.63 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.894 -179.818 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -160.7 162.06 32.45 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.125 179.891 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 160' ' ' TYR . . . . . 0.483 ' CE2' ' CD1' ' A' ' 112' ' ' PHE . 16.5 m-85 -125.61 127.56 46.53 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.921 -179.825 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.403 ' CG1' HG22 ' A' ' 138' ' ' ILE . 66.7 t -121.75 140.27 46.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.117 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 4.7 m -114.21 115.71 27.89 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.185 -179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 29.1 m-85 -90.47 134.2 34.51 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.928 -179.904 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 66.4 mt -59.36 -42.63 88.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.119 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 19.0 mtm-85 -99.57 112.04 24.31 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.877 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 2.7 t -48.86 -57.59 6.17 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.896 -179.822 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 32.7 tt0 -42.93 -52.46 5.15 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.88 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -52.34 -50.6 62.0 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.883 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 169' ' ' ALA . . . . . 0.401 ' O ' ' C ' ' A' ' 170' ' ' LEU . . . -54.77 -64.02 0.97 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.106 179.915 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . 0.401 ' C ' ' O ' ' A' ' 169' ' ' ALA . 55.9 mt -37.15 -58.54 0.79 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.888 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 171' ' ' ARG . . . . . 0.418 ' NH1' ' HB3' ' A' ' 171' ' ' ARG . 10.6 mtp-105 -60.61 -46.04 91.75 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.846 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . 0.556 ' HA ' ' CE1' ' A' ' 135' ' ' PHE . . . -47.38 -32.89 5.33 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.072 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 96.9 mt -82.85 -40.08 16.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.155 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 30.1 mt-30 -66.25 -23.28 66.38 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.893 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 1.8 t -93.9 -37.09 11.89 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.86 -179.927 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 9.0 t -70.18 -48.43 61.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.149 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 7.5 t30 -43.76 124.82 3.85 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.95 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 65.7 t30 70.62 52.03 0.32 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.898 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 54.5 t -134.12 135.34 54.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.123 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 83.4 t -86.96 120.57 36.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.119 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 85.0 t -124.7 116.54 47.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.1 179.948 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 34.3 t70 58.52 36.52 25.29 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.87 179.899 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 84.35 -20.17 15.17 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.456 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 43.0 ttm-85 -107.23 133.4 51.86 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.897 0.379 . . . . 0.0 110.861 -179.859 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 30.0 m -80.27 133.29 35.97 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.104 -179.884 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 27.4 mt -101.06 147.42 26.24 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.949 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -121.29 131.98 54.52 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.903 179.839 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -129.5 143.54 50.88 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.075 179.843 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 5.5 t -138.7 167.54 21.76 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.866 -179.785 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 190' ' ' LEU . . . . . 0.439 ' CD2' ' O ' ' A' ' 110' ' ' LEU . 2.0 tm? -132.61 128.9 38.13 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.925 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.346 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.447 179.878 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.306 0 N-CA-C 112.51 -0.236 . . . . 0.0 112.51 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 16.1 m -92.51 99.31 12.07 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.885 0.374 . . . . 0.0 110.845 -179.727 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 8.5 t -67.28 92.48 0.28 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.815 -179.773 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 174.84 46.26 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.473 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 73.5 m -45.51 -58.36 3.44 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.892 0.377 . . . . 0.0 110.837 -179.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 3.7 m -86.14 88.92 7.68 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.851 -179.793 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -99.08 -78.35 1.38 Allowed Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.486 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -72.49 121.21 19.24 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.789 0.328 . . . . 0.0 111.156 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 8.2 t -174.09 171.6 3.54 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.81 -179.76 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 22.9 m -85.4 150.45 3.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.114 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 86.5 mtm-85 -85.2 109.61 18.44 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.822 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 44.7 t -121.74 122.28 66.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.125 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 95.6 t -90.66 106.69 17.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.094 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 14.0 mm100 -114.66 88.56 2.89 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.858 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 74.8 mttt -88.79 -41.13 12.7 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.898 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 64.9 t30 -85.32 44.94 1.13 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.857 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 19.9 tp -136.06 117.55 14.79 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.898 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 79.5 t -92.64 110.7 23.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.187 179.804 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.417 ' CE1' ' HB2' ' A' ' 158' ' ' SER . 53.4 t80 -109.52 107.0 16.95 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.892 -179.931 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 69.4 t -108.73 142.57 20.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.149 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 22.4 m -126.43 171.74 14.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.136 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 69.54 48.37 44.19 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.493 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 30.9 mt -112.69 125.48 54.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.789 0.328 . . . . 0.0 110.916 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' SER . . . . . 0.423 ' O ' ' N ' ' A' ' 120' ' ' LEU . 26.9 t -71.79 141.4 49.69 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.895 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 36.5 tp60 -38.38 -32.33 0.07 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.9 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 15.7 mmt180 -70.79 -47.51 59.15 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.845 -179.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . 0.423 ' N ' ' O ' ' A' ' 117' ' ' SER . 58.7 mt -69.46 -32.74 71.85 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.913 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -64.46 83.79 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.14 179.779 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' ASP . . . . . 0.401 ' CB ' HG23 ' A' ' 125' ' ' VAL . 4.7 m-20 -148.66 144.06 17.96 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.59 0.709 . . . . 0.0 110.911 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.81 -45.55 1.52 Allowed 'Trans proline' 0 C--N 1.341 0.133 0 C-N-CA 122.684 2.256 . . . . 0.0 112.287 -179.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -71.48 -39.52 70.85 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.927 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.536 ' O ' ' CD1' ' A' ' 131' ' ' TYR . 74.6 t -63.21 -45.76 97.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.129 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . 0.488 HD21 ' CE1' ' A' ' 132' ' ' PHE . 95.6 mt -74.47 -34.91 63.26 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.889 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 53.0 mttt -64.61 -32.25 73.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.882 179.85 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 20.0 mmt180 -46.25 143.97 3.41 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.631 0.729 . . . . 0.0 110.85 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -4.21 13.56 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.665 2.243 . . . . 0.0 112.35 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 56.6 tt0 -100.67 -10.64 20.7 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.892 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' TYR . . . . . 0.536 ' CD1' ' O ' ' A' ' 125' ' ' VAL . 43.6 m-85 -103.17 -74.98 0.62 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.91 -179.864 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.488 ' CE1' HD21 ' A' ' 126' ' ' LEU . 28.2 m-85 -118.65 -40.62 2.87 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.898 179.988 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -47.93 -19.02 0.85 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.505 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.404 ' HD2' ' CD2' ' A' ' 135' ' ' PHE . 0.0 OUTLIER -51.52 -40.31 59.37 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.822 0.344 . . . . 0.0 110.914 -179.995 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' PHE . . . . . 0.514 ' CD2' ' HB3' ' A' ' 172' ' ' ALA . 47.8 m-85 -67.16 -44.06 80.68 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.896 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 176.94 169.66 38.47 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.544 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -60.63 136.76 58.16 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.745 0.307 . . . . 0.0 110.922 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 61.1 mt -96.64 148.82 5.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.114 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 56.4 t60 -101.02 -48.74 4.33 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.854 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 22.6 ttmt -134.98 140.54 45.77 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.879 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 15.9 t -132.73 112.75 19.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.159 179.814 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 93.8 t -116.77 137.73 49.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.116 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 4.1 mm -114.0 123.68 69.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.106 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 8.9 t-20 -113.03 114.02 26.29 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.901 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 6.2 p-10 -136.43 171.77 13.99 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.888 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 1.2 t -58.6 132.0 52.49 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.856 -179.877 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 93.5 m -81.07 -53.55 6.31 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.139 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 54.9 m -93.06 122.86 35.86 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.856 -179.852 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 5.8 t80 -108.55 120.05 41.32 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.898 -179.906 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -109.04 -52.91 2.71 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.068 -0.514 . . . . 0.0 111.072 179.882 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 109.09 36.83 2.08 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.469 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 1.8 m -102.35 -55.45 2.46 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.818 0.342 . . . . 0.0 110.877 -179.767 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 84.4 mt-30 -120.15 174.01 6.75 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.922 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . -108.41 83.25 0.33 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.503 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.8 177.25 5.79 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.698 2.265 . . . . 0.0 112.328 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 50.8 m -128.6 154.18 46.48 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.894 -179.889 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -114.41 166.46 11.66 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.103 179.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 158' ' ' SER . . . . . 0.417 ' HB2' ' CE1' ' A' ' 112' ' ' PHE . 4.8 p -134.93 150.99 50.48 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.865 -179.781 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -122.8 145.52 48.35 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.077 179.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 44.1 m-85 -119.42 107.16 13.0 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.945 -179.833 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.423 HG11 ' N ' ' A' ' 162' ' ' THR . 37.9 t -101.19 141.25 18.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.097 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 162' ' ' THR . . . . . 0.423 ' N ' HG11 ' A' ' 161' ' ' VAL . 63.0 m -111.22 123.33 49.98 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.093 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 30.5 m-85 -105.3 121.74 44.5 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.937 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . 0.412 HG23 ' NH1' ' A' ' 165' ' ' ARG . 74.2 mt -49.63 -37.14 11.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.137 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . 0.412 ' NH1' HG23 ' A' ' 164' ' ' ILE . 80.3 mmt-85 -107.11 114.75 29.0 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.898 179.93 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 69.0 m -51.68 -55.17 21.0 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.883 -179.803 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 24.8 mm-40 -42.96 -54.04 4.44 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.908 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -54.71 -46.11 74.13 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.871 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -60.84 -64.07 1.08 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.098 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 36.6 mt -38.28 -63.62 0.48 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.922 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 86.5 mtt180 -52.8 -51.85 59.19 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.873 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . 0.514 ' HB3' ' CD2' ' A' ' 135' ' ' PHE . . . -45.06 -32.88 1.88 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.096 179.904 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 82.2 mt -81.72 -35.28 13.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.091 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 33.4 mt-30 -64.69 -27.65 69.06 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.906 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 175' ' ' CYS . . . . . 0.441 ' O ' ' CG2' ' A' ' 179' ' ' VAL . 2.3 m -93.82 -34.29 13.22 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.87 -179.927 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 10.8 t -63.29 -33.74 62.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.147 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 177' ' ' ASN . . . . . 0.437 ' ND2' ' N ' ' A' ' 178' ' ' ASN . 1.1 t-20 -62.55 140.99 58.65 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.89 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 178' ' ' ASN . . . . . 0.437 ' N ' ' ND2' ' A' ' 177' ' ' ASN . 9.1 t-20 62.33 37.62 13.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.846 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 179' ' ' VAL . . . . . 0.441 ' CG2' ' O ' ' A' ' 175' ' ' CYS . 75.0 t -118.57 133.15 66.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.141 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 59.3 t -89.03 128.04 41.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.169 179.914 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 50.7 t -135.86 114.56 15.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.069 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 5.8 t70 63.5 28.53 15.34 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.901 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 89.21 -14.41 60.91 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.499 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 77.6 mtt85 -108.77 126.0 52.55 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.903 0.383 . . . . 0.0 110.805 -179.837 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 10.9 m -76.74 106.48 8.42 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.16 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 80.3 mt -70.24 157.05 38.39 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.907 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 16.2 tptm -135.65 115.01 12.53 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.939 179.82 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -110.13 142.96 40.9 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.083 179.88 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 86.1 p -156.71 165.39 36.37 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.873 -179.776 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 190' ' ' LEU . . . . . . . . . . . . . 4.3 pp -126.62 154.98 43.25 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.938 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 103.71 26.17 6.92 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.45 179.885 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 192' ' ' THR . . . . . . . . . . . . . 1.9 m -102.61 150.66 23.2 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.863 0.363 . . . . 0.0 111.135 -179.862 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 193' ' ' THR . . . . . . . . . . . . . 76.9 p -97.75 153.4 18.29 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.145 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 1.5 mmmm -104.63 -58.96 1.81 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.898 179.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 195' ' ' TYR . . . . . . . . . . . . . 4.9 p90 -103.51 172.7 6.66 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.943 -179.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 196' ' ' CYS . . . . . . . . . . . . . 9.5 t -105.74 120.01 40.61 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.92 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 9.9 t -47.73 -55.12 10.23 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.868 -179.754 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 198' ' ' TYR . . . . . 0.441 ' CD1' ' C ' ' A' ' 198' ' ' TYR . 4.8 t80 -42.51 -55.63 3.4 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.889 -179.885 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 28.9 t -38.63 122.37 1.13 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.862 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 200' ' ' GLY . . . . . 0.409 ' HA3' ' C ' ' A' ' 201' ' ' PRO . . . 171.99 -69.26 0.12 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.477 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 201' ' ' PRO . . . . . 0.409 ' C ' ' HA3' ' A' ' 200' ' ' GLY . 54.1 Cg_endo -69.75 179.08 23.26 Favored 'Cis proline' 0 C--N 1.342 0.188 0 C-N-CA 122.686 -1.797 . . . . 0.0 112.345 0.051 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 202' ' ' SER . . . . . 0.405 ' O ' ' C ' ' A' ' 203' ' ' SER . 3.7 t -160.28 133.81 6.94 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.813 -179.877 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 203' ' ' SER . . . . . 0.405 ' C ' ' O ' ' A' ' 202' ' ' SER . 96.5 p 37.2 40.16 0.17 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.872 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.261 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.458 -179.969 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.36 0 N-CA-C 112.517 -0.233 . . . . 0.0 112.517 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 31.0 m -77.38 86.46 3.77 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.895 0.378 . . . . 0.0 110.878 -179.73 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 7.5 t -75.49 168.47 19.95 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.87 -179.816 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -72.96 104.49 1.56 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.781 -0.724 . . . . 0.0 112.492 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 58.3 m -130.0 121.8 27.22 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.836 0.35 . . . . 0.0 110.858 -179.735 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 24.8 p -151.42 123.55 8.21 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.863 -179.808 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 128.38 -109.68 1.04 Allowed Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.46 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -49.42 141.68 8.72 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.79 0.329 . . . . 0.0 111.122 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 1.3 t -71.31 152.42 43.26 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.86 -179.787 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 1.4 m -66.33 104.26 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.064 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 7.6 ptp180 -119.32 147.09 44.71 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.886 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 12.7 p -116.11 120.94 66.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.154 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 21.2 t -119.45 138.85 48.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.076 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 7.1 mm100 -43.27 146.21 0.48 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.921 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 77.7 mttt -84.34 54.23 2.91 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.871 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 5.3 p-10 -125.3 39.31 4.0 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.902 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 12.3 tp -140.95 131.04 24.7 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.943 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 47.0 t -113.94 123.33 69.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.148 179.865 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.663 ' CZ ' ' CG1' ' A' ' 114' ' ' VAL . 37.6 t80 -111.17 106.56 15.61 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.891 -179.964 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 20.9 t -102.82 143.4 15.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.173 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . 0.663 ' CG1' ' CZ ' ' A' ' 112' ' ' PHE . 33.3 m -131.82 169.8 21.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.106 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 73.75 54.51 6.52 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.502 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 60.9 mt -117.31 129.96 56.23 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.84 0.352 . . . . 0.0 110.932 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 3.3 m -65.56 152.76 43.33 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.868 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 13.1 pt20 -50.9 -20.86 1.45 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.949 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 36.5 mtm180 -92.56 -42.75 9.51 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.88 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 62.8 mt -65.94 -34.74 78.8 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.948 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -62.54 85.29 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.075 179.842 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -148.48 144.09 18.13 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.626 0.727 . . . . 0.0 110.843 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.84 -42.17 3.55 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.677 2.251 . . . . 0.0 112.273 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -71.76 -44.4 64.12 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.9 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 28.7 t -60.86 -43.43 95.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.119 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 84.7 mt -68.39 -39.94 81.52 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.906 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.425 ' O ' ' C ' ' A' ' 128' ' ' ARG . 6.9 tmtt? -65.23 -37.92 88.76 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.841 179.866 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . 0.425 ' C ' ' O ' ' A' ' 127' ' ' LYS . 21.1 mmt180 -36.39 144.45 0.27 Allowed Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.628 0.728 . . . . 0.0 110.9 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.8 -5.17 15.59 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.679 2.253 . . . . 0.0 112.372 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' GLU . . . . . 0.415 ' O ' ' CG ' ' A' ' 130' ' ' GLU . 20.5 tt0 -100.88 10.29 41.3 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.898 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' TYR . . . . . . . . . . . . . 47.1 m-85 -127.54 -74.18 0.59 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.928 -179.853 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 69.7 m-85 -124.12 -11.44 7.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.862 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -71.12 -11.28 70.35 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.502 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -80.66 -30.79 36.54 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.794 0.331 . . . . 0.0 110.878 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 135' ' ' PHE . . . . . . . . . . . . . 22.9 m-85 -72.31 -26.06 61.8 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.827 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 167.41 -172.57 42.38 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.494 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 7.4 mtpm? -86.26 136.75 33.05 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.754 0.311 . . . . 0.0 110.917 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.442 ' CG2' HG22 ' A' ' 141' ' ' VAL . 82.5 mt -100.04 138.6 23.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.127 179.865 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -96.09 -46.51 6.45 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.848 179.878 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -141.04 141.05 34.34 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.916 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . 0.442 HG22 ' CG2' ' A' ' 138' ' ' ILE . 17.4 t -134.44 123.61 43.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.087 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 99.0 t -134.2 139.88 47.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.136 179.904 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 44.8 mm -96.89 140.41 17.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.146 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 3.7 m120 -129.09 115.87 18.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.89 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 2.7 m120 -100.8 133.48 45.22 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.884 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 46.1 m -94.4 158.82 15.39 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.88 -179.862 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 66.2 p -93.19 143.96 25.75 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.11 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 23.3 t -72.67 143.93 47.93 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.806 -179.825 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 31.2 t80 -118.07 147.79 42.92 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.945 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -56.22 146.98 21.88 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.069 179.896 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 78.98 -14.82 12.14 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.455 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 16.3 m -106.6 132.31 52.75 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.824 0.345 . . . . 0.0 110.847 -179.745 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 27.0 mp0 -116.92 138.81 51.29 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.901 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 74.49 83.11 0.38 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.509 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.82 162.53 41.74 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.651 2.234 . . . . 0.0 112.302 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 94.0 p -126.93 134.98 50.31 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.852 -179.825 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -98.31 145.69 26.42 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.094 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 80.5 p -115.15 173.65 6.39 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.87 -179.762 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -153.68 140.79 19.4 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.119 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 89.0 m-85 -111.38 123.47 50.28 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.933 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 9.7 t -123.53 139.05 51.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.092 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 58.0 m -108.41 128.6 54.92 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.117 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 25.3 m-85 -108.45 138.65 44.4 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.891 -179.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 50.7 mt -64.32 -38.11 81.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.123 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 32.6 mtm180 -103.85 114.14 28.17 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.889 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 46.9 m -51.9 -51.91 53.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.846 -179.762 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -50.91 -57.57 8.17 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.899 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -46.84 -45.58 20.29 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.888 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -61.18 -54.49 43.72 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.12 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 87.5 mt -44.2 -63.75 0.81 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.898 -179.915 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 10.5 mtp180 -54.09 -46.66 72.12 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.887 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -51.04 -33.26 24.59 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.121 179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 77.5 mt -78.26 -39.08 24.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.084 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 3.5 mp0 -68.47 -24.3 64.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.916 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 91.9 m -93.77 -27.89 16.23 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.862 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 10.6 t -74.23 -30.78 27.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.135 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -66.82 146.13 54.75 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.909 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 35.6 t30 57.83 46.31 17.14 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.88 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 91.5 t -124.91 133.42 69.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.117 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 88.2 t -96.52 114.55 33.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.13 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 96.4 t -123.29 106.22 17.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.188 179.885 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 23.8 t0 58.0 39.8 26.1 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.88 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 73.53 37.36 53.13 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.509 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 3.4 mmp_? -140.99 132.01 26.19 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.919 0.39 . . . . 0.0 110.821 -179.822 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 17.1 m -87.99 96.03 10.35 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.171 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 59.6 mt -69.94 124.32 23.75 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.869 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 17.3 tptp -123.53 113.11 18.29 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.851 179.845 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -111.95 148.18 34.3 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.105 179.821 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 8.6 t -150.83 170.9 18.15 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.902 -179.789 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 190' ' ' LEU . . . . . 0.415 HD21 ' N ' ' A' ' 191' ' ' GLY . 5.8 tt -131.17 141.54 50.09 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.945 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 191' ' ' GLY . . . . . 0.415 ' N ' HD21 ' A' ' 190' ' ' LEU . . . 102.27 -24.21 31.83 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.505 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 192' ' ' THR . . . . . . . . . . . . . 27.6 p -88.37 117.15 27.09 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.864 0.364 . . . . 0.0 111.168 -179.873 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 193' ' ' THR . . . . . . . . . . . . . 33.5 p -118.68 169.03 10.16 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.156 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 15.3 ttpt -66.43 118.42 10.05 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.933 179.881 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 195' ' ' TYR . . . . . . . . . . . . . 88.3 t80 -77.27 127.92 33.44 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.904 -179.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 196' ' ' CYS . . . . . . . . . . . . . 4.9 t -174.27 137.97 0.55 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.899 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 31.7 t -43.4 152.46 0.13 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.849 -179.742 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 198' ' ' TYR . . . . . . . . . . . . . 7.9 p90 -103.14 148.28 25.96 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.902 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 54.5 m -98.55 111.76 24.02 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.912 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . 80.59 174.92 48.73 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.455 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 201' ' ' PRO . . . . . 0.437 ' O ' ' C ' ' A' ' 202' ' ' SER . 53.8 Cg_endo -69.8 164.7 78.68 Favored 'Cis proline' 0 C--N 1.342 0.185 0 C-N-CA 122.672 -1.803 . . . . 0.0 112.354 0.097 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 202' ' ' SER . . . . . 0.437 ' C ' ' O ' ' A' ' 201' ' ' PRO . 6.0 t -35.16 107.86 0.06 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.858 -179.825 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 73.2 p -100.87 137.93 38.6 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.848 -179.814 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.347 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.505 -179.967 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.344 0 N-CA-C 112.481 -0.248 . . . . 0.0 112.481 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 7.8 t -152.82 139.13 18.46 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.869 0.366 . . . . 0.0 110.868 -179.738 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 18.7 m -118.99 175.47 5.75 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.824 -179.841 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 169.04 114.85 0.31 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.492 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.6 t -155.98 127.77 7.38 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.88 0.371 . . . . 0.0 110.902 -179.73 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 19.3 t -79.59 167.72 20.36 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.839 -179.792 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -143.77 56.58 0.55 Allowed Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.469 -179.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -87.04 144.11 27.04 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.821 0.343 . . . . 0.0 111.091 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 2.8 t -72.5 -46.0 56.79 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.888 -179.806 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -94.34 140.7 16.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.081 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 17.2 mtt180 -110.19 105.35 14.39 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.885 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 93.7 t -115.74 141.24 33.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.095 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 34.0 m -90.16 148.57 4.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.127 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 10.3 tt0 -156.66 122.08 4.73 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.932 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 3.3 mppt? -103.98 -27.37 12.19 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.953 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 40.9 t30 -88.25 42.31 1.06 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.908 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 13.8 tp -143.42 117.55 9.51 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.941 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 59.1 t -96.79 118.61 43.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.108 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.654 ' CD1' ' CE2' ' A' ' 160' ' ' TYR . 45.3 t80 -119.29 111.61 18.41 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.889 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 23.1 t -107.01 140.78 24.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.098 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 5.1 m -120.06 169.38 11.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.09 179.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 67.26 53.89 23.28 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.505 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . 0.406 ' CD1' ' HB2' ' A' ' 159' ' ' ALA . 38.3 mt -112.81 127.17 56.09 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.834 0.35 . . . . 0.0 110.915 -179.92 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' SER . . . . . 0.495 ' O ' ' N ' ' A' ' 120' ' ' LEU . 18.8 t -65.64 125.91 26.74 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.874 -179.902 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' GLN . . . . . 0.438 ' C ' ' O ' ' A' ' 117' ' ' SER . 8.5 mm-40 -34.93 -32.46 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.882 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.494 ' N ' ' O ' ' A' ' 117' ' ' SER . 24.7 ttm180 -72.07 -48.14 46.4 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.863 -179.916 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . 0.495 ' N ' ' O ' ' A' ' 117' ' ' SER . 84.1 mt -70.2 -35.56 74.0 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.951 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -61.68 87.17 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.062 179.79 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' ASP . . . . . 0.411 ' HB2' ' CG2' ' A' ' 125' ' ' VAL . 5.9 m-20 -147.59 152.67 42.14 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.609 0.719 . . . . 0.0 110.847 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 -50.18 0.49 Allowed 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.674 2.25 . . . . 0.0 112.376 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 25.3 mt-10 -71.49 -42.34 68.19 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.911 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.492 HG12 ' CZ ' ' A' ' 131' ' ' TYR . 48.2 t -57.08 -53.59 41.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.116 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 87.7 mt -68.25 -30.82 69.94 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.941 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 13.8 mmtt -64.95 -39.31 93.3 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.903 179.807 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 32.5 mtt180 -39.75 143.93 0.54 Allowed Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.648 0.737 . . . . 0.0 110.874 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 -1.15 7.99 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.652 2.235 . . . . 0.0 112.354 -179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -101.51 -24.54 14.14 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.864 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' TYR . . . . . 0.492 ' CZ ' HG12 ' A' ' 125' ' ' VAL . 43.9 m-85 -87.35 -74.67 0.43 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.933 -179.868 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 16.0 m-85 -118.81 -40.51 2.86 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.858 -179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -44.9 -20.89 0.26 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.45 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.421 ' C ' ' HD3' ' A' ' 134' ' ' LYS . 0.0 OUTLIER -54.52 -37.55 65.5 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.834 0.35 . . . . 0.0 110.919 -179.988 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 135' ' ' PHE . . . . . . . . . . . . . 22.2 m-85 -66.23 -44.12 84.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.865 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -176.31 -153.55 10.71 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.447 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 38.7 mtmt -97.42 108.31 21.01 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.779 0.323 . . . . 0.0 110.937 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 91.6 mt -69.7 142.88 15.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.156 179.883 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 3.0 t-160 -102.16 -56.37 2.28 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.885 179.877 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 33.4 tttt -119.01 151.48 38.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.905 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 41.4 t -143.05 108.85 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.155 179.849 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 96.9 t -115.82 126.94 73.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.158 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 26.7 mm -106.3 109.28 27.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.111 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 3.2 t-20 -96.06 137.14 35.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.881 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 1.5 p30 -134.45 159.06 42.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.842 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 23.0 t -96.36 163.73 12.94 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.881 -179.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 64.6 p -125.07 91.3 3.4 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.136 -179.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 1.3 t -115.86 155.62 27.6 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.83 -179.832 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 34.8 t80 -72.73 153.35 41.19 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.939 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -50.04 167.45 0.05 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.125 179.891 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 70.13 38.01 72.77 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.508 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 26.0 t -108.52 170.16 8.2 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.837 0.351 . . . . 0.0 110.861 -179.712 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 43.5 mt-30 -83.04 38.37 0.59 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.927 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 43.8 83.23 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.541 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.75 161.99 43.81 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.688 2.259 . . . . 0.0 112.334 -179.895 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 23.2 m -99.66 164.89 11.87 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.856 -179.836 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -119.74 171.99 8.01 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.108 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 67.7 p -123.31 169.64 11.11 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.875 -179.796 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 159' ' ' ALA . . . . . 0.406 ' HB2' ' CD1' ' A' ' 116' ' ' LEU . . . -147.64 149.76 33.11 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.108 179.941 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 160' ' ' TYR . . . . . 0.654 ' CE2' ' CD1' ' A' ' 112' ' ' PHE . 43.4 m-85 -124.26 124.75 43.1 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.901 -179.847 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 57.4 t -120.39 125.32 74.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.174 179.883 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 48.7 m -93.47 131.28 38.84 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.143 -179.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 9.5 m-85 -107.35 147.15 30.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.892 -179.89 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 48.2 mt -75.29 -47.53 34.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.128 179.916 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 35.1 mtp180 -91.54 114.23 26.71 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.856 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 75.5 m -49.35 -59.4 3.74 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.867 -179.814 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 55.8 mt-10 -47.96 -47.44 32.71 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.908 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -55.34 -45.85 76.39 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.881 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -56.93 -56.63 19.17 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.1 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 56.0 mt -47.26 -59.86 2.88 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.891 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 1.9 mpt_? -56.68 -42.51 79.16 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.866 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . 0.48 ' O ' ' CG2' ' A' ' 176' ' ' VAL . . . -55.24 -32.09 62.02 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.101 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 76.7 mt -79.78 -37.99 18.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.112 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 8.6 mm100 -64.66 -28.67 69.77 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.862 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 19.8 t -93.74 -28.95 15.64 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.852 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 176' ' ' VAL . . . . . 0.48 ' CG2' ' O ' ' A' ' 172' ' ' ALA . 9.9 t -71.7 -28.07 29.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.124 -179.978 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 1.8 t30 -70.76 141.61 51.45 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.895 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 25.7 t-20 61.35 49.33 5.41 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.923 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 79.5 t -117.0 133.66 63.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.131 179.918 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 58.7 t -98.16 105.97 18.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.14 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 56.3 t -115.73 131.2 68.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.189 179.862 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 44.96 29.05 0.42 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.856 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 80.39 31.46 37.52 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.737 -0.745 . . . . 0.0 112.471 -179.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 13.2 ttm180 -134.9 136.14 42.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.855 0.359 . . . . 0.0 110.888 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 26.5 m -82.69 99.51 9.66 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.162 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 62.9 mt -84.29 140.48 31.61 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.942 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 9.4 ttpp -135.19 146.83 49.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.877 179.828 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -134.29 155.47 50.14 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.075 179.842 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 8.8 t -155.59 164.18 38.98 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.835 -179.807 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 190' ' ' LEU . . . . . . . . . . . . . 4.7 pp -130.07 147.57 51.83 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.956 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 107.04 26.88 5.58 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.533 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 192' ' ' THR . . . . . . . . . . . . . 24.3 m -88.69 137.27 32.47 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.902 0.382 . . . . 0.0 111.087 -179.835 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 193' ' ' THR . . . . . . . . . . . . . 26.4 m -83.32 137.18 34.09 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.141 179.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 7.0 tmtm? -109.67 125.77 52.97 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.926 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 195' ' ' TYR . . . . . . . . . . . . . 35.3 t80 -62.97 88.88 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.885 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 196' ' ' CYS . . . . . . . . . . . . . 91.0 m -57.33 152.48 14.09 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.897 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 5.0 t -121.66 93.81 4.12 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.837 -179.737 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 198' ' ' TYR . . . . . . . . . . . . . 34.0 t80 -69.5 131.15 44.26 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.938 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 25.9 m -107.03 -66.4 1.02 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.869 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . 171.68 -163.96 36.63 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.535 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 201' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 129.23 14.06 Favored 'Cis proline' 0 C--N 1.342 0.193 0 C-N-CA 122.645 -1.815 . . . . 0.0 112.321 0.108 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 202' ' ' SER . . . . . . . . . . . . . 47.8 t -87.04 145.82 26.33 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.836 -179.848 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 88.5 p -76.35 135.27 39.53 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.879 -179.824 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.345 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.497 -179.967 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.362 0 N-CA-C 112.487 -0.245 . . . . 0.0 112.487 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 48.7 m -73.01 87.57 1.35 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.86 0.362 . . . . 0.0 110.85 -179.73 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 21.7 t -140.79 143.7 35.02 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.874 -179.839 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -116.62 76.53 0.28 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.458 -179.949 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 87.9 p -155.42 139.83 16.78 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.874 0.368 . . . . 0.0 110.824 -179.708 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 32.3 t -82.51 158.61 23.1 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.856 -179.835 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -144.05 71.43 0.38 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.534 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -91.2 155.26 18.72 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.781 0.324 . . . . 0.0 111.131 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 17.1 m -114.49 134.93 54.65 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.876 -179.778 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 74.9 t -109.03 116.61 52.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.126 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 85.3 mtt180 -109.95 137.88 47.11 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.896 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 4.6 m -76.01 122.96 31.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.14 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . 0.445 ' O ' ' C ' ' A' ' 107' ' ' GLN . 52.5 t -109.7 101.79 13.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.131 179.905 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.445 ' C ' ' O ' ' A' ' 106' ' ' VAL . 26.8 pt20 34.43 42.14 0.06 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.924 179.982 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 64.9 mttt -86.57 51.25 2.18 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.909 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 12.0 p-10 -112.41 27.54 9.56 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.91 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 15.3 tp -109.27 121.7 45.74 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.878 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 89.6 t -95.58 114.12 31.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.112 179.819 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.638 ' CE2' ' CG1' ' A' ' 114' ' ' VAL . 61.1 t80 -106.86 99.25 8.83 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.901 179.98 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 54.3 t -98.94 125.36 52.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.149 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . 0.638 ' CG1' ' CE2' ' A' ' 112' ' ' PHE . 12.0 m -118.89 168.88 10.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.126 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 77.39 39.52 26.02 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.505 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 32.5 mt -105.92 137.9 43.02 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.822 0.344 . . . . 0.0 110.89 -179.909 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 78.6 p -76.58 148.14 37.2 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.842 -179.941 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 34.5 mm-40 -42.2 -34.96 0.84 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.898 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 33.0 mtt180 -69.01 -47.47 65.39 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.872 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . 0.424 ' CD2' ' OD2' ' A' ' 182' ' ' ASP . 85.0 mt -71.78 -24.68 61.79 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.928 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -71.29 83.49 0.76 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.105 179.807 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 19.6 m-20 -148.95 144.38 18.07 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.619 0.723 . . . . 0.0 110.845 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.8 -45.67 1.48 Allowed 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.662 2.242 . . . . 0.0 112.38 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 19.9 mt-10 -73.19 -42.6 62.51 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.885 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.414 ' O ' ' CD1' ' A' ' 131' ' ' TYR . 56.4 t -59.04 -46.3 91.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.157 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 74.1 mt -68.69 -37.56 79.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.959 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 12.8 ttmm -68.0 -35.77 78.87 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.9 179.804 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 66.4 mtt-85 -44.89 147.91 1.05 Allowed Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.59 0.709 . . . . 0.0 110.882 180.0 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.71 -3.19 11.49 Favored 'Trans proline' 0 N--CA 1.465 -0.163 0 C-N-CA 122.711 2.274 . . . . 0.0 112.367 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -97.93 6.39 47.77 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.897 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' TYR . . . . . 0.414 ' CD1' ' O ' ' A' ' 125' ' ' VAL . 63.0 m-85 -131.32 -73.84 0.53 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.938 -179.858 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 71.0 m-85 -127.06 -6.04 6.1 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.901 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -70.9 -18.92 76.57 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.515 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 11.2 ptpt -88.72 -27.25 21.33 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.857 0.36 . . . . 0.0 110.893 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 135' ' ' PHE . . . . . 0.408 ' CE2' HG23 ' A' ' 176' ' ' VAL . 27.9 m-85 -63.97 -43.65 95.11 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.85 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -177.43 167.55 38.69 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.482 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 27.1 mtmm -67.06 120.06 13.05 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.728 0.299 . . . . 0.0 110.87 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.463 HG12 ' CG1' ' A' ' 161' ' ' VAL . 83.3 mt -95.12 146.43 6.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.074 179.892 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 4.2 t60 -107.13 -59.94 1.75 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.843 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 27.5 ttpp -125.53 145.63 50.02 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.913 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 21.3 t -130.19 132.79 64.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.129 179.847 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 3.5 t -125.96 140.73 47.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.13 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 23.8 mm -119.4 121.66 67.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.162 179.907 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 7.1 m-80 -116.57 105.58 12.61 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.907 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -92.03 165.83 12.98 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.878 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 25.2 p -68.43 120.08 13.95 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.882 -179.861 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 62.4 m -78.96 -58.85 3.03 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.168 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 36.9 t -76.34 128.09 34.17 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.894 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 50.0 m-85 -83.78 126.63 33.11 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.904 -179.856 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -85.25 -68.23 0.74 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.119 179.862 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 103.23 -19.6 45.44 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.497 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 57.6 m -109.47 -58.79 1.99 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.832 0.349 . . . . 0.0 110.834 -179.721 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 6.3 pt20 -88.46 152.48 21.86 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.906 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . -69.34 146.12 43.64 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.502 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 150.49 68.2 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.71 2.273 . . . . 0.0 112.32 -179.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 19.7 m -131.55 105.93 7.87 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.868 -179.849 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -84.38 167.18 16.74 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.107 179.902 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 95.8 p -142.51 162.53 35.22 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.869 -179.765 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -145.88 141.88 28.26 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.116 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 15.2 m-85 -115.19 112.6 22.74 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.95 -179.88 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.463 ' CG1' HG12 ' A' ' 138' ' ' ILE . 94.6 t -106.64 133.69 50.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.146 179.911 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 9.1 m -102.66 125.61 49.45 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.159 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 13.8 m-85 -103.53 136.5 43.13 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.909 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 89.3 mt -63.85 -49.69 80.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.108 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 28.3 mmt180 -100.72 119.16 38.2 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.894 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 4.1 m -50.09 -57.61 7.3 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.848 -179.787 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -41.18 -61.48 1.0 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.886 -179.933 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 31.3 m-20 -46.65 -46.15 19.69 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.857 179.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -57.86 -55.48 34.41 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.059 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 71.7 mt -45.0 -59.72 2.44 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.917 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 13.9 mtm180 -53.94 -53.18 56.33 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.84 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -45.03 -34.83 2.67 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.118 179.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 96.4 mt -81.67 -32.15 11.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.122 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 73.0 mt-30 -66.76 -27.33 67.51 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.874 -179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 1.8 t -93.81 -35.88 12.53 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.867 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 176' ' ' VAL . . . . . 0.408 HG23 ' CE2' ' A' ' 135' ' ' PHE . 10.7 t -64.84 -45.84 93.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.113 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -51.79 144.98 10.27 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.895 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 41.6 m-20 57.61 53.43 7.28 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.882 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 78.6 t -134.59 138.57 49.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.168 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 66.6 t -92.49 124.18 44.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.123 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 60.0 t -135.37 126.89 45.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.103 179.933 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 182' ' ' ASP . . . . . 0.424 ' OD2' ' CD2' ' A' ' 120' ' ' LEU . 4.4 m-20 59.29 25.47 14.11 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.85 179.908 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 90.21 -18.04 50.59 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.464 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 15.3 ptm180 -117.33 129.66 56.02 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.923 0.392 . . . . 0.0 110.849 -179.861 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 51.3 m -71.48 138.89 49.33 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.154 -179.896 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 54.6 mt -105.53 143.65 33.39 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.884 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -115.11 117.14 29.72 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.905 179.841 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -114.96 127.68 55.83 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.065 179.857 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 4.3 t -136.6 173.78 11.33 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.848 -179.771 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 190' ' ' LEU . . . . . . . . . . . . . 3.6 pp -130.29 160.95 32.37 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.929 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 59.34 30.98 68.76 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.453 179.878 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 192' ' ' THR . . . . . . . . . . . . . 82.5 p -90.01 131.43 35.9 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.91 0.386 . . . . 0.0 111.091 -179.847 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 193' ' ' THR . . . . . . . . . . . . . 11.2 m -124.81 141.03 52.39 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.118 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -70.42 167.67 17.74 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.916 179.909 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 195' ' ' TYR . . . . . . . . . . . . . 76.8 m-85 -67.63 123.74 21.32 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.978 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 196' ' ' CYS . . . . . . . . . . . . . 7.2 t -159.18 164.95 34.69 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.846 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 1.4 t -72.04 106.85 4.46 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.906 -179.765 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 198' ' ' TYR . . . . . . . . . . . . . 10.2 p90 -173.69 141.05 0.81 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.944 -179.847 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 2.2 m -123.99 172.19 9.15 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.864 -179.853 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . 78.13 -163.15 50.46 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.453 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 201' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 149.57 88.76 Favored 'Cis proline' 0 C--O 1.232 0.188 0 C-N-CA 122.68 -1.8 . . . . 0.0 112.367 0.013 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 202' ' ' SER . . . . . . . . . . . . . 54.8 p -85.3 177.9 7.67 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.868 -179.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 70.7 p -149.01 144.91 27.05 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.854 -179.802 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.348 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.503 -179.977 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.304 0 N-CA-C 112.475 -0.25 . . . . 0.0 112.475 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 33.3 t -62.94 112.91 2.78 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.846 0.355 . . . . 0.0 110.866 -179.75 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 3.9 m -81.67 85.62 6.54 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.843 -179.798 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -101.06 159.04 18.94 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.444 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.8 m -51.65 178.37 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.867 0.365 . . . . 0.0 110.894 -179.766 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 25.6 t -102.65 -58.84 1.8 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.894 -179.837 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 80.65 130.11 0.93 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.497 180.0 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -104.91 117.94 35.28 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.803 0.335 . . . . 0.0 111.109 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 7.8 t -153.2 159.18 42.61 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.902 -179.788 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.482 ' O ' ' CG1' ' A' ' 103' ' ' VAL . 6.2 p -86.56 117.61 31.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.148 179.962 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 28.3 ptt180 -117.99 145.03 45.03 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.897 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 12.1 p -90.18 144.3 9.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.085 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 33.8 m -84.23 124.25 39.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.11 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 8.3 tt0 -159.32 105.13 1.68 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.881 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 40.1 pttt -91.82 -26.18 18.64 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.915 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . 0.428 ' O ' ' CG ' ' A' ' 109' ' ' ASN . 8.6 t-20 -89.51 40.02 0.97 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.879 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 33.6 tp -141.16 118.21 11.23 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.883 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 95.3 t -100.58 103.39 14.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.085 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.598 ' CD1' ' CE2' ' A' ' 160' ' ' TYR . 39.1 t80 -101.69 113.24 26.22 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.864 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 40.1 t -112.87 126.51 70.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.126 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . 0.414 ' CG1' ' CE2' ' A' ' 112' ' ' PHE . 17.3 m -111.83 166.36 6.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.16 179.924 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 78.68 43.15 12.24 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.435 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 49.4 mt -112.99 118.26 34.34 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.828 0.347 . . . . 0.0 110.889 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 2.8 p -65.53 143.36 57.69 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.835 -179.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 65.8 mm-40 -39.85 -34.82 0.29 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.917 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 59.8 ttt180 -69.02 -49.06 61.06 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.891 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 61.7 mt -72.63 -20.55 61.25 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.929 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -78.53 83.26 4.73 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.083 179.799 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 17.0 m-20 -148.54 149.24 30.78 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-O 121.572 0.701 . . . . 0.0 110.887 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 -48.59 0.69 Allowed 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.664 2.243 . . . . 0.0 112.39 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 44.7 mm-40 -67.0 -42.07 85.64 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.885 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.425 HG13 ' CZ ' ' A' ' 131' ' ' TYR . 38.1 t -59.82 -47.34 91.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.107 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 94.6 mt -71.58 -32.73 68.4 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.927 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 68.2 mttt -67.19 -30.26 70.15 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.896 179.836 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 9.9 mmp_? -50.23 144.29 11.63 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.577 0.703 . . . . 0.0 110.884 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 0.01 6.29 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.669 2.246 . . . . 0.0 112.365 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 35.3 tt0 -101.05 -7.71 22.99 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.877 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' TYR . . . . . 0.425 ' CZ ' HG13 ' A' ' 125' ' ' VAL . 41.5 m-85 -111.96 -72.88 0.69 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.932 -179.871 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 33.4 m-85 -124.42 -21.67 4.86 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.869 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -52.57 -24.36 17.43 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.479 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 14.6 ptpt -90.49 -16.9 28.06 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.77 0.319 . . . . 0.0 110.848 -179.932 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 135' ' ' PHE . . . . . . . . . . . . . 15.5 m-85 -79.15 -29.11 42.91 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.858 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 172.05 168.33 33.38 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.479 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 7.2 mtmp? -75.67 101.27 4.93 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.806 0.336 . . . . 0.0 110.92 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 81.7 mt -68.64 134.09 30.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.145 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 2.3 t-160 -103.68 -50.7 3.35 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.859 179.893 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 51.8 tttt -134.0 132.13 39.74 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.906 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 49.1 t -120.11 133.23 67.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.113 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 99.6 t -129.88 129.42 65.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.115 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 19.0 mm -107.31 119.36 56.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.139 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 7.7 m120 -111.33 101.34 9.82 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.859 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 9.1 p-10 -82.64 171.47 14.0 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.9 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 1.3 t -68.21 149.66 49.25 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.837 -179.821 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 40.6 p -121.8 40.79 3.53 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.185 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 1.8 t -112.46 157.73 20.73 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.894 -179.859 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 56.7 t80 -61.43 148.8 40.52 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.933 -179.854 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -57.79 143.6 41.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.124 179.875 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 97.63 37.94 4.34 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.453 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 2.1 m -90.57 170.73 9.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.798 0.332 . . . . 0.0 110.883 -179.742 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 2.7 mp0 -121.6 85.09 2.35 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.908 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 114.08 74.27 0.62 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.514 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 124.12 10.78 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.71 2.273 . . . . 0.0 112.301 -179.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 17.5 m -136.63 128.6 29.37 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.859 -179.877 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -123.85 169.43 11.58 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.081 179.897 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 20.3 m -137.53 164.51 28.55 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.882 -179.804 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -142.95 140.08 30.95 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.128 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 160' ' ' TYR . . . . . 0.598 ' CE2' ' CD1' ' A' ' 112' ' ' PHE . 33.6 m-85 -113.7 116.71 29.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.933 -179.842 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 98.0 t -116.58 139.62 42.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.111 179.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 29.9 m -106.03 129.12 54.2 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.126 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 163' ' ' TYR . . . . . 0.406 ' O ' ' ND2' ' A' ' 109' ' ' ASN . 3.7 m-85 -109.51 148.28 31.48 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.982 -179.971 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 49.0 mt -76.45 -61.06 1.83 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.139 179.918 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 59.4 mtt180 -82.25 99.08 9.1 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.82 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 50.7 m -42.01 -53.34 3.92 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.878 -179.853 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 3.6 pt-20 -40.73 -59.34 1.42 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.906 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -56.7 -35.14 68.14 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.869 179.923 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -65.4 -60.18 3.23 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.122 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 39.6 mt -45.85 -51.76 12.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.903 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 2.2 mpt_? -61.07 -43.83 98.3 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.808 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -54.89 -31.81 60.27 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.134 179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 63.0 mt -81.16 -38.42 16.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.135 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 31.4 mm-40 -69.69 -22.09 63.45 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.935 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 3.4 t -93.8 -34.75 13.05 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.906 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 10.5 t -66.79 -38.17 80.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.081 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 1.7 t30 -63.34 140.57 58.89 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.874 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 25.5 t30 71.81 35.21 1.41 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.856 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 89.4 t -119.54 131.56 71.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.122 179.892 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 82.7 t -95.62 102.56 13.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.09 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 53.7 t -111.07 117.57 55.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.167 179.877 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 15.2 m-20 48.8 48.99 19.67 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.828 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 63.15 28.4 72.11 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.452 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 12.2 mtt85 -138.07 111.27 7.9 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.86 0.362 . . . . 0.0 110.89 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 36.5 m -70.63 101.21 1.99 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.126 -179.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 11.9 mt -68.45 129.6 40.4 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.914 179.928 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 22.9 tptm -124.85 120.55 32.03 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.932 179.816 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -119.82 151.82 38.24 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.127 179.857 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 8.6 t -158.38 164.01 36.72 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.849 -179.718 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 190' ' ' LEU . . . . . 0.455 ' O ' ' CD1' ' A' ' 190' ' ' LEU . 4.1 pp -128.18 130.3 47.83 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.897 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 106.36 27.95 5.36 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.478 179.879 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 192' ' ' THR . . . . . 0.486 HG21 ' CD2' ' A' ' 112' ' ' PHE . 14.7 t -92.09 155.82 17.8 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.878 0.37 . . . . 0.0 111.124 -179.845 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 193' ' ' THR . . . . . . . . . . . . . 23.2 m -96.1 116.58 29.2 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.148 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 12.1 ptpt -102.83 -27.77 12.47 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.873 179.887 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 195' ' ' TYR . . . . . . . . . . . . . 3.3 t80 -171.65 135.31 0.88 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.926 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 196' ' ' CYS . . . . . . . . . . . . . 21.1 t -95.46 84.68 4.04 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.882 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 3.6 m -164.26 167.08 20.35 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.875 -179.732 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 198' ' ' TYR . . . . . . . . . . . . . 23.7 t80 -115.6 116.9 28.93 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.923 -179.892 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 81.4 p -173.95 140.05 0.7 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.84 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . -66.92 -165.14 2.15 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.535 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 201' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.8 122.29 5.99 Favored 'Cis proline' 0 C--N 1.341 0.169 0 C-N-CA 122.689 -1.796 . . . . 0.0 112.313 0.061 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 202' ' ' SER . . . . . . . . . . . . . 21.9 m -91.68 163.46 14.09 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.845 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 9.6 m -115.69 -56.47 2.33 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.795 -179.781 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.283 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.462 -179.96 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.327 0 N-CA-C 112.515 -0.234 . . . . 0.0 112.515 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 97.4 p -114.94 106.99 14.8 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.857 0.36 . . . . 0.0 110.865 -179.745 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 1.9 m -65.21 133.44 51.5 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.843 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 66.56 150.18 0.12 Allowed Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.506 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 18.5 t -39.63 -59.51 1.12 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.878 0.37 . . . . 0.0 110.844 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 2.9 m -129.83 145.4 51.58 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.86 -179.776 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 80.37 107.65 0.28 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.5 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -74.83 154.33 38.33 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.765 0.316 . . . . 0.0 111.082 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 64.6 m -132.5 137.61 47.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.839 -179.818 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 34.4 m -75.78 148.49 7.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.145 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 34.8 mtp85 -120.17 98.31 6.01 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.902 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 87.5 t -115.8 100.69 10.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.172 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 8.0 p -114.34 131.76 65.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.131 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 13.7 tt0 -87.3 46.8 1.42 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.918 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 75.7 mttt -101.24 44.88 0.99 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.893 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 4.9 p-10 -110.41 50.55 0.8 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.878 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 11.2 tp -128.77 121.06 27.55 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.902 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 98.8 t -94.64 130.11 43.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.116 179.85 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.403 ' CE2' ' CG1' ' A' ' 114' ' ' VAL . 40.5 t80 -128.95 98.23 4.88 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.893 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 54.0 t -92.76 135.75 26.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.177 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . 0.403 ' CG1' ' CE2' ' A' ' 112' ' ' PHE . 4.7 m -124.96 164.4 23.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.12 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 76.28 47.85 10.26 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.518 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 59.8 mt -108.3 130.87 55.17 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.812 0.339 . . . . 0.0 110.929 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 14.0 m -69.21 155.4 40.47 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.902 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 40.8 mt-30 -46.84 -38.07 9.73 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.915 -179.927 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 19.6 tpt180 -74.66 -50.74 16.55 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.869 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 37.0 mt -62.15 -19.09 62.69 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.904 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -76.68 83.9 3.32 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.098 179.782 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -148.66 144.02 17.91 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.639 0.733 . . . . 0.0 110.865 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 -50.78 0.43 Allowed 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.694 2.263 . . . . 0.0 112.341 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 22.1 pt-20 -67.35 -38.36 84.7 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.87 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.456 HG11 ' CE1' ' A' ' 131' ' ' TYR . 84.2 t -63.62 -42.85 97.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.084 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 47.9 mt -72.02 -32.82 67.52 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.899 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 25.0 tttm -74.44 -29.94 61.69 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.914 179.849 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 49.8 mtp180 -47.11 148.8 1.87 Allowed Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.571 0.7 . . . . 0.0 110.882 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 -2.1 9.61 Favored 'Trans proline' 0 C--N 1.341 0.138 0 C-N-CA 122.665 2.243 . . . . 0.0 112.308 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 4.0 tp10 -91.83 -23.53 19.65 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.834 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' TYR . . . . . 0.456 ' CE1' HG11 ' A' ' 125' ' ' VAL . 26.0 m-85 -103.34 -69.55 0.79 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.913 -179.826 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.434 ' O ' ' N ' ' A' ' 135' ' ' PHE . 87.8 m-85 -126.23 -27.9 3.17 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.887 -179.971 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -43.87 -22.23 0.27 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.536 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.4 ' N ' ' O ' ' A' ' 132' ' ' PHE . 16.7 ptpt -85.09 -34.41 22.22 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.801 0.334 . . . . 0.0 110.865 -179.949 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 135' ' ' PHE . . . . . 0.508 ' CE2' HG23 ' A' ' 176' ' ' VAL . 12.9 m-85 -56.3 -39.26 72.42 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.857 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 178.77 -176.19 47.83 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.494 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 13.9 tttt -87.87 111.41 21.39 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.724 0.297 . . . . 0.0 110.902 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 61.5 mt -83.47 144.7 9.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.174 179.849 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 2.2 t60 -102.32 -44.27 5.45 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.851 179.915 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 24.1 ttpp -138.72 145.73 40.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.909 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 21.2 t -131.0 129.38 63.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.174 179.848 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 46.6 t -125.78 140.2 49.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.16 179.93 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 20.0 mm -121.92 126.83 75.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.176 179.883 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 19.0 m-20 -120.49 121.11 37.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.884 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 3.0 p-10 -104.08 157.66 16.96 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.875 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 65.9 p -89.82 159.47 16.99 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.874 -179.863 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 37.4 m -77.52 123.22 26.3 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.139 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 23.4 m -73.41 105.37 4.76 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.837 -179.829 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 40.9 t80 -110.01 141.22 43.11 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.908 -179.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -59.82 123.06 15.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.103 179.812 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 105.36 -0.43 40.36 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.495 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 28.4 t -90.97 130.07 36.93 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.787 0.327 . . . . 0.0 110.866 -179.757 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 29.1 tt0 -118.57 113.44 21.27 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.923 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 101.7 76.1 1.16 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.732 -0.746 . . . . 0.0 112.473 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 103.09 1.1 Allowed 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.738 2.292 . . . . 0.0 112.33 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 86.9 p -101.78 140.86 35.49 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.873 -179.845 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -127.61 167.74 15.96 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.13 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 83.5 p -126.13 166.08 17.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.89 -179.819 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -147.99 140.46 24.46 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.131 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 8.8 m-85 -114.71 136.37 53.13 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.917 -179.843 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 74.9 t -130.0 125.59 60.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.145 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 89.1 m -95.75 122.65 38.75 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.176 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 4.8 m-85 -108.16 141.43 39.9 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.936 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 65.3 mt -74.57 -39.52 47.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.073 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 38.4 mtm-85 -86.92 114.58 23.67 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.851 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 14.3 t -55.84 -59.66 4.56 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.845 -179.804 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 17.9 tt0 -51.68 -49.65 61.99 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.875 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 12.2 t0 -48.03 -46.25 32.97 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.886 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -61.67 -53.46 55.86 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.111 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 72.9 mt -44.68 -63.9 0.81 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.888 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 171' ' ' ARG . . . . . 0.418 ' O ' ' N ' ' A' ' 174' ' ' GLN . 14.9 mtp180 -59.59 -53.04 62.64 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.859 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -40.0 -37.73 0.63 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.081 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 67.4 mt -80.66 -36.7 15.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.133 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 174' ' ' GLN . . . . . 0.418 ' N ' ' O ' ' A' ' 171' ' ' ARG . 25.8 mm-40 -61.1 -26.88 67.97 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.9 179.905 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 2.5 t -93.75 -41.15 9.83 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.897 -179.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 176' ' ' VAL . . . . . 0.508 HG23 ' CE2' ' A' ' 135' ' ' PHE . 10.3 t -58.77 -39.44 76.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.092 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -62.43 136.43 57.9 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.896 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 14.6 t30 70.76 47.01 0.48 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.919 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 59.0 t -127.64 134.8 64.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.139 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 89.4 t -93.95 115.04 31.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.148 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 62.4 t -121.45 118.88 57.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.158 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 55.9 m-20 58.5 28.76 17.41 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.844 179.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 90.08 -19.52 42.0 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.497 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 25.4 ttm-85 -103.52 135.89 44.27 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.939 0.4 . . . . 0.0 110.851 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 71.2 m -86.8 131.83 34.01 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.186 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 25.4 mt -112.57 126.25 55.14 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.91 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 7.9 ttmt -109.48 136.64 48.56 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.87 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -125.64 149.52 48.36 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.096 179.844 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 7.3 t -159.37 167.71 28.14 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.828 -179.766 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 190' ' ' LEU . . . . . . . . . . . . . 4.2 pp -126.38 153.11 45.4 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.958 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 106.16 30.7 4.36 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.438 179.927 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 192' ' ' THR . . . . . . . . . . . . . 47.0 m -98.97 122.89 42.82 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.851 0.357 . . . . 0.0 111.151 -179.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 193' ' ' THR . . . . . . . . . . . . . 9.4 m -118.51 138.24 52.65 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.151 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 2.3 mptp? -78.07 131.37 37.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.902 179.896 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 195' ' ' TYR . . . . . . . . . . . . . 26.0 p90 -59.3 151.94 22.18 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.901 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 196' ' ' CYS . . . . . . . . . . . . . 44.7 t -126.06 75.53 1.52 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.856 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 55.1 m -103.56 151.88 22.37 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.831 -179.76 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 198' ' ' TYR . . . . . . . . . . . . . 83.1 t80 -166.38 146.05 5.94 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.932 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 68.6 m -132.24 159.15 39.89 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.843 -179.823 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . 178.57 -168.5 39.6 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.47 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 201' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 -48.32 0.27 Allowed 'Cis proline' 0 C--N 1.342 0.199 0 C-N-CA 122.706 -1.789 . . . . 0.0 112.322 0.014 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 202' ' ' SER . . . . . . . . . . . . . 73.9 p 47.45 41.55 12.97 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.835 -179.846 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 12.7 p -126.09 77.91 1.72 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.889 -179.842 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.297 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.459 179.998 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.352 0 N-CA-C 112.478 -0.249 . . . . 0.0 112.478 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 2.2 m -125.68 164.24 21.05 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.875 0.369 . . . . 0.0 110.911 -179.748 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 71.2 m -64.16 152.59 40.25 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.86 -179.817 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 116.32 174.95 17.71 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.481 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 39.3 p -120.03 167.03 12.6 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.856 0.36 . . . . 0.0 110.854 -179.715 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 46.6 m -114.74 128.11 56.12 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.839 -179.803 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 152.68 -121.89 1.23 Allowed Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.471 -179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -61.15 135.2 57.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.762 0.315 . . . . 0.0 111.103 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 1.7 t -74.24 -62.56 1.47 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.866 -179.782 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 99.6 t -107.31 127.31 63.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.118 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 14.8 tpt180 -95.01 100.62 12.42 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.866 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.432 HG13 ' N ' ' A' ' 106' ' ' VAL . 62.0 t -93.63 137.63 22.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.105 179.99 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . 0.432 ' N ' HG13 ' A' ' 105' ' ' VAL . 1.0 OUTLIER -111.49 148.27 14.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.083 179.945 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 5.3 mm100 -95.5 -44.56 7.47 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.909 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 20.0 mttt -79.92 81.27 6.21 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.887 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 2.4 t30 -124.86 -39.8 2.24 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.913 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 19.4 tp -91.78 123.01 34.84 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.938 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 75.1 t -93.1 115.99 33.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.102 179.886 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.556 ' CE1' ' HB2' ' A' ' 158' ' ' SER . 6.6 t80 -112.49 118.47 35.22 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.895 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 25.5 t -115.0 137.53 48.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.169 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 19.9 m -123.42 168.96 15.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.161 179.908 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 75.59 48.62 10.19 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.499 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 36.4 mt -114.68 131.18 56.83 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.807 0.336 . . . . 0.0 110.884 -179.887 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 13.0 t -68.99 152.0 45.81 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.88 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 4.2 tp-100 -51.52 -23.57 4.23 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.936 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 30.3 ttt180 -84.62 -45.56 12.39 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.889 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 96.7 mt -68.06 -28.83 67.71 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.87 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -66.36 83.05 0.09 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.096 179.834 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' ASP . . . . . 0.432 ' CB ' HG21 ' A' ' 125' ' ' VAL . 1.2 m-20 -145.47 143.97 21.58 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.625 0.726 . . . . 0.0 110.842 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 -38.89 7.25 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.726 2.284 . . . . 0.0 112.345 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -77.51 -44.83 27.44 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.895 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.556 ' O ' ' CD1' ' A' ' 131' ' ' TYR . 62.0 t -60.6 -38.32 78.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.076 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 81.4 mt -75.08 -44.5 47.07 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.89 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 22.7 ttpp -67.87 -25.82 65.71 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.897 179.861 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 12.9 mmt180 -47.76 144.01 5.6 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.657 0.742 . . . . 0.0 110.803 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 -8.39 23.48 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.745 2.297 . . . . 0.0 112.324 179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 46.7 mt-10 -98.83 8.35 45.07 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.89 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' TYR . . . . . 0.556 ' CD1' ' O ' ' A' ' 125' ' ' VAL . 59.3 m-85 -126.08 -74.26 0.61 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.927 -179.828 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.444 ' O ' ' N ' ' A' ' 134' ' ' LYS . 58.5 m-85 -116.26 -36.66 3.98 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.914 -180.0 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -40.39 -25.58 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.488 -179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.444 ' N ' ' O ' ' A' ' 132' ' ' PHE . 3.5 mtpp -42.7 -59.65 1.85 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.82 0.343 . . . . 0.0 110.875 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 135' ' ' PHE . . . . . 0.486 ' CD2' ' HB2' ' A' ' 172' ' ' ALA . 28.1 m-85 -50.93 -43.59 60.13 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.865 179.982 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 173.82 -172.99 45.69 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.46 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 20.9 mtpp -76.19 141.35 41.85 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.733 0.301 . . . . 0.0 110.887 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.438 HG23 ' N ' ' A' ' 139' ' ' HIS . 60.6 mt -99.52 141.26 17.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.125 179.866 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 139' ' ' HIS . . . . . 0.438 ' N ' HG23 ' A' ' 138' ' ' ILE . 11.2 t60 -84.97 -58.55 2.65 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.846 179.892 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 22.1 tttp -137.53 146.82 44.61 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.914 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 35.3 t -134.68 132.83 54.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.175 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 57.8 t -126.46 141.38 46.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.121 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 31.4 mm -119.87 132.65 69.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.095 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 5.2 t-20 -126.39 106.54 9.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.889 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 5.3 p30 -101.1 173.62 6.38 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.872 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 6.1 m -89.47 123.39 33.55 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.899 -179.885 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 17.9 p -99.61 -50.83 3.94 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.15 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 79.4 p -106.58 131.51 53.65 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.828 -179.808 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . 0.533 ' CG ' ' O ' ' A' ' 149' ' ' TYR . 29.7 p90 -107.06 99.78 9.31 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.942 -179.876 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -83.15 42.21 0.8 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.116 179.868 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 79.42 39.85 17.4 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.76 -0.734 . . . . 0.0 112.469 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 38.0 p -100.69 132.17 46.22 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.867 0.365 . . . . 0.0 110.829 -179.718 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 1.6 mp0 -81.58 106.33 13.44 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.905 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 57.59 81.18 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.489 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 133.22 25.08 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.684 2.256 . . . . 0.0 112.358 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 93.4 p -91.44 138.82 31.27 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.873 -179.84 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -93.96 169.47 10.25 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.092 179.932 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 158' ' ' SER . . . . . 0.556 ' HB2' ' CE1' ' A' ' 112' ' ' PHE . 86.9 p -140.72 153.52 45.96 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.85 -179.775 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -137.68 150.93 47.73 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.109 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 160' ' ' TYR . . . . . 0.486 ' CD1' ' N ' ' A' ' 160' ' ' TYR . 1.3 m-85 -115.57 125.79 53.4 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.919 -179.832 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.425 HG12 ' CE1' ' A' ' 163' ' ' TYR . 43.0 t -120.83 125.74 74.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.151 179.909 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 87.9 m -107.44 123.88 49.04 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.161 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 163' ' ' TYR . . . . . 0.425 ' CE1' HG12 ' A' ' 161' ' ' VAL . 30.3 m-85 -104.06 164.3 11.8 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.906 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 42.7 mt -94.05 -39.46 10.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.153 179.891 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 30.5 mtp180 -102.12 120.36 40.31 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.911 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 16.0 m -47.78 -56.49 7.28 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.823 -179.733 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 34.8 mt-10 -46.23 -52.46 12.42 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.904 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 23.3 m-20 -50.95 -48.18 60.95 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.801 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -55.29 -62.47 1.65 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.082 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 66.0 mt -41.63 -62.77 0.82 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.9 -179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 171' ' ' ARG . . . . . 0.414 ' O ' ' N ' ' A' ' 174' ' ' GLN . 20.0 mtp85 -51.76 -60.06 3.59 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.829 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . 0.486 ' HB2' ' CD2' ' A' ' 135' ' ' PHE . . . -38.75 -36.42 0.26 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.146 179.893 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 60.9 mt -80.96 -39.89 18.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.12 179.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 174' ' ' GLN . . . . . 0.414 ' N ' ' O ' ' A' ' 171' ' ' ARG . 51.3 mt-30 -66.93 -22.1 65.96 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.92 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 1.8 t -93.77 -37.27 11.87 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.913 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 176' ' ' VAL . . . . . 0.464 ' CG1' ' HB3' ' A' ' 188' ' ' ALA . 10.3 t -64.37 -33.77 64.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.082 -179.954 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 3.8 t30 -67.95 143.5 55.61 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.866 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 22.8 t30 65.52 48.94 1.91 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.905 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 53.0 t -127.27 135.64 62.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.14 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 59.3 t -96.9 100.31 10.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.148 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 66.9 t -107.52 97.98 6.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.175 179.909 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 6.8 t0 66.73 36.58 4.6 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.862 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 77.59 32.54 46.1 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.499 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 65.6 mtt85 -141.66 136.51 30.98 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.911 0.386 . . . . 0.0 110.866 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 26.6 m -94.73 95.0 8.44 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.161 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 79.8 mt -67.74 132.73 48.0 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.901 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 25.4 tptt -111.08 116.41 31.08 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.92 179.815 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . 0.464 ' HB3' ' CG1' ' A' ' 176' ' ' VAL . . . -112.38 134.28 54.01 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.101 179.824 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 7.7 t -158.51 171.75 19.56 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.815 -179.791 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 190' ' ' LEU . . . . . 0.547 ' C ' ' CD2' ' A' ' 190' ' ' LEU . 0.0 OUTLIER -119.25 158.77 25.37 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.936 179.998 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 191' ' ' GLY . . . . . 0.442 ' N ' HD22 ' A' ' 190' ' ' LEU . . . 64.01 29.3 74.48 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.491 179.91 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 192' ' ' THR . . . . . . . . . . . . . 6.9 m -94.84 118.37 31.66 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.897 0.379 . . . . 0.0 111.163 -179.859 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 193' ' ' THR . . . . . . . . . . . . . 60.5 p -126.41 166.32 17.41 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.108 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 20.5 mmmt -100.14 -57.45 2.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.893 179.907 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 195' ' ' TYR . . . . . . . . . . . . . 1.8 t80 -63.9 93.59 0.09 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.903 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 196' ' ' CYS . . . . . . . . . . . . . 25.7 p -49.97 138.08 15.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.899 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 64.1 p -141.62 153.64 44.89 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.825 -179.765 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 198' ' ' TYR . . . . . 0.563 ' CE2' ' O ' ' A' ' 199' ' ' SER . 67.1 t80 -148.47 167.23 25.86 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.96 -179.922 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 199' ' ' SER . . . . . 0.563 ' O ' ' CE2' ' A' ' 198' ' ' TYR . 37.5 p -136.65 164.48 28.12 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.877 -179.847 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . 128.61 -162.92 22.2 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.47 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 201' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 -27.86 6.6 Favored 'Cis proline' 0 C--N 1.341 0.161 0 C-N-CA 122.703 -1.79 . . . . 0.0 112.33 0.122 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 202' ' ' SER . . . . . . . . . . . . . 92.3 p -150.33 161.76 41.85 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.847 -179.838 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 44.1 t -101.46 134.65 44.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.826 -179.743 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.501 179.964 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.367 0 N-CA-C 112.507 -0.237 . . . . 0.0 112.507 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 23.7 p -156.35 128.38 7.42 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.87 0.367 . . . . 0.0 110.861 -179.768 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 85.4 p -108.88 148.13 31.09 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.874 -179.812 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 173.72 80.72 0.05 OUTLIER Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.464 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 21.9 p -125.7 166.23 17.15 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.856 0.36 . . . . 0.0 110.893 -179.81 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 3.7 t -109.93 102.37 11.13 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.855 -179.808 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 176.8 115.11 0.41 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.515 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -104.77 118.46 36.61 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.766 0.317 . . . . 0.0 111.077 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 2.1 m -166.13 171.55 12.24 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.835 -179.829 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 35.6 m -74.24 125.58 33.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.086 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 4.9 tpp85 -84.22 105.23 14.91 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.852 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 97.3 t -72.96 123.47 27.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.166 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 61.3 t -89.28 117.5 32.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.135 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 47.5 mm-40 -105.55 113.8 27.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.909 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 52.9 mttt -72.38 -44.55 62.38 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.871 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 1.2 p-10 -86.69 45.79 1.29 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.893 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 62.1 tp -139.47 120.47 14.57 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.92 179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 86.9 t -111.13 106.64 21.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.065 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.469 ' CE2' ' CG1' ' A' ' 114' ' ' VAL . 87.7 t80 -94.48 102.21 14.15 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.905 179.967 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 20.2 t -107.23 131.73 56.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.16 179.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . 0.469 ' CG1' ' CE2' ' A' ' 112' ' ' PHE . 6.1 m -119.2 155.01 21.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.113 179.942 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 90.81 44.35 4.54 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.452 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . 0.419 HD22 ' CD2' ' A' ' 186' ' ' LEU . 38.5 mt -110.25 125.0 52.65 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.823 0.344 . . . . 0.0 110.913 -179.943 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' SER . . . . . 0.484 ' O ' ' N ' ' A' ' 120' ' ' LEU . 22.8 p -69.09 139.97 54.81 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.84 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' GLN . . . . . 0.42 ' C ' ' O ' ' A' ' 117' ' ' SER . 37.4 mt-30 -36.38 -41.79 0.3 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.914 -179.924 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 26.6 mtm-85 -66.31 -44.12 84.33 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.886 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . 0.484 ' N ' ' O ' ' A' ' 117' ' ' SER . 34.5 mt -72.42 -24.74 61.27 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.912 -179.976 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -71.23 83.25 0.74 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.132 179.811 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' ASP . . . . . 0.449 ' CB ' HG22 ' A' ' 125' ' ' VAL . 20.0 m-20 -148.87 144.0 17.73 Favored Pre-proline 0 C--N 1.328 -0.364 0 CA-C-O 121.648 0.737 . . . . 0.0 110.88 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.73 -46.65 1.16 Allowed 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.69 2.26 . . . . 0.0 112.347 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 48.7 mt-10 -71.36 -43.31 67.16 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.924 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.556 HG13 ' CE2' ' A' ' 131' ' ' TYR . 90.5 t -60.19 -42.2 89.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.136 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . 0.465 HD22 ' CE1' ' A' ' 132' ' ' PHE . 64.6 mt -72.96 -39.48 66.15 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.898 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 18.6 ttmt -61.44 -31.95 71.92 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.9 179.855 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 91.7 mtt180 -43.02 143.94 1.17 Allowed Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.635 0.731 . . . . 0.0 110.88 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 -2.69 10.57 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.679 2.253 . . . . 0.0 112.384 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 25.7 mt-10 -97.57 -30.26 12.96 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.905 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' TYR . . . . . 0.556 ' CE2' HG13 ' A' ' 125' ' ' VAL . 44.2 m-85 -87.64 -74.91 0.43 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.921 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.465 ' CE1' HD22 ' A' ' 126' ' ' LEU . 42.6 m-85 -117.08 -36.84 3.69 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.88 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -49.34 -18.42 1.43 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.518 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -52.49 -34.22 48.34 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.832 0.349 . . . . 0.0 110.916 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 135' ' ' PHE . . . . . 0.565 ' CE2' ' HA ' ' A' ' 172' ' ' ALA . 79.8 m-85 -73.35 -42.02 62.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.897 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 166.89 -178.14 41.3 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.493 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 5.2 ttmm -60.01 140.28 56.88 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.762 0.315 . . . . 0.0 110.858 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 91.3 mt -105.67 139.03 28.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.112 179.862 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 34.3 t-80 -75.61 -55.15 5.94 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.866 179.868 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 140' ' ' LYS . . . . . 0.462 ' HD3' ' CG2' ' A' ' 142' ' ' VAL . 13.4 ttmm -149.49 144.16 26.11 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.916 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 23.9 t -122.43 103.63 13.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.109 179.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.462 ' CG2' ' HD3' ' A' ' 140' ' ' LYS . 63.1 t -100.65 140.82 18.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.157 179.873 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 26.7 mm -119.24 125.47 74.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.15 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 19.6 m-20 -121.2 142.75 49.6 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.88 179.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 18.4 p30 -138.15 140.57 39.92 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.871 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 43.7 p -84.09 94.21 8.29 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.87 -179.877 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 11.6 t -82.94 40.45 0.69 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.119 -179.926 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 74.4 m -108.29 164.08 12.63 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.89 -179.889 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . 0.574 ' O ' ' CD2' ' A' ' 149' ' ' TYR . 55.2 p90 -99.85 106.7 18.58 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.933 -179.919 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -107.74 -48.7 3.36 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.125 179.851 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 113.08 39.36 1.16 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.487 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 91.3 p -118.52 151.7 37.36 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.895 0.378 . . . . 0.0 110.827 -179.729 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 10.8 mm100 -89.75 100.42 13.23 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.896 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 95.2 83.16 1.62 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.464 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 140.43 42.7 Favored 'Trans proline' 0 C--N 1.341 0.139 0 C-N-CA 122.669 2.246 . . . . 0.0 112.391 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 82.0 p -101.01 143.15 31.5 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.844 -179.795 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -113.68 157.91 21.57 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.076 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 11.7 t -116.29 168.19 10.35 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.871 -179.763 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -148.48 147.29 28.95 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.058 179.893 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 160' ' ' TYR . . . . . 0.405 ' CD1' ' N ' ' A' ' 160' ' ' TYR . 4.5 m-85 -115.06 104.73 12.17 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.916 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 95.3 t -99.51 126.45 52.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.146 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 96.7 m -95.9 123.76 39.62 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.14 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 12.1 m-85 -106.13 121.99 45.27 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.949 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 46.0 mt -57.38 -51.5 68.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.097 -0.502 . . . . 0.0 111.154 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 39.7 mtp180 -85.72 118.08 25.0 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.847 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 22.6 t -48.72 -47.4 41.33 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.868 -179.82 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -54.36 -56.22 20.77 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.905 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -52.39 -31.9 36.17 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.867 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -70.49 -66.19 0.63 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.113 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . 0.409 HD21 ' CD1' ' A' ' 190' ' ' LEU . 31.1 mt -46.6 -56.17 6.5 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.894 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 84.9 mtt180 -56.59 -46.56 80.78 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.854 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . 0.565 ' HA ' ' CE2' ' A' ' 135' ' ' PHE . . . -51.88 -32.73 33.56 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.076 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 65.8 mt -79.13 -36.4 18.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.11 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 15.7 mm100 -65.84 -26.93 67.88 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.874 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 175' ' ' CYS . . . . . 0.401 ' O ' ' CG2' ' A' ' 179' ' ' VAL . 7.6 m -93.7 -36.63 12.23 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.907 -179.949 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 10.5 t -65.43 -40.11 87.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.083 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 7.4 p-10 -68.32 152.1 45.93 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.891 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 36.5 t30 57.1 48.77 14.84 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.882 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 179' ' ' VAL . . . . . 0.401 ' CG2' ' O ' ' A' ' 175' ' ' CYS . 94.3 t -133.56 140.21 47.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.113 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 87.1 t -99.08 105.35 17.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.097 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 91.8 t -112.06 98.73 7.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.133 179.901 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 30.9 t0 60.7 52.42 4.43 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.841 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 63.27 24.19 67.11 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.492 -179.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 66.3 mtp85 -131.61 111.91 12.14 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.874 0.369 . . . . 0.0 110.86 -179.826 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 28.2 m -76.09 93.19 3.28 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.127 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 186' ' ' LEU . . . . . 0.419 ' CD2' HD22 ' A' ' 116' ' ' LEU . 80.2 mt -68.54 128.99 38.61 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.931 179.916 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 2.5 mmmp? -117.6 118.29 31.73 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.877 179.847 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -107.19 145.56 32.46 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.127 179.819 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 4.5 t -143.33 169.32 17.88 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.857 -179.74 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 190' ' ' LEU . . . . . 0.409 ' CD1' HD21 ' A' ' 170' ' ' LEU . 8.6 tt -128.81 134.89 48.51 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.904 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 94.29 23.62 21.46 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.486 179.91 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 192' ' ' THR . . . . . . . . . . . . . 35.5 m -88.17 118.48 27.79 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.867 0.365 . . . . 0.0 111.176 -179.848 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 193' ' ' THR . . . . . . . . . . . . . 81.8 p -88.45 171.23 10.26 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.121 -179.914 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 3.7 mppt? -110.15 135.32 51.12 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.883 179.912 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 195' ' ' TYR . . . . . . . . . . . . . 40.9 m-85 -68.77 -47.89 65.07 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.875 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 196' ' ' CYS . . . . . . . . . . . . . 2.1 t -44.46 -62.39 1.2 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.924 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 46.7 t -65.76 98.38 0.39 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.879 -179.795 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 198' ' ' TYR . . . . . . . . . . . . . 74.6 t80 -91.51 96.26 10.39 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.889 -179.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 1.3 t -155.34 119.69 4.67 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.864 -179.868 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . -71.7 -66.15 2.2 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.5 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 201' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.8 -13.09 12.43 Favored 'Cis proline' 0 C--N 1.341 0.152 0 C-N-CA 122.649 -1.813 . . . . 0.0 112.36 0.044 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 202' ' ' SER . . . . . . . . . . . . . 17.3 t -65.54 109.15 2.25 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.829 -179.84 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 18.2 p -93.41 124.6 37.51 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.874 -179.826 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.27 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.49 -179.977 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.251 0 N-CA-C 112.48 -0.248 . . . . 0.0 112.48 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 74.9 m -138.58 126.74 22.77 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.919 0.39 . . . . 0.0 110.87 -179.719 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 93.4 p 44.98 38.81 3.22 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.881 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 103.56 -150.66 17.64 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.479 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 42.0 m -105.72 -60.34 1.64 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.857 0.36 . . . . 0.0 110.844 -179.733 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 29.0 p -173.4 171.8 3.89 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.848 -179.804 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -117.52 -179.28 17.49 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.458 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -50.52 161.36 0.33 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.824 0.345 . . . . 0.0 111.085 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 46.2 m -79.99 -49.36 11.94 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.867 -179.795 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 22.4 m -84.5 151.51 3.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.148 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 29.9 mtt85 -98.81 126.36 44.43 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.842 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 14.2 p -131.85 135.09 59.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.105 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 4.9 m -119.12 129.53 75.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.151 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 20.3 tp60 -164.54 153.92 13.49 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.914 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 22.5 mmtm -102.52 -52.06 3.19 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.918 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 29.0 p-10 -86.24 49.58 1.82 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.863 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 11.5 tp -130.53 146.77 52.12 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.908 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 85.2 t -122.55 111.75 31.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.105 179.872 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.433 ' CE1' ' HB2' ' A' ' 158' ' ' SER . 42.1 t80 -98.46 113.34 25.3 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.889 179.991 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.431 HG21 ' CZ ' ' A' ' 132' ' ' PHE . 92.8 t -110.68 137.23 43.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.117 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 35.9 m -126.91 168.19 20.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.147 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 74.29 41.67 37.42 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.476 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 50.5 mt -103.54 130.84 51.02 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.797 0.332 . . . . 0.0 110.94 -179.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' SER . . . . . 0.491 ' O ' ' N ' ' A' ' 120' ' ' LEU . 89.6 p -77.37 142.65 39.2 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.85 -179.934 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' GLN . . . . . 0.442 ' C ' ' O ' ' A' ' 117' ' ' SER . 55.0 mm-40 -34.85 -40.36 0.11 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.892 -179.938 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 25.0 mtm-85 -63.34 -47.26 82.93 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.871 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . 0.491 ' N ' ' O ' ' A' ' 117' ' ' SER . 20.7 mt -72.44 -29.44 63.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.936 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -65.46 82.99 0.06 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.099 179.81 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' ASP . . . . . 0.403 ' HB2' ' CG2' ' A' ' 125' ' ' VAL . 19.4 m-20 -149.0 143.84 17.46 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.599 0.714 . . . . 0.0 110.863 179.985 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 -44.26 2.19 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.682 2.255 . . . . 0.0 112.389 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 66.3 mm-40 -74.2 -38.61 63.54 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.886 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.586 ' O ' ' CD1' ' A' ' 131' ' ' TYR . 68.9 t -61.0 -49.5 84.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.103 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 92.8 mt -66.33 -43.36 86.36 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.943 179.936 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.467 ' HA ' ' CD1' ' A' ' 138' ' ' ILE . 31.1 tttm -61.64 -42.71 99.27 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.878 179.849 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . 0.424 ' C ' ' O ' ' A' ' 127' ' ' LYS . 21.4 mmt180 -35.61 143.28 0.26 Allowed Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.643 0.735 . . . . 0.0 110.826 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.75 -1.4 8.4 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.66 2.24 . . . . 0.0 112.34 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 10.2 mp0 -103.26 -0.98 29.57 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.884 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' TYR . . . . . 0.586 ' CD1' ' O ' ' A' ' 125' ' ' VAL . 47.0 m-85 -117.06 -74.15 0.62 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.913 -179.879 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.431 ' CZ ' HG21 ' A' ' 113' ' ' VAL . 46.5 m-85 -121.75 -17.85 7.28 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.91 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -72.08 -1.44 48.88 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.491 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 1.3 ptpp? -78.85 -19.67 51.46 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.78 0.324 . . . . 0.0 110.894 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 135' ' ' PHE . . . . . 0.565 ' CD2' ' HB2' ' A' ' 172' ' ' ALA . 58.2 m-85 -85.62 -38.17 18.72 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.856 -179.99 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -179.72 -174.52 45.74 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.511 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 45.9 mtpt -81.49 134.62 35.55 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.779 0.323 . . . . 0.0 110.889 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.467 ' CD1' ' HA ' ' A' ' 127' ' ' LYS . 65.1 mt -94.98 147.03 6.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.155 179.861 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 4.6 t60 -99.11 -43.61 6.59 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.891 179.901 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 26.5 ttpt -148.28 143.69 27.12 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.95 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 41.3 t -127.23 121.17 56.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.208 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 72.4 t -125.71 145.27 33.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.153 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 29.1 mm -115.8 141.82 31.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.118 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 48.2 t30 -129.45 142.92 50.67 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.916 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 44.7 t-20 -129.13 136.6 50.42 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.831 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 44.3 t -68.06 105.49 2.06 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.829 -179.844 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 42.9 p -92.03 -52.29 4.79 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.168 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 47.2 t -65.98 111.52 3.38 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.835 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 47.6 m-85 -71.4 107.65 4.44 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.961 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -84.44 41.22 0.82 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.076 179.911 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 88.61 -19.57 36.02 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.496 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 2.7 m -100.67 143.22 31.1 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.798 0.332 . . . . 0.0 110.876 -179.74 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 14.7 mp0 -101.16 132.77 46.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.891 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 74.25 61.35 3.24 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.506 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 -173.56 0.74 Allowed 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.672 2.248 . . . . 0.0 112.357 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 69.6 m -107.94 155.01 20.79 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.868 -179.854 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -103.92 149.14 25.38 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.079 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 158' ' ' SER . . . . . 0.433 ' HB2' ' CE1' ' A' ' 112' ' ' PHE . 53.1 p -117.21 171.59 7.85 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.89 -179.803 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -146.79 133.55 20.03 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.12 179.875 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 38.7 m-85 -104.48 113.75 27.53 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.905 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 98.7 t -109.13 123.93 65.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.129 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 40.4 m -98.02 123.88 42.24 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.134 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 9.8 m-85 -105.99 146.73 29.69 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.923 -179.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 86.9 mt -79.41 -36.24 17.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.133 179.883 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 31.9 mmm-85 -106.93 117.08 33.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.872 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 74.2 m -49.24 -51.11 35.39 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.846 -179.771 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 18.5 mm-40 -48.74 -51.02 31.11 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.897 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -54.26 -45.13 72.34 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.871 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -60.24 -62.61 1.74 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.094 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 50.6 mt -41.57 -66.38 0.35 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.9 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 79.2 mtp180 -48.37 -54.43 13.97 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.869 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . 0.565 ' HB2' ' CD2' ' A' ' 135' ' ' PHE . . . -43.51 -35.16 1.56 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.083 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 63.6 mt -77.92 -40.46 26.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.183 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 88.2 mm-40 -61.36 -27.57 68.61 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.914 179.918 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 175' ' ' CYS . . . . . 0.477 ' O ' ' CG2' ' A' ' 179' ' ' VAL . 1.9 m -93.82 -42.1 9.29 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.882 -179.914 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 10.3 t -58.07 -36.27 56.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.14 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 12.3 t-20 -68.41 150.83 47.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.873 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 178' ' ' ASN . . . . . 0.411 ' CG ' ' O ' ' A' ' 178' ' ' ASN . 37.4 t30 57.66 42.84 23.25 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.854 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 179' ' ' VAL . . . . . 0.477 ' CG2' ' O ' ' A' ' 175' ' ' CYS . 62.0 t -128.68 135.03 63.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.142 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 90.3 t -98.97 106.38 18.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.129 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 57.1 t -114.18 121.32 66.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.115 179.909 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 14.4 m-20 51.23 28.45 4.17 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.844 179.908 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 81.47 32.01 32.07 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.493 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 4.2 mpt_? -138.69 124.47 19.79 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.878 0.37 . . . . 0.0 110.878 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 19.4 m -76.65 93.28 3.6 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.122 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 51.0 mt -62.01 125.98 25.76 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.875 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 9.5 tptm -122.86 112.28 17.68 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.922 179.788 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -107.57 153.19 23.22 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.128 179.826 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 48.0 m -139.2 156.34 47.17 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.877 -179.765 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 190' ' ' LEU . . . . . 0.452 ' CD1' ' C ' ' A' ' 190' ' ' LEU . 1.5 tm? -120.2 102.28 8.4 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.913 179.968 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 55.2 27.85 47.7 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.494 179.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 192' ' ' THR . . . . . . . . . . . . . 51.3 p -138.06 138.57 38.91 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.848 0.356 . . . . 0.0 111.12 -179.829 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 193' ' ' THR . . . . . . . . . . . . . 8.5 t -119.41 -30.14 4.96 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.122 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 69.6 mttt -111.57 -72.18 0.73 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.912 179.866 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 195' ' ' TYR . . . . . . . . . . . . . 7.3 m-85 -108.64 131.83 54.5 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.904 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 196' ' ' CYS . . . . . . . . . . . . . 26.5 p -63.31 177.19 0.67 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.901 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 1.8 m -159.29 167.89 27.8 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.827 -179.771 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 198' ' ' TYR . . . . . . . . . . . . . 36.3 p90 -161.21 156.95 24.96 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.944 -179.857 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 65.0 p -167.9 148.98 5.22 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.883 -179.83 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . -115.31 -162.73 13.67 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.466 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 201' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 132.91 23.64 Favored 'Cis proline' 0 C--N 1.341 0.173 0 C-N-CA 122.674 -1.803 . . . . 0.0 112.36 -0.013 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 202' ' ' SER . . . . . . . . . . . . . 13.0 t -106.39 75.76 1.1 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.819 -179.788 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 1.1 t -108.58 152.3 24.95 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.837 -179.833 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.274 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.487 179.979 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.324 0 N-CA-C 112.438 -0.265 . . . . 0.0 112.438 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 29.1 m -160.78 112.65 1.9 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.839 0.352 . . . . 0.0 110.915 -179.772 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 82.9 p -97.67 168.07 10.57 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.825 -179.759 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 152.65 118.93 0.77 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.505 -179.952 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 15.0 t -111.23 143.54 41.82 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.867 0.365 . . . . 0.0 110.847 -179.739 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 23.8 t -126.53 118.89 25.83 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.86 -179.81 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -123.17 -174.87 14.37 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.461 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -95.44 136.24 36.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.824 0.345 . . . . 0.0 111.058 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 51.4 m -150.73 166.76 29.43 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.826 -179.782 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 30.1 m -73.15 139.16 19.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.183 179.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 57.2 ttp180 -126.62 136.86 53.07 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.842 -179.926 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 11.0 t -122.6 155.58 27.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.15 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 13.0 p -104.37 120.87 55.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.165 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 4.1 pt20 -173.82 120.88 0.31 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.954 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 35.4 pttt -91.85 41.35 1.07 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.92 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . 0.431 ' ND2' ' O ' ' A' ' 163' ' ' TYR . 26.1 t-20 -115.89 40.6 2.75 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.897 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 15.8 tp -143.94 142.06 30.55 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.938 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 99.1 t -122.47 110.97 28.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.13 179.833 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 46.4 t80 -102.83 108.03 19.1 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.853 -179.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 86.0 t -105.2 134.46 46.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.155 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 34.0 m -124.42 167.04 18.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.08 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 78.58 49.21 6.77 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.541 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 28.8 mt -113.78 139.89 48.75 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.823 0.344 . . . . 0.0 110.91 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 36.0 t -73.83 146.44 44.16 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.872 -179.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 25.4 mt-30 -42.19 -29.93 0.27 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.94 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 56.2 ttt180 -88.41 -38.23 15.23 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.872 -179.913 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 44.8 mt -65.18 -33.8 76.87 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.905 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -70.16 83.08 0.52 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.151 179.802 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 21.7 m-20 -148.93 147.1 23.07 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.605 0.717 . . . . 0.0 110.86 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 -37.24 9.53 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.708 2.272 . . . . 0.0 112.36 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 14.9 pt-20 -77.29 -44.43 29.74 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.87 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 86.1 t -61.71 -39.93 85.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.158 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 91.2 mt -74.2 -39.31 63.23 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.933 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 2.0 mmmp? -64.64 -30.81 71.83 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.86 179.867 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 14.7 mmt180 -42.44 143.93 1.03 Allowed Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.591 0.71 . . . . 0.0 110.876 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 -4.19 13.51 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.66 2.24 . . . . 0.0 112.337 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 4.8 tt0 -99.98 1.07 42.23 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.895 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' TYR . . . . . . . . . . . . . 30.7 m-85 -121.0 -74.93 0.6 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.888 -179.831 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 58.0 m-85 -122.99 -18.14 6.5 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.867 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -55.59 -23.03 34.41 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.499 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 12.4 ptpt -90.83 -11.36 39.58 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.796 0.331 . . . . 0.0 110.858 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 135' ' ' PHE . . . . . . . . . . . . . 22.9 m-85 -80.42 -33.23 37.12 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.925 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 173.65 -166.25 38.45 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.444 -179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 39.4 tptt -95.65 109.27 21.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.737 0.303 . . . . 0.0 110.911 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.453 HG21 ' CG2' ' A' ' 141' ' ' VAL . 86.2 mt -76.71 140.26 17.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.145 179.864 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 18.6 t60 -114.12 -51.07 2.79 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.9 179.871 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -127.28 135.63 50.84 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.868 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . 0.453 ' CG2' HG21 ' A' ' 138' ' ' ILE . 19.2 t -137.49 143.04 35.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.129 179.886 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.401 HG12 ' N ' ' A' ' 143' ' ' ILE . 74.6 t -145.34 140.18 22.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.132 179.959 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . 0.401 ' N ' HG12 ' A' ' 142' ' ' VAL . 24.6 mm -110.94 126.43 68.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.096 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 2.9 m120 -124.45 137.78 54.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.905 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 5.3 p30 -105.37 159.48 15.87 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.908 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 66.9 p -52.17 127.67 22.51 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.89 -179.84 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 22.4 p -99.14 -44.76 6.15 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.143 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 2.1 m -74.5 155.35 38.06 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.854 -179.852 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 79.7 m-85 -108.11 100.17 9.53 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.903 -179.878 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -85.81 -45.9 11.15 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.081 179.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 110.02 -20.01 26.91 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.519 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 48.3 m -67.06 142.53 57.12 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.826 0.346 . . . . 0.0 110.853 -179.735 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 2.1 mp0 -70.35 142.53 52.14 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.885 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 82.42 83.59 0.84 Allowed Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.447 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 152.68 69.35 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.688 2.259 . . . . 0.0 112.369 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 55.8 m -117.9 133.78 55.59 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.861 -179.815 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -112.85 149.71 32.73 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.091 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 89.9 p -113.71 158.27 21.14 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.852 -179.803 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -141.08 128.52 21.21 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.102 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 35.9 m-85 -99.91 126.56 46.06 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.932 -179.871 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 96.6 t -129.09 137.59 56.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.101 179.958 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 96.0 m -108.31 134.42 51.16 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.162 180.0 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 163' ' ' TYR . . . . . 0.431 ' O ' ' ND2' ' A' ' 109' ' ' ASN . 16.1 m-85 -111.8 129.51 56.11 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.937 -179.927 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 56.2 mt -61.46 -41.04 88.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.097 -0.502 . . . . 0.0 111.155 179.918 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 82.3 mtt-85 -91.66 113.78 26.14 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.895 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 23.2 t -52.16 -59.54 4.25 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.832 -179.751 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 54.1 tt0 -47.31 -49.19 24.56 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.898 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 4.9 t0 -52.48 -51.16 60.78 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.884 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -54.2 -57.74 10.0 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.078 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 42.0 mt -43.56 -61.43 1.39 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.931 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 41.9 mtt-85 -54.6 -43.51 72.24 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.85 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . 0.417 ' O ' ' CG2' ' A' ' 176' ' ' VAL . . . -54.39 -30.98 53.88 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.123 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 97.3 mt -82.54 -34.51 11.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.103 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 11.2 mm-40 -68.2 -27.82 66.72 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.911 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 175' ' ' CYS . . . . . 0.44 ' O ' ' CG2' ' A' ' 179' ' ' VAL . 2.0 m -93.75 -35.59 12.7 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.89 -179.954 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 176' ' ' VAL . . . . . 0.417 ' CG2' ' O ' ' A' ' 172' ' ' ALA . 10.5 t -66.48 -29.92 48.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.146 -179.974 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 4.3 t-20 -73.41 126.95 31.36 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.844 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 26.2 t-20 74.41 52.08 0.09 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.863 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 179' ' ' VAL . . . . . 0.44 ' CG2' ' O ' ' A' ' 175' ' ' CYS . 69.5 t -130.83 132.78 63.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.138 179.905 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 86.6 t -92.54 107.44 19.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.182 179.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 98.3 t -121.0 113.79 41.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.11 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 4.4 t70 58.78 26.51 14.82 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.905 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 81.33 26.67 51.16 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.508 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 3.1 mpt_? -136.27 123.48 21.77 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.932 0.396 . . . . 0.0 110.872 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 18.3 m -76.26 101.64 5.53 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.154 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 89.0 mt -78.18 125.21 29.03 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.957 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 38.1 mmtt -118.5 117.99 30.49 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.898 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -106.9 140.72 39.27 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.105 179.81 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 59.3 m -145.03 162.88 35.86 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.853 -179.768 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 190' ' ' LEU . . . . . 0.409 ' C ' HD11 ' A' ' 190' ' ' LEU . 3.5 pp -130.24 153.31 48.74 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.927 180.0 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 79.74 28.39 51.21 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.525 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 192' ' ' THR . . . . . . . . . . . . . 3.0 t -106.18 134.05 49.92 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.862 0.363 . . . . 0.0 111.183 -179.891 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 193' ' ' THR . . . . . . . . . . . . . 78.3 p -116.15 157.38 24.89 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.14 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 22.7 tptp -114.69 121.57 43.76 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.939 179.873 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 195' ' ' TYR . . . . . . . . . . . . . 31.0 m-85 -50.19 98.73 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.908 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 196' ' ' CYS . . . . . . . . . . . . . 29.6 p -103.17 128.8 50.0 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.934 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 23.3 t -143.89 142.38 30.76 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.839 -179.735 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 198' ' ' TYR . . . . . . . . . . . . . 11.1 p90 -154.4 173.42 16.24 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.92 -179.865 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 9.1 t -96.49 159.94 14.67 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.904 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . 60.92 -166.05 13.69 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.514 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 201' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.78 166.02 75.18 Favored 'Cis proline' 0 C--O 1.231 0.155 0 C-N-CA 122.689 -1.796 . . . . 0.0 112.372 0.067 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 202' ' ' SER . . . . . . . . . . . . . 2.5 m -50.06 154.12 1.22 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.828 -179.826 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 52.2 p -101.09 92.26 4.92 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.837 -179.832 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.289 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.465 179.977 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.327 0 N-CA-C 112.46 -0.256 . . . . 0.0 112.46 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 4.9 m -118.69 115.12 23.85 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.85 0.357 . . . . 0.0 110.879 -179.732 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 14.9 t -126.2 136.05 52.36 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.874 -179.826 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 92.33 65.21 1.11 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.517 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 44.5 t -65.79 145.66 55.7 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.855 0.359 . . . . 0.0 110.868 -179.722 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 59.7 p -88.87 174.11 8.14 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.857 -179.782 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -162.39 169.38 37.68 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.53 -180.0 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -49.89 166.26 0.07 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.793 0.33 . . . . 0.0 111.122 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 70.2 m -124.76 85.72 2.45 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.833 -179.762 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 14.7 p -82.76 148.84 4.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.136 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 13.6 ptp180 -103.48 96.35 6.68 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.825 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 42.6 t -97.28 139.01 20.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.129 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . 0.458 HG21 ' N ' ' A' ' 107' ' ' GLN . 7.2 p -110.19 142.79 21.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.181 179.905 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.458 ' N ' HG21 ' A' ' 106' ' ' VAL . 16.7 mm-40 62.69 49.82 3.67 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.93 -179.945 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 43.9 mtmt -70.86 99.13 1.69 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.931 179.92 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 1.8 p-10 -131.83 50.61 2.22 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.904 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 19.5 tp -142.71 112.7 7.02 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.876 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 71.2 t -114.38 124.05 70.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.161 179.804 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.507 ' CE1' ' HB2' ' A' ' 158' ' ' SER . 65.2 t80 -106.55 108.32 19.77 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.866 -179.919 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 40.2 t -110.7 132.18 59.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.1 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 23.7 m -121.71 160.7 23.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.137 179.919 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 86.33 51.99 3.35 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.496 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 82.4 mt -116.17 134.44 54.92 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.808 0.337 . . . . 0.0 110.96 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 10.6 t -69.48 149.26 48.47 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.854 -179.92 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 1.4 pp0? -47.58 -31.9 4.92 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.96 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 17.0 ttt180 -84.47 -39.75 18.53 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.898 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 83.1 mt -66.68 -28.95 68.86 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.918 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -70.69 85.18 0.64 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.105 179.81 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -148.11 144.29 18.69 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.596 0.712 . . . . 0.0 110.855 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.76 -49.45 0.56 Allowed 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.66 2.24 . . . . 0.0 112.357 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 26.0 mt-10 -66.68 -41.88 87.39 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.806 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.596 ' O ' ' CD2' ' A' ' 131' ' ' TYR . 87.8 t -62.64 -42.97 98.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.129 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 89.1 mt -73.18 -42.59 62.56 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.948 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 4.7 mtmp? -61.43 -27.49 68.59 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.934 179.809 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 13.5 mtm180 -53.89 144.01 38.61 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.633 0.73 . . . . 0.0 110.892 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.81 1.89 4.06 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.691 2.261 . . . . 0.0 112.309 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 8.1 mp0 -101.67 -13.85 17.62 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.924 180.0 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 131' ' ' TYR . . . . . 0.596 ' CD2' ' O ' ' A' ' 125' ' ' VAL . 52.6 m-85 -109.41 -71.17 0.77 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.899 -179.82 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.457 ' O ' ' N ' ' A' ' 134' ' ' LYS . 25.1 m-85 -122.14 -40.14 2.53 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.895 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . 0.404 ' C ' ' O ' ' A' ' 132' ' ' PHE . . . -38.17 -28.57 0.05 OUTLIER Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.709 -0.757 . . . . 0.0 112.48 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.457 ' N ' ' O ' ' A' ' 132' ' ' PHE . 8.8 ptmm? -52.89 -53.79 44.11 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.831 0.348 . . . . 0.0 110.873 -179.949 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 135' ' ' PHE . . . . . 0.413 ' CD1' ' HA ' ' A' ' 172' ' ' ALA . 70.3 m-85 -52.62 -40.22 62.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.909 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -177.66 178.62 48.4 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.476 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 28.2 mtpt -86.15 97.58 10.41 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.774 0.321 . . . . 0.0 110.915 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 71.7 mt -62.06 140.61 18.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.138 179.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 17.2 t-80 -97.34 -54.1 3.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.859 179.872 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 140' ' ' LYS . . . . . 0.422 ' HD2' ' C ' ' A' ' 140' ' ' LYS . 1.2 tmmt? -126.79 152.1 47.38 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.922 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 54.4 t -139.82 145.46 26.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.133 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 23.5 t -138.9 116.65 12.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.113 179.925 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 7.2 mm -101.57 127.81 54.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.157 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 34.6 m-80 -126.71 106.66 9.53 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.903 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 6.6 p30 -126.83 157.18 39.96 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.89 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 3.3 t -55.82 170.62 0.27 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.817 -179.814 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 31.0 m -76.68 -55.27 5.65 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.148 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 21.9 t -113.92 119.87 38.74 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.884 -179.842 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 27.5 p90 -112.97 133.16 55.06 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.903 -179.861 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -103.41 -44.33 5.17 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.139 179.854 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 116.44 39.42 0.86 Allowed Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.493 -179.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 7.3 m -114.55 174.07 6.14 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.771 0.32 . . . . 0.0 110.902 -179.757 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 13.6 pt20 -82.77 133.52 35.14 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.889 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 134.94 -71.98 0.48 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.507 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 120.91 7.62 Favored 'Trans proline' 0 C--N 1.342 0.228 0 C-N-CA 122.696 2.264 . . . . 0.0 112.325 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 4.2 m -120.81 161.15 21.98 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.882 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -108.39 163.66 13.01 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.082 179.938 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 158' ' ' SER . . . . . 0.507 ' HB2' ' CE1' ' A' ' 112' ' ' PHE . 34.8 p -138.57 156.05 47.83 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.826 -179.782 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -148.9 152.15 35.9 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.083 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 19.8 m-85 -111.94 121.59 45.44 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.906 -179.852 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 61.9 t -109.43 131.62 59.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.114 -0.493 . . . . 0.0 111.079 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 20.8 m -101.26 124.4 46.89 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.116 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 9.5 m-85 -104.53 137.53 42.24 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.946 -179.911 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 68.4 mt -62.21 -49.21 84.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.123 179.934 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 34.0 mtt85 -104.11 127.35 51.69 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.889 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 75.6 m -53.65 -58.2 8.05 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.881 -179.779 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 66.0 mm-40 -43.7 -49.24 7.9 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.872 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -55.54 -49.44 72.64 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.887 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -56.44 -56.03 26.28 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.054 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 39.5 mt -45.41 -63.3 0.98 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.918 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 46.3 mtp180 -53.75 -48.12 69.98 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.86 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . 0.471 ' O ' ' CG2' ' A' ' 176' ' ' VAL . . . -48.36 -34.14 10.18 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.145 179.899 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 67.3 mt -80.68 -37.26 16.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.147 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 42.5 mt-30 -63.48 -27.79 69.52 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.952 179.875 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 2.6 t -93.81 -36.73 12.12 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.889 -179.927 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 176' ' ' VAL . . . . . 0.471 ' CG2' ' O ' ' A' ' 172' ' ' ALA . 11.3 t -58.31 -42.46 83.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.133 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 22.6 t30 -65.94 141.68 58.14 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.855 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 7.3 t30 69.37 51.33 0.5 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.884 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 96.9 t -135.13 137.87 49.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.092 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 94.7 t -98.64 109.21 23.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.125 179.889 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 84.2 t -116.58 102.44 13.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.116 179.918 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 6.9 t70 58.29 35.96 25.28 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.87 179.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 78.61 26.22 59.35 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.484 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 30.0 mtt-85 -133.8 115.6 14.7 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.917 0.389 . . . . 0.0 110.839 -179.833 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 23.5 m -79.73 92.76 5.45 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.157 -179.939 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 73.3 mt -62.95 136.46 57.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.927 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 13.6 tptp -123.81 116.43 22.96 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.886 179.8 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -112.47 140.13 47.47 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.093 179.807 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 74.5 m -140.15 157.94 44.83 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.858 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 190' ' ' LEU . . . . . . . . . . . . . 7.3 tt -131.75 122.66 26.22 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.901 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 109.7 28.51 4.22 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.5 179.909 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 192' ' ' THR . . . . . . . . . . . . . 39.1 p -122.01 116.11 23.71 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.859 0.361 . . . . 0.0 111.123 -179.869 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 193' ' ' THR . . . . . . . . . . . . . 74.3 p -108.62 142.25 39.35 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.128 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 12.9 tmtt? -106.14 -55.97 2.25 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.857 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 195' ' ' TYR . . . . . . . . . . . . . 27.7 t80 -169.81 128.67 0.94 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.929 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 196' ' ' CYS . . . . . . . . . . . . . 20.9 p -164.61 152.93 12.4 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.928 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 66.9 p -40.44 129.29 2.42 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.839 -179.716 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 198' ' ' TYR . . . . . . . . . . . . . 14.2 p90 -105.49 170.02 8.13 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.889 -179.866 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 22.9 t -140.51 158.55 43.83 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.844 -179.815 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 200' ' ' GLY . . . . . 0.484 ' N ' ' O ' ' A' ' 201' ' ' PRO . . . 77.14 80.32 0.65 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.482 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 201' ' ' PRO . . . . . 0.484 ' O ' ' N ' ' A' ' 200' ' ' GLY . 53.4 Cg_endo -69.8 171.55 53.29 Favored 'Cis proline' 0 C--O 1.231 0.163 0 C-N-CA 122.666 -1.806 . . . . 0.0 112.33 0.052 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 202' ' ' SER . . . . . . . . . . . . . 10.2 t -108.77 -48.14 3.35 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.873 -179.825 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 45.0 m -105.14 165.61 10.97 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.833 -179.791 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.317 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.482 -179.984 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.314 0 N-CA-C 112.486 -0.246 . . . . 0.0 112.486 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 6.6 m -98.46 101.91 13.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.894 0.378 . . . . 0.0 110.839 -179.72 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 35.9 p -138.97 148.16 43.13 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.835 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 122.86 52.86 0.21 Allowed Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.483 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.8 t 65.85 41.9 3.65 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.853 0.359 . . . . 0.0 110.828 -179.731 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 42.2 m -97.18 173.82 7.04 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.854 -179.866 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 166.03 -177.75 40.97 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.48 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.437 ' O ' ' C ' ' A' ' 102' ' ' SER . . . -78.81 137.31 37.65 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.853 0.359 . . . . 0.0 111.052 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' SER . . . . . 0.437 ' C ' ' O ' ' A' ' 101' ' ' ALA . 5.2 t -35.27 -43.71 0.24 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.884 -179.824 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 99.7 t -73.06 131.63 34.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.145 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 11.9 mpt_? -78.2 124.25 27.85 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.877 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 2.6 p -129.13 132.87 66.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.141 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 9.8 p -118.68 153.8 20.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.116 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 18.8 mm100 62.31 52.52 3.07 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.949 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.432 ' HG2' ' CD1' ' A' ' 190' ' ' LEU . 3.1 mppt? -70.98 87.19 0.73 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.925 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . 0.409 ' CG ' ' O ' ' A' ' 109' ' ' ASN . 28.7 t-20 -102.66 42.62 1.13 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.884 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 23.3 tp -139.61 146.07 39.31 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.888 -179.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 45.1 t -133.07 107.7 11.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.107 179.828 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.562 ' CD1' ' CZ ' ' A' ' 160' ' ' TYR . 67.4 t80 -102.88 113.61 27.19 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.907 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 38.2 t -111.18 145.67 17.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.101 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 23.1 m -130.97 170.59 19.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.1 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 79.15 51.12 5.47 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.481 179.906 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 23.5 mt -118.03 131.03 56.5 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.829 0.347 . . . . 0.0 110.922 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' SER . . . . . 0.484 ' O ' ' N ' ' A' ' 119' ' ' ARG . 23.1 t -70.95 140.19 50.85 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.812 -179.868 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' GLN . . . . . 0.434 ' C ' ' O ' ' A' ' 117' ' ' SER . 9.5 tp-100 -35.54 -32.06 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.934 -179.979 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.484 ' N ' ' O ' ' A' ' 117' ' ' SER . 18.5 tpp180 -81.49 -47.12 13.56 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.856 -179.91 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . 0.453 ' N ' ' O ' ' A' ' 117' ' ' SER . 62.4 mt -61.83 -33.69 74.6 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.952 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -66.09 86.79 0.1 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.095 179.815 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' ASP . . . . . 0.407 ' CB ' HG21 ' A' ' 125' ' ' VAL . 0.6 OUTLIER -148.07 144.03 18.38 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.622 0.725 . . . . 0.0 110.871 179.969 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.81 -50.28 0.47 Allowed 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.649 2.232 . . . . 0.0 112.313 -179.984 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 42.7 mt-10 -68.14 -45.68 72.91 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.881 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.415 ' O ' ' CD1' ' A' ' 131' ' ' TYR . 58.4 t -60.03 -39.39 80.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.135 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 47.3 mt -74.63 -42.01 59.36 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.942 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.453 ' HA ' ' CD1' ' A' ' 138' ' ' ILE . 17.3 ttmt -59.48 -30.73 68.75 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.91 179.85 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 46.8 mtt180 -39.94 143.87 0.57 Allowed Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.583 0.706 . . . . 0.0 110.893 179.949 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 2.94 3.1 Favored 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.645 2.23 . . . . 0.0 112.319 -179.984 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -106.67 -30.09 9.2 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.879 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 131' ' ' TYR . . . . . 0.415 ' CD1' ' O ' ' A' ' 125' ' ' VAL . 43.4 m-85 -86.01 -75.05 0.39 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.933 -179.844 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 17.0 m-85 -115.32 -39.72 3.55 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.888 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -52.61 -20.55 7.81 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.488 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.422 ' HD2' ' CG ' ' A' ' 135' ' ' PHE . 0.0 OUTLIER -51.2 -40.96 59.86 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.791 0.329 . . . . 0.0 110.875 -179.964 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 135' ' ' PHE . . . . . 0.422 ' CG ' ' HD2' ' A' ' 134' ' ' LYS . 83.1 m-85 -66.26 -46.38 77.27 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.882 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -173.86 -159.87 21.13 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.506 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 17.0 tptm -91.15 116.23 28.65 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.799 0.333 . . . . 0.0 110.861 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.453 ' CD1' ' HA ' ' A' ' 127' ' ' LYS . 91.0 mt -73.03 141.89 15.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.081 179.899 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 71.4 t60 -96.15 -44.08 7.45 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.894 179.852 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 15.8 tttm -139.67 142.7 36.94 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.911 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 39.2 t -134.59 110.55 13.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.143 179.864 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.422 HG11 ' N ' ' A' ' 143' ' ' ILE . 64.9 t -116.06 137.98 48.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.11 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . 0.422 ' N ' HG11 ' A' ' 142' ' ' VAL . 43.1 mm -111.82 134.7 53.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.094 179.928 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 34.0 m-20 -131.04 110.97 11.6 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.851 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 5.8 p30 -104.43 146.19 29.21 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.918 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 66.5 m -77.4 120.55 22.56 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.851 -179.824 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 62.8 p -92.19 -46.46 7.73 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.107 -179.91 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 17.8 t -67.49 150.51 48.78 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.868 -179.859 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . 0.406 ' O ' ' CD1' ' A' ' 149' ' ' TYR . 18.7 p90 -81.27 109.98 16.3 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.917 -179.882 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -77.85 -43.66 29.64 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.113 179.86 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 93.06 38.85 5.31 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.485 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 95.3 p -116.53 175.36 5.6 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.877 0.37 . . . . 0.0 110.822 -179.698 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 4.6 tm0? -70.04 80.61 0.49 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.942 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 90.86 145.96 15.53 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.525 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 157.36 60.59 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.682 2.255 . . . . 0.0 112.31 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 3.5 m -138.39 130.22 28.12 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.878 -179.877 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -117.41 164.47 14.82 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.125 179.898 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 158' ' ' SER . . . . . 0.56 ' HB2' ' CE1' ' A' ' 112' ' ' PHE . 71.5 p -140.09 154.74 47.13 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.84 -179.779 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -139.08 152.14 47.29 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.082 179.893 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 160' ' ' TYR . . . . . 0.562 ' CZ ' ' CD1' ' A' ' 112' ' ' PHE . 8.5 m-85 -114.0 115.83 28.24 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.933 -179.837 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.447 HG11 ' N ' ' A' ' 162' ' ' THR . 29.9 t -110.35 142.61 22.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.134 179.924 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 162' ' ' THR . . . . . 0.447 ' N ' HG11 ' A' ' 161' ' ' VAL . 18.7 m -120.44 115.86 24.31 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.119 -179.934 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 25.0 m-85 -90.32 135.08 33.9 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.933 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 64.1 mt -57.73 -42.73 82.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.139 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 17.7 mmm180 -98.25 125.65 43.41 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.888 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 46.6 m -55.26 -62.87 1.38 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.855 -179.781 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 5.4 tp10 -41.89 -55.84 2.95 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.856 -179.906 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 5.9 m-20 -49.59 -45.65 48.21 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.863 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -57.1 -61.78 2.22 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.135 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 53.7 mt -42.45 -61.74 1.14 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.957 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 59.1 mtp180 -55.7 -51.56 66.87 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.882 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -42.2 -36.58 1.24 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.055 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 173' ' ' ILE . . . . . 0.431 ' CD1' HD23 ' A' ' 190' ' ' LEU . 95.2 mt -80.18 -39.1 18.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.257 -0.428 . . . . 0.0 111.177 179.969 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 30.6 mt-30 -62.07 -26.18 68.12 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.92 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 2.2 m -93.76 -38.21 11.4 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.854 -179.92 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 176' ' ' VAL . . . . . 0.421 ' CG1' ' HB2' ' A' ' 188' ' ' ALA . 10.2 t -63.61 -39.74 86.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.128 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 14.1 t30 -63.83 138.66 58.57 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.885 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 49.9 t30 67.74 48.19 1.07 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.913 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 87.0 t -130.1 130.14 65.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.172 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 98.1 t -89.75 109.06 20.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.111 179.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 87.0 t -117.17 109.85 29.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.1 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 61.9 m-20 59.85 38.49 21.26 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.831 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 73.71 34.12 56.99 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.486 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 59.0 mtt-85 -143.02 123.25 13.75 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.887 0.375 . . . . 0.0 110.88 -179.867 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 37.7 m -80.39 93.61 6.01 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.153 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 45.0 mt -66.07 147.0 54.02 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.876 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 13.9 tppt? -128.0 112.35 14.55 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.913 179.838 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . 0.421 ' HB2' ' CG1' ' A' ' 176' ' ' VAL . . . -102.93 129.24 49.58 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.09 179.853 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 19.4 m -161.58 145.11 12.55 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.838 -179.775 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 190' ' ' LEU . . . . . 0.432 ' CD1' ' HG2' ' A' ' 108' ' ' LYS . 4.3 pp -118.31 158.65 24.82 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.918 179.987 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 113.05 30.66 2.67 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.481 179.884 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 192' ' ' THR . . . . . . . . . . . . . 39.6 m -109.57 116.44 31.77 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.874 0.369 . . . . 0.0 111.168 -179.917 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 193' ' ' THR . . . . . . . . . . . . . 43.7 m -109.77 129.85 55.58 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.143 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 194' ' ' LYS . . . . . 0.43 ' O ' ' C ' ' A' ' 195' ' ' TYR . 54.5 tttt -84.19 42.48 0.88 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.864 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 195' ' ' TYR . . . . . 0.43 ' C ' ' O ' ' A' ' 194' ' ' LYS . 42.1 p90 35.66 43.45 0.17 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.948 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 196' ' ' CYS . . . . . . . . . . . . . 5.3 t -76.59 123.74 26.56 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.849 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 51.8 p -80.14 143.36 33.95 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.81 -179.746 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 198' ' ' TYR . . . . . 0.496 ' CD1' ' C ' ' A' ' 198' ' ' TYR . 2.9 p90 -175.03 167.51 3.52 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.94 -179.894 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 80.6 p -119.34 142.62 47.97 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.855 -179.853 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . 136.34 -162.83 25.14 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.487 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 201' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 163.64 81.22 Favored 'Cis proline' 0 C--O 1.231 0.161 0 C-N-CA 122.696 -1.793 . . . . 0.0 112.372 0.01 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 202' ' ' SER . . . . . . . . . . . . . 11.8 t -86.72 149.55 24.8 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.84 -179.829 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 13.4 t -40.99 129.43 2.72 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.855 -179.795 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.338 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.481 -179.973 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.335 0 N-CA-C 112.468 -0.253 . . . . 0.0 112.468 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 82.1 p -121.63 138.24 54.41 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.879 0.371 . . . . 0.0 110.841 -179.737 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 4.8 t -40.77 -52.3 3.0 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.85 -179.82 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 99.46 46.73 1.93 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.478 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 2.1 t -116.3 152.98 32.78 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.872 0.368 . . . . 0.0 110.854 -179.717 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 84.5 p -116.15 -44.81 2.88 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.853 -179.823 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 177.42 95.7 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.516 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -75.81 127.09 32.27 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.812 0.339 . . . . 0.0 111.085 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 78.2 p -138.54 129.02 26.12 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.865 -179.813 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 90.9 t -96.18 109.64 23.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.129 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 36.9 ttt-85 -125.11 107.41 10.76 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.854 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 84.3 t -115.52 130.06 70.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.117 179.954 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 8.3 p -74.12 153.75 6.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.133 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 62.2 mm-40 57.85 44.93 19.28 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.935 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 18.9 ptmt -76.7 47.69 0.52 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.917 179.942 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 1.1 p-10 -130.48 -37.11 1.41 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.918 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 8.7 tp -85.98 125.43 33.38 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.894 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 96.0 t -97.85 131.76 44.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.138 179.847 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.641 ' CD1' ' CE2' ' A' ' 160' ' ' TYR . 34.5 t80 -130.27 117.43 19.81 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.845 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 69.1 t -114.73 135.54 54.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.143 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . 0.449 ' CG1' ' HB3' ' A' ' 158' ' ' SER . 35.2 m -124.2 168.57 16.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.123 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 81.93 47.15 6.35 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.508 179.999 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 38.0 mt -113.45 137.76 51.08 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.888 0.375 . . . . 0.0 110.931 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' SER . . . . . 0.406 ' O ' ' N ' ' A' ' 120' ' ' LEU . 38.4 t -63.8 141.36 58.8 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.887 -179.915 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 37.0 tt0 -39.26 -37.71 0.45 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.939 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 33.8 tpt85 -79.33 -40.82 29.37 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.874 -179.914 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . 0.406 ' N ' ' O ' ' A' ' 117' ' ' SER . 35.8 mt -62.27 -35.88 80.34 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.931 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -66.24 82.99 0.09 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.108 179.787 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 13.1 m-20 -148.06 148.35 29.37 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.555 0.693 . . . . 0.0 110.895 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 -44.34 2.15 Favored 'Trans proline' 0 N--CA 1.465 -0.165 0 C-N-CA 122.711 2.274 . . . . 0.0 112.353 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -71.87 -39.64 69.5 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.901 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.587 ' O ' ' CD1' ' A' ' 131' ' ' TYR . 37.9 t -62.55 -45.32 99.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.133 -179.989 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . 0.412 HD23 ' CD1' ' A' ' 132' ' ' PHE . 67.0 mt -74.43 -40.92 61.65 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.891 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 31.6 mttt -58.32 -31.83 67.92 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.904 179.828 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 15.8 mmt85 -44.24 143.5 1.9 Allowed Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.617 0.722 . . . . 0.0 110.888 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.69 -0.56 7.03 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.72 2.28 . . . . 0.0 112.375 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 25.6 mp0 -101.46 -26.99 13.38 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.892 -179.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 131' ' ' TYR . . . . . 0.587 ' CD1' ' O ' ' A' ' 125' ' ' VAL . 39.8 m-85 -88.76 -75.15 0.44 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.921 -179.852 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.412 ' CD1' HD23 ' A' ' 126' ' ' LEU . 10.8 m-85 -110.45 -46.17 3.44 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.872 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -47.7 -21.21 1.37 Allowed Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.501 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.498 ' HD2' ' CD1' ' A' ' 135' ' ' PHE . 0.0 OUTLIER -53.88 -34.99 61.05 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.79 0.329 . . . . 0.0 110.884 -179.995 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 135' ' ' PHE . . . . . 0.498 ' CD1' ' HD2' ' A' ' 134' ' ' LYS . 70.8 m-85 -71.1 -46.03 62.52 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.905 179.958 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -172.6 -127.93 1.01 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.504 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -117.02 138.8 51.34 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.797 0.332 . . . . 0.0 110.938 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 82.1 mt -100.03 139.77 20.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.13 179.913 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 52.2 t60 -91.04 -54.14 4.08 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.852 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 35.9 ttpt -144.68 144.24 31.13 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.938 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 46.8 t -123.6 145.82 29.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.12 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 59.1 t -136.08 134.77 50.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.095 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 37.1 mm -110.47 132.46 58.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.092 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 43.6 t-20 -126.78 124.14 39.0 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.877 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 16.7 t-20 -117.36 144.97 44.37 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.883 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 3.1 t -72.57 139.57 47.55 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.861 -179.839 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 23.9 m -128.22 -41.67 1.57 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.151 -179.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 59.7 p -114.02 114.51 26.24 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.915 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 8.4 p90 -119.91 137.6 53.93 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.93 -179.881 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -104.58 86.23 2.46 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.101 179.87 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 56.92 40.05 89.88 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.487 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 44.4 m -109.11 130.91 55.49 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.789 0.328 . . . . 0.0 110.858 -179.729 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 8.5 pt20 -107.25 82.87 1.73 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.924 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 165.08 83.37 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.458 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.73 99.93 0.78 Allowed 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.674 2.249 . . . . 0.0 112.371 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 83.3 p -117.2 141.77 47.87 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.917 -179.863 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -114.74 156.24 25.2 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.12 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 158' ' ' SER . . . . . 0.463 ' HB2' ' CE1' ' A' ' 112' ' ' PHE . 22.0 p -128.37 174.12 9.59 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.859 -179.766 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -159.89 141.28 12.66 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.105 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 160' ' ' TYR . . . . . 0.641 ' CE2' ' CD1' ' A' ' 112' ' ' PHE . 35.5 m-85 -100.97 144.5 29.84 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.896 -179.848 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.414 HG11 ' N ' ' A' ' 162' ' ' THR . 80.2 t -132.19 135.49 58.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.156 179.879 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 162' ' ' THR . . . . . 0.414 ' N ' HG11 ' A' ' 161' ' ' VAL . 38.2 m -112.42 118.92 36.51 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.161 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 20.0 m-85 -102.44 143.89 31.6 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.953 -179.914 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 60.6 mt -68.19 -45.52 82.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.162 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 19.5 mtm180 -97.71 118.24 33.8 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.881 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 41.9 t -51.53 -58.5 6.13 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.846 -179.782 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 16.5 tt0 -42.4 -53.03 4.41 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.9 -179.938 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -51.85 -51.27 57.9 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.833 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -53.37 -63.27 1.2 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.077 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 39.5 mt -38.38 -57.83 1.08 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.905 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 171' ' ' ARG . . . . . 0.427 ' O ' ' N ' ' A' ' 174' ' ' GLN . 54.2 mtp180 -58.14 -57.97 10.5 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.873 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -37.67 -35.81 0.15 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.132 179.873 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 73.6 mt -82.47 -41.13 17.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.118 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 174' ' ' GLN . . . . . 0.427 ' N ' ' O ' ' A' ' 171' ' ' ARG . 15.0 mm100 -57.23 -28.28 62.76 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.895 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 3.4 t -93.77 -39.34 10.8 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.88 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 176' ' ' VAL . . . . . 0.455 ' O ' ' CG2' ' A' ' 179' ' ' VAL . 10.9 t -59.52 -48.51 87.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.132 -179.947 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 10.5 t-20 -59.08 139.12 57.2 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.893 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 4.7 t-20 70.25 45.91 0.63 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.876 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 179' ' ' VAL . . . . . 0.455 ' CG2' ' O ' ' A' ' 176' ' ' VAL . 84.3 t -125.18 137.72 56.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.138 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 95.6 t -96.51 98.57 7.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.155 179.922 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 47.7 t -111.11 111.82 37.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.169 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 57.12 42.81 25.15 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.88 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 67.03 35.08 88.74 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.511 -179.89 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 81.9 mtt85 -143.03 136.43 28.38 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.876 0.369 . . . . 0.0 110.906 -179.889 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 23.1 m -92.22 92.19 8.09 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.129 -179.885 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 44.8 mt -61.62 125.11 22.63 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.917 179.929 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 36.0 mmtt -103.09 114.01 27.95 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.862 179.848 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -111.35 132.52 54.35 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.109 179.837 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 16.8 m -149.81 145.28 26.51 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.843 -179.788 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 190' ' ' LEU . . . . . . . . . . . . . 1.3 pt? -123.81 151.1 43.73 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.932 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 73.44 27.25 68.11 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.518 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 192' ' ' THR . . . . . . . . . . . . . 9.8 m -127.46 140.53 52.09 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.872 0.368 . . . . 0.0 111.131 -179.864 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 193' ' ' THR . . . . . . . . . . . . . 13.1 t -107.4 -17.84 14.02 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.132 -179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 30.2 mmtm -97.25 165.72 11.9 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.9 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 195' ' ' TYR . . . . . . . . . . . . . 57.7 m-85 -77.93 -51.02 11.06 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.938 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 196' ' ' CYS . . . . . . . . . . . . . 30.1 p -170.1 130.51 0.96 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.872 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 7.7 t -170.58 161.69 7.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.824 -179.795 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 198' ' ' TYR . . . . . . . . . . . . . 17.3 t80 -64.75 92.76 0.1 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.891 -179.846 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 76.0 p -56.96 146.04 28.23 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.876 -179.874 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 200' ' ' GLY . . . . . 0.416 ' HA3' ' C ' ' A' ' 201' ' ' PRO . . . 158.0 -69.25 0.27 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.507 -179.998 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 201' ' ' PRO . . . . . 0.416 ' C ' ' HA3' ' A' ' 200' ' ' GLY . 53.8 Cg_endo -69.7 -32.23 4.04 Favored 'Cis proline' 0 C--N 1.341 0.157 0 C-N-CA 122.686 -1.797 . . . . 0.0 112.342 -0.017 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 202' ' ' SER . . . . . . . . . . . . . 1.3 t -168.44 134.2 1.81 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.847 -179.807 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 82.9 p -130.69 124.01 30.62 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.852 -179.829 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.366 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.521 179.997 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.315 0 N-CA-C 112.514 -0.234 . . . . 0.0 112.514 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 50.3 m -152.19 135.49 15.91 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.893 0.378 . . . . 0.0 110.831 -179.758 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 99.5 p -154.65 154.73 33.44 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.878 -179.837 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 94.05 179.83 38.41 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.44 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 22.7 t -129.34 -59.3 1.1 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.854 0.359 . . . . 0.0 110.853 -179.709 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 6.4 t -72.78 105.31 4.29 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.872 -179.83 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -103.09 -166.03 25.83 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.52 -179.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -93.3 120.45 33.6 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.808 0.337 . . . . 0.0 111.103 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 74.7 m -73.27 80.48 1.33 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.904 -179.822 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 10.8 m -89.86 151.66 3.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.18 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 17.7 ptt180 -126.44 147.17 49.84 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.845 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 79.6 t -119.89 112.65 37.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.131 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 1.2 p -93.21 134.07 32.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.133 179.915 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 49.8 tt0 -159.85 139.22 11.12 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.902 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 20.3 pttm -97.68 59.91 1.52 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.923 179.963 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -128.43 -38.59 1.74 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.914 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 17.1 tp -88.16 143.03 27.29 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.93 179.932 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 87.9 t -115.6 132.62 64.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.152 179.86 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.568 ' CE2' ' CG1' ' A' ' 114' ' ' VAL . 50.3 t80 -128.65 106.68 9.12 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.871 -179.936 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 55.9 t -103.46 122.05 55.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.12 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . 0.568 ' CG1' ' CE2' ' A' ' 112' ' ' PHE . 18.7 m -110.66 152.65 12.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.111 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 94.2 37.7 5.31 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.524 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 30.0 mt -101.64 134.38 44.86 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.834 0.35 . . . . 0.0 110.889 -179.907 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' SER . . . . . 0.437 ' O ' ' N ' ' A' ' 120' ' ' LEU . 24.4 t -68.71 141.33 55.33 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.874 -179.932 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 43.6 tt0 -42.27 -25.7 0.08 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.881 -179.926 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 6.3 tpm_? -89.83 -36.32 15.17 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.83 -179.914 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . 0.437 ' N ' ' O ' ' A' ' 117' ' ' SER . 32.2 mt -70.25 -32.25 70.01 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.879 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -70.19 84.67 0.55 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.117 179.77 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -146.31 146.71 28.64 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.588 0.709 . . . . 0.0 110.838 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 -46.23 1.28 Allowed 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.666 2.244 . . . . 0.0 112.333 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -70.64 -38.13 73.85 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.875 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.484 ' O ' ' CD1' ' A' ' 131' ' ' TYR . 87.3 t -65.76 -50.84 68.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.085 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . 0.499 HD22 ' CE1' ' A' ' 132' ' ' PHE . 89.8 mt -68.41 -37.16 80.08 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.901 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 27.6 mttm -62.25 -37.46 85.53 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.863 179.874 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 2.5 mmp_? -43.29 143.88 1.32 Allowed Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.607 0.718 . . . . 0.0 110.839 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 -4.28 13.72 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.651 2.234 . . . . 0.0 112.338 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 1.3 tm-20 -94.18 -16.26 23.86 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.918 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 131' ' ' TYR . . . . . 0.484 ' CD1' ' O ' ' A' ' 125' ' ' VAL . 61.8 m-85 -102.53 -72.06 0.7 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.929 -179.857 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.499 ' CE1' HD22 ' A' ' 126' ' ' LEU . 61.1 m-85 -122.44 -39.6 2.55 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.862 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -41.24 -26.43 0.19 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.484 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.406 ' N ' ' O ' ' A' ' 132' ' ' PHE . 8.5 ptmm? -47.0 -39.13 11.94 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.808 0.337 . . . . 0.0 110.946 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 135' ' ' PHE . . . . . 0.534 ' CE1' ' HA ' ' A' ' 172' ' ' ALA . 66.0 m-85 -63.18 -45.6 91.01 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.87 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 173.58 -148.19 10.03 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.483 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 16.6 tttm -95.42 115.71 27.8 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.828 0.347 . . . . 0.0 110.93 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 86.2 mt -71.63 140.09 18.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.109 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 34.3 t-80 -82.12 -59.62 2.5 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.883 179.871 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 140' ' ' LYS . . . . . 0.407 ' HG3' ' N ' ' A' ' 141' ' ' VAL . 39.9 tptt -140.13 151.22 45.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.966 179.942 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . 0.407 ' N ' ' HG3' ' A' ' 140' ' ' LYS . 88.3 t -136.97 122.42 26.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.133 179.933 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 43.7 t -125.9 120.23 56.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.132 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 18.2 mm -86.57 136.71 22.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.133 179.902 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 2.3 m-80 -128.48 134.35 48.7 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.897 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 88.5 m-20 -126.19 170.38 11.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.87 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 58.3 m -99.07 118.21 35.32 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.886 -179.863 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 10.7 t -118.47 40.8 3.13 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.128 -179.892 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 66.7 m -114.01 162.7 16.1 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.863 -179.849 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . 0.578 ' O ' ' CD2' ' A' ' 149' ' ' TYR . 46.5 p90 -115.98 95.65 5.21 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.933 -179.901 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -109.84 -42.35 4.27 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.113 179.882 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 108.83 39.94 1.65 Allowed Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.483 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 23.6 m -104.21 167.38 9.79 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.805 0.336 . . . . 0.0 110.881 -179.727 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 24.2 tp60 -106.23 141.44 37.57 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.921 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 49.02 82.62 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.482 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.73 170.54 16.3 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.687 2.258 . . . . 0.0 112.378 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 21.1 m -128.94 148.6 50.94 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.864 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -116.04 164.17 14.83 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.091 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 158' ' ' SER . . . . . 0.403 ' HB2' ' CE1' ' A' ' 112' ' ' PHE . 51.1 p -139.58 158.68 43.71 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.882 -179.827 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -139.71 145.0 37.8 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.081 179.878 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 160' ' ' TYR . . . . . 0.471 ' CZ ' ' CD1' ' A' ' 112' ' ' PHE . 89.1 m-85 -104.73 125.95 51.32 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.918 -179.841 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 85.7 t -122.11 130.92 74.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.133 179.895 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 20.6 m -111.53 129.79 55.94 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.122 -179.908 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 33.4 m-85 -105.27 160.0 15.44 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.918 -179.93 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 63.0 mt -84.51 -58.82 3.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.147 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 22.2 mmt180 -85.85 125.38 33.25 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.866 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 17.4 m -49.19 -60.55 2.7 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.878 -179.797 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 29.1 tt0 -40.89 -54.91 2.61 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.91 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 7.4 t70 -49.68 -49.91 45.62 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.901 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -57.67 -54.18 49.8 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.132 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 35.8 mt -44.09 -60.96 1.64 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.883 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 85.5 mtt180 -58.84 -42.99 90.6 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.892 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . 0.534 ' HA ' ' CE1' ' A' ' 135' ' ' PHE . . . -49.42 -35.24 18.55 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.096 179.939 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 82.6 mt -86.47 -40.7 14.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.153 179.97 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 77.3 mt-30 -62.39 -27.19 68.91 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.923 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 16.1 m -93.79 -42.21 9.25 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.941 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 176' ' ' VAL . . . . . 0.495 ' CG2' ' O ' ' A' ' 172' ' ' ALA . 9.9 t -59.05 -40.48 80.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.137 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 177' ' ' ASN . . . . . 0.435 ' C ' ' OD1' ' A' ' 177' ' ' ASN . 0.8 OUTLIER -66.49 145.18 55.93 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.916 179.982 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 19.1 t30 68.85 41.61 1.5 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.85 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 95.3 t -121.61 133.12 69.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.112 179.886 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 87.8 t -98.6 103.02 14.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.121 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 97.8 t -111.6 116.39 52.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.111 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER 47.4 43.09 15.13 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.911 179.947 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 71.22 31.29 66.41 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.464 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 32.0 mtp85 -137.09 109.42 7.33 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.883 0.373 . . . . 0.0 110.886 -179.884 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 29.7 m -71.78 92.35 1.21 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.163 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 62.7 mt -60.48 132.86 55.22 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.936 179.963 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -124.89 115.45 20.65 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.865 179.87 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -107.25 144.06 34.6 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.135 179.801 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 2.4 t -146.58 168.57 20.93 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.869 -179.763 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 190' ' ' LEU . . . . . 0.516 ' N ' ' CD1' ' A' ' 190' ' ' LEU . 0.0 OUTLIER -125.79 161.46 27.33 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.94 179.995 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 68.18 30.72 73.89 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.494 179.901 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 192' ' ' THR . . . . . 0.411 HG23 ' CD2' ' A' ' 112' ' ' PHE . 29.0 m -88.71 130.2 35.38 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.849 0.356 . . . . 0.0 111.133 -179.827 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 193' ' ' THR . . . . . . . . . . . . . 30.2 m -117.6 131.71 56.63 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.123 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 28.4 pttt -107.86 -16.98 14.18 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.867 179.912 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 195' ' ' TYR . . . . . 0.419 ' O ' ' C ' ' A' ' 196' ' ' CYS . 35.9 t80 -133.14 119.49 20.0 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.906 -179.97 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 196' ' ' CYS . . . . . 0.419 ' C ' ' O ' ' A' ' 195' ' ' TYR . 26.8 p -37.05 130.19 0.84 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.893 179.995 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 10.7 t -96.77 128.1 43.4 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.828 -179.71 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 198' ' ' TYR . . . . . . . . . . . . . 3.2 p90 -125.29 129.16 49.45 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.906 -179.885 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 6.3 t -167.51 126.57 1.33 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.864 -179.808 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . 113.2 175.67 19.33 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.503 179.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 201' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.77 177.11 30.02 Favored 'Cis proline' 0 C--O 1.231 0.167 0 C-N-CA 122.682 -1.799 . . . . 0.0 112.347 0.086 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 202' ' ' SER . . . . . . . . . . . . . 19.7 m -120.41 88.98 3.04 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.876 -179.837 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 90.0 p -160.17 150.82 18.74 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.864 -179.812 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.362 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.538 -179.953 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.271 0 N-CA-C 112.479 -0.249 . . . . 0.0 112.479 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 4.9 t -121.32 117.55 27.27 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.851 0.357 . . . . 0.0 110.828 -179.728 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 30.9 t -39.4 -44.25 1.32 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.861 -179.826 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -127.0 87.35 0.34 Allowed Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.485 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 1.1 t -103.51 130.05 50.82 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.83 0.347 . . . . 0.0 110.866 -179.734 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 2.4 t -140.85 129.66 23.03 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.896 -179.853 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 131.17 -78.36 0.38 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.459 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -58.56 154.56 13.97 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.799 0.333 . . . . 0.0 111.117 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 4.0 m -136.71 121.94 19.2 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.831 -179.78 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 93.6 t -92.37 125.28 45.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.129 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 11.6 ptm180 -106.64 146.4 30.78 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.923 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 98.9 t -98.82 104.52 16.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.119 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 34.9 m -117.45 146.58 21.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.12 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 7.5 tt0 -37.15 138.23 0.3 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.937 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 8.8 mptt -97.96 48.83 1.01 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.91 179.914 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 3.3 t30 -90.03 -36.84 14.69 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.836 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 20.0 tp -90.82 127.78 36.48 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.875 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 90.7 t -118.51 123.35 71.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.114 179.856 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.424 ' CD1' ' CZ ' ' A' ' 160' ' ' TYR . 39.2 t80 -113.34 126.06 54.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.853 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 55.6 t -119.74 141.07 41.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.128 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 19.8 m -119.73 171.76 7.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.134 179.889 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 73.75 53.56 7.2 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.514 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 29.7 mt -116.25 126.32 53.43 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.827 0.346 . . . . 0.0 110.9 -179.9 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 89.0 p -64.58 153.08 40.32 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.865 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 44.6 tt0 -52.6 -26.53 13.73 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.907 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -87.19 -43.29 12.34 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.88 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 51.9 mt -66.52 -21.16 66.17 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.964 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -71.68 82.99 0.87 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.123 179.755 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -148.98 144.01 17.65 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-O 121.63 0.729 . . . . 0.0 110.893 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -50.51 0.46 Allowed 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.728 2.285 . . . . 0.0 112.339 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 35.0 mt-10 -69.43 -45.39 69.27 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.859 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.592 ' O ' ' CD1' ' A' ' 131' ' ' TYR . 53.5 t -57.94 -42.33 82.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.156 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 77.0 mt -72.47 -44.73 61.91 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.87 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 12.0 ttpp -59.17 -35.13 72.99 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.881 179.853 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 38.4 mtt-85 -38.58 144.6 0.39 Allowed Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.567 0.699 . . . . 0.0 110.889 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.73 0.5 5.53 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.706 2.271 . . . . 0.0 112.329 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -104.98 -7.93 18.92 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.854 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 131' ' ' TYR . . . . . 0.592 ' CD1' ' O ' ' A' ' 125' ' ' VAL . 45.1 m-85 -111.47 -74.93 0.62 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.927 -179.861 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.435 ' O ' ' N ' ' A' ' 134' ' ' LYS . 14.2 m-85 -114.99 -36.34 4.46 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.886 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -42.56 -22.41 0.13 Allowed Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.486 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.435 ' N ' ' O ' ' A' ' 132' ' ' PHE . 5.3 mtpt -49.22 -59.5 3.62 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.813 0.34 . . . . 0.0 110.896 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 135' ' ' PHE . . . . . 0.56 ' CE1' ' HA ' ' A' ' 172' ' ' ALA . 82.2 m-85 -47.89 -42.55 27.18 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.889 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 173.84 -168.31 41.12 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.487 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 13.5 tttt -82.68 117.6 22.73 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.751 0.31 . . . . 0.0 110.901 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 68.5 mt -77.0 144.88 11.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.167 179.859 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 9.8 t-80 -88.89 -57.62 2.84 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.879 179.846 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 42.4 tttt -142.13 149.24 39.54 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.894 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 59.7 t -133.67 140.74 45.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.144 179.855 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 84.3 t -134.66 129.79 52.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.154 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 51.9 mm -100.33 131.32 48.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.136 179.916 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 4.4 m-80 -128.67 117.45 21.21 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.881 179.961 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 3.0 p-10 -100.14 140.3 34.58 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.885 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 43.9 t -80.51 121.69 26.08 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.881 -179.862 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 90.3 m -83.17 -42.65 17.06 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.134 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 17.0 t -102.71 109.67 21.34 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.894 -179.877 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 3.3 p90 -105.35 154.19 20.62 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.918 -179.847 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -75.08 -46.9 31.6 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.129 179.877 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 96.64 39.41 4.16 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.451 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 19.2 m -106.64 -57.15 2.1 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.813 0.339 . . . . 0.0 110.866 -179.769 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 17.7 mp0 -104.02 -52.29 2.98 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.881 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 160.57 176.77 33.04 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.487 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 121.08 7.77 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.695 2.263 . . . . 0.0 112.335 -179.929 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 80.0 p -132.65 112.5 12.08 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.855 -179.844 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -91.3 168.56 11.49 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.081 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 7.2 m -130.63 168.14 17.61 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.872 -179.82 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -146.74 150.96 36.39 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.106 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 160' ' ' TYR . . . . . 0.424 ' CZ ' ' CD1' ' A' ' 112' ' ' PHE . 7.1 m-85 -116.48 123.01 46.42 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.949 -179.838 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.449 HG11 ' N ' ' A' ' 162' ' ' THR . 87.3 t -112.56 142.2 25.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.124 179.941 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 162' ' ' THR . . . . . 0.449 ' N ' HG11 ' A' ' 161' ' ' VAL . 32.9 m -113.36 118.3 34.2 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.141 -179.926 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 24.4 m-85 -98.57 150.19 21.98 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.907 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 57.4 mt -88.94 -42.09 14.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.158 179.905 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 75.4 mtp180 -94.67 119.31 33.11 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.895 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 29.3 m -49.2 -60.09 3.11 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.859 -179.776 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 19.5 mt-10 -42.92 -53.02 4.91 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.899 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -49.84 -49.05 50.53 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.849 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -56.62 -58.73 6.82 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.119 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 56.2 mt -41.0 -59.65 1.4 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.863 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 54.0 mtp180 -59.99 -44.23 94.65 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.91 179.948 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . 0.56 ' HA ' ' CE1' ' A' ' 135' ' ' PHE . . . -47.96 -36.12 11.98 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.11 179.937 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 64.7 mt -79.87 -42.67 22.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.085 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 40.3 mt-30 -65.26 -24.61 67.36 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.928 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 175' ' ' CYS . . . . . 0.494 ' O ' ' CG2' ' A' ' 179' ' ' VAL . 3.3 t -93.89 -38.94 10.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.849 -179.932 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 176' ' ' VAL . . . . . 0.421 ' CG2' ' O ' ' A' ' 172' ' ' ALA . 9.8 t -64.34 -26.97 41.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.139 -179.985 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 12.5 t30 -75.61 146.63 40.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.869 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 42.1 t30 59.89 41.43 17.85 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.887 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 179' ' ' VAL . . . . . 0.494 ' CG2' ' O ' ' A' ' 175' ' ' CYS . 85.9 t -121.12 135.96 59.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.133 179.917 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 180' ' ' VAL . . . . . 0.409 ' N ' HG11 ' A' ' 179' ' ' VAL . 99.7 t -104.15 122.98 57.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.147 179.895 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . 0.41 HG22 ' CD1' ' A' ' 186' ' ' LEU . 60.6 t -128.28 103.38 9.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.114 179.949 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 5.9 m-20 55.24 37.82 29.47 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.857 179.91 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 81.02 36.78 20.81 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.476 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -141.55 121.36 13.53 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.893 0.378 . . . . 0.0 110.866 -179.855 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 27.6 m -84.23 92.9 8.07 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.144 -179.891 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 186' ' ' LEU . . . . . 0.41 ' CD1' HG22 ' A' ' 181' ' ' VAL . 88.5 mt -69.59 120.74 15.83 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.893 179.991 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 14.8 mtmm -121.51 122.89 40.73 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.892 179.8 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -107.7 146.18 32.43 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.104 179.834 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 53.2 m -139.05 169.52 17.64 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.862 -179.821 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 190' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -127.8 125.73 40.38 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.942 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 69.57 28.87 71.81 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.493 179.915 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 192' ' ' THR . . . . . . . . . . . . . 4.4 p -117.88 133.82 55.55 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.867 0.365 . . . . 0.0 111.128 -179.817 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 193' ' ' THR . . . . . . . . . . . . . 68.9 p -122.04 99.76 6.61 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.146 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 21.7 mmtt -99.91 86.0 3.19 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.909 179.908 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 195' ' ' TYR . . . . . . . . . . . . . 45.7 t80 -175.0 158.98 2.57 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.9 -179.925 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 196' ' ' CYS . . . . . . . . . . . . . 55.6 m -83.35 95.74 8.3 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.834 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 59.5 p -117.99 83.93 2.08 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.846 -179.757 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 198' ' ' TYR . . . . . 0.409 ' O ' ' CD1' ' A' ' 198' ' ' TYR . 10.9 p90 -103.67 104.48 14.52 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.906 -179.868 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 82.8 p -149.78 160.02 43.89 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.836 -179.865 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 200' ' ' GLY . . . . . 0.418 ' HA2' ' C ' ' A' ' 201' ' ' PRO . . . 88.99 172.07 46.06 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.494 -179.987 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 201' ' ' PRO . . . . . 0.418 ' C ' ' HA2' ' A' ' 200' ' ' GLY . 53.7 Cg_endo -69.8 165.13 77.57 Favored 'Cis proline' 0 C--N 1.341 0.162 0 C-N-CA 122.692 -1.795 . . . . 0.0 112.342 0.073 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 202' ' ' SER . . . . . . . . . . . . . 93.0 p -151.94 156.84 40.86 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.901 -179.855 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 17.6 t -98.11 149.89 22.03 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.818 -179.769 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.343 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.515 179.995 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.309 0 N-CA-C 112.496 -0.242 . . . . 0.0 112.496 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 8.6 t -169.84 115.78 0.54 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.89 0.376 . . . . 0.0 110.873 -179.7 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 50.9 m -104.69 122.37 45.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.861 -179.799 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -61.39 -115.1 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.519 -179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 52.1 p -142.6 116.63 9.4 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.872 0.368 . . . . 0.0 110.866 -179.736 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 11.8 p -38.75 -39.66 0.53 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.87 -179.86 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 117.93 114.88 2.68 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.498 -179.957 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.439 ' O ' ' C ' ' A' ' 102' ' ' SER . . . -55.5 118.12 4.19 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.798 0.332 . . . . 0.0 111.126 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' SER . . . . . 0.439 ' C ' ' O ' ' A' ' 101' ' ' ALA . 28.7 t 34.46 39.78 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.892 -179.734 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 82.7 t -94.91 99.65 9.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.148 179.939 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -100.15 109.74 22.01 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.905 -179.987 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.412 HG23 ' N ' ' A' ' 106' ' ' VAL . 13.5 p -114.43 141.19 31.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.118 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . 0.412 ' N ' HG23 ' A' ' 105' ' ' VAL . 94.7 t -118.93 95.86 3.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.11 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 9.6 mt-30 -151.82 118.52 5.74 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.905 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 28.2 ttmt -103.8 -37.82 7.3 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.931 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 16.1 p30 -93.12 39.38 1.05 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.908 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 26.2 tp -113.49 116.3 29.36 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.873 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 99.5 t -106.48 109.68 28.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.213 179.775 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.483 ' CZ ' ' CG1' ' A' ' 114' ' ' VAL . 40.4 t80 -100.64 107.09 18.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.924 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 75.0 t -106.35 138.57 31.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.139 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . 0.483 ' CG1' ' CZ ' ' A' ' 112' ' ' PHE . 31.0 m -122.68 160.79 24.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.101 179.913 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 81.54 53.21 3.89 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.491 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 32.9 mt -106.17 120.74 42.61 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.778 0.323 . . . . 0.0 110.938 -179.903 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' SER . . . . . 0.42 ' O ' ' N ' ' A' ' 120' ' ' LEU . 26.3 t -64.65 142.82 58.29 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.883 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 118' ' ' GLN . . . . . 0.439 ' C ' ' CD ' ' A' ' 118' ' ' GLN . 0.7 OUTLIER -36.65 -43.71 0.43 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.917 -179.942 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 25.9 tpt180 -74.2 -42.32 59.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.852 -179.926 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . 0.42 ' N ' ' O ' ' A' ' 117' ' ' SER . 40.1 mt -61.49 -31.35 71.33 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.922 -179.987 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -68.5 83.37 0.27 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.134 179.801 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 73.1 m-20 -148.96 143.18 16.79 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.574 0.702 . . . . 0.0 110.899 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.86 -50.78 0.42 Allowed 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.67 2.247 . . . . 0.0 112.335 -179.925 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -65.46 -51.33 60.91 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.881 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.644 ' CG1' ' CZ ' ' A' ' 131' ' ' TYR . 64.3 t -54.02 -46.59 65.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.112 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . 0.444 HD23 ' CE1' ' A' ' 132' ' ' PHE . 83.0 mt -66.99 -42.79 84.44 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.895 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 20.2 tttm -58.17 -40.46 81.51 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.884 179.845 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 34.6 mtp180 -38.24 143.29 0.43 Allowed Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.598 0.713 . . . . 0.0 110.872 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 1.53 4.37 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.626 2.217 . . . . 0.0 112.321 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 35.2 mm-40 -99.68 -27.99 13.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.848 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 131' ' ' TYR . . . . . 0.644 ' CZ ' ' CG1' ' A' ' 125' ' ' VAL . 55.7 m-85 -90.54 -68.27 0.8 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.92 -179.82 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.493 ' O ' ' N ' ' A' ' 134' ' ' LYS . 12.8 m-85 -116.95 -52.5 2.52 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.894 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . 0.402 ' C ' ' O ' ' A' ' 132' ' ' PHE . . . -37.8 -27.37 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.5 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.493 ' N ' ' O ' ' A' ' 132' ' ' PHE . 19.5 ptmt -43.04 -49.64 6.09 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.814 0.34 . . . . 0.0 110.851 -179.93 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 135' ' ' PHE . . . . . 0.482 ' CZ ' HG21 ' A' ' 176' ' ' VAL . 58.0 m-85 -63.3 -47.38 82.51 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.915 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -173.61 -172.26 38.85 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.755 -0.735 . . . . 0.0 112.477 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 22.8 mtmm -79.23 122.93 26.92 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.777 0.322 . . . . 0.0 110.872 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.438 HG22 ' N ' ' A' ' 139' ' ' HIS . 87.7 mt -79.92 141.64 15.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.111 179.871 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 139' ' ' HIS . . . . . 0.438 ' N ' HG22 ' A' ' 138' ' ' ILE . 61.5 t-80 -91.02 -49.07 6.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.852 179.868 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 76.8 tttt -146.28 153.47 40.61 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.897 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 42.2 t -132.4 140.24 48.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.156 179.881 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 93.3 t -133.23 131.52 58.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.143 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 43.5 mm -111.67 121.99 65.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.138 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 11.1 t30 -114.49 118.69 34.5 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.89 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 28.5 m-80 -103.67 147.86 26.73 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.869 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 23.0 t -87.71 129.66 35.08 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.839 -179.861 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 10.1 t -109.12 -42.68 4.35 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.169 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 25.3 t -67.61 123.35 20.23 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.844 -179.869 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 40.7 p90 -74.06 141.79 45.7 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.878 -179.872 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -102.65 -50.61 3.51 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.125 179.844 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 82.78 -19.75 10.97 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.489 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 66.9 m -111.18 -51.66 2.85 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.813 0.34 . . . . 0.0 110.848 -179.721 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . 0.412 ' O ' ' C ' ' A' ' 154' ' ' GLY . 37.4 mt-30 -107.23 112.46 25.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.878 -179.951 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . 0.412 ' C ' ' O ' ' A' ' 153' ' ' GLN . . . -37.18 146.12 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.467 -179.952 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.76 124.07 10.72 Favored 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.7 2.267 . . . . 0.0 112.342 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 90.0 p -126.99 122.78 35.49 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.817 -179.818 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -87.57 162.61 17.09 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.05 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 94.2 p -136.36 163.2 31.0 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.845 -179.813 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -146.76 148.77 32.29 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.067 179.917 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 160' ' ' TYR . . . . . 0.5 ' CZ ' ' HB3' ' A' ' 194' ' ' LYS . 11.0 m-85 -112.73 139.53 48.26 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.948 -179.873 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 71.4 t -130.3 121.43 51.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.16 179.896 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 87.2 m -99.52 129.0 45.66 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.13 -179.93 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 52.7 m-85 -110.37 147.07 34.68 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.906 -179.88 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 53.1 mt -67.42 -60.62 2.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.123 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 46.9 mtp85 -82.43 112.99 19.88 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.893 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 74.0 m -52.45 -49.38 64.74 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.882 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 16.5 tt0 -44.5 -55.64 4.93 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.921 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 64.8 m-20 -55.84 -45.86 78.29 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.858 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -58.48 -59.85 4.73 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.063 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 46.1 mt -42.65 -61.56 1.21 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.892 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 1.3 mpt_? -54.93 -50.38 68.99 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.835 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . 0.495 ' O ' ' CG2' ' A' ' 176' ' ' VAL . . . -43.52 -36.73 2.15 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.091 179.933 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 73.6 mt -78.77 -40.79 23.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.142 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 33.7 mt-30 -60.01 -30.22 69.0 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.915 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 1.8 m -93.8 -39.91 10.48 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.832 -179.895 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 176' ' ' VAL . . . . . 0.495 ' CG2' ' O ' ' A' ' 172' ' ' ALA . 10.6 t -59.56 -45.43 94.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.156 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 177' ' ' ASN . . . . . 0.448 ' OD1' ' N ' ' A' ' 178' ' ' ASN . 37.0 t30 -53.92 146.17 14.79 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.909 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 178' ' ' ASN . . . . . 0.448 ' N ' ' OD1' ' A' ' 177' ' ' ASN . 10.4 m120 57.83 47.26 15.61 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.891 -180.0 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 95.3 t -132.43 139.76 49.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.145 179.893 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 95.4 t -93.97 114.02 29.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.101 179.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 96.0 t -120.86 105.87 17.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.156 179.879 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 6.5 t0 65.62 35.32 7.13 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.878 179.928 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 81.19 -14.03 29.83 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.493 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 10.6 mpt_? -102.94 112.7 25.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.867 0.365 . . . . 0.0 110.863 -179.869 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 25.3 m -70.9 93.7 1.0 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.17 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 83.3 mt -70.97 149.5 46.61 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.947 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 13.5 ttpt -136.36 126.45 26.18 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.928 179.863 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -112.38 141.91 45.54 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.139 179.801 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 8.5 t -139.86 165.56 26.99 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.868 -179.748 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 190' ' ' LEU . . . . . . . . . . . . . 38.1 tp -127.14 135.82 51.24 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.918 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 105.58 24.68 6.94 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.498 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 192' ' ' THR . . . . . . . . . . . . . 34.3 p -128.35 119.31 24.81 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.854 0.359 . . . . 0.0 111.108 -179.815 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 193' ' ' THR . . . . . 0.403 ' O ' ' CG2' ' A' ' 193' ' ' THR . 1.9 t -107.38 128.4 54.44 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.144 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 194' ' ' LYS . . . . . 0.5 ' HB3' ' CZ ' ' A' ' 160' ' ' TYR . 22.8 pttt -63.6 153.12 36.88 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.916 179.912 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 195' ' ' TYR . . . . . . . . . . . . . 96.2 m-85 -86.67 88.47 7.67 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.894 -179.931 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 196' ' ' CYS . . . . . . . . . . . . . 43.0 t -100.44 152.33 20.49 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.864 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 29.8 t -134.22 140.36 46.43 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.901 -179.744 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 198' ' ' TYR . . . . . . . . . . . . . 8.4 p90 -148.53 164.89 32.85 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.91 -179.837 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 91.7 p -90.21 129.08 36.51 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.871 -179.865 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 200' ' ' GLY . . . . . 0.421 ' HA2' ' C ' ' A' ' 201' ' ' PRO . . . -131.11 171.94 20.85 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.52 180.0 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 201' ' ' PRO . . . . . 0.421 ' C ' ' HA2' ' A' ' 200' ' ' GLY . 53.3 Cg_endo -69.81 131.32 19.0 Favored 'Cis proline' 0 C--N 1.342 0.196 0 C-N-CA 122.647 -1.814 . . . . 0.0 112.337 0.12 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 202' ' ' SER . . . . . . . . . . . . . 77.3 p -77.95 87.79 4.13 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.876 -179.848 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 3.0 m 57.77 38.28 27.34 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.858 -179.845 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.358 0 C-N-CA 120.734 -0.745 . . . . 0.0 112.514 179.985 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.328 0 N-CA-C 112.482 -0.247 . . . . 0.0 112.482 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 12.2 m -38.15 107.72 0.07 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.875 0.369 . . . . 0.0 110.876 -179.778 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 24.6 m -154.92 170.23 22.2 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.873 -179.83 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 157.08 164.91 14.14 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.534 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 49.8 m -107.07 83.52 1.84 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.858 0.361 . . . . 0.0 110.898 -179.743 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 90.8 p -108.99 101.07 10.18 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.879 -179.824 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 124.03 105.21 1.66 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.493 -179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -75.06 141.94 43.78 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.782 0.325 . . . . 0.0 111.12 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 17.4 m -150.63 171.76 16.61 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.866 -179.808 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 35.0 m -75.95 151.66 6.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.113 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 14.3 ptt180 -93.38 125.18 37.85 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.887 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 16.6 m -128.36 127.12 66.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.117 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 98.9 t -87.23 102.08 11.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.121 179.899 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 45.2 mt-30 -115.68 78.1 1.15 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.974 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.431 ' O ' ' CD1' ' A' ' 190' ' ' LEU . 36.1 pttt -74.7 -35.03 62.74 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.91 179.989 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 59.4 t-20 -86.81 38.55 0.8 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.901 179.939 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 41.4 tp -141.68 129.13 21.29 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.904 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 94.7 t -116.78 119.43 61.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.112 179.852 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.559 ' CE1' ' HB2' ' A' ' 158' ' ' SER . 48.2 t80 -113.67 109.64 18.91 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.861 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 68.1 t -106.32 146.5 12.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.121 179.932 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 32.9 m -132.03 170.69 19.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.086 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 78.29 45.49 9.95 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.455 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 32.4 mt -117.91 136.79 53.24 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.877 0.37 . . . . 0.0 110.955 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 117' ' ' SER . . . . . 0.483 ' O ' ' N ' ' A' ' 119' ' ' ARG . 15.3 p -82.33 140.51 33.51 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.862 -179.892 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 118' ' ' GLN . . . . . 0.424 ' C ' ' O ' ' A' ' 117' ' ' SER . 82.8 mm-40 -35.02 -33.02 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.878 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.483 ' N ' ' O ' ' A' ' 117' ' ' SER . 72.8 mtm-85 -68.85 -50.22 51.69 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.827 -179.869 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . 0.462 ' N ' ' O ' ' A' ' 117' ' ' SER . 36.0 mt -70.97 -38.96 72.77 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.927 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -60.14 83.48 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.116 179.823 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 122' ' ' ASP . . . . . 0.4 ' N ' ' O ' ' A' ' 120' ' ' LEU . 6.0 m-20 -147.18 145.82 23.37 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.623 0.725 . . . . 0.0 110.888 179.962 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.76 -40.02 5.82 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.736 2.291 . . . . 0.0 112.327 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . 0.421 ' HG3' ' N ' ' A' ' 125' ' ' VAL . 16.8 pt-20 -75.8 -50.23 15.79 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.883 -179.967 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.45 HG12 ' CE2' ' A' ' 131' ' ' TYR . 53.2 t -56.51 -41.38 72.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.101 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 71.5 mt -74.68 -37.22 62.73 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.893 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.452 ' HA ' ' CD1' ' A' ' 138' ' ' ILE . 35.2 mttm -65.39 -22.9 66.84 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.906 179.832 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 64.1 mtt180 -48.5 143.75 7.27 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.571 0.701 . . . . 0.0 110.908 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 1.35 4.5 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.708 2.272 . . . . 0.0 112.335 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 26.9 mp0 -103.95 -42.02 5.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.908 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 131' ' ' TYR . . . . . 0.45 ' CE2' HG12 ' A' ' 125' ' ' VAL . 37.5 m-85 -72.77 -75.14 0.15 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.932 -179.872 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 45.6 m-85 -116.35 -32.85 5.15 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.867 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -52.49 -15.28 2.81 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.514 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 16.8 ptmt -67.7 -42.83 81.38 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.79 0.329 . . . . 0.0 110.895 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 135' ' ' PHE . . . . . 0.553 ' CE1' ' HA ' ' A' ' 172' ' ' ALA . 29.3 m-85 -60.63 -45.69 93.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.888 179.939 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -179.24 167.54 37.7 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.518 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 8.0 tmtm? -61.03 131.91 52.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.732 0.301 . . . . 0.0 110.878 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.452 ' CD1' ' HA ' ' A' ' 127' ' ' LYS . 95.1 mt -93.0 142.28 13.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.111 179.876 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 38.4 t60 -104.9 -59.6 1.72 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.803 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -129.17 136.52 50.26 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.916 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . 0.424 ' CG2' HG22 ' A' ' 138' ' ' ILE . 47.1 t -129.36 139.76 50.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.179 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 5.4 t -132.18 140.19 48.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.117 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 42.1 mm -114.48 121.42 66.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.159 179.926 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 7.5 m-80 -115.67 113.39 23.45 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.933 179.916 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 53.6 p30 -127.55 160.59 31.09 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.879 -179.974 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 2.7 t -63.52 117.43 6.74 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.844 -179.831 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 15.3 t -79.81 8.17 7.28 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.189 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 65.4 m -102.66 164.66 11.51 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.838 -179.81 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 17.2 m-85 -65.9 143.82 57.19 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.902 -179.883 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -52.26 156.9 1.54 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.09 179.873 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 112.29 36.85 1.56 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.519 -179.908 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 52.5 p -108.45 -178.93 3.73 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.818 0.342 . . . . 0.0 110.873 -179.736 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 58.1 mt-30 -79.54 79.92 5.97 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.888 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 79.07 83.41 0.64 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.498 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 81.35 0.83 Allowed 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.677 2.251 . . . . 0.0 112.336 -179.94 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 31.2 p -106.41 126.69 52.56 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.859 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -95.03 163.4 13.32 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.059 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 158' ' ' SER . . . . . 0.559 ' HB2' ' CE1' ' A' ' 112' ' ' PHE . 58.9 p -134.46 164.83 26.58 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.813 -179.757 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -147.15 136.43 22.58 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.108 179.898 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 160' ' ' TYR . . . . . 0.479 ' CE2' ' CD1' ' A' ' 112' ' ' PHE . 11.9 m-85 -104.96 113.11 26.51 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.902 -179.812 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.429 HG12 ' N ' ' A' ' 162' ' ' THR . 50.0 t -108.16 139.48 30.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.132 179.915 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 162' ' ' THR . . . . . 0.429 ' N ' HG12 ' A' ' 161' ' ' VAL . 54.3 m -106.56 126.58 52.45 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.146 -179.992 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 15.4 m-85 -109.02 127.79 54.4 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.947 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 64.8 mt -59.48 -52.18 63.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.145 179.889 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 33.4 mtp85 -84.98 110.36 18.84 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.834 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 166' ' ' SER . . . . . 0.416 ' O ' ' C ' ' A' ' 167' ' ' GLU . 68.5 m -49.73 -64.72 0.72 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.833 -179.808 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . 0.416 ' C ' ' O ' ' A' ' 166' ' ' SER . 15.3 mt-10 -37.29 -57.69 0.87 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.899 -179.961 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -51.22 -47.74 62.24 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.895 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -54.77 -58.61 6.87 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.08 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 41.1 mt -46.21 -56.95 4.99 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.879 -179.924 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 6.6 mpt_? -55.19 -51.86 65.17 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.856 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . 0.553 ' HA ' ' CE1' ' A' ' 135' ' ' PHE . . . -47.52 -33.04 5.87 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.06 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 56.9 mt -79.12 -34.38 16.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.124 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 44.7 mt-30 -70.69 -26.01 63.23 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.912 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 4.0 m -93.77 -36.11 12.44 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.932 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 9.8 t -67.94 -35.81 73.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.118 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 58.4 t30 -62.97 145.26 55.73 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.921 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 35.5 t30 55.62 51.68 12.21 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.916 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 76.7 t -125.89 142.37 42.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.104 179.934 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 91.3 t -104.24 105.12 17.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.128 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 85.7 t -119.11 105.01 16.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.174 179.921 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 1.6 t70 60.01 41.23 17.73 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.901 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 71.28 24.09 77.35 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.524 -179.932 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 3.5 mmp_? -126.93 114.23 17.58 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.884 0.373 . . . . 0.0 110.875 -179.837 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 7.8 m -70.7 103.19 2.49 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.122 -179.89 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 31.1 mt -71.52 126.1 28.78 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.934 179.932 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -131.02 114.55 15.33 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.89 179.837 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -118.54 137.62 53.1 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.046 179.862 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 7.3 t -125.89 166.78 16.26 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.875 -179.785 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 190' ' ' LEU . . . . . 0.431 ' CD1' ' O ' ' A' ' 108' ' ' LYS . 9.0 tp -131.8 143.41 50.19 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.897 -179.97 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 76.04 10.48 85.2 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.547 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 192' ' ' THR . . . . . . . . . . . . . 15.3 t -93.62 130.07 39.66 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.822 0.344 . . . . 0.0 111.175 -179.851 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 193' ' ' THR . . . . . . . . . . . . . 5.1 t -118.17 134.08 55.33 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.158 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 194' ' ' LYS . . . . . 0.436 ' O ' ' C ' ' A' ' 195' ' ' TYR . 0.1 OUTLIER -119.75 102.07 8.34 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.893 179.913 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 195' ' ' TYR . . . . . 0.436 ' C ' ' O ' ' A' ' 194' ' ' LYS . 5.6 t80 35.0 53.39 0.67 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.912 -179.997 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 196' ' ' CYS . . . . . . . . . . . . . 23.5 p -146.12 146.27 30.82 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.881 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 8.5 t -95.59 149.01 21.91 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.867 -179.782 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 198' ' ' TYR . . . . . . . . . . . . . 52.9 t80 -130.71 97.54 4.39 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.925 -179.907 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 1.7 t -89.22 124.89 34.79 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.82 -179.827 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . 122.77 -164.11 15.88 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.484 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 201' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.78 167.88 69.55 Favored 'Cis proline' 0 C--N 1.342 0.192 0 C-N-CA 122.68 -1.8 . . . . 0.0 112.323 0.089 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 202' ' ' SER . . . . . . . . . . . . . 14.1 p -119.28 90.8 3.4 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.835 -179.836 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 4.0 t -58.61 96.43 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.827 -179.816 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.291 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.497 179.992 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.315 0 N-CA-C 112.427 -0.269 . . . . 0.0 112.427 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 16.1 t -49.13 117.34 2.08 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.88 0.371 . . . . 0.0 110.781 -179.718 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 3.6 m 41.2 43.14 1.89 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.841 -179.865 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -118.94 69.88 0.33 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.475 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 26.3 p -149.42 147.36 28.17 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.868 0.366 . . . . 0.0 110.858 -179.783 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 30.6 m -89.25 170.9 10.19 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.833 -179.809 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -118.49 -45.33 0.48 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.692 -0.765 . . . . 0.0 112.503 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -46.79 147.65 1.24 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.766 0.317 . . . . 0.0 111.079 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 4.2 t -102.03 159.95 14.92 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.845 -179.799 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 90.4 t -65.4 99.04 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.114 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 14.4 tpp180 -112.24 138.77 48.46 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.887 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 11.2 p -116.44 114.54 46.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.141 179.929 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 10.5 p -117.64 138.36 48.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.119 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 51.9 mt-30 -52.45 125.12 15.25 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.936 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 35.9 mtmm -89.36 42.72 1.1 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.887 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 11.6 p-10 -112.21 39.96 2.31 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.858 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 13.9 tp -135.16 123.12 22.62 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.931 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.566 HG23 ' CD1' ' A' ' 163' ' ' TYR . 77.9 t -103.44 108.02 23.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.103 179.867 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.451 ' CD1' ' CE1' ' A' ' 160' ' ' TYR . 47.2 t80 -106.56 113.86 27.63 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.875 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 32.7 t -112.61 137.94 43.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.163 179.927 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 23.1 m -121.36 166.22 16.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.125 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 73.38 55.69 6.01 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.493 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 32.3 mt -117.81 127.76 54.2 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.813 0.339 . . . . 0.0 110.894 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 11.8 m -63.78 136.01 57.1 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.846 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 118' ' ' GLN . . . . . 0.454 ' OE1' ' ND2' ' A' ' 145' ' ' ASN . 4.8 tp-100 -41.97 -27.28 0.12 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.884 -179.974 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 1.8 mpt_? -78.4 -48.27 15.85 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.901 -179.932 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 42.8 mt -66.22 -38.7 88.56 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.932 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -60.91 88.12 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.069 179.839 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 24.9 m-20 -148.65 149.54 31.21 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.635 0.731 . . . . 0.0 110.852 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.82 -43.39 2.64 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.675 2.25 . . . . 0.0 112.325 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 27.6 mt-10 -76.39 -41.86 46.44 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.857 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.626 ' CG1' ' CZ ' ' A' ' 131' ' ' TYR . 74.3 t -60.24 -48.06 89.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.127 -179.987 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 42.3 mt -70.26 -40.25 74.49 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.886 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 32.1 mttm -61.54 -35.89 79.04 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.864 179.854 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 48.7 mtt85 -43.9 143.41 1.74 Allowed Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.592 0.711 . . . . 0.0 110.875 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 -3.54 12.19 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.707 2.272 . . . . 0.0 112.362 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -94.96 -36.13 11.71 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.944 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 131' ' ' TYR . . . . . 0.626 ' CZ ' ' CG1' ' A' ' 125' ' ' VAL . 57.1 m-85 -80.21 -74.23 0.32 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.888 -179.841 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.487 ' O ' ' N ' ' A' ' 134' ' ' LYS . 14.6 m-85 -116.9 -44.84 2.79 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.915 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . 0.439 ' C ' ' O ' ' A' ' 132' ' ' PHE . . . -35.39 -31.06 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.515 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.487 ' N ' ' O ' ' A' ' 132' ' ' PHE . 16.6 ptmt -45.86 -48.77 15.89 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.812 0.339 . . . . 0.0 110.887 -179.995 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 135' ' ' PHE . . . . . 0.549 ' CD2' ' HA ' ' A' ' 172' ' ' ALA . 78.9 m-85 -61.69 -43.91 97.95 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.882 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -173.94 -174.54 40.91 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.491 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 29.5 mtmt -90.09 102.18 14.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.753 0.311 . . . . 0.0 110.845 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 58.1 mt -61.33 148.38 9.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.104 179.847 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 61.4 t60 -101.55 -57.55 2.06 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.875 179.837 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 40.2 tttm -123.17 143.8 49.77 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.904 179.916 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 58.5 t -135.91 118.45 21.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.135 179.89 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 83.9 t -117.32 134.72 60.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.128 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 3.3 mm -106.46 125.39 62.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.129 179.923 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 4.4 m-80 -117.87 104.36 10.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.947 179.87 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 145' ' ' ASN . . . . . 0.454 ' ND2' ' OE1' ' A' ' 118' ' ' GLN . 35.4 m120 -85.73 138.2 32.27 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.893 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 25.9 t -45.35 149.98 0.49 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.885 -179.842 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 90.6 m -128.81 -56.35 1.2 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.138 -179.931 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 34.4 p -85.83 140.94 30.0 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.874 -179.866 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . 0.473 ' O ' ' CG ' ' A' ' 149' ' ' TYR . 3.7 p90 -100.81 122.84 44.1 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.906 -179.889 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -106.73 -56.51 2.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.093 179.879 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 94.76 39.72 4.57 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.501 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 20.0 m -102.17 -51.38 3.39 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.787 0.327 . . . . 0.0 110.831 -179.739 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 28.5 mm-40 -121.51 -44.11 2.37 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.895 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 145.28 -167.97 27.27 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.501 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.8 105.4 1.48 Allowed 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.681 2.254 . . . . 0.0 112.332 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 58.1 m -126.07 125.34 42.43 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.848 -179.807 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -106.5 165.32 11.36 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.064 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 79.0 p -130.12 167.38 18.44 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.842 -179.767 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -155.68 136.21 13.29 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.137 179.9 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 160' ' ' TYR . . . . . 0.451 ' CE1' ' CD1' ' A' ' 112' ' ' PHE . 98.3 m-85 -99.4 133.14 44.15 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.926 -179.869 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 75.2 t -125.6 122.28 62.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.179 179.893 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 87.4 m -94.97 124.18 38.87 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.197 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 163' ' ' TYR . . . . . 0.566 ' CD1' HG23 ' A' ' 111' ' ' VAL . 14.0 m-85 -100.2 147.77 25.35 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.925 -179.897 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 52.0 mt -73.5 -41.74 56.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.154 179.871 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 13.3 mmm180 -105.18 133.41 49.99 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.862 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 71.5 m -63.05 -68.18 0.36 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.834 -179.722 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 4.9 tp10 -42.93 -58.45 2.4 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.884 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -47.16 -46.48 23.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.921 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -58.98 -61.53 2.57 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.119 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . 0.434 ' CD2' HD21 ' A' ' 190' ' ' LEU . 59.0 mt -39.21 -52.75 1.94 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.914 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 171' ' ' ARG . . . . . 0.431 ' O ' ' N ' ' A' ' 174' ' ' GLN . 86.1 mtt180 -59.44 -58.61 7.83 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.898 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . 0.549 ' HA ' ' CD2' ' A' ' 135' ' ' PHE . . . -41.02 -35.59 0.56 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.098 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 173' ' ' ILE . . . . . 0.457 ' CG1' HG21 ' A' ' 111' ' ' VAL . 58.5 mt -76.89 -37.58 27.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.074 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 174' ' ' GLN . . . . . 0.431 ' N ' ' O ' ' A' ' 171' ' ' ARG . 61.5 mt-30 -64.68 -21.42 66.73 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.883 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 3.9 m -93.83 -40.39 10.2 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.873 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 9.1 t -62.45 -38.36 81.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.115 -179.984 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 5.1 t-20 -60.71 140.36 57.55 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.887 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 15.6 t-20 65.2 50.74 1.75 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.91 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 71.1 t -124.78 142.04 42.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.061 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 83.3 t -96.25 110.68 25.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.16 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 48.7 t -120.02 106.02 18.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.125 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 53.77 43.47 30.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.881 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 71.19 30.83 66.91 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.454 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 32.9 mtt-85 -138.24 122.71 18.41 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.882 0.372 . . . . 0.0 110.902 -179.874 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 17.7 m -82.47 96.91 8.15 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.143 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 95.8 mt -74.45 132.71 42.16 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.937 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 47.8 mttt -117.87 132.22 56.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.941 179.8 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -123.53 147.27 47.42 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.106 179.857 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 68.0 m -158.06 162.62 38.09 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.856 -179.806 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 190' ' ' LEU . . . . . 0.434 HD21 ' CD2' ' A' ' 170' ' ' LEU . 4.5 pp -129.77 156.33 44.49 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.894 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 93.82 29.66 9.67 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.507 179.867 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 192' ' ' THR . . . . . . . . . . . . . 13.5 t -105.01 149.5 25.73 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.846 0.355 . . . . 0.0 111.14 -179.84 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 193' ' ' THR . . . . . . . . . . . . . 7.3 t -112.9 141.02 47.2 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.152 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 10.3 pttt -62.22 134.53 56.66 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.884 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 195' ' ' TYR . . . . . . . . . . . . . 9.4 m-85 -80.85 92.49 6.11 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.933 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 196' ' ' CYS . . . . . . . . . . . . . 1.8 t -120.86 151.42 39.67 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.883 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 1.9 t -64.69 108.66 1.78 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.851 -179.743 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 198' ' ' TYR . . . . . . . . . . . . . 19.5 p90 -107.98 133.77 51.83 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.893 -179.854 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 29.9 t -158.81 146.4 17.78 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.889 -179.862 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . 77.29 -165.32 53.06 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.492 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 201' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 153.52 92.95 Favored 'Cis proline' 0 C--O 1.232 0.194 0 C-N-CA 122.704 -1.79 . . . . 0.0 112.366 0.027 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 202' ' ' SER . . . . . . . . . . . . . 7.9 m -64.84 117.35 7.41 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.865 -179.835 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 78.0 p -103.24 116.93 33.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.846 -179.804 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.31 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.506 -179.988 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.343 0 N-CA-C 112.494 -0.242 . . . . 0.0 112.494 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 75.7 m -123.15 154.91 38.01 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.901 0.381 . . . . 0.0 110.861 -179.762 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 40.2 t -70.02 147.38 50.16 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.875 -179.858 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 141.65 101.36 0.43 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.473 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 19.4 m -100.87 150.49 22.77 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.874 0.368 . . . . 0.0 110.848 -179.752 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 93.2 p 37.35 42.2 0.3 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.924 -179.796 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 68.89 -142.99 39.11 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.494 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -94.39 148.6 22.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.804 0.335 . . . . 0.0 111.075 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 52.0 p -101.4 125.34 48.02 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.84 -179.798 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 34.9 m -120.35 131.01 73.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.147 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 76.0 mtm-85 -124.1 143.38 50.5 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.835 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 91.5 t -74.07 110.66 8.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.141 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 69.3 t -115.52 141.56 32.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.101 179.949 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 8.0 pt20 -65.66 145.14 56.41 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.952 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 20.4 mmtp -101.66 -15.06 17.15 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.89 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 9.5 m-20 -101.17 51.7 0.85 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.91 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 14.1 tp -135.28 105.03 6.1 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.877 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 41.4 t -95.49 104.22 15.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.15 179.815 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.579 ' CD1' ' CE2' ' A' ' 160' ' ' TYR . 39.5 t80 -94.08 122.36 36.51 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.848 -179.948 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 42.3 t -117.82 133.55 64.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.145 179.92 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . 0.429 ' CG1' ' CE2' ' A' ' 112' ' ' PHE . 11.9 m -120.4 166.64 14.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.125 179.899 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 67.0 53.53 26.24 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.506 179.983 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 34.9 mt -105.98 146.57 29.89 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.844 0.354 . . . . 0.0 110.846 -179.86 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 29.2 m -77.35 153.98 33.24 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.801 -179.908 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 84.9 mm-40 -56.55 -44.9 81.37 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.892 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 10.6 ttt180 -74.38 -44.96 49.85 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.897 -179.925 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 66.2 mt -66.89 -24.84 66.16 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.932 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -76.06 83.71 2.93 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.11 179.773 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -148.3 150.34 34.32 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-O 121.62 0.724 . . . . 0.0 110.857 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.83 -50.62 0.44 Allowed 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.668 2.245 . . . . 0.0 112.319 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 7.0 mm-40 -65.35 -41.91 93.38 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.89 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.629 ' CG1' ' CZ ' ' A' ' 131' ' ' TYR . 85.9 t -61.79 -42.68 95.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.128 179.975 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . 0.537 HD23 ' CE1' ' A' ' 132' ' ' PHE . 79.4 mt -74.33 -40.32 62.25 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.929 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.447 ' HA ' ' CD1' ' A' ' 138' ' ' ILE . 43.0 tttt -61.03 -31.25 70.89 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.873 179.837 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 72.6 mtt-85 -44.13 142.88 2.02 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.573 0.701 . . . . 0.0 110.873 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 0.8 5.14 Favored 'Trans proline' 0 C--N 1.341 0.136 0 C-N-CA 122.662 2.241 . . . . 0.0 112.375 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 5.0 tp10 -103.99 -36.01 7.9 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.915 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 131' ' ' TYR . . . . . 0.629 ' CZ ' ' CG1' ' A' ' 125' ' ' VAL . 38.8 m-85 -75.91 -75.02 0.2 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.962 -179.869 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.537 ' CE1' HD23 ' A' ' 126' ' ' LEU . 19.9 m-85 -114.86 -40.58 3.5 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.858 -179.996 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -52.23 -20.47 6.93 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.51 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.423 ' C ' ' HD3' ' A' ' 134' ' ' LYS . 0.0 OUTLIER -53.54 -31.65 47.27 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.86 0.362 . . . . 0.0 110.903 -179.999 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 135' ' ' PHE . . . . . 0.537 ' CZ ' HG21 ' A' ' 176' ' ' VAL . 65.3 m-85 -73.21 -42.48 62.6 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.87 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -177.66 -163.41 29.41 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.47 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 16.9 mttp -79.58 142.14 35.95 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.774 0.321 . . . . 0.0 110.915 -179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.447 ' CD1' ' HA ' ' A' ' 127' ' ' LYS . 82.6 mt -105.25 132.19 52.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.146 179.899 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 3.8 t-160 -85.97 -59.64 2.24 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.857 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 73.6 tttt -132.72 146.1 51.58 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.936 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 24.2 t -129.38 130.08 67.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.153 179.876 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 96.1 t -134.34 147.49 30.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.133 179.879 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 15.3 mm -118.05 150.44 20.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.133 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 39.9 t30 -129.02 106.47 8.9 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.889 179.902 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 3.0 p30 -119.8 142.07 48.93 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.896 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 79.9 p -56.81 128.58 37.39 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.885 -179.866 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 22.6 p -89.07 -35.98 16.02 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.143 -179.92 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 60.1 p -86.82 148.55 25.34 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.885 -179.911 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 98.1 m-85 -69.13 113.57 6.61 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.945 -179.912 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -88.77 -61.08 1.79 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.105 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 81.74 37.72 15.87 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.501 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 43.1 m -110.69 163.22 13.96 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.802 0.334 . . . . 0.0 110.873 -179.728 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 18.3 tt0 -79.81 102.55 9.15 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.919 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 84.05 83.13 0.96 Allowed Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.487 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.75 120.67 7.42 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.674 2.249 . . . . 0.0 112.336 -179.955 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 78.7 p -86.56 123.23 31.53 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.825 -179.831 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -112.28 164.81 12.79 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.082 179.911 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 14.8 m -133.16 164.55 26.8 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.87 -179.797 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -150.81 166.47 30.4 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.131 179.922 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 160' ' ' TYR . . . . . 0.579 ' CE2' ' CD1' ' A' ' 112' ' ' PHE . 11.6 m-85 -136.29 126.4 26.2 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.913 -179.821 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 67.0 t -126.72 146.13 33.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.09 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 82.2 m -108.35 134.16 51.55 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.192 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 7.9 m-85 -111.96 120.75 42.95 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.924 -179.867 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 88.7 mt -49.75 -50.86 17.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.102 179.918 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 24.9 mtp85 -88.1 109.72 20.09 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.883 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 5.3 t -48.85 -59.3 3.69 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.855 -179.772 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 23.8 mt-10 -47.94 -46.29 31.94 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.89 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 6.5 t0 -56.13 -45.12 79.68 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.829 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -55.75 -52.42 63.98 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.116 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 26.8 mt -51.38 -59.4 4.27 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.894 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 74.3 mtp180 -55.09 -49.23 72.22 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.903 179.909 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . 0.494 ' O ' ' CG2' ' A' ' 176' ' ' VAL . . . -50.08 -33.16 17.61 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.066 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 55.2 mt -76.65 -38.4 30.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.128 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 10.3 mm100 -65.66 -30.54 71.25 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.884 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 175' ' ' CYS . . . . . 0.444 ' O ' ' CG2' ' A' ' 179' ' ' VAL . 3.0 t -93.72 -27.33 16.58 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.85 -179.94 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 176' ' ' VAL . . . . . 0.537 HG21 ' CZ ' ' A' ' 135' ' ' PHE . 10.4 t -77.9 -26.28 14.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.181 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -79.09 154.15 29.61 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.855 -179.972 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 178' ' ' ASN . . . . . 0.438 ' O ' ' CG ' ' A' ' 178' ' ' ASN . 32.5 t30 55.23 36.27 26.67 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.881 179.978 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 179' ' ' VAL . . . . . 0.444 ' CG2' ' O ' ' A' ' 175' ' ' CYS . 92.3 t -108.84 141.98 22.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.109 179.919 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 53.7 t -106.2 97.1 5.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.121 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . 0.443 ' O ' ' CG ' ' A' ' 182' ' ' ASP . 40.0 t -102.41 118.34 49.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.143 179.941 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 182' ' ' ASP . . . . . 0.443 ' CG ' ' O ' ' A' ' 181' ' ' VAL . 2.9 p30 47.26 31.65 1.84 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.851 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 86.02 20.7 54.87 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.453 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 5.5 tpm_? -118.21 133.97 55.43 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.904 0.383 . . . . 0.0 110.882 -179.857 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 17.3 m -90.76 95.13 9.99 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.164 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 71.1 mt -74.8 128.33 35.3 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.892 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 2.8 mmmp? -128.79 121.7 28.92 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.887 179.822 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -119.4 156.52 29.98 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.087 179.859 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 8.5 t -147.76 165.28 31.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.857 -179.813 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 190' ' ' LEU . . . . . . . . . . . . . 1.6 tm? -132.2 137.58 47.65 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.877 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 86.58 30.28 21.92 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.441 179.83 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 192' ' ' THR . . . . . 0.427 HG23 ' CB ' ' A' ' 112' ' ' PHE . 15.2 t -88.82 147.17 24.55 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.883 0.373 . . . . 0.0 111.103 -179.86 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 193' ' ' THR . . . . . . . . . . . . . 58.6 p -72.52 112.53 8.66 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.155 179.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 194' ' ' LYS . . . . . 0.419 ' HD2' ' C ' ' A' ' 194' ' ' LYS . 0.3 OUTLIER -99.92 104.73 16.39 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.954 179.881 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 195' ' ' TYR . . . . . . . . . . . . . 80.4 t80 -67.28 147.58 52.81 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.948 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 196' ' ' CYS . . . . . . . . . . . . . 27.0 p -158.55 168.16 27.66 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.912 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 15.5 t -104.46 138.76 40.37 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.817 -179.718 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 198' ' ' TYR . . . . . . . . . . . . . 12.6 t80 -118.25 144.96 45.38 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.922 -179.868 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 199' ' ' SER . . . . . 0.424 ' O ' ' N ' ' A' ' 202' ' ' SER . 1.2 t -127.46 -59.42 1.22 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.864 -179.856 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 200' ' ' GLY . . . . . 0.427 ' HA3' ' C ' ' A' ' 201' ' ' PRO . . . 124.98 -69.67 0.48 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.488 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 201' ' ' PRO . . . . . 0.427 ' C ' ' HA3' ' A' ' 200' ' ' GLY . 53.5 Cg_endo -69.73 155.69 93.06 Favored 'Cis proline' 0 C--N 1.341 0.156 0 C-N-CA 122.68 -1.8 . . . . 0.0 112.34 0.022 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 202' ' ' SER . . . . . 0.424 ' N ' ' O ' ' A' ' 199' ' ' SER . 30.6 t -40.68 140.51 0.68 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.859 -179.859 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 1.1 t 38.42 45.39 0.83 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.866 -179.807 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.281 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.492 -179.999 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 N-CA-C 112.495 -0.242 . . . . 0.0 112.495 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 3.9 t -50.45 124.92 11.56 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.92 0.39 . . . . 0.0 110.855 -179.735 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 69.2 m -124.55 -49.08 1.78 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.88 -179.819 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 113.04 81.47 1.08 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.491 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 70.7 m -101.67 97.98 8.32 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.9 0.381 . . . . 0.0 110.828 -179.706 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 24.1 p -145.95 119.31 8.99 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.907 -179.888 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 152.04 158.25 8.33 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.46 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -103.05 144.44 31.29 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.772 0.32 . . . . 0.0 111.088 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 25.8 p -174.26 149.52 1.4 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.828 -179.827 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 96.3 t -120.58 113.67 40.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.146 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -124.68 146.95 48.86 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.895 -179.968 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 77.6 t -82.18 113.86 22.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.137 179.943 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 14.9 p -100.0 126.85 53.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.097 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 67.0 mt-30 -132.97 157.88 44.06 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.916 179.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 30.0 pttt -96.76 35.11 1.57 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.908 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 34.3 p-10 -119.19 42.92 2.72 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.874 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . 0.439 ' O ' ' CD2' ' A' ' 190' ' ' LEU . 9.4 tp -132.84 123.55 26.29 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.941 179.964 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 69.5 t -108.95 106.67 21.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.131 179.899 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.511 ' CZ ' ' CG1' ' A' ' 114' ' ' VAL . 61.4 t80 -99.83 117.42 34.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.864 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 21.2 t -116.56 135.67 56.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.107 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . 0.511 ' CG1' ' CZ ' ' A' ' 112' ' ' PHE . 34.1 m -124.55 165.38 21.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.123 179.904 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 78.6 52.46 5.08 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.48 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 21.2 mt -109.16 133.67 52.72 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.85 0.357 . . . . 0.0 110.932 -179.917 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 40.2 t -66.53 147.83 52.74 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.853 -179.92 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.9 mt-30 -40.86 -47.3 2.91 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.917 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 39.3 mtp180 -71.47 -37.78 71.3 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.901 -179.922 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 51.7 mt -67.27 -26.7 66.68 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.943 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -74.01 83.81 1.76 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.098 179.763 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -148.99 142.99 16.56 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.592 0.711 . . . . 0.0 110.904 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.7 -49.26 0.59 Allowed 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.69 2.26 . . . . 0.0 112.359 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 51.4 mt-10 -69.48 -42.28 75.04 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.887 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.479 ' CG1' ' CZ ' ' A' ' 131' ' ' TYR . 60.3 t -59.16 -46.15 92.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.128 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 68.0 mt -69.81 -40.49 75.91 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.918 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 15.3 tttt -61.83 -27.88 69.09 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.937 179.809 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 13.8 mtp85 -45.24 143.6 2.52 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.632 0.729 . . . . 0.0 110.857 179.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 1.23 4.61 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.656 2.237 . . . . 0.0 112.347 -179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 7.1 tp10 -105.51 -35.55 7.42 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.931 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 131' ' ' TYR . . . . . 0.479 ' CZ ' ' CG1' ' A' ' 125' ' ' VAL . 38.0 m-85 -77.46 -75.11 0.22 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.911 -179.857 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 13.2 m-85 -116.23 -34.68 4.58 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.902 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -49.99 -23.9 5.93 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.527 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.42 ' C ' ' HD3' ' A' ' 134' ' ' LYS . 0.0 OUTLIER -56.03 -34.07 65.51 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.788 0.328 . . . . 0.0 110.913 -179.959 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 135' ' ' PHE . . . . . 0.556 ' CE1' ' HA ' ' A' ' 172' ' ' ALA . 19.4 m-85 -69.89 -47.06 64.02 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.875 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -174.12 177.28 46.42 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.502 -179.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 5.8 mmmt -74.57 110.25 8.71 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.747 0.308 . . . . 0.0 110.893 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.403 HG22 ' CG1' ' A' ' 161' ' ' VAL . 56.8 mt -75.64 143.53 13.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.126 179.924 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 19.8 t-160 -99.2 -58.73 1.87 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.864 179.903 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -127.78 141.9 51.45 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.869 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 3.9 t -130.94 139.86 50.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.114 179.887 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 69.5 t -135.45 139.84 45.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.132 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 16.7 mm -112.13 114.71 47.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.143 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 1.6 t30 -99.94 127.46 46.13 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.897 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 2.1 p-10 -107.15 152.69 23.71 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.872 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 7.4 t -81.41 133.6 35.43 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.868 -179.851 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 1.4 m -81.5 44.5 0.8 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.172 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 3.7 m -88.62 165.29 14.9 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.844 -179.829 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 61.7 m-85 -60.24 144.28 50.61 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.91 -179.884 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -64.74 133.45 52.09 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.145 179.838 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 93.77 39.75 4.86 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.512 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 9.9 m -89.45 147.64 23.9 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.821 0.343 . . . . 0.0 110.842 -179.699 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 39.7 tt0 -82.19 94.74 7.34 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.92 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 69.32 69.29 1.42 Allowed Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.479 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 128.95 16.74 Favored 'Trans proline' 0 C--O 1.232 0.181 0 C-N-CA 122.678 2.252 . . . . 0.0 112.352 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 53.9 p -79.95 125.26 29.52 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.861 -179.826 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -122.32 152.59 39.96 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.109 179.907 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 87.5 p -124.89 176.43 6.63 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.894 -179.818 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -160.7 162.06 32.45 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.125 179.891 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 160' ' ' TYR . . . . . 0.483 ' CE2' ' CD1' ' A' ' 112' ' ' PHE . 16.5 m-85 -125.61 127.56 46.53 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.921 -179.825 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.403 ' CG1' HG22 ' A' ' 138' ' ' ILE . 66.7 t -121.75 140.27 46.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.117 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 4.7 m -114.21 115.71 27.89 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.185 -179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 29.1 m-85 -90.47 134.2 34.51 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.928 -179.904 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 66.4 mt -59.36 -42.63 88.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.119 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 19.0 mtm-85 -99.57 112.04 24.31 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.877 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 2.7 t -48.86 -57.59 6.17 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.896 -179.822 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 32.7 tt0 -42.93 -52.46 5.15 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.88 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -52.34 -50.6 62.0 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.883 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 169' ' ' ALA . . . . . 0.401 ' O ' ' C ' ' A' ' 170' ' ' LEU . . . -54.77 -64.02 0.97 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.106 179.915 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . 0.401 ' C ' ' O ' ' A' ' 169' ' ' ALA . 55.9 mt -37.15 -58.54 0.79 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.888 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 171' ' ' ARG . . . . . 0.418 ' NH1' ' HB3' ' A' ' 171' ' ' ARG . 10.6 mtp-105 -60.61 -46.04 91.75 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.846 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . 0.556 ' HA ' ' CE1' ' A' ' 135' ' ' PHE . . . -47.38 -32.89 5.33 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.072 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 96.9 mt -82.85 -40.08 16.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.155 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 30.1 mt-30 -66.25 -23.28 66.38 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.893 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 1.8 t -93.9 -37.09 11.89 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.86 -179.927 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 9.0 t -70.18 -48.43 61.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.149 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 7.5 t30 -43.76 124.82 3.85 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.95 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 65.7 t30 70.62 52.03 0.32 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.898 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 54.5 t -134.12 135.34 54.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.123 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 83.4 t -86.96 120.57 36.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.119 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 85.0 t -124.7 116.54 47.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.1 179.948 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 34.3 t70 58.52 36.52 25.29 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.87 179.899 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 84.35 -20.17 15.17 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.456 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 43.0 ttm-85 -107.23 133.4 51.86 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.897 0.379 . . . . 0.0 110.861 -179.859 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 30.0 m -80.27 133.29 35.97 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.104 -179.884 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 27.4 mt -101.06 147.42 26.24 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.949 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -121.29 131.98 54.52 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.903 179.839 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -129.5 143.54 50.88 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.075 179.843 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 5.5 t -138.7 167.54 21.76 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.866 -179.785 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 190' ' ' LEU . . . . . 0.439 ' CD2' ' O ' ' A' ' 110' ' ' LEU . 2.0 tm? -132.61 128.9 38.13 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.925 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 99.91 27.81 7.68 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.447 179.878 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 192' ' ' THR . . . . . . . . . . . . . 30.4 p -89.04 152.95 21.38 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.84 0.352 . . . . 0.0 111.145 -179.879 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 193' ' ' THR . . . . . . . . . . . . . 40.7 p -87.64 141.76 28.36 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.123 -179.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -102.09 178.0 4.73 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.901 179.875 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 195' ' ' TYR . . . . . . . . . . . . . 45.9 t80 -116.92 99.17 6.9 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.897 -179.895 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 196' ' ' CYS . . . . . . . . . . . . . 12.0 t -146.2 151.04 36.97 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.851 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 3.2 m -118.59 128.77 54.87 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.888 -179.755 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 198' ' ' TYR . . . . . . . . . . . . . 9.3 p90 -45.78 133.41 8.3 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.881 -179.863 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 20.0 m -142.42 158.42 43.72 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.814 -179.838 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 200' ' ' GLY . . . . . 0.427 ' HA3' ' C ' ' A' ' 201' ' ' PRO . . . -84.68 -69.77 1.36 Allowed Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.505 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 201' ' ' PRO . . . . . 0.427 ' C ' ' HA3' ' A' ' 200' ' ' GLY . 53.1 Cg_endo -69.82 -19.78 11.15 Favored 'Cis proline' 0 C--N 1.342 0.209 0 C-N-CA 122.662 -1.808 . . . . 0.0 112.346 0.11 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 202' ' ' SER . . . . . . . . . . . . . 6.6 m -134.64 152.93 52.13 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.862 -179.851 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 66.5 m -66.79 -62.02 1.66 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.818 -179.801 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.346 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.509 -179.988 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 19.9 tp . . . . . 0 C--O 1.231 0.095 0 CA-C-O 120.857 0.36 . . . . 0.0 110.898 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 79.5 t -92.64 110.7 23.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.187 179.804 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.43 ' CE1' ' HB2' ' A' ' 158' ' ' SER . 53.4 t80 -109.52 107.0 16.95 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.892 -179.931 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 69.4 t -108.73 142.57 20.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.149 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 22.4 m -126.43 171.74 14.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.136 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 69.54 48.37 44.19 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.493 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 30.9 mt -112.69 125.48 54.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.789 0.328 . . . . 0.0 110.916 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 117' ' ' SER . . . . . 0.423 ' O ' ' N ' ' A' ' 120' ' ' LEU . 26.9 t -71.79 141.4 49.69 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.895 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 36.5 tp60 -38.38 -32.33 0.07 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.9 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 15.7 mmt180 -70.79 -47.51 59.15 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.845 -179.911 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 120' ' ' LEU . . . . . 0.423 ' N ' ' O ' ' A' ' 117' ' ' SER . 58.7 mt -69.46 -32.74 71.85 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.913 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -64.46 83.79 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.14 179.779 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -148.66 144.06 17.96 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.59 0.709 . . . . 0.0 110.911 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.81 -45.55 1.52 Allowed 'Trans proline' 0 C--N 1.341 0.133 0 C-N-CA 122.684 2.256 . . . . 0.0 112.287 -179.904 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -71.48 -39.52 70.85 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.927 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.609 HG13 ' CZ ' ' A' ' 131' ' ' TYR . 74.6 t -63.21 -45.76 97.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.129 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.477 HD22 ' CE1' ' A' ' 132' ' ' PHE . 95.6 mt -74.47 -34.91 63.26 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.889 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 53.0 mttt -64.61 -32.25 73.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.882 179.85 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 20.0 mmt180 -46.25 143.97 3.41 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.631 0.729 . . . . 0.0 110.85 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -4.21 13.56 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.665 2.243 . . . . 0.0 112.35 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 56.6 tt0 -100.67 -10.64 20.7 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.892 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 131' ' ' TYR . . . . . 0.609 ' CZ ' HG13 ' A' ' 125' ' ' VAL . 43.6 m-85 -103.17 -74.98 0.62 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.91 -179.864 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.477 ' CE1' HD22 ' A' ' 126' ' ' LEU . 28.2 m-85 -118.65 -40.62 2.87 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.898 179.988 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -47.93 -19.02 0.85 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.505 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.416 ' HD2' ' CD2' ' A' ' 135' ' ' PHE . 0.0 OUTLIER -51.52 -40.31 59.37 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.822 0.344 . . . . 0.0 110.914 -179.995 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 135' ' ' PHE . . . . . 0.485 ' CE1' ' HA ' ' A' ' 172' ' ' ALA . 47.8 m-85 -67.16 -44.06 80.68 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.896 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 176.94 169.66 38.47 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.544 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -60.63 136.76 58.16 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.745 0.307 . . . . 0.0 110.922 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.666 HG21 HG22 ' A' ' 141' ' ' VAL . 61.1 mt -96.64 148.82 5.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.114 179.868 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 56.4 t60 -101.02 -48.74 4.33 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.854 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 22.6 ttmt -134.98 140.54 45.77 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.879 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 141' ' ' VAL . . . . . 0.666 HG22 HG21 ' A' ' 138' ' ' ILE . 15.9 t -132.73 112.75 19.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.159 179.814 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 93.8 t -116.77 137.73 49.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.116 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 4.1 mm -114.0 123.68 69.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.106 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 8.9 t-20 -113.03 114.02 26.29 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.901 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 6.2 p-10 . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.888 -179.974 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 50.8 m . . . . . 0 C--O 1.23 0.074 0 CA-C-O 120.865 0.364 . . . . 0.0 110.894 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -114.41 166.46 11.66 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.103 179.905 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 158' ' ' SER . . . . . 0.43 ' HB2' ' CE1' ' A' ' 112' ' ' PHE . 4.8 p -134.93 150.99 50.48 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.865 -179.781 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -122.8 145.52 48.35 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.077 179.879 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 44.1 m-85 -119.42 107.16 13.0 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.945 -179.833 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 37.9 t -101.19 141.25 18.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.097 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 63.0 m -111.22 123.33 49.98 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.093 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 163' ' ' TYR . . . . . 0.825 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 30.5 m-85 -105.3 121.74 44.5 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.937 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 74.2 mt -49.63 -37.14 11.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.137 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 80.3 mmt-85 -107.11 114.75 29.0 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.898 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 69.0 m -51.68 -55.17 21.0 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.883 -179.803 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 24.8 mm-40 -42.96 -54.04 4.44 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.908 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -54.71 -46.11 74.13 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.871 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 169' ' ' ALA . . . . . 0.825 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -60.84 -64.07 1.08 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.098 179.948 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 36.6 mt -38.28 -63.62 0.48 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.922 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 86.5 mtt180 -52.8 -51.85 59.19 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.873 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 172' ' ' ALA . . . . . 0.695 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -45.06 -32.88 1.88 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.096 179.904 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 82.2 mt -81.72 -35.28 13.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.091 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 33.4 mt-30 -64.69 -27.65 69.06 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.906 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 175' ' ' CYS . . . . . 0.441 ' O ' ' CG2' ' A' ' 179' ' ' VAL . 2.3 m -93.82 -34.29 13.22 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.87 -179.927 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 176' ' ' VAL . . . . . 0.695 HG23 ' O ' ' A' ' 172' ' ' ALA . 10.8 t -63.29 -33.74 62.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.147 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 1.7 t30 -62.55 140.99 58.65 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.89 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 9.1 t-20 62.33 37.62 13.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.846 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 179' ' ' VAL . . . . . 0.441 ' CG2' ' O ' ' A' ' 175' ' ' CYS . 75.0 t -118.57 133.15 66.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.141 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 59.3 t -89.03 128.04 41.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.169 179.914 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 181' ' ' VAL . . . . . 0.485 HG21 HD12 ' A' ' 186' ' ' LEU . 50.7 t -135.86 114.56 15.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.069 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 5.8 t70 63.5 28.53 15.34 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.901 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 89.21 -14.41 60.91 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.499 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 77.6 mtt85 -108.77 126.0 52.55 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.903 0.383 . . . . 0.0 110.805 -179.837 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 10.9 m -76.74 106.48 8.42 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.16 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 186' ' ' LEU . . . . . 0.485 HD12 HG21 ' A' ' 181' ' ' VAL . 80.3 mt -70.24 157.05 38.39 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.907 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 16.2 tptm -135.65 115.01 12.53 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.939 179.82 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -110.13 142.96 40.9 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.083 179.88 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 86.1 p -156.71 165.39 36.37 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.873 -179.776 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 190' ' ' LEU . . . . . . . . . . . . . 4.3 pp -126.62 154.98 43.25 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.938 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.283 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.45 179.885 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 110' ' ' LEU . . . . . 0.407 HD11 ' HD1' ' A' ' 160' ' ' TYR . 12.3 tp . . . . . 0 C--O 1.231 0.108 0 CA-C-O 120.836 0.351 . . . . 0.0 110.943 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.775 HG22 HD11 ' A' ' 173' ' ' ILE . 47.0 t -113.94 123.33 69.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.148 179.865 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.663 ' CZ ' ' CG1' ' A' ' 114' ' ' VAL . 37.6 t80 -111.17 106.56 15.61 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.891 -179.964 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.514 HG22 ' HB2' ' A' ' 188' ' ' ALA . 20.9 t -102.82 143.4 15.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.173 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 114' ' ' VAL . . . . . 0.663 ' CG1' ' CZ ' ' A' ' 112' ' ' PHE . 33.3 m -131.82 169.8 21.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.106 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 73.75 54.51 6.52 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.502 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 60.9 mt -117.31 129.96 56.23 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.84 0.352 . . . . 0.0 110.932 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 3.3 m -65.56 152.76 43.33 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.868 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 13.1 pt20 -50.9 -20.86 1.45 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.949 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 36.5 mtm180 -92.56 -42.75 9.51 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.88 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 62.8 mt -65.94 -34.74 78.8 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.948 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -62.54 85.29 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.075 179.842 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -148.48 144.09 18.13 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.626 0.727 . . . . 0.0 110.843 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.84 -42.17 3.55 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.677 2.251 . . . . 0.0 112.273 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -71.76 -44.4 64.12 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.9 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.408 HG13 ' CZ ' ' A' ' 131' ' ' TYR . 28.7 t -60.86 -43.43 95.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.119 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.417 HD12 HD11 ' A' ' 143' ' ' ILE . 84.7 mt -68.39 -39.94 81.52 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.906 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.425 ' O ' ' C ' ' A' ' 128' ' ' ARG . 6.9 tmtt? -65.23 -37.92 88.76 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.841 179.866 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 128' ' ' ARG . . . . . 0.425 ' C ' ' O ' ' A' ' 127' ' ' LYS . 21.1 mmt180 -36.39 144.45 0.27 Allowed Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.628 0.728 . . . . 0.0 110.9 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.8 -5.17 15.59 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.679 2.253 . . . . 0.0 112.372 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 130' ' ' GLU . . . . . 0.415 ' CG ' ' O ' ' A' ' 130' ' ' GLU . 20.5 tt0 -100.88 10.29 41.3 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.898 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 131' ' ' TYR . . . . . 0.408 ' CZ ' HG13 ' A' ' 125' ' ' VAL . 47.1 m-85 -127.54 -74.18 0.59 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.928 -179.853 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 69.7 m-85 -124.12 -11.44 7.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.862 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -71.12 -11.28 70.35 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.502 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -80.66 -30.79 36.54 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.794 0.331 . . . . 0.0 110.878 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 135' ' ' PHE . . . . . . . . . . . . . 22.9 m-85 -72.31 -26.06 61.8 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.827 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 167.41 -172.57 42.38 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.494 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 7.4 mtpm? -86.26 136.75 33.05 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.754 0.311 . . . . 0.0 110.917 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.74 HG21 HG22 ' A' ' 141' ' ' VAL . 82.5 mt -100.04 138.6 23.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.127 179.865 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -96.09 -46.51 6.45 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.848 179.878 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -141.04 141.05 34.34 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.916 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 141' ' ' VAL . . . . . 0.74 HG22 HG21 ' A' ' 138' ' ' ILE . 17.4 t -134.44 123.61 43.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.087 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 99.0 t -134.2 139.88 47.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.136 179.904 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 143' ' ' ILE . . . . . 0.417 HD11 HD12 ' A' ' 126' ' ' LEU . 44.8 mm -96.89 140.41 17.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.146 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 3.7 m120 -129.09 115.87 18.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.89 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 2.7 m120 . . . . . 0 C--N 1.329 -0.316 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.884 -179.967 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 94.0 p . . . . . 0 C--O 1.231 0.092 0 CA-C-O 120.888 0.375 . . . . 0.0 110.852 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -98.31 145.69 26.42 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.094 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 80.5 p -115.15 173.65 6.39 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.87 -179.762 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -153.68 140.79 19.4 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.119 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 160' ' ' TYR . . . . . 0.407 ' HD1' HD11 ' A' ' 110' ' ' LEU . 89.0 m-85 -111.38 123.47 50.28 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.933 -179.883 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 9.7 t -123.53 139.05 51.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.092 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 58.0 m -108.41 128.6 54.92 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.117 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 163' ' ' TYR . . . . . 0.547 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 25.3 m-85 -108.45 138.65 44.4 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.891 -179.892 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 50.7 mt -64.32 -38.11 81.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.123 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 32.6 mtm180 -103.85 114.14 28.17 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.889 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 46.9 m -51.9 -51.91 53.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.846 -179.762 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -50.91 -57.57 8.17 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.899 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -46.84 -45.58 20.29 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.888 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 169' ' ' ALA . . . . . 0.547 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -61.18 -54.49 43.72 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.12 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 87.5 mt -44.2 -63.75 0.81 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.898 -179.915 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 10.5 mtp180 -54.09 -46.66 72.12 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.887 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 172' ' ' ALA . . . . . 0.681 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -51.04 -33.26 24.59 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.121 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 173' ' ' ILE . . . . . 0.775 HD11 HG22 ' A' ' 111' ' ' VAL . 77.5 mt -78.26 -39.08 24.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.084 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 3.5 mp0 -68.47 -24.3 64.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.916 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 91.9 m -93.77 -27.89 16.23 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.862 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 176' ' ' VAL . . . . . 0.681 HG23 ' O ' ' A' ' 172' ' ' ALA . 10.6 t -74.23 -30.78 27.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.135 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -66.82 146.13 54.75 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.909 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 35.6 t30 57.83 46.31 17.14 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.88 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 91.5 t -124.91 133.42 69.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.117 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 88.2 t -96.52 114.55 33.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.13 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 96.4 t -123.29 106.22 17.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.188 179.885 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 23.8 t0 58.0 39.8 26.1 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.88 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 73.53 37.36 53.13 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.509 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 3.4 mmp_? -140.99 132.01 26.19 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.919 0.39 . . . . 0.0 110.821 -179.822 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 17.1 m -87.99 96.03 10.35 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.171 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 59.6 mt -69.94 124.32 23.75 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.869 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 17.3 tptp -123.53 113.11 18.29 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.851 179.845 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 188' ' ' ALA . . . . . 0.514 ' HB2' HG22 ' A' ' 113' ' ' VAL . . . -111.95 148.18 34.3 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.105 179.821 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 8.6 t -150.83 170.9 18.15 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.902 -179.789 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 190' ' ' LEU . . . . . 0.879 HD23 ' N ' ' A' ' 191' ' ' GLY . 5.8 tt -131.17 141.54 50.09 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.945 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 191' ' ' GLY . . . . . 0.879 ' N ' HD23 ' A' ' 190' ' ' LEU . . . . . . . . 0 N--CA 1.451 -0.306 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.505 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 13.8 tp . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.792 0.33 . . . . 0.0 110.941 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 59.1 t -96.79 118.61 43.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.108 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.654 ' CD1' ' CE2' ' A' ' 160' ' ' TYR . 45.3 t80 -119.29 111.61 18.41 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.889 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.534 HG22 ' HB2' ' A' ' 188' ' ' ALA . 23.1 t -107.01 140.78 24.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.098 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 5.1 m -120.06 169.38 11.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.09 179.939 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 67.26 53.89 23.28 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.505 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 38.3 mt -112.81 127.17 56.09 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.834 0.35 . . . . 0.0 110.915 -179.92 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 117' ' ' SER . . . . . 0.495 ' O ' ' N ' ' A' ' 120' ' ' LEU . 18.8 t -65.64 125.91 26.74 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.874 -179.902 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 118' ' ' GLN . . . . . 0.438 ' C ' ' O ' ' A' ' 117' ' ' SER . 13.3 mm100 -34.93 -32.46 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.882 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.494 ' N ' ' O ' ' A' ' 117' ' ' SER . 24.7 ttm180 -72.07 -48.14 46.4 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.863 -179.916 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 120' ' ' LEU . . . . . 0.495 ' N ' ' O ' ' A' ' 117' ' ' SER . 84.1 mt -70.2 -35.56 74.0 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.951 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -61.68 87.17 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.062 179.79 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 122' ' ' ASP . . . . . 0.431 ' HB2' ' CG2' ' A' ' 125' ' ' VAL . 5.9 m-20 -147.59 152.67 42.14 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.609 0.719 . . . . 0.0 110.847 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 123' ' ' PRO . . . . . 0.466 ' HA ' HG11 ' A' ' 141' ' ' VAL . 53.8 Cg_endo -69.72 -50.18 0.49 Allowed 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.674 2.25 . . . . 0.0 112.376 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 25.3 mt-10 -71.49 -42.34 68.19 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.911 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.486 HG12 ' CE2' ' A' ' 131' ' ' TYR . 48.2 t -57.08 -53.59 41.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.116 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 87.7 mt -68.25 -30.82 69.94 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.941 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 13.8 mmtt -64.95 -39.31 93.3 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.903 179.807 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 32.5 mtt180 -39.75 143.93 0.54 Allowed Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.648 0.737 . . . . 0.0 110.874 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 -1.15 7.99 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.652 2.235 . . . . 0.0 112.354 -179.983 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -101.51 -24.54 14.14 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.864 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 131' ' ' TYR . . . . . 0.486 ' CE2' HG12 ' A' ' 125' ' ' VAL . 43.9 m-85 -87.35 -74.67 0.43 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.933 -179.868 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 16.0 m-85 -118.81 -40.51 2.86 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.858 -179.983 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -44.9 -20.89 0.26 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.45 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.421 ' HD3' ' C ' ' A' ' 134' ' ' LYS . 0.0 OUTLIER -54.52 -37.55 65.5 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.834 0.35 . . . . 0.0 110.919 -179.988 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 135' ' ' PHE . . . . . . . . . . . . . 22.2 m-85 -66.23 -44.12 84.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.865 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -176.31 -153.55 10.71 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.447 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 38.7 mtmt -97.42 108.31 21.01 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.779 0.323 . . . . 0.0 110.937 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.541 HG23 HG13 ' A' ' 161' ' ' VAL . 91.6 mt -69.7 142.88 15.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.156 179.883 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 3.0 t-160 -102.16 -56.37 2.28 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.885 179.877 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 33.4 tttt -119.01 151.48 38.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.905 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 141' ' ' VAL . . . . . 0.467 HG22 HG21 ' A' ' 138' ' ' ILE . 41.4 t -143.05 108.85 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.155 179.849 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 96.9 t -115.82 126.94 73.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.158 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 26.7 mm -106.3 109.28 27.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.111 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 144' ' ' ASN . . . . . 0.485 ' O ' ' HB1' ' A' ' 157' ' ' ALA . 3.2 t-20 -96.06 137.14 35.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.881 179.934 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 1.5 p30 . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.842 -179.994 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 23.2 m . . . . . 0 C--O 1.231 0.111 0 CA-C-O 120.856 0.36 . . . . 0.0 110.856 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 157' ' ' ALA . . . . . 0.485 ' HB1' ' O ' ' A' ' 144' ' ' ASN . . . -119.74 171.99 8.01 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.108 179.884 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 67.7 p -123.31 169.64 11.11 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.875 -179.796 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -147.64 149.76 33.11 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.108 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 160' ' ' TYR . . . . . 0.654 ' CE2' ' CD1' ' A' ' 112' ' ' PHE . 43.4 m-85 -124.26 124.75 43.1 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.901 -179.847 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.541 HG13 HG23 ' A' ' 138' ' ' ILE . 57.4 t -120.39 125.32 74.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.174 179.883 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 48.7 m -93.47 131.28 38.84 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.143 -179.951 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 163' ' ' TYR . . . . . 0.469 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 9.5 m-85 -107.35 147.15 30.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.892 -179.89 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 48.2 mt -75.29 -47.53 34.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.128 179.916 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 35.1 mtp180 -91.54 114.23 26.71 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.856 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 75.5 m -49.35 -59.4 3.74 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.867 -179.814 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 55.8 mt-10 -47.96 -47.44 32.71 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.908 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -55.34 -45.85 76.39 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.881 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 169' ' ' ALA . . . . . 0.469 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -56.93 -56.63 19.17 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.1 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 56.0 mt -47.26 -59.86 2.88 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.891 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 1.9 mpt_? -56.68 -42.51 79.16 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.866 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 172' ' ' ALA . . . . . 0.737 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -55.24 -32.09 62.02 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.101 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 76.7 mt -79.78 -37.99 18.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.112 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 8.6 mm100 -64.66 -28.67 69.77 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.862 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 19.8 t -93.74 -28.95 15.64 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.852 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 176' ' ' VAL . . . . . 0.737 HG23 ' O ' ' A' ' 172' ' ' ALA . 9.9 t -71.7 -28.07 29.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.124 -179.978 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 1.8 t30 -70.76 141.61 51.45 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.895 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 25.7 t-20 61.35 49.33 5.41 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.923 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 179' ' ' VAL . . . . . 0.425 HG12 HG23 ' A' ' 181' ' ' VAL . 79.5 t -117.0 133.66 63.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.131 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 58.7 t -98.16 105.97 18.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.14 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 181' ' ' VAL . . . . . 0.593 HG21 HD12 ' A' ' 186' ' ' LEU . 56.3 t -115.73 131.2 68.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.189 179.862 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 44.96 29.05 0.42 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.856 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 80.39 31.46 37.52 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.737 -0.745 . . . . 0.0 112.471 -179.942 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 13.2 ttm180 -134.9 136.14 42.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.855 0.359 . . . . 0.0 110.888 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 26.5 m -82.69 99.51 9.66 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.162 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 186' ' ' LEU . . . . . 0.593 HD12 HG21 ' A' ' 181' ' ' VAL . 62.9 mt -84.29 140.48 31.61 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.942 179.957 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 9.4 ttpp -135.19 146.83 49.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.877 179.828 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 188' ' ' ALA . . . . . 0.534 ' HB2' HG22 ' A' ' 113' ' ' VAL . . . -134.29 155.47 50.14 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.075 179.842 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 8.8 t -155.59 164.18 38.98 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.835 -179.807 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 190' ' ' LEU . . . . . 0.489 ' O ' HD12 ' A' ' 190' ' ' LEU . 4.7 pp -130.07 147.57 51.83 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.956 179.943 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.356 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.533 179.953 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 110' ' ' LEU . . . . . 0.472 HD11 ' HB3' ' A' ' 160' ' ' TYR . 15.3 tp . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.866 0.365 . . . . 0.0 110.878 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 89.6 t -95.58 114.12 31.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.112 179.819 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.638 ' CE2' ' CG1' ' A' ' 114' ' ' VAL . 61.1 t80 -106.86 99.25 8.83 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.901 179.98 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.663 HG22 ' HB2' ' A' ' 188' ' ' ALA . 54.3 t -98.94 125.36 52.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.149 179.997 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 114' ' ' VAL . . . . . 0.638 ' CG1' ' CE2' ' A' ' 112' ' ' PHE . 12.0 m -118.89 168.88 10.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.126 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 77.39 39.52 26.02 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.505 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 32.5 mt -105.92 137.9 43.02 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.822 0.344 . . . . 0.0 110.89 -179.909 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 78.6 p -76.58 148.14 37.2 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.842 -179.941 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 34.5 mm-40 -42.2 -34.96 0.84 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.898 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 33.0 mtt180 -69.01 -47.47 65.39 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.872 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 120' ' ' LEU . . . . . 0.865 HD21 ' OD2' ' A' ' 182' ' ' ASP . 85.0 mt -71.78 -24.68 61.79 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.928 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -71.29 83.49 0.76 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.105 179.807 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 19.6 m-20 -148.95 144.38 18.07 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.619 0.723 . . . . 0.0 110.845 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.8 -45.67 1.48 Allowed 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.662 2.242 . . . . 0.0 112.38 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 19.9 mt-10 -73.19 -42.6 62.51 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.885 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.414 ' O ' ' CD1' ' A' ' 131' ' ' TYR . 56.4 t -59.04 -46.3 91.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.157 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 74.1 mt -68.69 -37.56 79.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.959 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 12.8 ttmm -68.0 -35.77 78.87 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.9 179.804 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 66.4 mtt-85 -44.89 147.91 1.05 Allowed Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.59 0.709 . . . . 0.0 110.882 180.0 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.71 -3.19 11.49 Favored 'Trans proline' 0 N--CA 1.465 -0.163 0 C-N-CA 122.711 2.274 . . . . 0.0 112.367 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -97.93 6.39 47.77 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.897 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 131' ' ' TYR . . . . . 0.414 ' CD1' ' O ' ' A' ' 125' ' ' VAL . 63.0 m-85 -131.32 -73.84 0.53 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.938 -179.858 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 71.0 m-85 -127.06 -6.04 6.1 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.901 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -70.9 -18.92 76.57 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.515 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 11.2 ptpt -88.72 -27.25 21.33 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.857 0.36 . . . . 0.0 110.893 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 135' ' ' PHE . . . . . . . . . . . . . 27.9 m-85 -63.97 -43.65 95.11 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.85 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -177.43 167.55 38.69 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.482 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 27.1 mtmm -67.06 120.06 13.05 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.728 0.299 . . . . 0.0 110.87 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.458 HG12 ' CG1' ' A' ' 161' ' ' VAL . 83.3 mt -95.12 146.43 6.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.074 179.892 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 4.2 t60 -107.13 -59.94 1.75 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.843 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 27.5 ttpp -125.53 145.63 50.02 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.913 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 21.3 t -130.19 132.79 64.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.129 179.847 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 3.5 t -125.96 140.73 47.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.13 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 23.8 mm -119.4 121.66 67.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.162 179.907 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 4.2 m120 -116.57 105.58 12.61 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.907 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 19.4 p30 . . . . . 0 C--N 1.33 -0.279 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.878 -179.952 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 19.7 m . . . . . 0 C--O 1.23 0.066 0 CA-C-O 120.92 0.391 . . . . 0.0 110.868 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -84.38 167.18 16.74 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.107 179.902 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 95.8 p -142.51 162.53 35.22 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.869 -179.765 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -145.88 141.88 28.26 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.116 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 160' ' ' TYR . . . . . 0.472 ' HB3' HD11 ' A' ' 110' ' ' LEU . 15.2 m-85 -115.19 112.6 22.74 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.95 -179.88 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.458 ' CG1' HG12 ' A' ' 138' ' ' ILE . 94.6 t -106.64 133.69 50.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.146 179.911 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 9.1 m -102.66 125.61 49.45 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.159 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 163' ' ' TYR . . . . . 0.489 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 13.8 m-85 -103.53 136.5 43.13 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.909 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 89.3 mt -63.85 -49.69 80.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.108 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 28.3 mmt180 -100.72 119.16 38.2 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.894 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 4.1 m -50.09 -57.61 7.3 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.848 -179.787 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -41.18 -61.48 1.0 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.886 -179.933 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 31.3 m-20 -46.65 -46.15 19.69 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.857 179.998 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 169' ' ' ALA . . . . . 0.489 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -57.86 -55.48 34.41 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.059 179.983 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 71.7 mt -45.0 -59.72 2.44 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.917 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 13.9 mtm180 -53.94 -53.18 56.33 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.84 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 172' ' ' ALA . . . . . 0.521 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -45.03 -34.83 2.67 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.118 179.945 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 96.4 mt -81.67 -32.15 11.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.122 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 73.0 mt-30 -66.76 -27.33 67.51 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.874 -179.989 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 1.8 t -93.81 -35.88 12.53 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.867 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 176' ' ' VAL . . . . . 0.521 HG23 ' O ' ' A' ' 172' ' ' ALA . 10.7 t -64.84 -45.84 93.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.113 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -51.79 144.98 10.27 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.895 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 41.6 m-20 57.61 53.43 7.28 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.882 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 179' ' ' VAL . . . . . 0.675 ' O ' HG23 ' A' ' 185' ' ' THR . 78.6 t -134.59 138.57 49.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.168 179.879 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 66.6 t -92.49 124.18 44.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.123 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 60.0 t -135.37 126.89 45.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.103 179.933 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 182' ' ' ASP . . . . . 0.865 ' OD2' HD21 ' A' ' 120' ' ' LEU . 4.4 m-20 59.29 25.47 14.11 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.85 179.908 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 90.21 -18.04 50.59 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.464 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 15.3 ptm180 -117.33 129.66 56.02 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.923 0.392 . . . . 0.0 110.849 -179.861 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 185' ' ' THR . . . . . 0.675 HG23 ' O ' ' A' ' 179' ' ' VAL . 51.3 m -71.48 138.89 49.33 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.154 -179.896 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 54.6 mt -105.53 143.65 33.39 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.884 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -115.11 117.14 29.72 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.905 179.841 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 188' ' ' ALA . . . . . 0.663 ' HB2' HG22 ' A' ' 113' ' ' VAL . . . -114.96 127.68 55.83 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.065 179.857 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 4.3 t -136.6 173.78 11.33 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.848 -179.771 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 190' ' ' LEU . . . . . 0.514 ' O ' HD12 ' A' ' 190' ' ' LEU . 3.6 pp -130.29 160.95 32.37 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.929 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.284 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.453 179.878 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 33.6 tp . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.83 0.348 . . . . 0.0 110.883 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.4 HG22 HD11 ' A' ' 173' ' ' ILE . 95.3 t -100.58 103.39 14.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.085 179.858 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.598 ' CD1' ' CE2' ' A' ' 160' ' ' TYR . 39.1 t80 -101.69 113.24 26.22 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.864 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.67 HG22 ' HB2' ' A' ' 188' ' ' ALA . 40.1 t -112.87 126.51 70.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.126 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 114' ' ' VAL . . . . . 0.414 ' CG1' ' CE2' ' A' ' 112' ' ' PHE . 17.3 m -111.83 166.36 6.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.16 179.924 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 78.68 43.15 12.24 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.435 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 49.4 mt -112.99 118.26 34.34 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.828 0.347 . . . . 0.0 110.889 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 2.8 p -65.53 143.36 57.69 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.835 -179.908 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 65.8 mm-40 -39.85 -34.82 0.29 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.917 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 59.8 ttt180 -69.02 -49.06 61.06 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.891 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 61.7 mt -72.63 -20.55 61.25 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.929 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -78.53 83.26 4.73 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.083 179.799 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 17.0 m-20 -148.54 149.24 30.78 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-O 121.572 0.701 . . . . 0.0 110.887 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 -48.59 0.69 Allowed 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.664 2.243 . . . . 0.0 112.39 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 44.7 mm-40 -67.0 -42.07 85.64 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.885 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.529 HG13 ' CZ ' ' A' ' 131' ' ' TYR . 38.1 t -59.82 -47.34 91.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.107 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 94.6 mt -71.58 -32.73 68.4 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.927 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 68.2 mttt -67.19 -30.26 70.15 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.896 179.836 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 9.9 mmp_? -50.23 144.29 11.63 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.577 0.703 . . . . 0.0 110.884 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 0.01 6.29 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.669 2.246 . . . . 0.0 112.365 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 35.3 tt0 -101.05 -7.71 22.99 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.877 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 131' ' ' TYR . . . . . 0.529 ' CZ ' HG13 ' A' ' 125' ' ' VAL . 41.5 m-85 -111.96 -72.88 0.69 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.932 -179.871 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 33.4 m-85 -124.42 -21.67 4.86 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.869 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -52.57 -24.36 17.43 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.479 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 14.6 ptpt -90.49 -16.9 28.06 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.77 0.319 . . . . 0.0 110.848 -179.932 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 135' ' ' PHE . . . . . . . . . . . . . 15.5 m-85 -79.15 -29.11 42.91 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.858 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 172.05 168.33 33.38 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.479 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 7.2 mtmp? -75.67 101.27 4.93 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.806 0.336 . . . . 0.0 110.92 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.625 HG23 HG13 ' A' ' 161' ' ' VAL . 81.7 mt -68.64 134.09 30.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.145 179.9 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 2.3 t-160 -103.68 -50.7 3.35 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.859 179.893 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 51.8 tttt -134.0 132.13 39.74 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.906 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 141' ' ' VAL . . . . . 0.573 ' CG2' HG21 ' A' ' 138' ' ' ILE . 49.1 t -120.11 133.23 67.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.113 179.923 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 99.6 t -129.88 129.42 65.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.115 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 19.0 mm -107.31 119.36 56.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.139 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 7.7 m120 -111.33 101.34 9.82 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.859 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 9.1 p-10 . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.9 179.961 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 17.5 m . . . . . 0 C--O 1.23 0.073 0 CA-C-O 120.864 0.364 . . . . 0.0 110.859 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -123.85 169.43 11.58 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.081 179.897 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 158' ' ' SER . . . . . 0.4 ' HB3' ' CE1' ' A' ' 112' ' ' PHE . 20.3 m -137.53 164.51 28.55 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.882 -179.804 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -142.95 140.08 30.95 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.128 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 160' ' ' TYR . . . . . 0.598 ' CE2' ' CD1' ' A' ' 112' ' ' PHE . 33.6 m-85 -113.7 116.71 29.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.933 -179.842 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.625 HG13 HG23 ' A' ' 138' ' ' ILE . 98.0 t -116.58 139.62 42.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.111 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 29.9 m -106.03 129.12 54.2 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.126 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 3.7 m-85 -109.51 148.28 31.48 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.982 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 49.0 mt -76.45 -61.06 1.83 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.139 179.918 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 59.4 mtt180 -82.25 99.08 9.1 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.82 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 50.7 m -42.01 -53.34 3.92 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.878 -179.853 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 3.6 pt-20 -40.73 -59.34 1.42 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.906 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -56.7 -35.14 68.14 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.869 179.923 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -65.4 -60.18 3.23 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.122 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 39.6 mt -45.85 -51.76 12.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.903 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 2.2 mpt_? -61.07 -43.83 98.3 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.808 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 172' ' ' ALA . . . . . 0.617 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -54.89 -31.81 60.27 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.134 179.915 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 173' ' ' ILE . . . . . 0.4 HD11 HG22 ' A' ' 111' ' ' VAL . 63.0 mt -81.16 -38.42 16.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.135 179.987 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 31.4 mm-40 -69.69 -22.09 63.45 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.935 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 3.4 t -93.8 -34.75 13.05 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.906 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 176' ' ' VAL . . . . . 0.617 HG23 ' O ' ' A' ' 172' ' ' ALA . 10.5 t -66.79 -38.17 80.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.081 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 1.7 t30 -63.34 140.57 58.89 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.874 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 25.5 t30 71.81 35.21 1.41 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.856 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 89.4 t -119.54 131.56 71.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.122 179.892 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 82.7 t -95.62 102.56 13.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.09 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 53.7 t -111.07 117.57 55.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.167 179.877 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 15.2 m-20 48.8 48.99 19.67 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.828 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 63.15 28.4 72.11 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.452 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 12.2 mtt85 -138.07 111.27 7.9 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.86 0.362 . . . . 0.0 110.89 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 36.5 m -70.63 101.21 1.99 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.126 -179.945 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 11.9 mt -68.45 129.6 40.4 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.914 179.928 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 22.9 tptm -124.85 120.55 32.03 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.932 179.816 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 188' ' ' ALA . . . . . 0.67 ' HB2' HG22 ' A' ' 113' ' ' VAL . . . -119.82 151.82 38.24 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.127 179.857 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 8.6 t -158.38 164.01 36.72 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.849 -179.718 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 190' ' ' LEU . . . . . 0.844 ' O ' HD12 ' A' ' 190' ' ' LEU . 4.1 pp -128.18 130.3 47.83 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.897 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.333 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.478 179.879 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 11.2 tp . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.829 0.347 . . . . 0.0 110.902 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 98.8 t -94.64 130.11 43.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.116 179.85 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.418 ' CZ ' HG12 ' A' ' 114' ' ' VAL . 40.5 t80 -128.95 98.23 4.88 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.893 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.699 HG22 ' HB2' ' A' ' 188' ' ' ALA . 54.0 t -92.76 135.75 26.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.177 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 114' ' ' VAL . . . . . 0.418 HG12 ' CZ ' ' A' ' 112' ' ' PHE . 4.7 m -124.96 164.4 23.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.12 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 76.28 47.85 10.26 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.518 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 116' ' ' LEU . . . . . 0.56 HD23 HD22 ' A' ' 186' ' ' LEU . 59.8 mt -108.3 130.87 55.17 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.812 0.339 . . . . 0.0 110.929 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 14.0 m -69.21 155.4 40.47 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.902 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 40.8 mt-30 -46.84 -38.07 9.73 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.915 -179.927 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 19.6 tpt180 -74.66 -50.74 16.55 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.869 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 37.0 mt -62.15 -19.09 62.69 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.904 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -76.68 83.9 3.32 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.098 179.782 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -148.66 144.02 17.91 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.639 0.733 . . . . 0.0 110.865 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 -50.78 0.43 Allowed 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.694 2.263 . . . . 0.0 112.341 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 22.1 pt-20 -67.35 -38.36 84.7 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.87 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 84.2 t -63.62 -42.85 97.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.084 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.689 HD12 HD11 ' A' ' 143' ' ' ILE . 47.9 mt -72.02 -32.82 67.52 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.899 179.974 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 25.0 tttm -74.44 -29.94 61.69 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.914 179.849 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 49.8 mtp180 -47.11 148.8 1.87 Allowed Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.571 0.7 . . . . 0.0 110.882 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 -2.1 9.61 Favored 'Trans proline' 0 C--N 1.341 0.138 0 C-N-CA 122.665 2.243 . . . . 0.0 112.308 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 4.0 tp10 -91.83 -23.53 19.65 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.834 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 131' ' ' TYR . . . . . . . . . . . . . 26.0 m-85 -103.34 -69.55 0.79 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.913 -179.826 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.434 ' O ' ' N ' ' A' ' 135' ' ' PHE . 87.8 m-85 -126.23 -27.9 3.17 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.887 -179.971 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -43.87 -22.23 0.27 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.536 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.4 ' N ' ' O ' ' A' ' 132' ' ' PHE . 16.7 ptpt -85.09 -34.41 22.22 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.801 0.334 . . . . 0.0 110.865 -179.949 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 135' ' ' PHE . . . . . 0.488 ' CE2' HG23 ' A' ' 176' ' ' VAL . 12.9 m-85 -56.3 -39.26 72.42 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.857 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 178.77 -176.19 47.83 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.494 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 13.9 tttt -87.87 111.41 21.39 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.724 0.297 . . . . 0.0 110.902 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.495 HG21 HG22 ' A' ' 141' ' ' VAL . 61.5 mt -83.47 144.7 9.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.174 179.849 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 2.2 t60 -102.32 -44.27 5.45 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.851 179.915 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 24.1 ttpp -138.72 145.73 40.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.909 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 141' ' ' VAL . . . . . 0.495 HG22 HG21 ' A' ' 138' ' ' ILE . 21.2 t -131.0 129.38 63.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.174 179.848 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 46.6 t -125.78 140.2 49.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.16 179.93 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 143' ' ' ILE . . . . . 0.689 HD11 HD12 ' A' ' 126' ' ' LEU . 20.0 mm -121.92 126.83 75.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.176 179.883 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 19.0 m-20 -120.49 121.11 37.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.884 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 3.0 p-10 . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.875 -179.98 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 86.9 p . . . . . 0 C--O 1.231 0.103 0 CA-C-O 120.832 0.348 . . . . 0.0 110.873 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -127.61 167.74 15.96 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.13 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 83.5 p -126.13 166.08 17.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.89 -179.819 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -147.99 140.46 24.46 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.131 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 8.8 m-85 -114.71 136.37 53.13 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.917 -179.843 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 74.9 t -130.0 125.59 60.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.145 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 89.1 m -95.75 122.65 38.75 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.176 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 4.8 m-85 -108.16 141.43 39.9 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.936 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 65.3 mt -74.57 -39.52 47.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.073 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 38.4 mtm-85 -86.92 114.58 23.67 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.851 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 14.3 t -55.84 -59.66 4.56 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.845 -179.804 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 17.9 tt0 -51.68 -49.65 61.99 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.875 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 12.2 t0 -48.03 -46.25 32.97 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.886 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -61.67 -53.46 55.86 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.111 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 72.9 mt -44.68 -63.9 0.81 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.888 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 171' ' ' ARG . . . . . 0.418 ' O ' ' N ' ' A' ' 174' ' ' GLN . 14.9 mtp180 -59.59 -53.04 62.64 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.859 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 172' ' ' ALA . . . . . 0.502 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -40.0 -37.73 0.63 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.081 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 67.4 mt -80.66 -36.7 15.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.133 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 174' ' ' GLN . . . . . 0.418 ' N ' ' O ' ' A' ' 171' ' ' ARG . 25.8 mm-40 -61.1 -26.88 67.97 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.9 179.905 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 2.5 t -93.75 -41.15 9.83 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.897 -179.917 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 176' ' ' VAL . . . . . 0.502 HG23 ' O ' ' A' ' 172' ' ' ALA . 10.3 t -58.77 -39.44 76.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.092 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -62.43 136.43 57.9 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.896 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 14.6 t30 70.76 47.01 0.48 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.919 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 59.0 t -127.64 134.8 64.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.139 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 89.4 t -93.95 115.04 31.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.148 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 62.4 t -121.45 118.88 57.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.158 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 55.9 m-20 58.5 28.76 17.41 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.844 179.935 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 90.08 -19.52 42.0 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.497 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 25.4 ttm-85 -103.52 135.89 44.27 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.939 0.4 . . . . 0.0 110.851 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 71.2 m -86.8 131.83 34.01 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.186 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 186' ' ' LEU . . . . . 0.56 HD22 HD23 ' A' ' 116' ' ' LEU . 25.4 mt -112.57 126.25 55.14 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.91 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 7.9 ttmt -109.48 136.64 48.56 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.87 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 188' ' ' ALA . . . . . 0.699 ' HB2' HG22 ' A' ' 113' ' ' VAL . . . -125.64 149.52 48.36 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.096 179.844 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 7.3 t -159.37 167.71 28.14 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.828 -179.766 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 190' ' ' LEU . . . . . . . . . . . . . 4.2 pp -126.38 153.11 45.4 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.958 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.252 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.438 179.927 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 19.4 tp . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.807 0.337 . . . . 0.0 110.938 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.763 HG22 HD11 ' A' ' 173' ' ' ILE . 75.1 t -93.1 115.99 33.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.102 179.886 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.579 ' CE1' ' HB2' ' A' ' 158' ' ' SER . 6.6 t80 -112.49 118.47 35.22 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.895 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.42 HG22 ' HB2' ' A' ' 188' ' ' ALA . 25.5 t -115.0 137.53 48.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.169 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 114' ' ' VAL . . . . . 0.483 HG12 ' HE1' ' A' ' 112' ' ' PHE . 19.9 m -123.42 168.96 15.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.161 179.908 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 75.59 48.62 10.19 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.499 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 36.4 mt -114.68 131.18 56.83 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.807 0.336 . . . . 0.0 110.884 -179.887 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 13.0 t -68.99 152.0 45.81 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.88 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 4.2 tp-100 -51.52 -23.57 4.23 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.936 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 30.3 ttt180 -84.62 -45.56 12.39 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.889 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 96.7 mt -68.06 -28.83 67.71 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.87 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -66.36 83.05 0.09 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.096 179.834 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -145.47 143.97 21.58 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.625 0.726 . . . . 0.0 110.842 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 -38.89 7.25 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.726 2.284 . . . . 0.0 112.345 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -77.51 -44.83 27.44 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.895 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.556 ' O ' ' CD1' ' A' ' 131' ' ' TYR . 62.0 t -60.6 -38.32 78.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.076 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.806 HD12 HD11 ' A' ' 143' ' ' ILE . 81.4 mt -75.08 -44.5 47.07 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.89 180.0 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.61 ' HA ' HD12 ' A' ' 138' ' ' ILE . 22.7 ttpp -67.87 -25.82 65.71 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.897 179.861 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 12.9 mmt180 -47.76 144.01 5.6 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.657 0.742 . . . . 0.0 110.803 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 -8.39 23.48 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.745 2.297 . . . . 0.0 112.324 179.975 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 46.7 mt-10 -98.83 8.35 45.07 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.89 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 131' ' ' TYR . . . . . 0.556 ' CD1' ' O ' ' A' ' 125' ' ' VAL . 59.3 m-85 -126.08 -74.26 0.61 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.927 -179.828 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.444 ' O ' ' N ' ' A' ' 134' ' ' LYS . 58.5 m-85 -116.26 -36.66 3.98 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.914 -180.0 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -40.39 -25.58 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.488 -179.973 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.444 ' N ' ' O ' ' A' ' 132' ' ' PHE . 3.5 mtpp -42.7 -59.65 1.85 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.82 0.343 . . . . 0.0 110.875 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 135' ' ' PHE . . . . . 0.42 ' CE1' ' HA ' ' A' ' 172' ' ' ALA . 28.1 m-85 -50.93 -43.59 60.13 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.865 179.982 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 173.82 -172.99 45.69 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.46 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 20.9 mtpp -76.19 141.35 41.85 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.733 0.301 . . . . 0.0 110.887 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.68 HG21 ' CG2' ' A' ' 141' ' ' VAL . 60.6 mt -99.52 141.26 17.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.125 179.866 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 11.2 t60 -84.97 -58.55 2.65 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.846 179.892 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 22.1 tttp -137.53 146.82 44.61 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.914 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 141' ' ' VAL . . . . . 0.68 ' CG2' HG21 ' A' ' 138' ' ' ILE . 35.3 t -134.68 132.83 54.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.175 179.897 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 57.8 t -126.46 141.38 46.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.121 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 143' ' ' ILE . . . . . 0.806 HD11 HD12 ' A' ' 126' ' ' LEU . 31.4 mm -119.87 132.65 69.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.095 179.96 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 5.2 t-20 -126.39 106.54 9.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.889 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 5.3 p30 . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.872 -179.999 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 93.4 p . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.894 0.378 . . . . 0.0 110.873 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -93.96 169.47 10.25 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.092 179.932 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 158' ' ' SER . . . . . 0.579 ' HB2' ' CE1' ' A' ' 112' ' ' PHE . 86.9 p -140.72 153.52 45.96 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.85 -179.775 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -137.68 150.93 47.73 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.109 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 160' ' ' TYR . . . . . 0.486 ' N ' ' CD1' ' A' ' 160' ' ' TYR . 1.3 m-85 -115.57 125.79 53.4 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.919 -179.832 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.419 ' CG1' ' CE1' ' A' ' 163' ' ' TYR . 43.0 t -120.83 125.74 74.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.151 179.909 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 87.9 m -107.44 123.88 49.04 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.161 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 163' ' ' TYR . . . . . 0.419 ' CE1' ' CG1' ' A' ' 161' ' ' VAL . 30.3 m-85 -104.06 164.3 11.8 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.906 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 42.7 mt -94.05 -39.46 10.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.153 179.891 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 30.5 mtp180 -102.12 120.36 40.31 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.911 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 16.0 m -47.78 -56.49 7.28 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.823 -179.733 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 34.8 mt-10 -46.23 -52.46 12.42 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.904 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 23.3 m-20 -50.95 -48.18 60.95 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.801 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -55.29 -62.47 1.65 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.082 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 66.0 mt -41.63 -62.77 0.82 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.9 -179.963 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 171' ' ' ARG . . . . . 0.414 ' O ' ' N ' ' A' ' 174' ' ' GLN . 20.0 mtp85 -51.76 -60.06 3.59 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.829 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 172' ' ' ALA . . . . . 0.577 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -38.75 -36.42 0.26 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.146 179.893 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 173' ' ' ILE . . . . . 0.763 HD11 HG22 ' A' ' 111' ' ' VAL . 60.9 mt -80.96 -39.89 18.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.12 179.961 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 174' ' ' GLN . . . . . 0.414 ' N ' ' O ' ' A' ' 171' ' ' ARG . 51.3 mt-30 -66.93 -22.1 65.96 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.92 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 1.8 t -93.77 -37.27 11.87 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.913 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 176' ' ' VAL . . . . . 0.577 HG23 ' O ' ' A' ' 172' ' ' ALA . 10.3 t -64.37 -33.77 64.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.082 -179.954 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 3.8 t30 -67.95 143.5 55.61 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.866 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 22.8 t-20 65.52 48.94 1.91 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.905 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 179' ' ' VAL . . . . . 0.416 HG12 HG23 ' A' ' 181' ' ' VAL . 53.0 t -127.27 135.64 62.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.14 179.922 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 59.3 t -96.9 100.31 10.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.148 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 181' ' ' VAL . . . . . 0.468 HG21 HD12 ' A' ' 186' ' ' LEU . 66.9 t -107.52 97.98 6.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.175 179.909 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 6.8 t0 66.73 36.58 4.6 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.862 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 77.59 32.54 46.1 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.499 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 65.6 mtt85 -141.66 136.51 30.98 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.911 0.386 . . . . 0.0 110.866 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 26.6 m -94.73 95.0 8.44 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.161 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 186' ' ' LEU . . . . . 0.468 HD12 HG21 ' A' ' 181' ' ' VAL . 79.8 mt -67.74 132.73 48.0 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.901 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 25.4 tptt -111.08 116.41 31.08 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.92 179.815 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 188' ' ' ALA . . . . . 0.441 ' HB2' HG11 ' A' ' 176' ' ' VAL . . . -112.38 134.28 54.01 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.101 179.824 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 7.7 t -158.51 171.75 19.56 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.815 -179.791 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 190' ' ' LEU . . . . . 0.83 ' C ' HD22 ' A' ' 190' ' ' LEU . 0.0 OUTLIER -119.25 158.77 25.37 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.936 179.998 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 191' ' ' GLY . . . . . 0.448 ' N ' HD22 ' A' ' 190' ' ' LEU . . . . . . . . 0 N--CA 1.451 -0.356 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.491 179.91 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 110' ' ' LEU . . . . . 0.626 HD11 ' HD2' ' A' ' 160' ' ' TYR . 62.1 tp . . . . . 0 C--O 1.231 0.084 0 CA-C-O 120.838 0.351 . . . . 0.0 110.92 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.429 HG12 HG23 ' A' ' 113' ' ' VAL . 86.9 t -111.13 106.64 21.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.065 179.88 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.469 ' CE2' ' CG1' ' A' ' 114' ' ' VAL . 87.7 t80 -94.48 102.21 14.15 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.905 179.967 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.429 HG23 HG12 ' A' ' 111' ' ' VAL . 20.2 t -107.23 131.73 56.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.16 179.993 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 114' ' ' VAL . . . . . 0.469 ' CG1' ' CE2' ' A' ' 112' ' ' PHE . 6.1 m -119.2 155.01 21.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.113 179.942 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 90.81 44.35 4.54 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.452 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 116' ' ' LEU . . . . . 0.505 HD23 HD21 ' A' ' 186' ' ' LEU . 38.5 mt -110.25 125.0 52.65 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.823 0.344 . . . . 0.0 110.913 -179.943 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 117' ' ' SER . . . . . 0.484 ' O ' ' N ' ' A' ' 120' ' ' LEU . 22.8 p -69.09 139.97 54.81 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.84 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 118' ' ' GLN . . . . . 0.42 ' C ' ' O ' ' A' ' 117' ' ' SER . 37.4 mt-30 -36.38 -41.79 0.3 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.914 -179.924 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 26.6 mtm-85 -66.31 -44.12 84.33 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.886 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 120' ' ' LEU . . . . . 0.484 ' N ' ' O ' ' A' ' 117' ' ' SER . 34.5 mt -72.42 -24.74 61.27 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.912 -179.976 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -71.23 83.25 0.74 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.132 179.811 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 20.0 m-20 -148.87 144.0 17.73 Favored Pre-proline 0 C--N 1.328 -0.364 0 CA-C-O 121.648 0.737 . . . . 0.0 110.88 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 123' ' ' PRO . . . . . 0.403 ' HA ' HG11 ' A' ' 141' ' ' VAL . 54.1 Cg_endo -69.73 -46.65 1.16 Allowed 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.69 2.26 . . . . 0.0 112.347 -179.963 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 48.7 mt-10 -71.36 -43.31 67.16 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.924 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.523 ' O ' ' CD2' ' A' ' 131' ' ' TYR . 90.5 t -60.19 -42.2 89.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.136 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.573 HD12 HD11 ' A' ' 143' ' ' ILE . 64.6 mt -72.96 -39.48 66.15 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.898 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.716 ' HA ' HD12 ' A' ' 138' ' ' ILE . 18.6 ttmt -61.44 -31.95 71.92 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.9 179.855 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 91.7 mtt180 -43.02 143.94 1.17 Allowed Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.635 0.731 . . . . 0.0 110.88 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 -2.69 10.57 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.679 2.253 . . . . 0.0 112.384 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 25.7 mt-10 -97.57 -30.26 12.96 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.905 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 131' ' ' TYR . . . . . 0.523 ' CD2' ' O ' ' A' ' 125' ' ' VAL . 44.2 m-85 -87.64 -74.91 0.43 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.921 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.481 ' CE1' HD22 ' A' ' 126' ' ' LEU . 42.6 m-85 -117.08 -36.84 3.69 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.88 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -49.34 -18.42 1.43 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.518 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -52.49 -34.22 48.34 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.832 0.349 . . . . 0.0 110.916 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 135' ' ' PHE . . . . . 0.568 ' CE2' ' HA ' ' A' ' 172' ' ' ALA . 79.8 m-85 -73.35 -42.02 62.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.897 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 166.89 -178.14 41.3 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.493 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 5.2 ttmm -60.01 140.28 56.88 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.762 0.315 . . . . 0.0 110.858 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.716 HD12 ' HA ' ' A' ' 127' ' ' LYS . 91.3 mt -105.67 139.03 28.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.112 179.862 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 34.3 t-80 -75.61 -55.15 5.94 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.866 179.868 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 140' ' ' LYS . . . . . 0.478 ' HD3' ' CG2' ' A' ' 142' ' ' VAL . 13.4 ttmm -149.49 144.16 26.11 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.916 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 141' ' ' VAL . . . . . 0.494 HG22 HG21 ' A' ' 138' ' ' ILE . 23.9 t -122.43 103.63 13.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.109 179.927 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.478 ' CG2' ' HD3' ' A' ' 140' ' ' LYS . 63.1 t -100.65 140.82 18.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.157 179.873 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 143' ' ' ILE . . . . . 0.573 HD11 HD12 ' A' ' 126' ' ' LEU . 26.7 mm -119.24 125.47 74.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.15 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 19.6 m-20 -121.2 142.75 49.6 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.88 179.916 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 18.4 p30 . . . . . 0 C--N 1.329 -0.306 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.871 -179.983 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 82.0 p . . . . . 0 C--O 1.231 0.103 0 CA-C-O 120.905 0.383 . . . . 0.0 110.844 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -113.68 157.91 21.57 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.076 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 11.7 t -116.29 168.19 10.35 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.871 -179.763 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -148.48 147.29 28.95 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.058 179.893 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 160' ' ' TYR . . . . . 0.626 ' HD2' HD11 ' A' ' 110' ' ' LEU . 4.5 m-85 -115.06 104.73 12.17 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.916 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 95.3 t -99.51 126.45 52.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.146 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 96.7 m -95.9 123.76 39.62 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.14 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 163' ' ' TYR . . . . . 0.531 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 12.1 m-85 -106.13 121.99 45.27 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.949 -179.942 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 46.0 mt -57.38 -51.5 68.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.097 -0.502 . . . . 0.0 111.154 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 39.7 mtp180 -85.72 118.08 25.0 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.847 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 22.6 t -48.72 -47.4 41.33 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.868 -179.82 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -54.36 -56.22 20.77 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.905 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 168' ' ' ASP . . . . . 0.499 ' O ' ' HB2' ' A' ' 172' ' ' ALA . 0.9 OUTLIER -52.39 -31.9 36.17 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.867 179.959 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 169' ' ' ALA . . . . . 0.531 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -70.49 -66.19 0.63 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.113 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 31.1 mt -46.6 -56.17 6.5 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.894 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 84.9 mtt180 -56.59 -46.56 80.78 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.854 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 172' ' ' ALA . . . . . 0.568 ' HA ' ' CE2' ' A' ' 135' ' ' PHE . . . -51.88 -32.73 33.56 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.076 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 65.8 mt -79.13 -36.4 18.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.11 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 15.7 mm100 -65.84 -26.93 67.88 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.874 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 175' ' ' CYS . . . . . 0.48 ' O ' HG21 ' A' ' 179' ' ' VAL . 7.6 m -93.7 -36.63 12.23 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.907 -179.949 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 176' ' ' VAL . . . . . 0.554 HG23 ' O ' ' A' ' 172' ' ' ALA . 10.5 t -65.43 -40.11 87.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.083 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 7.4 p-10 -68.32 152.1 45.93 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.891 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 36.5 t30 57.1 48.77 14.84 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.882 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 179' ' ' VAL . . . . . 0.48 HG21 ' O ' ' A' ' 175' ' ' CYS . 94.3 t -133.56 140.21 47.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.113 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 87.1 t -99.08 105.35 17.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.097 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 181' ' ' VAL . . . . . 0.486 HG21 HD12 ' A' ' 186' ' ' LEU . 91.8 t -112.06 98.73 7.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.133 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 30.9 t0 60.7 52.42 4.43 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.841 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 63.27 24.19 67.11 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.492 -179.931 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 66.3 mtp85 -131.61 111.91 12.14 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.874 0.369 . . . . 0.0 110.86 -179.826 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 28.2 m -76.09 93.19 3.28 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.127 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 186' ' ' LEU . . . . . 0.505 HD21 HD23 ' A' ' 116' ' ' LEU . 80.2 mt -68.54 128.99 38.61 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.931 179.916 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 2.5 mmmp? -117.6 118.29 31.73 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.877 179.847 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -107.19 145.56 32.46 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.127 179.819 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 4.5 t -143.33 169.32 17.88 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.857 -179.74 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 190' ' ' LEU . . . . . 0.495 HD23 ' N ' ' A' ' 191' ' ' GLY . 8.6 tt -128.81 134.89 48.51 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.904 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 191' ' ' GLY . . . . . 0.495 ' N ' HD23 ' A' ' 190' ' ' LEU . . . . . . . . 0 N--CA 1.451 -0.306 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.486 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 11.5 tp . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.84 0.352 . . . . 0.0 110.908 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.446 HG22 HD11 ' A' ' 173' ' ' ILE . 85.2 t -122.55 111.75 31.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.105 179.872 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.437 ' CE1' ' HB2' ' A' ' 158' ' ' SER . 42.1 t80 -98.46 113.34 25.3 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.889 179.991 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.434 HG21 ' CZ ' ' A' ' 132' ' ' PHE . 92.8 t -110.68 137.23 43.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.117 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 35.9 m -126.91 168.19 20.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.147 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 74.29 41.67 37.42 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.476 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 50.5 mt -103.54 130.84 51.02 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.797 0.332 . . . . 0.0 110.94 -179.951 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 117' ' ' SER . . . . . 0.491 ' O ' ' N ' ' A' ' 120' ' ' LEU . 89.6 p -77.37 142.65 39.2 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.85 -179.934 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 118' ' ' GLN . . . . . 0.442 ' C ' ' O ' ' A' ' 117' ' ' SER . 55.0 mm-40 -34.85 -40.36 0.11 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.892 -179.938 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 25.0 mtm-85 -63.34 -47.26 82.93 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.871 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 120' ' ' LEU . . . . . 0.491 ' N ' ' O ' ' A' ' 117' ' ' SER . 20.7 mt -72.44 -29.44 63.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.936 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -65.46 82.99 0.06 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.099 179.81 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 122' ' ' ASP . . . . . 0.422 ' HB2' ' CG2' ' A' ' 125' ' ' VAL . 19.4 m-20 -149.0 143.84 17.46 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.599 0.714 . . . . 0.0 110.863 179.985 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 -44.26 2.19 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.682 2.255 . . . . 0.0 112.389 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 66.3 mm-40 -74.2 -38.61 63.54 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.886 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.586 ' O ' ' CD1' ' A' ' 131' ' ' TYR . 68.9 t -61.0 -49.5 84.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.103 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 92.8 mt -66.33 -43.36 86.36 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.943 179.936 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.478 ' HA ' ' CD1' ' A' ' 138' ' ' ILE . 31.1 tttm -61.64 -42.71 99.27 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.878 179.849 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 128' ' ' ARG . . . . . 0.424 ' C ' ' O ' ' A' ' 127' ' ' LYS . 21.4 mmt180 -35.61 143.28 0.26 Allowed Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.643 0.735 . . . . 0.0 110.826 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.75 -1.4 8.4 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.66 2.24 . . . . 0.0 112.34 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 10.2 mp0 -103.26 -0.98 29.57 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.884 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 131' ' ' TYR . . . . . 0.586 ' CD1' ' O ' ' A' ' 125' ' ' VAL . 47.0 m-85 -117.06 -74.15 0.62 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.913 -179.879 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.434 ' CZ ' HG21 ' A' ' 113' ' ' VAL . 46.5 m-85 -121.75 -17.85 7.28 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.91 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -72.08 -1.44 48.88 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.491 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 1.3 ptpp? -78.85 -19.67 51.46 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.78 0.324 . . . . 0.0 110.894 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 135' ' ' PHE . . . . . 0.419 ' CD2' ' HB1' ' A' ' 172' ' ' ALA . 58.2 m-85 -85.62 -38.17 18.72 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.856 -179.99 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -179.72 -174.52 45.74 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.511 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 45.9 mtpt -81.49 134.62 35.55 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.779 0.323 . . . . 0.0 110.889 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.478 ' CD1' ' HA ' ' A' ' 127' ' ' LYS . 65.1 mt -94.98 147.03 6.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.155 179.861 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 10.8 t-80 -99.11 -43.61 6.59 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.891 179.901 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 26.5 ttpt -148.28 143.69 27.12 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.95 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 141' ' ' VAL . . . . . 0.459 HG22 HG21 ' A' ' 138' ' ' ILE . 41.3 t -127.23 121.17 56.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.208 179.862 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 72.4 t -125.71 145.27 33.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.153 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 29.1 mm -115.8 141.82 31.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.118 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 48.2 t30 -129.45 142.92 50.67 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.916 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 44.7 t-20 . . . . . 0 C--N 1.33 -0.28 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.831 -179.981 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 69.6 m . . . . . 0 C--O 1.231 0.084 0 CA-C-O 120.848 0.356 . . . . 0.0 110.868 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -103.92 149.14 25.38 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.079 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 158' ' ' SER . . . . . 0.437 ' HB2' ' CE1' ' A' ' 112' ' ' PHE . 53.1 p -117.21 171.59 7.85 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.89 -179.803 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -146.79 133.55 20.03 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.12 179.875 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 38.7 m-85 -104.48 113.75 27.53 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.905 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 98.7 t -109.13 123.93 65.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.129 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 40.4 m -98.02 123.88 42.24 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.134 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 9.8 m-85 -105.99 146.73 29.69 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.923 -179.907 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 86.9 mt -79.41 -36.24 17.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.133 179.883 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 31.9 mmm-85 -106.93 117.08 33.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.872 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 74.2 m -49.24 -51.11 35.39 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.846 -179.771 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 18.5 mm-40 -48.74 -51.02 31.11 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.897 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -54.26 -45.13 72.34 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.871 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -60.24 -62.61 1.74 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.094 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 50.6 mt -41.57 -66.38 0.35 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.9 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 79.2 mtp180 -48.37 -54.43 13.97 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.869 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 172' ' ' ALA . . . . . 0.591 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -43.51 -35.16 1.56 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.083 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 173' ' ' ILE . . . . . 0.541 HG23 ' HB3' ' A' ' 188' ' ' ALA . 63.6 mt -77.92 -40.46 26.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.183 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 88.2 mm-40 -61.36 -27.57 68.61 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.914 179.918 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 175' ' ' CYS . . . . . 0.477 ' O ' ' CG2' ' A' ' 179' ' ' VAL . 1.9 m -93.82 -42.1 9.29 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.882 -179.914 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 176' ' ' VAL . . . . . 0.591 HG23 ' O ' ' A' ' 172' ' ' ALA . 10.3 t -58.07 -36.27 56.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.14 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 177' ' ' ASN . . . . . 0.418 ' O ' HG23 ' A' ' 179' ' ' VAL . 12.3 t-20 -68.41 150.83 47.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.873 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 178' ' ' ASN . . . . . 0.411 ' CG ' ' O ' ' A' ' 178' ' ' ASN . 37.4 t30 57.66 42.84 23.25 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.854 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 179' ' ' VAL . . . . . 0.477 ' CG2' ' O ' ' A' ' 175' ' ' CYS . 62.0 t -128.68 135.03 63.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.142 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 90.3 t -98.97 106.38 18.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.129 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 181' ' ' VAL . . . . . 0.457 HG21 HD12 ' A' ' 186' ' ' LEU . 57.1 t -114.18 121.32 66.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.115 179.909 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 14.4 m-20 51.23 28.45 4.17 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.844 179.908 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 81.47 32.01 32.07 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.493 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 4.2 mpt_? -138.69 124.47 19.79 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.878 0.37 . . . . 0.0 110.878 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 19.4 m -76.65 93.28 3.6 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.122 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 186' ' ' LEU . . . . . 0.457 HD12 HG21 ' A' ' 181' ' ' VAL . 51.0 mt -62.01 125.98 25.76 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.875 179.962 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 9.5 tptm -122.86 112.28 17.68 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.922 179.788 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 188' ' ' ALA . . . . . 0.541 ' HB3' HG23 ' A' ' 173' ' ' ILE . . . -107.57 153.19 23.22 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.128 179.826 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 48.0 m -139.2 156.34 47.17 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.877 -179.765 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 190' ' ' LEU . . . . . 0.588 HD13 ' C ' ' A' ' 190' ' ' LEU . 1.5 tm? -120.2 102.28 8.4 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.913 179.968 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.313 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.494 179.87 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 15.8 tp . . . . . 0 C--O 1.232 0.141 0 CA-C-O 120.834 0.35 . . . . 0.0 110.938 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 99.1 t -122.47 110.97 28.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.13 179.833 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.403 ' CE1' ' HB2' ' A' ' 158' ' ' SER . 46.4 t80 -102.83 108.03 19.1 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.853 -179.937 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 86.0 t -105.2 134.46 46.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.155 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 34.0 m -124.42 167.04 18.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.08 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 78.58 49.21 6.77 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.541 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 28.8 mt -113.78 139.89 48.75 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.823 0.344 . . . . 0.0 110.91 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 117' ' ' SER . . . . . 0.44 ' H ' HD12 ' A' ' 120' ' ' LEU . 36.0 t -73.83 146.44 44.16 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.872 -179.903 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 25.4 mt-30 -42.19 -29.93 0.27 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.94 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 56.2 ttt180 -88.41 -38.23 15.23 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.872 -179.913 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 120' ' ' LEU . . . . . 0.44 HD12 ' H ' ' A' ' 117' ' ' SER . 44.8 mt -65.18 -33.8 76.87 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.905 179.997 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 121' ' ' ALA . . . . . 0.424 ' HB1' HG23 ' A' ' 143' ' ' ILE . . . -70.16 83.08 0.52 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.151 179.802 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 21.7 m-20 -148.93 147.1 23.07 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.605 0.717 . . . . 0.0 110.86 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 -37.24 9.53 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.708 2.272 . . . . 0.0 112.36 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 14.9 pt-20 -77.29 -44.43 29.74 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.87 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 86.1 t -61.71 -39.93 85.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.158 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 91.2 mt -74.2 -39.31 63.23 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.933 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.63 ' HD2' HD12 ' A' ' 138' ' ' ILE . 2.0 mmmp? -64.64 -30.81 71.83 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.86 179.867 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 14.7 mmt180 -42.44 143.93 1.03 Allowed Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.591 0.71 . . . . 0.0 110.876 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 -4.19 13.51 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.66 2.24 . . . . 0.0 112.337 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 4.8 tt0 -99.98 1.07 42.23 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.895 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 131' ' ' TYR . . . . . . . . . . . . . 30.7 m-85 -121.0 -74.93 0.6 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.888 -179.831 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 58.0 m-85 -122.99 -18.14 6.5 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.867 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -55.59 -23.03 34.41 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.499 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 12.4 ptpt -90.83 -11.36 39.58 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.796 0.331 . . . . 0.0 110.858 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 135' ' ' PHE . . . . . . . . . . . . . 22.9 m-85 -80.42 -33.23 37.12 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.925 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 173.65 -166.25 38.45 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.444 -179.98 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 39.4 tptt -95.65 109.27 21.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.737 0.303 . . . . 0.0 110.911 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.63 HD12 ' HD2' ' A' ' 127' ' ' LYS . 86.2 mt -76.71 140.26 17.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.145 179.864 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 18.6 t60 -114.12 -51.07 2.79 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.9 179.871 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -127.28 135.63 50.84 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.868 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 141' ' ' VAL . . . . . 0.621 ' CG2' HG21 ' A' ' 138' ' ' ILE . 19.2 t -137.49 143.04 35.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.129 179.886 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 74.6 t -145.34 140.18 22.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.132 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 143' ' ' ILE . . . . . 0.424 HG23 ' HB1' ' A' ' 121' ' ' ALA . 24.6 mm -110.94 126.43 68.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.096 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 2.9 m120 -124.45 137.78 54.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.905 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 5.3 p30 . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.908 179.973 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 55.8 m . . . . . 0 C--O 1.231 0.086 0 CA-C-O 120.867 0.365 . . . . 0.0 110.861 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -112.85 149.71 32.73 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.091 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 158' ' ' SER . . . . . 0.403 ' HB2' ' CE1' ' A' ' 112' ' ' PHE . 89.9 p -113.71 158.27 21.14 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.852 -179.803 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -141.08 128.52 21.21 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.102 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 35.9 m-85 -99.91 126.56 46.06 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.932 -179.871 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.6 HG22 HG13 ' A' ' 141' ' ' VAL . 96.6 t -129.09 137.59 56.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.101 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 96.0 m -108.31 134.42 51.16 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.162 180.0 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 163' ' ' TYR . . . . . 0.6 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 16.1 m-85 -111.8 129.51 56.11 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.937 -179.927 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 56.2 mt -61.46 -41.04 88.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.097 -0.502 . . . . 0.0 111.155 179.918 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 82.3 mtt-85 -91.66 113.78 26.14 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.895 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 23.2 t -52.16 -59.54 4.25 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.832 -179.751 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 54.1 tt0 -47.31 -49.19 24.56 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.898 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 4.9 t0 -52.48 -51.16 60.78 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.884 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 169' ' ' ALA . . . . . 0.6 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -54.2 -57.74 10.0 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.078 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 42.0 mt -43.56 -61.43 1.39 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.931 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 41.9 mtt-85 -54.6 -43.51 72.24 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.85 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 172' ' ' ALA . . . . . 0.608 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -54.39 -30.98 53.88 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.123 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 97.3 mt -82.54 -34.51 11.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.103 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 11.2 mm-40 -68.2 -27.82 66.72 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.911 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 175' ' ' CYS . . . . . 0.44 ' O ' ' CG2' ' A' ' 179' ' ' VAL . 2.0 m -93.75 -35.59 12.7 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.89 -179.954 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 176' ' ' VAL . . . . . 0.608 HG23 ' O ' ' A' ' 172' ' ' ALA . 10.5 t -66.48 -29.92 48.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.146 -179.974 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 4.3 t-20 -73.41 126.95 31.36 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.844 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 26.2 t-20 74.41 52.08 0.09 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.863 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 179' ' ' VAL . . . . . 0.446 HG12 HG23 ' A' ' 181' ' ' VAL . 69.5 t -130.83 132.78 63.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.138 179.905 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 86.6 t -92.54 107.44 19.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.182 179.885 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 181' ' ' VAL . . . . . 0.446 HG23 HG12 ' A' ' 179' ' ' VAL . 98.3 t -121.0 113.79 41.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.11 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 4.4 t70 58.78 26.51 14.82 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.905 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 81.33 26.67 51.16 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.508 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 3.1 mpt_? -136.27 123.48 21.77 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.932 0.396 . . . . 0.0 110.872 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 18.3 m -76.26 101.64 5.53 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.154 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 89.0 mt -78.18 125.21 29.03 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.957 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 38.1 mmtt -118.5 117.99 30.49 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.898 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 188' ' ' ALA . . . . . 0.547 ' HB2' HG11 ' A' ' 176' ' ' VAL . . . -106.9 140.72 39.27 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.105 179.81 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 59.3 m -145.03 162.88 35.86 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.853 -179.768 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 190' ' ' LEU . . . . . 0.704 ' O ' HD12 ' A' ' 190' ' ' LEU . 3.5 pp -130.24 153.31 48.74 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.927 180.0 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.311 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.525 179.95 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 19.5 tp . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.826 0.346 . . . . 0.0 110.876 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.731 HG22 HD11 ' A' ' 173' ' ' ILE . 71.2 t -114.38 124.05 70.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.161 179.804 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.52 ' CE1' ' HB2' ' A' ' 158' ' ' SER . 65.2 t80 -106.55 108.32 19.77 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.866 -179.919 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.431 HG22 ' HB2' ' A' ' 188' ' ' ALA . 40.2 t -110.7 132.18 59.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.1 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 114' ' ' VAL . . . . . 0.549 HG12 ' HB3' ' A' ' 158' ' ' SER . 23.7 m -121.71 160.7 23.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.137 179.919 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 86.33 51.99 3.35 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.496 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 82.4 mt -116.17 134.44 54.92 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.808 0.337 . . . . 0.0 110.96 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 10.6 t -69.48 149.26 48.47 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.854 -179.92 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 1.4 pp0? -47.58 -31.9 4.92 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.96 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 17.0 ttt180 -84.47 -39.75 18.53 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.898 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 83.1 mt -66.68 -28.95 68.86 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.918 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 121' ' ' ALA . . . . . 0.483 ' HB1' ' CG2' ' A' ' 143' ' ' ILE . . . -70.69 85.18 0.64 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.105 179.81 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -148.11 144.29 18.69 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.596 0.712 . . . . 0.0 110.855 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.76 -49.45 0.56 Allowed 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.66 2.24 . . . . 0.0 112.357 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 26.0 mt-10 -66.68 -41.88 87.39 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.806 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.637 HG13 ' CE2' ' A' ' 131' ' ' TYR . 87.8 t -62.64 -42.97 98.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.129 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 89.1 mt -73.18 -42.59 62.56 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.948 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 4.7 mtmp? -61.43 -27.49 68.59 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.934 179.809 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 13.5 mtm180 -53.89 144.01 38.61 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.633 0.73 . . . . 0.0 110.892 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.81 1.89 4.06 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.691 2.261 . . . . 0.0 112.309 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 8.1 mp0 -101.67 -13.85 17.62 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.924 180.0 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 131' ' ' TYR . . . . . 0.637 ' CE2' HG13 ' A' ' 125' ' ' VAL . 52.6 m-85 -109.41 -71.17 0.77 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.899 -179.82 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.457 ' O ' ' N ' ' A' ' 134' ' ' LYS . 25.1 m-85 -122.14 -40.14 2.53 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.895 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 133' ' ' GLY . . . . . 0.404 ' C ' ' O ' ' A' ' 132' ' ' PHE . . . -38.17 -28.57 0.05 OUTLIER Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.709 -0.757 . . . . 0.0 112.48 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.457 ' N ' ' O ' ' A' ' 132' ' ' PHE . 8.8 ptmm? -52.89 -53.79 44.11 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.831 0.348 . . . . 0.0 110.873 -179.949 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 135' ' ' PHE . . . . . 0.41 ' CD1' ' HA ' ' A' ' 172' ' ' ALA . 70.3 m-85 -52.62 -40.22 62.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.909 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -177.66 178.62 48.4 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.476 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 28.2 mtpt -86.15 97.58 10.41 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.774 0.321 . . . . 0.0 110.915 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.428 HG21 ' CG2' ' A' ' 141' ' ' VAL . 71.7 mt -62.06 140.61 18.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.138 179.907 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 17.2 t-80 -97.34 -54.1 3.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.859 179.872 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 140' ' ' LYS . . . . . 0.614 ' HD3' HG23 ' A' ' 142' ' ' VAL . 1.2 tmmt? -126.79 152.1 47.38 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.922 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 141' ' ' VAL . . . . . 0.428 ' CG2' HG21 ' A' ' 138' ' ' ILE . 54.4 t -139.82 145.46 26.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.133 179.915 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.614 HG23 ' HD3' ' A' ' 140' ' ' LYS . 23.5 t -138.9 116.65 12.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.113 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 143' ' ' ILE . . . . . 0.483 ' CG2' ' HB1' ' A' ' 121' ' ' ALA . 7.2 mm -101.57 127.81 54.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.157 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 34.6 m-80 -126.71 106.66 9.53 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.903 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 6.6 p30 . . . . . 0 C--N 1.329 -0.303 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.89 -179.984 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 4.2 m . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.857 0.361 . . . . 0.0 110.882 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -108.39 163.66 13.01 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.082 179.938 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 158' ' ' SER . . . . . 0.549 ' HB3' HG12 ' A' ' 114' ' ' VAL . 34.8 p -138.57 156.05 47.83 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.826 -179.782 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -148.9 152.15 35.9 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.083 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 19.8 m-85 -111.94 121.59 45.44 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.906 -179.852 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 61.9 t -109.43 131.62 59.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.114 -0.493 . . . . 0.0 111.079 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 20.8 m -101.26 124.4 46.89 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.116 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 163' ' ' TYR . . . . . 0.646 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 9.5 m-85 -104.53 137.53 42.24 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.946 -179.911 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 68.4 mt -62.21 -49.21 84.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.123 179.934 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 34.0 mtt85 -104.11 127.35 51.69 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.889 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 75.6 m -53.65 -58.2 8.05 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.881 -179.779 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 66.0 mm-40 -43.7 -49.24 7.9 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.872 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -55.54 -49.44 72.64 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.887 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 169' ' ' ALA . . . . . 0.646 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -56.44 -56.03 26.28 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.054 179.989 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 39.5 mt -45.41 -63.3 0.98 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.918 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 46.3 mtp180 -53.75 -48.12 69.98 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.86 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 172' ' ' ALA . . . . . 0.787 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -48.36 -34.14 10.18 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.145 179.899 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 173' ' ' ILE . . . . . 0.731 HD11 HG22 ' A' ' 111' ' ' VAL . 67.3 mt -80.68 -37.26 16.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.147 179.999 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 42.5 mt-30 -63.48 -27.79 69.52 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.952 179.875 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 2.6 t -93.81 -36.73 12.12 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.889 -179.927 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 176' ' ' VAL . . . . . 0.787 HG23 ' O ' ' A' ' 172' ' ' ALA . 11.3 t -58.31 -42.46 83.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.133 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 22.6 t30 -65.94 141.68 58.14 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.855 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 7.3 t30 69.37 51.33 0.5 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.884 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 96.9 t -135.13 137.87 49.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.092 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 94.7 t -98.64 109.21 23.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.125 179.889 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 84.2 t -116.58 102.44 13.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.116 179.918 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 6.9 t70 58.29 35.96 25.28 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.87 179.907 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 78.61 26.22 59.35 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.484 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 30.0 mtt-85 -133.8 115.6 14.7 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.917 0.389 . . . . 0.0 110.839 -179.833 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 23.5 m -79.73 92.76 5.45 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.157 -179.939 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 73.3 mt -62.95 136.46 57.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.927 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 13.6 tptp -123.81 116.43 22.96 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.886 179.8 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 188' ' ' ALA . . . . . 0.431 ' HB2' HG22 ' A' ' 113' ' ' VAL . . . -112.47 140.13 47.47 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.093 179.807 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 74.5 m -140.15 157.94 44.83 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.858 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 190' ' ' LEU . . . . . 0.403 ' HB2' HD13 ' A' ' 173' ' ' ILE . 7.3 tt -131.75 122.66 26.22 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.901 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.331 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.5 179.909 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 23.3 tp . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.839 0.352 . . . . 0.0 110.888 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.53 HG22 HD11 ' A' ' 173' ' ' ILE . 45.1 t -133.07 107.7 11.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.107 179.828 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.562 ' CE1' ' HB2' ' A' ' 158' ' ' SER . 67.4 t80 -102.88 113.61 27.19 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.907 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 38.2 t -111.18 145.67 17.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.101 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 114' ' ' VAL . . . . . 0.44 HG12 ' HB3' ' A' ' 158' ' ' SER . 23.1 m -130.97 170.59 19.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.1 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 79.15 51.12 5.47 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.481 179.906 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 23.5 mt -118.03 131.03 56.5 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.829 0.347 . . . . 0.0 110.922 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 117' ' ' SER . . . . . 0.484 ' O ' ' N ' ' A' ' 119' ' ' ARG . 23.1 t -70.95 140.19 50.85 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.812 -179.868 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 118' ' ' GLN . . . . . 0.434 ' C ' ' O ' ' A' ' 117' ' ' SER . 9.5 tp-100 -35.54 -32.06 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.934 -179.979 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.484 ' N ' ' O ' ' A' ' 117' ' ' SER . 18.5 tpp180 -81.49 -47.12 13.56 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.856 -179.91 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 120' ' ' LEU . . . . . 0.453 ' N ' ' O ' ' A' ' 117' ' ' SER . 62.4 mt -61.83 -33.69 74.6 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.952 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -66.09 86.79 0.1 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.095 179.815 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 122' ' ' ASP . . . . . 0.508 ' O ' HD12 ' A' ' 126' ' ' LEU . 0.6 OUTLIER -148.07 144.03 18.38 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.622 0.725 . . . . 0.0 110.871 179.969 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 123' ' ' PRO . . . . . 0.446 ' HA ' HG11 ' A' ' 141' ' ' VAL . 53.3 Cg_endo -69.81 -50.28 0.47 Allowed 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.649 2.232 . . . . 0.0 112.313 -179.984 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 42.7 mt-10 -68.14 -45.68 72.91 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.881 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.415 ' O ' ' CD1' ' A' ' 131' ' ' TYR . 58.4 t -60.03 -39.39 80.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.135 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.508 HD12 ' O ' ' A' ' 122' ' ' ASP . 47.3 mt -74.63 -42.01 59.36 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.942 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.736 ' HA ' HD12 ' A' ' 138' ' ' ILE . 17.3 ttmt -59.48 -30.73 68.75 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.91 179.85 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 46.8 mtt180 -39.94 143.87 0.57 Allowed Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.583 0.706 . . . . 0.0 110.893 179.949 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 2.94 3.1 Favored 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.645 2.23 . . . . 0.0 112.319 -179.984 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -106.67 -30.09 9.2 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.879 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 131' ' ' TYR . . . . . 0.415 ' CD1' ' O ' ' A' ' 125' ' ' VAL . 43.4 m-85 -86.01 -75.05 0.39 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.933 -179.844 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 17.0 m-85 -115.32 -39.72 3.55 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.888 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -52.61 -20.55 7.81 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.488 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.446 ' HD2' ' CG ' ' A' ' 135' ' ' PHE . 0.0 OUTLIER -51.2 -40.96 59.86 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.791 0.329 . . . . 0.0 110.875 -179.964 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 135' ' ' PHE . . . . . 0.446 ' CG ' ' HD2' ' A' ' 134' ' ' LYS . 83.1 m-85 -66.26 -46.38 77.27 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.882 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -173.86 -159.87 21.13 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.506 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 17.0 tptm -91.15 116.23 28.65 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.799 0.333 . . . . 0.0 110.861 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.736 HD12 ' HA ' ' A' ' 127' ' ' LYS . 91.0 mt -73.03 141.89 15.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.081 179.899 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 71.4 t60 -96.15 -44.08 7.45 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.894 179.852 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 15.8 tttm -139.67 142.7 36.94 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.911 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 141' ' ' VAL . . . . . 0.713 HG22 HG21 ' A' ' 138' ' ' ILE . 39.2 t -134.59 110.55 13.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.143 179.864 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 64.9 t -116.06 137.98 48.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.11 179.949 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 143' ' ' ILE . . . . . 0.417 HD11 HD12 ' A' ' 126' ' ' LEU . 43.1 mm -111.82 134.7 53.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.094 179.928 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 34.0 m-20 -131.04 110.97 11.6 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.851 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 5.8 p30 . . . . . 0 C--N 1.33 -0.263 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.918 179.971 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 3.5 m . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.932 0.396 . . . . 0.0 110.878 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -117.41 164.47 14.82 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.125 179.898 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 158' ' ' SER . . . . . 0.562 ' HB2' ' CE1' ' A' ' 112' ' ' PHE . 71.5 p -140.09 154.74 47.13 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.84 -179.779 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -139.08 152.14 47.29 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.082 179.893 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 160' ' ' TYR . . . . . 0.562 ' CZ ' ' CD1' ' A' ' 112' ' ' PHE . 8.5 m-85 -114.0 115.83 28.24 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.933 -179.837 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 29.9 t -110.35 142.61 22.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.134 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 18.7 m -120.44 115.86 24.31 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.119 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 163' ' ' TYR . . . . . 0.661 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 25.0 m-85 -90.32 135.08 33.9 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.933 -179.929 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 64.1 mt -57.73 -42.73 82.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.139 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 17.7 mmm180 -98.25 125.65 43.41 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.888 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 46.6 m -55.26 -62.87 1.38 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.855 -179.781 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 5.4 tp10 -41.89 -55.84 2.95 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.856 -179.906 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 5.9 m-20 -49.59 -45.65 48.21 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.863 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 169' ' ' ALA . . . . . 0.661 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -57.1 -61.78 2.22 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.135 179.959 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 53.7 mt -42.45 -61.74 1.14 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.957 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 59.1 mtp180 -55.7 -51.56 66.87 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.882 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 172' ' ' ALA . . . . . 0.558 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -42.2 -36.58 1.24 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.055 179.915 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 173' ' ' ILE . . . . . 0.601 HD12 HD23 ' A' ' 190' ' ' LEU . 95.2 mt -80.18 -39.1 18.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.257 -0.428 . . . . 0.0 111.177 179.969 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 30.6 mt-30 -62.07 -26.18 68.12 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.92 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 2.2 m -93.76 -38.21 11.4 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.854 -179.92 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 176' ' ' VAL . . . . . 0.663 ' CG1' ' HB2' ' A' ' 188' ' ' ALA . 10.2 t -63.61 -39.74 86.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.128 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 14.1 t30 -63.83 138.66 58.57 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.885 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 49.9 t30 67.74 48.19 1.07 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.913 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 87.0 t -130.1 130.14 65.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.172 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 98.1 t -89.75 109.06 20.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.111 179.965 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 181' ' ' VAL . . . . . 0.503 ' CG2' HD12 ' A' ' 186' ' ' LEU . 87.0 t -117.17 109.85 29.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.1 179.961 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 61.9 m-20 59.85 38.49 21.26 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.831 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 73.71 34.12 56.99 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.486 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 59.0 mtt-85 -143.02 123.25 13.75 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.887 0.375 . . . . 0.0 110.88 -179.867 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 37.7 m -80.39 93.61 6.01 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.153 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 186' ' ' LEU . . . . . 0.503 HD12 ' CG2' ' A' ' 181' ' ' VAL . 45.0 mt -66.07 147.0 54.02 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.876 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 13.9 tppt? -128.0 112.35 14.55 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.913 179.838 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 188' ' ' ALA . . . . . 0.663 ' HB2' ' CG1' ' A' ' 176' ' ' VAL . . . -102.93 129.24 49.58 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.09 179.853 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 19.4 m -161.58 145.11 12.55 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.838 -179.775 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 190' ' ' LEU . . . . . 0.601 HD23 HD12 ' A' ' 173' ' ' ILE . 4.3 pp -118.31 158.65 24.82 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.918 179.987 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.305 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.481 179.884 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 8.7 tp . . . . . 0 C--O 1.231 0.127 0 CA-C-O 120.866 0.365 . . . . 0.0 110.894 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.877 HG22 HD11 ' A' ' 173' ' ' ILE . 96.0 t -97.85 131.76 44.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.138 179.847 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.641 ' CD1' ' CE2' ' A' ' 160' ' ' TYR . 34.5 t80 -130.27 117.43 19.81 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.845 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 69.1 t -114.73 135.54 54.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.143 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 114' ' ' VAL . . . . . 0.953 HG12 ' HB3' ' A' ' 158' ' ' SER . 35.2 m -124.2 168.57 16.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.123 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 81.93 47.15 6.35 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.508 179.999 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 38.0 mt -113.45 137.76 51.08 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.888 0.375 . . . . 0.0 110.931 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 117' ' ' SER . . . . . 0.406 ' O ' ' N ' ' A' ' 120' ' ' LEU . 38.4 t -63.8 141.36 58.8 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.887 -179.915 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 37.0 tt0 -39.26 -37.71 0.45 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.939 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 33.8 tpt85 -79.33 -40.82 29.37 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.874 -179.914 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 120' ' ' LEU . . . . . 0.406 ' N ' ' O ' ' A' ' 117' ' ' SER . 35.8 mt -62.27 -35.88 80.34 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.931 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -66.24 82.99 0.09 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.108 179.787 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 13.1 m-20 -148.06 148.35 29.37 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.555 0.693 . . . . 0.0 110.895 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 -44.34 2.15 Favored 'Trans proline' 0 N--CA 1.465 -0.165 0 C-N-CA 122.711 2.274 . . . . 0.0 112.353 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -71.87 -39.64 69.5 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.901 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.587 ' O ' ' CD1' ' A' ' 131' ' ' TYR . 37.9 t -62.55 -45.32 99.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.133 -179.989 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.565 HD22 ' CE1' ' A' ' 132' ' ' PHE . 67.0 mt -74.43 -40.92 61.65 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.891 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.459 ' HA ' HD12 ' A' ' 138' ' ' ILE . 31.6 mttt -58.32 -31.83 67.92 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.904 179.828 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 15.8 mmt85 -44.24 143.5 1.9 Allowed Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.617 0.722 . . . . 0.0 110.888 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.69 -0.56 7.03 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.72 2.28 . . . . 0.0 112.375 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 25.6 mp0 -101.46 -26.99 13.38 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.892 -179.948 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 131' ' ' TYR . . . . . 0.587 ' CD1' ' O ' ' A' ' 125' ' ' VAL . 39.8 m-85 -88.76 -75.15 0.44 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.921 -179.852 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.565 ' CE1' HD22 ' A' ' 126' ' ' LEU . 10.8 m-85 -110.45 -46.17 3.44 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.872 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -47.7 -21.21 1.37 Allowed Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.501 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.509 ' HD2' ' CD1' ' A' ' 135' ' ' PHE . 0.0 OUTLIER -53.88 -34.99 61.05 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.79 0.329 . . . . 0.0 110.884 -179.995 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 135' ' ' PHE . . . . . 0.509 ' CD1' ' HD2' ' A' ' 134' ' ' LYS . 70.8 m-85 -71.1 -46.03 62.52 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.905 179.958 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -172.6 -127.93 1.01 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.504 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 137' ' ' LYS . . . . . 0.482 ' HG3' HD12 ' A' ' 164' ' ' ILE . 0.3 OUTLIER -117.02 138.8 51.34 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.797 0.332 . . . . 0.0 110.938 179.994 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.459 HD12 ' HA ' ' A' ' 127' ' ' LYS . 82.1 mt -100.03 139.77 20.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.13 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 52.2 t60 -91.04 -54.14 4.08 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.852 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 35.9 ttpt -144.68 144.24 31.13 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.938 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 46.8 t -123.6 145.82 29.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.12 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 59.1 t -136.08 134.77 50.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.095 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 37.1 mm -110.47 132.46 58.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.092 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 43.6 t-20 -126.78 124.14 39.0 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.877 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 16.7 t-20 . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.883 -179.999 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 83.3 p . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.831 0.348 . . . . 0.0 110.917 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -114.74 156.24 25.2 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.12 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 158' ' ' SER . . . . . 0.953 ' HB3' HG12 ' A' ' 114' ' ' VAL . 22.0 p -128.37 174.12 9.59 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.859 -179.766 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -159.89 141.28 12.66 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.105 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 160' ' ' TYR . . . . . 0.641 ' CE2' ' CD1' ' A' ' 112' ' ' PHE . 35.5 m-85 -100.97 144.5 29.84 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.896 -179.848 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 80.2 t -132.19 135.49 58.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.156 179.879 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 38.2 m -112.42 118.92 36.51 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.161 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 163' ' ' TYR . . . . . 0.551 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 20.0 m-85 -102.44 143.89 31.6 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.953 -179.914 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 164' ' ' ILE . . . . . 0.482 HD12 ' HG3' ' A' ' 137' ' ' LYS . 60.6 mt -68.19 -45.52 82.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.162 179.897 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 19.5 mtm180 -97.71 118.24 33.8 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.881 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 41.9 t -51.53 -58.5 6.13 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.846 -179.782 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 16.5 tt0 -42.4 -53.03 4.41 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.9 -179.938 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -51.85 -51.27 57.9 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.833 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 169' ' ' ALA . . . . . 0.551 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -53.37 -63.27 1.2 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.077 179.989 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 39.5 mt -38.38 -57.83 1.08 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.905 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 171' ' ' ARG . . . . . 0.427 ' O ' ' N ' ' A' ' 174' ' ' GLN . 54.2 mtp180 -58.14 -57.97 10.5 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.873 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 172' ' ' ALA . . . . . 0.68 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -37.67 -35.81 0.15 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.132 179.873 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 173' ' ' ILE . . . . . 0.877 HD11 HG22 ' A' ' 111' ' ' VAL . 73.6 mt -82.47 -41.13 17.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.118 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 174' ' ' GLN . . . . . 0.427 ' N ' ' O ' ' A' ' 171' ' ' ARG . 15.0 mm100 -57.23 -28.28 62.76 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.895 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 3.4 t -93.77 -39.34 10.8 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.88 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 176' ' ' VAL . . . . . 0.68 HG23 ' O ' ' A' ' 172' ' ' ALA . 10.9 t -59.52 -48.51 87.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.132 -179.947 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 10.5 t-20 -59.08 139.12 57.2 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.893 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 4.7 t-20 70.25 45.91 0.63 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.876 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 179' ' ' VAL . . . . . 0.576 HG23 ' O ' ' A' ' 176' ' ' VAL . 84.3 t -125.18 137.72 56.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.138 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 95.6 t -96.51 98.57 7.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.155 179.922 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 181' ' ' VAL . . . . . 0.52 HG21 HD12 ' A' ' 186' ' ' LEU . 47.7 t -111.11 111.82 37.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.169 179.908 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 57.12 42.81 25.15 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.88 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 67.03 35.08 88.74 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.511 -179.89 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 81.9 mtt85 -143.03 136.43 28.38 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.876 0.369 . . . . 0.0 110.906 -179.889 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 23.1 m -92.22 92.19 8.09 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.129 -179.885 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 186' ' ' LEU . . . . . 0.52 HD12 HG21 ' A' ' 181' ' ' VAL . 44.8 mt -61.62 125.11 22.63 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.917 179.929 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 36.0 mmtt -103.09 114.01 27.95 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.862 179.848 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -111.35 132.52 54.35 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.109 179.837 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 16.8 m -149.81 145.28 26.51 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.843 -179.788 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 190' ' ' LEU . . . . . 0.491 ' HB3' HD13 ' A' ' 173' ' ' ILE . 1.3 pt? -123.81 151.1 43.73 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.932 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.296 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.518 179.911 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 17.1 tp . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.861 0.362 . . . . 0.0 110.93 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.687 HG22 HD11 ' A' ' 173' ' ' ILE . 87.9 t -115.6 132.62 64.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.152 179.86 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.568 ' CE2' ' CG1' ' A' ' 114' ' ' VAL . 50.3 t80 -128.65 106.68 9.12 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.871 -179.936 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.455 HG22 ' HB2' ' A' ' 188' ' ' ALA . 55.9 t -103.46 122.05 55.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.12 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 114' ' ' VAL . . . . . 0.568 ' CG1' ' CE2' ' A' ' 112' ' ' PHE . 18.7 m -110.66 152.65 12.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.111 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 94.2 37.7 5.31 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.524 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 116' ' ' LEU . . . . . 0.419 ' O ' ' HB3' ' A' ' 157' ' ' ALA . 30.0 mt -101.64 134.38 44.86 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.834 0.35 . . . . 0.0 110.889 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 117' ' ' SER . . . . . 0.437 ' O ' ' N ' ' A' ' 120' ' ' LEU . 24.4 t -68.71 141.33 55.33 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.874 -179.932 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 43.6 tt0 -42.27 -25.7 0.08 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.881 -179.926 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 6.3 tpm_? -89.83 -36.32 15.17 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.83 -179.914 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 120' ' ' LEU . . . . . 0.437 ' N ' ' O ' ' A' ' 117' ' ' SER . 32.2 mt -70.25 -32.25 70.01 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.879 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -70.19 84.67 0.55 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.117 179.77 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -146.31 146.71 28.64 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.588 0.709 . . . . 0.0 110.838 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 -46.23 1.28 Allowed 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.666 2.244 . . . . 0.0 112.333 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -70.64 -38.13 73.85 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.875 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.484 ' O ' ' CD1' ' A' ' 131' ' ' TYR . 87.3 t -65.76 -50.84 68.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.085 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.622 HD22 ' CE1' ' A' ' 132' ' ' PHE . 89.8 mt -68.41 -37.16 80.08 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.901 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.418 ' HA ' HD12 ' A' ' 138' ' ' ILE . 27.6 mttm -62.25 -37.46 85.53 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.863 179.874 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 2.5 mmp_? -43.29 143.88 1.32 Allowed Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.607 0.718 . . . . 0.0 110.839 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 -4.28 13.72 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.651 2.234 . . . . 0.0 112.338 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 1.3 tm-20 -94.18 -16.26 23.86 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.918 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 131' ' ' TYR . . . . . 0.484 ' CD1' ' O ' ' A' ' 125' ' ' VAL . 61.8 m-85 -102.53 -72.06 0.7 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.929 -179.857 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.622 ' CE1' HD22 ' A' ' 126' ' ' LEU . 61.1 m-85 -122.44 -39.6 2.55 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.862 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -41.24 -26.43 0.19 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.484 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.406 ' N ' ' O ' ' A' ' 132' ' ' PHE . 8.5 ptmm? -47.0 -39.13 11.94 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.808 0.337 . . . . 0.0 110.946 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 135' ' ' PHE . . . . . 0.54 ' CE1' ' HA ' ' A' ' 172' ' ' ALA . 66.0 m-85 -63.18 -45.6 91.01 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.87 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 173.58 -148.19 10.03 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.483 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 16.6 tttm -95.42 115.71 27.8 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.828 0.347 . . . . 0.0 110.93 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.548 HG21 ' CG2' ' A' ' 141' ' ' VAL . 86.2 mt -71.63 140.09 18.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.109 179.906 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 34.3 t-80 -82.12 -59.62 2.5 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.883 179.871 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 39.9 tptt -140.13 151.22 45.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.966 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 141' ' ' VAL . . . . . 0.548 ' CG2' HG21 ' A' ' 138' ' ' ILE . 88.3 t -136.97 122.42 26.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.133 179.933 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 43.7 t -125.9 120.23 56.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.132 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 18.2 mm -86.57 136.71 22.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.133 179.902 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 5.7 m120 -128.48 134.35 48.7 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.897 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 88.5 m-20 . . . . . 0 C--N 1.329 -0.312 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.87 -179.976 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 21.1 m . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.867 0.365 . . . . 0.0 110.864 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 157' ' ' ALA . . . . . 0.419 ' HB3' ' O ' ' A' ' 116' ' ' LEU . . . -116.04 164.17 14.83 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.091 179.922 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 158' ' ' SER . . . . . 0.4 ' HB2' ' CE1' ' A' ' 112' ' ' PHE . 51.1 p -139.58 158.68 43.71 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.882 -179.827 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -139.71 145.0 37.8 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.081 179.878 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 160' ' ' TYR . . . . . 0.471 ' CZ ' ' CD1' ' A' ' 112' ' ' PHE . 89.1 m-85 -104.73 125.95 51.32 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.918 -179.841 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 85.7 t -122.11 130.92 74.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.133 179.895 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 20.6 m -111.53 129.79 55.94 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.122 -179.908 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 163' ' ' TYR . . . . . 0.51 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 33.4 m-85 -105.27 160.0 15.44 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.918 -179.93 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 63.0 mt -84.51 -58.82 3.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.147 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 22.2 mmt180 -85.85 125.38 33.25 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.866 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 17.4 m -49.19 -60.55 2.7 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.878 -179.797 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 167' ' ' GLU . . . . . 0.47 ' HA ' HD12 ' A' ' 170' ' ' LEU . 29.1 tt0 -40.89 -54.91 2.61 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.91 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 7.4 t70 -49.68 -49.91 45.62 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.901 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 169' ' ' ALA . . . . . 0.51 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -57.67 -54.18 49.8 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.132 179.935 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 170' ' ' LEU . . . . . 0.47 HD12 ' HA ' ' A' ' 167' ' ' GLU . 35.8 mt -44.09 -60.96 1.64 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.883 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 85.5 mtt180 -58.84 -42.99 90.6 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.892 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 172' ' ' ALA . . . . . 0.659 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -49.42 -35.24 18.55 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.096 179.939 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 173' ' ' ILE . . . . . 0.687 HD11 HG22 ' A' ' 111' ' ' VAL . 82.6 mt -86.47 -40.7 14.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.153 179.97 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 77.3 mt-30 -62.39 -27.19 68.91 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.923 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 16.1 m -93.79 -42.21 9.25 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.941 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 176' ' ' VAL . . . . . 0.659 HG23 ' O ' ' A' ' 172' ' ' ALA . 9.9 t -59.05 -40.48 80.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.137 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 177' ' ' ASN . . . . . 0.435 ' C ' ' OD1' ' A' ' 177' ' ' ASN . 0.8 OUTLIER -66.49 145.18 55.93 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.916 179.982 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 19.1 t30 68.85 41.61 1.5 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.85 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 95.3 t -121.61 133.12 69.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.112 179.886 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 87.8 t -98.6 103.02 14.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.121 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 97.8 t -111.6 116.39 52.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.111 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER 47.4 43.09 15.13 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.911 179.947 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 71.22 31.29 66.41 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.464 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 32.0 mtp85 -137.09 109.42 7.33 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.883 0.373 . . . . 0.0 110.886 -179.884 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 29.7 m -71.78 92.35 1.21 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.163 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 62.7 mt -60.48 132.86 55.22 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.936 179.963 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -124.89 115.45 20.65 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.865 179.87 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 188' ' ' ALA . . . . . 0.455 ' HB2' HG22 ' A' ' 113' ' ' VAL . . . -107.25 144.06 34.6 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.135 179.801 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 2.4 t -146.58 168.57 20.93 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.869 -179.763 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 190' ' ' LEU . . . . . 0.771 ' N ' HD13 ' A' ' 190' ' ' LEU . 0.0 OUTLIER -125.79 161.46 27.33 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.94 179.995 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.346 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.494 179.901 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 20.0 tp . . . . . 0 C--O 1.231 0.087 0 CA-C-O 120.903 0.382 . . . . 0.0 110.875 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 90.7 t -118.51 123.35 71.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.114 179.856 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.437 ' CZ ' HG12 ' A' ' 114' ' ' VAL . 39.2 t80 -113.34 126.06 54.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.853 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.43 HG22 ' HB2' ' A' ' 188' ' ' ALA . 55.6 t -119.74 141.07 41.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.128 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 114' ' ' VAL . . . . . 0.437 HG12 ' CZ ' ' A' ' 112' ' ' PHE . 19.8 m -119.73 171.76 7.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.134 179.889 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 73.75 53.56 7.2 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.514 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 29.7 mt -116.25 126.32 53.43 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.827 0.346 . . . . 0.0 110.9 -179.9 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 89.0 p -64.58 153.08 40.32 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.865 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 44.6 tt0 -52.6 -26.53 13.73 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.907 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -87.19 -43.29 12.34 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.88 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 51.9 mt -66.52 -21.16 66.17 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.964 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -71.68 82.99 0.87 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.123 179.755 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -148.98 144.01 17.65 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-O 121.63 0.729 . . . . 0.0 110.893 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -50.51 0.46 Allowed 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.728 2.285 . . . . 0.0 112.339 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 35.0 mt-10 -69.43 -45.39 69.27 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.859 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.592 ' O ' ' CD1' ' A' ' 131' ' ' TYR . 53.5 t -57.94 -42.33 82.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.156 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 77.0 mt -72.47 -44.73 61.91 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.87 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.544 ' HA ' HD12 ' A' ' 138' ' ' ILE . 12.0 ttpp -59.17 -35.13 72.99 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.881 179.853 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 38.4 mtt-85 -38.58 144.6 0.39 Allowed Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.567 0.699 . . . . 0.0 110.889 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.73 0.5 5.53 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.706 2.271 . . . . 0.0 112.329 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -104.98 -7.93 18.92 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.854 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 131' ' ' TYR . . . . . 0.592 ' CD1' ' O ' ' A' ' 125' ' ' VAL . 45.1 m-85 -111.47 -74.93 0.62 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.927 -179.861 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.435 ' O ' ' N ' ' A' ' 134' ' ' LYS . 14.2 m-85 -114.99 -36.34 4.46 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.886 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -42.56 -22.41 0.13 Allowed Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.486 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.435 ' N ' ' O ' ' A' ' 132' ' ' PHE . 5.3 mtpt -49.22 -59.5 3.62 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.813 0.34 . . . . 0.0 110.896 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 135' ' ' PHE . . . . . 0.57 ' CE1' ' HA ' ' A' ' 172' ' ' ALA . 82.2 m-85 -47.89 -42.55 27.18 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.889 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 173.84 -168.31 41.12 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.487 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 13.5 tttt -82.68 117.6 22.73 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.751 0.31 . . . . 0.0 110.901 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.544 HD12 ' HA ' ' A' ' 127' ' ' LYS . 68.5 mt -77.0 144.88 11.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.167 179.859 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 9.8 t-80 -88.89 -57.62 2.84 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.879 179.846 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 42.4 tttt -142.13 149.24 39.54 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.894 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 141' ' ' VAL . . . . . 0.508 ' CG2' HG21 ' A' ' 138' ' ' ILE . 59.7 t -133.67 140.74 45.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.144 179.855 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 84.3 t -134.66 129.79 52.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.154 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 51.9 mm -100.33 131.32 48.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.136 179.916 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 3.7 m120 -128.67 117.45 21.21 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.881 179.961 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 3.0 p-10 . . . . . 0 C--N 1.329 -0.283 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.885 179.992 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 80.0 p . . . . . 0 C--O 1.23 0.064 0 CA-C-O 120.875 0.369 . . . . 0.0 110.855 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -91.3 168.56 11.49 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.081 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 7.2 m -130.63 168.14 17.61 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.872 -179.82 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -146.74 150.96 36.39 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.106 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 160' ' ' TYR . . . . . 0.424 ' CZ ' ' CD1' ' A' ' 112' ' ' PHE . 7.1 m-85 -116.48 123.01 46.42 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.949 -179.838 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 87.3 t -112.56 142.2 25.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.124 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 32.9 m -113.36 118.3 34.2 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.141 -179.926 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 24.4 m-85 -98.57 150.19 21.98 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.907 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 57.4 mt -88.94 -42.09 14.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.158 179.905 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 75.4 mtp180 -94.67 119.31 33.11 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.895 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 29.3 m -49.2 -60.09 3.11 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.859 -179.776 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 19.5 mt-10 -42.92 -53.02 4.91 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.899 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -49.84 -49.05 50.53 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.849 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -56.62 -58.73 6.82 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.119 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 56.2 mt -41.0 -59.65 1.4 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.863 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 54.0 mtp180 -59.99 -44.23 94.65 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.91 179.948 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 172' ' ' ALA . . . . . 0.613 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -47.96 -36.12 11.98 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.11 179.937 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 64.7 mt -79.87 -42.67 22.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.085 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 40.3 mt-30 -65.26 -24.61 67.36 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.928 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 175' ' ' CYS . . . . . 0.494 ' O ' ' CG2' ' A' ' 179' ' ' VAL . 3.3 t -93.89 -38.94 10.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.849 -179.932 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 176' ' ' VAL . . . . . 0.613 HG23 ' O ' ' A' ' 172' ' ' ALA . 9.8 t -64.34 -26.97 41.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.139 -179.985 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 12.5 t30 -75.61 146.63 40.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.869 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 42.1 t30 59.89 41.43 17.85 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.887 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 179' ' ' VAL . . . . . 0.494 ' CG2' ' O ' ' A' ' 175' ' ' CYS . 85.9 t -121.12 135.96 59.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.133 179.917 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 99.7 t -104.15 122.98 57.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.147 179.895 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 181' ' ' VAL . . . . . 0.465 HG21 ' CD1' ' A' ' 186' ' ' LEU . 60.6 t -128.28 103.38 9.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.114 179.949 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 5.9 m-20 55.24 37.82 29.47 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.857 179.91 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 81.02 36.78 20.81 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.476 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -141.55 121.36 13.53 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.893 0.378 . . . . 0.0 110.866 -179.855 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 27.6 m -84.23 92.9 8.07 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.144 -179.891 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 186' ' ' LEU . . . . . 0.465 ' CD1' HG21 ' A' ' 181' ' ' VAL . 88.5 mt -69.59 120.74 15.83 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.893 179.991 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 14.8 mtmm -121.51 122.89 40.73 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.892 179.8 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 188' ' ' ALA . . . . . 0.43 ' HB2' HG22 ' A' ' 113' ' ' VAL . . . -107.7 146.18 32.43 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.104 179.834 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 53.2 m -139.05 169.52 17.64 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.862 -179.821 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 190' ' ' LEU . . . . . 0.433 ' HA ' HD22 ' A' ' 190' ' ' LEU . 0.7 OUTLIER -127.8 125.73 40.38 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.942 179.977 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.283 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.493 179.915 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 26.2 tp . . . . . 0 C--O 1.231 0.106 0 CA-C-O 120.894 0.378 . . . . 0.0 110.873 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 99.5 t -106.48 109.68 28.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.213 179.775 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.483 ' CZ ' ' CG1' ' A' ' 114' ' ' VAL . 40.4 t80 -100.64 107.09 18.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.924 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 75.0 t -106.35 138.57 31.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.139 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 114' ' ' VAL . . . . . 0.483 ' CG1' ' CZ ' ' A' ' 112' ' ' PHE . 31.0 m -122.68 160.79 24.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.101 179.913 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 81.54 53.21 3.89 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.491 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 32.9 mt -106.17 120.74 42.61 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.778 0.323 . . . . 0.0 110.938 -179.903 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 117' ' ' SER . . . . . 0.42 ' O ' ' N ' ' A' ' 120' ' ' LEU . 26.3 t -64.65 142.82 58.29 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.883 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 118' ' ' GLN . . . . . 0.439 ' C ' ' CD ' ' A' ' 118' ' ' GLN . 0.7 OUTLIER -36.65 -43.71 0.43 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.917 -179.942 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 25.9 tpt180 -74.2 -42.32 59.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.852 -179.926 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 120' ' ' LEU . . . . . 0.42 ' N ' ' O ' ' A' ' 117' ' ' SER . 40.1 mt -61.49 -31.35 71.33 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.922 -179.987 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -68.5 83.37 0.27 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.134 179.801 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 73.1 m-20 -148.96 143.18 16.79 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.574 0.702 . . . . 0.0 110.899 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.86 -50.78 0.42 Allowed 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.67 2.247 . . . . 0.0 112.335 -179.925 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -65.46 -51.33 60.91 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.881 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.644 ' CG1' ' CZ ' ' A' ' 131' ' ' TYR . 64.3 t -54.02 -46.59 65.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.112 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.423 HD22 ' CE1' ' A' ' 132' ' ' PHE . 83.0 mt -66.99 -42.79 84.44 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.895 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.539 ' HA ' HD12 ' A' ' 138' ' ' ILE . 20.2 tttm -58.17 -40.46 81.51 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.884 179.845 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 34.6 mtp180 -38.24 143.29 0.43 Allowed Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.598 0.713 . . . . 0.0 110.872 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 1.53 4.37 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.626 2.217 . . . . 0.0 112.321 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 35.2 mm-40 -99.68 -27.99 13.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.848 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 131' ' ' TYR . . . . . 0.644 ' CZ ' ' CG1' ' A' ' 125' ' ' VAL . 55.7 m-85 -90.54 -68.27 0.8 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.92 -179.82 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.493 ' O ' ' N ' ' A' ' 134' ' ' LYS . 12.8 m-85 -116.95 -52.5 2.52 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.894 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 133' ' ' GLY . . . . . 0.402 ' C ' ' O ' ' A' ' 132' ' ' PHE . . . -37.8 -27.37 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.5 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.493 ' N ' ' O ' ' A' ' 132' ' ' PHE . 19.5 ptmt -43.04 -49.64 6.09 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.814 0.34 . . . . 0.0 110.851 -179.93 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 135' ' ' PHE . . . . . 0.469 ' CZ ' ' CG2' ' A' ' 176' ' ' VAL . 58.0 m-85 -63.3 -47.38 82.51 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.915 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -173.61 -172.26 38.85 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.755 -0.735 . . . . 0.0 112.477 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 22.8 mtmm -79.23 122.93 26.92 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.777 0.322 . . . . 0.0 110.872 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.539 HD12 ' HA ' ' A' ' 127' ' ' LYS . 87.7 mt -79.92 141.64 15.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.111 179.871 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 61.5 t-80 -91.02 -49.07 6.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.852 179.868 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 76.8 tttt -146.28 153.47 40.61 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.897 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 42.2 t -132.4 140.24 48.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.156 179.881 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 93.3 t -133.23 131.52 58.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.143 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 43.5 mm -111.67 121.99 65.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.138 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 11.1 t30 -114.49 118.69 34.5 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.89 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 28.5 m-80 . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.869 -179.992 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 90.0 p . . . . . 0 C--O 1.23 0.076 0 CA-C-O 120.9 0.381 . . . . 0.0 110.817 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -87.57 162.61 17.09 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.05 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 94.2 p -136.36 163.2 31.0 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.845 -179.813 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -146.76 148.77 32.29 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.067 179.917 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 11.0 m-85 -112.73 139.53 48.26 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.948 -179.873 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 71.4 t -130.3 121.43 51.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.16 179.896 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 87.2 m -99.52 129.0 45.66 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.13 -179.93 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 163' ' ' TYR . . . . . 0.554 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 52.7 m-85 -110.37 147.07 34.68 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.906 -179.88 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 53.1 mt -67.42 -60.62 2.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.123 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 46.9 mtp85 -82.43 112.99 19.88 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.893 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 74.0 m -52.45 -49.38 64.74 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.882 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 16.5 tt0 -44.5 -55.64 4.93 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.921 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 64.8 m-20 -55.84 -45.86 78.29 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.858 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 169' ' ' ALA . . . . . 0.554 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -58.48 -59.85 4.73 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.063 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 46.1 mt -42.65 -61.56 1.21 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.892 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 1.3 mpt_? -54.93 -50.38 68.99 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.835 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 172' ' ' ALA . . . . . 0.706 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -43.52 -36.73 2.15 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.091 179.933 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 173' ' ' ILE . . . . . 0.476 HG23 ' HB3' ' A' ' 188' ' ' ALA . 73.6 mt -78.77 -40.79 23.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.142 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 33.7 mt-30 -60.01 -30.22 69.0 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.915 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 1.8 m -93.8 -39.91 10.48 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.832 -179.895 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 176' ' ' VAL . . . . . 0.706 HG23 ' O ' ' A' ' 172' ' ' ALA . 10.6 t -59.56 -45.43 94.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.156 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 177' ' ' ASN . . . . . 0.448 ' OD1' ' N ' ' A' ' 178' ' ' ASN . 37.0 t30 -53.92 146.17 14.79 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.909 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 178' ' ' ASN . . . . . 0.448 ' N ' ' OD1' ' A' ' 177' ' ' ASN . 10.4 m120 57.83 47.26 15.61 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.891 -180.0 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 95.3 t -132.43 139.76 49.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.145 179.893 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 95.4 t -93.97 114.02 29.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.101 179.96 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 96.0 t -120.86 105.87 17.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.156 179.879 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 6.5 t0 65.62 35.32 7.13 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.878 179.928 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 81.19 -14.03 29.83 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.493 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 10.6 mpt_? -102.94 112.7 25.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.867 0.365 . . . . 0.0 110.863 -179.869 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 25.3 m -70.9 93.7 1.0 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.17 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 83.3 mt -70.97 149.5 46.61 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.947 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 13.5 ttpt -136.36 126.45 26.18 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.928 179.863 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 188' ' ' ALA . . . . . 0.476 ' HB3' HG23 ' A' ' 173' ' ' ILE . . . -112.38 141.91 45.54 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.139 179.801 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 8.5 t -139.86 165.56 26.99 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.868 -179.748 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 190' ' ' LEU . . . . . . . . . . . . . 38.1 tp -127.14 135.82 51.24 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.918 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.498 179.875 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 110' ' ' LEU . . . . . 0.674 ' O ' HD12 ' A' ' 190' ' ' LEU . 41.4 tp . . . . . 0 C--O 1.23 0.062 0 CA-C-O 120.896 0.379 . . . . 0.0 110.904 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.509 HG22 HD11 ' A' ' 173' ' ' ILE . 94.7 t -116.78 119.43 61.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.112 179.852 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.567 ' CE1' ' HB2' ' A' ' 158' ' ' SER . 48.2 t80 -113.67 109.64 18.91 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.861 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.687 HG22 ' HB2' ' A' ' 188' ' ' ALA . 68.1 t -106.32 146.5 12.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.121 179.932 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 114' ' ' VAL . . . . . 0.444 HG12 ' HB3' ' A' ' 158' ' ' SER . 32.9 m -132.03 170.69 19.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.086 179.942 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 78.29 45.49 9.95 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.455 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 32.4 mt -117.91 136.79 53.24 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.877 0.37 . . . . 0.0 110.955 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 117' ' ' SER . . . . . 0.483 ' O ' ' N ' ' A' ' 119' ' ' ARG . 15.3 p -82.33 140.51 33.51 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.862 -179.892 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 118' ' ' GLN . . . . . 0.424 ' C ' ' O ' ' A' ' 117' ' ' SER . 82.8 mm-40 -35.02 -33.02 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.878 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.483 ' N ' ' O ' ' A' ' 117' ' ' SER . 72.8 mtm-85 -68.85 -50.22 51.69 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.827 -179.869 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 120' ' ' LEU . . . . . 0.462 ' N ' ' O ' ' A' ' 117' ' ' SER . 36.0 mt -70.97 -38.96 72.77 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.927 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -60.14 83.48 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.116 179.823 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 122' ' ' ASP . . . . . 0.4 ' N ' ' O ' ' A' ' 120' ' ' LEU . 6.0 m-20 -147.18 145.82 23.37 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.623 0.725 . . . . 0.0 110.888 179.962 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.76 -40.02 5.82 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.736 2.291 . . . . 0.0 112.327 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 124' ' ' GLU . . . . . 0.433 ' HG3' ' N ' ' A' ' 125' ' ' VAL . 16.8 pt-20 -75.8 -50.23 15.79 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.883 -179.967 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.476 HG13 ' CE2' ' A' ' 131' ' ' TYR . 53.2 t -56.51 -41.38 72.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.101 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.454 HD22 ' CE1' ' A' ' 132' ' ' PHE . 71.5 mt -74.68 -37.22 62.73 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.893 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.679 ' HA ' HD12 ' A' ' 138' ' ' ILE . 35.2 mttm -65.39 -22.9 66.84 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.906 179.832 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 64.1 mtt180 -48.5 143.75 7.27 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.571 0.701 . . . . 0.0 110.908 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 1.35 4.5 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.708 2.272 . . . . 0.0 112.335 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 26.9 mp0 -103.95 -42.02 5.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.908 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 131' ' ' TYR . . . . . 0.476 ' CE2' HG13 ' A' ' 125' ' ' VAL . 37.5 m-85 -72.77 -75.14 0.15 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.932 -179.872 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.454 ' CE1' HD22 ' A' ' 126' ' ' LEU . 45.6 m-85 -116.35 -32.85 5.15 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.867 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -52.49 -15.28 2.81 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.514 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 16.8 ptmt -67.7 -42.83 81.38 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.79 0.329 . . . . 0.0 110.895 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 135' ' ' PHE . . . . . 0.555 ' CE1' ' HA ' ' A' ' 172' ' ' ALA . 29.3 m-85 -60.63 -45.69 93.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.888 179.939 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -179.24 167.54 37.7 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.518 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 8.0 tmtm? -61.03 131.91 52.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.732 0.301 . . . . 0.0 110.878 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.679 HD12 ' HA ' ' A' ' 127' ' ' LYS . 95.1 mt -93.0 142.28 13.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.111 179.876 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 38.4 t60 -104.9 -59.6 1.72 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.803 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 140' ' ' LYS . . . . . 0.413 ' HD3' ' CG2' ' A' ' 142' ' ' VAL . 1.0 OUTLIER -129.17 136.52 50.26 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.916 -179.977 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 141' ' ' VAL . . . . . 0.646 ' CG2' HG21 ' A' ' 138' ' ' ILE . 47.1 t -129.36 139.76 50.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.179 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.413 ' CG2' ' HD3' ' A' ' 140' ' ' LYS . 5.4 t -132.18 140.19 48.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.117 179.929 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 42.1 mm -114.48 121.42 66.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.159 179.926 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 5.7 m120 -115.67 113.39 23.45 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.933 179.916 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 53.6 p30 . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.879 -179.974 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 31.2 p . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.86 0.362 . . . . 0.0 110.859 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -95.03 163.4 13.32 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.059 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 158' ' ' SER . . . . . 0.567 ' HB2' ' CE1' ' A' ' 112' ' ' PHE . 58.9 p -134.46 164.83 26.58 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.813 -179.757 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -147.15 136.43 22.58 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.108 179.898 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 160' ' ' TYR . . . . . 0.479 ' CE2' ' CD1' ' A' ' 112' ' ' PHE . 11.9 m-85 -104.96 113.11 26.51 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.902 -179.812 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 50.0 t -108.16 139.48 30.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.132 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 54.3 m -106.56 126.58 52.45 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.146 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 163' ' ' TYR . . . . . 0.628 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 15.4 m-85 -109.02 127.79 54.4 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.947 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 64.8 mt -59.48 -52.18 63.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.145 179.889 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 33.4 mtp85 -84.98 110.36 18.84 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.834 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 166' ' ' SER . . . . . 0.416 ' O ' ' C ' ' A' ' 167' ' ' GLU . 68.5 m -49.73 -64.72 0.72 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.833 -179.808 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 167' ' ' GLU . . . . . 0.416 ' C ' ' O ' ' A' ' 166' ' ' SER . 15.3 mt-10 -37.29 -57.69 0.87 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.899 -179.961 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -51.22 -47.74 62.24 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.895 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 169' ' ' ALA . . . . . 0.628 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -54.77 -58.61 6.87 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.08 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 41.1 mt -46.21 -56.95 4.99 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.879 -179.924 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 6.6 mpt_? -55.19 -51.86 65.17 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.856 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 172' ' ' ALA . . . . . 0.555 ' HA ' ' CE1' ' A' ' 135' ' ' PHE . . . -47.52 -33.04 5.87 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.06 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 173' ' ' ILE . . . . . 0.509 HD11 HG22 ' A' ' 111' ' ' VAL . 56.9 mt -79.12 -34.38 16.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.124 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 44.7 mt-30 -70.69 -26.01 63.23 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.912 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 4.0 m -93.77 -36.11 12.44 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.932 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 176' ' ' VAL . . . . . 0.491 HG23 ' O ' ' A' ' 172' ' ' ALA . 9.8 t -67.94 -35.81 73.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.118 -179.976 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 58.4 t30 -62.97 145.26 55.73 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.921 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 35.5 t30 55.62 51.68 12.21 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.916 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 179' ' ' VAL . . . . . 0.47 HG12 HG23 ' A' ' 181' ' ' VAL . 76.7 t -125.89 142.37 42.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.104 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 91.3 t -104.24 105.12 17.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.128 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 181' ' ' VAL . . . . . 0.47 HG23 HG12 ' A' ' 179' ' ' VAL . 85.7 t -119.11 105.01 16.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.174 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 1.6 t70 60.01 41.23 17.73 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.901 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 71.28 24.09 77.35 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.524 -179.932 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 3.5 mmp_? -126.93 114.23 17.58 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.884 0.373 . . . . 0.0 110.875 -179.837 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 7.8 m -70.7 103.19 2.49 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.122 -179.89 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 31.1 mt -71.52 126.1 28.78 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.934 179.932 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -131.02 114.55 15.33 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.89 179.837 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 188' ' ' ALA . . . . . 0.687 ' HB2' HG22 ' A' ' 113' ' ' VAL . . . -118.54 137.62 53.1 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.046 179.862 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 7.3 t -125.89 166.78 16.26 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.875 -179.785 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 190' ' ' LEU . . . . . 0.674 HD12 ' O ' ' A' ' 110' ' ' LEU . 9.0 tp -131.8 143.41 50.19 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.897 -179.97 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.345 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.547 179.925 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 13.9 tp . . . . . 0 C--O 1.232 0.162 0 CA-C-O 120.843 0.354 . . . . 0.0 110.931 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 1.088 HG22 HD11 ' A' ' 173' ' ' ILE . 77.9 t -103.44 108.02 23.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.103 179.867 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.451 ' CD1' ' CE1' ' A' ' 160' ' ' TYR . 47.2 t80 -106.56 113.86 27.63 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.875 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.579 HG22 ' HB2' ' A' ' 188' ' ' ALA . 32.7 t -112.61 137.94 43.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.163 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 23.1 m -121.36 166.22 16.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.125 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 115' ' ' GLY . . . . . 0.412 ' O ' HD23 ' A' ' 186' ' ' LEU . . . 73.38 55.69 6.01 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.493 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 32.3 mt -117.81 127.76 54.2 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.813 0.339 . . . . 0.0 110.894 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 11.8 m -63.78 136.01 57.1 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.846 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 8.2 tp60 -41.97 -27.28 0.12 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.884 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 1.8 mpt_? -78.4 -48.27 15.85 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.901 -179.932 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 42.8 mt -66.22 -38.7 88.56 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.932 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -60.91 88.12 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.069 179.839 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 24.9 m-20 -148.65 149.54 31.21 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.635 0.731 . . . . 0.0 110.852 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.82 -43.39 2.64 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.675 2.25 . . . . 0.0 112.325 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 27.6 mt-10 -76.39 -41.86 46.44 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.857 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.723 HG13 ' CZ ' ' A' ' 131' ' ' TYR . 74.3 t -60.24 -48.06 89.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.127 -179.987 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 42.3 mt -70.26 -40.25 74.49 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.886 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.504 ' HA ' HD12 ' A' ' 138' ' ' ILE . 32.1 mttm -61.54 -35.89 79.04 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.864 179.854 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 48.7 mtt85 -43.9 143.41 1.74 Allowed Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.592 0.711 . . . . 0.0 110.875 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 -3.54 12.19 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.707 2.272 . . . . 0.0 112.362 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -94.96 -36.13 11.71 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.944 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 131' ' ' TYR . . . . . 0.723 ' CZ ' HG13 ' A' ' 125' ' ' VAL . 57.1 m-85 -80.21 -74.23 0.32 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.888 -179.841 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.487 ' O ' ' N ' ' A' ' 134' ' ' LYS . 14.6 m-85 -116.9 -44.84 2.79 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.915 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 133' ' ' GLY . . . . . 0.439 ' C ' ' O ' ' A' ' 132' ' ' PHE . . . -35.39 -31.06 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.515 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.487 ' N ' ' O ' ' A' ' 132' ' ' PHE . 16.6 ptmt -45.86 -48.77 15.89 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.812 0.339 . . . . 0.0 110.887 -179.995 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 135' ' ' PHE . . . . . 0.545 ' CD2' ' HA ' ' A' ' 172' ' ' ALA . 78.9 m-85 -61.69 -43.91 97.95 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.882 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -173.94 -174.54 40.91 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.491 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 29.5 mtmt -90.09 102.18 14.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.753 0.311 . . . . 0.0 110.845 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.504 HD12 ' HA ' ' A' ' 127' ' ' LYS . 58.1 mt -61.33 148.38 9.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.104 179.847 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 61.4 t60 -101.55 -57.55 2.06 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.875 179.837 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 40.2 tttm -123.17 143.8 49.77 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.904 179.916 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 141' ' ' VAL . . . . . 0.463 HG22 HG21 ' A' ' 138' ' ' ILE . 58.5 t -135.91 118.45 21.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.135 179.89 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 83.9 t -117.32 134.72 60.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.128 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 3.3 mm -106.46 125.39 62.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.129 179.923 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 4.4 m-80 -117.87 104.36 10.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.947 179.87 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 70.1 m-80 . . . . . 0 C--N 1.33 -0.277 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.893 -179.965 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 58.1 m . . . . . 0 C--O 1.231 0.107 0 CA-C-O 120.874 0.368 . . . . 0.0 110.848 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -106.5 165.32 11.36 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.064 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 158' ' ' SER . . . . . 0.407 ' HB2' ' CE1' ' A' ' 112' ' ' PHE . 79.0 p -130.12 167.38 18.44 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.842 -179.767 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -155.68 136.21 13.29 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.137 179.9 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 160' ' ' TYR . . . . . 0.451 ' CE1' ' CD1' ' A' ' 112' ' ' PHE . 98.3 m-85 -99.4 133.14 44.15 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.926 -179.869 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.44 HG13 ' CG2' ' A' ' 138' ' ' ILE . 75.2 t -125.6 122.28 62.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.179 179.893 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 87.4 m -94.97 124.18 38.87 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.197 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 163' ' ' TYR . . . . . 0.494 ' CB ' ' HB2' ' A' ' 169' ' ' ALA . 14.0 m-85 -100.2 147.77 25.35 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.925 -179.897 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 52.0 mt -73.5 -41.74 56.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.154 179.871 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 13.3 mmm180 -105.18 133.41 49.99 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.862 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 71.5 m -63.05 -68.18 0.36 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.834 -179.722 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 4.9 tp10 -42.93 -58.45 2.4 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.884 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -47.16 -46.48 23.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.921 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 169' ' ' ALA . . . . . 0.494 ' HB2' ' CB ' ' A' ' 163' ' ' TYR . . . -58.98 -61.53 2.57 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.119 179.938 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 59.0 mt -39.21 -52.75 1.94 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.914 179.994 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 171' ' ' ARG . . . . . 0.431 ' O ' ' N ' ' A' ' 174' ' ' GLN . 86.1 mtt180 -59.44 -58.61 7.83 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.898 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 172' ' ' ALA . . . . . 0.545 ' HA ' ' CD2' ' A' ' 135' ' ' PHE . . . -41.02 -35.59 0.56 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.098 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 173' ' ' ILE . . . . . 1.088 HD11 HG22 ' A' ' 111' ' ' VAL . 58.5 mt -76.89 -37.58 27.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.074 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 174' ' ' GLN . . . . . 0.431 ' N ' ' O ' ' A' ' 171' ' ' ARG . 61.5 mt-30 -64.68 -21.42 66.73 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.883 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 3.9 m -93.83 -40.39 10.2 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.873 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 176' ' ' VAL . . . . . 0.479 ' O ' HG23 ' A' ' 179' ' ' VAL . 9.1 t -62.45 -38.36 81.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.115 -179.984 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 5.1 t-20 -60.71 140.36 57.55 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.887 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 15.6 t-20 65.2 50.74 1.75 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.91 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 179' ' ' VAL . . . . . 0.479 HG23 ' O ' ' A' ' 176' ' ' VAL . 71.1 t -124.78 142.04 42.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.061 179.946 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 83.3 t -96.25 110.68 25.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.16 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 181' ' ' VAL . . . . . 0.744 HG21 HD12 ' A' ' 186' ' ' LEU . 48.7 t -120.02 106.02 18.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.125 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 53.77 43.47 30.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.881 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 71.19 30.83 66.91 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.454 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 32.9 mtt-85 -138.24 122.71 18.41 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.882 0.372 . . . . 0.0 110.902 -179.874 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 17.7 m -82.47 96.91 8.15 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.143 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 186' ' ' LEU . . . . . 0.744 HD12 HG21 ' A' ' 181' ' ' VAL . 95.8 mt -74.45 132.71 42.16 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.937 179.928 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 47.8 mttt -117.87 132.22 56.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.941 179.8 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 188' ' ' ALA . . . . . 0.579 ' HB2' HG22 ' A' ' 113' ' ' VAL . . . -123.53 147.27 47.42 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.106 179.857 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 68.0 m -158.06 162.62 38.09 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.856 -179.806 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 190' ' ' LEU . . . . . . . . . . . . . 4.5 pp -129.77 156.33 44.49 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.894 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.337 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.507 179.867 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 110' ' ' LEU . . . . . 0.506 ' O ' HD22 ' A' ' 190' ' ' LEU . 14.1 tp . . . . . 0 C--O 1.23 0.059 0 CA-C-O 120.86 0.362 . . . . 0.0 110.877 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.593 HG22 HD11 ' A' ' 173' ' ' ILE . 41.4 t -95.49 104.22 15.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.15 179.815 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.579 ' CD1' ' CE2' ' A' ' 160' ' ' TYR . 39.5 t80 -94.08 122.36 36.51 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.848 -179.948 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.401 HG22 ' HB2' ' A' ' 188' ' ' ALA . 42.3 t -117.82 133.55 64.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.145 179.92 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 114' ' ' VAL . . . . . 0.429 ' CG1' ' CE2' ' A' ' 112' ' ' PHE . 11.9 m -120.4 166.64 14.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.125 179.899 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 67.0 53.53 26.24 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.506 179.983 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 34.9 mt -105.98 146.57 29.89 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.844 0.354 . . . . 0.0 110.846 -179.86 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 29.2 m -77.35 153.98 33.24 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.801 -179.908 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 84.9 mm-40 -56.55 -44.9 81.37 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.892 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 10.6 ttt180 -74.38 -44.96 49.85 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.897 -179.925 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 66.2 mt -66.89 -24.84 66.16 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.932 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -76.06 83.71 2.93 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.11 179.773 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -148.3 150.34 34.32 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-O 121.62 0.724 . . . . 0.0 110.857 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.83 -50.62 0.44 Allowed 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.668 2.245 . . . . 0.0 112.319 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 7.0 mm-40 -65.35 -41.91 93.38 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.89 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.67 HG13 ' CZ ' ' A' ' 131' ' ' TYR . 85.9 t -61.79 -42.68 95.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.128 179.975 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.545 HD22 ' CE1' ' A' ' 132' ' ' PHE . 79.4 mt -74.33 -40.32 62.25 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.929 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.459 ' HA ' ' CD1' ' A' ' 138' ' ' ILE . 43.0 tttt -61.03 -31.25 70.89 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.873 179.837 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 72.6 mtt-85 -44.13 142.88 2.02 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.573 0.701 . . . . 0.0 110.873 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 0.8 5.14 Favored 'Trans proline' 0 C--N 1.341 0.136 0 C-N-CA 122.662 2.241 . . . . 0.0 112.375 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 5.0 tp10 -103.99 -36.01 7.9 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.915 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 131' ' ' TYR . . . . . 0.67 ' CZ ' HG13 ' A' ' 125' ' ' VAL . 38.8 m-85 -75.91 -75.02 0.2 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.962 -179.869 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.545 ' CE1' HD22 ' A' ' 126' ' ' LEU . 19.9 m-85 -114.86 -40.58 3.5 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.858 -179.996 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -52.23 -20.47 6.93 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.51 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.423 ' HD3' ' C ' ' A' ' 134' ' ' LYS . 0.0 OUTLIER -53.54 -31.65 47.27 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.86 0.362 . . . . 0.0 110.903 -179.999 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 135' ' ' PHE . . . . . 0.454 ' CE2' ' CG2' ' A' ' 176' ' ' VAL . 65.3 m-85 -73.21 -42.48 62.6 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.87 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -177.66 -163.41 29.41 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.47 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 16.9 mttp -79.58 142.14 35.95 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.774 0.321 . . . . 0.0 110.915 -179.966 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.558 HG21 HG22 ' A' ' 141' ' ' VAL . 82.6 mt -105.25 132.19 52.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.146 179.899 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 8.3 t-80 -85.97 -59.64 2.24 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.857 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 73.6 tttt -132.72 146.1 51.58 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.936 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 141' ' ' VAL . . . . . 0.558 HG22 HG21 ' A' ' 138' ' ' ILE . 24.2 t -129.38 130.08 67.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.153 179.876 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 96.1 t -134.34 147.49 30.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.133 179.879 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 15.3 mm -118.05 150.44 20.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.133 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 39.9 t30 -129.02 106.47 8.9 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.889 179.902 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 3.0 p30 . . . . . 0 C--N 1.329 -0.303 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.896 179.986 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 78.7 p . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.886 0.374 . . . . 0.0 110.825 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -112.28 164.81 12.79 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.082 179.911 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 14.8 m -133.16 164.55 26.8 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.87 -179.797 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -150.81 166.47 30.4 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.131 179.922 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 160' ' ' TYR . . . . . 0.579 ' CE2' ' CD1' ' A' ' 112' ' ' PHE . 11.6 m-85 -136.29 126.4 26.2 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.913 -179.821 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 67.0 t -126.72 146.13 33.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.09 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 82.2 m -108.35 134.16 51.55 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.192 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 163' ' ' TYR . . . . . 0.651 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 7.9 m-85 -111.96 120.75 42.95 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.924 -179.867 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 88.7 mt -49.75 -50.86 17.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.102 179.918 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 24.9 mtp85 -88.1 109.72 20.09 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.883 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 5.3 t -48.85 -59.3 3.69 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.855 -179.772 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 23.8 mt-10 -47.94 -46.29 31.94 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.89 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 6.5 t0 -56.13 -45.12 79.68 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.829 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 169' ' ' ALA . . . . . 0.651 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -55.75 -52.42 63.98 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.116 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 26.8 mt -51.38 -59.4 4.27 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.894 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 74.3 mtp180 -55.09 -49.23 72.22 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.903 179.909 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 172' ' ' ALA . . . . . 0.638 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -50.08 -33.16 17.61 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.066 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 173' ' ' ILE . . . . . 0.593 HD11 HG22 ' A' ' 111' ' ' VAL . 55.2 mt -76.65 -38.4 30.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.128 -179.996 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 10.3 mm100 -65.66 -30.54 71.25 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.884 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 175' ' ' CYS . . . . . 0.444 ' O ' ' CG2' ' A' ' 179' ' ' VAL . 3.0 t -93.72 -27.33 16.58 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.85 -179.94 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 176' ' ' VAL . . . . . 0.638 HG23 ' O ' ' A' ' 172' ' ' ALA . 10.4 t -77.9 -26.28 14.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.181 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -79.09 154.15 29.61 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.855 -179.972 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 178' ' ' ASN . . . . . 0.438 ' O ' ' CG ' ' A' ' 178' ' ' ASN . 32.5 t30 55.23 36.27 26.67 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.881 179.978 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 179' ' ' VAL . . . . . 0.444 ' CG2' ' O ' ' A' ' 175' ' ' CYS . 92.3 t -108.84 141.98 22.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.109 179.919 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 53.7 t -106.2 97.1 5.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.121 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 181' ' ' VAL . . . . . 0.48 HG12 ' OD2' ' A' ' 182' ' ' ASP . 40.0 t -102.41 118.34 49.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.143 179.941 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 182' ' ' ASP . . . . . 0.48 ' OD2' HG12 ' A' ' 181' ' ' VAL . 2.9 p30 47.26 31.65 1.84 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.851 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 86.02 20.7 54.87 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.453 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 5.5 tpm_? -118.21 133.97 55.43 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.904 0.383 . . . . 0.0 110.882 -179.857 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 17.3 m -90.76 95.13 9.99 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.164 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 71.1 mt -74.8 128.33 35.3 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.892 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 2.8 mmmp? -128.79 121.7 28.92 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.887 179.822 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 188' ' ' ALA . . . . . 0.401 ' HB2' HG22 ' A' ' 113' ' ' VAL . . . -119.4 156.52 29.98 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.087 179.859 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 8.5 t -147.76 165.28 31.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.857 -179.813 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 190' ' ' LEU . . . . . 0.789 HD13 ' N ' ' A' ' 191' ' ' GLY . 1.6 tm? -132.2 137.58 47.65 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.877 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 191' ' ' GLY . . . . . 0.789 ' N ' HD13 ' A' ' 190' ' ' LEU . . . . . . . . 0 N--CA 1.452 -0.299 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.441 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 110' ' ' LEU . . . . . 0.637 ' O ' HD22 ' A' ' 190' ' ' LEU . 9.4 tp . . . . . 0 C--O 1.231 0.092 0 CA-C-O 120.842 0.353 . . . . 0.0 110.941 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.471 HG22 HD11 ' A' ' 173' ' ' ILE . 69.5 t -108.95 106.67 21.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.131 179.899 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.511 ' CZ ' ' CG1' ' A' ' 114' ' ' VAL . 61.4 t80 -99.83 117.42 34.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.864 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 21.2 t -116.56 135.67 56.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.107 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 114' ' ' VAL . . . . . 0.511 ' CG1' ' CZ ' ' A' ' 112' ' ' PHE . 34.1 m -124.55 165.38 21.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.123 179.904 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 78.6 52.46 5.08 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.48 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 21.2 mt -109.16 133.67 52.72 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.85 0.357 . . . . 0.0 110.932 -179.917 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 40.2 t -66.53 147.83 52.74 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.853 -179.92 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.9 mt-30 -40.86 -47.3 2.91 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.917 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 39.3 mtp180 -71.47 -37.78 71.3 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.901 -179.922 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 51.7 mt -67.27 -26.7 66.68 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.943 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -74.01 83.81 1.76 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.098 179.763 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -148.99 142.99 16.56 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.592 0.711 . . . . 0.0 110.904 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.7 -49.26 0.59 Allowed 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.69 2.26 . . . . 0.0 112.359 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 51.4 mt-10 -69.48 -42.28 75.04 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.887 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.479 ' CG1' ' CZ ' ' A' ' 131' ' ' TYR . 60.3 t -59.16 -46.15 92.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.128 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 68.0 mt -69.81 -40.49 75.91 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.918 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.514 ' HA ' HD12 ' A' ' 138' ' ' ILE . 15.3 tttt -61.83 -27.88 69.09 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.937 179.809 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 13.8 mtp85 -45.24 143.6 2.52 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.632 0.729 . . . . 0.0 110.857 179.98 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 1.23 4.61 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.656 2.237 . . . . 0.0 112.347 -179.997 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 7.1 tp10 -105.51 -35.55 7.42 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.931 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 131' ' ' TYR . . . . . 0.479 ' CZ ' ' CG1' ' A' ' 125' ' ' VAL . 38.0 m-85 -77.46 -75.11 0.22 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.911 -179.857 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 13.2 m-85 -116.23 -34.68 4.58 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.902 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -49.99 -23.9 5.93 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.527 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.424 ' HD3' ' C ' ' A' ' 134' ' ' LYS . 0.0 OUTLIER -56.03 -34.07 65.51 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.788 0.328 . . . . 0.0 110.913 -179.959 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 135' ' ' PHE . . . . . 0.563 ' CE1' ' HA ' ' A' ' 172' ' ' ALA . 19.4 m-85 -69.89 -47.06 64.02 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.875 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -174.12 177.28 46.42 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.502 -179.947 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 5.8 mmmt -74.57 110.25 8.71 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.747 0.308 . . . . 0.0 110.893 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.607 HG21 HG22 ' A' ' 141' ' ' VAL . 56.8 mt -75.64 143.53 13.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.126 179.924 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 19.8 t-160 -99.2 -58.73 1.87 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.864 179.903 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 140' ' ' LYS . . . . . 0.725 ' HD3' HG23 ' A' ' 142' ' ' VAL . 0.2 OUTLIER -127.78 141.9 51.45 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.869 179.984 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 141' ' ' VAL . . . . . 0.607 HG22 HG21 ' A' ' 138' ' ' ILE . 3.9 t -130.94 139.86 50.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.114 179.887 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.725 HG23 ' HD3' ' A' ' 140' ' ' LYS . 69.5 t -135.45 139.84 45.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.132 179.93 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 16.7 mm -112.13 114.71 47.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.143 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 1.6 t30 -99.94 127.46 46.13 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.897 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 12.0 p30 . . . . . 0 C--N 1.33 -0.276 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.872 -179.987 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 53.9 p . . . . . 0 C--O 1.23 0.056 0 CA-C-O 120.874 0.369 . . . . 0.0 110.861 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -122.32 152.59 39.96 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.109 179.907 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 87.5 p -124.89 176.43 6.63 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.894 -179.818 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -160.7 162.06 32.45 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.125 179.891 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 160' ' ' TYR . . . . . 0.483 ' CE2' ' CD1' ' A' ' 112' ' ' PHE . 16.5 m-85 -125.61 127.56 46.53 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.921 -179.825 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.41 HG22 HG13 ' A' ' 141' ' ' VAL . 66.7 t -121.75 140.27 46.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.117 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 4.7 m -114.21 115.71 27.89 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.185 -179.997 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 163' ' ' TYR . . . . . 0.638 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 29.1 m-85 -90.47 134.2 34.51 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.928 -179.904 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 66.4 mt -59.36 -42.63 88.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.119 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 19.0 mtm-85 -99.57 112.04 24.31 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.877 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 2.7 t -48.86 -57.59 6.17 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.896 -179.822 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 32.7 tt0 -42.93 -52.46 5.15 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.88 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -52.34 -50.6 62.0 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.883 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 169' ' ' ALA . . . . . 0.638 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -54.77 -64.02 0.97 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.106 179.915 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 170' ' ' LEU . . . . . 0.401 ' C ' ' O ' ' A' ' 169' ' ' ALA . 55.9 mt -37.15 -58.54 0.79 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.888 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 171' ' ' ARG . . . . . 0.432 ' HB3' ' NH1' ' A' ' 171' ' ' ARG . 10.6 mtp-105 -60.61 -46.04 91.75 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.846 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 172' ' ' ALA . . . . . 0.563 ' HA ' ' CE1' ' A' ' 135' ' ' PHE . . . -47.38 -32.89 5.33 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.072 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 173' ' ' ILE . . . . . 0.471 HD11 HG22 ' A' ' 111' ' ' VAL . 96.9 mt -82.85 -40.08 16.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.155 179.963 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 30.1 mt-30 -66.25 -23.28 66.38 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.893 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 1.8 t -93.9 -37.09 11.89 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.86 -179.927 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 176' ' ' VAL . . . . . 0.428 HG23 ' CZ ' ' A' ' 135' ' ' PHE . 9.0 t -70.18 -48.43 61.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.149 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 7.5 t30 -43.76 124.82 3.85 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.95 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 65.7 t30 70.62 52.03 0.32 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.898 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 54.5 t -134.12 135.34 54.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.123 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 83.4 t -86.96 120.57 36.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.119 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 181' ' ' VAL . . . . . 0.705 HG21 HD12 ' A' ' 186' ' ' LEU . 85.0 t -124.7 116.54 47.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.1 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 34.3 t70 58.52 36.52 25.29 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.87 179.899 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 84.35 -20.17 15.17 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.456 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 43.0 ttm-85 -107.23 133.4 51.86 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.897 0.379 . . . . 0.0 110.861 -179.859 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 30.0 m -80.27 133.29 35.97 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.104 -179.884 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 186' ' ' LEU . . . . . 0.705 HD12 HG21 ' A' ' 181' ' ' VAL . 27.4 mt -101.06 147.42 26.24 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.949 179.924 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -121.29 131.98 54.52 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.903 179.839 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -129.5 143.54 50.88 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.075 179.843 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 5.5 t -138.7 167.54 21.76 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.866 -179.785 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 190' ' ' LEU . . . . . 0.753 HD13 ' N ' ' A' ' 191' ' ' GLY . 2.0 tm? -132.61 128.9 38.13 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.925 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 191' ' ' GLY . . . . . 0.753 ' N ' HD13 ' A' ' 190' ' ' LEU . . . . . . . . 0 N--CA 1.451 -0.346 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.447 179.878 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.306 0 N-CA-C 112.51 -0.236 . . . . 0.0 112.51 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 16.1 m -92.51 99.31 12.07 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.885 0.374 . . . . 0.0 110.845 -179.727 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 8.5 t -67.28 92.48 0.28 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.815 -179.773 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 174.84 46.26 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.473 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 73.5 m -45.51 -58.36 3.44 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.892 0.377 . . . . 0.0 110.837 -179.699 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 3.7 m -86.14 88.92 7.68 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.851 -179.793 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -99.08 -78.35 1.38 Allowed Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.486 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -72.49 121.21 19.24 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.789 0.328 . . . . 0.0 111.156 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 8.2 t -174.09 171.6 3.54 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.81 -179.76 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.537 HG23 HG23 ' A' ' 105' ' ' VAL . 22.9 m -85.4 150.45 3.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.114 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 86.5 mtm-85 -85.2 109.61 18.44 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.822 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.537 HG23 HG23 ' A' ' 103' ' ' VAL . 44.7 t -121.74 122.28 66.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.125 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 95.6 t -90.66 106.69 17.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.094 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 14.0 mm100 -114.66 88.56 2.89 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.858 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 74.8 mttt -88.79 -41.13 12.7 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.898 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 64.9 t30 -85.32 44.94 1.13 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.857 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 19.9 tp -136.06 117.55 14.79 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.898 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 79.5 t -92.64 110.7 23.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.187 179.804 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.43 ' CE1' ' HB2' ' A' ' 158' ' ' SER . 53.4 t80 -109.52 107.0 16.95 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.892 -179.931 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 69.4 t -108.73 142.57 20.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.149 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 22.4 m -126.43 171.74 14.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.136 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 69.54 48.37 44.19 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.493 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 30.9 mt -112.69 125.48 54.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.789 0.328 . . . . 0.0 110.916 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 117' ' ' SER . . . . . 0.423 ' O ' ' N ' ' A' ' 120' ' ' LEU . 26.9 t -71.79 141.4 49.69 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.895 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 36.5 tp60 -38.38 -32.33 0.07 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.9 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 15.7 mmt180 -70.79 -47.51 59.15 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.845 -179.911 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 120' ' ' LEU . . . . . 0.423 ' N ' ' O ' ' A' ' 117' ' ' SER . 58.7 mt -69.46 -32.74 71.85 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.913 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -64.46 83.79 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.14 179.779 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -148.66 144.06 17.96 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.59 0.709 . . . . 0.0 110.911 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.81 -45.55 1.52 Allowed 'Trans proline' 0 C--N 1.341 0.133 0 C-N-CA 122.684 2.256 . . . . 0.0 112.287 -179.904 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -71.48 -39.52 70.85 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.927 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.609 HG13 ' CZ ' ' A' ' 131' ' ' TYR . 74.6 t -63.21 -45.76 97.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.129 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.477 HD22 ' CE1' ' A' ' 132' ' ' PHE . 95.6 mt -74.47 -34.91 63.26 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.889 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 53.0 mttt -64.61 -32.25 73.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.882 179.85 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 20.0 mmt180 -46.25 143.97 3.41 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.631 0.729 . . . . 0.0 110.85 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -4.21 13.56 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.665 2.243 . . . . 0.0 112.35 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 56.6 tt0 -100.67 -10.64 20.7 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.892 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 131' ' ' TYR . . . . . 0.609 ' CZ ' HG13 ' A' ' 125' ' ' VAL . 43.6 m-85 -103.17 -74.98 0.62 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.91 -179.864 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.477 ' CE1' HD22 ' A' ' 126' ' ' LEU . 28.2 m-85 -118.65 -40.62 2.87 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.898 179.988 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -47.93 -19.02 0.85 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.505 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.416 ' HD2' ' CD2' ' A' ' 135' ' ' PHE . 0.0 OUTLIER -51.52 -40.31 59.37 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.822 0.344 . . . . 0.0 110.914 -179.995 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 135' ' ' PHE . . . . . 0.485 ' CE1' ' HA ' ' A' ' 172' ' ' ALA . 47.8 m-85 -67.16 -44.06 80.68 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.896 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 176.94 169.66 38.47 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.544 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -60.63 136.76 58.16 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.745 0.307 . . . . 0.0 110.922 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.666 HG21 HG22 ' A' ' 141' ' ' VAL . 61.1 mt -96.64 148.82 5.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.114 179.868 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 56.4 t60 -101.02 -48.74 4.33 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.854 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 22.6 ttmt -134.98 140.54 45.77 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.879 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 141' ' ' VAL . . . . . 0.666 HG22 HG21 ' A' ' 138' ' ' ILE . 15.9 t -132.73 112.75 19.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.159 179.814 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 93.8 t -116.77 137.73 49.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.116 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 4.1 mm -114.0 123.68 69.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.106 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 8.9 t-20 -113.03 114.02 26.29 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.901 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 6.2 p-10 -136.43 171.77 13.99 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.888 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 1.2 t -58.6 132.0 52.49 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.856 -179.877 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 93.5 m -81.07 -53.55 6.31 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.139 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 54.9 m -93.06 122.86 35.86 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.856 -179.852 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 5.8 t80 -108.55 120.05 41.32 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.898 -179.906 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -109.04 -52.91 2.71 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.068 -0.514 . . . . 0.0 111.072 179.882 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 109.09 36.83 2.08 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.469 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 1.8 m -102.35 -55.45 2.46 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.818 0.342 . . . . 0.0 110.877 -179.767 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 84.4 mt-30 -120.15 174.01 6.75 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.922 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . -108.41 83.25 0.33 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.503 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.8 177.25 5.79 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.698 2.265 . . . . 0.0 112.328 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 50.8 m -128.6 154.18 46.48 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.894 -179.889 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -114.41 166.46 11.66 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.103 179.905 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 158' ' ' SER . . . . . 0.43 ' HB2' ' CE1' ' A' ' 112' ' ' PHE . 4.8 p -134.93 150.99 50.48 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.865 -179.781 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -122.8 145.52 48.35 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.077 179.879 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 44.1 m-85 -119.42 107.16 13.0 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.945 -179.833 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 37.9 t -101.19 141.25 18.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.097 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 63.0 m -111.22 123.33 49.98 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.093 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 163' ' ' TYR . . . . . 0.825 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 30.5 m-85 -105.3 121.74 44.5 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.937 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 74.2 mt -49.63 -37.14 11.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.137 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 80.3 mmt-85 -107.11 114.75 29.0 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.898 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 69.0 m -51.68 -55.17 21.0 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.883 -179.803 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 24.8 mm-40 -42.96 -54.04 4.44 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.908 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -54.71 -46.11 74.13 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.871 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 169' ' ' ALA . . . . . 0.825 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -60.84 -64.07 1.08 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.098 179.948 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 36.6 mt -38.28 -63.62 0.48 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.922 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 86.5 mtt180 -52.8 -51.85 59.19 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.873 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 172' ' ' ALA . . . . . 0.695 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -45.06 -32.88 1.88 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.096 179.904 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 82.2 mt -81.72 -35.28 13.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.091 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 33.4 mt-30 -64.69 -27.65 69.06 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.906 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 175' ' ' CYS . . . . . 0.441 ' O ' ' CG2' ' A' ' 179' ' ' VAL . 2.3 m -93.82 -34.29 13.22 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.87 -179.927 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 176' ' ' VAL . . . . . 0.695 HG23 ' O ' ' A' ' 172' ' ' ALA . 10.8 t -63.29 -33.74 62.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.147 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 1.7 t30 -62.55 140.99 58.65 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.89 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 9.1 t-20 62.33 37.62 13.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.846 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 179' ' ' VAL . . . . . 0.441 ' CG2' ' O ' ' A' ' 175' ' ' CYS . 75.0 t -118.57 133.15 66.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.141 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 59.3 t -89.03 128.04 41.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.169 179.914 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 181' ' ' VAL . . . . . 0.485 HG21 HD12 ' A' ' 186' ' ' LEU . 50.7 t -135.86 114.56 15.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.069 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 5.8 t70 63.5 28.53 15.34 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.901 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 89.21 -14.41 60.91 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.499 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 77.6 mtt85 -108.77 126.0 52.55 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.903 0.383 . . . . 0.0 110.805 -179.837 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 10.9 m -76.74 106.48 8.42 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.16 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 186' ' ' LEU . . . . . 0.485 HD12 HG21 ' A' ' 181' ' ' VAL . 80.3 mt -70.24 157.05 38.39 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.907 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 16.2 tptm -135.65 115.01 12.53 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.939 179.82 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -110.13 142.96 40.9 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.083 179.88 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 86.1 p -156.71 165.39 36.37 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.873 -179.776 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 190' ' ' LEU . . . . . . . . . . . . . 4.3 pp -126.62 154.98 43.25 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.938 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 103.71 26.17 6.92 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.45 179.885 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 192' ' ' THR . . . . . . . . . . . . . 1.9 m -102.61 150.66 23.2 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.863 0.363 . . . . 0.0 111.135 -179.862 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 193' ' ' THR . . . . . . . . . . . . . 76.9 p -97.75 153.4 18.29 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.145 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 1.5 mmmm -104.63 -58.96 1.81 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.898 179.905 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 195' ' ' TYR . . . . . . . . . . . . . 4.9 p90 -103.51 172.7 6.66 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.943 -179.927 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 196' ' ' CYS . . . . . . . . . . . . . 9.5 t -105.74 120.01 40.61 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.92 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 9.9 t -47.73 -55.12 10.23 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.868 -179.754 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 198' ' ' TYR . . . . . 0.441 ' CD1' ' C ' ' A' ' 198' ' ' TYR . 4.8 t80 -42.51 -55.63 3.4 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.889 -179.885 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 28.9 t -38.63 122.37 1.13 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.862 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 200' ' ' GLY . . . . . 0.4 ' HA3' ' C ' ' A' ' 201' ' ' PRO . . . 171.99 -69.26 0.12 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.477 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 201' ' ' PRO . . . . . 0.4 ' C ' ' HA3' ' A' ' 200' ' ' GLY . 54.1 Cg_endo -69.75 179.08 23.26 Favored 'Cis proline' 0 C--N 1.342 0.188 0 C-N-CA 122.686 -1.797 . . . . 0.0 112.345 0.051 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 202' ' ' SER . . . . . 0.405 ' O ' ' C ' ' A' ' 203' ' ' SER . 3.7 t -160.28 133.81 6.94 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.813 -179.877 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 203' ' ' SER . . . . . 0.405 ' C ' ' O ' ' A' ' 202' ' ' SER . 96.5 p 37.2 40.16 0.17 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.872 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.261 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.458 -179.969 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.36 0 N-CA-C 112.517 -0.233 . . . . 0.0 112.517 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 31.0 m -77.38 86.46 3.77 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.895 0.378 . . . . 0.0 110.878 -179.73 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 7.5 t -75.49 168.47 19.95 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.87 -179.816 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -72.96 104.49 1.56 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.781 -0.724 . . . . 0.0 112.492 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 58.3 m -130.0 121.8 27.22 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.836 0.35 . . . . 0.0 110.858 -179.735 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 24.8 p -151.42 123.55 8.21 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.863 -179.808 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 128.38 -109.68 1.04 Allowed Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.46 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -49.42 141.68 8.72 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.79 0.329 . . . . 0.0 111.122 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 1.3 t -71.31 152.42 43.26 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.86 -179.787 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.403 HG22 ' H ' ' A' ' 103' ' ' VAL . 1.4 m -66.33 104.26 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.064 179.94 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 7.6 ptp180 -119.32 147.09 44.71 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.886 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.501 ' O ' HG13 ' A' ' 105' ' ' VAL . 12.7 p -116.11 120.94 66.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.154 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 21.2 t -119.45 138.85 48.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.076 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 7.1 mm100 -43.27 146.21 0.48 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.921 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 77.7 mttt -84.34 54.23 2.91 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.871 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 5.3 p-10 -125.3 39.31 4.0 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.902 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 110' ' ' LEU . . . . . 0.407 HD11 ' HD1' ' A' ' 160' ' ' TYR . 12.3 tp -140.95 131.04 24.7 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.943 179.94 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.775 HG22 HD11 ' A' ' 173' ' ' ILE . 47.0 t -113.94 123.33 69.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.148 179.865 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.663 ' CZ ' ' CG1' ' A' ' 114' ' ' VAL . 37.6 t80 -111.17 106.56 15.61 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.891 -179.964 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.514 HG22 ' HB2' ' A' ' 188' ' ' ALA . 20.9 t -102.82 143.4 15.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.173 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.663 ' CG1' ' CZ ' ' A' ' 112' ' ' PHE . 33.3 m -131.82 169.8 21.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.106 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 73.75 54.51 6.52 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.502 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 60.9 mt -117.31 129.96 56.23 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.84 0.352 . . . . 0.0 110.932 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 3.3 m -65.56 152.76 43.33 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.868 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 13.1 pt20 -50.9 -20.86 1.45 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.949 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 36.5 mtm180 -92.56 -42.75 9.51 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.88 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 62.8 mt -65.94 -34.74 78.8 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.948 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -62.54 85.29 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.075 179.842 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -148.48 144.09 18.13 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.626 0.727 . . . . 0.0 110.843 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.84 -42.17 3.55 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.677 2.251 . . . . 0.0 112.273 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -71.76 -44.4 64.12 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.9 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.408 HG13 ' CZ ' ' A' ' 131' ' ' TYR . 28.7 t -60.86 -43.43 95.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.119 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.417 HD12 HD11 ' A' ' 143' ' ' ILE . 84.7 mt -68.39 -39.94 81.52 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.906 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.425 ' O ' ' C ' ' A' ' 128' ' ' ARG . 6.9 tmtt? -65.23 -37.92 88.76 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.841 179.866 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 128' ' ' ARG . . . . . 0.425 ' C ' ' O ' ' A' ' 127' ' ' LYS . 21.1 mmt180 -36.39 144.45 0.27 Allowed Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.628 0.728 . . . . 0.0 110.9 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.8 -5.17 15.59 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.679 2.253 . . . . 0.0 112.372 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 130' ' ' GLU . . . . . 0.415 ' CG ' ' O ' ' A' ' 130' ' ' GLU . 20.5 tt0 -100.88 10.29 41.3 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.898 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 131' ' ' TYR . . . . . 0.408 ' CZ ' HG13 ' A' ' 125' ' ' VAL . 47.1 m-85 -127.54 -74.18 0.59 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.928 -179.853 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 69.7 m-85 -124.12 -11.44 7.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.862 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -71.12 -11.28 70.35 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.502 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -80.66 -30.79 36.54 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.794 0.331 . . . . 0.0 110.878 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 135' ' ' PHE . . . . . . . . . . . . . 22.9 m-85 -72.31 -26.06 61.8 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.827 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 167.41 -172.57 42.38 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.494 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 7.4 mtpm? -86.26 136.75 33.05 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.754 0.311 . . . . 0.0 110.917 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.74 HG21 HG22 ' A' ' 141' ' ' VAL . 82.5 mt -100.04 138.6 23.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.127 179.865 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -96.09 -46.51 6.45 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.848 179.878 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -141.04 141.05 34.34 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.916 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 141' ' ' VAL . . . . . 0.74 HG22 HG21 ' A' ' 138' ' ' ILE . 17.4 t -134.44 123.61 43.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.087 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 99.0 t -134.2 139.88 47.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.136 179.904 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 143' ' ' ILE . . . . . 0.417 HD11 HD12 ' A' ' 126' ' ' LEU . 44.8 mm -96.89 140.41 17.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.146 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 3.7 m120 -129.09 115.87 18.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.89 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 2.7 m120 -100.8 133.48 45.22 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.884 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 46.1 m -94.4 158.82 15.39 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.88 -179.862 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 66.2 p -93.19 143.96 25.75 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.11 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 23.3 t -72.67 143.93 47.93 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.806 -179.825 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 31.2 t80 -118.07 147.79 42.92 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.945 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -56.22 146.98 21.88 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.069 179.896 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 78.98 -14.82 12.14 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.455 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 16.3 m -106.6 132.31 52.75 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.824 0.345 . . . . 0.0 110.847 -179.745 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 27.0 mp0 -116.92 138.81 51.29 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.901 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 74.49 83.11 0.38 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.509 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.82 162.53 41.74 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.651 2.234 . . . . 0.0 112.302 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 94.0 p -126.93 134.98 50.31 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.852 -179.825 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -98.31 145.69 26.42 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.094 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 80.5 p -115.15 173.65 6.39 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.87 -179.762 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -153.68 140.79 19.4 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.119 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 160' ' ' TYR . . . . . 0.407 ' HD1' HD11 ' A' ' 110' ' ' LEU . 89.0 m-85 -111.38 123.47 50.28 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.933 -179.883 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 9.7 t -123.53 139.05 51.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.092 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 58.0 m -108.41 128.6 54.92 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.117 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 163' ' ' TYR . . . . . 0.547 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 25.3 m-85 -108.45 138.65 44.4 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.891 -179.892 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 50.7 mt -64.32 -38.11 81.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.123 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 32.6 mtm180 -103.85 114.14 28.17 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.889 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 46.9 m -51.9 -51.91 53.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.846 -179.762 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -50.91 -57.57 8.17 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.899 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -46.84 -45.58 20.29 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.888 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 169' ' ' ALA . . . . . 0.547 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -61.18 -54.49 43.72 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.12 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 87.5 mt -44.2 -63.75 0.81 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.898 -179.915 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 10.5 mtp180 -54.09 -46.66 72.12 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.887 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 172' ' ' ALA . . . . . 0.681 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -51.04 -33.26 24.59 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.121 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 173' ' ' ILE . . . . . 0.775 HD11 HG22 ' A' ' 111' ' ' VAL . 77.5 mt -78.26 -39.08 24.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.084 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 3.5 mp0 -68.47 -24.3 64.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.916 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 91.9 m -93.77 -27.89 16.23 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.862 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 176' ' ' VAL . . . . . 0.681 HG23 ' O ' ' A' ' 172' ' ' ALA . 10.6 t -74.23 -30.78 27.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.135 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -66.82 146.13 54.75 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.909 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 35.6 t30 57.83 46.31 17.14 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.88 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 91.5 t -124.91 133.42 69.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.117 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 88.2 t -96.52 114.55 33.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.13 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 96.4 t -123.29 106.22 17.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.188 179.885 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 23.8 t0 58.0 39.8 26.1 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.88 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 73.53 37.36 53.13 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.509 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 3.4 mmp_? -140.99 132.01 26.19 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.919 0.39 . . . . 0.0 110.821 -179.822 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 17.1 m -87.99 96.03 10.35 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.171 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 59.6 mt -69.94 124.32 23.75 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.869 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 17.3 tptp -123.53 113.11 18.29 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.851 179.845 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 188' ' ' ALA . . . . . 0.514 ' HB2' HG22 ' A' ' 113' ' ' VAL . . . -111.95 148.18 34.3 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.105 179.821 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 8.6 t -150.83 170.9 18.15 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.902 -179.789 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 190' ' ' LEU . . . . . 0.879 HD23 ' N ' ' A' ' 191' ' ' GLY . 5.8 tt -131.17 141.54 50.09 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.945 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 191' ' ' GLY . . . . . 0.879 ' N ' HD23 ' A' ' 190' ' ' LEU . . . 102.27 -24.21 31.83 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.505 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 192' ' ' THR . . . . . . . . . . . . . 27.6 p -88.37 117.15 27.09 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.864 0.364 . . . . 0.0 111.168 -179.873 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 193' ' ' THR . . . . . . . . . . . . . 33.5 p -118.68 169.03 10.16 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.156 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 15.3 ttpt -66.43 118.42 10.05 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.933 179.881 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 195' ' ' TYR . . . . . . . . . . . . . 88.3 t80 -77.27 127.92 33.44 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.904 -179.911 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 196' ' ' CYS . . . . . . . . . . . . . 4.9 t -174.27 137.97 0.55 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.899 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 31.7 t -43.4 152.46 0.13 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.849 -179.742 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 198' ' ' TYR . . . . . . . . . . . . . 7.9 p90 -103.14 148.28 25.96 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.902 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 54.5 m -98.55 111.76 24.02 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.912 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . 80.59 174.92 48.73 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.455 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 201' ' ' PRO . . . . . 0.437 ' O ' ' C ' ' A' ' 202' ' ' SER . 53.8 Cg_endo -69.8 164.7 78.68 Favored 'Cis proline' 0 C--N 1.342 0.185 0 C-N-CA 122.672 -1.803 . . . . 0.0 112.354 0.097 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 202' ' ' SER . . . . . 0.437 ' C ' ' O ' ' A' ' 201' ' ' PRO . 6.0 t -35.16 107.86 0.06 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.858 -179.825 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 73.2 p -100.87 137.93 38.6 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.848 -179.814 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.347 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.505 -179.967 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.344 0 N-CA-C 112.481 -0.248 . . . . 0.0 112.481 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 7.8 t -152.82 139.13 18.46 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.869 0.366 . . . . 0.0 110.868 -179.738 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 18.7 m -118.99 175.47 5.75 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.824 -179.841 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 169.04 114.85 0.31 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.492 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.6 t -155.98 127.77 7.38 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.88 0.371 . . . . 0.0 110.902 -179.73 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 19.3 t -79.59 167.72 20.36 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.839 -179.792 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -143.77 56.58 0.55 Allowed Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.469 -179.955 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -87.04 144.11 27.04 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.821 0.343 . . . . 0.0 111.091 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 2.8 t -72.5 -46.0 56.79 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.888 -179.806 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -94.34 140.7 16.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.081 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 17.2 mtt180 -110.19 105.35 14.39 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.885 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 93.7 t -115.74 141.24 33.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.095 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 34.0 m -90.16 148.57 4.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.127 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 10.3 tt0 -156.66 122.08 4.73 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.932 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.502 ' HB3' HD21 ' A' ' 170' ' ' LEU . 3.3 mppt? -103.98 -27.37 12.19 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.953 179.929 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 18.9 t-20 -88.25 42.31 1.06 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.908 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 13.8 tp -143.42 117.55 9.51 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.941 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 59.1 t -96.79 118.61 43.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.108 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.654 ' CD1' ' CE2' ' A' ' 160' ' ' TYR . 45.3 t80 -119.29 111.61 18.41 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.889 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.534 HG22 ' HB2' ' A' ' 188' ' ' ALA . 23.1 t -107.01 140.78 24.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.098 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 5.1 m -120.06 169.38 11.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.09 179.939 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 67.26 53.89 23.28 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.505 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 38.3 mt -112.81 127.17 56.09 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.834 0.35 . . . . 0.0 110.915 -179.92 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 117' ' ' SER . . . . . 0.495 ' O ' ' N ' ' A' ' 120' ' ' LEU . 18.8 t -65.64 125.91 26.74 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.874 -179.902 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 118' ' ' GLN . . . . . 0.438 ' C ' ' O ' ' A' ' 117' ' ' SER . 13.3 mm100 -34.93 -32.46 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.882 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.494 ' N ' ' O ' ' A' ' 117' ' ' SER . 24.7 ttm180 -72.07 -48.14 46.4 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.863 -179.916 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 120' ' ' LEU . . . . . 0.495 ' N ' ' O ' ' A' ' 117' ' ' SER . 84.1 mt -70.2 -35.56 74.0 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.951 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -61.68 87.17 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.062 179.79 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 122' ' ' ASP . . . . . 0.431 ' HB2' ' CG2' ' A' ' 125' ' ' VAL . 5.9 m-20 -147.59 152.67 42.14 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.609 0.719 . . . . 0.0 110.847 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 123' ' ' PRO . . . . . 0.466 ' HA ' HG11 ' A' ' 141' ' ' VAL . 53.8 Cg_endo -69.72 -50.18 0.49 Allowed 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.674 2.25 . . . . 0.0 112.376 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 25.3 mt-10 -71.49 -42.34 68.19 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.911 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.486 HG12 ' CE2' ' A' ' 131' ' ' TYR . 48.2 t -57.08 -53.59 41.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.116 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 87.7 mt -68.25 -30.82 69.94 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.941 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 13.8 mmtt -64.95 -39.31 93.3 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.903 179.807 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 32.5 mtt180 -39.75 143.93 0.54 Allowed Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.648 0.737 . . . . 0.0 110.874 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 -1.15 7.99 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.652 2.235 . . . . 0.0 112.354 -179.983 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -101.51 -24.54 14.14 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.864 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 131' ' ' TYR . . . . . 0.486 ' CE2' HG12 ' A' ' 125' ' ' VAL . 43.9 m-85 -87.35 -74.67 0.43 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.933 -179.868 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 16.0 m-85 -118.81 -40.51 2.86 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.858 -179.983 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -44.9 -20.89 0.26 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.45 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.421 ' HD3' ' C ' ' A' ' 134' ' ' LYS . 0.0 OUTLIER -54.52 -37.55 65.5 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.834 0.35 . . . . 0.0 110.919 -179.988 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 135' ' ' PHE . . . . . . . . . . . . . 22.2 m-85 -66.23 -44.12 84.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.865 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -176.31 -153.55 10.71 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.447 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 38.7 mtmt -97.42 108.31 21.01 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.779 0.323 . . . . 0.0 110.937 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.541 HG23 HG13 ' A' ' 161' ' ' VAL . 91.6 mt -69.7 142.88 15.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.156 179.883 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 3.0 t-160 -102.16 -56.37 2.28 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.885 179.877 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 33.4 tttt -119.01 151.48 38.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.905 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 141' ' ' VAL . . . . . 0.467 HG22 HG21 ' A' ' 138' ' ' ILE . 41.4 t -143.05 108.85 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.155 179.849 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 96.9 t -115.82 126.94 73.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.158 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 26.7 mm -106.3 109.28 27.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.111 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 144' ' ' ASN . . . . . 0.485 ' O ' ' HB1' ' A' ' 157' ' ' ALA . 3.2 t-20 -96.06 137.14 35.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.881 179.934 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 1.5 p30 -134.45 159.06 42.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.842 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 23.0 t -96.36 163.73 12.94 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.881 -179.889 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 64.6 p -125.07 91.3 3.4 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.136 -179.948 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 1.3 t -115.86 155.62 27.6 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.83 -179.832 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 34.8 t80 -72.73 153.35 41.19 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.939 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -50.04 167.45 0.05 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.125 179.891 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 70.13 38.01 72.77 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.508 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 26.0 t -108.52 170.16 8.2 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.837 0.351 . . . . 0.0 110.861 -179.712 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 43.5 mt-30 -83.04 38.37 0.59 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.927 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 43.8 83.23 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.541 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.75 161.99 43.81 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.688 2.259 . . . . 0.0 112.334 -179.895 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 23.2 m -99.66 164.89 11.87 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.856 -179.836 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 157' ' ' ALA . . . . . 0.485 ' HB1' ' O ' ' A' ' 144' ' ' ASN . . . -119.74 171.99 8.01 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.108 179.884 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 67.7 p -123.31 169.64 11.11 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.875 -179.796 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -147.64 149.76 33.11 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.108 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 160' ' ' TYR . . . . . 0.654 ' CE2' ' CD1' ' A' ' 112' ' ' PHE . 43.4 m-85 -124.26 124.75 43.1 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.901 -179.847 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.541 HG13 HG23 ' A' ' 138' ' ' ILE . 57.4 t -120.39 125.32 74.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.174 179.883 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 48.7 m -93.47 131.28 38.84 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.143 -179.951 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 163' ' ' TYR . . . . . 0.469 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 9.5 m-85 -107.35 147.15 30.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.892 -179.89 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 48.2 mt -75.29 -47.53 34.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.128 179.916 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 35.1 mtp180 -91.54 114.23 26.71 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.856 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 75.5 m -49.35 -59.4 3.74 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.867 -179.814 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 55.8 mt-10 -47.96 -47.44 32.71 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.908 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -55.34 -45.85 76.39 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.881 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 169' ' ' ALA . . . . . 0.469 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -56.93 -56.63 19.17 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.1 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 170' ' ' LEU . . . . . 0.502 HD21 ' HB3' ' A' ' 108' ' ' LYS . 56.0 mt -47.26 -59.86 2.88 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.891 -179.941 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 1.9 mpt_? -56.68 -42.51 79.16 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.866 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 172' ' ' ALA . . . . . 0.737 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -55.24 -32.09 62.02 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.101 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 76.7 mt -79.78 -37.99 18.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.112 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 8.6 mm100 -64.66 -28.67 69.77 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.862 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 19.8 t -93.74 -28.95 15.64 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.852 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 176' ' ' VAL . . . . . 0.737 HG23 ' O ' ' A' ' 172' ' ' ALA . 9.9 t -71.7 -28.07 29.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.124 -179.978 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 1.8 t30 -70.76 141.61 51.45 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.895 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 25.7 t-20 61.35 49.33 5.41 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.923 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 179' ' ' VAL . . . . . 0.425 HG12 HG23 ' A' ' 181' ' ' VAL . 79.5 t -117.0 133.66 63.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.131 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 58.7 t -98.16 105.97 18.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.14 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 181' ' ' VAL . . . . . 0.593 HG21 HD12 ' A' ' 186' ' ' LEU . 56.3 t -115.73 131.2 68.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.189 179.862 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 44.96 29.05 0.42 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.856 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 80.39 31.46 37.52 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.737 -0.745 . . . . 0.0 112.471 -179.942 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 13.2 ttm180 -134.9 136.14 42.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.855 0.359 . . . . 0.0 110.888 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 26.5 m -82.69 99.51 9.66 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.162 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 186' ' ' LEU . . . . . 0.593 HD12 HG21 ' A' ' 181' ' ' VAL . 62.9 mt -84.29 140.48 31.61 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.942 179.957 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 9.4 ttpp -135.19 146.83 49.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.877 179.828 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 188' ' ' ALA . . . . . 0.534 ' HB2' HG22 ' A' ' 113' ' ' VAL . . . -134.29 155.47 50.14 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.075 179.842 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 8.8 t -155.59 164.18 38.98 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.835 -179.807 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 190' ' ' LEU . . . . . 0.489 ' O ' HD12 ' A' ' 190' ' ' LEU . 4.7 pp -130.07 147.57 51.83 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.956 179.943 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 107.04 26.88 5.58 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.533 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 192' ' ' THR . . . . . . . . . . . . . 24.3 m -88.69 137.27 32.47 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.902 0.382 . . . . 0.0 111.087 -179.835 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 193' ' ' THR . . . . . . . . . . . . . 26.4 m -83.32 137.18 34.09 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.141 179.993 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 7.0 tmtm? -109.67 125.77 52.97 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.926 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 195' ' ' TYR . . . . . . . . . . . . . 35.3 t80 -62.97 88.88 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.885 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 196' ' ' CYS . . . . . . . . . . . . . 91.0 m -57.33 152.48 14.09 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.897 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 5.0 t -121.66 93.81 4.12 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.837 -179.737 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 198' ' ' TYR . . . . . . . . . . . . . 34.0 t80 -69.5 131.15 44.26 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.938 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 25.9 m -107.03 -66.4 1.02 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.869 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . 171.68 -163.96 36.63 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.535 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 201' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 129.23 14.06 Favored 'Cis proline' 0 C--N 1.342 0.193 0 C-N-CA 122.645 -1.815 . . . . 0.0 112.321 0.108 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 202' ' ' SER . . . . . . . . . . . . . 47.8 t -87.04 145.82 26.33 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.836 -179.848 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 88.5 p -76.35 135.27 39.53 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.879 -179.824 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.345 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.497 -179.967 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.362 0 N-CA-C 112.487 -0.245 . . . . 0.0 112.487 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 48.7 m -73.01 87.57 1.35 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.86 0.362 . . . . 0.0 110.85 -179.73 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 21.7 t -140.79 143.7 35.02 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.874 -179.839 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -116.62 76.53 0.28 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.458 -179.949 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 87.9 p -155.42 139.83 16.78 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.874 0.368 . . . . 0.0 110.824 -179.708 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 32.3 t -82.51 158.61 23.1 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.856 -179.835 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -144.05 71.43 0.38 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.534 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -91.2 155.26 18.72 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.781 0.324 . . . . 0.0 111.131 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 17.1 m -114.49 134.93 54.65 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.876 -179.778 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 74.9 t -109.03 116.61 52.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.126 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 85.3 mtt180 -109.95 137.88 47.11 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.896 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 4.6 m -76.01 122.96 31.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.14 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 106' ' ' VAL . . . . . 0.451 HG12 ' HG2' ' A' ' 107' ' ' GLN . 52.5 t -109.7 101.79 13.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.131 179.905 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.451 ' HG2' HG12 ' A' ' 106' ' ' VAL . 26.8 pt20 34.43 42.14 0.06 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.924 179.982 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.408 ' HB3' HD13 ' A' ' 190' ' ' LEU . 64.9 mttt -86.57 51.25 2.18 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.909 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 12.0 p-10 -112.41 27.54 9.56 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.91 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 110' ' ' LEU . . . . . 0.472 HD11 ' HB3' ' A' ' 160' ' ' TYR . 15.3 tp -109.27 121.7 45.74 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.878 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 89.6 t -95.58 114.12 31.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.112 179.819 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.638 ' CE2' ' CG1' ' A' ' 114' ' ' VAL . 61.1 t80 -106.86 99.25 8.83 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.901 179.98 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.663 HG22 ' HB2' ' A' ' 188' ' ' ALA . 54.3 t -98.94 125.36 52.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.149 179.997 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.638 ' CG1' ' CE2' ' A' ' 112' ' ' PHE . 12.0 m -118.89 168.88 10.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.126 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 77.39 39.52 26.02 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.505 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 32.5 mt -105.92 137.9 43.02 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.822 0.344 . . . . 0.0 110.89 -179.909 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 78.6 p -76.58 148.14 37.2 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.842 -179.941 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 34.5 mm-40 -42.2 -34.96 0.84 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.898 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 33.0 mtt180 -69.01 -47.47 65.39 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.872 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 120' ' ' LEU . . . . . 0.865 HD21 ' OD2' ' A' ' 182' ' ' ASP . 85.0 mt -71.78 -24.68 61.79 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.928 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -71.29 83.49 0.76 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.105 179.807 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 19.6 m-20 -148.95 144.38 18.07 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.619 0.723 . . . . 0.0 110.845 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.8 -45.67 1.48 Allowed 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.662 2.242 . . . . 0.0 112.38 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 19.9 mt-10 -73.19 -42.6 62.51 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.885 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.414 ' O ' ' CD1' ' A' ' 131' ' ' TYR . 56.4 t -59.04 -46.3 91.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.157 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 74.1 mt -68.69 -37.56 79.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.959 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 12.8 ttmm -68.0 -35.77 78.87 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.9 179.804 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 66.4 mtt-85 -44.89 147.91 1.05 Allowed Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.59 0.709 . . . . 0.0 110.882 180.0 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.71 -3.19 11.49 Favored 'Trans proline' 0 N--CA 1.465 -0.163 0 C-N-CA 122.711 2.274 . . . . 0.0 112.367 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -97.93 6.39 47.77 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.897 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 131' ' ' TYR . . . . . 0.414 ' CD1' ' O ' ' A' ' 125' ' ' VAL . 63.0 m-85 -131.32 -73.84 0.53 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.938 -179.858 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 71.0 m-85 -127.06 -6.04 6.1 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.901 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -70.9 -18.92 76.57 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.515 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 11.2 ptpt -88.72 -27.25 21.33 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.857 0.36 . . . . 0.0 110.893 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 135' ' ' PHE . . . . . . . . . . . . . 27.9 m-85 -63.97 -43.65 95.11 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.85 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -177.43 167.55 38.69 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.482 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 27.1 mtmm -67.06 120.06 13.05 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.728 0.299 . . . . 0.0 110.87 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.458 HG12 ' CG1' ' A' ' 161' ' ' VAL . 83.3 mt -95.12 146.43 6.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.074 179.892 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 4.2 t60 -107.13 -59.94 1.75 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.843 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 27.5 ttpp -125.53 145.63 50.02 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.913 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 21.3 t -130.19 132.79 64.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.129 179.847 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 3.5 t -125.96 140.73 47.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.13 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 23.8 mm -119.4 121.66 67.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.162 179.907 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 4.2 m120 -116.57 105.58 12.61 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.907 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 19.4 p30 -92.03 165.83 12.98 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.878 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 25.2 p -68.43 120.08 13.95 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.882 -179.861 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 62.4 m -78.96 -58.85 3.03 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.168 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 36.9 t -76.34 128.09 34.17 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.894 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 50.0 m-85 -83.78 126.63 33.11 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.904 -179.856 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -85.25 -68.23 0.74 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.119 179.862 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 103.23 -19.6 45.44 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.497 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 57.6 m -109.47 -58.79 1.99 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.832 0.349 . . . . 0.0 110.834 -179.721 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 6.3 pt20 -88.46 152.48 21.86 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.906 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . -69.34 146.12 43.64 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.502 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 150.49 68.2 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.71 2.273 . . . . 0.0 112.32 -179.892 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 19.7 m -131.55 105.93 7.87 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.868 -179.849 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -84.38 167.18 16.74 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.107 179.902 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 95.8 p -142.51 162.53 35.22 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.869 -179.765 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -145.88 141.88 28.26 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.116 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 160' ' ' TYR . . . . . 0.472 ' HB3' HD11 ' A' ' 110' ' ' LEU . 15.2 m-85 -115.19 112.6 22.74 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.95 -179.88 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.458 ' CG1' HG12 ' A' ' 138' ' ' ILE . 94.6 t -106.64 133.69 50.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.146 179.911 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 9.1 m -102.66 125.61 49.45 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.159 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 163' ' ' TYR . . . . . 0.489 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 13.8 m-85 -103.53 136.5 43.13 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.909 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 89.3 mt -63.85 -49.69 80.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.108 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 28.3 mmt180 -100.72 119.16 38.2 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.894 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 4.1 m -50.09 -57.61 7.3 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.848 -179.787 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -41.18 -61.48 1.0 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.886 -179.933 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 31.3 m-20 -46.65 -46.15 19.69 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.857 179.998 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 169' ' ' ALA . . . . . 0.489 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -57.86 -55.48 34.41 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.059 179.983 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 71.7 mt -45.0 -59.72 2.44 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.917 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 13.9 mtm180 -53.94 -53.18 56.33 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.84 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 172' ' ' ALA . . . . . 0.521 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -45.03 -34.83 2.67 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.118 179.945 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 96.4 mt -81.67 -32.15 11.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.122 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 73.0 mt-30 -66.76 -27.33 67.51 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.874 -179.989 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 1.8 t -93.81 -35.88 12.53 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.867 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 176' ' ' VAL . . . . . 0.521 HG23 ' O ' ' A' ' 172' ' ' ALA . 10.7 t -64.84 -45.84 93.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.113 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -51.79 144.98 10.27 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.895 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 41.6 m-20 57.61 53.43 7.28 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.882 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 179' ' ' VAL . . . . . 0.675 ' O ' HG23 ' A' ' 185' ' ' THR . 78.6 t -134.59 138.57 49.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.168 179.879 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 66.6 t -92.49 124.18 44.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.123 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 60.0 t -135.37 126.89 45.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.103 179.933 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 182' ' ' ASP . . . . . 0.865 ' OD2' HD21 ' A' ' 120' ' ' LEU . 4.4 m-20 59.29 25.47 14.11 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.85 179.908 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 90.21 -18.04 50.59 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.464 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 15.3 ptm180 -117.33 129.66 56.02 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.923 0.392 . . . . 0.0 110.849 -179.861 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 185' ' ' THR . . . . . 0.675 HG23 ' O ' ' A' ' 179' ' ' VAL . 51.3 m -71.48 138.89 49.33 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.154 -179.896 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 54.6 mt -105.53 143.65 33.39 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.884 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -115.11 117.14 29.72 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.905 179.841 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 188' ' ' ALA . . . . . 0.663 ' HB2' HG22 ' A' ' 113' ' ' VAL . . . -114.96 127.68 55.83 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.065 179.857 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 4.3 t -136.6 173.78 11.33 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.848 -179.771 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 190' ' ' LEU . . . . . 0.514 ' O ' HD12 ' A' ' 190' ' ' LEU . 3.6 pp -130.29 160.95 32.37 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.929 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 59.34 30.98 68.76 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.453 179.878 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 192' ' ' THR . . . . . . . . . . . . . 82.5 p -90.01 131.43 35.9 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.91 0.386 . . . . 0.0 111.091 -179.847 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 193' ' ' THR . . . . . . . . . . . . . 11.2 m -124.81 141.03 52.39 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.118 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -70.42 167.67 17.74 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.916 179.909 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 195' ' ' TYR . . . . . . . . . . . . . 76.8 m-85 -67.63 123.74 21.32 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.978 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 196' ' ' CYS . . . . . . . . . . . . . 7.2 t -159.18 164.95 34.69 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.846 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 1.4 t -72.04 106.85 4.46 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.906 -179.765 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 198' ' ' TYR . . . . . . . . . . . . . 10.2 p90 -173.69 141.05 0.81 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.944 -179.847 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 2.2 m -123.99 172.19 9.15 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.864 -179.853 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . 78.13 -163.15 50.46 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.453 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 201' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 149.57 88.76 Favored 'Cis proline' 0 C--O 1.232 0.188 0 C-N-CA 122.68 -1.8 . . . . 0.0 112.367 0.013 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 202' ' ' SER . . . . . . . . . . . . . 54.8 p -85.3 177.9 7.67 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.868 -179.844 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 70.7 p -149.01 144.91 27.05 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.854 -179.802 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.348 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.503 -179.977 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.304 0 N-CA-C 112.475 -0.25 . . . . 0.0 112.475 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 33.3 t -62.94 112.91 2.78 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.846 0.355 . . . . 0.0 110.866 -179.75 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 3.9 m -81.67 85.62 6.54 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.843 -179.798 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -101.06 159.04 18.94 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.444 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.8 m -51.65 178.37 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.867 0.365 . . . . 0.0 110.894 -179.766 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 25.6 t -102.65 -58.84 1.8 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.894 -179.837 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 80.65 130.11 0.93 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.497 180.0 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -104.91 117.94 35.28 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.803 0.335 . . . . 0.0 111.109 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 7.8 t -153.2 159.18 42.61 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.902 -179.788 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.592 HG13 ' O ' ' A' ' 103' ' ' VAL . 6.2 p -86.56 117.61 31.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.148 179.962 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 28.3 ptt180 -117.99 145.03 45.03 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.897 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 12.1 p -90.18 144.3 9.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.085 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 106' ' ' VAL . . . . . 0.454 ' O ' HG23 ' A' ' 106' ' ' VAL . 33.8 m -84.23 124.25 39.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.11 179.9 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 8.3 tt0 -159.32 105.13 1.68 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.881 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 40.1 pttt -91.82 -26.18 18.64 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.915 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 109' ' ' ASN . . . . . 0.428 ' CG ' ' O ' ' A' ' 109' ' ' ASN . 8.6 t-20 -89.51 40.02 0.97 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.879 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 33.6 tp -141.16 118.21 11.23 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.883 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.4 HG22 HD11 ' A' ' 173' ' ' ILE . 95.3 t -100.58 103.39 14.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.085 179.858 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.598 ' CD1' ' CE2' ' A' ' 160' ' ' TYR . 39.1 t80 -101.69 113.24 26.22 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.864 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.67 HG22 ' HB2' ' A' ' 188' ' ' ALA . 40.1 t -112.87 126.51 70.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.126 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.414 ' CG1' ' CE2' ' A' ' 112' ' ' PHE . 17.3 m -111.83 166.36 6.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.16 179.924 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 78.68 43.15 12.24 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.435 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 49.4 mt -112.99 118.26 34.34 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.828 0.347 . . . . 0.0 110.889 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 2.8 p -65.53 143.36 57.69 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.835 -179.908 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 65.8 mm-40 -39.85 -34.82 0.29 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.917 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 59.8 ttt180 -69.02 -49.06 61.06 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.891 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 61.7 mt -72.63 -20.55 61.25 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.929 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -78.53 83.26 4.73 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.083 179.799 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 17.0 m-20 -148.54 149.24 30.78 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-O 121.572 0.701 . . . . 0.0 110.887 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 -48.59 0.69 Allowed 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.664 2.243 . . . . 0.0 112.39 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 44.7 mm-40 -67.0 -42.07 85.64 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.885 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.529 HG13 ' CZ ' ' A' ' 131' ' ' TYR . 38.1 t -59.82 -47.34 91.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.107 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 94.6 mt -71.58 -32.73 68.4 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.927 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 68.2 mttt -67.19 -30.26 70.15 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.896 179.836 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 9.9 mmp_? -50.23 144.29 11.63 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.577 0.703 . . . . 0.0 110.884 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 0.01 6.29 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.669 2.246 . . . . 0.0 112.365 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 35.3 tt0 -101.05 -7.71 22.99 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.877 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 131' ' ' TYR . . . . . 0.529 ' CZ ' HG13 ' A' ' 125' ' ' VAL . 41.5 m-85 -111.96 -72.88 0.69 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.932 -179.871 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 33.4 m-85 -124.42 -21.67 4.86 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.869 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -52.57 -24.36 17.43 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.479 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 14.6 ptpt -90.49 -16.9 28.06 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.77 0.319 . . . . 0.0 110.848 -179.932 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 135' ' ' PHE . . . . . . . . . . . . . 15.5 m-85 -79.15 -29.11 42.91 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.858 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 172.05 168.33 33.38 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.479 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 7.2 mtmp? -75.67 101.27 4.93 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.806 0.336 . . . . 0.0 110.92 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.625 HG23 HG13 ' A' ' 161' ' ' VAL . 81.7 mt -68.64 134.09 30.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.145 179.9 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 2.3 t-160 -103.68 -50.7 3.35 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.859 179.893 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 51.8 tttt -134.0 132.13 39.74 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.906 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 141' ' ' VAL . . . . . 0.573 ' CG2' HG21 ' A' ' 138' ' ' ILE . 49.1 t -120.11 133.23 67.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.113 179.923 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 99.6 t -129.88 129.42 65.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.115 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 19.0 mm -107.31 119.36 56.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.139 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 7.7 m120 -111.33 101.34 9.82 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.859 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 9.1 p-10 -82.64 171.47 14.0 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.9 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 1.3 t -68.21 149.66 49.25 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.837 -179.821 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 40.6 p -121.8 40.79 3.53 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.185 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 1.8 t -112.46 157.73 20.73 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.894 -179.859 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 56.7 t80 -61.43 148.8 40.52 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.933 -179.854 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -57.79 143.6 41.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.124 179.875 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 97.63 37.94 4.34 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.453 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 2.1 m -90.57 170.73 9.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.798 0.332 . . . . 0.0 110.883 -179.742 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 2.7 mp0 -121.6 85.09 2.35 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.908 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 114.08 74.27 0.62 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.514 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 124.12 10.78 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.71 2.273 . . . . 0.0 112.301 -179.939 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 17.5 m -136.63 128.6 29.37 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.859 -179.877 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -123.85 169.43 11.58 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.081 179.897 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 158' ' ' SER . . . . . 0.4 ' HB3' ' CE1' ' A' ' 112' ' ' PHE . 20.3 m -137.53 164.51 28.55 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.882 -179.804 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -142.95 140.08 30.95 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.128 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 160' ' ' TYR . . . . . 0.598 ' CE2' ' CD1' ' A' ' 112' ' ' PHE . 33.6 m-85 -113.7 116.71 29.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.933 -179.842 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.625 HG13 HG23 ' A' ' 138' ' ' ILE . 98.0 t -116.58 139.62 42.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.111 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 29.9 m -106.03 129.12 54.2 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.126 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 3.7 m-85 -109.51 148.28 31.48 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.982 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 49.0 mt -76.45 -61.06 1.83 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.139 179.918 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 59.4 mtt180 -82.25 99.08 9.1 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.82 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 50.7 m -42.01 -53.34 3.92 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.878 -179.853 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 3.6 pt-20 -40.73 -59.34 1.42 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.906 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -56.7 -35.14 68.14 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.869 179.923 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -65.4 -60.18 3.23 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.122 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 39.6 mt -45.85 -51.76 12.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.903 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 2.2 mpt_? -61.07 -43.83 98.3 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.808 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 172' ' ' ALA . . . . . 0.617 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -54.89 -31.81 60.27 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.134 179.915 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 173' ' ' ILE . . . . . 0.4 HD11 HG22 ' A' ' 111' ' ' VAL . 63.0 mt -81.16 -38.42 16.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.135 179.987 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 31.4 mm-40 -69.69 -22.09 63.45 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.935 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 3.4 t -93.8 -34.75 13.05 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.906 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 176' ' ' VAL . . . . . 0.617 HG23 ' O ' ' A' ' 172' ' ' ALA . 10.5 t -66.79 -38.17 80.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.081 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 1.7 t30 -63.34 140.57 58.89 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.874 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 25.5 t30 71.81 35.21 1.41 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.856 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 89.4 t -119.54 131.56 71.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.122 179.892 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 82.7 t -95.62 102.56 13.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.09 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 53.7 t -111.07 117.57 55.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.167 179.877 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 15.2 m-20 48.8 48.99 19.67 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.828 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 63.15 28.4 72.11 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.452 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 12.2 mtt85 -138.07 111.27 7.9 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.86 0.362 . . . . 0.0 110.89 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 36.5 m -70.63 101.21 1.99 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.126 -179.945 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 11.9 mt -68.45 129.6 40.4 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.914 179.928 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 22.9 tptm -124.85 120.55 32.03 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.932 179.816 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 188' ' ' ALA . . . . . 0.67 ' HB2' HG22 ' A' ' 113' ' ' VAL . . . -119.82 151.82 38.24 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.127 179.857 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 8.6 t -158.38 164.01 36.72 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.849 -179.718 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 190' ' ' LEU . . . . . 0.844 ' O ' HD12 ' A' ' 190' ' ' LEU . 4.1 pp -128.18 130.3 47.83 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.897 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 106.36 27.95 5.36 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.478 179.879 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 192' ' ' THR . . . . . 0.529 HG21 ' CD2' ' A' ' 112' ' ' PHE . 14.7 t -92.09 155.82 17.8 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.878 0.37 . . . . 0.0 111.124 -179.845 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 193' ' ' THR . . . . . . . . . . . . . 23.2 m -96.1 116.58 29.2 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.148 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 12.1 ptpt -102.83 -27.77 12.47 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.873 179.887 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 195' ' ' TYR . . . . . . . . . . . . . 3.3 t80 -171.65 135.31 0.88 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.926 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 196' ' ' CYS . . . . . . . . . . . . . 21.1 t -95.46 84.68 4.04 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.882 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 3.6 m -164.26 167.08 20.35 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.875 -179.732 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 198' ' ' TYR . . . . . . . . . . . . . 23.7 t80 -115.6 116.9 28.93 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.923 -179.892 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 81.4 p -173.95 140.05 0.7 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.84 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . -66.92 -165.14 2.15 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.535 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 201' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.8 122.29 5.99 Favored 'Cis proline' 0 C--N 1.341 0.169 0 C-N-CA 122.689 -1.796 . . . . 0.0 112.313 0.061 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 202' ' ' SER . . . . . . . . . . . . . 21.9 m -91.68 163.46 14.09 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.845 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 9.6 m -115.69 -56.47 2.33 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.795 -179.781 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.283 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.462 -179.96 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.327 0 N-CA-C 112.515 -0.234 . . . . 0.0 112.515 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 97.4 p -114.94 106.99 14.8 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.857 0.36 . . . . 0.0 110.865 -179.745 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 1.9 m -65.21 133.44 51.5 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.843 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 66.56 150.18 0.12 Allowed Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.506 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 18.5 t -39.63 -59.51 1.12 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.878 0.37 . . . . 0.0 110.844 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 2.9 m -129.83 145.4 51.58 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.86 -179.776 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 80.37 107.65 0.28 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.5 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -74.83 154.33 38.33 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.765 0.316 . . . . 0.0 111.082 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 64.6 m -132.5 137.61 47.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.839 -179.818 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 34.4 m -75.78 148.49 7.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.145 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 34.8 mtp85 -120.17 98.31 6.01 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.902 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 87.5 t -115.8 100.69 10.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.172 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 106' ' ' VAL . . . . . 0.415 HG21 ' HD2' ' A' ' 108' ' ' LYS . 8.0 p -114.34 131.76 65.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.131 179.907 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 13.7 tt0 -87.3 46.8 1.42 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.918 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.415 ' HD2' HG21 ' A' ' 106' ' ' VAL . 75.7 mttt -101.24 44.88 0.99 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.893 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 4.9 p-10 -110.41 50.55 0.8 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.878 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 11.2 tp -128.77 121.06 27.55 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.902 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 98.8 t -94.64 130.11 43.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.116 179.85 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.418 ' CZ ' HG12 ' A' ' 114' ' ' VAL . 40.5 t80 -128.95 98.23 4.88 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.893 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.699 HG22 ' HB2' ' A' ' 188' ' ' ALA . 54.0 t -92.76 135.75 26.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.177 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.418 HG12 ' CZ ' ' A' ' 112' ' ' PHE . 4.7 m -124.96 164.4 23.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.12 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 76.28 47.85 10.26 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.518 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 116' ' ' LEU . . . . . 0.56 HD23 HD22 ' A' ' 186' ' ' LEU . 59.8 mt -108.3 130.87 55.17 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.812 0.339 . . . . 0.0 110.929 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 14.0 m -69.21 155.4 40.47 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.902 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 40.8 mt-30 -46.84 -38.07 9.73 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.915 -179.927 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 19.6 tpt180 -74.66 -50.74 16.55 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.869 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 37.0 mt -62.15 -19.09 62.69 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.904 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -76.68 83.9 3.32 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.098 179.782 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -148.66 144.02 17.91 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.639 0.733 . . . . 0.0 110.865 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 -50.78 0.43 Allowed 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.694 2.263 . . . . 0.0 112.341 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 22.1 pt-20 -67.35 -38.36 84.7 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.87 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 84.2 t -63.62 -42.85 97.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.084 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.689 HD12 HD11 ' A' ' 143' ' ' ILE . 47.9 mt -72.02 -32.82 67.52 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.899 179.974 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 25.0 tttm -74.44 -29.94 61.69 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.914 179.849 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 49.8 mtp180 -47.11 148.8 1.87 Allowed Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.571 0.7 . . . . 0.0 110.882 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 -2.1 9.61 Favored 'Trans proline' 0 C--N 1.341 0.138 0 C-N-CA 122.665 2.243 . . . . 0.0 112.308 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 4.0 tp10 -91.83 -23.53 19.65 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.834 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 131' ' ' TYR . . . . . . . . . . . . . 26.0 m-85 -103.34 -69.55 0.79 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.913 -179.826 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.434 ' O ' ' N ' ' A' ' 135' ' ' PHE . 87.8 m-85 -126.23 -27.9 3.17 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.887 -179.971 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -43.87 -22.23 0.27 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.536 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.4 ' N ' ' O ' ' A' ' 132' ' ' PHE . 16.7 ptpt -85.09 -34.41 22.22 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.801 0.334 . . . . 0.0 110.865 -179.949 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 135' ' ' PHE . . . . . 0.488 ' CE2' HG23 ' A' ' 176' ' ' VAL . 12.9 m-85 -56.3 -39.26 72.42 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.857 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 178.77 -176.19 47.83 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.494 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 13.9 tttt -87.87 111.41 21.39 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.724 0.297 . . . . 0.0 110.902 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.495 HG21 HG22 ' A' ' 141' ' ' VAL . 61.5 mt -83.47 144.7 9.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.174 179.849 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 2.2 t60 -102.32 -44.27 5.45 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.851 179.915 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 24.1 ttpp -138.72 145.73 40.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.909 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 141' ' ' VAL . . . . . 0.495 HG22 HG21 ' A' ' 138' ' ' ILE . 21.2 t -131.0 129.38 63.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.174 179.848 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 46.6 t -125.78 140.2 49.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.16 179.93 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 143' ' ' ILE . . . . . 0.689 HD11 HD12 ' A' ' 126' ' ' LEU . 20.0 mm -121.92 126.83 75.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.176 179.883 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 19.0 m-20 -120.49 121.11 37.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.884 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 3.0 p-10 -104.08 157.66 16.96 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.875 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 65.9 p -89.82 159.47 16.99 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.874 -179.863 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 37.4 m -77.52 123.22 26.3 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.139 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 23.4 m -73.41 105.37 4.76 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.837 -179.829 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 40.9 t80 -110.01 141.22 43.11 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.908 -179.911 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -59.82 123.06 15.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.103 179.812 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 105.36 -0.43 40.36 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.495 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 28.4 t -90.97 130.07 36.93 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.787 0.327 . . . . 0.0 110.866 -179.757 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 29.1 tt0 -118.57 113.44 21.27 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.923 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 101.7 76.1 1.16 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.732 -0.746 . . . . 0.0 112.473 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 103.09 1.1 Allowed 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.738 2.292 . . . . 0.0 112.33 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 86.9 p -101.78 140.86 35.49 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.873 -179.845 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -127.61 167.74 15.96 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.13 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 83.5 p -126.13 166.08 17.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.89 -179.819 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -147.99 140.46 24.46 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.131 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 8.8 m-85 -114.71 136.37 53.13 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.917 -179.843 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 74.9 t -130.0 125.59 60.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.145 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 89.1 m -95.75 122.65 38.75 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.176 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 4.8 m-85 -108.16 141.43 39.9 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.936 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 65.3 mt -74.57 -39.52 47.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.073 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 38.4 mtm-85 -86.92 114.58 23.67 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.851 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 14.3 t -55.84 -59.66 4.56 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.845 -179.804 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 17.9 tt0 -51.68 -49.65 61.99 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.875 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 12.2 t0 -48.03 -46.25 32.97 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.886 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -61.67 -53.46 55.86 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.111 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 72.9 mt -44.68 -63.9 0.81 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.888 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 171' ' ' ARG . . . . . 0.418 ' O ' ' N ' ' A' ' 174' ' ' GLN . 14.9 mtp180 -59.59 -53.04 62.64 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.859 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 172' ' ' ALA . . . . . 0.502 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -40.0 -37.73 0.63 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.081 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 67.4 mt -80.66 -36.7 15.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.133 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 174' ' ' GLN . . . . . 0.418 ' N ' ' O ' ' A' ' 171' ' ' ARG . 25.8 mm-40 -61.1 -26.88 67.97 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.9 179.905 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 2.5 t -93.75 -41.15 9.83 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.897 -179.917 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 176' ' ' VAL . . . . . 0.502 HG23 ' O ' ' A' ' 172' ' ' ALA . 10.3 t -58.77 -39.44 76.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.092 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -62.43 136.43 57.9 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.896 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 14.6 t30 70.76 47.01 0.48 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.919 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 59.0 t -127.64 134.8 64.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.139 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 89.4 t -93.95 115.04 31.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.148 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 62.4 t -121.45 118.88 57.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.158 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 55.9 m-20 58.5 28.76 17.41 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.844 179.935 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 90.08 -19.52 42.0 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.497 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 25.4 ttm-85 -103.52 135.89 44.27 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.939 0.4 . . . . 0.0 110.851 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 71.2 m -86.8 131.83 34.01 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.186 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 186' ' ' LEU . . . . . 0.56 HD22 HD23 ' A' ' 116' ' ' LEU . 25.4 mt -112.57 126.25 55.14 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.91 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 7.9 ttmt -109.48 136.64 48.56 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.87 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 188' ' ' ALA . . . . . 0.699 ' HB2' HG22 ' A' ' 113' ' ' VAL . . . -125.64 149.52 48.36 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.096 179.844 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 7.3 t -159.37 167.71 28.14 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.828 -179.766 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 190' ' ' LEU . . . . . . . . . . . . . 4.2 pp -126.38 153.11 45.4 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.958 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 106.16 30.7 4.36 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.438 179.927 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 192' ' ' THR . . . . . . . . . . . . . 47.0 m -98.97 122.89 42.82 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.851 0.357 . . . . 0.0 111.151 -179.872 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 193' ' ' THR . . . . . . . . . . . . . 9.4 m -118.51 138.24 52.65 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.151 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 2.3 mptp? -78.07 131.37 37.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.902 179.896 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 195' ' ' TYR . . . . . . . . . . . . . 26.0 p90 -59.3 151.94 22.18 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.901 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 196' ' ' CYS . . . . . . . . . . . . . 44.7 t -126.06 75.53 1.52 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.856 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 55.1 m -103.56 151.88 22.37 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.831 -179.76 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 198' ' ' TYR . . . . . . . . . . . . . 83.1 t80 -166.38 146.05 5.94 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.932 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 68.6 m -132.24 159.15 39.89 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.843 -179.823 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . 178.57 -168.5 39.6 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.47 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 201' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 -48.32 0.27 Allowed 'Cis proline' 0 C--N 1.342 0.199 0 C-N-CA 122.706 -1.789 . . . . 0.0 112.322 0.014 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 202' ' ' SER . . . . . . . . . . . . . 73.9 p 47.45 41.55 12.97 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.835 -179.846 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 12.7 p -126.09 77.91 1.72 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.889 -179.842 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.297 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.459 179.998 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.352 0 N-CA-C 112.478 -0.249 . . . . 0.0 112.478 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 2.2 m -125.68 164.24 21.05 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.875 0.369 . . . . 0.0 110.911 -179.748 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 71.2 m -64.16 152.59 40.25 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.86 -179.817 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 116.32 174.95 17.71 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.481 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 39.3 p -120.03 167.03 12.6 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.856 0.36 . . . . 0.0 110.854 -179.715 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 46.6 m -114.74 128.11 56.12 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.839 -179.803 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 152.68 -121.89 1.23 Allowed Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.471 -179.963 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -61.15 135.2 57.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.762 0.315 . . . . 0.0 111.103 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 1.7 t -74.24 -62.56 1.47 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.866 -179.782 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 99.6 t -107.31 127.31 63.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.118 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 14.8 tpt180 -95.01 100.62 12.42 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.866 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 62.0 t -93.63 137.63 22.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.105 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -111.49 148.27 14.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.083 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 5.3 mm100 -95.5 -44.56 7.47 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.909 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.497 ' HB2' HD21 ' A' ' 170' ' ' LEU . 20.0 mttt -79.92 81.27 6.21 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.887 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 22.3 t-20 -124.86 -39.8 2.24 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.913 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 19.4 tp -91.78 123.01 34.84 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.938 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.763 HG22 HD11 ' A' ' 173' ' ' ILE . 75.1 t -93.1 115.99 33.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.102 179.886 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.579 ' CE1' ' HB2' ' A' ' 158' ' ' SER . 6.6 t80 -112.49 118.47 35.22 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.895 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.42 HG22 ' HB2' ' A' ' 188' ' ' ALA . 25.5 t -115.0 137.53 48.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.169 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.483 HG12 ' HE1' ' A' ' 112' ' ' PHE . 19.9 m -123.42 168.96 15.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.161 179.908 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 75.59 48.62 10.19 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.499 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 36.4 mt -114.68 131.18 56.83 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.807 0.336 . . . . 0.0 110.884 -179.887 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 13.0 t -68.99 152.0 45.81 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.88 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 4.2 tp-100 -51.52 -23.57 4.23 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.936 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 30.3 ttt180 -84.62 -45.56 12.39 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.889 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 96.7 mt -68.06 -28.83 67.71 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.87 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -66.36 83.05 0.09 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.096 179.834 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -145.47 143.97 21.58 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.625 0.726 . . . . 0.0 110.842 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 -38.89 7.25 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.726 2.284 . . . . 0.0 112.345 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -77.51 -44.83 27.44 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.895 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.556 ' O ' ' CD1' ' A' ' 131' ' ' TYR . 62.0 t -60.6 -38.32 78.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.076 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.806 HD12 HD11 ' A' ' 143' ' ' ILE . 81.4 mt -75.08 -44.5 47.07 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.89 180.0 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.61 ' HA ' HD12 ' A' ' 138' ' ' ILE . 22.7 ttpp -67.87 -25.82 65.71 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.897 179.861 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 12.9 mmt180 -47.76 144.01 5.6 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.657 0.742 . . . . 0.0 110.803 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 -8.39 23.48 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.745 2.297 . . . . 0.0 112.324 179.975 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 46.7 mt-10 -98.83 8.35 45.07 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.89 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 131' ' ' TYR . . . . . 0.556 ' CD1' ' O ' ' A' ' 125' ' ' VAL . 59.3 m-85 -126.08 -74.26 0.61 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.927 -179.828 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.444 ' O ' ' N ' ' A' ' 134' ' ' LYS . 58.5 m-85 -116.26 -36.66 3.98 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.914 -180.0 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -40.39 -25.58 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.488 -179.973 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.444 ' N ' ' O ' ' A' ' 132' ' ' PHE . 3.5 mtpp -42.7 -59.65 1.85 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.82 0.343 . . . . 0.0 110.875 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 135' ' ' PHE . . . . . 0.42 ' CE1' ' HA ' ' A' ' 172' ' ' ALA . 28.1 m-85 -50.93 -43.59 60.13 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.865 179.982 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 173.82 -172.99 45.69 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.46 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 20.9 mtpp -76.19 141.35 41.85 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.733 0.301 . . . . 0.0 110.887 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.68 HG21 ' CG2' ' A' ' 141' ' ' VAL . 60.6 mt -99.52 141.26 17.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.125 179.866 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 11.2 t60 -84.97 -58.55 2.65 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.846 179.892 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 22.1 tttp -137.53 146.82 44.61 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.914 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 141' ' ' VAL . . . . . 0.68 ' CG2' HG21 ' A' ' 138' ' ' ILE . 35.3 t -134.68 132.83 54.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.175 179.897 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 57.8 t -126.46 141.38 46.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.121 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 143' ' ' ILE . . . . . 0.806 HD11 HD12 ' A' ' 126' ' ' LEU . 31.4 mm -119.87 132.65 69.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.095 179.96 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 5.2 t-20 -126.39 106.54 9.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.889 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 5.3 p30 -101.1 173.62 6.38 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.872 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 6.1 m -89.47 123.39 33.55 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.899 -179.885 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 17.9 p -99.61 -50.83 3.94 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.15 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 79.4 p -106.58 131.51 53.65 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.828 -179.808 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 149' ' ' TYR . . . . . 0.533 ' O ' ' CG ' ' A' ' 149' ' ' TYR . 29.7 p90 -107.06 99.78 9.31 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.942 -179.876 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -83.15 42.21 0.8 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.116 179.868 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 79.42 39.85 17.4 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.76 -0.734 . . . . 0.0 112.469 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 38.0 p -100.69 132.17 46.22 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.867 0.365 . . . . 0.0 110.829 -179.718 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 1.6 mp0 -81.58 106.33 13.44 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.905 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 57.59 81.18 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.489 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 133.22 25.08 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.684 2.256 . . . . 0.0 112.358 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 93.4 p -91.44 138.82 31.27 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.873 -179.84 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -93.96 169.47 10.25 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.092 179.932 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 158' ' ' SER . . . . . 0.579 ' HB2' ' CE1' ' A' ' 112' ' ' PHE . 86.9 p -140.72 153.52 45.96 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.85 -179.775 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -137.68 150.93 47.73 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.109 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 160' ' ' TYR . . . . . 0.486 ' N ' ' CD1' ' A' ' 160' ' ' TYR . 1.3 m-85 -115.57 125.79 53.4 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.919 -179.832 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.419 ' CG1' ' CE1' ' A' ' 163' ' ' TYR . 43.0 t -120.83 125.74 74.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.151 179.909 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 87.9 m -107.44 123.88 49.04 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.161 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 163' ' ' TYR . . . . . 0.419 ' CE1' ' CG1' ' A' ' 161' ' ' VAL . 30.3 m-85 -104.06 164.3 11.8 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.906 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 42.7 mt -94.05 -39.46 10.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.153 179.891 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 30.5 mtp180 -102.12 120.36 40.31 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.911 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 16.0 m -47.78 -56.49 7.28 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.823 -179.733 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 34.8 mt-10 -46.23 -52.46 12.42 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.904 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 23.3 m-20 -50.95 -48.18 60.95 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.801 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -55.29 -62.47 1.65 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.082 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 170' ' ' LEU . . . . . 0.497 HD21 ' HB2' ' A' ' 108' ' ' LYS . 66.0 mt -41.63 -62.77 0.82 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.9 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 171' ' ' ARG . . . . . 0.414 ' O ' ' N ' ' A' ' 174' ' ' GLN . 20.0 mtp85 -51.76 -60.06 3.59 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.829 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 172' ' ' ALA . . . . . 0.577 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -38.75 -36.42 0.26 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.146 179.893 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 173' ' ' ILE . . . . . 0.763 HD11 HG22 ' A' ' 111' ' ' VAL . 60.9 mt -80.96 -39.89 18.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.12 179.961 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 174' ' ' GLN . . . . . 0.414 ' N ' ' O ' ' A' ' 171' ' ' ARG . 51.3 mt-30 -66.93 -22.1 65.96 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.92 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 1.8 t -93.77 -37.27 11.87 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.913 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 176' ' ' VAL . . . . . 0.577 HG23 ' O ' ' A' ' 172' ' ' ALA . 10.3 t -64.37 -33.77 64.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.082 -179.954 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 3.8 t30 -67.95 143.5 55.61 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.866 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 22.8 t-20 65.52 48.94 1.91 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.905 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 179' ' ' VAL . . . . . 0.416 HG12 HG23 ' A' ' 181' ' ' VAL . 53.0 t -127.27 135.64 62.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.14 179.922 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 59.3 t -96.9 100.31 10.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.148 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 181' ' ' VAL . . . . . 0.468 HG21 HD12 ' A' ' 186' ' ' LEU . 66.9 t -107.52 97.98 6.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.175 179.909 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 6.8 t0 66.73 36.58 4.6 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.862 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 77.59 32.54 46.1 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.499 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 65.6 mtt85 -141.66 136.51 30.98 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.911 0.386 . . . . 0.0 110.866 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 26.6 m -94.73 95.0 8.44 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.161 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 186' ' ' LEU . . . . . 0.468 HD12 HG21 ' A' ' 181' ' ' VAL . 79.8 mt -67.74 132.73 48.0 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.901 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 25.4 tptt -111.08 116.41 31.08 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.92 179.815 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 188' ' ' ALA . . . . . 0.441 ' HB2' HG11 ' A' ' 176' ' ' VAL . . . -112.38 134.28 54.01 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.101 179.824 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 7.7 t -158.51 171.75 19.56 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.815 -179.791 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 190' ' ' LEU . . . . . 0.83 ' C ' HD22 ' A' ' 190' ' ' LEU . 0.0 OUTLIER -119.25 158.77 25.37 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.936 179.998 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 191' ' ' GLY . . . . . 0.448 ' N ' HD22 ' A' ' 190' ' ' LEU . . . 64.01 29.3 74.48 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.491 179.91 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 192' ' ' THR . . . . . . . . . . . . . 6.9 m -94.84 118.37 31.66 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.897 0.379 . . . . 0.0 111.163 -179.859 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 193' ' ' THR . . . . . . . . . . . . . 60.5 p -126.41 166.32 17.41 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.108 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 20.5 mmmt -100.14 -57.45 2.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.893 179.907 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 195' ' ' TYR . . . . . . . . . . . . . 1.8 t80 -63.9 93.59 0.09 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.903 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 196' ' ' CYS . . . . . . . . . . . . . 25.7 p -49.97 138.08 15.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.899 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 64.1 p -141.62 153.64 44.89 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.825 -179.765 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 198' ' ' TYR . . . . . 0.563 ' CE2' ' O ' ' A' ' 199' ' ' SER . 67.1 t80 -148.47 167.23 25.86 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.96 -179.922 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 199' ' ' SER . . . . . 0.563 ' O ' ' CE2' ' A' ' 198' ' ' TYR . 37.5 p -136.65 164.48 28.12 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.877 -179.847 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . 128.61 -162.92 22.2 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.47 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 201' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 -27.86 6.6 Favored 'Cis proline' 0 C--N 1.341 0.161 0 C-N-CA 122.703 -1.79 . . . . 0.0 112.33 0.122 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 202' ' ' SER . . . . . . . . . . . . . 92.3 p -150.33 161.76 41.85 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.847 -179.838 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 44.1 t -101.46 134.65 44.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.826 -179.743 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.501 179.964 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.367 0 N-CA-C 112.507 -0.237 . . . . 0.0 112.507 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 23.7 p -156.35 128.38 7.42 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.87 0.367 . . . . 0.0 110.861 -179.768 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 85.4 p -108.88 148.13 31.09 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.874 -179.812 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 173.72 80.72 0.05 OUTLIER Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.464 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 21.9 p -125.7 166.23 17.15 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.856 0.36 . . . . 0.0 110.893 -179.81 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 3.7 t -109.93 102.37 11.13 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.855 -179.808 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 176.8 115.11 0.41 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.515 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -104.77 118.46 36.61 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.766 0.317 . . . . 0.0 111.077 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 2.1 m -166.13 171.55 12.24 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.835 -179.829 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.43 HG23 ' O ' ' A' ' 103' ' ' VAL . 35.6 m -74.24 125.58 33.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.086 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 4.9 tpp85 -84.22 105.23 14.91 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.852 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 97.3 t -72.96 123.47 27.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.166 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 61.3 t -89.28 117.5 32.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.135 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 47.5 mm-40 -105.55 113.8 27.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.909 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 52.9 mttt -72.38 -44.55 62.38 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.871 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 1.2 p-10 -86.69 45.79 1.29 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.893 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 110' ' ' LEU . . . . . 0.626 HD11 ' HD2' ' A' ' 160' ' ' TYR . 62.1 tp -139.47 120.47 14.57 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.92 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.429 HG12 HG23 ' A' ' 113' ' ' VAL . 86.9 t -111.13 106.64 21.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.065 179.88 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.469 ' CE2' ' CG1' ' A' ' 114' ' ' VAL . 87.7 t80 -94.48 102.21 14.15 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.905 179.967 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.429 HG23 HG12 ' A' ' 111' ' ' VAL . 20.2 t -107.23 131.73 56.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.16 179.993 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.469 ' CG1' ' CE2' ' A' ' 112' ' ' PHE . 6.1 m -119.2 155.01 21.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.113 179.942 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 90.81 44.35 4.54 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.452 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 116' ' ' LEU . . . . . 0.505 HD23 HD21 ' A' ' 186' ' ' LEU . 38.5 mt -110.25 125.0 52.65 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.823 0.344 . . . . 0.0 110.913 -179.943 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 117' ' ' SER . . . . . 0.484 ' O ' ' N ' ' A' ' 120' ' ' LEU . 22.8 p -69.09 139.97 54.81 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.84 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 118' ' ' GLN . . . . . 0.42 ' C ' ' O ' ' A' ' 117' ' ' SER . 37.4 mt-30 -36.38 -41.79 0.3 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.914 -179.924 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 26.6 mtm-85 -66.31 -44.12 84.33 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.886 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 120' ' ' LEU . . . . . 0.484 ' N ' ' O ' ' A' ' 117' ' ' SER . 34.5 mt -72.42 -24.74 61.27 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.912 -179.976 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -71.23 83.25 0.74 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.132 179.811 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 20.0 m-20 -148.87 144.0 17.73 Favored Pre-proline 0 C--N 1.328 -0.364 0 CA-C-O 121.648 0.737 . . . . 0.0 110.88 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 123' ' ' PRO . . . . . 0.403 ' HA ' HG11 ' A' ' 141' ' ' VAL . 54.1 Cg_endo -69.73 -46.65 1.16 Allowed 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.69 2.26 . . . . 0.0 112.347 -179.963 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 48.7 mt-10 -71.36 -43.31 67.16 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.924 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.523 ' O ' ' CD2' ' A' ' 131' ' ' TYR . 90.5 t -60.19 -42.2 89.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.136 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.573 HD12 HD11 ' A' ' 143' ' ' ILE . 64.6 mt -72.96 -39.48 66.15 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.898 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.716 ' HA ' HD12 ' A' ' 138' ' ' ILE . 18.6 ttmt -61.44 -31.95 71.92 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.9 179.855 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 91.7 mtt180 -43.02 143.94 1.17 Allowed Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.635 0.731 . . . . 0.0 110.88 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 -2.69 10.57 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.679 2.253 . . . . 0.0 112.384 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 25.7 mt-10 -97.57 -30.26 12.96 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.905 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 131' ' ' TYR . . . . . 0.523 ' CD2' ' O ' ' A' ' 125' ' ' VAL . 44.2 m-85 -87.64 -74.91 0.43 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.921 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.481 ' CE1' HD22 ' A' ' 126' ' ' LEU . 42.6 m-85 -117.08 -36.84 3.69 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.88 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -49.34 -18.42 1.43 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.518 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -52.49 -34.22 48.34 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.832 0.349 . . . . 0.0 110.916 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 135' ' ' PHE . . . . . 0.568 ' CE2' ' HA ' ' A' ' 172' ' ' ALA . 79.8 m-85 -73.35 -42.02 62.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.897 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 166.89 -178.14 41.3 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.493 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 5.2 ttmm -60.01 140.28 56.88 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.762 0.315 . . . . 0.0 110.858 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.716 HD12 ' HA ' ' A' ' 127' ' ' LYS . 91.3 mt -105.67 139.03 28.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.112 179.862 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 34.3 t-80 -75.61 -55.15 5.94 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.866 179.868 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 140' ' ' LYS . . . . . 0.478 ' HD3' ' CG2' ' A' ' 142' ' ' VAL . 13.4 ttmm -149.49 144.16 26.11 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.916 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 141' ' ' VAL . . . . . 0.494 HG22 HG21 ' A' ' 138' ' ' ILE . 23.9 t -122.43 103.63 13.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.109 179.927 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.478 ' CG2' ' HD3' ' A' ' 140' ' ' LYS . 63.1 t -100.65 140.82 18.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.157 179.873 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 143' ' ' ILE . . . . . 0.573 HD11 HD12 ' A' ' 126' ' ' LEU . 26.7 mm -119.24 125.47 74.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.15 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 19.6 m-20 -121.2 142.75 49.6 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.88 179.916 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 18.4 p30 -138.15 140.57 39.92 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.871 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 43.7 p -84.09 94.21 8.29 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.87 -179.877 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 11.6 t -82.94 40.45 0.69 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.119 -179.926 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 74.4 m -108.29 164.08 12.63 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.89 -179.889 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 149' ' ' TYR . . . . . 0.574 ' CD2' ' O ' ' A' ' 149' ' ' TYR . 55.2 p90 -99.85 106.7 18.58 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.933 -179.919 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -107.74 -48.7 3.36 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.125 179.851 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 113.08 39.36 1.16 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.487 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 91.3 p -118.52 151.7 37.36 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.895 0.378 . . . . 0.0 110.827 -179.729 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 10.8 mm100 -89.75 100.42 13.23 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.896 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 95.2 83.16 1.62 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.464 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 140.43 42.7 Favored 'Trans proline' 0 C--N 1.341 0.139 0 C-N-CA 122.669 2.246 . . . . 0.0 112.391 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 82.0 p -101.01 143.15 31.5 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.844 -179.795 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -113.68 157.91 21.57 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.076 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 11.7 t -116.29 168.19 10.35 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.871 -179.763 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -148.48 147.29 28.95 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.058 179.893 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 160' ' ' TYR . . . . . 0.626 ' HD2' HD11 ' A' ' 110' ' ' LEU . 4.5 m-85 -115.06 104.73 12.17 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.916 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 95.3 t -99.51 126.45 52.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.146 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 96.7 m -95.9 123.76 39.62 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.14 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 163' ' ' TYR . . . . . 0.531 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 12.1 m-85 -106.13 121.99 45.27 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.949 -179.942 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 46.0 mt -57.38 -51.5 68.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.097 -0.502 . . . . 0.0 111.154 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 39.7 mtp180 -85.72 118.08 25.0 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.847 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 22.6 t -48.72 -47.4 41.33 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.868 -179.82 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -54.36 -56.22 20.77 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.905 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 168' ' ' ASP . . . . . 0.499 ' O ' ' HB2' ' A' ' 172' ' ' ALA . 0.9 OUTLIER -52.39 -31.9 36.17 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.867 179.959 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 169' ' ' ALA . . . . . 0.531 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -70.49 -66.19 0.63 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.113 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 31.1 mt -46.6 -56.17 6.5 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.894 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 84.9 mtt180 -56.59 -46.56 80.78 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.854 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 172' ' ' ALA . . . . . 0.568 ' HA ' ' CE2' ' A' ' 135' ' ' PHE . . . -51.88 -32.73 33.56 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.076 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 65.8 mt -79.13 -36.4 18.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.11 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 15.7 mm100 -65.84 -26.93 67.88 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.874 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 175' ' ' CYS . . . . . 0.48 ' O ' HG21 ' A' ' 179' ' ' VAL . 7.6 m -93.7 -36.63 12.23 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.907 -179.949 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 176' ' ' VAL . . . . . 0.554 HG23 ' O ' ' A' ' 172' ' ' ALA . 10.5 t -65.43 -40.11 87.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.083 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 7.4 p-10 -68.32 152.1 45.93 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.891 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 36.5 t30 57.1 48.77 14.84 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.882 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 179' ' ' VAL . . . . . 0.48 HG21 ' O ' ' A' ' 175' ' ' CYS . 94.3 t -133.56 140.21 47.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.113 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 87.1 t -99.08 105.35 17.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.097 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 181' ' ' VAL . . . . . 0.486 HG21 HD12 ' A' ' 186' ' ' LEU . 91.8 t -112.06 98.73 7.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.133 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 30.9 t0 60.7 52.42 4.43 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.841 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 63.27 24.19 67.11 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.492 -179.931 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 66.3 mtp85 -131.61 111.91 12.14 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.874 0.369 . . . . 0.0 110.86 -179.826 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 28.2 m -76.09 93.19 3.28 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.127 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 186' ' ' LEU . . . . . 0.505 HD21 HD23 ' A' ' 116' ' ' LEU . 80.2 mt -68.54 128.99 38.61 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.931 179.916 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 2.5 mmmp? -117.6 118.29 31.73 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.877 179.847 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -107.19 145.56 32.46 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.127 179.819 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 4.5 t -143.33 169.32 17.88 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.857 -179.74 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 190' ' ' LEU . . . . . 0.495 HD23 ' N ' ' A' ' 191' ' ' GLY . 8.6 tt -128.81 134.89 48.51 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.904 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 191' ' ' GLY . . . . . 0.495 ' N ' HD23 ' A' ' 190' ' ' LEU . . . 94.29 23.62 21.46 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.486 179.91 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 192' ' ' THR . . . . . . . . . . . . . 35.5 m -88.17 118.48 27.79 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.867 0.365 . . . . 0.0 111.176 -179.848 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 193' ' ' THR . . . . . . . . . . . . . 81.8 p -88.45 171.23 10.26 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.121 -179.914 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 3.7 mppt? -110.15 135.32 51.12 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.883 179.912 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 195' ' ' TYR . . . . . . . . . . . . . 40.9 m-85 -68.77 -47.89 65.07 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.875 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 196' ' ' CYS . . . . . . . . . . . . . 2.1 t -44.46 -62.39 1.2 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.924 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 46.7 t -65.76 98.38 0.39 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.879 -179.795 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 198' ' ' TYR . . . . . . . . . . . . . 74.6 t80 -91.51 96.26 10.39 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.889 -179.875 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 1.3 t -155.34 119.69 4.67 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.864 -179.868 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 200' ' ' GLY . . . . . 0.434 ' N ' ' HA ' ' A' ' 201' ' ' PRO . . . -71.7 -66.15 2.2 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.5 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 201' ' ' PRO . . . . . 0.434 ' HA ' ' N ' ' A' ' 200' ' ' GLY . 53.9 Cg_endo -69.8 -13.09 12.43 Favored 'Cis proline' 0 C--N 1.341 0.152 0 C-N-CA 122.649 -1.813 . . . . 0.0 112.36 0.044 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 202' ' ' SER . . . . . . . . . . . . . 17.3 t -65.54 109.15 2.25 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.829 -179.84 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 18.2 p -93.41 124.6 37.51 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.874 -179.826 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.27 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.49 -179.977 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.251 0 N-CA-C 112.48 -0.248 . . . . 0.0 112.48 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 74.9 m -138.58 126.74 22.77 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.919 0.39 . . . . 0.0 110.87 -179.719 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 93.4 p 44.98 38.81 3.22 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.881 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 103.56 -150.66 17.64 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.479 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 42.0 m -105.72 -60.34 1.64 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.857 0.36 . . . . 0.0 110.844 -179.733 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 29.0 p -173.4 171.8 3.89 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.848 -179.804 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -117.52 -179.28 17.49 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.458 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -50.52 161.36 0.33 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.824 0.345 . . . . 0.0 111.085 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 46.2 m -79.99 -49.36 11.94 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.867 -179.795 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 22.4 m -84.5 151.51 3.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.148 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 29.9 mtt85 -98.81 126.36 44.43 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.842 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 14.2 p -131.85 135.09 59.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.105 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 4.9 m -119.12 129.53 75.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.151 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 20.3 tp60 -164.54 153.92 13.49 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.914 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.597 ' O ' HD21 ' A' ' 190' ' ' LEU . 22.5 mmtm -102.52 -52.06 3.19 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.918 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 29.0 p-10 -86.24 49.58 1.82 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.863 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 11.5 tp -130.53 146.77 52.12 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.908 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.446 HG22 HD11 ' A' ' 173' ' ' ILE . 85.2 t -122.55 111.75 31.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.105 179.872 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.437 ' CE1' ' HB2' ' A' ' 158' ' ' SER . 42.1 t80 -98.46 113.34 25.3 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.889 179.991 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.434 HG21 ' CZ ' ' A' ' 132' ' ' PHE . 92.8 t -110.68 137.23 43.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.117 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 35.9 m -126.91 168.19 20.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.147 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 74.29 41.67 37.42 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.476 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 50.5 mt -103.54 130.84 51.02 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.797 0.332 . . . . 0.0 110.94 -179.951 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 117' ' ' SER . . . . . 0.491 ' O ' ' N ' ' A' ' 120' ' ' LEU . 89.6 p -77.37 142.65 39.2 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.85 -179.934 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 118' ' ' GLN . . . . . 0.442 ' C ' ' O ' ' A' ' 117' ' ' SER . 55.0 mm-40 -34.85 -40.36 0.11 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.892 -179.938 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 25.0 mtm-85 -63.34 -47.26 82.93 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.871 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 120' ' ' LEU . . . . . 0.491 ' N ' ' O ' ' A' ' 117' ' ' SER . 20.7 mt -72.44 -29.44 63.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.936 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -65.46 82.99 0.06 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.099 179.81 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 122' ' ' ASP . . . . . 0.422 ' HB2' ' CG2' ' A' ' 125' ' ' VAL . 19.4 m-20 -149.0 143.84 17.46 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.599 0.714 . . . . 0.0 110.863 179.985 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 -44.26 2.19 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.682 2.255 . . . . 0.0 112.389 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 66.3 mm-40 -74.2 -38.61 63.54 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.886 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.586 ' O ' ' CD1' ' A' ' 131' ' ' TYR . 68.9 t -61.0 -49.5 84.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.103 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 92.8 mt -66.33 -43.36 86.36 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.943 179.936 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.478 ' HA ' ' CD1' ' A' ' 138' ' ' ILE . 31.1 tttm -61.64 -42.71 99.27 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.878 179.849 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 128' ' ' ARG . . . . . 0.424 ' C ' ' O ' ' A' ' 127' ' ' LYS . 21.4 mmt180 -35.61 143.28 0.26 Allowed Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.643 0.735 . . . . 0.0 110.826 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.75 -1.4 8.4 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.66 2.24 . . . . 0.0 112.34 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 10.2 mp0 -103.26 -0.98 29.57 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.884 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 131' ' ' TYR . . . . . 0.586 ' CD1' ' O ' ' A' ' 125' ' ' VAL . 47.0 m-85 -117.06 -74.15 0.62 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.913 -179.879 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.434 ' CZ ' HG21 ' A' ' 113' ' ' VAL . 46.5 m-85 -121.75 -17.85 7.28 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.91 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -72.08 -1.44 48.88 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.491 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 1.3 ptpp? -78.85 -19.67 51.46 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.78 0.324 . . . . 0.0 110.894 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 135' ' ' PHE . . . . . 0.419 ' CD2' ' HB1' ' A' ' 172' ' ' ALA . 58.2 m-85 -85.62 -38.17 18.72 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.856 -179.99 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -179.72 -174.52 45.74 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.511 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 45.9 mtpt -81.49 134.62 35.55 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.779 0.323 . . . . 0.0 110.889 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.478 ' CD1' ' HA ' ' A' ' 127' ' ' LYS . 65.1 mt -94.98 147.03 6.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.155 179.861 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 10.8 t-80 -99.11 -43.61 6.59 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.891 179.901 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 26.5 ttpt -148.28 143.69 27.12 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.95 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 141' ' ' VAL . . . . . 0.459 HG22 HG21 ' A' ' 138' ' ' ILE . 41.3 t -127.23 121.17 56.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.208 179.862 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 72.4 t -125.71 145.27 33.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.153 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 29.1 mm -115.8 141.82 31.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.118 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 48.2 t30 -129.45 142.92 50.67 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.916 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 44.7 t-20 -129.13 136.6 50.42 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.831 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 44.3 t -68.06 105.49 2.06 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.829 -179.844 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 42.9 p -92.03 -52.29 4.79 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.168 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 47.2 t -65.98 111.52 3.38 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.835 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 47.6 m-85 -71.4 107.65 4.44 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.961 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -84.44 41.22 0.82 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.076 179.911 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 88.61 -19.57 36.02 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.496 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 2.7 m -100.67 143.22 31.1 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.798 0.332 . . . . 0.0 110.876 -179.74 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 14.7 mp0 -101.16 132.77 46.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.891 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 74.25 61.35 3.24 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.506 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 -173.56 0.74 Allowed 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.672 2.248 . . . . 0.0 112.357 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 69.6 m -107.94 155.01 20.79 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.868 -179.854 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -103.92 149.14 25.38 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.079 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 158' ' ' SER . . . . . 0.437 ' HB2' ' CE1' ' A' ' 112' ' ' PHE . 53.1 p -117.21 171.59 7.85 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.89 -179.803 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -146.79 133.55 20.03 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.12 179.875 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 38.7 m-85 -104.48 113.75 27.53 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.905 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 98.7 t -109.13 123.93 65.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.129 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 40.4 m -98.02 123.88 42.24 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.134 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 9.8 m-85 -105.99 146.73 29.69 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.923 -179.907 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 86.9 mt -79.41 -36.24 17.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.133 179.883 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 31.9 mmm-85 -106.93 117.08 33.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.872 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 74.2 m -49.24 -51.11 35.39 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.846 -179.771 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 18.5 mm-40 -48.74 -51.02 31.11 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.897 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -54.26 -45.13 72.34 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.871 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -60.24 -62.61 1.74 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.094 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 50.6 mt -41.57 -66.38 0.35 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.9 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 79.2 mtp180 -48.37 -54.43 13.97 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.869 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 172' ' ' ALA . . . . . 0.591 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -43.51 -35.16 1.56 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.083 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 173' ' ' ILE . . . . . 0.541 HG23 ' HB3' ' A' ' 188' ' ' ALA . 63.6 mt -77.92 -40.46 26.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.183 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 88.2 mm-40 -61.36 -27.57 68.61 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.914 179.918 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 175' ' ' CYS . . . . . 0.477 ' O ' ' CG2' ' A' ' 179' ' ' VAL . 1.9 m -93.82 -42.1 9.29 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.882 -179.914 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 176' ' ' VAL . . . . . 0.591 HG23 ' O ' ' A' ' 172' ' ' ALA . 10.3 t -58.07 -36.27 56.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.14 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 177' ' ' ASN . . . . . 0.418 ' O ' HG23 ' A' ' 179' ' ' VAL . 12.3 t-20 -68.41 150.83 47.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.873 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 178' ' ' ASN . . . . . 0.411 ' CG ' ' O ' ' A' ' 178' ' ' ASN . 37.4 t30 57.66 42.84 23.25 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.854 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 179' ' ' VAL . . . . . 0.477 ' CG2' ' O ' ' A' ' 175' ' ' CYS . 62.0 t -128.68 135.03 63.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.142 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 90.3 t -98.97 106.38 18.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.129 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 181' ' ' VAL . . . . . 0.457 HG21 HD12 ' A' ' 186' ' ' LEU . 57.1 t -114.18 121.32 66.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.115 179.909 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 14.4 m-20 51.23 28.45 4.17 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.844 179.908 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 81.47 32.01 32.07 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.493 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 4.2 mpt_? -138.69 124.47 19.79 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.878 0.37 . . . . 0.0 110.878 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 19.4 m -76.65 93.28 3.6 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.122 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 186' ' ' LEU . . . . . 0.457 HD12 HG21 ' A' ' 181' ' ' VAL . 51.0 mt -62.01 125.98 25.76 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.875 179.962 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 9.5 tptm -122.86 112.28 17.68 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.922 179.788 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 188' ' ' ALA . . . . . 0.541 ' HB3' HG23 ' A' ' 173' ' ' ILE . . . -107.57 153.19 23.22 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.128 179.826 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 48.0 m -139.2 156.34 47.17 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.877 -179.765 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 190' ' ' LEU . . . . . 0.597 HD21 ' O ' ' A' ' 108' ' ' LYS . 1.5 tm? -120.2 102.28 8.4 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.913 179.968 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 55.2 27.85 47.7 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.494 179.87 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 192' ' ' THR . . . . . 0.416 HG21 ' HA ' ' A' ' 196' ' ' CYS . 51.3 p -138.06 138.57 38.91 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.848 0.356 . . . . 0.0 111.12 -179.829 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 193' ' ' THR . . . . . 0.524 HG23 ' HG3' ' A' ' 194' ' ' LYS . 8.5 t -119.41 -30.14 4.96 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.122 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 194' ' ' LYS . . . . . 0.524 ' HG3' HG23 ' A' ' 193' ' ' THR . 69.6 mttt -111.57 -72.18 0.73 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.912 179.866 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 195' ' ' TYR . . . . . . . . . . . . . 7.3 m-85 -108.64 131.83 54.5 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.904 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 196' ' ' CYS . . . . . 0.416 ' HA ' HG21 ' A' ' 192' ' ' THR . 26.5 p -63.31 177.19 0.67 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.901 179.964 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 1.8 m -159.29 167.89 27.8 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.827 -179.771 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 198' ' ' TYR . . . . . . . . . . . . . 36.3 p90 -161.21 156.95 24.96 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.944 -179.857 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 65.0 p -167.9 148.98 5.22 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.883 -179.83 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . -115.31 -162.73 13.67 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.466 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 201' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 132.91 23.64 Favored 'Cis proline' 0 C--N 1.341 0.173 0 C-N-CA 122.674 -1.803 . . . . 0.0 112.36 -0.013 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 202' ' ' SER . . . . . . . . . . . . . 13.0 t -106.39 75.76 1.1 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.819 -179.788 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 1.1 t -108.58 152.3 24.95 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.837 -179.833 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.274 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.487 179.979 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.324 0 N-CA-C 112.438 -0.265 . . . . 0.0 112.438 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 29.1 m -160.78 112.65 1.9 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.839 0.352 . . . . 0.0 110.915 -179.772 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 82.9 p -97.67 168.07 10.57 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.825 -179.759 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 152.65 118.93 0.77 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.505 -179.952 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 15.0 t -111.23 143.54 41.82 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.867 0.365 . . . . 0.0 110.847 -179.739 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 23.8 t -126.53 118.89 25.83 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.86 -179.81 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -123.17 -174.87 14.37 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.461 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -95.44 136.24 36.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.824 0.345 . . . . 0.0 111.058 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 51.4 m -150.73 166.76 29.43 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.826 -179.782 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 30.1 m -73.15 139.16 19.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.183 179.894 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 57.2 ttp180 -126.62 136.86 53.07 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.842 -179.926 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 11.0 t -122.6 155.58 27.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.15 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 106' ' ' VAL . . . . . 0.517 HG13 ' O ' ' A' ' 106' ' ' VAL . 13.0 p -104.37 120.87 55.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.165 179.919 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 4.1 pt20 -173.82 120.88 0.31 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.954 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 35.4 pttt -91.85 41.35 1.07 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.92 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 109' ' ' ASN . . . . . 0.431 ' ND2' ' O ' ' A' ' 163' ' ' TYR . 26.1 t-20 -115.89 40.6 2.75 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.897 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 15.8 tp -143.94 142.06 30.55 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.938 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 99.1 t -122.47 110.97 28.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.13 179.833 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.408 ' CB ' HG21 ' A' ' 192' ' ' THR . 46.4 t80 -102.83 108.03 19.1 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.853 -179.937 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 86.0 t -105.2 134.46 46.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.155 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 34.0 m -124.42 167.04 18.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.08 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 78.58 49.21 6.77 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.541 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 28.8 mt -113.78 139.89 48.75 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.823 0.344 . . . . 0.0 110.91 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 117' ' ' SER . . . . . 0.44 ' H ' HD12 ' A' ' 120' ' ' LEU . 36.0 t -73.83 146.44 44.16 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.872 -179.903 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 25.4 mt-30 -42.19 -29.93 0.27 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.94 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 56.2 ttt180 -88.41 -38.23 15.23 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.872 -179.913 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 120' ' ' LEU . . . . . 0.44 HD12 ' H ' ' A' ' 117' ' ' SER . 44.8 mt -65.18 -33.8 76.87 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.905 179.997 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 121' ' ' ALA . . . . . 0.424 ' HB1' HG23 ' A' ' 143' ' ' ILE . . . -70.16 83.08 0.52 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.151 179.802 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 21.7 m-20 -148.93 147.1 23.07 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.605 0.717 . . . . 0.0 110.86 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 -37.24 9.53 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.708 2.272 . . . . 0.0 112.36 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 14.9 pt-20 -77.29 -44.43 29.74 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.87 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 86.1 t -61.71 -39.93 85.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.158 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 91.2 mt -74.2 -39.31 63.23 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.933 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.63 ' HD2' HD12 ' A' ' 138' ' ' ILE . 2.0 mmmp? -64.64 -30.81 71.83 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.86 179.867 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 14.7 mmt180 -42.44 143.93 1.03 Allowed Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.591 0.71 . . . . 0.0 110.876 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 -4.19 13.51 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.66 2.24 . . . . 0.0 112.337 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 4.8 tt0 -99.98 1.07 42.23 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.895 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 131' ' ' TYR . . . . . . . . . . . . . 30.7 m-85 -121.0 -74.93 0.6 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.888 -179.831 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 58.0 m-85 -122.99 -18.14 6.5 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.867 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -55.59 -23.03 34.41 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.499 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 12.4 ptpt -90.83 -11.36 39.58 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.796 0.331 . . . . 0.0 110.858 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 135' ' ' PHE . . . . . . . . . . . . . 22.9 m-85 -80.42 -33.23 37.12 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.925 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 173.65 -166.25 38.45 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.444 -179.98 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 39.4 tptt -95.65 109.27 21.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.737 0.303 . . . . 0.0 110.911 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.63 HD12 ' HD2' ' A' ' 127' ' ' LYS . 86.2 mt -76.71 140.26 17.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.145 179.864 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 18.6 t60 -114.12 -51.07 2.79 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.9 179.871 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -127.28 135.63 50.84 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.868 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 141' ' ' VAL . . . . . 0.621 ' CG2' HG21 ' A' ' 138' ' ' ILE . 19.2 t -137.49 143.04 35.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.129 179.886 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 74.6 t -145.34 140.18 22.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.132 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 143' ' ' ILE . . . . . 0.424 HG23 ' HB1' ' A' ' 121' ' ' ALA . 24.6 mm -110.94 126.43 68.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.096 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 2.9 m120 -124.45 137.78 54.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.905 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 5.3 p30 -105.37 159.48 15.87 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.908 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 66.9 p -52.17 127.67 22.51 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.89 -179.84 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 22.4 p -99.14 -44.76 6.15 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.143 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 2.1 m -74.5 155.35 38.06 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.854 -179.852 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 79.7 m-85 -108.11 100.17 9.53 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.903 -179.878 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -85.81 -45.9 11.15 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.081 179.892 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 110.02 -20.01 26.91 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.519 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 48.3 m -67.06 142.53 57.12 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.826 0.346 . . . . 0.0 110.853 -179.735 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 2.1 mp0 -70.35 142.53 52.14 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.885 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 82.42 83.59 0.84 Allowed Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.447 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 152.68 69.35 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.688 2.259 . . . . 0.0 112.369 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 55.8 m -117.9 133.78 55.59 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.861 -179.815 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -112.85 149.71 32.73 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.091 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 158' ' ' SER . . . . . 0.403 ' HB2' ' CE1' ' A' ' 112' ' ' PHE . 89.9 p -113.71 158.27 21.14 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.852 -179.803 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -141.08 128.52 21.21 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.102 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 35.9 m-85 -99.91 126.56 46.06 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.932 -179.871 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.6 HG22 HG13 ' A' ' 141' ' ' VAL . 96.6 t -129.09 137.59 56.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.101 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 96.0 m -108.31 134.42 51.16 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.162 180.0 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 163' ' ' TYR . . . . . 0.6 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 16.1 m-85 -111.8 129.51 56.11 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.937 -179.927 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 56.2 mt -61.46 -41.04 88.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.097 -0.502 . . . . 0.0 111.155 179.918 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 82.3 mtt-85 -91.66 113.78 26.14 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.895 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 23.2 t -52.16 -59.54 4.25 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.832 -179.751 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 54.1 tt0 -47.31 -49.19 24.56 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.898 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 4.9 t0 -52.48 -51.16 60.78 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.884 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 169' ' ' ALA . . . . . 0.6 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -54.2 -57.74 10.0 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.078 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 42.0 mt -43.56 -61.43 1.39 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.931 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 41.9 mtt-85 -54.6 -43.51 72.24 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.85 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 172' ' ' ALA . . . . . 0.608 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -54.39 -30.98 53.88 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.123 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 97.3 mt -82.54 -34.51 11.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.103 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 11.2 mm-40 -68.2 -27.82 66.72 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.911 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 175' ' ' CYS . . . . . 0.44 ' O ' ' CG2' ' A' ' 179' ' ' VAL . 2.0 m -93.75 -35.59 12.7 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.89 -179.954 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 176' ' ' VAL . . . . . 0.608 HG23 ' O ' ' A' ' 172' ' ' ALA . 10.5 t -66.48 -29.92 48.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.146 -179.974 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 4.3 t-20 -73.41 126.95 31.36 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.844 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 26.2 t-20 74.41 52.08 0.09 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.863 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 179' ' ' VAL . . . . . 0.446 HG12 HG23 ' A' ' 181' ' ' VAL . 69.5 t -130.83 132.78 63.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.138 179.905 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 86.6 t -92.54 107.44 19.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.182 179.885 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 181' ' ' VAL . . . . . 0.446 HG23 HG12 ' A' ' 179' ' ' VAL . 98.3 t -121.0 113.79 41.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.11 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 4.4 t70 58.78 26.51 14.82 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.905 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 81.33 26.67 51.16 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.508 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 3.1 mpt_? -136.27 123.48 21.77 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.932 0.396 . . . . 0.0 110.872 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 18.3 m -76.26 101.64 5.53 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.154 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 89.0 mt -78.18 125.21 29.03 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.957 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 38.1 mmtt -118.5 117.99 30.49 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.898 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 188' ' ' ALA . . . . . 0.547 ' HB2' HG11 ' A' ' 176' ' ' VAL . . . -106.9 140.72 39.27 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.105 179.81 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 59.3 m -145.03 162.88 35.86 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.853 -179.768 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 190' ' ' LEU . . . . . 0.704 ' O ' HD12 ' A' ' 190' ' ' LEU . 3.5 pp -130.24 153.31 48.74 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.927 180.0 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 79.74 28.39 51.21 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.525 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 192' ' ' THR . . . . . 0.408 HG21 ' CB ' ' A' ' 112' ' ' PHE . 3.0 t -106.18 134.05 49.92 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.862 0.363 . . . . 0.0 111.183 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 193' ' ' THR . . . . . . . . . . . . . 78.3 p -116.15 157.38 24.89 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.14 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 22.7 tptp -114.69 121.57 43.76 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.939 179.873 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 195' ' ' TYR . . . . . . . . . . . . . 31.0 m-85 -50.19 98.73 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.908 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 196' ' ' CYS . . . . . . . . . . . . . 29.6 p -103.17 128.8 50.0 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.934 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 23.3 t -143.89 142.38 30.76 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.839 -179.735 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 198' ' ' TYR . . . . . . . . . . . . . 11.1 p90 -154.4 173.42 16.24 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.92 -179.865 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 9.1 t -96.49 159.94 14.67 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.904 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . 60.92 -166.05 13.69 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.514 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 201' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.78 166.02 75.18 Favored 'Cis proline' 0 C--O 1.231 0.155 0 C-N-CA 122.689 -1.796 . . . . 0.0 112.372 0.067 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 202' ' ' SER . . . . . . . . . . . . . 2.5 m -50.06 154.12 1.22 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.828 -179.826 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 52.2 p -101.09 92.26 4.92 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.837 -179.832 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.289 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.465 179.977 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.327 0 N-CA-C 112.46 -0.256 . . . . 0.0 112.46 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 4.9 m -118.69 115.12 23.85 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.85 0.357 . . . . 0.0 110.879 -179.732 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 14.9 t -126.2 136.05 52.36 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.874 -179.826 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 92.33 65.21 1.11 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.517 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 44.5 t -65.79 145.66 55.7 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.855 0.359 . . . . 0.0 110.868 -179.722 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 59.7 p -88.87 174.11 8.14 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.857 -179.782 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -162.39 169.38 37.68 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.53 -180.0 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -49.89 166.26 0.07 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.793 0.33 . . . . 0.0 111.122 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 70.2 m -124.76 85.72 2.45 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.833 -179.762 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 14.7 p -82.76 148.84 4.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.136 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 13.6 ptp180 -103.48 96.35 6.68 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.825 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 42.6 t -97.28 139.01 20.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.129 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 7.2 p -110.19 142.79 21.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.181 179.905 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 16.7 mm-40 62.69 49.82 3.67 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.93 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 43.9 mtmt -70.86 99.13 1.69 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.931 179.92 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 1.8 p-10 -131.83 50.61 2.22 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.904 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 19.5 tp -142.71 112.7 7.02 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.876 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.731 HG22 HD11 ' A' ' 173' ' ' ILE . 71.2 t -114.38 124.05 70.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.161 179.804 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.52 ' CE1' ' HB2' ' A' ' 158' ' ' SER . 65.2 t80 -106.55 108.32 19.77 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.866 -179.919 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.431 HG22 ' HB2' ' A' ' 188' ' ' ALA . 40.2 t -110.7 132.18 59.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.1 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.549 HG12 ' HB3' ' A' ' 158' ' ' SER . 23.7 m -121.71 160.7 23.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.137 179.919 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 86.33 51.99 3.35 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.496 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 82.4 mt -116.17 134.44 54.92 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.808 0.337 . . . . 0.0 110.96 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 10.6 t -69.48 149.26 48.47 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.854 -179.92 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 1.4 pp0? -47.58 -31.9 4.92 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.96 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 17.0 ttt180 -84.47 -39.75 18.53 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.898 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 83.1 mt -66.68 -28.95 68.86 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.918 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 121' ' ' ALA . . . . . 0.483 ' HB1' ' CG2' ' A' ' 143' ' ' ILE . . . -70.69 85.18 0.64 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.105 179.81 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -148.11 144.29 18.69 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.596 0.712 . . . . 0.0 110.855 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.76 -49.45 0.56 Allowed 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.66 2.24 . . . . 0.0 112.357 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 26.0 mt-10 -66.68 -41.88 87.39 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.806 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.637 HG13 ' CE2' ' A' ' 131' ' ' TYR . 87.8 t -62.64 -42.97 98.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.129 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 89.1 mt -73.18 -42.59 62.56 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.948 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 4.7 mtmp? -61.43 -27.49 68.59 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.934 179.809 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 13.5 mtm180 -53.89 144.01 38.61 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.633 0.73 . . . . 0.0 110.892 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.81 1.89 4.06 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.691 2.261 . . . . 0.0 112.309 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 8.1 mp0 -101.67 -13.85 17.62 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.924 180.0 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 131' ' ' TYR . . . . . 0.637 ' CE2' HG13 ' A' ' 125' ' ' VAL . 52.6 m-85 -109.41 -71.17 0.77 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.899 -179.82 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.457 ' O ' ' N ' ' A' ' 134' ' ' LYS . 25.1 m-85 -122.14 -40.14 2.53 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.895 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 133' ' ' GLY . . . . . 0.404 ' C ' ' O ' ' A' ' 132' ' ' PHE . . . -38.17 -28.57 0.05 OUTLIER Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.709 -0.757 . . . . 0.0 112.48 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.457 ' N ' ' O ' ' A' ' 132' ' ' PHE . 8.8 ptmm? -52.89 -53.79 44.11 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.831 0.348 . . . . 0.0 110.873 -179.949 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 135' ' ' PHE . . . . . 0.41 ' CD1' ' HA ' ' A' ' 172' ' ' ALA . 70.3 m-85 -52.62 -40.22 62.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.909 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -177.66 178.62 48.4 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.476 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 28.2 mtpt -86.15 97.58 10.41 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.774 0.321 . . . . 0.0 110.915 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.428 HG21 ' CG2' ' A' ' 141' ' ' VAL . 71.7 mt -62.06 140.61 18.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.138 179.907 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 17.2 t-80 -97.34 -54.1 3.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.859 179.872 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 140' ' ' LYS . . . . . 0.614 ' HD3' HG23 ' A' ' 142' ' ' VAL . 1.2 tmmt? -126.79 152.1 47.38 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.922 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 141' ' ' VAL . . . . . 0.428 ' CG2' HG21 ' A' ' 138' ' ' ILE . 54.4 t -139.82 145.46 26.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.133 179.915 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.614 HG23 ' HD3' ' A' ' 140' ' ' LYS . 23.5 t -138.9 116.65 12.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.113 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 143' ' ' ILE . . . . . 0.483 ' CG2' ' HB1' ' A' ' 121' ' ' ALA . 7.2 mm -101.57 127.81 54.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.157 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 34.6 m-80 -126.71 106.66 9.53 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.903 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 6.6 p30 -126.83 157.18 39.96 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.89 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 3.3 t -55.82 170.62 0.27 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.817 -179.814 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 31.0 m -76.68 -55.27 5.65 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.148 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 21.9 t -113.92 119.87 38.74 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.884 -179.842 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 27.5 p90 -112.97 133.16 55.06 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.903 -179.861 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -103.41 -44.33 5.17 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.139 179.854 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 116.44 39.42 0.86 Allowed Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.493 -179.994 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 7.3 m -114.55 174.07 6.14 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.771 0.32 . . . . 0.0 110.902 -179.757 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 13.6 pt20 -82.77 133.52 35.14 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.889 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 134.94 -71.98 0.48 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.507 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 120.91 7.62 Favored 'Trans proline' 0 C--N 1.342 0.228 0 C-N-CA 122.696 2.264 . . . . 0.0 112.325 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 4.2 m -120.81 161.15 21.98 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.882 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -108.39 163.66 13.01 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.082 179.938 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 158' ' ' SER . . . . . 0.549 ' HB3' HG12 ' A' ' 114' ' ' VAL . 34.8 p -138.57 156.05 47.83 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.826 -179.782 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -148.9 152.15 35.9 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.083 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 19.8 m-85 -111.94 121.59 45.44 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.906 -179.852 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 61.9 t -109.43 131.62 59.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.114 -0.493 . . . . 0.0 111.079 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 20.8 m -101.26 124.4 46.89 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.116 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 163' ' ' TYR . . . . . 0.646 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 9.5 m-85 -104.53 137.53 42.24 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.946 -179.911 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 68.4 mt -62.21 -49.21 84.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.123 179.934 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 34.0 mtt85 -104.11 127.35 51.69 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.889 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 75.6 m -53.65 -58.2 8.05 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.881 -179.779 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 66.0 mm-40 -43.7 -49.24 7.9 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.872 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -55.54 -49.44 72.64 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.887 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 169' ' ' ALA . . . . . 0.646 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -56.44 -56.03 26.28 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.054 179.989 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 39.5 mt -45.41 -63.3 0.98 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.918 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 46.3 mtp180 -53.75 -48.12 69.98 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.86 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 172' ' ' ALA . . . . . 0.787 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -48.36 -34.14 10.18 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.145 179.899 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 173' ' ' ILE . . . . . 0.731 HD11 HG22 ' A' ' 111' ' ' VAL . 67.3 mt -80.68 -37.26 16.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.147 179.999 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 42.5 mt-30 -63.48 -27.79 69.52 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.952 179.875 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 2.6 t -93.81 -36.73 12.12 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.889 -179.927 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 176' ' ' VAL . . . . . 0.787 HG23 ' O ' ' A' ' 172' ' ' ALA . 11.3 t -58.31 -42.46 83.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.133 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 22.6 t30 -65.94 141.68 58.14 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.855 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 7.3 t30 69.37 51.33 0.5 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.884 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 96.9 t -135.13 137.87 49.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.092 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 94.7 t -98.64 109.21 23.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.125 179.889 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 84.2 t -116.58 102.44 13.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.116 179.918 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 6.9 t70 58.29 35.96 25.28 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.87 179.907 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 78.61 26.22 59.35 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.484 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 30.0 mtt-85 -133.8 115.6 14.7 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.917 0.389 . . . . 0.0 110.839 -179.833 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 23.5 m -79.73 92.76 5.45 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.157 -179.939 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 73.3 mt -62.95 136.46 57.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.927 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 13.6 tptp -123.81 116.43 22.96 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.886 179.8 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 188' ' ' ALA . . . . . 0.431 ' HB2' HG22 ' A' ' 113' ' ' VAL . . . -112.47 140.13 47.47 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.093 179.807 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 74.5 m -140.15 157.94 44.83 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.858 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 190' ' ' LEU . . . . . 0.403 ' HB2' HD13 ' A' ' 173' ' ' ILE . 7.3 tt -131.75 122.66 26.22 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.901 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 109.7 28.51 4.22 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.5 179.909 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 192' ' ' THR . . . . . . . . . . . . . 39.1 p -122.01 116.11 23.71 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.859 0.361 . . . . 0.0 111.123 -179.869 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 193' ' ' THR . . . . . . . . . . . . . 74.3 p -108.62 142.25 39.35 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.128 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 12.9 tmtt? -106.14 -55.97 2.25 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.857 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 195' ' ' TYR . . . . . . . . . . . . . 27.7 t80 -169.81 128.67 0.94 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.929 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 196' ' ' CYS . . . . . . . . . . . . . 20.9 p -164.61 152.93 12.4 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.928 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 66.9 p -40.44 129.29 2.42 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.839 -179.716 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 198' ' ' TYR . . . . . . . . . . . . . 14.2 p90 -105.49 170.02 8.13 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.889 -179.866 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 22.9 t -140.51 158.55 43.83 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.844 -179.815 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 200' ' ' GLY . . . . . 0.484 ' N ' ' O ' ' A' ' 201' ' ' PRO . . . 77.14 80.32 0.65 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.482 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 201' ' ' PRO . . . . . 0.484 ' O ' ' N ' ' A' ' 200' ' ' GLY . 53.4 Cg_endo -69.8 171.55 53.29 Favored 'Cis proline' 0 C--O 1.231 0.163 0 C-N-CA 122.666 -1.806 . . . . 0.0 112.33 0.052 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 202' ' ' SER . . . . . . . . . . . . . 10.2 t -108.77 -48.14 3.35 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.873 -179.825 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 45.0 m -105.14 165.61 10.97 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.833 -179.791 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.317 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.482 -179.984 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.314 0 N-CA-C 112.486 -0.246 . . . . 0.0 112.486 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 6.6 m -98.46 101.91 13.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.894 0.378 . . . . 0.0 110.839 -179.72 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 35.9 p -138.97 148.16 43.13 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.835 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 122.86 52.86 0.21 Allowed Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.483 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.8 t 65.85 41.9 3.65 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.853 0.359 . . . . 0.0 110.828 -179.731 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 42.2 m -97.18 173.82 7.04 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.854 -179.866 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 166.03 -177.75 40.97 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.48 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.437 ' O ' ' C ' ' A' ' 102' ' ' SER . . . -78.81 137.31 37.65 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.853 0.359 . . . . 0.0 111.052 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 102' ' ' SER . . . . . 0.437 ' C ' ' O ' ' A' ' 101' ' ' ALA . 5.2 t -35.27 -43.71 0.24 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.884 -179.824 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 99.7 t -73.06 131.63 34.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.145 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 11.9 mpt_? -78.2 124.25 27.85 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.877 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.498 HG13 ' HD2' ' A' ' 108' ' ' LYS . 2.6 p -129.13 132.87 66.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.141 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 9.8 p -118.68 153.8 20.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.116 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 18.8 mm100 62.31 52.52 3.07 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.949 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.498 ' HD2' HG13 ' A' ' 105' ' ' VAL . 3.1 mppt? -70.98 87.19 0.73 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.925 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 109' ' ' ASN . . . . . 0.409 ' CG ' ' O ' ' A' ' 109' ' ' ASN . 28.7 t-20 -102.66 42.62 1.13 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.884 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 23.3 tp -139.61 146.07 39.31 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.888 -179.995 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.53 HG22 HD11 ' A' ' 173' ' ' ILE . 45.1 t -133.07 107.7 11.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.107 179.828 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.562 ' CE1' ' HB2' ' A' ' 158' ' ' SER . 67.4 t80 -102.88 113.61 27.19 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.907 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 38.2 t -111.18 145.67 17.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.101 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.44 HG12 ' HB3' ' A' ' 158' ' ' SER . 23.1 m -130.97 170.59 19.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.1 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 79.15 51.12 5.47 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.481 179.906 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 23.5 mt -118.03 131.03 56.5 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.829 0.347 . . . . 0.0 110.922 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 117' ' ' SER . . . . . 0.484 ' O ' ' N ' ' A' ' 119' ' ' ARG . 23.1 t -70.95 140.19 50.85 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.812 -179.868 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 118' ' ' GLN . . . . . 0.434 ' C ' ' O ' ' A' ' 117' ' ' SER . 9.5 tp-100 -35.54 -32.06 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.934 -179.979 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.484 ' N ' ' O ' ' A' ' 117' ' ' SER . 18.5 tpp180 -81.49 -47.12 13.56 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.856 -179.91 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 120' ' ' LEU . . . . . 0.453 ' N ' ' O ' ' A' ' 117' ' ' SER . 62.4 mt -61.83 -33.69 74.6 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.952 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -66.09 86.79 0.1 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.095 179.815 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 122' ' ' ASP . . . . . 0.508 ' O ' HD12 ' A' ' 126' ' ' LEU . 0.6 OUTLIER -148.07 144.03 18.38 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.622 0.725 . . . . 0.0 110.871 179.969 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 123' ' ' PRO . . . . . 0.446 ' HA ' HG11 ' A' ' 141' ' ' VAL . 53.3 Cg_endo -69.81 -50.28 0.47 Allowed 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.649 2.232 . . . . 0.0 112.313 -179.984 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 42.7 mt-10 -68.14 -45.68 72.91 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.881 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.415 ' O ' ' CD1' ' A' ' 131' ' ' TYR . 58.4 t -60.03 -39.39 80.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.135 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.508 HD12 ' O ' ' A' ' 122' ' ' ASP . 47.3 mt -74.63 -42.01 59.36 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.942 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.736 ' HA ' HD12 ' A' ' 138' ' ' ILE . 17.3 ttmt -59.48 -30.73 68.75 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.91 179.85 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 46.8 mtt180 -39.94 143.87 0.57 Allowed Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.583 0.706 . . . . 0.0 110.893 179.949 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 2.94 3.1 Favored 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.645 2.23 . . . . 0.0 112.319 -179.984 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -106.67 -30.09 9.2 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.879 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 131' ' ' TYR . . . . . 0.415 ' CD1' ' O ' ' A' ' 125' ' ' VAL . 43.4 m-85 -86.01 -75.05 0.39 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.933 -179.844 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 17.0 m-85 -115.32 -39.72 3.55 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.888 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -52.61 -20.55 7.81 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.488 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.446 ' HD2' ' CG ' ' A' ' 135' ' ' PHE . 0.0 OUTLIER -51.2 -40.96 59.86 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.791 0.329 . . . . 0.0 110.875 -179.964 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 135' ' ' PHE . . . . . 0.446 ' CG ' ' HD2' ' A' ' 134' ' ' LYS . 83.1 m-85 -66.26 -46.38 77.27 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.882 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -173.86 -159.87 21.13 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.506 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 17.0 tptm -91.15 116.23 28.65 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.799 0.333 . . . . 0.0 110.861 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.736 HD12 ' HA ' ' A' ' 127' ' ' LYS . 91.0 mt -73.03 141.89 15.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.081 179.899 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 71.4 t60 -96.15 -44.08 7.45 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.894 179.852 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 15.8 tttm -139.67 142.7 36.94 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.911 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 141' ' ' VAL . . . . . 0.713 HG22 HG21 ' A' ' 138' ' ' ILE . 39.2 t -134.59 110.55 13.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.143 179.864 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 64.9 t -116.06 137.98 48.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.11 179.949 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 143' ' ' ILE . . . . . 0.417 HD11 HD12 ' A' ' 126' ' ' LEU . 43.1 mm -111.82 134.7 53.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.094 179.928 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 34.0 m-20 -131.04 110.97 11.6 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.851 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 5.8 p30 -104.43 146.19 29.21 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.918 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 66.5 m -77.4 120.55 22.56 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.851 -179.824 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 62.8 p -92.19 -46.46 7.73 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.107 -179.91 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 17.8 t -67.49 150.51 48.78 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.868 -179.859 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 149' ' ' TYR . . . . . 0.406 ' O ' ' CD1' ' A' ' 149' ' ' TYR . 18.7 p90 -81.27 109.98 16.3 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.917 -179.882 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -77.85 -43.66 29.64 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.113 179.86 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 93.06 38.85 5.31 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.485 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 95.3 p -116.53 175.36 5.6 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.877 0.37 . . . . 0.0 110.822 -179.698 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 4.6 tm0? -70.04 80.61 0.49 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.942 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 90.86 145.96 15.53 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.525 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 157.36 60.59 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.682 2.255 . . . . 0.0 112.31 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 3.5 m -138.39 130.22 28.12 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.878 -179.877 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -117.41 164.47 14.82 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.125 179.898 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 158' ' ' SER . . . . . 0.562 ' HB2' ' CE1' ' A' ' 112' ' ' PHE . 71.5 p -140.09 154.74 47.13 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.84 -179.779 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -139.08 152.14 47.29 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.082 179.893 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 160' ' ' TYR . . . . . 0.562 ' CZ ' ' CD1' ' A' ' 112' ' ' PHE . 8.5 m-85 -114.0 115.83 28.24 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.933 -179.837 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 29.9 t -110.35 142.61 22.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.134 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 18.7 m -120.44 115.86 24.31 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.119 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 163' ' ' TYR . . . . . 0.661 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 25.0 m-85 -90.32 135.08 33.9 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.933 -179.929 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 64.1 mt -57.73 -42.73 82.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.139 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 17.7 mmm180 -98.25 125.65 43.41 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.888 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 46.6 m -55.26 -62.87 1.38 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.855 -179.781 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 5.4 tp10 -41.89 -55.84 2.95 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.856 -179.906 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 5.9 m-20 -49.59 -45.65 48.21 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.863 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 169' ' ' ALA . . . . . 0.661 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -57.1 -61.78 2.22 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.135 179.959 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 53.7 mt -42.45 -61.74 1.14 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.957 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 59.1 mtp180 -55.7 -51.56 66.87 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.882 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 172' ' ' ALA . . . . . 0.558 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -42.2 -36.58 1.24 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.055 179.915 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 173' ' ' ILE . . . . . 0.601 HD12 HD23 ' A' ' 190' ' ' LEU . 95.2 mt -80.18 -39.1 18.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.257 -0.428 . . . . 0.0 111.177 179.969 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 30.6 mt-30 -62.07 -26.18 68.12 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.92 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 2.2 m -93.76 -38.21 11.4 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.854 -179.92 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 176' ' ' VAL . . . . . 0.663 ' CG1' ' HB2' ' A' ' 188' ' ' ALA . 10.2 t -63.61 -39.74 86.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.128 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 14.1 t30 -63.83 138.66 58.57 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.885 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 49.9 t30 67.74 48.19 1.07 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.913 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 87.0 t -130.1 130.14 65.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.172 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 98.1 t -89.75 109.06 20.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.111 179.965 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 181' ' ' VAL . . . . . 0.503 ' CG2' HD12 ' A' ' 186' ' ' LEU . 87.0 t -117.17 109.85 29.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.1 179.961 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 61.9 m-20 59.85 38.49 21.26 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.831 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 73.71 34.12 56.99 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.486 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 59.0 mtt-85 -143.02 123.25 13.75 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.887 0.375 . . . . 0.0 110.88 -179.867 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 37.7 m -80.39 93.61 6.01 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.153 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 186' ' ' LEU . . . . . 0.503 HD12 ' CG2' ' A' ' 181' ' ' VAL . 45.0 mt -66.07 147.0 54.02 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.876 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 13.9 tppt? -128.0 112.35 14.55 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.913 179.838 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 188' ' ' ALA . . . . . 0.663 ' HB2' ' CG1' ' A' ' 176' ' ' VAL . . . -102.93 129.24 49.58 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.09 179.853 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 19.4 m -161.58 145.11 12.55 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.838 -179.775 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 190' ' ' LEU . . . . . 0.601 HD23 HD12 ' A' ' 173' ' ' ILE . 4.3 pp -118.31 158.65 24.82 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.918 179.987 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 113.05 30.66 2.67 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.481 179.884 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 192' ' ' THR . . . . . . . . . . . . . 39.6 m -109.57 116.44 31.77 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.874 0.369 . . . . 0.0 111.168 -179.917 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 193' ' ' THR . . . . . . . . . . . . . 43.7 m -109.77 129.85 55.58 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.143 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 194' ' ' LYS . . . . . 0.43 ' O ' ' C ' ' A' ' 195' ' ' TYR . 54.5 tttt -84.19 42.48 0.88 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.864 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 195' ' ' TYR . . . . . 0.43 ' C ' ' O ' ' A' ' 194' ' ' LYS . 42.1 p90 35.66 43.45 0.17 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.948 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 196' ' ' CYS . . . . . . . . . . . . . 5.3 t -76.59 123.74 26.56 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.849 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 51.8 p -80.14 143.36 33.95 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.81 -179.746 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 198' ' ' TYR . . . . . 0.496 ' C ' ' CD1' ' A' ' 198' ' ' TYR . 2.9 p90 -175.03 167.51 3.52 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.94 -179.894 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 80.6 p -119.34 142.62 47.97 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.855 -179.853 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . 136.34 -162.83 25.14 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.487 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 201' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 163.64 81.22 Favored 'Cis proline' 0 C--O 1.231 0.161 0 C-N-CA 122.696 -1.793 . . . . 0.0 112.372 0.01 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 202' ' ' SER . . . . . . . . . . . . . 11.8 t -86.72 149.55 24.8 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.84 -179.829 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 13.4 t -40.99 129.43 2.72 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.855 -179.795 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.338 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.481 -179.973 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.335 0 N-CA-C 112.468 -0.253 . . . . 0.0 112.468 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 82.1 p -121.63 138.24 54.41 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.879 0.371 . . . . 0.0 110.841 -179.737 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 4.8 t -40.77 -52.3 3.0 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.85 -179.82 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 99.46 46.73 1.93 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.478 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 2.1 t -116.3 152.98 32.78 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.872 0.368 . . . . 0.0 110.854 -179.717 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 84.5 p -116.15 -44.81 2.88 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.853 -179.823 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 177.42 95.7 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.516 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -75.81 127.09 32.27 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.812 0.339 . . . . 0.0 111.085 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 78.2 p -138.54 129.02 26.12 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.865 -179.813 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 90.9 t -96.18 109.64 23.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.129 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 36.9 ttt-85 -125.11 107.41 10.76 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.854 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 84.3 t -115.52 130.06 70.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.117 179.954 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 8.3 p -74.12 153.75 6.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.133 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 62.2 mm-40 57.85 44.93 19.28 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.935 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 18.9 ptmt -76.7 47.69 0.52 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.917 179.942 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 1.1 p-10 -130.48 -37.11 1.41 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.918 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 8.7 tp -85.98 125.43 33.38 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.894 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.877 HG22 HD11 ' A' ' 173' ' ' ILE . 96.0 t -97.85 131.76 44.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.138 179.847 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.641 ' CD1' ' CE2' ' A' ' 160' ' ' TYR . 34.5 t80 -130.27 117.43 19.81 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.845 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 69.1 t -114.73 135.54 54.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.143 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.953 HG12 ' HB3' ' A' ' 158' ' ' SER . 35.2 m -124.2 168.57 16.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.123 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 81.93 47.15 6.35 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.508 179.999 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 38.0 mt -113.45 137.76 51.08 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.888 0.375 . . . . 0.0 110.931 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 117' ' ' SER . . . . . 0.406 ' O ' ' N ' ' A' ' 120' ' ' LEU . 38.4 t -63.8 141.36 58.8 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.887 -179.915 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 37.0 tt0 -39.26 -37.71 0.45 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.939 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 33.8 tpt85 -79.33 -40.82 29.37 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.874 -179.914 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 120' ' ' LEU . . . . . 0.406 ' N ' ' O ' ' A' ' 117' ' ' SER . 35.8 mt -62.27 -35.88 80.34 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.931 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -66.24 82.99 0.09 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.108 179.787 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 13.1 m-20 -148.06 148.35 29.37 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.555 0.693 . . . . 0.0 110.895 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 -44.34 2.15 Favored 'Trans proline' 0 N--CA 1.465 -0.165 0 C-N-CA 122.711 2.274 . . . . 0.0 112.353 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -71.87 -39.64 69.5 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.901 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.587 ' O ' ' CD1' ' A' ' 131' ' ' TYR . 37.9 t -62.55 -45.32 99.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.133 -179.989 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.565 HD22 ' CE1' ' A' ' 132' ' ' PHE . 67.0 mt -74.43 -40.92 61.65 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.891 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.459 ' HA ' HD12 ' A' ' 138' ' ' ILE . 31.6 mttt -58.32 -31.83 67.92 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.904 179.828 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 15.8 mmt85 -44.24 143.5 1.9 Allowed Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.617 0.722 . . . . 0.0 110.888 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.69 -0.56 7.03 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.72 2.28 . . . . 0.0 112.375 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 25.6 mp0 -101.46 -26.99 13.38 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.892 -179.948 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 131' ' ' TYR . . . . . 0.587 ' CD1' ' O ' ' A' ' 125' ' ' VAL . 39.8 m-85 -88.76 -75.15 0.44 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.921 -179.852 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.565 ' CE1' HD22 ' A' ' 126' ' ' LEU . 10.8 m-85 -110.45 -46.17 3.44 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.872 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -47.7 -21.21 1.37 Allowed Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.501 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.509 ' HD2' ' CD1' ' A' ' 135' ' ' PHE . 0.0 OUTLIER -53.88 -34.99 61.05 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.79 0.329 . . . . 0.0 110.884 -179.995 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 135' ' ' PHE . . . . . 0.509 ' CD1' ' HD2' ' A' ' 134' ' ' LYS . 70.8 m-85 -71.1 -46.03 62.52 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.905 179.958 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -172.6 -127.93 1.01 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.504 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 137' ' ' LYS . . . . . 0.482 ' HG3' HD12 ' A' ' 164' ' ' ILE . 0.3 OUTLIER -117.02 138.8 51.34 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.797 0.332 . . . . 0.0 110.938 179.994 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.459 HD12 ' HA ' ' A' ' 127' ' ' LYS . 82.1 mt -100.03 139.77 20.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.13 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 52.2 t60 -91.04 -54.14 4.08 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.852 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 35.9 ttpt -144.68 144.24 31.13 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.938 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 46.8 t -123.6 145.82 29.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.12 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 59.1 t -136.08 134.77 50.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.095 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 37.1 mm -110.47 132.46 58.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.092 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 43.6 t-20 -126.78 124.14 39.0 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.877 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 16.7 t-20 -117.36 144.97 44.37 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.883 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 3.1 t -72.57 139.57 47.55 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.861 -179.839 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 23.9 m -128.22 -41.67 1.57 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.151 -179.923 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 59.7 p -114.02 114.51 26.24 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.915 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 8.4 p90 -119.91 137.6 53.93 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.93 -179.881 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -104.58 86.23 2.46 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.101 179.87 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 56.92 40.05 89.88 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.487 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 44.4 m -109.11 130.91 55.49 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.789 0.328 . . . . 0.0 110.858 -179.729 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 8.5 pt20 -107.25 82.87 1.73 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.924 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 165.08 83.37 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.458 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.73 99.93 0.78 Allowed 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.674 2.249 . . . . 0.0 112.371 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 83.3 p -117.2 141.77 47.87 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.917 -179.863 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -114.74 156.24 25.2 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.12 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 158' ' ' SER . . . . . 0.953 ' HB3' HG12 ' A' ' 114' ' ' VAL . 22.0 p -128.37 174.12 9.59 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.859 -179.766 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -159.89 141.28 12.66 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.105 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 160' ' ' TYR . . . . . 0.641 ' CE2' ' CD1' ' A' ' 112' ' ' PHE . 35.5 m-85 -100.97 144.5 29.84 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.896 -179.848 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 80.2 t -132.19 135.49 58.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.156 179.879 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 38.2 m -112.42 118.92 36.51 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.161 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 163' ' ' TYR . . . . . 0.551 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 20.0 m-85 -102.44 143.89 31.6 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.953 -179.914 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 164' ' ' ILE . . . . . 0.482 HD12 ' HG3' ' A' ' 137' ' ' LYS . 60.6 mt -68.19 -45.52 82.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.162 179.897 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 19.5 mtm180 -97.71 118.24 33.8 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.881 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 41.9 t -51.53 -58.5 6.13 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.846 -179.782 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 16.5 tt0 -42.4 -53.03 4.41 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.9 -179.938 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -51.85 -51.27 57.9 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.833 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 169' ' ' ALA . . . . . 0.551 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -53.37 -63.27 1.2 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.077 179.989 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 39.5 mt -38.38 -57.83 1.08 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.905 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 171' ' ' ARG . . . . . 0.427 ' O ' ' N ' ' A' ' 174' ' ' GLN . 54.2 mtp180 -58.14 -57.97 10.5 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.873 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 172' ' ' ALA . . . . . 0.68 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -37.67 -35.81 0.15 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.132 179.873 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 173' ' ' ILE . . . . . 0.877 HD11 HG22 ' A' ' 111' ' ' VAL . 73.6 mt -82.47 -41.13 17.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.118 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 174' ' ' GLN . . . . . 0.427 ' N ' ' O ' ' A' ' 171' ' ' ARG . 15.0 mm100 -57.23 -28.28 62.76 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.895 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 3.4 t -93.77 -39.34 10.8 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.88 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 176' ' ' VAL . . . . . 0.68 HG23 ' O ' ' A' ' 172' ' ' ALA . 10.9 t -59.52 -48.51 87.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.132 -179.947 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 10.5 t-20 -59.08 139.12 57.2 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.893 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 4.7 t-20 70.25 45.91 0.63 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.876 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 179' ' ' VAL . . . . . 0.576 HG23 ' O ' ' A' ' 176' ' ' VAL . 84.3 t -125.18 137.72 56.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.138 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 95.6 t -96.51 98.57 7.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.155 179.922 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 181' ' ' VAL . . . . . 0.52 HG21 HD12 ' A' ' 186' ' ' LEU . 47.7 t -111.11 111.82 37.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.169 179.908 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 57.12 42.81 25.15 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.88 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 67.03 35.08 88.74 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.511 -179.89 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 81.9 mtt85 -143.03 136.43 28.38 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.876 0.369 . . . . 0.0 110.906 -179.889 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 23.1 m -92.22 92.19 8.09 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.129 -179.885 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 186' ' ' LEU . . . . . 0.52 HD12 HG21 ' A' ' 181' ' ' VAL . 44.8 mt -61.62 125.11 22.63 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.917 179.929 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 36.0 mmtt -103.09 114.01 27.95 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.862 179.848 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -111.35 132.52 54.35 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.109 179.837 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 16.8 m -149.81 145.28 26.51 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.843 -179.788 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 190' ' ' LEU . . . . . 0.491 ' HB3' HD13 ' A' ' 173' ' ' ILE . 1.3 pt? -123.81 151.1 43.73 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.932 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 73.44 27.25 68.11 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.518 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 192' ' ' THR . . . . . . . . . . . . . 9.8 m -127.46 140.53 52.09 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.872 0.368 . . . . 0.0 111.131 -179.864 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 193' ' ' THR . . . . . . . . . . . . . 13.1 t -107.4 -17.84 14.02 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.132 -179.97 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 30.2 mmtm -97.25 165.72 11.9 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.9 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 195' ' ' TYR . . . . . . . . . . . . . 57.7 m-85 -77.93 -51.02 11.06 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.938 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 196' ' ' CYS . . . . . . . . . . . . . 30.1 p -170.1 130.51 0.96 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.872 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 7.7 t -170.58 161.69 7.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.824 -179.795 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 198' ' ' TYR . . . . . . . . . . . . . 17.3 t80 -64.75 92.76 0.1 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.891 -179.846 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 76.0 p -56.96 146.04 28.23 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.876 -179.874 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 200' ' ' GLY . . . . . 0.405 ' HA3' ' C ' ' A' ' 201' ' ' PRO . . . 158.0 -69.25 0.27 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.507 -179.998 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 201' ' ' PRO . . . . . 0.405 ' C ' ' HA3' ' A' ' 200' ' ' GLY . 53.8 Cg_endo -69.7 -32.23 4.04 Favored 'Cis proline' 0 C--N 1.341 0.157 0 C-N-CA 122.686 -1.797 . . . . 0.0 112.342 -0.017 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 202' ' ' SER . . . . . . . . . . . . . 1.3 t -168.44 134.2 1.81 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.847 -179.807 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 82.9 p -130.69 124.01 30.62 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.852 -179.829 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.366 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.521 179.997 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.315 0 N-CA-C 112.514 -0.234 . . . . 0.0 112.514 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 50.3 m -152.19 135.49 15.91 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.893 0.378 . . . . 0.0 110.831 -179.758 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 99.5 p -154.65 154.73 33.44 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.878 -179.837 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 94.05 179.83 38.41 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.44 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 22.7 t -129.34 -59.3 1.1 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.854 0.359 . . . . 0.0 110.853 -179.709 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 6.4 t -72.78 105.31 4.29 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.872 -179.83 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -103.09 -166.03 25.83 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.52 -179.992 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -93.3 120.45 33.6 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.808 0.337 . . . . 0.0 111.103 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 74.7 m -73.27 80.48 1.33 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.904 -179.822 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 10.8 m -89.86 151.66 3.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.18 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 17.7 ptt180 -126.44 147.17 49.84 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.845 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 79.6 t -119.89 112.65 37.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.131 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 1.2 p -93.21 134.07 32.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.133 179.915 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 49.8 tt0 -159.85 139.22 11.12 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.902 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.437 ' HG3' HD21 ' A' ' 170' ' ' LEU . 20.3 pttm -97.68 59.91 1.52 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.923 179.963 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -128.43 -38.59 1.74 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.914 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 17.1 tp -88.16 143.03 27.29 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.93 179.932 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.687 HG22 HD11 ' A' ' 173' ' ' ILE . 87.9 t -115.6 132.62 64.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.152 179.86 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.568 ' CE2' ' CG1' ' A' ' 114' ' ' VAL . 50.3 t80 -128.65 106.68 9.12 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.871 -179.936 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.455 HG22 ' HB2' ' A' ' 188' ' ' ALA . 55.9 t -103.46 122.05 55.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.12 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.568 ' CG1' ' CE2' ' A' ' 112' ' ' PHE . 18.7 m -110.66 152.65 12.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.111 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 94.2 37.7 5.31 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.524 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 116' ' ' LEU . . . . . 0.419 ' O ' ' HB3' ' A' ' 157' ' ' ALA . 30.0 mt -101.64 134.38 44.86 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.834 0.35 . . . . 0.0 110.889 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 117' ' ' SER . . . . . 0.437 ' O ' ' N ' ' A' ' 120' ' ' LEU . 24.4 t -68.71 141.33 55.33 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.874 -179.932 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 43.6 tt0 -42.27 -25.7 0.08 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.881 -179.926 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 6.3 tpm_? -89.83 -36.32 15.17 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.83 -179.914 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 120' ' ' LEU . . . . . 0.437 ' N ' ' O ' ' A' ' 117' ' ' SER . 32.2 mt -70.25 -32.25 70.01 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.879 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -70.19 84.67 0.55 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.117 179.77 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -146.31 146.71 28.64 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.588 0.709 . . . . 0.0 110.838 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 -46.23 1.28 Allowed 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.666 2.244 . . . . 0.0 112.333 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -70.64 -38.13 73.85 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.875 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.484 ' O ' ' CD1' ' A' ' 131' ' ' TYR . 87.3 t -65.76 -50.84 68.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.085 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.622 HD22 ' CE1' ' A' ' 132' ' ' PHE . 89.8 mt -68.41 -37.16 80.08 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.901 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.418 ' HA ' HD12 ' A' ' 138' ' ' ILE . 27.6 mttm -62.25 -37.46 85.53 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.863 179.874 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 2.5 mmp_? -43.29 143.88 1.32 Allowed Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.607 0.718 . . . . 0.0 110.839 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 -4.28 13.72 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.651 2.234 . . . . 0.0 112.338 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 1.3 tm-20 -94.18 -16.26 23.86 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.918 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 131' ' ' TYR . . . . . 0.484 ' CD1' ' O ' ' A' ' 125' ' ' VAL . 61.8 m-85 -102.53 -72.06 0.7 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.929 -179.857 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.622 ' CE1' HD22 ' A' ' 126' ' ' LEU . 61.1 m-85 -122.44 -39.6 2.55 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.862 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -41.24 -26.43 0.19 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.484 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.406 ' N ' ' O ' ' A' ' 132' ' ' PHE . 8.5 ptmm? -47.0 -39.13 11.94 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.808 0.337 . . . . 0.0 110.946 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 135' ' ' PHE . . . . . 0.54 ' CE1' ' HA ' ' A' ' 172' ' ' ALA . 66.0 m-85 -63.18 -45.6 91.01 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.87 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 173.58 -148.19 10.03 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.483 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 16.6 tttm -95.42 115.71 27.8 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.828 0.347 . . . . 0.0 110.93 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.548 HG21 ' CG2' ' A' ' 141' ' ' VAL . 86.2 mt -71.63 140.09 18.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.109 179.906 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 34.3 t-80 -82.12 -59.62 2.5 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.883 179.871 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 39.9 tptt -140.13 151.22 45.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.966 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 141' ' ' VAL . . . . . 0.548 ' CG2' HG21 ' A' ' 138' ' ' ILE . 88.3 t -136.97 122.42 26.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.133 179.933 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 43.7 t -125.9 120.23 56.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.132 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 18.2 mm -86.57 136.71 22.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.133 179.902 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 5.7 m120 -128.48 134.35 48.7 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.897 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 88.5 m-20 -126.19 170.38 11.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.87 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 58.3 m -99.07 118.21 35.32 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.886 -179.863 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 10.7 t -118.47 40.8 3.13 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.128 -179.892 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 66.7 m -114.01 162.7 16.1 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.863 -179.849 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 149' ' ' TYR . . . . . 0.578 ' CD2' ' O ' ' A' ' 149' ' ' TYR . 46.5 p90 -115.98 95.65 5.21 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.933 -179.901 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -109.84 -42.35 4.27 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.113 179.882 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 108.83 39.94 1.65 Allowed Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.483 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 23.6 m -104.21 167.38 9.79 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.805 0.336 . . . . 0.0 110.881 -179.727 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 6.7 tp-100 -106.23 141.44 37.57 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.921 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 49.02 82.62 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.482 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.73 170.54 16.3 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.687 2.258 . . . . 0.0 112.378 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 21.1 m -128.94 148.6 50.94 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.864 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 157' ' ' ALA . . . . . 0.419 ' HB3' ' O ' ' A' ' 116' ' ' LEU . . . -116.04 164.17 14.83 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.091 179.922 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 158' ' ' SER . . . . . 0.4 ' HB2' ' CE1' ' A' ' 112' ' ' PHE . 51.1 p -139.58 158.68 43.71 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.882 -179.827 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -139.71 145.0 37.8 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.081 179.878 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 160' ' ' TYR . . . . . 0.471 ' CZ ' ' CD1' ' A' ' 112' ' ' PHE . 89.1 m-85 -104.73 125.95 51.32 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.918 -179.841 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 85.7 t -122.11 130.92 74.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.133 179.895 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 20.6 m -111.53 129.79 55.94 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.122 -179.908 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 163' ' ' TYR . . . . . 0.51 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 33.4 m-85 -105.27 160.0 15.44 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.918 -179.93 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 63.0 mt -84.51 -58.82 3.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.147 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 22.2 mmt180 -85.85 125.38 33.25 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.866 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 17.4 m -49.19 -60.55 2.7 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.878 -179.797 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 167' ' ' GLU . . . . . 0.47 ' HA ' HD12 ' A' ' 170' ' ' LEU . 29.1 tt0 -40.89 -54.91 2.61 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.91 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 7.4 t70 -49.68 -49.91 45.62 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.901 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 169' ' ' ALA . . . . . 0.51 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -57.67 -54.18 49.8 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.132 179.935 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 170' ' ' LEU . . . . . 0.47 HD12 ' HA ' ' A' ' 167' ' ' GLU . 35.8 mt -44.09 -60.96 1.64 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.883 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 85.5 mtt180 -58.84 -42.99 90.6 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.892 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 172' ' ' ALA . . . . . 0.659 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -49.42 -35.24 18.55 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.096 179.939 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 173' ' ' ILE . . . . . 0.687 HD11 HG22 ' A' ' 111' ' ' VAL . 82.6 mt -86.47 -40.7 14.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.153 179.97 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 77.3 mt-30 -62.39 -27.19 68.91 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.923 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 16.1 m -93.79 -42.21 9.25 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.941 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 176' ' ' VAL . . . . . 0.659 HG23 ' O ' ' A' ' 172' ' ' ALA . 9.9 t -59.05 -40.48 80.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.137 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 177' ' ' ASN . . . . . 0.435 ' C ' ' OD1' ' A' ' 177' ' ' ASN . 0.8 OUTLIER -66.49 145.18 55.93 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.916 179.982 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 19.1 t30 68.85 41.61 1.5 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.85 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 95.3 t -121.61 133.12 69.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.112 179.886 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 87.8 t -98.6 103.02 14.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.121 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 97.8 t -111.6 116.39 52.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.111 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER 47.4 43.09 15.13 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.911 179.947 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 71.22 31.29 66.41 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.464 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 32.0 mtp85 -137.09 109.42 7.33 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.883 0.373 . . . . 0.0 110.886 -179.884 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 29.7 m -71.78 92.35 1.21 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.163 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 62.7 mt -60.48 132.86 55.22 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.936 179.963 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -124.89 115.45 20.65 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.865 179.87 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 188' ' ' ALA . . . . . 0.455 ' HB2' HG22 ' A' ' 113' ' ' VAL . . . -107.25 144.06 34.6 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.135 179.801 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 2.4 t -146.58 168.57 20.93 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.869 -179.763 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 190' ' ' LEU . . . . . 0.771 ' N ' HD13 ' A' ' 190' ' ' LEU . 0.0 OUTLIER -125.79 161.46 27.33 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.94 179.995 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 68.18 30.72 73.89 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.494 179.901 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 192' ' ' THR . . . . . 0.4 HG21 ' CD2' ' A' ' 112' ' ' PHE . 29.0 m -88.71 130.2 35.38 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.849 0.356 . . . . 0.0 111.133 -179.827 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 193' ' ' THR . . . . . . . . . . . . . 30.2 m -117.6 131.71 56.63 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.123 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 28.4 pttt -107.86 -16.98 14.18 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.867 179.912 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 195' ' ' TYR . . . . . 0.419 ' O ' ' C ' ' A' ' 196' ' ' CYS . 35.9 t80 -133.14 119.49 20.0 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.906 -179.97 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 196' ' ' CYS . . . . . 0.419 ' C ' ' O ' ' A' ' 195' ' ' TYR . 26.8 p -37.05 130.19 0.84 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.893 179.995 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 10.7 t -96.77 128.1 43.4 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.828 -179.71 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 198' ' ' TYR . . . . . . . . . . . . . 3.2 p90 -125.29 129.16 49.45 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.906 -179.885 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 6.3 t -167.51 126.57 1.33 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.864 -179.808 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . 113.2 175.67 19.33 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.503 179.997 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 201' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.77 177.11 30.02 Favored 'Cis proline' 0 C--O 1.231 0.167 0 C-N-CA 122.682 -1.799 . . . . 0.0 112.347 0.086 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 202' ' ' SER . . . . . . . . . . . . . 19.7 m -120.41 88.98 3.04 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.876 -179.837 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 90.0 p -160.17 150.82 18.74 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.864 -179.812 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.362 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.538 -179.953 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.271 0 N-CA-C 112.479 -0.249 . . . . 0.0 112.479 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 4.9 t -121.32 117.55 27.27 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.851 0.357 . . . . 0.0 110.828 -179.728 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 30.9 t -39.4 -44.25 1.32 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.861 -179.826 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -127.0 87.35 0.34 Allowed Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.485 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 1.1 t -103.51 130.05 50.82 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.83 0.347 . . . . 0.0 110.866 -179.734 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 2.4 t -140.85 129.66 23.03 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.896 -179.853 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 131.17 -78.36 0.38 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.459 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -58.56 154.56 13.97 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.799 0.333 . . . . 0.0 111.117 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 4.0 m -136.71 121.94 19.2 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.831 -179.78 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 93.6 t -92.37 125.28 45.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.129 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 11.6 ptm180 -106.64 146.4 30.78 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.923 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 98.9 t -98.82 104.52 16.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.119 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 34.9 m -117.45 146.58 21.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.12 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 7.5 tt0 -37.15 138.23 0.3 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.937 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.425 ' HA ' HD11 ' A' ' 190' ' ' LEU . 8.8 mptt -97.96 48.83 1.01 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.91 179.914 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 3.3 t30 -90.03 -36.84 14.69 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.836 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 20.0 tp -90.82 127.78 36.48 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.875 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 90.7 t -118.51 123.35 71.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.114 179.856 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.437 ' CZ ' HG12 ' A' ' 114' ' ' VAL . 39.2 t80 -113.34 126.06 54.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.853 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.43 HG22 ' HB2' ' A' ' 188' ' ' ALA . 55.6 t -119.74 141.07 41.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.128 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.437 HG12 ' CZ ' ' A' ' 112' ' ' PHE . 19.8 m -119.73 171.76 7.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.134 179.889 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 73.75 53.56 7.2 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.514 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 29.7 mt -116.25 126.32 53.43 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.827 0.346 . . . . 0.0 110.9 -179.9 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 89.0 p -64.58 153.08 40.32 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.865 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 44.6 tt0 -52.6 -26.53 13.73 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.907 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -87.19 -43.29 12.34 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.88 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 51.9 mt -66.52 -21.16 66.17 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.964 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -71.68 82.99 0.87 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.123 179.755 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -148.98 144.01 17.65 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-O 121.63 0.729 . . . . 0.0 110.893 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -50.51 0.46 Allowed 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.728 2.285 . . . . 0.0 112.339 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 35.0 mt-10 -69.43 -45.39 69.27 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.859 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.592 ' O ' ' CD1' ' A' ' 131' ' ' TYR . 53.5 t -57.94 -42.33 82.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.156 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 77.0 mt -72.47 -44.73 61.91 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.87 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.544 ' HA ' HD12 ' A' ' 138' ' ' ILE . 12.0 ttpp -59.17 -35.13 72.99 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.881 179.853 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 38.4 mtt-85 -38.58 144.6 0.39 Allowed Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.567 0.699 . . . . 0.0 110.889 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.73 0.5 5.53 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.706 2.271 . . . . 0.0 112.329 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -104.98 -7.93 18.92 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.854 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 131' ' ' TYR . . . . . 0.592 ' CD1' ' O ' ' A' ' 125' ' ' VAL . 45.1 m-85 -111.47 -74.93 0.62 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.927 -179.861 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.435 ' O ' ' N ' ' A' ' 134' ' ' LYS . 14.2 m-85 -114.99 -36.34 4.46 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.886 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -42.56 -22.41 0.13 Allowed Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.486 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.435 ' N ' ' O ' ' A' ' 132' ' ' PHE . 5.3 mtpt -49.22 -59.5 3.62 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.813 0.34 . . . . 0.0 110.896 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 135' ' ' PHE . . . . . 0.57 ' CE1' ' HA ' ' A' ' 172' ' ' ALA . 82.2 m-85 -47.89 -42.55 27.18 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.889 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 173.84 -168.31 41.12 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.487 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 13.5 tttt -82.68 117.6 22.73 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.751 0.31 . . . . 0.0 110.901 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.544 HD12 ' HA ' ' A' ' 127' ' ' LYS . 68.5 mt -77.0 144.88 11.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.167 179.859 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 9.8 t-80 -88.89 -57.62 2.84 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.879 179.846 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 42.4 tttt -142.13 149.24 39.54 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.894 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 141' ' ' VAL . . . . . 0.508 ' CG2' HG21 ' A' ' 138' ' ' ILE . 59.7 t -133.67 140.74 45.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.144 179.855 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 84.3 t -134.66 129.79 52.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.154 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 51.9 mm -100.33 131.32 48.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.136 179.916 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 3.7 m120 -128.67 117.45 21.21 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.881 179.961 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 3.0 p-10 -100.14 140.3 34.58 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.885 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 43.9 t -80.51 121.69 26.08 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.881 -179.862 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 90.3 m -83.17 -42.65 17.06 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.134 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 17.0 t -102.71 109.67 21.34 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.894 -179.877 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 3.3 p90 -105.35 154.19 20.62 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.918 -179.847 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -75.08 -46.9 31.6 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.129 179.877 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 96.64 39.41 4.16 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.451 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 19.2 m -106.64 -57.15 2.1 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.813 0.339 . . . . 0.0 110.866 -179.769 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 17.7 mp0 -104.02 -52.29 2.98 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.881 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 160.57 176.77 33.04 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.487 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 121.08 7.77 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.695 2.263 . . . . 0.0 112.335 -179.929 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 80.0 p -132.65 112.5 12.08 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.855 -179.844 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -91.3 168.56 11.49 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.081 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 7.2 m -130.63 168.14 17.61 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.872 -179.82 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -146.74 150.96 36.39 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.106 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 160' ' ' TYR . . . . . 0.424 ' CZ ' ' CD1' ' A' ' 112' ' ' PHE . 7.1 m-85 -116.48 123.01 46.42 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.949 -179.838 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 87.3 t -112.56 142.2 25.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.124 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 32.9 m -113.36 118.3 34.2 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.141 -179.926 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 24.4 m-85 -98.57 150.19 21.98 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.907 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 57.4 mt -88.94 -42.09 14.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.158 179.905 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 75.4 mtp180 -94.67 119.31 33.11 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.895 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 29.3 m -49.2 -60.09 3.11 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.859 -179.776 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 19.5 mt-10 -42.92 -53.02 4.91 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.899 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -49.84 -49.05 50.53 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.849 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -56.62 -58.73 6.82 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.119 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 56.2 mt -41.0 -59.65 1.4 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.863 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 54.0 mtp180 -59.99 -44.23 94.65 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.91 179.948 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 172' ' ' ALA . . . . . 0.613 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -47.96 -36.12 11.98 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.11 179.937 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 64.7 mt -79.87 -42.67 22.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.085 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 40.3 mt-30 -65.26 -24.61 67.36 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.928 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 175' ' ' CYS . . . . . 0.494 ' O ' ' CG2' ' A' ' 179' ' ' VAL . 3.3 t -93.89 -38.94 10.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.849 -179.932 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 176' ' ' VAL . . . . . 0.613 HG23 ' O ' ' A' ' 172' ' ' ALA . 9.8 t -64.34 -26.97 41.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.139 -179.985 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 12.5 t30 -75.61 146.63 40.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.869 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 42.1 t30 59.89 41.43 17.85 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.887 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 179' ' ' VAL . . . . . 0.494 ' CG2' ' O ' ' A' ' 175' ' ' CYS . 85.9 t -121.12 135.96 59.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.133 179.917 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 99.7 t -104.15 122.98 57.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.147 179.895 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 181' ' ' VAL . . . . . 0.465 HG21 ' CD1' ' A' ' 186' ' ' LEU . 60.6 t -128.28 103.38 9.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.114 179.949 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 5.9 m-20 55.24 37.82 29.47 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.857 179.91 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 81.02 36.78 20.81 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.476 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -141.55 121.36 13.53 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.893 0.378 . . . . 0.0 110.866 -179.855 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 27.6 m -84.23 92.9 8.07 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.144 -179.891 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 186' ' ' LEU . . . . . 0.465 ' CD1' HG21 ' A' ' 181' ' ' VAL . 88.5 mt -69.59 120.74 15.83 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.893 179.991 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 14.8 mtmm -121.51 122.89 40.73 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.892 179.8 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 188' ' ' ALA . . . . . 0.43 ' HB2' HG22 ' A' ' 113' ' ' VAL . . . -107.7 146.18 32.43 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.104 179.834 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 53.2 m -139.05 169.52 17.64 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.862 -179.821 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 190' ' ' LEU . . . . . 0.433 ' HA ' HD22 ' A' ' 190' ' ' LEU . 0.7 OUTLIER -127.8 125.73 40.38 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.942 179.977 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 69.57 28.87 71.81 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.493 179.915 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 192' ' ' THR . . . . . . . . . . . . . 4.4 p -117.88 133.82 55.55 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.867 0.365 . . . . 0.0 111.128 -179.817 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 193' ' ' THR . . . . . . . . . . . . . 68.9 p -122.04 99.76 6.61 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.146 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 21.7 mmtt -99.91 86.0 3.19 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.909 179.908 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 195' ' ' TYR . . . . . . . . . . . . . 45.7 t80 -175.0 158.98 2.57 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.9 -179.925 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 196' ' ' CYS . . . . . . . . . . . . . 55.6 m -83.35 95.74 8.3 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.834 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 59.5 p -117.99 83.93 2.08 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.846 -179.757 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 198' ' ' TYR . . . . . 0.409 ' CD1' ' O ' ' A' ' 198' ' ' TYR . 10.9 p90 -103.67 104.48 14.52 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.906 -179.868 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 82.8 p -149.78 160.02 43.89 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.836 -179.865 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 200' ' ' GLY . . . . . 0.426 ' HA2' ' C ' ' A' ' 201' ' ' PRO . . . 88.99 172.07 46.06 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.494 -179.987 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 201' ' ' PRO . . . . . 0.426 ' C ' ' HA2' ' A' ' 200' ' ' GLY . 53.7 Cg_endo -69.8 165.13 77.57 Favored 'Cis proline' 0 C--N 1.341 0.162 0 C-N-CA 122.692 -1.795 . . . . 0.0 112.342 0.073 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 202' ' ' SER . . . . . . . . . . . . . 93.0 p -151.94 156.84 40.86 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.901 -179.855 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 17.6 t -98.11 149.89 22.03 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.818 -179.769 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.343 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.515 179.995 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.309 0 N-CA-C 112.496 -0.242 . . . . 0.0 112.496 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 8.6 t -169.84 115.78 0.54 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.89 0.376 . . . . 0.0 110.873 -179.7 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 50.9 m -104.69 122.37 45.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.861 -179.799 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -61.39 -115.1 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.519 -179.985 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 52.1 p -142.6 116.63 9.4 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.872 0.368 . . . . 0.0 110.866 -179.736 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 11.8 p -38.75 -39.66 0.53 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.87 -179.86 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 117.93 114.88 2.68 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.498 -179.957 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.622 ' O ' HG23 ' A' ' 103' ' ' VAL . . . -55.5 118.12 4.19 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.798 0.332 . . . . 0.0 111.126 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 102' ' ' SER . . . . . 0.439 ' C ' ' O ' ' A' ' 101' ' ' ALA . 28.7 t 34.46 39.78 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.892 -179.734 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.622 HG23 ' O ' ' A' ' 101' ' ' ALA . 82.7 t -94.91 99.65 9.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.148 179.939 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -100.15 109.74 22.01 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.905 -179.987 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.752 HG21 ' HB ' ' A' ' 193' ' ' THR . 13.5 p -114.43 141.19 31.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.118 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 94.7 t -118.93 95.86 3.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.11 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.451 ' CD ' HD22 ' A' ' 110' ' ' LEU . 37.8 mt-30 -151.82 118.52 5.74 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.905 179.994 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 28.2 ttmt -103.8 -37.82 7.3 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.931 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 16.1 p30 -93.12 39.38 1.05 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.908 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 110' ' ' LEU . . . . . 0.451 HD22 ' CD ' ' A' ' 107' ' ' GLN . 26.2 tp -113.49 116.3 29.36 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.873 -179.999 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 99.5 t -106.48 109.68 28.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.213 179.775 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.483 ' CZ ' ' CG1' ' A' ' 114' ' ' VAL . 40.4 t80 -100.64 107.09 18.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.924 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 75.0 t -106.35 138.57 31.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.139 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.483 ' CG1' ' CZ ' ' A' ' 112' ' ' PHE . 31.0 m -122.68 160.79 24.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.101 179.913 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 81.54 53.21 3.89 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.491 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 32.9 mt -106.17 120.74 42.61 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.778 0.323 . . . . 0.0 110.938 -179.903 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 117' ' ' SER . . . . . 0.42 ' O ' ' N ' ' A' ' 120' ' ' LEU . 26.3 t -64.65 142.82 58.29 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.883 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 118' ' ' GLN . . . . . 0.439 ' CD ' ' C ' ' A' ' 118' ' ' GLN . 0.7 OUTLIER -36.65 -43.71 0.43 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.917 -179.942 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 25.9 tpt180 -74.2 -42.32 59.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.852 -179.926 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 120' ' ' LEU . . . . . 0.42 ' N ' ' O ' ' A' ' 117' ' ' SER . 40.1 mt -61.49 -31.35 71.33 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.922 -179.987 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -68.5 83.37 0.27 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.134 179.801 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 73.1 m-20 -148.96 143.18 16.79 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.574 0.702 . . . . 0.0 110.899 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.86 -50.78 0.42 Allowed 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.67 2.247 . . . . 0.0 112.335 -179.925 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -65.46 -51.33 60.91 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.881 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.644 ' CG1' ' CZ ' ' A' ' 131' ' ' TYR . 64.3 t -54.02 -46.59 65.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.112 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.423 HD22 ' CE1' ' A' ' 132' ' ' PHE . 83.0 mt -66.99 -42.79 84.44 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.895 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.539 ' HA ' HD12 ' A' ' 138' ' ' ILE . 20.2 tttm -58.17 -40.46 81.51 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.884 179.845 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 34.6 mtp180 -38.24 143.29 0.43 Allowed Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.598 0.713 . . . . 0.0 110.872 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 1.53 4.37 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.626 2.217 . . . . 0.0 112.321 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 35.2 mm-40 -99.68 -27.99 13.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.848 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 131' ' ' TYR . . . . . 0.644 ' CZ ' ' CG1' ' A' ' 125' ' ' VAL . 55.7 m-85 -90.54 -68.27 0.8 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.92 -179.82 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.493 ' O ' ' N ' ' A' ' 134' ' ' LYS . 12.8 m-85 -116.95 -52.5 2.52 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.894 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 133' ' ' GLY . . . . . 0.402 ' C ' ' O ' ' A' ' 132' ' ' PHE . . . -37.8 -27.37 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.5 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.493 ' N ' ' O ' ' A' ' 132' ' ' PHE . 19.5 ptmt -43.04 -49.64 6.09 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.814 0.34 . . . . 0.0 110.851 -179.93 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 135' ' ' PHE . . . . . 0.469 ' CZ ' ' CG2' ' A' ' 176' ' ' VAL . 58.0 m-85 -63.3 -47.38 82.51 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.915 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -173.61 -172.26 38.85 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.755 -0.735 . . . . 0.0 112.477 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 22.8 mtmm -79.23 122.93 26.92 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.777 0.322 . . . . 0.0 110.872 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.539 HD12 ' HA ' ' A' ' 127' ' ' LYS . 87.7 mt -79.92 141.64 15.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.111 179.871 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 61.5 t-80 -91.02 -49.07 6.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.852 179.868 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 76.8 tttt -146.28 153.47 40.61 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.897 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 42.2 t -132.4 140.24 48.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.156 179.881 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 93.3 t -133.23 131.52 58.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.143 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 43.5 mm -111.67 121.99 65.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.138 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 11.1 t30 -114.49 118.69 34.5 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.89 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 28.5 m-80 -103.67 147.86 26.73 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.869 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 23.0 t -87.71 129.66 35.08 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.839 -179.861 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 147' ' ' THR . . . . . 0.445 HG23 ' N ' ' A' ' 148' ' ' SER . 10.1 t -109.12 -42.68 4.35 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.169 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 148' ' ' SER . . . . . 0.445 ' N ' HG23 ' A' ' 147' ' ' THR . 25.3 t -67.61 123.35 20.23 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.844 -179.869 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 40.7 p90 -74.06 141.79 45.7 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.878 -179.872 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -102.65 -50.61 3.51 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.125 179.844 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 82.78 -19.75 10.97 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.489 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 66.9 m -111.18 -51.66 2.85 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.813 0.34 . . . . 0.0 110.848 -179.721 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 153' ' ' GLN . . . . . 0.412 ' O ' ' C ' ' A' ' 154' ' ' GLY . 37.4 mt-30 -107.23 112.46 25.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.878 -179.951 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 154' ' ' GLY . . . . . 0.412 ' C ' ' O ' ' A' ' 153' ' ' GLN . . . -37.18 146.12 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.467 -179.952 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.76 124.07 10.72 Favored 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.7 2.267 . . . . 0.0 112.342 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 90.0 p -126.99 122.78 35.49 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.817 -179.818 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -87.57 162.61 17.09 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.05 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 94.2 p -136.36 163.2 31.0 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.845 -179.813 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -146.76 148.77 32.29 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.067 179.917 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 160' ' ' TYR . . . . . 0.506 ' CZ ' ' HB3' ' A' ' 194' ' ' LYS . 11.0 m-85 -112.73 139.53 48.26 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.948 -179.873 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 71.4 t -130.3 121.43 51.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.16 179.896 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 87.2 m -99.52 129.0 45.66 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.13 -179.93 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 163' ' ' TYR . . . . . 0.554 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 52.7 m-85 -110.37 147.07 34.68 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.906 -179.88 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 53.1 mt -67.42 -60.62 2.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.123 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 46.9 mtp85 -82.43 112.99 19.88 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.893 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 74.0 m -52.45 -49.38 64.74 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.882 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 16.5 tt0 -44.5 -55.64 4.93 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.921 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 64.8 m-20 -55.84 -45.86 78.29 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.858 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 169' ' ' ALA . . . . . 0.554 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -58.48 -59.85 4.73 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.063 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 46.1 mt -42.65 -61.56 1.21 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.892 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 1.3 mpt_? -54.93 -50.38 68.99 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.835 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 172' ' ' ALA . . . . . 0.706 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -43.52 -36.73 2.15 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.091 179.933 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 173' ' ' ILE . . . . . 0.476 HG23 ' HB3' ' A' ' 188' ' ' ALA . 73.6 mt -78.77 -40.79 23.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.142 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 33.7 mt-30 -60.01 -30.22 69.0 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.915 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 1.8 m -93.8 -39.91 10.48 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.832 -179.895 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 176' ' ' VAL . . . . . 0.706 HG23 ' O ' ' A' ' 172' ' ' ALA . 10.6 t -59.56 -45.43 94.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.156 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 177' ' ' ASN . . . . . 0.448 ' OD1' ' N ' ' A' ' 178' ' ' ASN . 37.0 t30 -53.92 146.17 14.79 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.909 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 178' ' ' ASN . . . . . 0.448 ' N ' ' OD1' ' A' ' 177' ' ' ASN . 10.4 m120 57.83 47.26 15.61 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.891 -180.0 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 95.3 t -132.43 139.76 49.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.145 179.893 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 95.4 t -93.97 114.02 29.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.101 179.96 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 96.0 t -120.86 105.87 17.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.156 179.879 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 6.5 t0 65.62 35.32 7.13 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.878 179.928 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 81.19 -14.03 29.83 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.493 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 10.6 mpt_? -102.94 112.7 25.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.867 0.365 . . . . 0.0 110.863 -179.869 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 25.3 m -70.9 93.7 1.0 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.17 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 83.3 mt -70.97 149.5 46.61 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.947 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 13.5 ttpt -136.36 126.45 26.18 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.928 179.863 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 188' ' ' ALA . . . . . 0.476 ' HB3' HG23 ' A' ' 173' ' ' ILE . . . -112.38 141.91 45.54 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.139 179.801 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 8.5 t -139.86 165.56 26.99 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.868 -179.748 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 190' ' ' LEU . . . . . . . . . . . . . 38.1 tp -127.14 135.82 51.24 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.918 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 105.58 24.68 6.94 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.498 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 192' ' ' THR . . . . . 0.439 ' O ' HD21 ' A' ' 110' ' ' LEU . 34.3 p -128.35 119.31 24.81 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.854 0.359 . . . . 0.0 111.108 -179.815 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 193' ' ' THR . . . . . 0.752 ' HB ' HG21 ' A' ' 105' ' ' VAL . 1.9 t -107.38 128.4 54.44 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.144 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 194' ' ' LYS . . . . . 0.506 ' HB3' ' CZ ' ' A' ' 160' ' ' TYR . 22.8 pttt -63.6 153.12 36.88 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.916 179.912 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 195' ' ' TYR . . . . . . . . . . . . . 96.2 m-85 -86.67 88.47 7.67 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.894 -179.931 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 196' ' ' CYS . . . . . . . . . . . . . 43.0 t -100.44 152.33 20.49 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.864 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 29.8 t -134.22 140.36 46.43 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.901 -179.744 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 198' ' ' TYR . . . . . . . . . . . . . 8.4 p90 -148.53 164.89 32.85 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.91 -179.837 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 91.7 p -90.21 129.08 36.51 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.871 -179.865 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 200' ' ' GLY . . . . . 0.43 ' HA2' ' C ' ' A' ' 201' ' ' PRO . . . -131.11 171.94 20.85 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.52 180.0 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 201' ' ' PRO . . . . . 0.43 ' C ' ' HA2' ' A' ' 200' ' ' GLY . 53.3 Cg_endo -69.81 131.32 19.0 Favored 'Cis proline' 0 C--N 1.342 0.196 0 C-N-CA 122.647 -1.814 . . . . 0.0 112.337 0.12 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 202' ' ' SER . . . . . . . . . . . . . 77.3 p -77.95 87.79 4.13 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.876 -179.848 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 3.0 m 57.77 38.28 27.34 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.858 -179.845 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.358 0 C-N-CA 120.734 -0.745 . . . . 0.0 112.514 179.985 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.328 0 N-CA-C 112.482 -0.247 . . . . 0.0 112.482 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 12.2 m -38.15 107.72 0.07 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.875 0.369 . . . . 0.0 110.876 -179.778 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 24.6 m -154.92 170.23 22.2 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.873 -179.83 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 157.08 164.91 14.14 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.534 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 49.8 m -107.07 83.52 1.84 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.858 0.361 . . . . 0.0 110.898 -179.743 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 90.8 p -108.99 101.07 10.18 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.879 -179.824 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 124.03 105.21 1.66 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.493 -179.956 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -75.06 141.94 43.78 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.782 0.325 . . . . 0.0 111.12 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 17.4 m -150.63 171.76 16.61 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.866 -179.808 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 35.0 m -75.95 151.66 6.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.113 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 14.3 ptt180 -93.38 125.18 37.85 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.887 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 16.6 m -128.36 127.12 66.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.117 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 98.9 t -87.23 102.08 11.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.121 179.899 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 45.2 mt-30 -115.68 78.1 1.15 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.974 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.93 ' O ' HD11 ' A' ' 190' ' ' LEU . 36.1 pttt -74.7 -35.03 62.74 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.91 179.989 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 59.4 t-20 -86.81 38.55 0.8 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.901 179.939 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 110' ' ' LEU . . . . . 0.674 ' O ' HD12 ' A' ' 190' ' ' LEU . 41.4 tp -141.68 129.13 21.29 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.904 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.509 HG22 HD11 ' A' ' 173' ' ' ILE . 94.7 t -116.78 119.43 61.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.112 179.852 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.567 ' CE1' ' HB2' ' A' ' 158' ' ' SER . 48.2 t80 -113.67 109.64 18.91 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.861 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.687 HG22 ' HB2' ' A' ' 188' ' ' ALA . 68.1 t -106.32 146.5 12.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.121 179.932 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.444 HG12 ' HB3' ' A' ' 158' ' ' SER . 32.9 m -132.03 170.69 19.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.086 179.942 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 78.29 45.49 9.95 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.455 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 32.4 mt -117.91 136.79 53.24 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.877 0.37 . . . . 0.0 110.955 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 117' ' ' SER . . . . . 0.483 ' O ' ' N ' ' A' ' 119' ' ' ARG . 15.3 p -82.33 140.51 33.51 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.862 -179.892 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 118' ' ' GLN . . . . . 0.424 ' C ' ' O ' ' A' ' 117' ' ' SER . 82.8 mm-40 -35.02 -33.02 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.878 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.483 ' N ' ' O ' ' A' ' 117' ' ' SER . 72.8 mtm-85 -68.85 -50.22 51.69 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.827 -179.869 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 120' ' ' LEU . . . . . 0.462 ' N ' ' O ' ' A' ' 117' ' ' SER . 36.0 mt -70.97 -38.96 72.77 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.927 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -60.14 83.48 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.116 179.823 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 122' ' ' ASP . . . . . 0.4 ' N ' ' O ' ' A' ' 120' ' ' LEU . 6.0 m-20 -147.18 145.82 23.37 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.623 0.725 . . . . 0.0 110.888 179.962 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.76 -40.02 5.82 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.736 2.291 . . . . 0.0 112.327 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 124' ' ' GLU . . . . . 0.433 ' HG3' ' N ' ' A' ' 125' ' ' VAL . 16.8 pt-20 -75.8 -50.23 15.79 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.883 -179.967 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.476 HG13 ' CE2' ' A' ' 131' ' ' TYR . 53.2 t -56.51 -41.38 72.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.101 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.454 HD22 ' CE1' ' A' ' 132' ' ' PHE . 71.5 mt -74.68 -37.22 62.73 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.893 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.679 ' HA ' HD12 ' A' ' 138' ' ' ILE . 35.2 mttm -65.39 -22.9 66.84 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.906 179.832 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 64.1 mtt180 -48.5 143.75 7.27 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.571 0.701 . . . . 0.0 110.908 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 1.35 4.5 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.708 2.272 . . . . 0.0 112.335 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 26.9 mp0 -103.95 -42.02 5.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.908 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 131' ' ' TYR . . . . . 0.476 ' CE2' HG13 ' A' ' 125' ' ' VAL . 37.5 m-85 -72.77 -75.14 0.15 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.932 -179.872 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.454 ' CE1' HD22 ' A' ' 126' ' ' LEU . 45.6 m-85 -116.35 -32.85 5.15 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.867 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -52.49 -15.28 2.81 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.514 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 16.8 ptmt -67.7 -42.83 81.38 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.79 0.329 . . . . 0.0 110.895 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 135' ' ' PHE . . . . . 0.555 ' CE1' ' HA ' ' A' ' 172' ' ' ALA . 29.3 m-85 -60.63 -45.69 93.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.888 179.939 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -179.24 167.54 37.7 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.518 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 8.0 tmtm? -61.03 131.91 52.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.732 0.301 . . . . 0.0 110.878 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.679 HD12 ' HA ' ' A' ' 127' ' ' LYS . 95.1 mt -93.0 142.28 13.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.111 179.876 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 38.4 t60 -104.9 -59.6 1.72 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.803 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 140' ' ' LYS . . . . . 0.413 ' HD3' ' CG2' ' A' ' 142' ' ' VAL . 1.0 OUTLIER -129.17 136.52 50.26 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.916 -179.977 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 141' ' ' VAL . . . . . 0.646 ' CG2' HG21 ' A' ' 138' ' ' ILE . 47.1 t -129.36 139.76 50.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.179 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.413 ' CG2' ' HD3' ' A' ' 140' ' ' LYS . 5.4 t -132.18 140.19 48.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.117 179.929 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 42.1 mm -114.48 121.42 66.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.159 179.926 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 5.7 m120 -115.67 113.39 23.45 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.933 179.916 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 53.6 p30 -127.55 160.59 31.09 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.879 -179.974 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 2.7 t -63.52 117.43 6.74 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.844 -179.831 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 15.3 t -79.81 8.17 7.28 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.189 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 65.4 m -102.66 164.66 11.51 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.838 -179.81 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 17.2 m-85 -65.9 143.82 57.19 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.902 -179.883 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -52.26 156.9 1.54 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.09 179.873 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 112.29 36.85 1.56 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.519 -179.908 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 52.5 p -108.45 -178.93 3.73 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.818 0.342 . . . . 0.0 110.873 -179.736 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 58.1 mt-30 -79.54 79.92 5.97 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.888 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 79.07 83.41 0.64 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.498 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 81.35 0.83 Allowed 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.677 2.251 . . . . 0.0 112.336 -179.94 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 31.2 p -106.41 126.69 52.56 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.859 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -95.03 163.4 13.32 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.059 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 158' ' ' SER . . . . . 0.567 ' HB2' ' CE1' ' A' ' 112' ' ' PHE . 58.9 p -134.46 164.83 26.58 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.813 -179.757 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -147.15 136.43 22.58 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.108 179.898 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 160' ' ' TYR . . . . . 0.479 ' CE2' ' CD1' ' A' ' 112' ' ' PHE . 11.9 m-85 -104.96 113.11 26.51 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.902 -179.812 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 50.0 t -108.16 139.48 30.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.132 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 54.3 m -106.56 126.58 52.45 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.146 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 163' ' ' TYR . . . . . 0.628 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 15.4 m-85 -109.02 127.79 54.4 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.947 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 64.8 mt -59.48 -52.18 63.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.145 179.889 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 33.4 mtp85 -84.98 110.36 18.84 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.834 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 166' ' ' SER . . . . . 0.416 ' O ' ' C ' ' A' ' 167' ' ' GLU . 68.5 m -49.73 -64.72 0.72 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.833 -179.808 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 167' ' ' GLU . . . . . 0.416 ' C ' ' O ' ' A' ' 166' ' ' SER . 15.3 mt-10 -37.29 -57.69 0.87 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.899 -179.961 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -51.22 -47.74 62.24 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.895 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 169' ' ' ALA . . . . . 0.628 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -54.77 -58.61 6.87 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.08 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 41.1 mt -46.21 -56.95 4.99 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.879 -179.924 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 6.6 mpt_? -55.19 -51.86 65.17 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.856 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 172' ' ' ALA . . . . . 0.555 ' HA ' ' CE1' ' A' ' 135' ' ' PHE . . . -47.52 -33.04 5.87 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.06 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 173' ' ' ILE . . . . . 0.509 HD11 HG22 ' A' ' 111' ' ' VAL . 56.9 mt -79.12 -34.38 16.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.124 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 44.7 mt-30 -70.69 -26.01 63.23 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.912 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 4.0 m -93.77 -36.11 12.44 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.932 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 176' ' ' VAL . . . . . 0.491 HG23 ' O ' ' A' ' 172' ' ' ALA . 9.8 t -67.94 -35.81 73.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.118 -179.976 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 58.4 t30 -62.97 145.26 55.73 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.921 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 35.5 t30 55.62 51.68 12.21 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.916 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 179' ' ' VAL . . . . . 0.47 HG12 HG23 ' A' ' 181' ' ' VAL . 76.7 t -125.89 142.37 42.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.104 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 91.3 t -104.24 105.12 17.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.128 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 181' ' ' VAL . . . . . 0.47 HG23 HG12 ' A' ' 179' ' ' VAL . 85.7 t -119.11 105.01 16.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.174 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 1.6 t70 60.01 41.23 17.73 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.901 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 71.28 24.09 77.35 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.524 -179.932 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 3.5 mmp_? -126.93 114.23 17.58 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.884 0.373 . . . . 0.0 110.875 -179.837 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 7.8 m -70.7 103.19 2.49 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.122 -179.89 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 31.1 mt -71.52 126.1 28.78 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.934 179.932 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -131.02 114.55 15.33 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.89 179.837 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 188' ' ' ALA . . . . . 0.687 ' HB2' HG22 ' A' ' 113' ' ' VAL . . . -118.54 137.62 53.1 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.046 179.862 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 7.3 t -125.89 166.78 16.26 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.875 -179.785 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 190' ' ' LEU . . . . . 0.93 HD11 ' O ' ' A' ' 108' ' ' LYS . 9.0 tp -131.8 143.41 50.19 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.897 -179.97 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 76.04 10.48 85.2 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.547 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 192' ' ' THR . . . . . . . . . . . . . 15.3 t -93.62 130.07 39.66 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.822 0.344 . . . . 0.0 111.175 -179.851 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 193' ' ' THR . . . . . . . . . . . . . 5.1 t -118.17 134.08 55.33 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.158 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 194' ' ' LYS . . . . . 0.436 ' O ' ' C ' ' A' ' 195' ' ' TYR . 0.1 OUTLIER -119.75 102.07 8.34 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.893 179.913 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 195' ' ' TYR . . . . . 0.436 ' C ' ' O ' ' A' ' 194' ' ' LYS . 5.6 t80 35.0 53.39 0.67 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.912 -179.997 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 196' ' ' CYS . . . . . . . . . . . . . 23.5 p -146.12 146.27 30.82 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.881 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 8.5 t -95.59 149.01 21.91 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.867 -179.782 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 198' ' ' TYR . . . . . . . . . . . . . 52.9 t80 -130.71 97.54 4.39 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.925 -179.907 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 1.7 t -89.22 124.89 34.79 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.82 -179.827 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . 122.77 -164.11 15.88 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.484 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 201' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.78 167.88 69.55 Favored 'Cis proline' 0 C--N 1.342 0.192 0 C-N-CA 122.68 -1.8 . . . . 0.0 112.323 0.089 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 202' ' ' SER . . . . . . . . . . . . . 14.1 p -119.28 90.8 3.4 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.835 -179.836 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 4.0 t -58.61 96.43 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.827 -179.816 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.291 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.497 179.992 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.315 0 N-CA-C 112.427 -0.269 . . . . 0.0 112.427 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 16.1 t -49.13 117.34 2.08 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.88 0.371 . . . . 0.0 110.781 -179.718 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 3.6 m 41.2 43.14 1.89 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.841 -179.865 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -118.94 69.88 0.33 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.475 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 26.3 p -149.42 147.36 28.17 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.868 0.366 . . . . 0.0 110.858 -179.783 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 30.6 m -89.25 170.9 10.19 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.833 -179.809 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -118.49 -45.33 0.48 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.692 -0.765 . . . . 0.0 112.503 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -46.79 147.65 1.24 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.766 0.317 . . . . 0.0 111.079 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 4.2 t -102.03 159.95 14.92 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.845 -179.799 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 90.4 t -65.4 99.04 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.114 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 14.4 tpp180 -112.24 138.77 48.46 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.887 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.558 HG13 ' O ' ' A' ' 105' ' ' VAL . 11.2 p -116.44 114.54 46.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.141 179.929 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 10.5 p -117.64 138.36 48.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.119 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 51.9 mt-30 -52.45 125.12 15.25 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.936 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 35.9 mtmm -89.36 42.72 1.1 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.887 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 11.6 p-10 -112.21 39.96 2.31 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.858 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 13.9 tp -135.16 123.12 22.62 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.931 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 1.088 HG22 HD11 ' A' ' 173' ' ' ILE . 77.9 t -103.44 108.02 23.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.103 179.867 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.451 ' CD1' ' CE1' ' A' ' 160' ' ' TYR . 47.2 t80 -106.56 113.86 27.63 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.875 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.579 HG22 ' HB2' ' A' ' 188' ' ' ALA . 32.7 t -112.61 137.94 43.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.163 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 23.1 m -121.36 166.22 16.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.125 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 115' ' ' GLY . . . . . 0.412 ' O ' HD23 ' A' ' 186' ' ' LEU . . . 73.38 55.69 6.01 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.493 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 32.3 mt -117.81 127.76 54.2 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.813 0.339 . . . . 0.0 110.894 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 11.8 m -63.78 136.01 57.1 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.846 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 8.2 tp60 -41.97 -27.28 0.12 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.884 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 1.8 mpt_? -78.4 -48.27 15.85 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.901 -179.932 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 42.8 mt -66.22 -38.7 88.56 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.932 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -60.91 88.12 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.069 179.839 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 24.9 m-20 -148.65 149.54 31.21 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.635 0.731 . . . . 0.0 110.852 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.82 -43.39 2.64 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.675 2.25 . . . . 0.0 112.325 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 27.6 mt-10 -76.39 -41.86 46.44 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.857 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.723 HG13 ' CZ ' ' A' ' 131' ' ' TYR . 74.3 t -60.24 -48.06 89.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.127 -179.987 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 42.3 mt -70.26 -40.25 74.49 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.886 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.504 ' HA ' HD12 ' A' ' 138' ' ' ILE . 32.1 mttm -61.54 -35.89 79.04 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.864 179.854 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 48.7 mtt85 -43.9 143.41 1.74 Allowed Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.592 0.711 . . . . 0.0 110.875 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 -3.54 12.19 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.707 2.272 . . . . 0.0 112.362 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -94.96 -36.13 11.71 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.944 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 131' ' ' TYR . . . . . 0.723 ' CZ ' HG13 ' A' ' 125' ' ' VAL . 57.1 m-85 -80.21 -74.23 0.32 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.888 -179.841 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.487 ' O ' ' N ' ' A' ' 134' ' ' LYS . 14.6 m-85 -116.9 -44.84 2.79 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.915 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 133' ' ' GLY . . . . . 0.439 ' C ' ' O ' ' A' ' 132' ' ' PHE . . . -35.39 -31.06 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.515 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.487 ' N ' ' O ' ' A' ' 132' ' ' PHE . 16.6 ptmt -45.86 -48.77 15.89 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.812 0.339 . . . . 0.0 110.887 -179.995 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 135' ' ' PHE . . . . . 0.545 ' CD2' ' HA ' ' A' ' 172' ' ' ALA . 78.9 m-85 -61.69 -43.91 97.95 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.882 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -173.94 -174.54 40.91 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.491 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 29.5 mtmt -90.09 102.18 14.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.753 0.311 . . . . 0.0 110.845 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.504 HD12 ' HA ' ' A' ' 127' ' ' LYS . 58.1 mt -61.33 148.38 9.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.104 179.847 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 61.4 t60 -101.55 -57.55 2.06 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.875 179.837 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 40.2 tttm -123.17 143.8 49.77 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.904 179.916 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 141' ' ' VAL . . . . . 0.463 HG22 HG21 ' A' ' 138' ' ' ILE . 58.5 t -135.91 118.45 21.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.135 179.89 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 83.9 t -117.32 134.72 60.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.128 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 3.3 mm -106.46 125.39 62.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.129 179.923 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 4.4 m-80 -117.87 104.36 10.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.947 179.87 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 70.1 m-80 -85.73 138.2 32.27 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.893 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 25.9 t -45.35 149.98 0.49 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.885 -179.842 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 90.6 m -128.81 -56.35 1.2 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.138 -179.931 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 34.4 p -85.83 140.94 30.0 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.874 -179.866 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 149' ' ' TYR . . . . . 0.473 ' O ' ' CG ' ' A' ' 149' ' ' TYR . 3.7 p90 -100.81 122.84 44.1 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.906 -179.889 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -106.73 -56.51 2.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.093 179.879 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 94.76 39.72 4.57 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.501 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 20.0 m -102.17 -51.38 3.39 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.787 0.327 . . . . 0.0 110.831 -179.739 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 28.5 mm-40 -121.51 -44.11 2.37 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.895 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 145.28 -167.97 27.27 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.501 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.8 105.4 1.48 Allowed 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.681 2.254 . . . . 0.0 112.332 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 58.1 m -126.07 125.34 42.43 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.848 -179.807 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -106.5 165.32 11.36 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.064 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 158' ' ' SER . . . . . 0.407 ' HB2' ' CE1' ' A' ' 112' ' ' PHE . 79.0 p -130.12 167.38 18.44 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.842 -179.767 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -155.68 136.21 13.29 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.137 179.9 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 160' ' ' TYR . . . . . 0.451 ' CE1' ' CD1' ' A' ' 112' ' ' PHE . 98.3 m-85 -99.4 133.14 44.15 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.926 -179.869 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.44 HG13 ' CG2' ' A' ' 138' ' ' ILE . 75.2 t -125.6 122.28 62.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.179 179.893 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 87.4 m -94.97 124.18 38.87 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.197 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 163' ' ' TYR . . . . . 0.494 ' CB ' ' HB2' ' A' ' 169' ' ' ALA . 14.0 m-85 -100.2 147.77 25.35 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.925 -179.897 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 52.0 mt -73.5 -41.74 56.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.154 179.871 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 13.3 mmm180 -105.18 133.41 49.99 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.862 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 71.5 m -63.05 -68.18 0.36 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.834 -179.722 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 4.9 tp10 -42.93 -58.45 2.4 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.884 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -47.16 -46.48 23.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.921 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 169' ' ' ALA . . . . . 0.494 ' HB2' ' CB ' ' A' ' 163' ' ' TYR . . . -58.98 -61.53 2.57 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.119 179.938 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 59.0 mt -39.21 -52.75 1.94 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.914 179.994 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 171' ' ' ARG . . . . . 0.431 ' O ' ' N ' ' A' ' 174' ' ' GLN . 86.1 mtt180 -59.44 -58.61 7.83 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.898 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 172' ' ' ALA . . . . . 0.545 ' HA ' ' CD2' ' A' ' 135' ' ' PHE . . . -41.02 -35.59 0.56 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.098 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 173' ' ' ILE . . . . . 1.088 HD11 HG22 ' A' ' 111' ' ' VAL . 58.5 mt -76.89 -37.58 27.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.074 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 174' ' ' GLN . . . . . 0.431 ' N ' ' O ' ' A' ' 171' ' ' ARG . 61.5 mt-30 -64.68 -21.42 66.73 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.883 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 3.9 m -93.83 -40.39 10.2 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.873 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 176' ' ' VAL . . . . . 0.479 ' O ' HG23 ' A' ' 179' ' ' VAL . 9.1 t -62.45 -38.36 81.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.115 -179.984 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 5.1 t-20 -60.71 140.36 57.55 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.887 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 15.6 t-20 65.2 50.74 1.75 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.91 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 179' ' ' VAL . . . . . 0.479 HG23 ' O ' ' A' ' 176' ' ' VAL . 71.1 t -124.78 142.04 42.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.061 179.946 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 83.3 t -96.25 110.68 25.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.16 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 181' ' ' VAL . . . . . 0.744 HG21 HD12 ' A' ' 186' ' ' LEU . 48.7 t -120.02 106.02 18.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.125 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 53.77 43.47 30.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.881 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 71.19 30.83 66.91 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.454 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 32.9 mtt-85 -138.24 122.71 18.41 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.882 0.372 . . . . 0.0 110.902 -179.874 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 17.7 m -82.47 96.91 8.15 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.143 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 186' ' ' LEU . . . . . 0.744 HD12 HG21 ' A' ' 181' ' ' VAL . 95.8 mt -74.45 132.71 42.16 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.937 179.928 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 47.8 mttt -117.87 132.22 56.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.941 179.8 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 188' ' ' ALA . . . . . 0.579 ' HB2' HG22 ' A' ' 113' ' ' VAL . . . -123.53 147.27 47.42 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.106 179.857 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 68.0 m -158.06 162.62 38.09 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.856 -179.806 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 190' ' ' LEU . . . . . . . . . . . . . 4.5 pp -129.77 156.33 44.49 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.894 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 93.82 29.66 9.67 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.507 179.867 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 192' ' ' THR . . . . . . . . . . . . . 13.5 t -105.01 149.5 25.73 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.846 0.355 . . . . 0.0 111.14 -179.84 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 193' ' ' THR . . . . . . . . . . . . . 7.3 t -112.9 141.02 47.2 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.152 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 10.3 pttt -62.22 134.53 56.66 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.884 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 195' ' ' TYR . . . . . . . . . . . . . 9.4 m-85 -80.85 92.49 6.11 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.933 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 196' ' ' CYS . . . . . . . . . . . . . 1.8 t -120.86 151.42 39.67 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.883 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 1.9 t -64.69 108.66 1.78 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.851 -179.743 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 198' ' ' TYR . . . . . . . . . . . . . 19.5 p90 -107.98 133.77 51.83 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.893 -179.854 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 29.9 t -158.81 146.4 17.78 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.889 -179.862 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . 77.29 -165.32 53.06 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.492 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 201' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 153.52 92.95 Favored 'Cis proline' 0 C--O 1.232 0.194 0 C-N-CA 122.704 -1.79 . . . . 0.0 112.366 0.027 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 202' ' ' SER . . . . . . . . . . . . . 7.9 m -64.84 117.35 7.41 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.865 -179.835 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 78.0 p -103.24 116.93 33.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.846 -179.804 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.31 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.506 -179.988 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.343 0 N-CA-C 112.494 -0.242 . . . . 0.0 112.494 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 75.7 m -123.15 154.91 38.01 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.901 0.381 . . . . 0.0 110.861 -179.762 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 40.2 t -70.02 147.38 50.16 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.875 -179.858 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 141.65 101.36 0.43 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.473 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 19.4 m -100.87 150.49 22.77 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.874 0.368 . . . . 0.0 110.848 -179.752 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 93.2 p 37.35 42.2 0.3 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.924 -179.796 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 68.89 -142.99 39.11 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.494 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -94.39 148.6 22.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.804 0.335 . . . . 0.0 111.075 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 52.0 p -101.4 125.34 48.02 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.84 -179.798 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 34.9 m -120.35 131.01 73.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.147 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 76.0 mtm-85 -124.1 143.38 50.5 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.835 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 91.5 t -74.07 110.66 8.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.141 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 69.3 t -115.52 141.56 32.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.101 179.949 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 8.0 pt20 -65.66 145.14 56.41 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.952 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 20.4 mmtp -101.66 -15.06 17.15 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.89 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 9.5 m-20 -101.17 51.7 0.85 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.91 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 110' ' ' LEU . . . . . 0.506 ' O ' HD22 ' A' ' 190' ' ' LEU . 14.1 tp -135.28 105.03 6.1 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.877 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.593 HG22 HD11 ' A' ' 173' ' ' ILE . 41.4 t -95.49 104.22 15.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.15 179.815 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.579 ' CD1' ' CE2' ' A' ' 160' ' ' TYR . 39.5 t80 -94.08 122.36 36.51 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.848 -179.948 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.401 HG22 ' HB2' ' A' ' 188' ' ' ALA . 42.3 t -117.82 133.55 64.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.145 179.92 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.429 ' CG1' ' CE2' ' A' ' 112' ' ' PHE . 11.9 m -120.4 166.64 14.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.125 179.899 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 67.0 53.53 26.24 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.506 179.983 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 34.9 mt -105.98 146.57 29.89 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.844 0.354 . . . . 0.0 110.846 -179.86 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 29.2 m -77.35 153.98 33.24 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.801 -179.908 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 84.9 mm-40 -56.55 -44.9 81.37 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.892 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 10.6 ttt180 -74.38 -44.96 49.85 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.897 -179.925 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 66.2 mt -66.89 -24.84 66.16 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.932 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -76.06 83.71 2.93 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.11 179.773 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -148.3 150.34 34.32 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-O 121.62 0.724 . . . . 0.0 110.857 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.83 -50.62 0.44 Allowed 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.668 2.245 . . . . 0.0 112.319 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 7.0 mm-40 -65.35 -41.91 93.38 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.89 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.67 HG13 ' CZ ' ' A' ' 131' ' ' TYR . 85.9 t -61.79 -42.68 95.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.128 179.975 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.545 HD22 ' CE1' ' A' ' 132' ' ' PHE . 79.4 mt -74.33 -40.32 62.25 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.929 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.459 ' HA ' ' CD1' ' A' ' 138' ' ' ILE . 43.0 tttt -61.03 -31.25 70.89 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.873 179.837 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 72.6 mtt-85 -44.13 142.88 2.02 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.573 0.701 . . . . 0.0 110.873 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 0.8 5.14 Favored 'Trans proline' 0 C--N 1.341 0.136 0 C-N-CA 122.662 2.241 . . . . 0.0 112.375 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 5.0 tp10 -103.99 -36.01 7.9 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.915 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 131' ' ' TYR . . . . . 0.67 ' CZ ' HG13 ' A' ' 125' ' ' VAL . 38.8 m-85 -75.91 -75.02 0.2 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.962 -179.869 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.545 ' CE1' HD22 ' A' ' 126' ' ' LEU . 19.9 m-85 -114.86 -40.58 3.5 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.858 -179.996 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -52.23 -20.47 6.93 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.51 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.423 ' HD3' ' C ' ' A' ' 134' ' ' LYS . 0.0 OUTLIER -53.54 -31.65 47.27 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.86 0.362 . . . . 0.0 110.903 -179.999 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 135' ' ' PHE . . . . . 0.454 ' CE2' ' CG2' ' A' ' 176' ' ' VAL . 65.3 m-85 -73.21 -42.48 62.6 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.87 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -177.66 -163.41 29.41 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.47 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 16.9 mttp -79.58 142.14 35.95 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.774 0.321 . . . . 0.0 110.915 -179.966 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.558 HG21 HG22 ' A' ' 141' ' ' VAL . 82.6 mt -105.25 132.19 52.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.146 179.899 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 8.3 t-80 -85.97 -59.64 2.24 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.857 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 73.6 tttt -132.72 146.1 51.58 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.936 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 141' ' ' VAL . . . . . 0.558 HG22 HG21 ' A' ' 138' ' ' ILE . 24.2 t -129.38 130.08 67.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.153 179.876 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 96.1 t -134.34 147.49 30.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.133 179.879 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 15.3 mm -118.05 150.44 20.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.133 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 39.9 t30 -129.02 106.47 8.9 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.889 179.902 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 3.0 p30 -119.8 142.07 48.93 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.896 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 79.9 p -56.81 128.58 37.39 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.885 -179.866 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 22.6 p -89.07 -35.98 16.02 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.143 -179.92 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 60.1 p -86.82 148.55 25.34 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.885 -179.911 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 98.1 m-85 -69.13 113.57 6.61 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.945 -179.912 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -88.77 -61.08 1.79 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.105 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 81.74 37.72 15.87 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.501 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 43.1 m -110.69 163.22 13.96 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.802 0.334 . . . . 0.0 110.873 -179.728 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 18.3 tt0 -79.81 102.55 9.15 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.919 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 84.05 83.13 0.96 Allowed Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.487 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.75 120.67 7.42 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.674 2.249 . . . . 0.0 112.336 -179.955 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 78.7 p -86.56 123.23 31.53 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.825 -179.831 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -112.28 164.81 12.79 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.082 179.911 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 14.8 m -133.16 164.55 26.8 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.87 -179.797 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -150.81 166.47 30.4 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.131 179.922 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 160' ' ' TYR . . . . . 0.579 ' CE2' ' CD1' ' A' ' 112' ' ' PHE . 11.6 m-85 -136.29 126.4 26.2 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.913 -179.821 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 67.0 t -126.72 146.13 33.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.09 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 82.2 m -108.35 134.16 51.55 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.192 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 163' ' ' TYR . . . . . 0.651 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 7.9 m-85 -111.96 120.75 42.95 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.924 -179.867 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 88.7 mt -49.75 -50.86 17.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.102 179.918 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 24.9 mtp85 -88.1 109.72 20.09 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.883 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 5.3 t -48.85 -59.3 3.69 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.855 -179.772 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 23.8 mt-10 -47.94 -46.29 31.94 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.89 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 6.5 t0 -56.13 -45.12 79.68 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.829 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 169' ' ' ALA . . . . . 0.651 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -55.75 -52.42 63.98 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.116 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 26.8 mt -51.38 -59.4 4.27 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.894 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 74.3 mtp180 -55.09 -49.23 72.22 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.903 179.909 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 172' ' ' ALA . . . . . 0.638 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -50.08 -33.16 17.61 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.066 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 173' ' ' ILE . . . . . 0.593 HD11 HG22 ' A' ' 111' ' ' VAL . 55.2 mt -76.65 -38.4 30.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.128 -179.996 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 10.3 mm100 -65.66 -30.54 71.25 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.884 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 175' ' ' CYS . . . . . 0.444 ' O ' ' CG2' ' A' ' 179' ' ' VAL . 3.0 t -93.72 -27.33 16.58 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.85 -179.94 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 176' ' ' VAL . . . . . 0.638 HG23 ' O ' ' A' ' 172' ' ' ALA . 10.4 t -77.9 -26.28 14.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.181 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -79.09 154.15 29.61 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.855 -179.972 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 178' ' ' ASN . . . . . 0.438 ' O ' ' CG ' ' A' ' 178' ' ' ASN . 32.5 t30 55.23 36.27 26.67 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.881 179.978 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 179' ' ' VAL . . . . . 0.444 ' CG2' ' O ' ' A' ' 175' ' ' CYS . 92.3 t -108.84 141.98 22.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.109 179.919 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 53.7 t -106.2 97.1 5.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.121 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 181' ' ' VAL . . . . . 0.48 HG12 ' OD2' ' A' ' 182' ' ' ASP . 40.0 t -102.41 118.34 49.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.143 179.941 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 182' ' ' ASP . . . . . 0.48 ' OD2' HG12 ' A' ' 181' ' ' VAL . 2.9 p30 47.26 31.65 1.84 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.851 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 86.02 20.7 54.87 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.453 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 5.5 tpm_? -118.21 133.97 55.43 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.904 0.383 . . . . 0.0 110.882 -179.857 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 17.3 m -90.76 95.13 9.99 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.164 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 71.1 mt -74.8 128.33 35.3 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.892 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 2.8 mmmp? -128.79 121.7 28.92 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.887 179.822 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 188' ' ' ALA . . . . . 0.401 ' HB2' HG22 ' A' ' 113' ' ' VAL . . . -119.4 156.52 29.98 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.087 179.859 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 8.5 t -147.76 165.28 31.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.857 -179.813 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 190' ' ' LEU . . . . . 0.789 HD13 ' N ' ' A' ' 191' ' ' GLY . 1.6 tm? -132.2 137.58 47.65 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.877 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 191' ' ' GLY . . . . . 0.789 ' N ' HD13 ' A' ' 190' ' ' LEU . . . 86.58 30.28 21.92 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.441 179.83 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 192' ' ' THR . . . . . 0.448 HG21 ' CB ' ' A' ' 112' ' ' PHE . 15.2 t -88.82 147.17 24.55 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.883 0.373 . . . . 0.0 111.103 -179.86 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 193' ' ' THR . . . . . . . . . . . . . 58.6 p -72.52 112.53 8.66 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.155 179.969 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 194' ' ' LYS . . . . . 0.414 ' C ' ' HD2' ' A' ' 194' ' ' LYS . 0.3 OUTLIER -99.92 104.73 16.39 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.954 179.881 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 195' ' ' TYR . . . . . . . . . . . . . 80.4 t80 -67.28 147.58 52.81 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.948 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 196' ' ' CYS . . . . . 0.4 ' HB3' ' NZ ' ' A' ' 194' ' ' LYS . 27.0 p -158.55 168.16 27.66 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.912 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 15.5 t -104.46 138.76 40.37 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.817 -179.718 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 198' ' ' TYR . . . . . . . . . . . . . 12.6 t80 -118.25 144.96 45.38 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.922 -179.868 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 199' ' ' SER . . . . . 0.487 ' C ' ' HA ' ' A' ' 201' ' ' PRO . 1.2 t -127.46 -59.42 1.22 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.864 -179.856 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 200' ' ' GLY . . . . . 0.415 ' HA3' ' C ' ' A' ' 201' ' ' PRO . . . 124.98 -69.67 0.48 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.488 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 201' ' ' PRO . . . . . 0.487 ' HA ' ' C ' ' A' ' 199' ' ' SER . 53.5 Cg_endo -69.73 155.69 93.06 Favored 'Cis proline' 0 C--N 1.341 0.156 0 C-N-CA 122.68 -1.8 . . . . 0.0 112.34 0.022 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 202' ' ' SER . . . . . 0.424 ' N ' ' O ' ' A' ' 199' ' ' SER . 30.6 t -40.68 140.51 0.68 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.859 -179.859 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 1.1 t 38.42 45.39 0.83 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.866 -179.807 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.281 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.492 -179.999 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 N-CA-C 112.495 -0.242 . . . . 0.0 112.495 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 3.9 t -50.45 124.92 11.56 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.92 0.39 . . . . 0.0 110.855 -179.735 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 69.2 m -124.55 -49.08 1.78 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.88 -179.819 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 113.04 81.47 1.08 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.491 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 70.7 m -101.67 97.98 8.32 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.9 0.381 . . . . 0.0 110.828 -179.706 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 24.1 p -145.95 119.31 8.99 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.907 -179.888 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 152.04 158.25 8.33 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.46 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -103.05 144.44 31.29 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.772 0.32 . . . . 0.0 111.088 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 25.8 p -174.26 149.52 1.4 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.828 -179.827 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 96.3 t -120.58 113.67 40.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.146 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -124.68 146.95 48.86 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.895 -179.968 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 77.6 t -82.18 113.86 22.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.137 179.943 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 106' ' ' VAL . . . . . 0.432 HG13 ' O ' ' A' ' 106' ' ' VAL . 14.9 p -100.0 126.85 53.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.097 179.911 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 67.0 mt-30 -132.97 157.88 44.06 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.916 179.976 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 30.0 pttt -96.76 35.11 1.57 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.908 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 34.3 p-10 -119.19 42.92 2.72 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.874 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 110' ' ' LEU . . . . . 0.776 HD22 ' HE3' ' A' ' 194' ' ' LYS . 9.4 tp -132.84 123.55 26.29 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.941 179.964 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.471 HG22 HD11 ' A' ' 173' ' ' ILE . 69.5 t -108.95 106.67 21.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.131 179.899 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.511 ' CZ ' ' CG1' ' A' ' 114' ' ' VAL . 61.4 t80 -99.83 117.42 34.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.864 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 21.2 t -116.56 135.67 56.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.107 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.511 ' CG1' ' CZ ' ' A' ' 112' ' ' PHE . 34.1 m -124.55 165.38 21.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.123 179.904 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 78.6 52.46 5.08 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.48 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 21.2 mt -109.16 133.67 52.72 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.85 0.357 . . . . 0.0 110.932 -179.917 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 40.2 t -66.53 147.83 52.74 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.853 -179.92 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.9 mt-30 -40.86 -47.3 2.91 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.917 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 39.3 mtp180 -71.47 -37.78 71.3 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.901 -179.922 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 51.7 mt -67.27 -26.7 66.68 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.943 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -74.01 83.81 1.76 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.098 179.763 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -148.99 142.99 16.56 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.592 0.711 . . . . 0.0 110.904 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.7 -49.26 0.59 Allowed 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.69 2.26 . . . . 0.0 112.359 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 51.4 mt-10 -69.48 -42.28 75.04 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.887 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.479 ' CG1' ' CZ ' ' A' ' 131' ' ' TYR . 60.3 t -59.16 -46.15 92.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.128 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 68.0 mt -69.81 -40.49 75.91 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.918 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.514 ' HA ' HD12 ' A' ' 138' ' ' ILE . 15.3 tttt -61.83 -27.88 69.09 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.937 179.809 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 13.8 mtp85 -45.24 143.6 2.52 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.632 0.729 . . . . 0.0 110.857 179.98 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 1.23 4.61 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.656 2.237 . . . . 0.0 112.347 -179.997 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 7.1 tp10 -105.51 -35.55 7.42 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.931 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 131' ' ' TYR . . . . . 0.479 ' CZ ' ' CG1' ' A' ' 125' ' ' VAL . 38.0 m-85 -77.46 -75.11 0.22 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.911 -179.857 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 13.2 m-85 -116.23 -34.68 4.58 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.902 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -49.99 -23.9 5.93 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.527 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.424 ' HD3' ' C ' ' A' ' 134' ' ' LYS . 0.0 OUTLIER -56.03 -34.07 65.51 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.788 0.328 . . . . 0.0 110.913 -179.959 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 135' ' ' PHE . . . . . 0.563 ' CE1' ' HA ' ' A' ' 172' ' ' ALA . 19.4 m-85 -69.89 -47.06 64.02 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.875 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -174.12 177.28 46.42 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.502 -179.947 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 5.8 mmmt -74.57 110.25 8.71 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.747 0.308 . . . . 0.0 110.893 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.607 HG21 HG22 ' A' ' 141' ' ' VAL . 56.8 mt -75.64 143.53 13.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.126 179.924 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 19.8 t-160 -99.2 -58.73 1.87 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.864 179.903 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 140' ' ' LYS . . . . . 0.725 ' HD3' HG23 ' A' ' 142' ' ' VAL . 0.2 OUTLIER -127.78 141.9 51.45 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.869 179.984 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 141' ' ' VAL . . . . . 0.607 HG22 HG21 ' A' ' 138' ' ' ILE . 3.9 t -130.94 139.86 50.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.114 179.887 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.725 HG23 ' HD3' ' A' ' 140' ' ' LYS . 69.5 t -135.45 139.84 45.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.132 179.93 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 16.7 mm -112.13 114.71 47.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.143 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 1.6 t30 -99.94 127.46 46.13 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.897 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 12.0 p30 -107.15 152.69 23.71 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.872 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 7.4 t -81.41 133.6 35.43 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.868 -179.851 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 1.4 m -81.5 44.5 0.8 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.172 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 3.7 m -88.62 165.29 14.9 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.844 -179.829 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 61.7 m-85 -60.24 144.28 50.61 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.91 -179.884 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -64.74 133.45 52.09 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.145 179.838 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 93.77 39.75 4.86 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.512 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 9.9 m -89.45 147.64 23.9 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.821 0.343 . . . . 0.0 110.842 -179.699 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 39.7 tt0 -82.19 94.74 7.34 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.92 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 69.32 69.29 1.42 Allowed Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.479 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 128.95 16.74 Favored 'Trans proline' 0 C--O 1.232 0.181 0 C-N-CA 122.678 2.252 . . . . 0.0 112.352 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 53.9 p -79.95 125.26 29.52 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.861 -179.826 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -122.32 152.59 39.96 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.109 179.907 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 87.5 p -124.89 176.43 6.63 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.894 -179.818 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -160.7 162.06 32.45 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.125 179.891 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 160' ' ' TYR . . . . . 0.483 ' CE2' ' CD1' ' A' ' 112' ' ' PHE . 16.5 m-85 -125.61 127.56 46.53 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.921 -179.825 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.41 HG22 HG13 ' A' ' 141' ' ' VAL . 66.7 t -121.75 140.27 46.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.117 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 4.7 m -114.21 115.71 27.89 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.185 -179.997 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 163' ' ' TYR . . . . . 0.638 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 29.1 m-85 -90.47 134.2 34.51 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.928 -179.904 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 66.4 mt -59.36 -42.63 88.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.119 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 19.0 mtm-85 -99.57 112.04 24.31 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.877 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 2.7 t -48.86 -57.59 6.17 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.896 -179.822 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 32.7 tt0 -42.93 -52.46 5.15 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.88 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -52.34 -50.6 62.0 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.883 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 169' ' ' ALA . . . . . 0.638 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -54.77 -64.02 0.97 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.106 179.915 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 170' ' ' LEU . . . . . 0.401 ' C ' ' O ' ' A' ' 169' ' ' ALA . 55.9 mt -37.15 -58.54 0.79 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.888 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 171' ' ' ARG . . . . . 0.432 ' HB3' ' NH1' ' A' ' 171' ' ' ARG . 10.6 mtp-105 -60.61 -46.04 91.75 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.846 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 172' ' ' ALA . . . . . 0.563 ' HA ' ' CE1' ' A' ' 135' ' ' PHE . . . -47.38 -32.89 5.33 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.072 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 173' ' ' ILE . . . . . 0.471 HD11 HG22 ' A' ' 111' ' ' VAL . 96.9 mt -82.85 -40.08 16.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.155 179.963 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 30.1 mt-30 -66.25 -23.28 66.38 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.893 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 1.8 t -93.9 -37.09 11.89 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.86 -179.927 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 176' ' ' VAL . . . . . 0.428 HG23 ' CZ ' ' A' ' 135' ' ' PHE . 9.0 t -70.18 -48.43 61.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.149 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 7.5 t30 -43.76 124.82 3.85 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.95 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 65.7 t30 70.62 52.03 0.32 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.898 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 54.5 t -134.12 135.34 54.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.123 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 83.4 t -86.96 120.57 36.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.119 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 181' ' ' VAL . . . . . 0.705 HG21 HD12 ' A' ' 186' ' ' LEU . 85.0 t -124.7 116.54 47.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.1 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 34.3 t70 58.52 36.52 25.29 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.87 179.899 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 84.35 -20.17 15.17 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.456 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 43.0 ttm-85 -107.23 133.4 51.86 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.897 0.379 . . . . 0.0 110.861 -179.859 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 30.0 m -80.27 133.29 35.97 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.104 -179.884 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 186' ' ' LEU . . . . . 0.705 HD12 HG21 ' A' ' 181' ' ' VAL . 27.4 mt -101.06 147.42 26.24 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.949 179.924 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -121.29 131.98 54.52 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.903 179.839 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -129.5 143.54 50.88 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.075 179.843 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 5.5 t -138.7 167.54 21.76 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.866 -179.785 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 190' ' ' LEU . . . . . 0.753 HD13 ' N ' ' A' ' 191' ' ' GLY . 2.0 tm? -132.61 128.9 38.13 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.925 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 191' ' ' GLY . . . . . 0.753 ' N ' HD13 ' A' ' 190' ' ' LEU . . . 99.91 27.81 7.68 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.447 179.878 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 192' ' ' THR . . . . . . . . . . . . . 30.4 p -89.04 152.95 21.38 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.84 0.352 . . . . 0.0 111.145 -179.879 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 193' ' ' THR . . . . . . . . . . . . . 40.7 p -87.64 141.76 28.36 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.123 -179.979 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 194' ' ' LYS . . . . . 0.776 ' HE3' HD22 ' A' ' 110' ' ' LEU . 0.0 OUTLIER -102.09 178.0 4.73 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.901 179.875 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 195' ' ' TYR . . . . . . . . . . . . . 45.9 t80 -116.92 99.17 6.9 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.897 -179.895 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 196' ' ' CYS . . . . . . . . . . . . . 12.0 t -146.2 151.04 36.97 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.851 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 3.2 m -118.59 128.77 54.87 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.888 -179.755 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 198' ' ' TYR . . . . . . . . . . . . . 9.3 p90 -45.78 133.41 8.3 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.881 -179.863 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 20.0 m -142.42 158.42 43.72 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.814 -179.838 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 200' ' ' GLY . . . . . 0.417 ' HA3' ' C ' ' A' ' 201' ' ' PRO . . . -84.68 -69.77 1.36 Allowed Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.505 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 201' ' ' PRO . . . . . 0.417 ' C ' ' HA3' ' A' ' 200' ' ' GLY . 53.1 Cg_endo -69.82 -19.78 11.15 Favored 'Cis proline' 0 C--N 1.342 0.209 0 C-N-CA 122.662 -1.808 . . . . 0.0 112.346 0.11 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 202' ' ' SER . . . . . . . . . . . . . 6.6 m -134.64 152.93 52.13 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.862 -179.851 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 66.5 m -66.79 -62.02 1.66 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.818 -179.801 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.346 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.509 -179.988 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 19.9 tp . . . . . 0 C--O 1.231 0.095 0 CA-C-O 120.857 0.36 . . . . 0.0 110.898 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 79.5 t -92.64 110.7 23.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.187 179.804 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.43 ' CE1' ' HB2' ' A' ' 158' ' ' SER . 53.4 t80 -109.52 107.0 16.95 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.892 -179.931 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 69.4 t -108.73 142.57 20.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.149 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 22.4 m -126.43 171.74 14.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.136 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 69.54 48.37 44.19 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.493 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 30.9 mt -112.69 125.48 54.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.789 0.328 . . . . 0.0 110.916 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . 0.423 ' O ' ' N ' ' A' ' 120' ' ' LEU . 26.9 t -71.79 141.4 49.69 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.895 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 36.5 tp60 -38.38 -32.33 0.07 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.9 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 15.7 mmt180 -70.79 -47.51 59.15 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.845 -179.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 120' ' ' LEU . . . . . 0.423 ' N ' ' O ' ' A' ' 117' ' ' SER . 58.7 mt -69.46 -32.74 71.85 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.913 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -64.46 83.79 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.14 179.779 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -148.66 144.06 17.96 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.59 0.709 . . . . 0.0 110.911 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.81 -45.55 1.52 Allowed 'Trans proline' 0 C--N 1.341 0.133 0 C-N-CA 122.684 2.256 . . . . 0.0 112.287 -179.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -71.48 -39.52 70.85 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.927 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.609 HG13 ' CZ ' ' A' ' 131' ' ' TYR . 74.6 t -63.21 -45.76 97.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.129 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.477 HD22 ' CE1' ' A' ' 132' ' ' PHE . 95.6 mt -74.47 -34.91 63.26 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.889 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 53.0 mttt -64.61 -32.25 73.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.882 179.85 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 20.0 mmt180 -46.25 143.97 3.41 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.631 0.729 . . . . 0.0 110.85 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -4.21 13.56 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.665 2.243 . . . . 0.0 112.35 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 56.6 tt0 -100.67 -10.64 20.7 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.892 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 131' ' ' TYR . . . . . 0.609 ' CZ ' HG13 ' A' ' 125' ' ' VAL . 43.6 m-85 -103.17 -74.98 0.62 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.91 -179.864 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.477 ' CE1' HD22 ' A' ' 126' ' ' LEU . 28.2 m-85 -118.65 -40.62 2.87 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.898 179.988 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -47.93 -19.02 0.85 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.505 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.416 ' HD2' ' CD2' ' A' ' 135' ' ' PHE . 0.0 OUTLIER -51.52 -40.31 59.37 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.822 0.344 . . . . 0.0 110.914 -179.995 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 135' ' ' PHE . . . . . 0.485 ' CE1' ' HA ' ' A' ' 172' ' ' ALA . 47.8 m-85 -67.16 -44.06 80.68 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.896 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 176.94 169.66 38.47 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.544 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -60.63 136.76 58.16 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.745 0.307 . . . . 0.0 110.922 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.666 HG21 HG22 ' A' ' 141' ' ' VAL . 61.1 mt -96.64 148.82 5.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.114 179.868 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 56.4 t60 -101.02 -48.74 4.33 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.854 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 22.6 ttmt -134.98 140.54 45.77 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.879 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . 0.666 HG22 HG21 ' A' ' 138' ' ' ILE . 15.9 t -132.73 112.75 19.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.159 179.814 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 93.8 t -116.77 137.73 49.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.116 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 4.1 mm -114.0 123.68 69.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.106 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 8.9 t-20 -113.03 114.02 26.29 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.901 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 6.2 p-10 . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.888 -179.974 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 50.8 m . . . . . 0 C--O 1.23 0.074 0 CA-C-O 120.865 0.364 . . . . 0.0 110.894 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -114.41 166.46 11.66 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.103 179.905 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . 0.43 ' HB2' ' CE1' ' A' ' 112' ' ' PHE . 4.8 p -134.93 150.99 50.48 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.865 -179.781 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -122.8 145.52 48.35 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.077 179.879 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 44.1 m-85 -119.42 107.16 13.0 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.945 -179.833 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 37.9 t -101.19 141.25 18.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.097 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 63.0 m -111.22 123.33 49.98 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.093 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 163' ' ' TYR . . . . . 0.825 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 30.5 m-85 -105.3 121.74 44.5 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.937 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 74.2 mt -49.63 -37.14 11.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.137 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 80.3 mmt-85 -107.11 114.75 29.0 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.898 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 69.0 m -51.68 -55.17 21.0 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.883 -179.803 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 24.8 mm-40 -42.96 -54.04 4.44 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.908 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -54.71 -46.11 74.13 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.871 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 169' ' ' ALA . . . . . 0.825 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -60.84 -64.07 1.08 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.098 179.948 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 36.6 mt -38.28 -63.62 0.48 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.922 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 86.5 mtt180 -52.8 -51.85 59.19 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.873 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . 0.695 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -45.06 -32.88 1.88 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.096 179.904 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 82.2 mt -81.72 -35.28 13.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.091 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 33.4 mt-30 -64.69 -27.65 69.06 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.906 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 175' ' ' CYS . . . . . 0.441 ' O ' ' CG2' ' A' ' 179' ' ' VAL . 2.3 m -93.82 -34.29 13.22 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.87 -179.927 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 176' ' ' VAL . . . . . 0.695 HG23 ' O ' ' A' ' 172' ' ' ALA . 10.8 t -63.29 -33.74 62.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.147 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 177' ' ' ASN . . . . . 0.437 ' ND2' ' N ' ' A' ' 178' ' ' ASN . 1.1 t-20 -62.55 140.99 58.65 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.89 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 178' ' ' ASN . . . . . 0.437 ' N ' ' ND2' ' A' ' 177' ' ' ASN . 9.1 t-20 62.33 37.62 13.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.846 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 179' ' ' VAL . . . . . 0.441 ' CG2' ' O ' ' A' ' 175' ' ' CYS . 75.0 t -118.57 133.15 66.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.141 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 59.3 t -89.03 128.04 41.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.169 179.914 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . 0.485 HG21 HD12 ' A' ' 186' ' ' LEU . 50.7 t -135.86 114.56 15.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.069 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 5.8 t70 63.5 28.53 15.34 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.901 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 89.21 -14.41 60.91 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.499 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 77.6 mtt85 -108.77 126.0 52.55 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.903 0.383 . . . . 0.0 110.805 -179.837 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 10.9 m -76.74 106.48 8.42 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.16 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 186' ' ' LEU . . . . . 0.485 HD12 HG21 ' A' ' 181' ' ' VAL . 80.3 mt -70.24 157.05 38.39 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.907 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 16.2 tptm -135.65 115.01 12.53 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.939 179.82 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -110.13 142.96 40.9 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.083 179.88 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 86.1 p -156.71 165.39 36.37 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.873 -179.776 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 190' ' ' LEU . . . . . . . . . . . . . 4.3 pp -126.62 154.98 43.25 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.938 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.283 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.45 179.885 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . 0.407 HD11 ' HD1' ' A' ' 160' ' ' TYR . 12.3 tp . . . . . 0 C--O 1.231 0.108 0 CA-C-O 120.836 0.351 . . . . 0.0 110.943 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.775 HG22 HD11 ' A' ' 173' ' ' ILE . 47.0 t -113.94 123.33 69.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.148 179.865 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.663 ' CZ ' ' CG1' ' A' ' 114' ' ' VAL . 37.6 t80 -111.17 106.56 15.61 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.891 -179.964 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.514 HG22 ' HB2' ' A' ' 188' ' ' ALA . 20.9 t -102.82 143.4 15.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.173 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . 0.663 ' CG1' ' CZ ' ' A' ' 112' ' ' PHE . 33.3 m -131.82 169.8 21.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.106 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 73.75 54.51 6.52 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.502 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 60.9 mt -117.31 129.96 56.23 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.84 0.352 . . . . 0.0 110.932 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 3.3 m -65.56 152.76 43.33 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.868 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 13.1 pt20 -50.9 -20.86 1.45 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.949 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 36.5 mtm180 -92.56 -42.75 9.51 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.88 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 62.8 mt -65.94 -34.74 78.8 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.948 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -62.54 85.29 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.075 179.842 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -148.48 144.09 18.13 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.626 0.727 . . . . 0.0 110.843 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.84 -42.17 3.55 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.677 2.251 . . . . 0.0 112.273 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -71.76 -44.4 64.12 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.9 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.408 HG13 ' CZ ' ' A' ' 131' ' ' TYR . 28.7 t -60.86 -43.43 95.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.119 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.417 HD12 HD11 ' A' ' 143' ' ' ILE . 84.7 mt -68.39 -39.94 81.52 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.906 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.425 ' O ' ' C ' ' A' ' 128' ' ' ARG . 6.9 tmtt? -65.23 -37.92 88.76 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.841 179.866 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 128' ' ' ARG . . . . . 0.425 ' C ' ' O ' ' A' ' 127' ' ' LYS . 21.1 mmt180 -36.39 144.45 0.27 Allowed Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.628 0.728 . . . . 0.0 110.9 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.8 -5.17 15.59 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.679 2.253 . . . . 0.0 112.372 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 130' ' ' GLU . . . . . 0.415 ' O ' ' CG ' ' A' ' 130' ' ' GLU . 20.5 tt0 -100.88 10.29 41.3 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.898 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 131' ' ' TYR . . . . . 0.408 ' CZ ' HG13 ' A' ' 125' ' ' VAL . 47.1 m-85 -127.54 -74.18 0.59 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.928 -179.853 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 69.7 m-85 -124.12 -11.44 7.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.862 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -71.12 -11.28 70.35 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.502 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -80.66 -30.79 36.54 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.794 0.331 . . . . 0.0 110.878 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 135' ' ' PHE . . . . . . . . . . . . . 22.9 m-85 -72.31 -26.06 61.8 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.827 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 167.41 -172.57 42.38 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.494 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 7.4 mtpm? -86.26 136.75 33.05 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.754 0.311 . . . . 0.0 110.917 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.74 HG21 HG22 ' A' ' 141' ' ' VAL . 82.5 mt -100.04 138.6 23.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.127 179.865 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -96.09 -46.51 6.45 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.848 179.878 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -141.04 141.05 34.34 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.916 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . 0.74 HG22 HG21 ' A' ' 138' ' ' ILE . 17.4 t -134.44 123.61 43.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.087 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 99.0 t -134.2 139.88 47.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.136 179.904 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . 0.417 HD11 HD12 ' A' ' 126' ' ' LEU . 44.8 mm -96.89 140.41 17.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.146 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 3.7 m120 -129.09 115.87 18.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.89 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 2.7 m120 . . . . . 0 C--N 1.329 -0.316 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.884 -179.967 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 94.0 p . . . . . 0 C--O 1.231 0.092 0 CA-C-O 120.888 0.375 . . . . 0.0 110.852 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -98.31 145.69 26.42 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.094 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 80.5 p -115.15 173.65 6.39 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.87 -179.762 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -153.68 140.79 19.4 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.119 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 160' ' ' TYR . . . . . 0.407 ' HD1' HD11 ' A' ' 110' ' ' LEU . 89.0 m-85 -111.38 123.47 50.28 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.933 -179.883 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 9.7 t -123.53 139.05 51.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.092 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 58.0 m -108.41 128.6 54.92 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.117 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 163' ' ' TYR . . . . . 0.547 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 25.3 m-85 -108.45 138.65 44.4 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.891 -179.892 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 50.7 mt -64.32 -38.11 81.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.123 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 32.6 mtm180 -103.85 114.14 28.17 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.889 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 46.9 m -51.9 -51.91 53.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.846 -179.762 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -50.91 -57.57 8.17 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.899 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -46.84 -45.58 20.29 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.888 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 169' ' ' ALA . . . . . 0.547 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -61.18 -54.49 43.72 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.12 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 87.5 mt -44.2 -63.75 0.81 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.898 -179.915 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 10.5 mtp180 -54.09 -46.66 72.12 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.887 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . 0.681 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -51.04 -33.26 24.59 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.121 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 173' ' ' ILE . . . . . 0.775 HD11 HG22 ' A' ' 111' ' ' VAL . 77.5 mt -78.26 -39.08 24.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.084 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 3.5 mp0 -68.47 -24.3 64.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.916 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 91.9 m -93.77 -27.89 16.23 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.862 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 176' ' ' VAL . . . . . 0.681 HG23 ' O ' ' A' ' 172' ' ' ALA . 10.6 t -74.23 -30.78 27.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.135 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -66.82 146.13 54.75 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.909 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 35.6 t30 57.83 46.31 17.14 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.88 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 91.5 t -124.91 133.42 69.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.117 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 88.2 t -96.52 114.55 33.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.13 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 96.4 t -123.29 106.22 17.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.188 179.885 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 23.8 t0 58.0 39.8 26.1 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.88 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 73.53 37.36 53.13 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.509 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 3.4 mmp_? -140.99 132.01 26.19 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.919 0.39 . . . . 0.0 110.821 -179.822 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 17.1 m -87.99 96.03 10.35 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.171 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 59.6 mt -69.94 124.32 23.75 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.869 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 17.3 tptp -123.53 113.11 18.29 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.851 179.845 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . 0.514 ' HB2' HG22 ' A' ' 113' ' ' VAL . . . -111.95 148.18 34.3 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.105 179.821 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 8.6 t -150.83 170.9 18.15 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.902 -179.789 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 190' ' ' LEU . . . . . 0.879 HD23 ' N ' ' A' ' 191' ' ' GLY . 5.8 tt -131.17 141.54 50.09 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.945 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 191' ' ' GLY . . . . . 0.879 ' N ' HD23 ' A' ' 190' ' ' LEU . . . . . . . . 0 N--CA 1.451 -0.306 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.505 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 13.8 tp . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.792 0.33 . . . . 0.0 110.941 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 59.1 t -96.79 118.61 43.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.108 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.654 ' CD1' ' CE2' ' A' ' 160' ' ' TYR . 45.3 t80 -119.29 111.61 18.41 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.889 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.534 HG22 ' HB2' ' A' ' 188' ' ' ALA . 23.1 t -107.01 140.78 24.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.098 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 5.1 m -120.06 169.38 11.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.09 179.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 67.26 53.89 23.28 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.505 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 38.3 mt -112.81 127.17 56.09 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.834 0.35 . . . . 0.0 110.915 -179.92 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . 0.495 ' O ' ' N ' ' A' ' 120' ' ' LEU . 18.8 t -65.64 125.91 26.74 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.874 -179.902 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 118' ' ' GLN . . . . . 0.438 ' C ' ' O ' ' A' ' 117' ' ' SER . 8.5 mm-40 -34.93 -32.46 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.882 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.494 ' N ' ' O ' ' A' ' 117' ' ' SER . 24.7 ttm180 -72.07 -48.14 46.4 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.863 -179.916 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 120' ' ' LEU . . . . . 0.495 ' N ' ' O ' ' A' ' 117' ' ' SER . 84.1 mt -70.2 -35.56 74.0 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.951 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -61.68 87.17 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.062 179.79 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 122' ' ' ASP . . . . . 0.431 ' HB2' ' CG2' ' A' ' 125' ' ' VAL . 5.9 m-20 -147.59 152.67 42.14 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.609 0.719 . . . . 0.0 110.847 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' PRO . . . . . 0.466 ' HA ' HG11 ' A' ' 141' ' ' VAL . 53.8 Cg_endo -69.72 -50.18 0.49 Allowed 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.674 2.25 . . . . 0.0 112.376 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 25.3 mt-10 -71.49 -42.34 68.19 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.911 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.486 HG12 ' CE2' ' A' ' 131' ' ' TYR . 48.2 t -57.08 -53.59 41.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.116 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 87.7 mt -68.25 -30.82 69.94 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.941 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 13.8 mmtt -64.95 -39.31 93.3 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.903 179.807 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 32.5 mtt180 -39.75 143.93 0.54 Allowed Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.648 0.737 . . . . 0.0 110.874 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 -1.15 7.99 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.652 2.235 . . . . 0.0 112.354 -179.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -101.51 -24.54 14.14 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.864 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 131' ' ' TYR . . . . . 0.486 ' CE2' HG12 ' A' ' 125' ' ' VAL . 43.9 m-85 -87.35 -74.67 0.43 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.933 -179.868 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 16.0 m-85 -118.81 -40.51 2.86 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.858 -179.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -44.9 -20.89 0.26 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.45 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.421 ' C ' ' HD3' ' A' ' 134' ' ' LYS . 0.0 OUTLIER -54.52 -37.55 65.5 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.834 0.35 . . . . 0.0 110.919 -179.988 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 135' ' ' PHE . . . . . . . . . . . . . 22.2 m-85 -66.23 -44.12 84.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.865 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -176.31 -153.55 10.71 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.447 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 38.7 mtmt -97.42 108.31 21.01 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.779 0.323 . . . . 0.0 110.937 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.541 HG23 HG13 ' A' ' 161' ' ' VAL . 91.6 mt -69.7 142.88 15.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.156 179.883 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 3.0 t-160 -102.16 -56.37 2.28 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.885 179.877 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 33.4 tttt -119.01 151.48 38.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.905 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . 0.467 HG22 HG21 ' A' ' 138' ' ' ILE . 41.4 t -143.05 108.85 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.155 179.849 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 96.9 t -115.82 126.94 73.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.158 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 26.7 mm -106.3 109.28 27.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.111 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 144' ' ' ASN . . . . . 0.485 ' O ' ' HB1' ' A' ' 157' ' ' ALA . 3.2 t-20 -96.06 137.14 35.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.881 179.934 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 1.5 p30 . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.842 -179.994 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 23.2 m . . . . . 0 C--O 1.231 0.111 0 CA-C-O 120.856 0.36 . . . . 0.0 110.856 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 157' ' ' ALA . . . . . 0.485 ' HB1' ' O ' ' A' ' 144' ' ' ASN . . . -119.74 171.99 8.01 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.108 179.884 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 67.7 p -123.31 169.64 11.11 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.875 -179.796 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -147.64 149.76 33.11 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.108 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 160' ' ' TYR . . . . . 0.654 ' CE2' ' CD1' ' A' ' 112' ' ' PHE . 43.4 m-85 -124.26 124.75 43.1 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.901 -179.847 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.541 HG13 HG23 ' A' ' 138' ' ' ILE . 57.4 t -120.39 125.32 74.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.174 179.883 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 48.7 m -93.47 131.28 38.84 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.143 -179.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 163' ' ' TYR . . . . . 0.469 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 9.5 m-85 -107.35 147.15 30.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.892 -179.89 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 48.2 mt -75.29 -47.53 34.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.128 179.916 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 35.1 mtp180 -91.54 114.23 26.71 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.856 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 75.5 m -49.35 -59.4 3.74 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.867 -179.814 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 55.8 mt-10 -47.96 -47.44 32.71 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.908 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -55.34 -45.85 76.39 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.881 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 169' ' ' ALA . . . . . 0.469 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -56.93 -56.63 19.17 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.1 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 56.0 mt -47.26 -59.86 2.88 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.891 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 1.9 mpt_? -56.68 -42.51 79.16 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.866 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . 0.737 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -55.24 -32.09 62.02 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.101 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 76.7 mt -79.78 -37.99 18.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.112 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 8.6 mm100 -64.66 -28.67 69.77 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.862 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 19.8 t -93.74 -28.95 15.64 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.852 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 176' ' ' VAL . . . . . 0.737 HG23 ' O ' ' A' ' 172' ' ' ALA . 9.9 t -71.7 -28.07 29.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.124 -179.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 1.8 t30 -70.76 141.61 51.45 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.895 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 25.7 t-20 61.35 49.33 5.41 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.923 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 179' ' ' VAL . . . . . 0.425 HG12 HG23 ' A' ' 181' ' ' VAL . 79.5 t -117.0 133.66 63.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.131 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 58.7 t -98.16 105.97 18.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.14 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . 0.593 HG21 HD12 ' A' ' 186' ' ' LEU . 56.3 t -115.73 131.2 68.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.189 179.862 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 44.96 29.05 0.42 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.856 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 80.39 31.46 37.52 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.737 -0.745 . . . . 0.0 112.471 -179.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 13.2 ttm180 -134.9 136.14 42.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.855 0.359 . . . . 0.0 110.888 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 26.5 m -82.69 99.51 9.66 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.162 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 186' ' ' LEU . . . . . 0.593 HD12 HG21 ' A' ' 181' ' ' VAL . 62.9 mt -84.29 140.48 31.61 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.942 179.957 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 9.4 ttpp -135.19 146.83 49.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.877 179.828 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . 0.534 ' HB2' HG22 ' A' ' 113' ' ' VAL . . . -134.29 155.47 50.14 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.075 179.842 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 8.8 t -155.59 164.18 38.98 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.835 -179.807 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 190' ' ' LEU . . . . . 0.489 ' O ' HD12 ' A' ' 190' ' ' LEU . 4.7 pp -130.07 147.57 51.83 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.956 179.943 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.356 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.533 179.953 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . 0.472 HD11 ' HB3' ' A' ' 160' ' ' TYR . 15.3 tp . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.866 0.365 . . . . 0.0 110.878 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 89.6 t -95.58 114.12 31.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.112 179.819 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.638 ' CE2' ' CG1' ' A' ' 114' ' ' VAL . 61.1 t80 -106.86 99.25 8.83 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.901 179.98 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.663 HG22 ' HB2' ' A' ' 188' ' ' ALA . 54.3 t -98.94 125.36 52.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.149 179.997 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . 0.638 ' CG1' ' CE2' ' A' ' 112' ' ' PHE . 12.0 m -118.89 168.88 10.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.126 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 77.39 39.52 26.02 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.505 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 32.5 mt -105.92 137.9 43.02 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.822 0.344 . . . . 0.0 110.89 -179.909 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 78.6 p -76.58 148.14 37.2 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.842 -179.941 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 34.5 mm-40 -42.2 -34.96 0.84 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.898 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 33.0 mtt180 -69.01 -47.47 65.39 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.872 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 120' ' ' LEU . . . . . 0.865 HD21 ' OD2' ' A' ' 182' ' ' ASP . 85.0 mt -71.78 -24.68 61.79 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.928 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -71.29 83.49 0.76 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.105 179.807 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 19.6 m-20 -148.95 144.38 18.07 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.619 0.723 . . . . 0.0 110.845 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.8 -45.67 1.48 Allowed 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.662 2.242 . . . . 0.0 112.38 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 19.9 mt-10 -73.19 -42.6 62.51 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.885 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.414 ' O ' ' CD1' ' A' ' 131' ' ' TYR . 56.4 t -59.04 -46.3 91.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.157 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 74.1 mt -68.69 -37.56 79.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.959 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 12.8 ttmm -68.0 -35.77 78.87 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.9 179.804 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 66.4 mtt-85 -44.89 147.91 1.05 Allowed Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.59 0.709 . . . . 0.0 110.882 180.0 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.71 -3.19 11.49 Favored 'Trans proline' 0 N--CA 1.465 -0.163 0 C-N-CA 122.711 2.274 . . . . 0.0 112.367 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -97.93 6.39 47.77 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.897 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 131' ' ' TYR . . . . . 0.414 ' CD1' ' O ' ' A' ' 125' ' ' VAL . 63.0 m-85 -131.32 -73.84 0.53 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.938 -179.858 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 71.0 m-85 -127.06 -6.04 6.1 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.901 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -70.9 -18.92 76.57 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.515 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 11.2 ptpt -88.72 -27.25 21.33 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.857 0.36 . . . . 0.0 110.893 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 135' ' ' PHE . . . . . . . . . . . . . 27.9 m-85 -63.97 -43.65 95.11 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.85 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -177.43 167.55 38.69 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.482 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 27.1 mtmm -67.06 120.06 13.05 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.728 0.299 . . . . 0.0 110.87 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.458 HG12 ' CG1' ' A' ' 161' ' ' VAL . 83.3 mt -95.12 146.43 6.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.074 179.892 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 4.2 t60 -107.13 -59.94 1.75 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.843 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 27.5 ttpp -125.53 145.63 50.02 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.913 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 21.3 t -130.19 132.79 64.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.129 179.847 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 3.5 t -125.96 140.73 47.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.13 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 23.8 mm -119.4 121.66 67.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.162 179.907 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 7.1 m-80 -116.57 105.58 12.61 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.907 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.33 -0.279 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.878 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 19.7 m . . . . . 0 C--O 1.23 0.066 0 CA-C-O 120.92 0.391 . . . . 0.0 110.868 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -84.38 167.18 16.74 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.107 179.902 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 95.8 p -142.51 162.53 35.22 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.869 -179.765 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -145.88 141.88 28.26 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.116 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 160' ' ' TYR . . . . . 0.472 ' HB3' HD11 ' A' ' 110' ' ' LEU . 15.2 m-85 -115.19 112.6 22.74 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.95 -179.88 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.458 ' CG1' HG12 ' A' ' 138' ' ' ILE . 94.6 t -106.64 133.69 50.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.146 179.911 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 9.1 m -102.66 125.61 49.45 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.159 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 163' ' ' TYR . . . . . 0.489 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 13.8 m-85 -103.53 136.5 43.13 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.909 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 89.3 mt -63.85 -49.69 80.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.108 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 28.3 mmt180 -100.72 119.16 38.2 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.894 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 4.1 m -50.09 -57.61 7.3 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.848 -179.787 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -41.18 -61.48 1.0 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.886 -179.933 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 31.3 m-20 -46.65 -46.15 19.69 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.857 179.998 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 169' ' ' ALA . . . . . 0.489 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -57.86 -55.48 34.41 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.059 179.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 71.7 mt -45.0 -59.72 2.44 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.917 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 13.9 mtm180 -53.94 -53.18 56.33 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.84 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . 0.521 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -45.03 -34.83 2.67 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.118 179.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 96.4 mt -81.67 -32.15 11.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.122 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 73.0 mt-30 -66.76 -27.33 67.51 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.874 -179.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 1.8 t -93.81 -35.88 12.53 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.867 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 176' ' ' VAL . . . . . 0.521 HG23 ' O ' ' A' ' 172' ' ' ALA . 10.7 t -64.84 -45.84 93.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.113 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -51.79 144.98 10.27 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.895 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 41.6 m-20 57.61 53.43 7.28 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.882 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 179' ' ' VAL . . . . . 0.675 ' O ' HG23 ' A' ' 185' ' ' THR . 78.6 t -134.59 138.57 49.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.168 179.879 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 66.6 t -92.49 124.18 44.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.123 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 60.0 t -135.37 126.89 45.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.103 179.933 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 182' ' ' ASP . . . . . 0.865 ' OD2' HD21 ' A' ' 120' ' ' LEU . 4.4 m-20 59.29 25.47 14.11 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.85 179.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 90.21 -18.04 50.59 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.464 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 15.3 ptm180 -117.33 129.66 56.02 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.923 0.392 . . . . 0.0 110.849 -179.861 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 185' ' ' THR . . . . . 0.675 HG23 ' O ' ' A' ' 179' ' ' VAL . 51.3 m -71.48 138.89 49.33 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.154 -179.896 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 54.6 mt -105.53 143.65 33.39 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.884 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -115.11 117.14 29.72 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.905 179.841 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . 0.663 ' HB2' HG22 ' A' ' 113' ' ' VAL . . . -114.96 127.68 55.83 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.065 179.857 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 4.3 t -136.6 173.78 11.33 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.848 -179.771 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 190' ' ' LEU . . . . . 0.514 HD12 ' O ' ' A' ' 190' ' ' LEU . 3.6 pp -130.29 160.95 32.37 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.929 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.284 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.453 179.878 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 33.6 tp . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.83 0.348 . . . . 0.0 110.883 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.4 HG22 HD11 ' A' ' 173' ' ' ILE . 95.3 t -100.58 103.39 14.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.085 179.858 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.598 ' CD1' ' CE2' ' A' ' 160' ' ' TYR . 39.1 t80 -101.69 113.24 26.22 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.864 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.67 HG22 ' HB2' ' A' ' 188' ' ' ALA . 40.1 t -112.87 126.51 70.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.126 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . 0.414 ' CG1' ' CE2' ' A' ' 112' ' ' PHE . 17.3 m -111.83 166.36 6.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.16 179.924 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 78.68 43.15 12.24 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.435 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 49.4 mt -112.99 118.26 34.34 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.828 0.347 . . . . 0.0 110.889 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 2.8 p -65.53 143.36 57.69 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.835 -179.908 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 65.8 mm-40 -39.85 -34.82 0.29 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.917 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 59.8 ttt180 -69.02 -49.06 61.06 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.891 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 61.7 mt -72.63 -20.55 61.25 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.929 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -78.53 83.26 4.73 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.083 179.799 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 17.0 m-20 -148.54 149.24 30.78 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-O 121.572 0.701 . . . . 0.0 110.887 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 -48.59 0.69 Allowed 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.664 2.243 . . . . 0.0 112.39 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 44.7 mm-40 -67.0 -42.07 85.64 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.885 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.529 HG13 ' CZ ' ' A' ' 131' ' ' TYR . 38.1 t -59.82 -47.34 91.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.107 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 94.6 mt -71.58 -32.73 68.4 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.927 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 68.2 mttt -67.19 -30.26 70.15 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.896 179.836 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 9.9 mmp_? -50.23 144.29 11.63 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.577 0.703 . . . . 0.0 110.884 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 0.01 6.29 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.669 2.246 . . . . 0.0 112.365 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 35.3 tt0 -101.05 -7.71 22.99 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.877 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 131' ' ' TYR . . . . . 0.529 ' CZ ' HG13 ' A' ' 125' ' ' VAL . 41.5 m-85 -111.96 -72.88 0.69 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.932 -179.871 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 33.4 m-85 -124.42 -21.67 4.86 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.869 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -52.57 -24.36 17.43 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.479 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 14.6 ptpt -90.49 -16.9 28.06 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.77 0.319 . . . . 0.0 110.848 -179.932 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 135' ' ' PHE . . . . . . . . . . . . . 15.5 m-85 -79.15 -29.11 42.91 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.858 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 172.05 168.33 33.38 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.479 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 7.2 mtmp? -75.67 101.27 4.93 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.806 0.336 . . . . 0.0 110.92 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.625 HG23 HG13 ' A' ' 161' ' ' VAL . 81.7 mt -68.64 134.09 30.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.145 179.9 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 2.3 t-160 -103.68 -50.7 3.35 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.859 179.893 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 51.8 tttt -134.0 132.13 39.74 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.906 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . 0.573 ' CG2' HG21 ' A' ' 138' ' ' ILE . 49.1 t -120.11 133.23 67.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.113 179.923 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 99.6 t -129.88 129.42 65.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.115 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 19.0 mm -107.31 119.36 56.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.139 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 7.7 m120 -111.33 101.34 9.82 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.859 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 9.1 p-10 . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.9 179.961 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 17.5 m . . . . . 0 C--O 1.23 0.073 0 CA-C-O 120.864 0.364 . . . . 0.0 110.859 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -123.85 169.43 11.58 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.081 179.897 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . 0.4 ' HB3' ' CE1' ' A' ' 112' ' ' PHE . 20.3 m -137.53 164.51 28.55 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.882 -179.804 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -142.95 140.08 30.95 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.128 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 160' ' ' TYR . . . . . 0.598 ' CE2' ' CD1' ' A' ' 112' ' ' PHE . 33.6 m-85 -113.7 116.71 29.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.933 -179.842 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.625 HG13 HG23 ' A' ' 138' ' ' ILE . 98.0 t -116.58 139.62 42.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.111 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 29.9 m -106.03 129.12 54.2 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.126 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 3.7 m-85 -109.51 148.28 31.48 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.982 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 49.0 mt -76.45 -61.06 1.83 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.139 179.918 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 59.4 mtt180 -82.25 99.08 9.1 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.82 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 50.7 m -42.01 -53.34 3.92 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.878 -179.853 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 3.6 pt-20 -40.73 -59.34 1.42 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.906 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -56.7 -35.14 68.14 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.869 179.923 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -65.4 -60.18 3.23 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.122 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 39.6 mt -45.85 -51.76 12.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.903 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 2.2 mpt_? -61.07 -43.83 98.3 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.808 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . 0.617 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -54.89 -31.81 60.27 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.134 179.915 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 173' ' ' ILE . . . . . 0.4 HD11 HG22 ' A' ' 111' ' ' VAL . 63.0 mt -81.16 -38.42 16.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.135 179.987 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 31.4 mm-40 -69.69 -22.09 63.45 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.935 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 3.4 t -93.8 -34.75 13.05 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.906 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 176' ' ' VAL . . . . . 0.617 HG23 ' O ' ' A' ' 172' ' ' ALA . 10.5 t -66.79 -38.17 80.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.081 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 1.7 t30 -63.34 140.57 58.89 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.874 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 25.5 t30 71.81 35.21 1.41 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.856 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 89.4 t -119.54 131.56 71.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.122 179.892 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 82.7 t -95.62 102.56 13.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.09 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 53.7 t -111.07 117.57 55.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.167 179.877 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 15.2 m-20 48.8 48.99 19.67 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.828 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 63.15 28.4 72.11 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.452 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 12.2 mtt85 -138.07 111.27 7.9 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.86 0.362 . . . . 0.0 110.89 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 36.5 m -70.63 101.21 1.99 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.126 -179.945 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 11.9 mt -68.45 129.6 40.4 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.914 179.928 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 22.9 tptm -124.85 120.55 32.03 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.932 179.816 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . 0.67 ' HB2' HG22 ' A' ' 113' ' ' VAL . . . -119.82 151.82 38.24 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.127 179.857 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 8.6 t -158.38 164.01 36.72 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.849 -179.718 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 190' ' ' LEU . . . . . 0.844 HD12 ' O ' ' A' ' 190' ' ' LEU . 4.1 pp -128.18 130.3 47.83 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.897 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.333 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.478 179.879 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 11.2 tp . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.829 0.347 . . . . 0.0 110.902 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 98.8 t -94.64 130.11 43.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.116 179.85 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.418 ' CZ ' HG12 ' A' ' 114' ' ' VAL . 40.5 t80 -128.95 98.23 4.88 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.893 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.699 HG22 ' HB2' ' A' ' 188' ' ' ALA . 54.0 t -92.76 135.75 26.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.177 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . 0.418 HG12 ' CZ ' ' A' ' 112' ' ' PHE . 4.7 m -124.96 164.4 23.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.12 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 76.28 47.85 10.26 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.518 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 116' ' ' LEU . . . . . 0.56 HD23 HD22 ' A' ' 186' ' ' LEU . 59.8 mt -108.3 130.87 55.17 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.812 0.339 . . . . 0.0 110.929 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 14.0 m -69.21 155.4 40.47 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.902 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 40.8 mt-30 -46.84 -38.07 9.73 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.915 -179.927 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 19.6 tpt180 -74.66 -50.74 16.55 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.869 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 37.0 mt -62.15 -19.09 62.69 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.904 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -76.68 83.9 3.32 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.098 179.782 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -148.66 144.02 17.91 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.639 0.733 . . . . 0.0 110.865 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 -50.78 0.43 Allowed 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.694 2.263 . . . . 0.0 112.341 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 22.1 pt-20 -67.35 -38.36 84.7 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.87 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 84.2 t -63.62 -42.85 97.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.084 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.689 HD12 HD11 ' A' ' 143' ' ' ILE . 47.9 mt -72.02 -32.82 67.52 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.899 179.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 25.0 tttm -74.44 -29.94 61.69 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.914 179.849 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 49.8 mtp180 -47.11 148.8 1.87 Allowed Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.571 0.7 . . . . 0.0 110.882 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 -2.1 9.61 Favored 'Trans proline' 0 C--N 1.341 0.138 0 C-N-CA 122.665 2.243 . . . . 0.0 112.308 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 4.0 tp10 -91.83 -23.53 19.65 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.834 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 131' ' ' TYR . . . . . . . . . . . . . 26.0 m-85 -103.34 -69.55 0.79 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.913 -179.826 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.434 ' O ' ' N ' ' A' ' 135' ' ' PHE . 87.8 m-85 -126.23 -27.9 3.17 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.887 -179.971 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -43.87 -22.23 0.27 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.536 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.4 ' N ' ' O ' ' A' ' 132' ' ' PHE . 16.7 ptpt -85.09 -34.41 22.22 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.801 0.334 . . . . 0.0 110.865 -179.949 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 135' ' ' PHE . . . . . 0.488 ' CE2' HG23 ' A' ' 176' ' ' VAL . 12.9 m-85 -56.3 -39.26 72.42 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.857 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 178.77 -176.19 47.83 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.494 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 13.9 tttt -87.87 111.41 21.39 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.724 0.297 . . . . 0.0 110.902 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.495 HG21 HG22 ' A' ' 141' ' ' VAL . 61.5 mt -83.47 144.7 9.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.174 179.849 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 2.2 t60 -102.32 -44.27 5.45 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.851 179.915 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 24.1 ttpp -138.72 145.73 40.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.909 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . 0.495 HG22 HG21 ' A' ' 138' ' ' ILE . 21.2 t -131.0 129.38 63.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.174 179.848 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 46.6 t -125.78 140.2 49.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.16 179.93 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . 0.689 HD11 HD12 ' A' ' 126' ' ' LEU . 20.0 mm -121.92 126.83 75.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.176 179.883 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 19.0 m-20 -120.49 121.11 37.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.884 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 3.0 p-10 . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.875 -179.98 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 86.9 p . . . . . 0 C--O 1.231 0.103 0 CA-C-O 120.832 0.348 . . . . 0.0 110.873 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -127.61 167.74 15.96 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.13 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 83.5 p -126.13 166.08 17.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.89 -179.819 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -147.99 140.46 24.46 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.131 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 8.8 m-85 -114.71 136.37 53.13 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.917 -179.843 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 74.9 t -130.0 125.59 60.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.145 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 89.1 m -95.75 122.65 38.75 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.176 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 4.8 m-85 -108.16 141.43 39.9 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.936 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 65.3 mt -74.57 -39.52 47.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.073 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 38.4 mtm-85 -86.92 114.58 23.67 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.851 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 14.3 t -55.84 -59.66 4.56 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.845 -179.804 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 17.9 tt0 -51.68 -49.65 61.99 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.875 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 12.2 t0 -48.03 -46.25 32.97 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.886 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -61.67 -53.46 55.86 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.111 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 72.9 mt -44.68 -63.9 0.81 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.888 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 171' ' ' ARG . . . . . 0.418 ' O ' ' N ' ' A' ' 174' ' ' GLN . 14.9 mtp180 -59.59 -53.04 62.64 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.859 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . 0.502 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -40.0 -37.73 0.63 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.081 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 67.4 mt -80.66 -36.7 15.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.133 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 174' ' ' GLN . . . . . 0.418 ' N ' ' O ' ' A' ' 171' ' ' ARG . 25.8 mm-40 -61.1 -26.88 67.97 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.9 179.905 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 2.5 t -93.75 -41.15 9.83 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.897 -179.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 176' ' ' VAL . . . . . 0.502 HG23 ' O ' ' A' ' 172' ' ' ALA . 10.3 t -58.77 -39.44 76.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.092 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -62.43 136.43 57.9 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.896 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 14.6 t30 70.76 47.01 0.48 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.919 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 59.0 t -127.64 134.8 64.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.139 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 89.4 t -93.95 115.04 31.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.148 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 62.4 t -121.45 118.88 57.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.158 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 55.9 m-20 58.5 28.76 17.41 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.844 179.935 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 90.08 -19.52 42.0 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.497 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 25.4 ttm-85 -103.52 135.89 44.27 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.939 0.4 . . . . 0.0 110.851 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 71.2 m -86.8 131.83 34.01 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.186 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 186' ' ' LEU . . . . . 0.56 HD22 HD23 ' A' ' 116' ' ' LEU . 25.4 mt -112.57 126.25 55.14 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.91 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 7.9 ttmt -109.48 136.64 48.56 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.87 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . 0.699 ' HB2' HG22 ' A' ' 113' ' ' VAL . . . -125.64 149.52 48.36 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.096 179.844 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 7.3 t -159.37 167.71 28.14 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.828 -179.766 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 190' ' ' LEU . . . . . . . . . . . . . 4.2 pp -126.38 153.11 45.4 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.958 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.252 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.438 179.927 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 19.4 tp . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.807 0.337 . . . . 0.0 110.938 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.763 HG22 HD11 ' A' ' 173' ' ' ILE . 75.1 t -93.1 115.99 33.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.102 179.886 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.579 ' CE1' ' HB2' ' A' ' 158' ' ' SER . 6.6 t80 -112.49 118.47 35.22 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.895 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.42 HG22 ' HB2' ' A' ' 188' ' ' ALA . 25.5 t -115.0 137.53 48.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.169 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . 0.483 HG12 ' HE1' ' A' ' 112' ' ' PHE . 19.9 m -123.42 168.96 15.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.161 179.908 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 75.59 48.62 10.19 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.499 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 36.4 mt -114.68 131.18 56.83 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.807 0.336 . . . . 0.0 110.884 -179.887 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 13.0 t -68.99 152.0 45.81 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.88 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 4.2 tp-100 -51.52 -23.57 4.23 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.936 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 30.3 ttt180 -84.62 -45.56 12.39 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.889 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 96.7 mt -68.06 -28.83 67.71 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.87 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -66.36 83.05 0.09 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.096 179.834 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -145.47 143.97 21.58 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.625 0.726 . . . . 0.0 110.842 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 -38.89 7.25 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.726 2.284 . . . . 0.0 112.345 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -77.51 -44.83 27.44 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.895 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.556 ' O ' ' CD1' ' A' ' 131' ' ' TYR . 62.0 t -60.6 -38.32 78.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.076 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.806 HD12 HD11 ' A' ' 143' ' ' ILE . 81.4 mt -75.08 -44.5 47.07 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.89 180.0 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.61 ' HA ' HD12 ' A' ' 138' ' ' ILE . 22.7 ttpp -67.87 -25.82 65.71 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.897 179.861 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 12.9 mmt180 -47.76 144.01 5.6 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.657 0.742 . . . . 0.0 110.803 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 -8.39 23.48 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.745 2.297 . . . . 0.0 112.324 179.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 46.7 mt-10 -98.83 8.35 45.07 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.89 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 131' ' ' TYR . . . . . 0.556 ' CD1' ' O ' ' A' ' 125' ' ' VAL . 59.3 m-85 -126.08 -74.26 0.61 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.927 -179.828 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.444 ' O ' ' N ' ' A' ' 134' ' ' LYS . 58.5 m-85 -116.26 -36.66 3.98 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.914 -180.0 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -40.39 -25.58 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.488 -179.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.444 ' N ' ' O ' ' A' ' 132' ' ' PHE . 3.5 mtpp -42.7 -59.65 1.85 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.82 0.343 . . . . 0.0 110.875 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 135' ' ' PHE . . . . . 0.42 ' CE1' ' HA ' ' A' ' 172' ' ' ALA . 28.1 m-85 -50.93 -43.59 60.13 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.865 179.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 173.82 -172.99 45.69 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.46 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 20.9 mtpp -76.19 141.35 41.85 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.733 0.301 . . . . 0.0 110.887 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.68 HG21 ' CG2' ' A' ' 141' ' ' VAL . 60.6 mt -99.52 141.26 17.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.125 179.866 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 11.2 t60 -84.97 -58.55 2.65 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.846 179.892 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 22.1 tttp -137.53 146.82 44.61 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.914 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . 0.68 ' CG2' HG21 ' A' ' 138' ' ' ILE . 35.3 t -134.68 132.83 54.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.175 179.897 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 57.8 t -126.46 141.38 46.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.121 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . 0.806 HD11 HD12 ' A' ' 126' ' ' LEU . 31.4 mm -119.87 132.65 69.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.095 179.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 5.2 t-20 -126.39 106.54 9.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.889 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 5.3 p30 . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.872 -179.999 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 93.4 p . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.894 0.378 . . . . 0.0 110.873 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -93.96 169.47 10.25 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.092 179.932 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . 0.579 ' HB2' ' CE1' ' A' ' 112' ' ' PHE . 86.9 p -140.72 153.52 45.96 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.85 -179.775 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -137.68 150.93 47.73 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.109 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 160' ' ' TYR . . . . . 0.486 ' CD1' ' N ' ' A' ' 160' ' ' TYR . 1.3 m-85 -115.57 125.79 53.4 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.919 -179.832 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.419 ' CG1' ' CE1' ' A' ' 163' ' ' TYR . 43.0 t -120.83 125.74 74.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.151 179.909 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 87.9 m -107.44 123.88 49.04 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.161 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 163' ' ' TYR . . . . . 0.419 ' CE1' ' CG1' ' A' ' 161' ' ' VAL . 30.3 m-85 -104.06 164.3 11.8 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.906 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 42.7 mt -94.05 -39.46 10.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.153 179.891 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 30.5 mtp180 -102.12 120.36 40.31 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.911 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 16.0 m -47.78 -56.49 7.28 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.823 -179.733 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 34.8 mt-10 -46.23 -52.46 12.42 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.904 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 23.3 m-20 -50.95 -48.18 60.95 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.801 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -55.29 -62.47 1.65 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.082 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 66.0 mt -41.63 -62.77 0.82 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.9 -179.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 171' ' ' ARG . . . . . 0.414 ' O ' ' N ' ' A' ' 174' ' ' GLN . 20.0 mtp85 -51.76 -60.06 3.59 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.829 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . 0.577 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -38.75 -36.42 0.26 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.146 179.893 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 173' ' ' ILE . . . . . 0.763 HD11 HG22 ' A' ' 111' ' ' VAL . 60.9 mt -80.96 -39.89 18.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.12 179.961 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 174' ' ' GLN . . . . . 0.414 ' N ' ' O ' ' A' ' 171' ' ' ARG . 51.3 mt-30 -66.93 -22.1 65.96 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.92 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 1.8 t -93.77 -37.27 11.87 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.913 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 176' ' ' VAL . . . . . 0.577 HG23 ' O ' ' A' ' 172' ' ' ALA . 10.3 t -64.37 -33.77 64.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.082 -179.954 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 3.8 t30 -67.95 143.5 55.61 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.866 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 22.8 t30 65.52 48.94 1.91 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.905 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 179' ' ' VAL . . . . . 0.416 HG12 HG23 ' A' ' 181' ' ' VAL . 53.0 t -127.27 135.64 62.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.14 179.922 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 59.3 t -96.9 100.31 10.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.148 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . 0.468 HG21 HD12 ' A' ' 186' ' ' LEU . 66.9 t -107.52 97.98 6.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.175 179.909 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 6.8 t0 66.73 36.58 4.6 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.862 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 77.59 32.54 46.1 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.499 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 65.6 mtt85 -141.66 136.51 30.98 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.911 0.386 . . . . 0.0 110.866 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 26.6 m -94.73 95.0 8.44 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.161 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 186' ' ' LEU . . . . . 0.468 HD12 HG21 ' A' ' 181' ' ' VAL . 79.8 mt -67.74 132.73 48.0 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.901 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 25.4 tptt -111.08 116.41 31.08 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.92 179.815 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . 0.441 ' HB2' HG11 ' A' ' 176' ' ' VAL . . . -112.38 134.28 54.01 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.101 179.824 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 7.7 t -158.51 171.75 19.56 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.815 -179.791 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 190' ' ' LEU . . . . . 0.83 HD22 ' C ' ' A' ' 190' ' ' LEU . 0.0 OUTLIER -119.25 158.77 25.37 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.936 179.998 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 191' ' ' GLY . . . . . 0.448 ' N ' HD22 ' A' ' 190' ' ' LEU . . . . . . . . 0 N--CA 1.451 -0.356 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.491 179.91 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . 0.626 HD11 ' HD2' ' A' ' 160' ' ' TYR . 62.1 tp . . . . . 0 C--O 1.231 0.084 0 CA-C-O 120.838 0.351 . . . . 0.0 110.92 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.429 HG12 HG23 ' A' ' 113' ' ' VAL . 86.9 t -111.13 106.64 21.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.065 179.88 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.469 ' CE2' ' CG1' ' A' ' 114' ' ' VAL . 87.7 t80 -94.48 102.21 14.15 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.905 179.967 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.429 HG23 HG12 ' A' ' 111' ' ' VAL . 20.2 t -107.23 131.73 56.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.16 179.993 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . 0.469 ' CG1' ' CE2' ' A' ' 112' ' ' PHE . 6.1 m -119.2 155.01 21.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.113 179.942 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 90.81 44.35 4.54 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.452 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 116' ' ' LEU . . . . . 0.505 HD23 HD21 ' A' ' 186' ' ' LEU . 38.5 mt -110.25 125.0 52.65 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.823 0.344 . . . . 0.0 110.913 -179.943 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . 0.484 ' O ' ' N ' ' A' ' 120' ' ' LEU . 22.8 p -69.09 139.97 54.81 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.84 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 118' ' ' GLN . . . . . 0.42 ' C ' ' O ' ' A' ' 117' ' ' SER . 37.4 mt-30 -36.38 -41.79 0.3 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.914 -179.924 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 26.6 mtm-85 -66.31 -44.12 84.33 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.886 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 120' ' ' LEU . . . . . 0.484 ' N ' ' O ' ' A' ' 117' ' ' SER . 34.5 mt -72.42 -24.74 61.27 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.912 -179.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -71.23 83.25 0.74 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.132 179.811 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 20.0 m-20 -148.87 144.0 17.73 Favored Pre-proline 0 C--N 1.328 -0.364 0 CA-C-O 121.648 0.737 . . . . 0.0 110.88 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 123' ' ' PRO . . . . . 0.403 ' HA ' HG11 ' A' ' 141' ' ' VAL . 54.1 Cg_endo -69.73 -46.65 1.16 Allowed 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.69 2.26 . . . . 0.0 112.347 -179.963 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 48.7 mt-10 -71.36 -43.31 67.16 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.924 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.523 ' O ' ' CD2' ' A' ' 131' ' ' TYR . 90.5 t -60.19 -42.2 89.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.136 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.573 HD12 HD11 ' A' ' 143' ' ' ILE . 64.6 mt -72.96 -39.48 66.15 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.898 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.716 ' HA ' HD12 ' A' ' 138' ' ' ILE . 18.6 ttmt -61.44 -31.95 71.92 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.9 179.855 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 91.7 mtt180 -43.02 143.94 1.17 Allowed Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.635 0.731 . . . . 0.0 110.88 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 -2.69 10.57 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.679 2.253 . . . . 0.0 112.384 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 25.7 mt-10 -97.57 -30.26 12.96 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.905 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 131' ' ' TYR . . . . . 0.523 ' CD2' ' O ' ' A' ' 125' ' ' VAL . 44.2 m-85 -87.64 -74.91 0.43 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.921 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.481 ' CE1' HD22 ' A' ' 126' ' ' LEU . 42.6 m-85 -117.08 -36.84 3.69 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.88 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -49.34 -18.42 1.43 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.518 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -52.49 -34.22 48.34 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.832 0.349 . . . . 0.0 110.916 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 135' ' ' PHE . . . . . 0.568 ' CE2' ' HA ' ' A' ' 172' ' ' ALA . 79.8 m-85 -73.35 -42.02 62.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.897 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 166.89 -178.14 41.3 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.493 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 5.2 ttmm -60.01 140.28 56.88 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.762 0.315 . . . . 0.0 110.858 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.716 HD12 ' HA ' ' A' ' 127' ' ' LYS . 91.3 mt -105.67 139.03 28.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.112 179.862 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 34.3 t-80 -75.61 -55.15 5.94 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.866 179.868 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 140' ' ' LYS . . . . . 0.478 ' HD3' ' CG2' ' A' ' 142' ' ' VAL . 13.4 ttmm -149.49 144.16 26.11 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.916 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . 0.494 HG22 HG21 ' A' ' 138' ' ' ILE . 23.9 t -122.43 103.63 13.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.109 179.927 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.478 ' CG2' ' HD3' ' A' ' 140' ' ' LYS . 63.1 t -100.65 140.82 18.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.157 179.873 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . 0.573 HD11 HD12 ' A' ' 126' ' ' LEU . 26.7 mm -119.24 125.47 74.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.15 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 19.6 m-20 -121.2 142.75 49.6 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.88 179.916 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 18.4 p30 . . . . . 0 C--N 1.329 -0.306 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.871 -179.983 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 82.0 p . . . . . 0 C--O 1.231 0.103 0 CA-C-O 120.905 0.383 . . . . 0.0 110.844 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -113.68 157.91 21.57 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.076 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 11.7 t -116.29 168.19 10.35 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.871 -179.763 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -148.48 147.29 28.95 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.058 179.893 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 160' ' ' TYR . . . . . 0.626 ' HD2' HD11 ' A' ' 110' ' ' LEU . 4.5 m-85 -115.06 104.73 12.17 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.916 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 95.3 t -99.51 126.45 52.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.146 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 96.7 m -95.9 123.76 39.62 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.14 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 163' ' ' TYR . . . . . 0.531 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 12.1 m-85 -106.13 121.99 45.27 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.949 -179.942 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 46.0 mt -57.38 -51.5 68.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.097 -0.502 . . . . 0.0 111.154 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 39.7 mtp180 -85.72 118.08 25.0 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.847 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 22.6 t -48.72 -47.4 41.33 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.868 -179.82 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -54.36 -56.22 20.77 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.905 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . 0.499 ' O ' ' HB2' ' A' ' 172' ' ' ALA . 0.9 OUTLIER -52.39 -31.9 36.17 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.867 179.959 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 169' ' ' ALA . . . . . 0.531 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -70.49 -66.19 0.63 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.113 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 31.1 mt -46.6 -56.17 6.5 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.894 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 84.9 mtt180 -56.59 -46.56 80.78 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.854 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . 0.568 ' HA ' ' CE2' ' A' ' 135' ' ' PHE . . . -51.88 -32.73 33.56 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.076 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 65.8 mt -79.13 -36.4 18.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.11 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 15.7 mm100 -65.84 -26.93 67.88 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.874 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 175' ' ' CYS . . . . . 0.48 ' O ' HG21 ' A' ' 179' ' ' VAL . 7.6 m -93.7 -36.63 12.23 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.907 -179.949 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 176' ' ' VAL . . . . . 0.554 HG23 ' O ' ' A' ' 172' ' ' ALA . 10.5 t -65.43 -40.11 87.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.083 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 7.4 p-10 -68.32 152.1 45.93 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.891 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 36.5 t30 57.1 48.77 14.84 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.882 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 179' ' ' VAL . . . . . 0.48 HG21 ' O ' ' A' ' 175' ' ' CYS . 94.3 t -133.56 140.21 47.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.113 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 87.1 t -99.08 105.35 17.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.097 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . 0.486 HG21 HD12 ' A' ' 186' ' ' LEU . 91.8 t -112.06 98.73 7.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.133 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 30.9 t0 60.7 52.42 4.43 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.841 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 63.27 24.19 67.11 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.492 -179.931 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 66.3 mtp85 -131.61 111.91 12.14 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.874 0.369 . . . . 0.0 110.86 -179.826 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 28.2 m -76.09 93.19 3.28 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.127 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 186' ' ' LEU . . . . . 0.505 HD21 HD23 ' A' ' 116' ' ' LEU . 80.2 mt -68.54 128.99 38.61 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.931 179.916 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 2.5 mmmp? -117.6 118.29 31.73 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.877 179.847 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -107.19 145.56 32.46 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.127 179.819 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 4.5 t -143.33 169.32 17.88 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.857 -179.74 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 190' ' ' LEU . . . . . 0.495 HD23 ' N ' ' A' ' 191' ' ' GLY . 8.6 tt -128.81 134.89 48.51 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.904 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 191' ' ' GLY . . . . . 0.495 ' N ' HD23 ' A' ' 190' ' ' LEU . . . . . . . . 0 N--CA 1.451 -0.306 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.486 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 11.5 tp . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.84 0.352 . . . . 0.0 110.908 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.446 HG22 HD11 ' A' ' 173' ' ' ILE . 85.2 t -122.55 111.75 31.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.105 179.872 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.437 ' CE1' ' HB2' ' A' ' 158' ' ' SER . 42.1 t80 -98.46 113.34 25.3 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.889 179.991 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.434 HG21 ' CZ ' ' A' ' 132' ' ' PHE . 92.8 t -110.68 137.23 43.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.117 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 35.9 m -126.91 168.19 20.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.147 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 74.29 41.67 37.42 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.476 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 50.5 mt -103.54 130.84 51.02 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.797 0.332 . . . . 0.0 110.94 -179.951 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . 0.491 ' O ' ' N ' ' A' ' 120' ' ' LEU . 89.6 p -77.37 142.65 39.2 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.85 -179.934 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 118' ' ' GLN . . . . . 0.442 ' C ' ' O ' ' A' ' 117' ' ' SER . 55.0 mm-40 -34.85 -40.36 0.11 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.892 -179.938 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 25.0 mtm-85 -63.34 -47.26 82.93 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.871 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 120' ' ' LEU . . . . . 0.491 ' N ' ' O ' ' A' ' 117' ' ' SER . 20.7 mt -72.44 -29.44 63.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.936 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -65.46 82.99 0.06 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.099 179.81 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 122' ' ' ASP . . . . . 0.422 ' HB2' ' CG2' ' A' ' 125' ' ' VAL . 19.4 m-20 -149.0 143.84 17.46 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.599 0.714 . . . . 0.0 110.863 179.985 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 -44.26 2.19 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.682 2.255 . . . . 0.0 112.389 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 66.3 mm-40 -74.2 -38.61 63.54 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.886 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.586 ' O ' ' CD1' ' A' ' 131' ' ' TYR . 68.9 t -61.0 -49.5 84.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.103 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 92.8 mt -66.33 -43.36 86.36 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.943 179.936 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.478 ' HA ' ' CD1' ' A' ' 138' ' ' ILE . 31.1 tttm -61.64 -42.71 99.27 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.878 179.849 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 128' ' ' ARG . . . . . 0.424 ' C ' ' O ' ' A' ' 127' ' ' LYS . 21.4 mmt180 -35.61 143.28 0.26 Allowed Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.643 0.735 . . . . 0.0 110.826 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.75 -1.4 8.4 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.66 2.24 . . . . 0.0 112.34 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 10.2 mp0 -103.26 -0.98 29.57 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.884 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 131' ' ' TYR . . . . . 0.586 ' CD1' ' O ' ' A' ' 125' ' ' VAL . 47.0 m-85 -117.06 -74.15 0.62 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.913 -179.879 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.434 ' CZ ' HG21 ' A' ' 113' ' ' VAL . 46.5 m-85 -121.75 -17.85 7.28 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.91 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -72.08 -1.44 48.88 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.491 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 1.3 ptpp? -78.85 -19.67 51.46 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.78 0.324 . . . . 0.0 110.894 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 135' ' ' PHE . . . . . 0.419 ' CD2' ' HB1' ' A' ' 172' ' ' ALA . 58.2 m-85 -85.62 -38.17 18.72 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.856 -179.99 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -179.72 -174.52 45.74 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.511 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 45.9 mtpt -81.49 134.62 35.55 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.779 0.323 . . . . 0.0 110.889 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.478 ' CD1' ' HA ' ' A' ' 127' ' ' LYS . 65.1 mt -94.98 147.03 6.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.155 179.861 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 4.6 t60 -99.11 -43.61 6.59 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.891 179.901 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 26.5 ttpt -148.28 143.69 27.12 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.95 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . 0.459 HG22 HG21 ' A' ' 138' ' ' ILE . 41.3 t -127.23 121.17 56.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.208 179.862 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 72.4 t -125.71 145.27 33.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.153 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 29.1 mm -115.8 141.82 31.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.118 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 48.2 t30 -129.45 142.92 50.67 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.916 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 44.7 t-20 . . . . . 0 C--N 1.33 -0.28 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.831 -179.981 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 69.6 m . . . . . 0 C--O 1.231 0.084 0 CA-C-O 120.848 0.356 . . . . 0.0 110.868 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -103.92 149.14 25.38 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.079 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . 0.437 ' HB2' ' CE1' ' A' ' 112' ' ' PHE . 53.1 p -117.21 171.59 7.85 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.89 -179.803 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -146.79 133.55 20.03 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.12 179.875 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 38.7 m-85 -104.48 113.75 27.53 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.905 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 98.7 t -109.13 123.93 65.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.129 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 40.4 m -98.02 123.88 42.24 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.134 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 9.8 m-85 -105.99 146.73 29.69 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.923 -179.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 86.9 mt -79.41 -36.24 17.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.133 179.883 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 31.9 mmm-85 -106.93 117.08 33.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.872 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 74.2 m -49.24 -51.11 35.39 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.846 -179.771 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 18.5 mm-40 -48.74 -51.02 31.11 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.897 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -54.26 -45.13 72.34 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.871 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -60.24 -62.61 1.74 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.094 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 50.6 mt -41.57 -66.38 0.35 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.9 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 79.2 mtp180 -48.37 -54.43 13.97 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.869 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . 0.591 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -43.51 -35.16 1.56 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.083 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 173' ' ' ILE . . . . . 0.541 HG23 ' HB3' ' A' ' 188' ' ' ALA . 63.6 mt -77.92 -40.46 26.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.183 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 88.2 mm-40 -61.36 -27.57 68.61 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.914 179.918 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 175' ' ' CYS . . . . . 0.477 ' O ' ' CG2' ' A' ' 179' ' ' VAL . 1.9 m -93.82 -42.1 9.29 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.882 -179.914 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 176' ' ' VAL . . . . . 0.591 HG23 ' O ' ' A' ' 172' ' ' ALA . 10.3 t -58.07 -36.27 56.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.14 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 177' ' ' ASN . . . . . 0.418 ' O ' HG23 ' A' ' 179' ' ' VAL . 12.3 t-20 -68.41 150.83 47.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.873 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 178' ' ' ASN . . . . . 0.411 ' CG ' ' O ' ' A' ' 178' ' ' ASN . 37.4 t30 57.66 42.84 23.25 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.854 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 179' ' ' VAL . . . . . 0.477 ' CG2' ' O ' ' A' ' 175' ' ' CYS . 62.0 t -128.68 135.03 63.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.142 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 90.3 t -98.97 106.38 18.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.129 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . 0.457 HG21 HD12 ' A' ' 186' ' ' LEU . 57.1 t -114.18 121.32 66.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.115 179.909 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 14.4 m-20 51.23 28.45 4.17 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.844 179.908 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 81.47 32.01 32.07 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.493 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 4.2 mpt_? -138.69 124.47 19.79 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.878 0.37 . . . . 0.0 110.878 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 19.4 m -76.65 93.28 3.6 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.122 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 186' ' ' LEU . . . . . 0.457 HD12 HG21 ' A' ' 181' ' ' VAL . 51.0 mt -62.01 125.98 25.76 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.875 179.962 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 9.5 tptm -122.86 112.28 17.68 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.922 179.788 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . 0.541 ' HB3' HG23 ' A' ' 173' ' ' ILE . . . -107.57 153.19 23.22 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.128 179.826 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 48.0 m -139.2 156.34 47.17 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.877 -179.765 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 190' ' ' LEU . . . . . 0.588 HD13 ' C ' ' A' ' 190' ' ' LEU . 1.5 tm? -120.2 102.28 8.4 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.913 179.968 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.313 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.494 179.87 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 15.8 tp . . . . . 0 C--O 1.232 0.141 0 CA-C-O 120.834 0.35 . . . . 0.0 110.938 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 99.1 t -122.47 110.97 28.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.13 179.833 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.403 ' CE1' ' HB2' ' A' ' 158' ' ' SER . 46.4 t80 -102.83 108.03 19.1 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.853 -179.937 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 86.0 t -105.2 134.46 46.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.155 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 34.0 m -124.42 167.04 18.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.08 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 78.58 49.21 6.77 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.541 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 28.8 mt -113.78 139.89 48.75 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.823 0.344 . . . . 0.0 110.91 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . 0.44 ' H ' HD12 ' A' ' 120' ' ' LEU . 36.0 t -73.83 146.44 44.16 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.872 -179.903 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 25.4 mt-30 -42.19 -29.93 0.27 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.94 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 56.2 ttt180 -88.41 -38.23 15.23 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.872 -179.913 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 120' ' ' LEU . . . . . 0.44 HD12 ' H ' ' A' ' 117' ' ' SER . 44.8 mt -65.18 -33.8 76.87 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.905 179.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . 0.424 ' HB1' HG23 ' A' ' 143' ' ' ILE . . . -70.16 83.08 0.52 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.151 179.802 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 21.7 m-20 -148.93 147.1 23.07 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.605 0.717 . . . . 0.0 110.86 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 -37.24 9.53 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.708 2.272 . . . . 0.0 112.36 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 14.9 pt-20 -77.29 -44.43 29.74 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.87 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 86.1 t -61.71 -39.93 85.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.158 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 91.2 mt -74.2 -39.31 63.23 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.933 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.63 ' HD2' HD12 ' A' ' 138' ' ' ILE . 2.0 mmmp? -64.64 -30.81 71.83 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.86 179.867 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 14.7 mmt180 -42.44 143.93 1.03 Allowed Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.591 0.71 . . . . 0.0 110.876 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 -4.19 13.51 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.66 2.24 . . . . 0.0 112.337 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 4.8 tt0 -99.98 1.07 42.23 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.895 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 131' ' ' TYR . . . . . . . . . . . . . 30.7 m-85 -121.0 -74.93 0.6 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.888 -179.831 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 58.0 m-85 -122.99 -18.14 6.5 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.867 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -55.59 -23.03 34.41 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.499 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 12.4 ptpt -90.83 -11.36 39.58 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.796 0.331 . . . . 0.0 110.858 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 135' ' ' PHE . . . . . . . . . . . . . 22.9 m-85 -80.42 -33.23 37.12 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.925 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 173.65 -166.25 38.45 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.444 -179.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 39.4 tptt -95.65 109.27 21.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.737 0.303 . . . . 0.0 110.911 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.63 HD12 ' HD2' ' A' ' 127' ' ' LYS . 86.2 mt -76.71 140.26 17.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.145 179.864 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 18.6 t60 -114.12 -51.07 2.79 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.9 179.871 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -127.28 135.63 50.84 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.868 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . 0.621 ' CG2' HG21 ' A' ' 138' ' ' ILE . 19.2 t -137.49 143.04 35.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.129 179.886 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 74.6 t -145.34 140.18 22.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.132 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . 0.424 HG23 ' HB1' ' A' ' 121' ' ' ALA . 24.6 mm -110.94 126.43 68.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.096 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 2.9 m120 -124.45 137.78 54.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.905 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 5.3 p30 . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.908 179.973 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 55.8 m . . . . . 0 C--O 1.231 0.086 0 CA-C-O 120.867 0.365 . . . . 0.0 110.861 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -112.85 149.71 32.73 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.091 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . 0.403 ' HB2' ' CE1' ' A' ' 112' ' ' PHE . 89.9 p -113.71 158.27 21.14 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.852 -179.803 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -141.08 128.52 21.21 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.102 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 35.9 m-85 -99.91 126.56 46.06 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.932 -179.871 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.6 HG22 HG13 ' A' ' 141' ' ' VAL . 96.6 t -129.09 137.59 56.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.101 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 96.0 m -108.31 134.42 51.16 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.162 180.0 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 163' ' ' TYR . . . . . 0.6 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 16.1 m-85 -111.8 129.51 56.11 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.937 -179.927 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 56.2 mt -61.46 -41.04 88.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.097 -0.502 . . . . 0.0 111.155 179.918 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 82.3 mtt-85 -91.66 113.78 26.14 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.895 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 23.2 t -52.16 -59.54 4.25 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.832 -179.751 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 54.1 tt0 -47.31 -49.19 24.56 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.898 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 4.9 t0 -52.48 -51.16 60.78 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.884 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 169' ' ' ALA . . . . . 0.6 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -54.2 -57.74 10.0 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.078 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 42.0 mt -43.56 -61.43 1.39 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.931 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 41.9 mtt-85 -54.6 -43.51 72.24 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.85 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . 0.608 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -54.39 -30.98 53.88 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.123 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 97.3 mt -82.54 -34.51 11.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.103 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 11.2 mm-40 -68.2 -27.82 66.72 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.911 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 175' ' ' CYS . . . . . 0.44 ' O ' ' CG2' ' A' ' 179' ' ' VAL . 2.0 m -93.75 -35.59 12.7 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.89 -179.954 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 176' ' ' VAL . . . . . 0.608 HG23 ' O ' ' A' ' 172' ' ' ALA . 10.5 t -66.48 -29.92 48.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.146 -179.974 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 4.3 t-20 -73.41 126.95 31.36 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.844 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 26.2 t-20 74.41 52.08 0.09 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.863 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 179' ' ' VAL . . . . . 0.446 HG12 HG23 ' A' ' 181' ' ' VAL . 69.5 t -130.83 132.78 63.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.138 179.905 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 86.6 t -92.54 107.44 19.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.182 179.885 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . 0.446 HG23 HG12 ' A' ' 179' ' ' VAL . 98.3 t -121.0 113.79 41.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.11 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 4.4 t70 58.78 26.51 14.82 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.905 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 81.33 26.67 51.16 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.508 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 3.1 mpt_? -136.27 123.48 21.77 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.932 0.396 . . . . 0.0 110.872 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 18.3 m -76.26 101.64 5.53 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.154 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 89.0 mt -78.18 125.21 29.03 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.957 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 38.1 mmtt -118.5 117.99 30.49 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.898 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . 0.547 ' HB2' HG11 ' A' ' 176' ' ' VAL . . . -106.9 140.72 39.27 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.105 179.81 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 59.3 m -145.03 162.88 35.86 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.853 -179.768 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 190' ' ' LEU . . . . . 0.704 HD12 ' O ' ' A' ' 190' ' ' LEU . 3.5 pp -130.24 153.31 48.74 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.927 180.0 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.311 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.525 179.95 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 19.5 tp . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.826 0.346 . . . . 0.0 110.876 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.731 HG22 HD11 ' A' ' 173' ' ' ILE . 71.2 t -114.38 124.05 70.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.161 179.804 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.52 ' CE1' ' HB2' ' A' ' 158' ' ' SER . 65.2 t80 -106.55 108.32 19.77 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.866 -179.919 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.431 HG22 ' HB2' ' A' ' 188' ' ' ALA . 40.2 t -110.7 132.18 59.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.1 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . 0.549 HG12 ' HB3' ' A' ' 158' ' ' SER . 23.7 m -121.71 160.7 23.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.137 179.919 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 86.33 51.99 3.35 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.496 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 82.4 mt -116.17 134.44 54.92 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.808 0.337 . . . . 0.0 110.96 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 10.6 t -69.48 149.26 48.47 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.854 -179.92 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 1.4 pp0? -47.58 -31.9 4.92 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.96 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 17.0 ttt180 -84.47 -39.75 18.53 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.898 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 83.1 mt -66.68 -28.95 68.86 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.918 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . 0.483 ' HB1' ' CG2' ' A' ' 143' ' ' ILE . . . -70.69 85.18 0.64 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.105 179.81 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -148.11 144.29 18.69 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.596 0.712 . . . . 0.0 110.855 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.76 -49.45 0.56 Allowed 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.66 2.24 . . . . 0.0 112.357 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 26.0 mt-10 -66.68 -41.88 87.39 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.806 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.637 HG13 ' CE2' ' A' ' 131' ' ' TYR . 87.8 t -62.64 -42.97 98.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.129 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 89.1 mt -73.18 -42.59 62.56 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.948 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 4.7 mtmp? -61.43 -27.49 68.59 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.934 179.809 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 13.5 mtm180 -53.89 144.01 38.61 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.633 0.73 . . . . 0.0 110.892 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.81 1.89 4.06 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.691 2.261 . . . . 0.0 112.309 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 8.1 mp0 -101.67 -13.85 17.62 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.924 180.0 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 131' ' ' TYR . . . . . 0.637 ' CE2' HG13 ' A' ' 125' ' ' VAL . 52.6 m-85 -109.41 -71.17 0.77 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.899 -179.82 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.457 ' O ' ' N ' ' A' ' 134' ' ' LYS . 25.1 m-85 -122.14 -40.14 2.53 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.895 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . 0.404 ' C ' ' O ' ' A' ' 132' ' ' PHE . . . -38.17 -28.57 0.05 OUTLIER Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.709 -0.757 . . . . 0.0 112.48 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.457 ' N ' ' O ' ' A' ' 132' ' ' PHE . 8.8 ptmm? -52.89 -53.79 44.11 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.831 0.348 . . . . 0.0 110.873 -179.949 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 135' ' ' PHE . . . . . 0.41 ' CD1' ' HA ' ' A' ' 172' ' ' ALA . 70.3 m-85 -52.62 -40.22 62.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.909 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -177.66 178.62 48.4 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.476 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 28.2 mtpt -86.15 97.58 10.41 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.774 0.321 . . . . 0.0 110.915 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.428 HG21 ' CG2' ' A' ' 141' ' ' VAL . 71.7 mt -62.06 140.61 18.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.138 179.907 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 17.2 t-80 -97.34 -54.1 3.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.859 179.872 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 140' ' ' LYS . . . . . 0.614 ' HD3' HG23 ' A' ' 142' ' ' VAL . 1.2 tmmt? -126.79 152.1 47.38 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.922 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . 0.428 ' CG2' HG21 ' A' ' 138' ' ' ILE . 54.4 t -139.82 145.46 26.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.133 179.915 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.614 HG23 ' HD3' ' A' ' 140' ' ' LYS . 23.5 t -138.9 116.65 12.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.113 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . 0.483 ' CG2' ' HB1' ' A' ' 121' ' ' ALA . 7.2 mm -101.57 127.81 54.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.157 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 34.6 m-80 -126.71 106.66 9.53 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.903 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 6.6 p30 . . . . . 0 C--N 1.329 -0.303 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.89 -179.984 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 4.2 m . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.857 0.361 . . . . 0.0 110.882 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -108.39 163.66 13.01 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.082 179.938 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . 0.549 ' HB3' HG12 ' A' ' 114' ' ' VAL . 34.8 p -138.57 156.05 47.83 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.826 -179.782 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -148.9 152.15 35.9 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.083 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 19.8 m-85 -111.94 121.59 45.44 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.906 -179.852 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 61.9 t -109.43 131.62 59.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.114 -0.493 . . . . 0.0 111.079 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 20.8 m -101.26 124.4 46.89 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.116 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 163' ' ' TYR . . . . . 0.646 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 9.5 m-85 -104.53 137.53 42.24 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.946 -179.911 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 68.4 mt -62.21 -49.21 84.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.123 179.934 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 34.0 mtt85 -104.11 127.35 51.69 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.889 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 75.6 m -53.65 -58.2 8.05 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.881 -179.779 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 66.0 mm-40 -43.7 -49.24 7.9 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.872 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -55.54 -49.44 72.64 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.887 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 169' ' ' ALA . . . . . 0.646 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -56.44 -56.03 26.28 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.054 179.989 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 39.5 mt -45.41 -63.3 0.98 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.918 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 46.3 mtp180 -53.75 -48.12 69.98 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.86 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . 0.787 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -48.36 -34.14 10.18 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.145 179.899 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 173' ' ' ILE . . . . . 0.731 HD11 HG22 ' A' ' 111' ' ' VAL . 67.3 mt -80.68 -37.26 16.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.147 179.999 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 42.5 mt-30 -63.48 -27.79 69.52 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.952 179.875 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 2.6 t -93.81 -36.73 12.12 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.889 -179.927 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 176' ' ' VAL . . . . . 0.787 HG23 ' O ' ' A' ' 172' ' ' ALA . 11.3 t -58.31 -42.46 83.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.133 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 22.6 t30 -65.94 141.68 58.14 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.855 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 7.3 t30 69.37 51.33 0.5 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.884 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 96.9 t -135.13 137.87 49.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.092 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 94.7 t -98.64 109.21 23.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.125 179.889 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 84.2 t -116.58 102.44 13.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.116 179.918 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 6.9 t70 58.29 35.96 25.28 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.87 179.907 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 78.61 26.22 59.35 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.484 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 30.0 mtt-85 -133.8 115.6 14.7 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.917 0.389 . . . . 0.0 110.839 -179.833 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 23.5 m -79.73 92.76 5.45 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.157 -179.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 73.3 mt -62.95 136.46 57.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.927 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 13.6 tptp -123.81 116.43 22.96 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.886 179.8 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . 0.431 ' HB2' HG22 ' A' ' 113' ' ' VAL . . . -112.47 140.13 47.47 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.093 179.807 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 74.5 m -140.15 157.94 44.83 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.858 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 190' ' ' LEU . . . . . 0.403 ' HB2' HD13 ' A' ' 173' ' ' ILE . 7.3 tt -131.75 122.66 26.22 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.901 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.331 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.5 179.909 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 23.3 tp . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.839 0.352 . . . . 0.0 110.888 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.53 HG22 HD11 ' A' ' 173' ' ' ILE . 45.1 t -133.07 107.7 11.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.107 179.828 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.562 ' CE1' ' HB2' ' A' ' 158' ' ' SER . 67.4 t80 -102.88 113.61 27.19 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.907 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 38.2 t -111.18 145.67 17.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.101 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . 0.44 HG12 ' HB3' ' A' ' 158' ' ' SER . 23.1 m -130.97 170.59 19.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.1 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 79.15 51.12 5.47 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.481 179.906 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 23.5 mt -118.03 131.03 56.5 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.829 0.347 . . . . 0.0 110.922 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . 0.484 ' O ' ' N ' ' A' ' 119' ' ' ARG . 23.1 t -70.95 140.19 50.85 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.812 -179.868 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 118' ' ' GLN . . . . . 0.434 ' C ' ' O ' ' A' ' 117' ' ' SER . 9.5 tp-100 -35.54 -32.06 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.934 -179.979 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.484 ' N ' ' O ' ' A' ' 117' ' ' SER . 18.5 tpp180 -81.49 -47.12 13.56 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.856 -179.91 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 120' ' ' LEU . . . . . 0.453 ' N ' ' O ' ' A' ' 117' ' ' SER . 62.4 mt -61.83 -33.69 74.6 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.952 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -66.09 86.79 0.1 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.095 179.815 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 122' ' ' ASP . . . . . 0.508 ' O ' HD12 ' A' ' 126' ' ' LEU . 0.6 OUTLIER -148.07 144.03 18.38 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.622 0.725 . . . . 0.0 110.871 179.969 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 123' ' ' PRO . . . . . 0.446 ' HA ' HG11 ' A' ' 141' ' ' VAL . 53.3 Cg_endo -69.81 -50.28 0.47 Allowed 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.649 2.232 . . . . 0.0 112.313 -179.984 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 42.7 mt-10 -68.14 -45.68 72.91 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.881 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.415 ' O ' ' CD1' ' A' ' 131' ' ' TYR . 58.4 t -60.03 -39.39 80.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.135 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.508 HD12 ' O ' ' A' ' 122' ' ' ASP . 47.3 mt -74.63 -42.01 59.36 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.942 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.736 ' HA ' HD12 ' A' ' 138' ' ' ILE . 17.3 ttmt -59.48 -30.73 68.75 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.91 179.85 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 46.8 mtt180 -39.94 143.87 0.57 Allowed Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.583 0.706 . . . . 0.0 110.893 179.949 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 2.94 3.1 Favored 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.645 2.23 . . . . 0.0 112.319 -179.984 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -106.67 -30.09 9.2 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.879 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 131' ' ' TYR . . . . . 0.415 ' CD1' ' O ' ' A' ' 125' ' ' VAL . 43.4 m-85 -86.01 -75.05 0.39 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.933 -179.844 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 17.0 m-85 -115.32 -39.72 3.55 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.888 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -52.61 -20.55 7.81 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.488 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.446 ' HD2' ' CG ' ' A' ' 135' ' ' PHE . 0.0 OUTLIER -51.2 -40.96 59.86 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.791 0.329 . . . . 0.0 110.875 -179.964 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 135' ' ' PHE . . . . . 0.446 ' CG ' ' HD2' ' A' ' 134' ' ' LYS . 83.1 m-85 -66.26 -46.38 77.27 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.882 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -173.86 -159.87 21.13 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.506 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 17.0 tptm -91.15 116.23 28.65 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.799 0.333 . . . . 0.0 110.861 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.736 HD12 ' HA ' ' A' ' 127' ' ' LYS . 91.0 mt -73.03 141.89 15.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.081 179.899 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 71.4 t60 -96.15 -44.08 7.45 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.894 179.852 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 15.8 tttm -139.67 142.7 36.94 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.911 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . 0.713 HG22 HG21 ' A' ' 138' ' ' ILE . 39.2 t -134.59 110.55 13.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.143 179.864 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 64.9 t -116.06 137.98 48.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.11 179.949 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . 0.417 HD11 HD12 ' A' ' 126' ' ' LEU . 43.1 mm -111.82 134.7 53.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.094 179.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 34.0 m-20 -131.04 110.97 11.6 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.851 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 5.8 p30 . . . . . 0 C--N 1.33 -0.263 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.918 179.971 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 3.5 m . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.932 0.396 . . . . 0.0 110.878 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -117.41 164.47 14.82 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.125 179.898 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . 0.562 ' HB2' ' CE1' ' A' ' 112' ' ' PHE . 71.5 p -140.09 154.74 47.13 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.84 -179.779 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -139.08 152.14 47.29 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.082 179.893 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 160' ' ' TYR . . . . . 0.562 ' CZ ' ' CD1' ' A' ' 112' ' ' PHE . 8.5 m-85 -114.0 115.83 28.24 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.933 -179.837 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 29.9 t -110.35 142.61 22.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.134 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 18.7 m -120.44 115.86 24.31 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.119 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 163' ' ' TYR . . . . . 0.661 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 25.0 m-85 -90.32 135.08 33.9 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.933 -179.929 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 64.1 mt -57.73 -42.73 82.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.139 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 17.7 mmm180 -98.25 125.65 43.41 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.888 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 46.6 m -55.26 -62.87 1.38 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.855 -179.781 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 5.4 tp10 -41.89 -55.84 2.95 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.856 -179.906 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 5.9 m-20 -49.59 -45.65 48.21 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.863 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 169' ' ' ALA . . . . . 0.661 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -57.1 -61.78 2.22 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.135 179.959 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 53.7 mt -42.45 -61.74 1.14 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.957 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 59.1 mtp180 -55.7 -51.56 66.87 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.882 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . 0.558 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -42.2 -36.58 1.24 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.055 179.915 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 173' ' ' ILE . . . . . 0.601 HD12 HD23 ' A' ' 190' ' ' LEU . 95.2 mt -80.18 -39.1 18.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.257 -0.428 . . . . 0.0 111.177 179.969 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 30.6 mt-30 -62.07 -26.18 68.12 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.92 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 2.2 m -93.76 -38.21 11.4 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.854 -179.92 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 176' ' ' VAL . . . . . 0.663 ' CG1' ' HB2' ' A' ' 188' ' ' ALA . 10.2 t -63.61 -39.74 86.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.128 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 14.1 t30 -63.83 138.66 58.57 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.885 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 49.9 t30 67.74 48.19 1.07 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.913 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 87.0 t -130.1 130.14 65.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.172 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 98.1 t -89.75 109.06 20.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.111 179.965 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . 0.503 ' CG2' HD12 ' A' ' 186' ' ' LEU . 87.0 t -117.17 109.85 29.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.1 179.961 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 61.9 m-20 59.85 38.49 21.26 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.831 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 73.71 34.12 56.99 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.486 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 59.0 mtt-85 -143.02 123.25 13.75 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.887 0.375 . . . . 0.0 110.88 -179.867 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 37.7 m -80.39 93.61 6.01 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.153 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 186' ' ' LEU . . . . . 0.503 HD12 ' CG2' ' A' ' 181' ' ' VAL . 45.0 mt -66.07 147.0 54.02 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.876 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 13.9 tppt? -128.0 112.35 14.55 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.913 179.838 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . 0.663 ' HB2' ' CG1' ' A' ' 176' ' ' VAL . . . -102.93 129.24 49.58 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.09 179.853 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 19.4 m -161.58 145.11 12.55 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.838 -179.775 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 190' ' ' LEU . . . . . 0.601 HD23 HD12 ' A' ' 173' ' ' ILE . 4.3 pp -118.31 158.65 24.82 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.918 179.987 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.305 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.481 179.884 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 8.7 tp . . . . . 0 C--O 1.231 0.127 0 CA-C-O 120.866 0.365 . . . . 0.0 110.894 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.877 HG22 HD11 ' A' ' 173' ' ' ILE . 96.0 t -97.85 131.76 44.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.138 179.847 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.641 ' CD1' ' CE2' ' A' ' 160' ' ' TYR . 34.5 t80 -130.27 117.43 19.81 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.845 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 69.1 t -114.73 135.54 54.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.143 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . 0.953 HG12 ' HB3' ' A' ' 158' ' ' SER . 35.2 m -124.2 168.57 16.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.123 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 81.93 47.15 6.35 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.508 179.999 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 38.0 mt -113.45 137.76 51.08 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.888 0.375 . . . . 0.0 110.931 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . 0.406 ' O ' ' N ' ' A' ' 120' ' ' LEU . 38.4 t -63.8 141.36 58.8 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.887 -179.915 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 37.0 tt0 -39.26 -37.71 0.45 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.939 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 33.8 tpt85 -79.33 -40.82 29.37 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.874 -179.914 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 120' ' ' LEU . . . . . 0.406 ' N ' ' O ' ' A' ' 117' ' ' SER . 35.8 mt -62.27 -35.88 80.34 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.931 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -66.24 82.99 0.09 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.108 179.787 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 13.1 m-20 -148.06 148.35 29.37 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.555 0.693 . . . . 0.0 110.895 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 -44.34 2.15 Favored 'Trans proline' 0 N--CA 1.465 -0.165 0 C-N-CA 122.711 2.274 . . . . 0.0 112.353 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -71.87 -39.64 69.5 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.901 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.587 ' O ' ' CD1' ' A' ' 131' ' ' TYR . 37.9 t -62.55 -45.32 99.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.133 -179.989 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.565 HD22 ' CE1' ' A' ' 132' ' ' PHE . 67.0 mt -74.43 -40.92 61.65 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.891 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.459 ' HA ' HD12 ' A' ' 138' ' ' ILE . 31.6 mttt -58.32 -31.83 67.92 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.904 179.828 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 15.8 mmt85 -44.24 143.5 1.9 Allowed Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.617 0.722 . . . . 0.0 110.888 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.69 -0.56 7.03 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.72 2.28 . . . . 0.0 112.375 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 25.6 mp0 -101.46 -26.99 13.38 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.892 -179.948 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 131' ' ' TYR . . . . . 0.587 ' CD1' ' O ' ' A' ' 125' ' ' VAL . 39.8 m-85 -88.76 -75.15 0.44 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.921 -179.852 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.565 ' CE1' HD22 ' A' ' 126' ' ' LEU . 10.8 m-85 -110.45 -46.17 3.44 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.872 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -47.7 -21.21 1.37 Allowed Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.501 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.509 ' HD2' ' CD1' ' A' ' 135' ' ' PHE . 0.0 OUTLIER -53.88 -34.99 61.05 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.79 0.329 . . . . 0.0 110.884 -179.995 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 135' ' ' PHE . . . . . 0.509 ' CD1' ' HD2' ' A' ' 134' ' ' LYS . 70.8 m-85 -71.1 -46.03 62.52 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.905 179.958 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -172.6 -127.93 1.01 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.504 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . 0.482 ' HG3' HD12 ' A' ' 164' ' ' ILE . 0.3 OUTLIER -117.02 138.8 51.34 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.797 0.332 . . . . 0.0 110.938 179.994 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.459 HD12 ' HA ' ' A' ' 127' ' ' LYS . 82.1 mt -100.03 139.77 20.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.13 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 52.2 t60 -91.04 -54.14 4.08 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.852 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 35.9 ttpt -144.68 144.24 31.13 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.938 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 46.8 t -123.6 145.82 29.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.12 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 59.1 t -136.08 134.77 50.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.095 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 37.1 mm -110.47 132.46 58.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.092 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 43.6 t-20 -126.78 124.14 39.0 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.877 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 16.7 t-20 . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.883 -179.999 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 83.3 p . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.831 0.348 . . . . 0.0 110.917 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -114.74 156.24 25.2 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.12 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . 0.953 ' HB3' HG12 ' A' ' 114' ' ' VAL . 22.0 p -128.37 174.12 9.59 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.859 -179.766 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -159.89 141.28 12.66 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.105 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 160' ' ' TYR . . . . . 0.641 ' CE2' ' CD1' ' A' ' 112' ' ' PHE . 35.5 m-85 -100.97 144.5 29.84 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.896 -179.848 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 80.2 t -132.19 135.49 58.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.156 179.879 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 38.2 m -112.42 118.92 36.51 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.161 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 163' ' ' TYR . . . . . 0.551 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 20.0 m-85 -102.44 143.89 31.6 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.953 -179.914 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 164' ' ' ILE . . . . . 0.482 HD12 ' HG3' ' A' ' 137' ' ' LYS . 60.6 mt -68.19 -45.52 82.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.162 179.897 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 19.5 mtm180 -97.71 118.24 33.8 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.881 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 41.9 t -51.53 -58.5 6.13 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.846 -179.782 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 16.5 tt0 -42.4 -53.03 4.41 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.9 -179.938 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -51.85 -51.27 57.9 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.833 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 169' ' ' ALA . . . . . 0.551 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -53.37 -63.27 1.2 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.077 179.989 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 39.5 mt -38.38 -57.83 1.08 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.905 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 171' ' ' ARG . . . . . 0.427 ' O ' ' N ' ' A' ' 174' ' ' GLN . 54.2 mtp180 -58.14 -57.97 10.5 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.873 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . 0.68 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -37.67 -35.81 0.15 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.132 179.873 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 173' ' ' ILE . . . . . 0.877 HD11 HG22 ' A' ' 111' ' ' VAL . 73.6 mt -82.47 -41.13 17.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.118 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 174' ' ' GLN . . . . . 0.427 ' N ' ' O ' ' A' ' 171' ' ' ARG . 15.0 mm100 -57.23 -28.28 62.76 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.895 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 3.4 t -93.77 -39.34 10.8 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.88 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 176' ' ' VAL . . . . . 0.68 HG23 ' O ' ' A' ' 172' ' ' ALA . 10.9 t -59.52 -48.51 87.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.132 -179.947 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 10.5 t-20 -59.08 139.12 57.2 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.893 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 4.7 t-20 70.25 45.91 0.63 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.876 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 179' ' ' VAL . . . . . 0.576 HG23 ' O ' ' A' ' 176' ' ' VAL . 84.3 t -125.18 137.72 56.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.138 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 95.6 t -96.51 98.57 7.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.155 179.922 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . 0.52 HG21 HD12 ' A' ' 186' ' ' LEU . 47.7 t -111.11 111.82 37.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.169 179.908 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 57.12 42.81 25.15 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.88 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 67.03 35.08 88.74 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.511 -179.89 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 81.9 mtt85 -143.03 136.43 28.38 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.876 0.369 . . . . 0.0 110.906 -179.889 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 23.1 m -92.22 92.19 8.09 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.129 -179.885 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 186' ' ' LEU . . . . . 0.52 HD12 HG21 ' A' ' 181' ' ' VAL . 44.8 mt -61.62 125.11 22.63 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.917 179.929 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 36.0 mmtt -103.09 114.01 27.95 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.862 179.848 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -111.35 132.52 54.35 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.109 179.837 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 16.8 m -149.81 145.28 26.51 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.843 -179.788 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 190' ' ' LEU . . . . . 0.491 ' HB3' HD13 ' A' ' 173' ' ' ILE . 1.3 pt? -123.81 151.1 43.73 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.932 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.296 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.518 179.911 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 17.1 tp . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.861 0.362 . . . . 0.0 110.93 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.687 HG22 HD11 ' A' ' 173' ' ' ILE . 87.9 t -115.6 132.62 64.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.152 179.86 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.568 ' CE2' ' CG1' ' A' ' 114' ' ' VAL . 50.3 t80 -128.65 106.68 9.12 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.871 -179.936 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.455 HG22 ' HB2' ' A' ' 188' ' ' ALA . 55.9 t -103.46 122.05 55.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.12 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . 0.568 ' CG1' ' CE2' ' A' ' 112' ' ' PHE . 18.7 m -110.66 152.65 12.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.111 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 94.2 37.7 5.31 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.524 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 116' ' ' LEU . . . . . 0.419 ' O ' ' HB3' ' A' ' 157' ' ' ALA . 30.0 mt -101.64 134.38 44.86 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.834 0.35 . . . . 0.0 110.889 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . 0.437 ' O ' ' N ' ' A' ' 120' ' ' LEU . 24.4 t -68.71 141.33 55.33 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.874 -179.932 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 43.6 tt0 -42.27 -25.7 0.08 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.881 -179.926 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 6.3 tpm_? -89.83 -36.32 15.17 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.83 -179.914 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 120' ' ' LEU . . . . . 0.437 ' N ' ' O ' ' A' ' 117' ' ' SER . 32.2 mt -70.25 -32.25 70.01 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.879 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -70.19 84.67 0.55 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.117 179.77 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -146.31 146.71 28.64 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.588 0.709 . . . . 0.0 110.838 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 -46.23 1.28 Allowed 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.666 2.244 . . . . 0.0 112.333 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -70.64 -38.13 73.85 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.875 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.484 ' O ' ' CD1' ' A' ' 131' ' ' TYR . 87.3 t -65.76 -50.84 68.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.085 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.622 HD22 ' CE1' ' A' ' 132' ' ' PHE . 89.8 mt -68.41 -37.16 80.08 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.901 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.418 ' HA ' HD12 ' A' ' 138' ' ' ILE . 27.6 mttm -62.25 -37.46 85.53 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.863 179.874 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 2.5 mmp_? -43.29 143.88 1.32 Allowed Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.607 0.718 . . . . 0.0 110.839 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 -4.28 13.72 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.651 2.234 . . . . 0.0 112.338 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 1.3 tm-20 -94.18 -16.26 23.86 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.918 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 131' ' ' TYR . . . . . 0.484 ' CD1' ' O ' ' A' ' 125' ' ' VAL . 61.8 m-85 -102.53 -72.06 0.7 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.929 -179.857 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.622 ' CE1' HD22 ' A' ' 126' ' ' LEU . 61.1 m-85 -122.44 -39.6 2.55 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.862 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -41.24 -26.43 0.19 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.484 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.406 ' N ' ' O ' ' A' ' 132' ' ' PHE . 8.5 ptmm? -47.0 -39.13 11.94 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.808 0.337 . . . . 0.0 110.946 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 135' ' ' PHE . . . . . 0.54 ' CE1' ' HA ' ' A' ' 172' ' ' ALA . 66.0 m-85 -63.18 -45.6 91.01 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.87 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 173.58 -148.19 10.03 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.483 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 16.6 tttm -95.42 115.71 27.8 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.828 0.347 . . . . 0.0 110.93 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.548 HG21 ' CG2' ' A' ' 141' ' ' VAL . 86.2 mt -71.63 140.09 18.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.109 179.906 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 34.3 t-80 -82.12 -59.62 2.5 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.883 179.871 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 39.9 tptt -140.13 151.22 45.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.966 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . 0.548 ' CG2' HG21 ' A' ' 138' ' ' ILE . 88.3 t -136.97 122.42 26.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.133 179.933 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 43.7 t -125.9 120.23 56.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.132 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 18.2 mm -86.57 136.71 22.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.133 179.902 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 2.3 m-80 -128.48 134.35 48.7 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.897 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 88.5 m-20 . . . . . 0 C--N 1.329 -0.312 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.87 -179.976 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 21.1 m . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.867 0.365 . . . . 0.0 110.864 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 157' ' ' ALA . . . . . 0.419 ' HB3' ' O ' ' A' ' 116' ' ' LEU . . . -116.04 164.17 14.83 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.091 179.922 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . 0.4 ' HB2' ' CE1' ' A' ' 112' ' ' PHE . 51.1 p -139.58 158.68 43.71 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.882 -179.827 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -139.71 145.0 37.8 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.081 179.878 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 160' ' ' TYR . . . . . 0.471 ' CZ ' ' CD1' ' A' ' 112' ' ' PHE . 89.1 m-85 -104.73 125.95 51.32 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.918 -179.841 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 85.7 t -122.11 130.92 74.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.133 179.895 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 20.6 m -111.53 129.79 55.94 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.122 -179.908 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 163' ' ' TYR . . . . . 0.51 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 33.4 m-85 -105.27 160.0 15.44 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.918 -179.93 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 63.0 mt -84.51 -58.82 3.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.147 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 22.2 mmt180 -85.85 125.38 33.25 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.866 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 17.4 m -49.19 -60.55 2.7 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.878 -179.797 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 167' ' ' GLU . . . . . 0.47 ' HA ' HD12 ' A' ' 170' ' ' LEU . 29.1 tt0 -40.89 -54.91 2.61 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.91 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 7.4 t70 -49.68 -49.91 45.62 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.901 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 169' ' ' ALA . . . . . 0.51 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -57.67 -54.18 49.8 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.132 179.935 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . 0.47 HD12 ' HA ' ' A' ' 167' ' ' GLU . 35.8 mt -44.09 -60.96 1.64 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.883 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 85.5 mtt180 -58.84 -42.99 90.6 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.892 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . 0.659 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -49.42 -35.24 18.55 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.096 179.939 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 173' ' ' ILE . . . . . 0.687 HD11 HG22 ' A' ' 111' ' ' VAL . 82.6 mt -86.47 -40.7 14.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.153 179.97 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 77.3 mt-30 -62.39 -27.19 68.91 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.923 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 16.1 m -93.79 -42.21 9.25 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.941 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 176' ' ' VAL . . . . . 0.659 HG23 ' O ' ' A' ' 172' ' ' ALA . 9.9 t -59.05 -40.48 80.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.137 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 177' ' ' ASN . . . . . 0.435 ' C ' ' OD1' ' A' ' 177' ' ' ASN . 0.8 OUTLIER -66.49 145.18 55.93 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.916 179.982 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 19.1 t30 68.85 41.61 1.5 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.85 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 95.3 t -121.61 133.12 69.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.112 179.886 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 87.8 t -98.6 103.02 14.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.121 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 97.8 t -111.6 116.39 52.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.111 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER 47.4 43.09 15.13 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.911 179.947 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 71.22 31.29 66.41 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.464 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 32.0 mtp85 -137.09 109.42 7.33 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.883 0.373 . . . . 0.0 110.886 -179.884 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 29.7 m -71.78 92.35 1.21 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.163 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 62.7 mt -60.48 132.86 55.22 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.936 179.963 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -124.89 115.45 20.65 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.865 179.87 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . 0.455 ' HB2' HG22 ' A' ' 113' ' ' VAL . . . -107.25 144.06 34.6 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.135 179.801 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 2.4 t -146.58 168.57 20.93 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.869 -179.763 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 190' ' ' LEU . . . . . 0.771 ' N ' HD13 ' A' ' 190' ' ' LEU . 0.0 OUTLIER -125.79 161.46 27.33 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.94 179.995 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.346 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.494 179.901 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 20.0 tp . . . . . 0 C--O 1.231 0.087 0 CA-C-O 120.903 0.382 . . . . 0.0 110.875 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 90.7 t -118.51 123.35 71.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.114 179.856 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.437 ' CZ ' HG12 ' A' ' 114' ' ' VAL . 39.2 t80 -113.34 126.06 54.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.853 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.43 HG22 ' HB2' ' A' ' 188' ' ' ALA . 55.6 t -119.74 141.07 41.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.128 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . 0.437 HG12 ' CZ ' ' A' ' 112' ' ' PHE . 19.8 m -119.73 171.76 7.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.134 179.889 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 73.75 53.56 7.2 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.514 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 29.7 mt -116.25 126.32 53.43 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.827 0.346 . . . . 0.0 110.9 -179.9 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 89.0 p -64.58 153.08 40.32 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.865 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 44.6 tt0 -52.6 -26.53 13.73 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.907 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -87.19 -43.29 12.34 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.88 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 51.9 mt -66.52 -21.16 66.17 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.964 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -71.68 82.99 0.87 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.123 179.755 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -148.98 144.01 17.65 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-O 121.63 0.729 . . . . 0.0 110.893 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -50.51 0.46 Allowed 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.728 2.285 . . . . 0.0 112.339 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 35.0 mt-10 -69.43 -45.39 69.27 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.859 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.592 ' O ' ' CD1' ' A' ' 131' ' ' TYR . 53.5 t -57.94 -42.33 82.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.156 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 77.0 mt -72.47 -44.73 61.91 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.87 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.544 ' HA ' HD12 ' A' ' 138' ' ' ILE . 12.0 ttpp -59.17 -35.13 72.99 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.881 179.853 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 38.4 mtt-85 -38.58 144.6 0.39 Allowed Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.567 0.699 . . . . 0.0 110.889 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.73 0.5 5.53 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.706 2.271 . . . . 0.0 112.329 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -104.98 -7.93 18.92 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.854 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 131' ' ' TYR . . . . . 0.592 ' CD1' ' O ' ' A' ' 125' ' ' VAL . 45.1 m-85 -111.47 -74.93 0.62 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.927 -179.861 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.435 ' O ' ' N ' ' A' ' 134' ' ' LYS . 14.2 m-85 -114.99 -36.34 4.46 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.886 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -42.56 -22.41 0.13 Allowed Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.486 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.435 ' N ' ' O ' ' A' ' 132' ' ' PHE . 5.3 mtpt -49.22 -59.5 3.62 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.813 0.34 . . . . 0.0 110.896 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 135' ' ' PHE . . . . . 0.57 ' CE1' ' HA ' ' A' ' 172' ' ' ALA . 82.2 m-85 -47.89 -42.55 27.18 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.889 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 173.84 -168.31 41.12 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.487 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 13.5 tttt -82.68 117.6 22.73 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.751 0.31 . . . . 0.0 110.901 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.544 HD12 ' HA ' ' A' ' 127' ' ' LYS . 68.5 mt -77.0 144.88 11.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.167 179.859 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 9.8 t-80 -88.89 -57.62 2.84 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.879 179.846 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 42.4 tttt -142.13 149.24 39.54 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.894 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . 0.508 ' CG2' HG21 ' A' ' 138' ' ' ILE . 59.7 t -133.67 140.74 45.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.144 179.855 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 84.3 t -134.66 129.79 52.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.154 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 51.9 mm -100.33 131.32 48.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.136 179.916 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 4.4 m-80 -128.67 117.45 21.21 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.881 179.961 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 3.0 p-10 . . . . . 0 C--N 1.329 -0.283 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.885 179.992 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 80.0 p . . . . . 0 C--O 1.23 0.064 0 CA-C-O 120.875 0.369 . . . . 0.0 110.855 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -91.3 168.56 11.49 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.081 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 7.2 m -130.63 168.14 17.61 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.872 -179.82 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -146.74 150.96 36.39 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.106 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 160' ' ' TYR . . . . . 0.424 ' CZ ' ' CD1' ' A' ' 112' ' ' PHE . 7.1 m-85 -116.48 123.01 46.42 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.949 -179.838 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 87.3 t -112.56 142.2 25.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.124 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 32.9 m -113.36 118.3 34.2 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.141 -179.926 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 24.4 m-85 -98.57 150.19 21.98 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.907 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 57.4 mt -88.94 -42.09 14.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.158 179.905 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 75.4 mtp180 -94.67 119.31 33.11 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.895 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 29.3 m -49.2 -60.09 3.11 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.859 -179.776 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 19.5 mt-10 -42.92 -53.02 4.91 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.899 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -49.84 -49.05 50.53 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.849 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -56.62 -58.73 6.82 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.119 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 56.2 mt -41.0 -59.65 1.4 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.863 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 54.0 mtp180 -59.99 -44.23 94.65 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.91 179.948 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . 0.613 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -47.96 -36.12 11.98 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.11 179.937 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 64.7 mt -79.87 -42.67 22.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.085 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 40.3 mt-30 -65.26 -24.61 67.36 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.928 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 175' ' ' CYS . . . . . 0.494 ' O ' ' CG2' ' A' ' 179' ' ' VAL . 3.3 t -93.89 -38.94 10.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.849 -179.932 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 176' ' ' VAL . . . . . 0.613 HG23 ' O ' ' A' ' 172' ' ' ALA . 9.8 t -64.34 -26.97 41.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.139 -179.985 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 12.5 t30 -75.61 146.63 40.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.869 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 42.1 t30 59.89 41.43 17.85 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.887 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 179' ' ' VAL . . . . . 0.494 ' CG2' ' O ' ' A' ' 175' ' ' CYS . 85.9 t -121.12 135.96 59.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.133 179.917 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 99.7 t -104.15 122.98 57.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.147 179.895 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . 0.465 HG21 ' CD1' ' A' ' 186' ' ' LEU . 60.6 t -128.28 103.38 9.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.114 179.949 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 5.9 m-20 55.24 37.82 29.47 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.857 179.91 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 81.02 36.78 20.81 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.476 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -141.55 121.36 13.53 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.893 0.378 . . . . 0.0 110.866 -179.855 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 27.6 m -84.23 92.9 8.07 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.144 -179.891 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 186' ' ' LEU . . . . . 0.465 ' CD1' HG21 ' A' ' 181' ' ' VAL . 88.5 mt -69.59 120.74 15.83 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.893 179.991 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 14.8 mtmm -121.51 122.89 40.73 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.892 179.8 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . 0.43 ' HB2' HG22 ' A' ' 113' ' ' VAL . . . -107.7 146.18 32.43 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.104 179.834 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 53.2 m -139.05 169.52 17.64 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.862 -179.821 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 190' ' ' LEU . . . . . 0.433 ' HA ' HD22 ' A' ' 190' ' ' LEU . 0.7 OUTLIER -127.8 125.73 40.38 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.942 179.977 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.283 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.493 179.915 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 26.2 tp . . . . . 0 C--O 1.231 0.106 0 CA-C-O 120.894 0.378 . . . . 0.0 110.873 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 99.5 t -106.48 109.68 28.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.213 179.775 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.483 ' CZ ' ' CG1' ' A' ' 114' ' ' VAL . 40.4 t80 -100.64 107.09 18.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.924 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 75.0 t -106.35 138.57 31.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.139 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . 0.483 ' CG1' ' CZ ' ' A' ' 112' ' ' PHE . 31.0 m -122.68 160.79 24.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.101 179.913 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 81.54 53.21 3.89 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.491 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 32.9 mt -106.17 120.74 42.61 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.778 0.323 . . . . 0.0 110.938 -179.903 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . 0.42 ' O ' ' N ' ' A' ' 120' ' ' LEU . 26.3 t -64.65 142.82 58.29 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.883 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 118' ' ' GLN . . . . . 0.439 ' C ' ' CD ' ' A' ' 118' ' ' GLN . 0.7 OUTLIER -36.65 -43.71 0.43 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.917 -179.942 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 25.9 tpt180 -74.2 -42.32 59.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.852 -179.926 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 120' ' ' LEU . . . . . 0.42 ' N ' ' O ' ' A' ' 117' ' ' SER . 40.1 mt -61.49 -31.35 71.33 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.922 -179.987 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -68.5 83.37 0.27 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.134 179.801 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 73.1 m-20 -148.96 143.18 16.79 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.574 0.702 . . . . 0.0 110.899 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.86 -50.78 0.42 Allowed 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.67 2.247 . . . . 0.0 112.335 -179.925 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -65.46 -51.33 60.91 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.881 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.644 ' CG1' ' CZ ' ' A' ' 131' ' ' TYR . 64.3 t -54.02 -46.59 65.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.112 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.423 HD22 ' CE1' ' A' ' 132' ' ' PHE . 83.0 mt -66.99 -42.79 84.44 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.895 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.539 ' HA ' HD12 ' A' ' 138' ' ' ILE . 20.2 tttm -58.17 -40.46 81.51 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.884 179.845 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 34.6 mtp180 -38.24 143.29 0.43 Allowed Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.598 0.713 . . . . 0.0 110.872 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 1.53 4.37 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.626 2.217 . . . . 0.0 112.321 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 35.2 mm-40 -99.68 -27.99 13.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.848 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 131' ' ' TYR . . . . . 0.644 ' CZ ' ' CG1' ' A' ' 125' ' ' VAL . 55.7 m-85 -90.54 -68.27 0.8 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.92 -179.82 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.493 ' O ' ' N ' ' A' ' 134' ' ' LYS . 12.8 m-85 -116.95 -52.5 2.52 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.894 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . 0.402 ' C ' ' O ' ' A' ' 132' ' ' PHE . . . -37.8 -27.37 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.5 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.493 ' N ' ' O ' ' A' ' 132' ' ' PHE . 19.5 ptmt -43.04 -49.64 6.09 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.814 0.34 . . . . 0.0 110.851 -179.93 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 135' ' ' PHE . . . . . 0.469 ' CZ ' ' CG2' ' A' ' 176' ' ' VAL . 58.0 m-85 -63.3 -47.38 82.51 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.915 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -173.61 -172.26 38.85 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.755 -0.735 . . . . 0.0 112.477 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 22.8 mtmm -79.23 122.93 26.92 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.777 0.322 . . . . 0.0 110.872 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.539 HD12 ' HA ' ' A' ' 127' ' ' LYS . 87.7 mt -79.92 141.64 15.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.111 179.871 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 61.5 t-80 -91.02 -49.07 6.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.852 179.868 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 76.8 tttt -146.28 153.47 40.61 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.897 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 42.2 t -132.4 140.24 48.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.156 179.881 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 93.3 t -133.23 131.52 58.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.143 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 43.5 mm -111.67 121.99 65.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.138 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 11.1 t30 -114.49 118.69 34.5 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.89 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 28.5 m-80 . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.869 -179.992 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 90.0 p . . . . . 0 C--O 1.23 0.076 0 CA-C-O 120.9 0.381 . . . . 0.0 110.817 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -87.57 162.61 17.09 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.05 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 94.2 p -136.36 163.2 31.0 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.845 -179.813 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -146.76 148.77 32.29 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.067 179.917 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 11.0 m-85 -112.73 139.53 48.26 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.948 -179.873 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 71.4 t -130.3 121.43 51.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.16 179.896 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 87.2 m -99.52 129.0 45.66 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.13 -179.93 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 163' ' ' TYR . . . . . 0.554 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 52.7 m-85 -110.37 147.07 34.68 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.906 -179.88 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 53.1 mt -67.42 -60.62 2.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.123 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 46.9 mtp85 -82.43 112.99 19.88 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.893 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 74.0 m -52.45 -49.38 64.74 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.882 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 16.5 tt0 -44.5 -55.64 4.93 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.921 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 64.8 m-20 -55.84 -45.86 78.29 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.858 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 169' ' ' ALA . . . . . 0.554 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -58.48 -59.85 4.73 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.063 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 46.1 mt -42.65 -61.56 1.21 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.892 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 1.3 mpt_? -54.93 -50.38 68.99 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.835 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . 0.706 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -43.52 -36.73 2.15 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.091 179.933 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 173' ' ' ILE . . . . . 0.476 HG23 ' HB3' ' A' ' 188' ' ' ALA . 73.6 mt -78.77 -40.79 23.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.142 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 33.7 mt-30 -60.01 -30.22 69.0 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.915 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 1.8 m -93.8 -39.91 10.48 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.832 -179.895 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 176' ' ' VAL . . . . . 0.706 HG23 ' O ' ' A' ' 172' ' ' ALA . 10.6 t -59.56 -45.43 94.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.156 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 177' ' ' ASN . . . . . 0.448 ' OD1' ' N ' ' A' ' 178' ' ' ASN . 37.0 t30 -53.92 146.17 14.79 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.909 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 178' ' ' ASN . . . . . 0.448 ' N ' ' OD1' ' A' ' 177' ' ' ASN . 10.4 m120 57.83 47.26 15.61 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.891 -180.0 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 95.3 t -132.43 139.76 49.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.145 179.893 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 95.4 t -93.97 114.02 29.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.101 179.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 96.0 t -120.86 105.87 17.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.156 179.879 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 6.5 t0 65.62 35.32 7.13 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.878 179.928 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 81.19 -14.03 29.83 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.493 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 10.6 mpt_? -102.94 112.7 25.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.867 0.365 . . . . 0.0 110.863 -179.869 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 25.3 m -70.9 93.7 1.0 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.17 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 83.3 mt -70.97 149.5 46.61 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.947 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 13.5 ttpt -136.36 126.45 26.18 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.928 179.863 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . 0.476 ' HB3' HG23 ' A' ' 173' ' ' ILE . . . -112.38 141.91 45.54 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.139 179.801 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 8.5 t -139.86 165.56 26.99 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.868 -179.748 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 190' ' ' LEU . . . . . . . . . . . . . 38.1 tp -127.14 135.82 51.24 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.918 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.498 179.875 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . 0.674 ' O ' HD12 ' A' ' 190' ' ' LEU . 41.4 tp . . . . . 0 C--O 1.23 0.062 0 CA-C-O 120.896 0.379 . . . . 0.0 110.904 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.509 HG22 HD11 ' A' ' 173' ' ' ILE . 94.7 t -116.78 119.43 61.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.112 179.852 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.567 ' CE1' ' HB2' ' A' ' 158' ' ' SER . 48.2 t80 -113.67 109.64 18.91 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.861 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.687 HG22 ' HB2' ' A' ' 188' ' ' ALA . 68.1 t -106.32 146.5 12.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.121 179.932 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . 0.444 HG12 ' HB3' ' A' ' 158' ' ' SER . 32.9 m -132.03 170.69 19.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.086 179.942 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 78.29 45.49 9.95 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.455 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 32.4 mt -117.91 136.79 53.24 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.877 0.37 . . . . 0.0 110.955 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . 0.483 ' O ' ' N ' ' A' ' 119' ' ' ARG . 15.3 p -82.33 140.51 33.51 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.862 -179.892 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 118' ' ' GLN . . . . . 0.424 ' C ' ' O ' ' A' ' 117' ' ' SER . 82.8 mm-40 -35.02 -33.02 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.878 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.483 ' N ' ' O ' ' A' ' 117' ' ' SER . 72.8 mtm-85 -68.85 -50.22 51.69 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.827 -179.869 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 120' ' ' LEU . . . . . 0.462 ' N ' ' O ' ' A' ' 117' ' ' SER . 36.0 mt -70.97 -38.96 72.77 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.927 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -60.14 83.48 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.116 179.823 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 122' ' ' ASP . . . . . 0.4 ' N ' ' O ' ' A' ' 120' ' ' LEU . 6.0 m-20 -147.18 145.82 23.37 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.623 0.725 . . . . 0.0 110.888 179.962 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.76 -40.02 5.82 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.736 2.291 . . . . 0.0 112.327 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . 0.433 ' HG3' ' N ' ' A' ' 125' ' ' VAL . 16.8 pt-20 -75.8 -50.23 15.79 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.883 -179.967 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.476 HG13 ' CE2' ' A' ' 131' ' ' TYR . 53.2 t -56.51 -41.38 72.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.101 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.454 HD22 ' CE1' ' A' ' 132' ' ' PHE . 71.5 mt -74.68 -37.22 62.73 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.893 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.679 ' HA ' HD12 ' A' ' 138' ' ' ILE . 35.2 mttm -65.39 -22.9 66.84 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.906 179.832 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 64.1 mtt180 -48.5 143.75 7.27 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.571 0.701 . . . . 0.0 110.908 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 1.35 4.5 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.708 2.272 . . . . 0.0 112.335 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 26.9 mp0 -103.95 -42.02 5.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.908 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 131' ' ' TYR . . . . . 0.476 ' CE2' HG13 ' A' ' 125' ' ' VAL . 37.5 m-85 -72.77 -75.14 0.15 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.932 -179.872 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.454 ' CE1' HD22 ' A' ' 126' ' ' LEU . 45.6 m-85 -116.35 -32.85 5.15 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.867 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -52.49 -15.28 2.81 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.514 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 16.8 ptmt -67.7 -42.83 81.38 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.79 0.329 . . . . 0.0 110.895 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 135' ' ' PHE . . . . . 0.555 ' CE1' ' HA ' ' A' ' 172' ' ' ALA . 29.3 m-85 -60.63 -45.69 93.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.888 179.939 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -179.24 167.54 37.7 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.518 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 8.0 tmtm? -61.03 131.91 52.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.732 0.301 . . . . 0.0 110.878 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.679 HD12 ' HA ' ' A' ' 127' ' ' LYS . 95.1 mt -93.0 142.28 13.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.111 179.876 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 38.4 t60 -104.9 -59.6 1.72 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.803 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 140' ' ' LYS . . . . . 0.413 ' HD3' ' CG2' ' A' ' 142' ' ' VAL . 1.0 OUTLIER -129.17 136.52 50.26 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.916 -179.977 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . 0.646 ' CG2' HG21 ' A' ' 138' ' ' ILE . 47.1 t -129.36 139.76 50.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.179 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.413 ' CG2' ' HD3' ' A' ' 140' ' ' LYS . 5.4 t -132.18 140.19 48.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.117 179.929 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 42.1 mm -114.48 121.42 66.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.159 179.926 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 7.5 m-80 -115.67 113.39 23.45 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.933 179.916 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 53.6 p30 . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.879 -179.974 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 31.2 p . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.86 0.362 . . . . 0.0 110.859 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -95.03 163.4 13.32 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.059 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . 0.567 ' HB2' ' CE1' ' A' ' 112' ' ' PHE . 58.9 p -134.46 164.83 26.58 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.813 -179.757 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -147.15 136.43 22.58 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.108 179.898 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 160' ' ' TYR . . . . . 0.479 ' CE2' ' CD1' ' A' ' 112' ' ' PHE . 11.9 m-85 -104.96 113.11 26.51 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.902 -179.812 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 50.0 t -108.16 139.48 30.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.132 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 54.3 m -106.56 126.58 52.45 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.146 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 163' ' ' TYR . . . . . 0.628 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 15.4 m-85 -109.02 127.79 54.4 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.947 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 64.8 mt -59.48 -52.18 63.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.145 179.889 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 33.4 mtp85 -84.98 110.36 18.84 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.834 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 166' ' ' SER . . . . . 0.416 ' O ' ' C ' ' A' ' 167' ' ' GLU . 68.5 m -49.73 -64.72 0.72 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.833 -179.808 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 167' ' ' GLU . . . . . 0.416 ' C ' ' O ' ' A' ' 166' ' ' SER . 15.3 mt-10 -37.29 -57.69 0.87 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.899 -179.961 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -51.22 -47.74 62.24 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.895 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 169' ' ' ALA . . . . . 0.628 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -54.77 -58.61 6.87 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.08 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 41.1 mt -46.21 -56.95 4.99 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.879 -179.924 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 6.6 mpt_? -55.19 -51.86 65.17 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.856 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . 0.555 ' HA ' ' CE1' ' A' ' 135' ' ' PHE . . . -47.52 -33.04 5.87 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.06 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 173' ' ' ILE . . . . . 0.509 HD11 HG22 ' A' ' 111' ' ' VAL . 56.9 mt -79.12 -34.38 16.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.124 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 44.7 mt-30 -70.69 -26.01 63.23 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.912 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 4.0 m -93.77 -36.11 12.44 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.932 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 176' ' ' VAL . . . . . 0.491 HG23 ' O ' ' A' ' 172' ' ' ALA . 9.8 t -67.94 -35.81 73.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.118 -179.976 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 58.4 t30 -62.97 145.26 55.73 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.921 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 35.5 t30 55.62 51.68 12.21 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.916 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 179' ' ' VAL . . . . . 0.47 HG12 HG23 ' A' ' 181' ' ' VAL . 76.7 t -125.89 142.37 42.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.104 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 91.3 t -104.24 105.12 17.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.128 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . 0.47 HG23 HG12 ' A' ' 179' ' ' VAL . 85.7 t -119.11 105.01 16.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.174 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 1.6 t70 60.01 41.23 17.73 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.901 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 71.28 24.09 77.35 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.524 -179.932 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 3.5 mmp_? -126.93 114.23 17.58 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.884 0.373 . . . . 0.0 110.875 -179.837 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 7.8 m -70.7 103.19 2.49 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.122 -179.89 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 31.1 mt -71.52 126.1 28.78 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.934 179.932 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -131.02 114.55 15.33 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.89 179.837 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . 0.687 ' HB2' HG22 ' A' ' 113' ' ' VAL . . . -118.54 137.62 53.1 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.046 179.862 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 7.3 t -125.89 166.78 16.26 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.875 -179.785 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 190' ' ' LEU . . . . . 0.674 HD12 ' O ' ' A' ' 110' ' ' LEU . 9.0 tp -131.8 143.41 50.19 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.897 -179.97 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.345 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.547 179.925 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 13.9 tp . . . . . 0 C--O 1.232 0.162 0 CA-C-O 120.843 0.354 . . . . 0.0 110.931 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 1.088 HG22 HD11 ' A' ' 173' ' ' ILE . 77.9 t -103.44 108.02 23.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.103 179.867 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.451 ' CD1' ' CE1' ' A' ' 160' ' ' TYR . 47.2 t80 -106.56 113.86 27.63 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.875 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.579 HG22 ' HB2' ' A' ' 188' ' ' ALA . 32.7 t -112.61 137.94 43.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.163 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 23.1 m -121.36 166.22 16.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.125 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . 0.412 ' O ' HD23 ' A' ' 186' ' ' LEU . . . 73.38 55.69 6.01 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.493 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 32.3 mt -117.81 127.76 54.2 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.813 0.339 . . . . 0.0 110.894 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 11.8 m -63.78 136.01 57.1 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.846 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 118' ' ' GLN . . . . . 0.454 ' OE1' ' ND2' ' A' ' 145' ' ' ASN . 4.8 tp-100 -41.97 -27.28 0.12 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.884 -179.974 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 1.8 mpt_? -78.4 -48.27 15.85 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.901 -179.932 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 42.8 mt -66.22 -38.7 88.56 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.932 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -60.91 88.12 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.069 179.839 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 24.9 m-20 -148.65 149.54 31.21 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.635 0.731 . . . . 0.0 110.852 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.82 -43.39 2.64 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.675 2.25 . . . . 0.0 112.325 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 27.6 mt-10 -76.39 -41.86 46.44 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.857 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.723 HG13 ' CZ ' ' A' ' 131' ' ' TYR . 74.3 t -60.24 -48.06 89.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.127 -179.987 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 42.3 mt -70.26 -40.25 74.49 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.886 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.504 ' HA ' HD12 ' A' ' 138' ' ' ILE . 32.1 mttm -61.54 -35.89 79.04 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.864 179.854 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 48.7 mtt85 -43.9 143.41 1.74 Allowed Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.592 0.711 . . . . 0.0 110.875 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 -3.54 12.19 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.707 2.272 . . . . 0.0 112.362 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -94.96 -36.13 11.71 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.944 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 131' ' ' TYR . . . . . 0.723 ' CZ ' HG13 ' A' ' 125' ' ' VAL . 57.1 m-85 -80.21 -74.23 0.32 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.888 -179.841 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.487 ' O ' ' N ' ' A' ' 134' ' ' LYS . 14.6 m-85 -116.9 -44.84 2.79 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.915 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . 0.439 ' C ' ' O ' ' A' ' 132' ' ' PHE . . . -35.39 -31.06 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.515 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.487 ' N ' ' O ' ' A' ' 132' ' ' PHE . 16.6 ptmt -45.86 -48.77 15.89 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.812 0.339 . . . . 0.0 110.887 -179.995 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 135' ' ' PHE . . . . . 0.545 ' CD2' ' HA ' ' A' ' 172' ' ' ALA . 78.9 m-85 -61.69 -43.91 97.95 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.882 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -173.94 -174.54 40.91 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.491 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 29.5 mtmt -90.09 102.18 14.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.753 0.311 . . . . 0.0 110.845 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.504 HD12 ' HA ' ' A' ' 127' ' ' LYS . 58.1 mt -61.33 148.38 9.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.104 179.847 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 61.4 t60 -101.55 -57.55 2.06 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.875 179.837 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 40.2 tttm -123.17 143.8 49.77 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.904 179.916 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . 0.463 HG22 HG21 ' A' ' 138' ' ' ILE . 58.5 t -135.91 118.45 21.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.135 179.89 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 83.9 t -117.32 134.72 60.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.128 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 3.3 mm -106.46 125.39 62.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.129 179.923 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 4.4 m-80 -117.87 104.36 10.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.947 179.87 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 145' ' ' ASN . . . . . 0.454 ' ND2' ' OE1' ' A' ' 118' ' ' GLN . 35.4 m120 . . . . . 0 C--N 1.33 -0.277 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.893 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 58.1 m . . . . . 0 C--O 1.231 0.107 0 CA-C-O 120.874 0.368 . . . . 0.0 110.848 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -106.5 165.32 11.36 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.064 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . 0.407 ' HB2' ' CE1' ' A' ' 112' ' ' PHE . 79.0 p -130.12 167.38 18.44 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.842 -179.767 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -155.68 136.21 13.29 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.137 179.9 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 160' ' ' TYR . . . . . 0.451 ' CE1' ' CD1' ' A' ' 112' ' ' PHE . 98.3 m-85 -99.4 133.14 44.15 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.926 -179.869 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.44 HG13 ' CG2' ' A' ' 138' ' ' ILE . 75.2 t -125.6 122.28 62.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.179 179.893 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 87.4 m -94.97 124.18 38.87 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.197 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 163' ' ' TYR . . . . . 0.494 ' CB ' ' HB2' ' A' ' 169' ' ' ALA . 14.0 m-85 -100.2 147.77 25.35 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.925 -179.897 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 52.0 mt -73.5 -41.74 56.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.154 179.871 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 13.3 mmm180 -105.18 133.41 49.99 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.862 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 71.5 m -63.05 -68.18 0.36 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.834 -179.722 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 4.9 tp10 -42.93 -58.45 2.4 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.884 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -47.16 -46.48 23.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.921 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 169' ' ' ALA . . . . . 0.494 ' HB2' ' CB ' ' A' ' 163' ' ' TYR . . . -58.98 -61.53 2.57 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.119 179.938 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 59.0 mt -39.21 -52.75 1.94 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.914 179.994 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 171' ' ' ARG . . . . . 0.431 ' O ' ' N ' ' A' ' 174' ' ' GLN . 86.1 mtt180 -59.44 -58.61 7.83 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.898 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . 0.545 ' HA ' ' CD2' ' A' ' 135' ' ' PHE . . . -41.02 -35.59 0.56 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.098 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 173' ' ' ILE . . . . . 1.088 HD11 HG22 ' A' ' 111' ' ' VAL . 58.5 mt -76.89 -37.58 27.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.074 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 174' ' ' GLN . . . . . 0.431 ' N ' ' O ' ' A' ' 171' ' ' ARG . 61.5 mt-30 -64.68 -21.42 66.73 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.883 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 3.9 m -93.83 -40.39 10.2 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.873 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 176' ' ' VAL . . . . . 0.479 ' O ' HG23 ' A' ' 179' ' ' VAL . 9.1 t -62.45 -38.36 81.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.115 -179.984 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 5.1 t-20 -60.71 140.36 57.55 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.887 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 15.6 t-20 65.2 50.74 1.75 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.91 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 179' ' ' VAL . . . . . 0.479 HG23 ' O ' ' A' ' 176' ' ' VAL . 71.1 t -124.78 142.04 42.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.061 179.946 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 83.3 t -96.25 110.68 25.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.16 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . 0.744 HG21 HD12 ' A' ' 186' ' ' LEU . 48.7 t -120.02 106.02 18.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.125 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 53.77 43.47 30.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.881 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 71.19 30.83 66.91 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.454 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 32.9 mtt-85 -138.24 122.71 18.41 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.882 0.372 . . . . 0.0 110.902 -179.874 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 17.7 m -82.47 96.91 8.15 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.143 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 186' ' ' LEU . . . . . 0.744 HD12 HG21 ' A' ' 181' ' ' VAL . 95.8 mt -74.45 132.71 42.16 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.937 179.928 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 47.8 mttt -117.87 132.22 56.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.941 179.8 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . 0.579 ' HB2' HG22 ' A' ' 113' ' ' VAL . . . -123.53 147.27 47.42 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.106 179.857 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 68.0 m -158.06 162.62 38.09 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.856 -179.806 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 190' ' ' LEU . . . . . . . . . . . . . 4.5 pp -129.77 156.33 44.49 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.894 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.337 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.507 179.867 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . 0.506 ' O ' HD22 ' A' ' 190' ' ' LEU . 14.1 tp . . . . . 0 C--O 1.23 0.059 0 CA-C-O 120.86 0.362 . . . . 0.0 110.877 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.593 HG22 HD11 ' A' ' 173' ' ' ILE . 41.4 t -95.49 104.22 15.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.15 179.815 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.579 ' CD1' ' CE2' ' A' ' 160' ' ' TYR . 39.5 t80 -94.08 122.36 36.51 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.848 -179.948 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.401 HG22 ' HB2' ' A' ' 188' ' ' ALA . 42.3 t -117.82 133.55 64.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.145 179.92 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . 0.429 ' CG1' ' CE2' ' A' ' 112' ' ' PHE . 11.9 m -120.4 166.64 14.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.125 179.899 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 67.0 53.53 26.24 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.506 179.983 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 34.9 mt -105.98 146.57 29.89 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.844 0.354 . . . . 0.0 110.846 -179.86 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 29.2 m -77.35 153.98 33.24 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.801 -179.908 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 84.9 mm-40 -56.55 -44.9 81.37 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.892 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 10.6 ttt180 -74.38 -44.96 49.85 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.897 -179.925 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 66.2 mt -66.89 -24.84 66.16 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.932 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -76.06 83.71 2.93 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.11 179.773 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -148.3 150.34 34.32 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-O 121.62 0.724 . . . . 0.0 110.857 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.83 -50.62 0.44 Allowed 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.668 2.245 . . . . 0.0 112.319 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 7.0 mm-40 -65.35 -41.91 93.38 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.89 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.67 HG13 ' CZ ' ' A' ' 131' ' ' TYR . 85.9 t -61.79 -42.68 95.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.128 179.975 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.545 HD22 ' CE1' ' A' ' 132' ' ' PHE . 79.4 mt -74.33 -40.32 62.25 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.929 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.459 ' HA ' ' CD1' ' A' ' 138' ' ' ILE . 43.0 tttt -61.03 -31.25 70.89 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.873 179.837 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 72.6 mtt-85 -44.13 142.88 2.02 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.573 0.701 . . . . 0.0 110.873 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 0.8 5.14 Favored 'Trans proline' 0 C--N 1.341 0.136 0 C-N-CA 122.662 2.241 . . . . 0.0 112.375 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 5.0 tp10 -103.99 -36.01 7.9 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.915 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 131' ' ' TYR . . . . . 0.67 ' CZ ' HG13 ' A' ' 125' ' ' VAL . 38.8 m-85 -75.91 -75.02 0.2 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.962 -179.869 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.545 ' CE1' HD22 ' A' ' 126' ' ' LEU . 19.9 m-85 -114.86 -40.58 3.5 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.858 -179.996 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -52.23 -20.47 6.93 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.51 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.423 ' C ' ' HD3' ' A' ' 134' ' ' LYS . 0.0 OUTLIER -53.54 -31.65 47.27 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.86 0.362 . . . . 0.0 110.903 -179.999 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 135' ' ' PHE . . . . . 0.454 ' CE2' ' CG2' ' A' ' 176' ' ' VAL . 65.3 m-85 -73.21 -42.48 62.6 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.87 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -177.66 -163.41 29.41 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.47 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 16.9 mttp -79.58 142.14 35.95 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.774 0.321 . . . . 0.0 110.915 -179.966 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.558 HG21 HG22 ' A' ' 141' ' ' VAL . 82.6 mt -105.25 132.19 52.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.146 179.899 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 3.8 t-160 -85.97 -59.64 2.24 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.857 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 73.6 tttt -132.72 146.1 51.58 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.936 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . 0.558 HG22 HG21 ' A' ' 138' ' ' ILE . 24.2 t -129.38 130.08 67.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.153 179.876 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 96.1 t -134.34 147.49 30.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.133 179.879 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 15.3 mm -118.05 150.44 20.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.133 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 39.9 t30 -129.02 106.47 8.9 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.889 179.902 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 3.0 p30 . . . . . 0 C--N 1.329 -0.303 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.896 179.986 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 78.7 p . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.886 0.374 . . . . 0.0 110.825 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -112.28 164.81 12.79 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.082 179.911 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 14.8 m -133.16 164.55 26.8 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.87 -179.797 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -150.81 166.47 30.4 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.131 179.922 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 160' ' ' TYR . . . . . 0.579 ' CE2' ' CD1' ' A' ' 112' ' ' PHE . 11.6 m-85 -136.29 126.4 26.2 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.913 -179.821 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 67.0 t -126.72 146.13 33.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.09 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 82.2 m -108.35 134.16 51.55 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.192 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 163' ' ' TYR . . . . . 0.651 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 7.9 m-85 -111.96 120.75 42.95 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.924 -179.867 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 88.7 mt -49.75 -50.86 17.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.102 179.918 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 24.9 mtp85 -88.1 109.72 20.09 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.883 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 5.3 t -48.85 -59.3 3.69 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.855 -179.772 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 23.8 mt-10 -47.94 -46.29 31.94 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.89 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 6.5 t0 -56.13 -45.12 79.68 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.829 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 169' ' ' ALA . . . . . 0.651 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -55.75 -52.42 63.98 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.116 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 26.8 mt -51.38 -59.4 4.27 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.894 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 74.3 mtp180 -55.09 -49.23 72.22 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.903 179.909 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . 0.638 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -50.08 -33.16 17.61 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.066 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 173' ' ' ILE . . . . . 0.593 HD11 HG22 ' A' ' 111' ' ' VAL . 55.2 mt -76.65 -38.4 30.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.128 -179.996 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 10.3 mm100 -65.66 -30.54 71.25 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.884 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 175' ' ' CYS . . . . . 0.444 ' O ' ' CG2' ' A' ' 179' ' ' VAL . 3.0 t -93.72 -27.33 16.58 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.85 -179.94 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 176' ' ' VAL . . . . . 0.638 HG23 ' O ' ' A' ' 172' ' ' ALA . 10.4 t -77.9 -26.28 14.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.181 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -79.09 154.15 29.61 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.855 -179.972 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 178' ' ' ASN . . . . . 0.438 ' O ' ' CG ' ' A' ' 178' ' ' ASN . 32.5 t30 55.23 36.27 26.67 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.881 179.978 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 179' ' ' VAL . . . . . 0.444 ' CG2' ' O ' ' A' ' 175' ' ' CYS . 92.3 t -108.84 141.98 22.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.109 179.919 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 53.7 t -106.2 97.1 5.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.121 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . 0.48 HG12 ' OD2' ' A' ' 182' ' ' ASP . 40.0 t -102.41 118.34 49.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.143 179.941 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 182' ' ' ASP . . . . . 0.48 ' OD2' HG12 ' A' ' 181' ' ' VAL . 2.9 p30 47.26 31.65 1.84 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.851 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 86.02 20.7 54.87 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.453 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 5.5 tpm_? -118.21 133.97 55.43 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.904 0.383 . . . . 0.0 110.882 -179.857 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 17.3 m -90.76 95.13 9.99 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.164 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 71.1 mt -74.8 128.33 35.3 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.892 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 2.8 mmmp? -128.79 121.7 28.92 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.887 179.822 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . 0.401 ' HB2' HG22 ' A' ' 113' ' ' VAL . . . -119.4 156.52 29.98 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.087 179.859 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 8.5 t -147.76 165.28 31.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.857 -179.813 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 190' ' ' LEU . . . . . 0.789 HD13 ' N ' ' A' ' 191' ' ' GLY . 1.6 tm? -132.2 137.58 47.65 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.877 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 191' ' ' GLY . . . . . 0.789 ' N ' HD13 ' A' ' 190' ' ' LEU . . . . . . . . 0 N--CA 1.452 -0.299 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.441 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . 0.637 ' O ' HD22 ' A' ' 190' ' ' LEU . 9.4 tp . . . . . 0 C--O 1.231 0.092 0 CA-C-O 120.842 0.353 . . . . 0.0 110.941 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.471 HG22 HD11 ' A' ' 173' ' ' ILE . 69.5 t -108.95 106.67 21.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.131 179.899 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.511 ' CZ ' ' CG1' ' A' ' 114' ' ' VAL . 61.4 t80 -99.83 117.42 34.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.864 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 21.2 t -116.56 135.67 56.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.107 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . 0.511 ' CG1' ' CZ ' ' A' ' 112' ' ' PHE . 34.1 m -124.55 165.38 21.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.123 179.904 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 78.6 52.46 5.08 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.48 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 21.2 mt -109.16 133.67 52.72 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.85 0.357 . . . . 0.0 110.932 -179.917 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 40.2 t -66.53 147.83 52.74 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.853 -179.92 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.9 mt-30 -40.86 -47.3 2.91 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.917 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 39.3 mtp180 -71.47 -37.78 71.3 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.901 -179.922 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 51.7 mt -67.27 -26.7 66.68 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.943 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -74.01 83.81 1.76 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.098 179.763 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -148.99 142.99 16.56 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.592 0.711 . . . . 0.0 110.904 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.7 -49.26 0.59 Allowed 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.69 2.26 . . . . 0.0 112.359 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 51.4 mt-10 -69.48 -42.28 75.04 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.887 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.479 ' CG1' ' CZ ' ' A' ' 131' ' ' TYR . 60.3 t -59.16 -46.15 92.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.128 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 68.0 mt -69.81 -40.49 75.91 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.918 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.514 ' HA ' HD12 ' A' ' 138' ' ' ILE . 15.3 tttt -61.83 -27.88 69.09 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.937 179.809 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 13.8 mtp85 -45.24 143.6 2.52 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.632 0.729 . . . . 0.0 110.857 179.98 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 1.23 4.61 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.656 2.237 . . . . 0.0 112.347 -179.997 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 7.1 tp10 -105.51 -35.55 7.42 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.931 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 131' ' ' TYR . . . . . 0.479 ' CZ ' ' CG1' ' A' ' 125' ' ' VAL . 38.0 m-85 -77.46 -75.11 0.22 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.911 -179.857 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 13.2 m-85 -116.23 -34.68 4.58 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.902 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -49.99 -23.9 5.93 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.527 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.424 ' C ' ' HD3' ' A' ' 134' ' ' LYS . 0.0 OUTLIER -56.03 -34.07 65.51 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.788 0.328 . . . . 0.0 110.913 -179.959 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 135' ' ' PHE . . . . . 0.563 ' CE1' ' HA ' ' A' ' 172' ' ' ALA . 19.4 m-85 -69.89 -47.06 64.02 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.875 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -174.12 177.28 46.42 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.502 -179.947 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 5.8 mmmt -74.57 110.25 8.71 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.747 0.308 . . . . 0.0 110.893 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.607 HG21 HG22 ' A' ' 141' ' ' VAL . 56.8 mt -75.64 143.53 13.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.126 179.924 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 19.8 t-160 -99.2 -58.73 1.87 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.864 179.903 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 140' ' ' LYS . . . . . 0.725 ' HD3' HG23 ' A' ' 142' ' ' VAL . 0.2 OUTLIER -127.78 141.9 51.45 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.869 179.984 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . 0.607 HG22 HG21 ' A' ' 138' ' ' ILE . 3.9 t -130.94 139.86 50.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.114 179.887 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.725 HG23 ' HD3' ' A' ' 140' ' ' LYS . 69.5 t -135.45 139.84 45.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.132 179.93 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 16.7 mm -112.13 114.71 47.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.143 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 1.6 t30 -99.94 127.46 46.13 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.897 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 2.1 p-10 . . . . . 0 C--N 1.33 -0.276 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.872 -179.987 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 53.9 p . . . . . 0 C--O 1.23 0.056 0 CA-C-O 120.874 0.369 . . . . 0.0 110.861 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -122.32 152.59 39.96 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.109 179.907 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 87.5 p -124.89 176.43 6.63 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.894 -179.818 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -160.7 162.06 32.45 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.125 179.891 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 160' ' ' TYR . . . . . 0.483 ' CE2' ' CD1' ' A' ' 112' ' ' PHE . 16.5 m-85 -125.61 127.56 46.53 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.921 -179.825 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.41 HG22 HG13 ' A' ' 141' ' ' VAL . 66.7 t -121.75 140.27 46.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.117 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 4.7 m -114.21 115.71 27.89 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.185 -179.997 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 163' ' ' TYR . . . . . 0.638 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 29.1 m-85 -90.47 134.2 34.51 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.928 -179.904 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 66.4 mt -59.36 -42.63 88.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.119 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 19.0 mtm-85 -99.57 112.04 24.31 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.877 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 2.7 t -48.86 -57.59 6.17 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.896 -179.822 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 32.7 tt0 -42.93 -52.46 5.15 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.88 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -52.34 -50.6 62.0 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.883 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 169' ' ' ALA . . . . . 0.638 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -54.77 -64.02 0.97 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.106 179.915 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . 0.401 ' C ' ' O ' ' A' ' 169' ' ' ALA . 55.9 mt -37.15 -58.54 0.79 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.888 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 171' ' ' ARG . . . . . 0.432 ' HB3' ' NH1' ' A' ' 171' ' ' ARG . 10.6 mtp-105 -60.61 -46.04 91.75 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.846 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . 0.563 ' HA ' ' CE1' ' A' ' 135' ' ' PHE . . . -47.38 -32.89 5.33 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.072 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 173' ' ' ILE . . . . . 0.471 HD11 HG22 ' A' ' 111' ' ' VAL . 96.9 mt -82.85 -40.08 16.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.155 179.963 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 30.1 mt-30 -66.25 -23.28 66.38 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.893 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 1.8 t -93.9 -37.09 11.89 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.86 -179.927 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 176' ' ' VAL . . . . . 0.428 HG23 ' CZ ' ' A' ' 135' ' ' PHE . 9.0 t -70.18 -48.43 61.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.149 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 7.5 t30 -43.76 124.82 3.85 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.95 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 65.7 t30 70.62 52.03 0.32 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.898 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 54.5 t -134.12 135.34 54.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.123 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 83.4 t -86.96 120.57 36.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.119 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . 0.705 HG21 HD12 ' A' ' 186' ' ' LEU . 85.0 t -124.7 116.54 47.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.1 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 34.3 t70 58.52 36.52 25.29 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.87 179.899 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 84.35 -20.17 15.17 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.456 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 43.0 ttm-85 -107.23 133.4 51.86 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.897 0.379 . . . . 0.0 110.861 -179.859 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 30.0 m -80.27 133.29 35.97 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.104 -179.884 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 186' ' ' LEU . . . . . 0.705 HD12 HG21 ' A' ' 181' ' ' VAL . 27.4 mt -101.06 147.42 26.24 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.949 179.924 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -121.29 131.98 54.52 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.903 179.839 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -129.5 143.54 50.88 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.075 179.843 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 5.5 t -138.7 167.54 21.76 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.866 -179.785 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 190' ' ' LEU . . . . . 0.753 HD13 ' N ' ' A' ' 191' ' ' GLY . 2.0 tm? -132.61 128.9 38.13 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.925 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 191' ' ' GLY . . . . . 0.753 ' N ' HD13 ' A' ' 190' ' ' LEU . . . . . . . . 0 N--CA 1.451 -0.346 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.447 179.878 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.306 0 N-CA-C 112.51 -0.236 . . . . 0.0 112.51 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 16.1 m -92.51 99.31 12.07 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.885 0.374 . . . . 0.0 110.845 -179.727 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 8.5 t -67.28 92.48 0.28 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.815 -179.773 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 174.84 46.26 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.473 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 73.5 m -45.51 -58.36 3.44 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.892 0.377 . . . . 0.0 110.837 -179.699 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 3.7 m -86.14 88.92 7.68 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.851 -179.793 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -99.08 -78.35 1.38 Allowed Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.486 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -72.49 121.21 19.24 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.789 0.328 . . . . 0.0 111.156 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 8.2 t -174.09 171.6 3.54 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.81 -179.76 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.537 HG23 HG23 ' A' ' 105' ' ' VAL . 22.9 m -85.4 150.45 3.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.114 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 86.5 mtm-85 -85.2 109.61 18.44 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.822 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.537 HG23 HG23 ' A' ' 103' ' ' VAL . 44.7 t -121.74 122.28 66.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.125 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 95.6 t -90.66 106.69 17.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.094 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 14.0 mm100 -114.66 88.56 2.89 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.858 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 74.8 mttt -88.79 -41.13 12.7 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.898 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 64.9 t30 -85.32 44.94 1.13 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.857 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 19.9 tp -136.06 117.55 14.79 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.898 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 79.5 t -92.64 110.7 23.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.187 179.804 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.43 ' CE1' ' HB2' ' A' ' 158' ' ' SER . 53.4 t80 -109.52 107.0 16.95 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.892 -179.931 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 69.4 t -108.73 142.57 20.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.149 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 22.4 m -126.43 171.74 14.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.136 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 69.54 48.37 44.19 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.493 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 30.9 mt -112.69 125.48 54.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.789 0.328 . . . . 0.0 110.916 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . 0.423 ' O ' ' N ' ' A' ' 120' ' ' LEU . 26.9 t -71.79 141.4 49.69 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.895 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 36.5 tp60 -38.38 -32.33 0.07 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.9 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 15.7 mmt180 -70.79 -47.51 59.15 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.845 -179.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . 0.423 ' N ' ' O ' ' A' ' 117' ' ' SER . 58.7 mt -69.46 -32.74 71.85 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.913 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -64.46 83.79 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.14 179.779 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -148.66 144.06 17.96 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.59 0.709 . . . . 0.0 110.911 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.81 -45.55 1.52 Allowed 'Trans proline' 0 C--N 1.341 0.133 0 C-N-CA 122.684 2.256 . . . . 0.0 112.287 -179.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -71.48 -39.52 70.85 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.927 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.609 HG13 ' CZ ' ' A' ' 131' ' ' TYR . 74.6 t -63.21 -45.76 97.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.129 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.477 HD22 ' CE1' ' A' ' 132' ' ' PHE . 95.6 mt -74.47 -34.91 63.26 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.889 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 53.0 mttt -64.61 -32.25 73.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.882 179.85 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 20.0 mmt180 -46.25 143.97 3.41 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.631 0.729 . . . . 0.0 110.85 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -4.21 13.56 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.665 2.243 . . . . 0.0 112.35 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 56.6 tt0 -100.67 -10.64 20.7 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.892 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' TYR . . . . . 0.609 ' CZ ' HG13 ' A' ' 125' ' ' VAL . 43.6 m-85 -103.17 -74.98 0.62 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.91 -179.864 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.477 ' CE1' HD22 ' A' ' 126' ' ' LEU . 28.2 m-85 -118.65 -40.62 2.87 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.898 179.988 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -47.93 -19.02 0.85 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.505 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.416 ' HD2' ' CD2' ' A' ' 135' ' ' PHE . 0.0 OUTLIER -51.52 -40.31 59.37 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.822 0.344 . . . . 0.0 110.914 -179.995 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' PHE . . . . . 0.485 ' CE1' ' HA ' ' A' ' 172' ' ' ALA . 47.8 m-85 -67.16 -44.06 80.68 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.896 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 176.94 169.66 38.47 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.544 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -60.63 136.76 58.16 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.745 0.307 . . . . 0.0 110.922 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.666 HG21 HG22 ' A' ' 141' ' ' VAL . 61.1 mt -96.64 148.82 5.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.114 179.868 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 56.4 t60 -101.02 -48.74 4.33 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.854 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 22.6 ttmt -134.98 140.54 45.77 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.879 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . 0.666 HG22 HG21 ' A' ' 138' ' ' ILE . 15.9 t -132.73 112.75 19.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.159 179.814 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 93.8 t -116.77 137.73 49.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.116 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 4.1 mm -114.0 123.68 69.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.106 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 8.9 t-20 -113.03 114.02 26.29 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.901 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 6.2 p-10 -136.43 171.77 13.99 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.888 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 1.2 t -58.6 132.0 52.49 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.856 -179.877 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 93.5 m -81.07 -53.55 6.31 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.139 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 54.9 m -93.06 122.86 35.86 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.856 -179.852 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 5.8 t80 -108.55 120.05 41.32 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.898 -179.906 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -109.04 -52.91 2.71 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.068 -0.514 . . . . 0.0 111.072 179.882 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 109.09 36.83 2.08 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.469 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 1.8 m -102.35 -55.45 2.46 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.818 0.342 . . . . 0.0 110.877 -179.767 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 84.4 mt-30 -120.15 174.01 6.75 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.922 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . -108.41 83.25 0.33 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.503 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.8 177.25 5.79 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.698 2.265 . . . . 0.0 112.328 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 50.8 m -128.6 154.18 46.48 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.894 -179.889 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -114.41 166.46 11.66 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.103 179.905 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . 0.43 ' HB2' ' CE1' ' A' ' 112' ' ' PHE . 4.8 p -134.93 150.99 50.48 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.865 -179.781 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -122.8 145.52 48.35 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.077 179.879 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 44.1 m-85 -119.42 107.16 13.0 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.945 -179.833 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 37.9 t -101.19 141.25 18.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.097 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 63.0 m -111.22 123.33 49.98 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.093 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 163' ' ' TYR . . . . . 0.825 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 30.5 m-85 -105.3 121.74 44.5 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.937 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 74.2 mt -49.63 -37.14 11.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.137 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 80.3 mmt-85 -107.11 114.75 29.0 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.898 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 69.0 m -51.68 -55.17 21.0 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.883 -179.803 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 24.8 mm-40 -42.96 -54.04 4.44 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.908 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -54.71 -46.11 74.13 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.871 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 169' ' ' ALA . . . . . 0.825 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -60.84 -64.07 1.08 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.098 179.948 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 36.6 mt -38.28 -63.62 0.48 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.922 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 86.5 mtt180 -52.8 -51.85 59.19 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.873 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . 0.695 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -45.06 -32.88 1.88 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.096 179.904 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 82.2 mt -81.72 -35.28 13.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.091 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 33.4 mt-30 -64.69 -27.65 69.06 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.906 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 175' ' ' CYS . . . . . 0.441 ' O ' ' CG2' ' A' ' 179' ' ' VAL . 2.3 m -93.82 -34.29 13.22 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.87 -179.927 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 176' ' ' VAL . . . . . 0.695 HG23 ' O ' ' A' ' 172' ' ' ALA . 10.8 t -63.29 -33.74 62.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.147 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 177' ' ' ASN . . . . . 0.437 ' ND2' ' N ' ' A' ' 178' ' ' ASN . 1.1 t-20 -62.55 140.99 58.65 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.89 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 178' ' ' ASN . . . . . 0.437 ' N ' ' ND2' ' A' ' 177' ' ' ASN . 9.1 t-20 62.33 37.62 13.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.846 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 179' ' ' VAL . . . . . 0.441 ' CG2' ' O ' ' A' ' 175' ' ' CYS . 75.0 t -118.57 133.15 66.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.141 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 59.3 t -89.03 128.04 41.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.169 179.914 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . 0.485 HG21 HD12 ' A' ' 186' ' ' LEU . 50.7 t -135.86 114.56 15.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.069 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 5.8 t70 63.5 28.53 15.34 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.901 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 89.21 -14.41 60.91 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.499 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 77.6 mtt85 -108.77 126.0 52.55 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.903 0.383 . . . . 0.0 110.805 -179.837 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 10.9 m -76.74 106.48 8.42 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.16 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 186' ' ' LEU . . . . . 0.485 HD12 HG21 ' A' ' 181' ' ' VAL . 80.3 mt -70.24 157.05 38.39 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.907 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 16.2 tptm -135.65 115.01 12.53 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.939 179.82 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -110.13 142.96 40.9 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.083 179.88 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 86.1 p -156.71 165.39 36.37 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.873 -179.776 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 190' ' ' LEU . . . . . . . . . . . . . 4.3 pp -126.62 154.98 43.25 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.938 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 103.71 26.17 6.92 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.45 179.885 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 192' ' ' THR . . . . . . . . . . . . . 1.9 m -102.61 150.66 23.2 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.863 0.363 . . . . 0.0 111.135 -179.862 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 193' ' ' THR . . . . . . . . . . . . . 76.9 p -97.75 153.4 18.29 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.145 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 1.5 mmmm -104.63 -58.96 1.81 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.898 179.905 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 195' ' ' TYR . . . . . . . . . . . . . 4.9 p90 -103.51 172.7 6.66 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.943 -179.927 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 196' ' ' CYS . . . . . . . . . . . . . 9.5 t -105.74 120.01 40.61 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.92 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 9.9 t -47.73 -55.12 10.23 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.868 -179.754 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 198' ' ' TYR . . . . . 0.441 ' CD1' ' C ' ' A' ' 198' ' ' TYR . 4.8 t80 -42.51 -55.63 3.4 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.889 -179.885 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 28.9 t -38.63 122.37 1.13 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.862 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 200' ' ' GLY . . . . . 0.4 ' HA3' ' C ' ' A' ' 201' ' ' PRO . . . 171.99 -69.26 0.12 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.477 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 201' ' ' PRO . . . . . 0.4 ' C ' ' HA3' ' A' ' 200' ' ' GLY . 54.1 Cg_endo -69.75 179.08 23.26 Favored 'Cis proline' 0 C--N 1.342 0.188 0 C-N-CA 122.686 -1.797 . . . . 0.0 112.345 0.051 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 202' ' ' SER . . . . . 0.405 ' O ' ' C ' ' A' ' 203' ' ' SER . 3.7 t -160.28 133.81 6.94 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.813 -179.877 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 203' ' ' SER . . . . . 0.405 ' C ' ' O ' ' A' ' 202' ' ' SER . 96.5 p 37.2 40.16 0.17 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.872 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.261 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.458 -179.969 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.36 0 N-CA-C 112.517 -0.233 . . . . 0.0 112.517 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 31.0 m -77.38 86.46 3.77 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.895 0.378 . . . . 0.0 110.878 -179.73 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 7.5 t -75.49 168.47 19.95 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.87 -179.816 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -72.96 104.49 1.56 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.781 -0.724 . . . . 0.0 112.492 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 58.3 m -130.0 121.8 27.22 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.836 0.35 . . . . 0.0 110.858 -179.735 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 24.8 p -151.42 123.55 8.21 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.863 -179.808 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 128.38 -109.68 1.04 Allowed Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.46 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -49.42 141.68 8.72 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.79 0.329 . . . . 0.0 111.122 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 1.3 t -71.31 152.42 43.26 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.86 -179.787 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.403 HG22 ' H ' ' A' ' 103' ' ' VAL . 1.4 m -66.33 104.26 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.064 179.94 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 7.6 ptp180 -119.32 147.09 44.71 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.886 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.501 HG13 ' O ' ' A' ' 105' ' ' VAL . 12.7 p -116.11 120.94 66.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.154 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 21.2 t -119.45 138.85 48.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.076 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 7.1 mm100 -43.27 146.21 0.48 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.921 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 77.7 mttt -84.34 54.23 2.91 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.871 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 5.3 p-10 -125.3 39.31 4.0 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.902 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . 0.407 HD11 ' HD1' ' A' ' 160' ' ' TYR . 12.3 tp -140.95 131.04 24.7 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.943 179.94 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.775 HG22 HD11 ' A' ' 173' ' ' ILE . 47.0 t -113.94 123.33 69.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.148 179.865 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.663 ' CZ ' ' CG1' ' A' ' 114' ' ' VAL . 37.6 t80 -111.17 106.56 15.61 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.891 -179.964 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.514 HG22 ' HB2' ' A' ' 188' ' ' ALA . 20.9 t -102.82 143.4 15.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.173 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.663 ' CG1' ' CZ ' ' A' ' 112' ' ' PHE . 33.3 m -131.82 169.8 21.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.106 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 73.75 54.51 6.52 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.502 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 60.9 mt -117.31 129.96 56.23 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.84 0.352 . . . . 0.0 110.932 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 3.3 m -65.56 152.76 43.33 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.868 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 13.1 pt20 -50.9 -20.86 1.45 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.949 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 36.5 mtm180 -92.56 -42.75 9.51 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.88 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 62.8 mt -65.94 -34.74 78.8 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.948 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -62.54 85.29 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.075 179.842 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -148.48 144.09 18.13 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.626 0.727 . . . . 0.0 110.843 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.84 -42.17 3.55 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.677 2.251 . . . . 0.0 112.273 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -71.76 -44.4 64.12 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.9 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.408 HG13 ' CZ ' ' A' ' 131' ' ' TYR . 28.7 t -60.86 -43.43 95.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.119 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.417 HD12 HD11 ' A' ' 143' ' ' ILE . 84.7 mt -68.39 -39.94 81.52 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.906 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.425 ' O ' ' C ' ' A' ' 128' ' ' ARG . 6.9 tmtt? -65.23 -37.92 88.76 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.841 179.866 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . 0.425 ' C ' ' O ' ' A' ' 127' ' ' LYS . 21.1 mmt180 -36.39 144.45 0.27 Allowed Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.628 0.728 . . . . 0.0 110.9 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.8 -5.17 15.59 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.679 2.253 . . . . 0.0 112.372 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' GLU . . . . . 0.415 ' O ' ' CG ' ' A' ' 130' ' ' GLU . 20.5 tt0 -100.88 10.29 41.3 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.898 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' TYR . . . . . 0.408 ' CZ ' HG13 ' A' ' 125' ' ' VAL . 47.1 m-85 -127.54 -74.18 0.59 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.928 -179.853 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 69.7 m-85 -124.12 -11.44 7.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.862 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -71.12 -11.28 70.35 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.502 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -80.66 -30.79 36.54 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.794 0.331 . . . . 0.0 110.878 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 135' ' ' PHE . . . . . . . . . . . . . 22.9 m-85 -72.31 -26.06 61.8 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.827 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 167.41 -172.57 42.38 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.494 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 7.4 mtpm? -86.26 136.75 33.05 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.754 0.311 . . . . 0.0 110.917 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.74 HG21 HG22 ' A' ' 141' ' ' VAL . 82.5 mt -100.04 138.6 23.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.127 179.865 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -96.09 -46.51 6.45 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.848 179.878 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -141.04 141.05 34.34 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.916 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . 0.74 HG22 HG21 ' A' ' 138' ' ' ILE . 17.4 t -134.44 123.61 43.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.087 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 99.0 t -134.2 139.88 47.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.136 179.904 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . 0.417 HD11 HD12 ' A' ' 126' ' ' LEU . 44.8 mm -96.89 140.41 17.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.146 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 3.7 m120 -129.09 115.87 18.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.89 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 2.7 m120 -100.8 133.48 45.22 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.884 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 46.1 m -94.4 158.82 15.39 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.88 -179.862 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 66.2 p -93.19 143.96 25.75 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.11 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 23.3 t -72.67 143.93 47.93 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.806 -179.825 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 31.2 t80 -118.07 147.79 42.92 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.945 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -56.22 146.98 21.88 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.069 179.896 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 78.98 -14.82 12.14 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.455 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 16.3 m -106.6 132.31 52.75 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.824 0.345 . . . . 0.0 110.847 -179.745 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 27.0 mp0 -116.92 138.81 51.29 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.901 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 74.49 83.11 0.38 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.509 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.82 162.53 41.74 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.651 2.234 . . . . 0.0 112.302 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 94.0 p -126.93 134.98 50.31 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.852 -179.825 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -98.31 145.69 26.42 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.094 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 80.5 p -115.15 173.65 6.39 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.87 -179.762 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -153.68 140.79 19.4 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.119 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 160' ' ' TYR . . . . . 0.407 ' HD1' HD11 ' A' ' 110' ' ' LEU . 89.0 m-85 -111.38 123.47 50.28 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.933 -179.883 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 9.7 t -123.53 139.05 51.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.092 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 58.0 m -108.41 128.6 54.92 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.117 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 163' ' ' TYR . . . . . 0.547 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 25.3 m-85 -108.45 138.65 44.4 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.891 -179.892 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 50.7 mt -64.32 -38.11 81.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.123 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 32.6 mtm180 -103.85 114.14 28.17 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.889 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 46.9 m -51.9 -51.91 53.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.846 -179.762 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -50.91 -57.57 8.17 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.899 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -46.84 -45.58 20.29 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.888 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 169' ' ' ALA . . . . . 0.547 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -61.18 -54.49 43.72 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.12 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 87.5 mt -44.2 -63.75 0.81 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.898 -179.915 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 10.5 mtp180 -54.09 -46.66 72.12 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.887 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . 0.681 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -51.04 -33.26 24.59 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.121 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 173' ' ' ILE . . . . . 0.775 HD11 HG22 ' A' ' 111' ' ' VAL . 77.5 mt -78.26 -39.08 24.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.084 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 3.5 mp0 -68.47 -24.3 64.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.916 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 91.9 m -93.77 -27.89 16.23 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.862 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 176' ' ' VAL . . . . . 0.681 HG23 ' O ' ' A' ' 172' ' ' ALA . 10.6 t -74.23 -30.78 27.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.135 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -66.82 146.13 54.75 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.909 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 35.6 t30 57.83 46.31 17.14 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.88 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 91.5 t -124.91 133.42 69.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.117 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 88.2 t -96.52 114.55 33.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.13 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 96.4 t -123.29 106.22 17.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.188 179.885 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 23.8 t0 58.0 39.8 26.1 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.88 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 73.53 37.36 53.13 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.509 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 3.4 mmp_? -140.99 132.01 26.19 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.919 0.39 . . . . 0.0 110.821 -179.822 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 17.1 m -87.99 96.03 10.35 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.171 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 59.6 mt -69.94 124.32 23.75 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.869 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 17.3 tptp -123.53 113.11 18.29 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.851 179.845 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . 0.514 ' HB2' HG22 ' A' ' 113' ' ' VAL . . . -111.95 148.18 34.3 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.105 179.821 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 8.6 t -150.83 170.9 18.15 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.902 -179.789 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 190' ' ' LEU . . . . . 0.879 HD23 ' N ' ' A' ' 191' ' ' GLY . 5.8 tt -131.17 141.54 50.09 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.945 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 191' ' ' GLY . . . . . 0.879 ' N ' HD23 ' A' ' 190' ' ' LEU . . . 102.27 -24.21 31.83 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.505 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 192' ' ' THR . . . . . . . . . . . . . 27.6 p -88.37 117.15 27.09 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.864 0.364 . . . . 0.0 111.168 -179.873 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 193' ' ' THR . . . . . . . . . . . . . 33.5 p -118.68 169.03 10.16 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.156 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 15.3 ttpt -66.43 118.42 10.05 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.933 179.881 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 195' ' ' TYR . . . . . . . . . . . . . 88.3 t80 -77.27 127.92 33.44 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.904 -179.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 196' ' ' CYS . . . . . . . . . . . . . 4.9 t -174.27 137.97 0.55 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.899 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 31.7 t -43.4 152.46 0.13 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.849 -179.742 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 198' ' ' TYR . . . . . . . . . . . . . 7.9 p90 -103.14 148.28 25.96 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.902 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 54.5 m -98.55 111.76 24.02 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.912 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . 80.59 174.92 48.73 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.455 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 201' ' ' PRO . . . . . 0.437 ' O ' ' C ' ' A' ' 202' ' ' SER . 53.8 Cg_endo -69.8 164.7 78.68 Favored 'Cis proline' 0 C--N 1.342 0.185 0 C-N-CA 122.672 -1.803 . . . . 0.0 112.354 0.097 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 202' ' ' SER . . . . . 0.437 ' C ' ' O ' ' A' ' 201' ' ' PRO . 6.0 t -35.16 107.86 0.06 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.858 -179.825 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 73.2 p -100.87 137.93 38.6 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.848 -179.814 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.347 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.505 -179.967 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.344 0 N-CA-C 112.481 -0.248 . . . . 0.0 112.481 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 7.8 t -152.82 139.13 18.46 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.869 0.366 . . . . 0.0 110.868 -179.738 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 18.7 m -118.99 175.47 5.75 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.824 -179.841 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 169.04 114.85 0.31 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.492 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.6 t -155.98 127.77 7.38 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.88 0.371 . . . . 0.0 110.902 -179.73 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 19.3 t -79.59 167.72 20.36 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.839 -179.792 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -143.77 56.58 0.55 Allowed Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.469 -179.955 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -87.04 144.11 27.04 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.821 0.343 . . . . 0.0 111.091 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 2.8 t -72.5 -46.0 56.79 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.888 -179.806 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -94.34 140.7 16.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.081 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 17.2 mtt180 -110.19 105.35 14.39 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.885 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 93.7 t -115.74 141.24 33.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.095 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 34.0 m -90.16 148.57 4.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.127 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 10.3 tt0 -156.66 122.08 4.73 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.932 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.502 ' HB3' HD21 ' A' ' 170' ' ' LEU . 3.3 mppt? -103.98 -27.37 12.19 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.953 179.929 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 40.9 t30 -88.25 42.31 1.06 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.908 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 13.8 tp -143.42 117.55 9.51 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.941 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 59.1 t -96.79 118.61 43.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.108 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.654 ' CD1' ' CE2' ' A' ' 160' ' ' TYR . 45.3 t80 -119.29 111.61 18.41 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.889 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.534 HG22 ' HB2' ' A' ' 188' ' ' ALA . 23.1 t -107.01 140.78 24.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.098 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 5.1 m -120.06 169.38 11.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.09 179.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 67.26 53.89 23.28 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.505 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 38.3 mt -112.81 127.17 56.09 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.834 0.35 . . . . 0.0 110.915 -179.92 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . 0.495 ' O ' ' N ' ' A' ' 120' ' ' LEU . 18.8 t -65.64 125.91 26.74 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.874 -179.902 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' GLN . . . . . 0.438 ' C ' ' O ' ' A' ' 117' ' ' SER . 8.5 mm-40 -34.93 -32.46 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.882 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.494 ' N ' ' O ' ' A' ' 117' ' ' SER . 24.7 ttm180 -72.07 -48.14 46.4 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.863 -179.916 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . 0.495 ' N ' ' O ' ' A' ' 117' ' ' SER . 84.1 mt -70.2 -35.56 74.0 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.951 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -61.68 87.17 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.062 179.79 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' ASP . . . . . 0.431 ' HB2' ' CG2' ' A' ' 125' ' ' VAL . 5.9 m-20 -147.59 152.67 42.14 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.609 0.719 . . . . 0.0 110.847 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . 0.466 ' HA ' HG11 ' A' ' 141' ' ' VAL . 53.8 Cg_endo -69.72 -50.18 0.49 Allowed 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.674 2.25 . . . . 0.0 112.376 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 25.3 mt-10 -71.49 -42.34 68.19 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.911 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.486 HG12 ' CE2' ' A' ' 131' ' ' TYR . 48.2 t -57.08 -53.59 41.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.116 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 87.7 mt -68.25 -30.82 69.94 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.941 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 13.8 mmtt -64.95 -39.31 93.3 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.903 179.807 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 32.5 mtt180 -39.75 143.93 0.54 Allowed Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.648 0.737 . . . . 0.0 110.874 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 -1.15 7.99 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.652 2.235 . . . . 0.0 112.354 -179.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -101.51 -24.54 14.14 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.864 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' TYR . . . . . 0.486 ' CE2' HG12 ' A' ' 125' ' ' VAL . 43.9 m-85 -87.35 -74.67 0.43 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.933 -179.868 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 16.0 m-85 -118.81 -40.51 2.86 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.858 -179.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -44.9 -20.89 0.26 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.45 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.421 ' C ' ' HD3' ' A' ' 134' ' ' LYS . 0.0 OUTLIER -54.52 -37.55 65.5 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.834 0.35 . . . . 0.0 110.919 -179.988 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 135' ' ' PHE . . . . . . . . . . . . . 22.2 m-85 -66.23 -44.12 84.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.865 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -176.31 -153.55 10.71 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.447 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 38.7 mtmt -97.42 108.31 21.01 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.779 0.323 . . . . 0.0 110.937 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.541 HG23 HG13 ' A' ' 161' ' ' VAL . 91.6 mt -69.7 142.88 15.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.156 179.883 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 3.0 t-160 -102.16 -56.37 2.28 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.885 179.877 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 33.4 tttt -119.01 151.48 38.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.905 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . 0.467 HG22 HG21 ' A' ' 138' ' ' ILE . 41.4 t -143.05 108.85 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.155 179.849 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 96.9 t -115.82 126.94 73.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.158 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 26.7 mm -106.3 109.28 27.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.111 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 144' ' ' ASN . . . . . 0.485 ' O ' ' HB1' ' A' ' 157' ' ' ALA . 3.2 t-20 -96.06 137.14 35.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.881 179.934 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 1.5 p30 -134.45 159.06 42.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.842 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 23.0 t -96.36 163.73 12.94 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.881 -179.889 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 64.6 p -125.07 91.3 3.4 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.136 -179.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 1.3 t -115.86 155.62 27.6 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.83 -179.832 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 34.8 t80 -72.73 153.35 41.19 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.939 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -50.04 167.45 0.05 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.125 179.891 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 70.13 38.01 72.77 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.508 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 26.0 t -108.52 170.16 8.2 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.837 0.351 . . . . 0.0 110.861 -179.712 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 43.5 mt-30 -83.04 38.37 0.59 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.927 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 43.8 83.23 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.541 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.75 161.99 43.81 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.688 2.259 . . . . 0.0 112.334 -179.895 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 23.2 m -99.66 164.89 11.87 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.856 -179.836 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . 0.485 ' HB1' ' O ' ' A' ' 144' ' ' ASN . . . -119.74 171.99 8.01 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.108 179.884 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 67.7 p -123.31 169.64 11.11 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.875 -179.796 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -147.64 149.76 33.11 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.108 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 160' ' ' TYR . . . . . 0.654 ' CE2' ' CD1' ' A' ' 112' ' ' PHE . 43.4 m-85 -124.26 124.75 43.1 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.901 -179.847 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.541 HG13 HG23 ' A' ' 138' ' ' ILE . 57.4 t -120.39 125.32 74.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.174 179.883 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 48.7 m -93.47 131.28 38.84 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.143 -179.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 163' ' ' TYR . . . . . 0.469 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 9.5 m-85 -107.35 147.15 30.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.892 -179.89 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 48.2 mt -75.29 -47.53 34.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.128 179.916 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 35.1 mtp180 -91.54 114.23 26.71 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.856 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 75.5 m -49.35 -59.4 3.74 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.867 -179.814 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 55.8 mt-10 -47.96 -47.44 32.71 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.908 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -55.34 -45.85 76.39 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.881 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 169' ' ' ALA . . . . . 0.469 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -56.93 -56.63 19.17 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.1 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . 0.502 HD21 ' HB3' ' A' ' 108' ' ' LYS . 56.0 mt -47.26 -59.86 2.88 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.891 -179.941 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 1.9 mpt_? -56.68 -42.51 79.16 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.866 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . 0.737 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -55.24 -32.09 62.02 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.101 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 76.7 mt -79.78 -37.99 18.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.112 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 8.6 mm100 -64.66 -28.67 69.77 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.862 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 19.8 t -93.74 -28.95 15.64 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.852 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 176' ' ' VAL . . . . . 0.737 HG23 ' O ' ' A' ' 172' ' ' ALA . 9.9 t -71.7 -28.07 29.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.124 -179.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 1.8 t30 -70.76 141.61 51.45 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.895 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 25.7 t-20 61.35 49.33 5.41 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.923 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 179' ' ' VAL . . . . . 0.425 HG12 HG23 ' A' ' 181' ' ' VAL . 79.5 t -117.0 133.66 63.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.131 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 58.7 t -98.16 105.97 18.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.14 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . 0.593 HG21 HD12 ' A' ' 186' ' ' LEU . 56.3 t -115.73 131.2 68.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.189 179.862 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 44.96 29.05 0.42 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.856 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 80.39 31.46 37.52 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.737 -0.745 . . . . 0.0 112.471 -179.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 13.2 ttm180 -134.9 136.14 42.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.855 0.359 . . . . 0.0 110.888 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 26.5 m -82.69 99.51 9.66 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.162 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 186' ' ' LEU . . . . . 0.593 HD12 HG21 ' A' ' 181' ' ' VAL . 62.9 mt -84.29 140.48 31.61 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.942 179.957 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 9.4 ttpp -135.19 146.83 49.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.877 179.828 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . 0.534 ' HB2' HG22 ' A' ' 113' ' ' VAL . . . -134.29 155.47 50.14 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.075 179.842 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 8.8 t -155.59 164.18 38.98 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.835 -179.807 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 190' ' ' LEU . . . . . 0.489 ' O ' HD12 ' A' ' 190' ' ' LEU . 4.7 pp -130.07 147.57 51.83 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.956 179.943 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 107.04 26.88 5.58 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.533 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 192' ' ' THR . . . . . . . . . . . . . 24.3 m -88.69 137.27 32.47 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.902 0.382 . . . . 0.0 111.087 -179.835 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 193' ' ' THR . . . . . . . . . . . . . 26.4 m -83.32 137.18 34.09 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.141 179.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 7.0 tmtm? -109.67 125.77 52.97 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.926 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 195' ' ' TYR . . . . . . . . . . . . . 35.3 t80 -62.97 88.88 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.885 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 196' ' ' CYS . . . . . . . . . . . . . 91.0 m -57.33 152.48 14.09 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.897 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 5.0 t -121.66 93.81 4.12 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.837 -179.737 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 198' ' ' TYR . . . . . . . . . . . . . 34.0 t80 -69.5 131.15 44.26 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.938 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 25.9 m -107.03 -66.4 1.02 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.869 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . 171.68 -163.96 36.63 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.535 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 201' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 129.23 14.06 Favored 'Cis proline' 0 C--N 1.342 0.193 0 C-N-CA 122.645 -1.815 . . . . 0.0 112.321 0.108 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 202' ' ' SER . . . . . . . . . . . . . 47.8 t -87.04 145.82 26.33 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.836 -179.848 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 88.5 p -76.35 135.27 39.53 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.879 -179.824 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.345 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.497 -179.967 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.362 0 N-CA-C 112.487 -0.245 . . . . 0.0 112.487 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 48.7 m -73.01 87.57 1.35 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.86 0.362 . . . . 0.0 110.85 -179.73 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 21.7 t -140.79 143.7 35.02 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.874 -179.839 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -116.62 76.53 0.28 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.458 -179.949 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 87.9 p -155.42 139.83 16.78 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.874 0.368 . . . . 0.0 110.824 -179.708 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 32.3 t -82.51 158.61 23.1 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.856 -179.835 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -144.05 71.43 0.38 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.534 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -91.2 155.26 18.72 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.781 0.324 . . . . 0.0 111.131 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 17.1 m -114.49 134.93 54.65 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.876 -179.778 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 74.9 t -109.03 116.61 52.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.126 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 85.3 mtt180 -109.95 137.88 47.11 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.896 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 4.6 m -76.01 122.96 31.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.14 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 0.451 HG12 ' HG2' ' A' ' 107' ' ' GLN . 52.5 t -109.7 101.79 13.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.131 179.905 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.451 ' HG2' HG12 ' A' ' 106' ' ' VAL . 26.8 pt20 34.43 42.14 0.06 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.924 179.982 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.408 ' HB3' HD13 ' A' ' 190' ' ' LEU . 64.9 mttt -86.57 51.25 2.18 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.909 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 12.0 p-10 -112.41 27.54 9.56 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.91 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . 0.472 HD11 ' HB3' ' A' ' 160' ' ' TYR . 15.3 tp -109.27 121.7 45.74 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.878 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 89.6 t -95.58 114.12 31.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.112 179.819 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.638 ' CE2' ' CG1' ' A' ' 114' ' ' VAL . 61.1 t80 -106.86 99.25 8.83 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.901 179.98 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.663 HG22 ' HB2' ' A' ' 188' ' ' ALA . 54.3 t -98.94 125.36 52.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.149 179.997 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.638 ' CG1' ' CE2' ' A' ' 112' ' ' PHE . 12.0 m -118.89 168.88 10.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.126 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 77.39 39.52 26.02 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.505 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 32.5 mt -105.92 137.9 43.02 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.822 0.344 . . . . 0.0 110.89 -179.909 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 78.6 p -76.58 148.14 37.2 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.842 -179.941 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 34.5 mm-40 -42.2 -34.96 0.84 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.898 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 33.0 mtt180 -69.01 -47.47 65.39 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.872 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . 0.865 HD21 ' OD2' ' A' ' 182' ' ' ASP . 85.0 mt -71.78 -24.68 61.79 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.928 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -71.29 83.49 0.76 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.105 179.807 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 19.6 m-20 -148.95 144.38 18.07 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.619 0.723 . . . . 0.0 110.845 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.8 -45.67 1.48 Allowed 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.662 2.242 . . . . 0.0 112.38 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 19.9 mt-10 -73.19 -42.6 62.51 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.885 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.414 ' O ' ' CD1' ' A' ' 131' ' ' TYR . 56.4 t -59.04 -46.3 91.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.157 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 74.1 mt -68.69 -37.56 79.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.959 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 12.8 ttmm -68.0 -35.77 78.87 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.9 179.804 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 66.4 mtt-85 -44.89 147.91 1.05 Allowed Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.59 0.709 . . . . 0.0 110.882 180.0 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.71 -3.19 11.49 Favored 'Trans proline' 0 N--CA 1.465 -0.163 0 C-N-CA 122.711 2.274 . . . . 0.0 112.367 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -97.93 6.39 47.77 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.897 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' TYR . . . . . 0.414 ' CD1' ' O ' ' A' ' 125' ' ' VAL . 63.0 m-85 -131.32 -73.84 0.53 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.938 -179.858 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 71.0 m-85 -127.06 -6.04 6.1 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.901 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -70.9 -18.92 76.57 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.515 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 11.2 ptpt -88.72 -27.25 21.33 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.857 0.36 . . . . 0.0 110.893 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 135' ' ' PHE . . . . . . . . . . . . . 27.9 m-85 -63.97 -43.65 95.11 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.85 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -177.43 167.55 38.69 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.482 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 27.1 mtmm -67.06 120.06 13.05 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.728 0.299 . . . . 0.0 110.87 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.458 HG12 ' CG1' ' A' ' 161' ' ' VAL . 83.3 mt -95.12 146.43 6.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.074 179.892 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 4.2 t60 -107.13 -59.94 1.75 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.843 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 27.5 ttpp -125.53 145.63 50.02 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.913 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 21.3 t -130.19 132.79 64.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.129 179.847 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 3.5 t -125.96 140.73 47.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.13 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 23.8 mm -119.4 121.66 67.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.162 179.907 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 7.1 m-80 -116.57 105.58 12.61 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.907 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -92.03 165.83 12.98 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.878 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 25.2 p -68.43 120.08 13.95 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.882 -179.861 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 62.4 m -78.96 -58.85 3.03 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.168 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 36.9 t -76.34 128.09 34.17 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.894 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 50.0 m-85 -83.78 126.63 33.11 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.904 -179.856 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -85.25 -68.23 0.74 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.119 179.862 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 103.23 -19.6 45.44 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.497 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 57.6 m -109.47 -58.79 1.99 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.832 0.349 . . . . 0.0 110.834 -179.721 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 6.3 pt20 -88.46 152.48 21.86 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.906 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . -69.34 146.12 43.64 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.502 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 150.49 68.2 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.71 2.273 . . . . 0.0 112.32 -179.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 19.7 m -131.55 105.93 7.87 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.868 -179.849 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -84.38 167.18 16.74 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.107 179.902 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 95.8 p -142.51 162.53 35.22 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.869 -179.765 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -145.88 141.88 28.26 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.116 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 160' ' ' TYR . . . . . 0.472 ' HB3' HD11 ' A' ' 110' ' ' LEU . 15.2 m-85 -115.19 112.6 22.74 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.95 -179.88 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.458 ' CG1' HG12 ' A' ' 138' ' ' ILE . 94.6 t -106.64 133.69 50.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.146 179.911 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 9.1 m -102.66 125.61 49.45 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.159 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 163' ' ' TYR . . . . . 0.489 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 13.8 m-85 -103.53 136.5 43.13 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.909 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 89.3 mt -63.85 -49.69 80.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.108 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 28.3 mmt180 -100.72 119.16 38.2 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.894 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 4.1 m -50.09 -57.61 7.3 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.848 -179.787 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -41.18 -61.48 1.0 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.886 -179.933 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 31.3 m-20 -46.65 -46.15 19.69 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.857 179.998 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 169' ' ' ALA . . . . . 0.489 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -57.86 -55.48 34.41 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.059 179.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 71.7 mt -45.0 -59.72 2.44 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.917 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 13.9 mtm180 -53.94 -53.18 56.33 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.84 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . 0.521 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -45.03 -34.83 2.67 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.118 179.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 96.4 mt -81.67 -32.15 11.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.122 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 73.0 mt-30 -66.76 -27.33 67.51 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.874 -179.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 1.8 t -93.81 -35.88 12.53 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.867 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 176' ' ' VAL . . . . . 0.521 HG23 ' O ' ' A' ' 172' ' ' ALA . 10.7 t -64.84 -45.84 93.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.113 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -51.79 144.98 10.27 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.895 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 41.6 m-20 57.61 53.43 7.28 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.882 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 179' ' ' VAL . . . . . 0.675 ' O ' HG23 ' A' ' 185' ' ' THR . 78.6 t -134.59 138.57 49.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.168 179.879 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 66.6 t -92.49 124.18 44.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.123 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 60.0 t -135.37 126.89 45.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.103 179.933 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 182' ' ' ASP . . . . . 0.865 ' OD2' HD21 ' A' ' 120' ' ' LEU . 4.4 m-20 59.29 25.47 14.11 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.85 179.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 90.21 -18.04 50.59 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.464 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 15.3 ptm180 -117.33 129.66 56.02 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.923 0.392 . . . . 0.0 110.849 -179.861 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 185' ' ' THR . . . . . 0.675 HG23 ' O ' ' A' ' 179' ' ' VAL . 51.3 m -71.48 138.89 49.33 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.154 -179.896 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 54.6 mt -105.53 143.65 33.39 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.884 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -115.11 117.14 29.72 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.905 179.841 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . 0.663 ' HB2' HG22 ' A' ' 113' ' ' VAL . . . -114.96 127.68 55.83 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.065 179.857 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 4.3 t -136.6 173.78 11.33 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.848 -179.771 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 190' ' ' LEU . . . . . 0.514 HD12 ' O ' ' A' ' 190' ' ' LEU . 3.6 pp -130.29 160.95 32.37 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.929 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 59.34 30.98 68.76 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.453 179.878 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 192' ' ' THR . . . . . . . . . . . . . 82.5 p -90.01 131.43 35.9 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.91 0.386 . . . . 0.0 111.091 -179.847 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 193' ' ' THR . . . . . . . . . . . . . 11.2 m -124.81 141.03 52.39 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.118 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -70.42 167.67 17.74 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.916 179.909 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 195' ' ' TYR . . . . . . . . . . . . . 76.8 m-85 -67.63 123.74 21.32 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.978 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 196' ' ' CYS . . . . . . . . . . . . . 7.2 t -159.18 164.95 34.69 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.846 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 1.4 t -72.04 106.85 4.46 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.906 -179.765 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 198' ' ' TYR . . . . . . . . . . . . . 10.2 p90 -173.69 141.05 0.81 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.944 -179.847 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 2.2 m -123.99 172.19 9.15 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.864 -179.853 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . 78.13 -163.15 50.46 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.453 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 201' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 149.57 88.76 Favored 'Cis proline' 0 C--O 1.232 0.188 0 C-N-CA 122.68 -1.8 . . . . 0.0 112.367 0.013 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 202' ' ' SER . . . . . . . . . . . . . 54.8 p -85.3 177.9 7.67 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.868 -179.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 70.7 p -149.01 144.91 27.05 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.854 -179.802 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.348 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.503 -179.977 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.304 0 N-CA-C 112.475 -0.25 . . . . 0.0 112.475 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 33.3 t -62.94 112.91 2.78 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.846 0.355 . . . . 0.0 110.866 -179.75 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 3.9 m -81.67 85.62 6.54 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.843 -179.798 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -101.06 159.04 18.94 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.444 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.8 m -51.65 178.37 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.867 0.365 . . . . 0.0 110.894 -179.766 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 25.6 t -102.65 -58.84 1.8 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.894 -179.837 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 80.65 130.11 0.93 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.497 180.0 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -104.91 117.94 35.28 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.803 0.335 . . . . 0.0 111.109 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 7.8 t -153.2 159.18 42.61 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.902 -179.788 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.592 ' O ' HG13 ' A' ' 103' ' ' VAL . 6.2 p -86.56 117.61 31.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.148 179.962 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 28.3 ptt180 -117.99 145.03 45.03 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.897 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 12.1 p -90.18 144.3 9.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.085 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 0.454 ' O ' HG23 ' A' ' 106' ' ' VAL . 33.8 m -84.23 124.25 39.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.11 179.9 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 8.3 tt0 -159.32 105.13 1.68 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.881 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 40.1 pttt -91.82 -26.18 18.64 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.915 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . 0.428 ' CG ' ' O ' ' A' ' 109' ' ' ASN . 8.6 t-20 -89.51 40.02 0.97 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.879 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 33.6 tp -141.16 118.21 11.23 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.883 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.4 HG22 HD11 ' A' ' 173' ' ' ILE . 95.3 t -100.58 103.39 14.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.085 179.858 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.598 ' CD1' ' CE2' ' A' ' 160' ' ' TYR . 39.1 t80 -101.69 113.24 26.22 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.864 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.67 HG22 ' HB2' ' A' ' 188' ' ' ALA . 40.1 t -112.87 126.51 70.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.126 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.414 ' CG1' ' CE2' ' A' ' 112' ' ' PHE . 17.3 m -111.83 166.36 6.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.16 179.924 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 78.68 43.15 12.24 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.435 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 49.4 mt -112.99 118.26 34.34 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.828 0.347 . . . . 0.0 110.889 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 2.8 p -65.53 143.36 57.69 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.835 -179.908 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 65.8 mm-40 -39.85 -34.82 0.29 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.917 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 59.8 ttt180 -69.02 -49.06 61.06 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.891 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 61.7 mt -72.63 -20.55 61.25 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.929 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -78.53 83.26 4.73 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.083 179.799 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 17.0 m-20 -148.54 149.24 30.78 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-O 121.572 0.701 . . . . 0.0 110.887 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 -48.59 0.69 Allowed 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.664 2.243 . . . . 0.0 112.39 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 44.7 mm-40 -67.0 -42.07 85.64 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.885 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.529 HG13 ' CZ ' ' A' ' 131' ' ' TYR . 38.1 t -59.82 -47.34 91.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.107 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 94.6 mt -71.58 -32.73 68.4 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.927 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 68.2 mttt -67.19 -30.26 70.15 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.896 179.836 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 9.9 mmp_? -50.23 144.29 11.63 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.577 0.703 . . . . 0.0 110.884 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 0.01 6.29 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.669 2.246 . . . . 0.0 112.365 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 35.3 tt0 -101.05 -7.71 22.99 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.877 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' TYR . . . . . 0.529 ' CZ ' HG13 ' A' ' 125' ' ' VAL . 41.5 m-85 -111.96 -72.88 0.69 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.932 -179.871 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 33.4 m-85 -124.42 -21.67 4.86 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.869 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -52.57 -24.36 17.43 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.479 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 14.6 ptpt -90.49 -16.9 28.06 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.77 0.319 . . . . 0.0 110.848 -179.932 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 135' ' ' PHE . . . . . . . . . . . . . 15.5 m-85 -79.15 -29.11 42.91 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.858 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 172.05 168.33 33.38 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.479 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 7.2 mtmp? -75.67 101.27 4.93 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.806 0.336 . . . . 0.0 110.92 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.625 HG23 HG13 ' A' ' 161' ' ' VAL . 81.7 mt -68.64 134.09 30.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.145 179.9 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 2.3 t-160 -103.68 -50.7 3.35 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.859 179.893 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 51.8 tttt -134.0 132.13 39.74 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.906 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . 0.573 ' CG2' HG21 ' A' ' 138' ' ' ILE . 49.1 t -120.11 133.23 67.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.113 179.923 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 99.6 t -129.88 129.42 65.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.115 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 19.0 mm -107.31 119.36 56.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.139 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 7.7 m120 -111.33 101.34 9.82 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.859 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 9.1 p-10 -82.64 171.47 14.0 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.9 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 1.3 t -68.21 149.66 49.25 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.837 -179.821 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 40.6 p -121.8 40.79 3.53 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.185 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 1.8 t -112.46 157.73 20.73 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.894 -179.859 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 56.7 t80 -61.43 148.8 40.52 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.933 -179.854 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -57.79 143.6 41.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.124 179.875 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 97.63 37.94 4.34 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.453 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 2.1 m -90.57 170.73 9.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.798 0.332 . . . . 0.0 110.883 -179.742 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 2.7 mp0 -121.6 85.09 2.35 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.908 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 114.08 74.27 0.62 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.514 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 124.12 10.78 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.71 2.273 . . . . 0.0 112.301 -179.939 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 17.5 m -136.63 128.6 29.37 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.859 -179.877 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -123.85 169.43 11.58 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.081 179.897 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . 0.4 ' HB3' ' CE1' ' A' ' 112' ' ' PHE . 20.3 m -137.53 164.51 28.55 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.882 -179.804 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -142.95 140.08 30.95 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.128 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 160' ' ' TYR . . . . . 0.598 ' CE2' ' CD1' ' A' ' 112' ' ' PHE . 33.6 m-85 -113.7 116.71 29.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.933 -179.842 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.625 HG13 HG23 ' A' ' 138' ' ' ILE . 98.0 t -116.58 139.62 42.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.111 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 29.9 m -106.03 129.12 54.2 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.126 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 3.7 m-85 -109.51 148.28 31.48 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.982 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 49.0 mt -76.45 -61.06 1.83 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.139 179.918 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 59.4 mtt180 -82.25 99.08 9.1 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.82 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 50.7 m -42.01 -53.34 3.92 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.878 -179.853 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 3.6 pt-20 -40.73 -59.34 1.42 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.906 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -56.7 -35.14 68.14 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.869 179.923 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -65.4 -60.18 3.23 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.122 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 39.6 mt -45.85 -51.76 12.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.903 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 2.2 mpt_? -61.07 -43.83 98.3 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.808 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . 0.617 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -54.89 -31.81 60.27 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.134 179.915 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 173' ' ' ILE . . . . . 0.4 HD11 HG22 ' A' ' 111' ' ' VAL . 63.0 mt -81.16 -38.42 16.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.135 179.987 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 31.4 mm-40 -69.69 -22.09 63.45 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.935 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 3.4 t -93.8 -34.75 13.05 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.906 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 176' ' ' VAL . . . . . 0.617 HG23 ' O ' ' A' ' 172' ' ' ALA . 10.5 t -66.79 -38.17 80.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.081 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 1.7 t30 -63.34 140.57 58.89 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.874 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 25.5 t30 71.81 35.21 1.41 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.856 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 89.4 t -119.54 131.56 71.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.122 179.892 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 82.7 t -95.62 102.56 13.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.09 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 53.7 t -111.07 117.57 55.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.167 179.877 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 15.2 m-20 48.8 48.99 19.67 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.828 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 63.15 28.4 72.11 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.452 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 12.2 mtt85 -138.07 111.27 7.9 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.86 0.362 . . . . 0.0 110.89 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 36.5 m -70.63 101.21 1.99 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.126 -179.945 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 11.9 mt -68.45 129.6 40.4 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.914 179.928 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 22.9 tptm -124.85 120.55 32.03 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.932 179.816 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . 0.67 ' HB2' HG22 ' A' ' 113' ' ' VAL . . . -119.82 151.82 38.24 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.127 179.857 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 8.6 t -158.38 164.01 36.72 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.849 -179.718 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 190' ' ' LEU . . . . . 0.844 ' O ' HD12 ' A' ' 190' ' ' LEU . 4.1 pp -128.18 130.3 47.83 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.897 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 106.36 27.95 5.36 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.478 179.879 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 192' ' ' THR . . . . . 0.529 HG21 ' CD2' ' A' ' 112' ' ' PHE . 14.7 t -92.09 155.82 17.8 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.878 0.37 . . . . 0.0 111.124 -179.845 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 193' ' ' THR . . . . . . . . . . . . . 23.2 m -96.1 116.58 29.2 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.148 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 12.1 ptpt -102.83 -27.77 12.47 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.873 179.887 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 195' ' ' TYR . . . . . . . . . . . . . 3.3 t80 -171.65 135.31 0.88 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.926 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 196' ' ' CYS . . . . . . . . . . . . . 21.1 t -95.46 84.68 4.04 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.882 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 3.6 m -164.26 167.08 20.35 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.875 -179.732 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 198' ' ' TYR . . . . . . . . . . . . . 23.7 t80 -115.6 116.9 28.93 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.923 -179.892 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 81.4 p -173.95 140.05 0.7 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.84 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . -66.92 -165.14 2.15 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.535 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 201' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.8 122.29 5.99 Favored 'Cis proline' 0 C--N 1.341 0.169 0 C-N-CA 122.689 -1.796 . . . . 0.0 112.313 0.061 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 202' ' ' SER . . . . . . . . . . . . . 21.9 m -91.68 163.46 14.09 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.845 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 9.6 m -115.69 -56.47 2.33 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.795 -179.781 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.283 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.462 -179.96 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.327 0 N-CA-C 112.515 -0.234 . . . . 0.0 112.515 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 97.4 p -114.94 106.99 14.8 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.857 0.36 . . . . 0.0 110.865 -179.745 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 1.9 m -65.21 133.44 51.5 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.843 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 66.56 150.18 0.12 Allowed Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.506 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 18.5 t -39.63 -59.51 1.12 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.878 0.37 . . . . 0.0 110.844 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 2.9 m -129.83 145.4 51.58 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.86 -179.776 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 80.37 107.65 0.28 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.5 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -74.83 154.33 38.33 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.765 0.316 . . . . 0.0 111.082 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 64.6 m -132.5 137.61 47.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.839 -179.818 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 34.4 m -75.78 148.49 7.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.145 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 34.8 mtp85 -120.17 98.31 6.01 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.902 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 87.5 t -115.8 100.69 10.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.172 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 0.415 HG21 ' HD2' ' A' ' 108' ' ' LYS . 8.0 p -114.34 131.76 65.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.131 179.907 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 13.7 tt0 -87.3 46.8 1.42 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.918 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.415 ' HD2' HG21 ' A' ' 106' ' ' VAL . 75.7 mttt -101.24 44.88 0.99 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.893 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 4.9 p-10 -110.41 50.55 0.8 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.878 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 11.2 tp -128.77 121.06 27.55 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.902 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 98.8 t -94.64 130.11 43.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.116 179.85 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.418 ' CZ ' HG12 ' A' ' 114' ' ' VAL . 40.5 t80 -128.95 98.23 4.88 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.893 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.699 HG22 ' HB2' ' A' ' 188' ' ' ALA . 54.0 t -92.76 135.75 26.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.177 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.418 HG12 ' CZ ' ' A' ' 112' ' ' PHE . 4.7 m -124.96 164.4 23.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.12 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 76.28 47.85 10.26 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.518 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . 0.56 HD23 HD22 ' A' ' 186' ' ' LEU . 59.8 mt -108.3 130.87 55.17 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.812 0.339 . . . . 0.0 110.929 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 14.0 m -69.21 155.4 40.47 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.902 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 40.8 mt-30 -46.84 -38.07 9.73 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.915 -179.927 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 19.6 tpt180 -74.66 -50.74 16.55 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.869 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 37.0 mt -62.15 -19.09 62.69 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.904 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -76.68 83.9 3.32 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.098 179.782 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -148.66 144.02 17.91 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.639 0.733 . . . . 0.0 110.865 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 -50.78 0.43 Allowed 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.694 2.263 . . . . 0.0 112.341 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 22.1 pt-20 -67.35 -38.36 84.7 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.87 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 84.2 t -63.62 -42.85 97.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.084 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.689 HD12 HD11 ' A' ' 143' ' ' ILE . 47.9 mt -72.02 -32.82 67.52 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.899 179.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 25.0 tttm -74.44 -29.94 61.69 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.914 179.849 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 49.8 mtp180 -47.11 148.8 1.87 Allowed Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.571 0.7 . . . . 0.0 110.882 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 -2.1 9.61 Favored 'Trans proline' 0 C--N 1.341 0.138 0 C-N-CA 122.665 2.243 . . . . 0.0 112.308 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 4.0 tp10 -91.83 -23.53 19.65 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.834 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' TYR . . . . . . . . . . . . . 26.0 m-85 -103.34 -69.55 0.79 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.913 -179.826 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.434 ' O ' ' N ' ' A' ' 135' ' ' PHE . 87.8 m-85 -126.23 -27.9 3.17 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.887 -179.971 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -43.87 -22.23 0.27 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.536 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.4 ' N ' ' O ' ' A' ' 132' ' ' PHE . 16.7 ptpt -85.09 -34.41 22.22 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.801 0.334 . . . . 0.0 110.865 -179.949 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 135' ' ' PHE . . . . . 0.488 ' CE2' HG23 ' A' ' 176' ' ' VAL . 12.9 m-85 -56.3 -39.26 72.42 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.857 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 178.77 -176.19 47.83 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.494 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 13.9 tttt -87.87 111.41 21.39 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.724 0.297 . . . . 0.0 110.902 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.495 HG21 HG22 ' A' ' 141' ' ' VAL . 61.5 mt -83.47 144.7 9.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.174 179.849 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 2.2 t60 -102.32 -44.27 5.45 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.851 179.915 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 24.1 ttpp -138.72 145.73 40.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.909 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . 0.495 HG22 HG21 ' A' ' 138' ' ' ILE . 21.2 t -131.0 129.38 63.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.174 179.848 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 46.6 t -125.78 140.2 49.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.16 179.93 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . 0.689 HD11 HD12 ' A' ' 126' ' ' LEU . 20.0 mm -121.92 126.83 75.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.176 179.883 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 19.0 m-20 -120.49 121.11 37.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.884 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 3.0 p-10 -104.08 157.66 16.96 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.875 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 65.9 p -89.82 159.47 16.99 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.874 -179.863 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 37.4 m -77.52 123.22 26.3 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.139 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 23.4 m -73.41 105.37 4.76 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.837 -179.829 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 40.9 t80 -110.01 141.22 43.11 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.908 -179.911 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -59.82 123.06 15.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.103 179.812 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 105.36 -0.43 40.36 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.495 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 28.4 t -90.97 130.07 36.93 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.787 0.327 . . . . 0.0 110.866 -179.757 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 29.1 tt0 -118.57 113.44 21.27 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.923 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 101.7 76.1 1.16 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.732 -0.746 . . . . 0.0 112.473 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 103.09 1.1 Allowed 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.738 2.292 . . . . 0.0 112.33 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 86.9 p -101.78 140.86 35.49 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.873 -179.845 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -127.61 167.74 15.96 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.13 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 83.5 p -126.13 166.08 17.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.89 -179.819 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -147.99 140.46 24.46 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.131 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 8.8 m-85 -114.71 136.37 53.13 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.917 -179.843 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 74.9 t -130.0 125.59 60.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.145 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 89.1 m -95.75 122.65 38.75 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.176 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 4.8 m-85 -108.16 141.43 39.9 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.936 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 65.3 mt -74.57 -39.52 47.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.073 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 38.4 mtm-85 -86.92 114.58 23.67 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.851 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 14.3 t -55.84 -59.66 4.56 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.845 -179.804 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 17.9 tt0 -51.68 -49.65 61.99 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.875 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 12.2 t0 -48.03 -46.25 32.97 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.886 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -61.67 -53.46 55.86 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.111 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 72.9 mt -44.68 -63.9 0.81 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.888 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 171' ' ' ARG . . . . . 0.418 ' O ' ' N ' ' A' ' 174' ' ' GLN . 14.9 mtp180 -59.59 -53.04 62.64 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.859 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . 0.502 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -40.0 -37.73 0.63 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.081 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 67.4 mt -80.66 -36.7 15.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.133 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 174' ' ' GLN . . . . . 0.418 ' N ' ' O ' ' A' ' 171' ' ' ARG . 25.8 mm-40 -61.1 -26.88 67.97 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.9 179.905 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 2.5 t -93.75 -41.15 9.83 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.897 -179.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 176' ' ' VAL . . . . . 0.502 HG23 ' O ' ' A' ' 172' ' ' ALA . 10.3 t -58.77 -39.44 76.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.092 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -62.43 136.43 57.9 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.896 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 14.6 t30 70.76 47.01 0.48 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.919 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 59.0 t -127.64 134.8 64.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.139 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 89.4 t -93.95 115.04 31.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.148 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 62.4 t -121.45 118.88 57.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.158 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 55.9 m-20 58.5 28.76 17.41 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.844 179.935 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 90.08 -19.52 42.0 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.497 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 25.4 ttm-85 -103.52 135.89 44.27 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.939 0.4 . . . . 0.0 110.851 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 71.2 m -86.8 131.83 34.01 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.186 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 186' ' ' LEU . . . . . 0.56 HD22 HD23 ' A' ' 116' ' ' LEU . 25.4 mt -112.57 126.25 55.14 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.91 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 7.9 ttmt -109.48 136.64 48.56 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.87 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . 0.699 ' HB2' HG22 ' A' ' 113' ' ' VAL . . . -125.64 149.52 48.36 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.096 179.844 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 7.3 t -159.37 167.71 28.14 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.828 -179.766 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 190' ' ' LEU . . . . . . . . . . . . . 4.2 pp -126.38 153.11 45.4 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.958 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 106.16 30.7 4.36 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.438 179.927 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 192' ' ' THR . . . . . . . . . . . . . 47.0 m -98.97 122.89 42.82 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.851 0.357 . . . . 0.0 111.151 -179.872 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 193' ' ' THR . . . . . . . . . . . . . 9.4 m -118.51 138.24 52.65 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.151 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 2.3 mptp? -78.07 131.37 37.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.902 179.896 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 195' ' ' TYR . . . . . . . . . . . . . 26.0 p90 -59.3 151.94 22.18 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.901 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 196' ' ' CYS . . . . . . . . . . . . . 44.7 t -126.06 75.53 1.52 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.856 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 55.1 m -103.56 151.88 22.37 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.831 -179.76 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 198' ' ' TYR . . . . . . . . . . . . . 83.1 t80 -166.38 146.05 5.94 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.932 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 68.6 m -132.24 159.15 39.89 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.843 -179.823 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . 178.57 -168.5 39.6 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.47 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 201' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 -48.32 0.27 Allowed 'Cis proline' 0 C--N 1.342 0.199 0 C-N-CA 122.706 -1.789 . . . . 0.0 112.322 0.014 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 202' ' ' SER . . . . . . . . . . . . . 73.9 p 47.45 41.55 12.97 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.835 -179.846 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 12.7 p -126.09 77.91 1.72 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.889 -179.842 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.297 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.459 179.998 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.352 0 N-CA-C 112.478 -0.249 . . . . 0.0 112.478 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 2.2 m -125.68 164.24 21.05 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.875 0.369 . . . . 0.0 110.911 -179.748 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 71.2 m -64.16 152.59 40.25 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.86 -179.817 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 116.32 174.95 17.71 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.481 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 39.3 p -120.03 167.03 12.6 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.856 0.36 . . . . 0.0 110.854 -179.715 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 46.6 m -114.74 128.11 56.12 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.839 -179.803 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 152.68 -121.89 1.23 Allowed Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.471 -179.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -61.15 135.2 57.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.762 0.315 . . . . 0.0 111.103 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 1.7 t -74.24 -62.56 1.47 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.866 -179.782 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 99.6 t -107.31 127.31 63.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.118 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 14.8 tpt180 -95.01 100.62 12.42 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.866 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 62.0 t -93.63 137.63 22.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.105 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -111.49 148.27 14.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.083 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 5.3 mm100 -95.5 -44.56 7.47 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.909 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.497 ' HB2' HD21 ' A' ' 170' ' ' LEU . 20.0 mttt -79.92 81.27 6.21 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.887 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 2.4 t30 -124.86 -39.8 2.24 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.913 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 19.4 tp -91.78 123.01 34.84 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.938 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.763 HG22 HD11 ' A' ' 173' ' ' ILE . 75.1 t -93.1 115.99 33.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.102 179.886 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.579 ' CE1' ' HB2' ' A' ' 158' ' ' SER . 6.6 t80 -112.49 118.47 35.22 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.895 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.42 HG22 ' HB2' ' A' ' 188' ' ' ALA . 25.5 t -115.0 137.53 48.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.169 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.483 HG12 ' HE1' ' A' ' 112' ' ' PHE . 19.9 m -123.42 168.96 15.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.161 179.908 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 75.59 48.62 10.19 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.499 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 36.4 mt -114.68 131.18 56.83 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.807 0.336 . . . . 0.0 110.884 -179.887 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 13.0 t -68.99 152.0 45.81 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.88 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 4.2 tp-100 -51.52 -23.57 4.23 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.936 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 30.3 ttt180 -84.62 -45.56 12.39 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.889 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 96.7 mt -68.06 -28.83 67.71 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.87 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -66.36 83.05 0.09 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.096 179.834 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -145.47 143.97 21.58 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.625 0.726 . . . . 0.0 110.842 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 -38.89 7.25 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.726 2.284 . . . . 0.0 112.345 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -77.51 -44.83 27.44 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.895 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.556 ' O ' ' CD1' ' A' ' 131' ' ' TYR . 62.0 t -60.6 -38.32 78.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.076 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.806 HD12 HD11 ' A' ' 143' ' ' ILE . 81.4 mt -75.08 -44.5 47.07 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.89 180.0 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.61 ' HA ' HD12 ' A' ' 138' ' ' ILE . 22.7 ttpp -67.87 -25.82 65.71 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.897 179.861 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 12.9 mmt180 -47.76 144.01 5.6 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.657 0.742 . . . . 0.0 110.803 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 -8.39 23.48 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.745 2.297 . . . . 0.0 112.324 179.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 46.7 mt-10 -98.83 8.35 45.07 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.89 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' TYR . . . . . 0.556 ' CD1' ' O ' ' A' ' 125' ' ' VAL . 59.3 m-85 -126.08 -74.26 0.61 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.927 -179.828 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.444 ' O ' ' N ' ' A' ' 134' ' ' LYS . 58.5 m-85 -116.26 -36.66 3.98 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.914 -180.0 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -40.39 -25.58 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.488 -179.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.444 ' N ' ' O ' ' A' ' 132' ' ' PHE . 3.5 mtpp -42.7 -59.65 1.85 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.82 0.343 . . . . 0.0 110.875 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 135' ' ' PHE . . . . . 0.42 ' CE1' ' HA ' ' A' ' 172' ' ' ALA . 28.1 m-85 -50.93 -43.59 60.13 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.865 179.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 173.82 -172.99 45.69 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.46 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 20.9 mtpp -76.19 141.35 41.85 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.733 0.301 . . . . 0.0 110.887 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.68 HG21 ' CG2' ' A' ' 141' ' ' VAL . 60.6 mt -99.52 141.26 17.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.125 179.866 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 11.2 t60 -84.97 -58.55 2.65 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.846 179.892 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 22.1 tttp -137.53 146.82 44.61 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.914 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . 0.68 ' CG2' HG21 ' A' ' 138' ' ' ILE . 35.3 t -134.68 132.83 54.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.175 179.897 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 57.8 t -126.46 141.38 46.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.121 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . 0.806 HD11 HD12 ' A' ' 126' ' ' LEU . 31.4 mm -119.87 132.65 69.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.095 179.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 5.2 t-20 -126.39 106.54 9.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.889 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 5.3 p30 -101.1 173.62 6.38 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.872 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 6.1 m -89.47 123.39 33.55 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.899 -179.885 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 17.9 p -99.61 -50.83 3.94 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.15 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 79.4 p -106.58 131.51 53.65 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.828 -179.808 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . 0.533 ' CG ' ' O ' ' A' ' 149' ' ' TYR . 29.7 p90 -107.06 99.78 9.31 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.942 -179.876 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -83.15 42.21 0.8 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.116 179.868 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 79.42 39.85 17.4 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.76 -0.734 . . . . 0.0 112.469 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 38.0 p -100.69 132.17 46.22 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.867 0.365 . . . . 0.0 110.829 -179.718 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 1.6 mp0 -81.58 106.33 13.44 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.905 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 57.59 81.18 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.489 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 133.22 25.08 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.684 2.256 . . . . 0.0 112.358 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 93.4 p -91.44 138.82 31.27 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.873 -179.84 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -93.96 169.47 10.25 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.092 179.932 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . 0.579 ' HB2' ' CE1' ' A' ' 112' ' ' PHE . 86.9 p -140.72 153.52 45.96 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.85 -179.775 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -137.68 150.93 47.73 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.109 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 160' ' ' TYR . . . . . 0.486 ' CD1' ' N ' ' A' ' 160' ' ' TYR . 1.3 m-85 -115.57 125.79 53.4 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.919 -179.832 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.419 ' CG1' ' CE1' ' A' ' 163' ' ' TYR . 43.0 t -120.83 125.74 74.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.151 179.909 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 87.9 m -107.44 123.88 49.04 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.161 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 163' ' ' TYR . . . . . 0.419 ' CE1' ' CG1' ' A' ' 161' ' ' VAL . 30.3 m-85 -104.06 164.3 11.8 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.906 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 42.7 mt -94.05 -39.46 10.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.153 179.891 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 30.5 mtp180 -102.12 120.36 40.31 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.911 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 16.0 m -47.78 -56.49 7.28 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.823 -179.733 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 34.8 mt-10 -46.23 -52.46 12.42 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.904 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 23.3 m-20 -50.95 -48.18 60.95 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.801 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -55.29 -62.47 1.65 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.082 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . 0.497 HD21 ' HB2' ' A' ' 108' ' ' LYS . 66.0 mt -41.63 -62.77 0.82 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.9 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 171' ' ' ARG . . . . . 0.414 ' O ' ' N ' ' A' ' 174' ' ' GLN . 20.0 mtp85 -51.76 -60.06 3.59 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.829 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . 0.577 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -38.75 -36.42 0.26 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.146 179.893 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 173' ' ' ILE . . . . . 0.763 HD11 HG22 ' A' ' 111' ' ' VAL . 60.9 mt -80.96 -39.89 18.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.12 179.961 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 174' ' ' GLN . . . . . 0.414 ' N ' ' O ' ' A' ' 171' ' ' ARG . 51.3 mt-30 -66.93 -22.1 65.96 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.92 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 1.8 t -93.77 -37.27 11.87 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.913 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 176' ' ' VAL . . . . . 0.577 HG23 ' O ' ' A' ' 172' ' ' ALA . 10.3 t -64.37 -33.77 64.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.082 -179.954 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 3.8 t30 -67.95 143.5 55.61 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.866 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 22.8 t30 65.52 48.94 1.91 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.905 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 179' ' ' VAL . . . . . 0.416 HG12 HG23 ' A' ' 181' ' ' VAL . 53.0 t -127.27 135.64 62.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.14 179.922 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 59.3 t -96.9 100.31 10.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.148 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . 0.468 HG21 HD12 ' A' ' 186' ' ' LEU . 66.9 t -107.52 97.98 6.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.175 179.909 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 6.8 t0 66.73 36.58 4.6 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.862 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 77.59 32.54 46.1 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.499 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 65.6 mtt85 -141.66 136.51 30.98 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.911 0.386 . . . . 0.0 110.866 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 26.6 m -94.73 95.0 8.44 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.161 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 186' ' ' LEU . . . . . 0.468 HD12 HG21 ' A' ' 181' ' ' VAL . 79.8 mt -67.74 132.73 48.0 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.901 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 25.4 tptt -111.08 116.41 31.08 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.92 179.815 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . 0.441 ' HB2' HG11 ' A' ' 176' ' ' VAL . . . -112.38 134.28 54.01 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.101 179.824 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 7.7 t -158.51 171.75 19.56 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.815 -179.791 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 190' ' ' LEU . . . . . 0.83 HD22 ' C ' ' A' ' 190' ' ' LEU . 0.0 OUTLIER -119.25 158.77 25.37 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.936 179.998 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 191' ' ' GLY . . . . . 0.448 ' N ' HD22 ' A' ' 190' ' ' LEU . . . 64.01 29.3 74.48 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.491 179.91 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 192' ' ' THR . . . . . . . . . . . . . 6.9 m -94.84 118.37 31.66 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.897 0.379 . . . . 0.0 111.163 -179.859 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 193' ' ' THR . . . . . . . . . . . . . 60.5 p -126.41 166.32 17.41 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.108 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 20.5 mmmt -100.14 -57.45 2.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.893 179.907 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 195' ' ' TYR . . . . . . . . . . . . . 1.8 t80 -63.9 93.59 0.09 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.903 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 196' ' ' CYS . . . . . . . . . . . . . 25.7 p -49.97 138.08 15.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.899 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 64.1 p -141.62 153.64 44.89 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.825 -179.765 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 198' ' ' TYR . . . . . 0.563 ' CE2' ' O ' ' A' ' 199' ' ' SER . 67.1 t80 -148.47 167.23 25.86 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.96 -179.922 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . 0.563 ' O ' ' CE2' ' A' ' 198' ' ' TYR . 37.5 p -136.65 164.48 28.12 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.877 -179.847 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . 128.61 -162.92 22.2 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.47 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 201' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 -27.86 6.6 Favored 'Cis proline' 0 C--N 1.341 0.161 0 C-N-CA 122.703 -1.79 . . . . 0.0 112.33 0.122 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 202' ' ' SER . . . . . . . . . . . . . 92.3 p -150.33 161.76 41.85 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.847 -179.838 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 44.1 t -101.46 134.65 44.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.826 -179.743 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.501 179.964 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.367 0 N-CA-C 112.507 -0.237 . . . . 0.0 112.507 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 23.7 p -156.35 128.38 7.42 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.87 0.367 . . . . 0.0 110.861 -179.768 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 85.4 p -108.88 148.13 31.09 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.874 -179.812 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 173.72 80.72 0.05 OUTLIER Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.464 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 21.9 p -125.7 166.23 17.15 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.856 0.36 . . . . 0.0 110.893 -179.81 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 3.7 t -109.93 102.37 11.13 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.855 -179.808 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 176.8 115.11 0.41 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.515 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -104.77 118.46 36.61 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.766 0.317 . . . . 0.0 111.077 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 2.1 m -166.13 171.55 12.24 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.835 -179.829 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.43 ' O ' HG23 ' A' ' 103' ' ' VAL . 35.6 m -74.24 125.58 33.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.086 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 4.9 tpp85 -84.22 105.23 14.91 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.852 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 97.3 t -72.96 123.47 27.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.166 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 61.3 t -89.28 117.5 32.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.135 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 47.5 mm-40 -105.55 113.8 27.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.909 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 52.9 mttt -72.38 -44.55 62.38 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.871 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 1.2 p-10 -86.69 45.79 1.29 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.893 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . 0.626 HD11 ' HD2' ' A' ' 160' ' ' TYR . 62.1 tp -139.47 120.47 14.57 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.92 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.429 HG12 HG23 ' A' ' 113' ' ' VAL . 86.9 t -111.13 106.64 21.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.065 179.88 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.469 ' CE2' ' CG1' ' A' ' 114' ' ' VAL . 87.7 t80 -94.48 102.21 14.15 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.905 179.967 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.429 HG23 HG12 ' A' ' 111' ' ' VAL . 20.2 t -107.23 131.73 56.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.16 179.993 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.469 ' CG1' ' CE2' ' A' ' 112' ' ' PHE . 6.1 m -119.2 155.01 21.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.113 179.942 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 90.81 44.35 4.54 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.452 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . 0.505 HD23 HD21 ' A' ' 186' ' ' LEU . 38.5 mt -110.25 125.0 52.65 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.823 0.344 . . . . 0.0 110.913 -179.943 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . 0.484 ' O ' ' N ' ' A' ' 120' ' ' LEU . 22.8 p -69.09 139.97 54.81 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.84 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' GLN . . . . . 0.42 ' C ' ' O ' ' A' ' 117' ' ' SER . 37.4 mt-30 -36.38 -41.79 0.3 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.914 -179.924 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 26.6 mtm-85 -66.31 -44.12 84.33 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.886 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . 0.484 ' N ' ' O ' ' A' ' 117' ' ' SER . 34.5 mt -72.42 -24.74 61.27 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.912 -179.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -71.23 83.25 0.74 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.132 179.811 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 20.0 m-20 -148.87 144.0 17.73 Favored Pre-proline 0 C--N 1.328 -0.364 0 CA-C-O 121.648 0.737 . . . . 0.0 110.88 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . 0.403 ' HA ' HG11 ' A' ' 141' ' ' VAL . 54.1 Cg_endo -69.73 -46.65 1.16 Allowed 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.69 2.26 . . . . 0.0 112.347 -179.963 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 48.7 mt-10 -71.36 -43.31 67.16 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.924 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.523 ' O ' ' CD2' ' A' ' 131' ' ' TYR . 90.5 t -60.19 -42.2 89.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.136 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.573 HD12 HD11 ' A' ' 143' ' ' ILE . 64.6 mt -72.96 -39.48 66.15 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.898 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.716 ' HA ' HD12 ' A' ' 138' ' ' ILE . 18.6 ttmt -61.44 -31.95 71.92 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.9 179.855 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 91.7 mtt180 -43.02 143.94 1.17 Allowed Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.635 0.731 . . . . 0.0 110.88 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 -2.69 10.57 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.679 2.253 . . . . 0.0 112.384 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 25.7 mt-10 -97.57 -30.26 12.96 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.905 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' TYR . . . . . 0.523 ' CD2' ' O ' ' A' ' 125' ' ' VAL . 44.2 m-85 -87.64 -74.91 0.43 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.921 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.481 ' CE1' HD22 ' A' ' 126' ' ' LEU . 42.6 m-85 -117.08 -36.84 3.69 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.88 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -49.34 -18.42 1.43 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.518 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -52.49 -34.22 48.34 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.832 0.349 . . . . 0.0 110.916 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 135' ' ' PHE . . . . . 0.568 ' CE2' ' HA ' ' A' ' 172' ' ' ALA . 79.8 m-85 -73.35 -42.02 62.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.897 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 166.89 -178.14 41.3 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.493 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 5.2 ttmm -60.01 140.28 56.88 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.762 0.315 . . . . 0.0 110.858 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.716 HD12 ' HA ' ' A' ' 127' ' ' LYS . 91.3 mt -105.67 139.03 28.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.112 179.862 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 34.3 t-80 -75.61 -55.15 5.94 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.866 179.868 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 140' ' ' LYS . . . . . 0.478 ' HD3' ' CG2' ' A' ' 142' ' ' VAL . 13.4 ttmm -149.49 144.16 26.11 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.916 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . 0.494 HG22 HG21 ' A' ' 138' ' ' ILE . 23.9 t -122.43 103.63 13.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.109 179.927 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.478 ' CG2' ' HD3' ' A' ' 140' ' ' LYS . 63.1 t -100.65 140.82 18.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.157 179.873 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . 0.573 HD11 HD12 ' A' ' 126' ' ' LEU . 26.7 mm -119.24 125.47 74.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.15 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 19.6 m-20 -121.2 142.75 49.6 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.88 179.916 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 18.4 p30 -138.15 140.57 39.92 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.871 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 43.7 p -84.09 94.21 8.29 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.87 -179.877 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 11.6 t -82.94 40.45 0.69 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.119 -179.926 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 74.4 m -108.29 164.08 12.63 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.89 -179.889 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . 0.574 ' O ' ' CD2' ' A' ' 149' ' ' TYR . 55.2 p90 -99.85 106.7 18.58 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.933 -179.919 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -107.74 -48.7 3.36 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.125 179.851 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 113.08 39.36 1.16 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.487 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 91.3 p -118.52 151.7 37.36 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.895 0.378 . . . . 0.0 110.827 -179.729 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 10.8 mm100 -89.75 100.42 13.23 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.896 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 95.2 83.16 1.62 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.464 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 140.43 42.7 Favored 'Trans proline' 0 C--N 1.341 0.139 0 C-N-CA 122.669 2.246 . . . . 0.0 112.391 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 82.0 p -101.01 143.15 31.5 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.844 -179.795 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -113.68 157.91 21.57 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.076 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 11.7 t -116.29 168.19 10.35 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.871 -179.763 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -148.48 147.29 28.95 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.058 179.893 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 160' ' ' TYR . . . . . 0.626 ' HD2' HD11 ' A' ' 110' ' ' LEU . 4.5 m-85 -115.06 104.73 12.17 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.916 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 95.3 t -99.51 126.45 52.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.146 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 96.7 m -95.9 123.76 39.62 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.14 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 163' ' ' TYR . . . . . 0.531 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 12.1 m-85 -106.13 121.99 45.27 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.949 -179.942 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 46.0 mt -57.38 -51.5 68.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.097 -0.502 . . . . 0.0 111.154 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 39.7 mtp180 -85.72 118.08 25.0 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.847 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 22.6 t -48.72 -47.4 41.33 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.868 -179.82 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -54.36 -56.22 20.77 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.905 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . 0.499 ' O ' ' HB2' ' A' ' 172' ' ' ALA . 0.9 OUTLIER -52.39 -31.9 36.17 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.867 179.959 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 169' ' ' ALA . . . . . 0.531 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -70.49 -66.19 0.63 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.113 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 31.1 mt -46.6 -56.17 6.5 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.894 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 84.9 mtt180 -56.59 -46.56 80.78 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.854 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . 0.568 ' HA ' ' CE2' ' A' ' 135' ' ' PHE . . . -51.88 -32.73 33.56 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.076 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 65.8 mt -79.13 -36.4 18.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.11 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 15.7 mm100 -65.84 -26.93 67.88 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.874 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 175' ' ' CYS . . . . . 0.48 ' O ' HG21 ' A' ' 179' ' ' VAL . 7.6 m -93.7 -36.63 12.23 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.907 -179.949 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 176' ' ' VAL . . . . . 0.554 HG23 ' O ' ' A' ' 172' ' ' ALA . 10.5 t -65.43 -40.11 87.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.083 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 7.4 p-10 -68.32 152.1 45.93 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.891 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 36.5 t30 57.1 48.77 14.84 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.882 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 179' ' ' VAL . . . . . 0.48 HG21 ' O ' ' A' ' 175' ' ' CYS . 94.3 t -133.56 140.21 47.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.113 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 87.1 t -99.08 105.35 17.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.097 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . 0.486 HG21 HD12 ' A' ' 186' ' ' LEU . 91.8 t -112.06 98.73 7.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.133 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 30.9 t0 60.7 52.42 4.43 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.841 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 63.27 24.19 67.11 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.492 -179.931 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 66.3 mtp85 -131.61 111.91 12.14 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.874 0.369 . . . . 0.0 110.86 -179.826 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 28.2 m -76.09 93.19 3.28 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.127 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 186' ' ' LEU . . . . . 0.505 HD21 HD23 ' A' ' 116' ' ' LEU . 80.2 mt -68.54 128.99 38.61 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.931 179.916 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 2.5 mmmp? -117.6 118.29 31.73 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.877 179.847 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -107.19 145.56 32.46 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.127 179.819 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 4.5 t -143.33 169.32 17.88 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.857 -179.74 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 190' ' ' LEU . . . . . 0.495 HD23 ' N ' ' A' ' 191' ' ' GLY . 8.6 tt -128.81 134.89 48.51 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.904 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 191' ' ' GLY . . . . . 0.495 ' N ' HD23 ' A' ' 190' ' ' LEU . . . 94.29 23.62 21.46 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.486 179.91 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 192' ' ' THR . . . . . . . . . . . . . 35.5 m -88.17 118.48 27.79 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.867 0.365 . . . . 0.0 111.176 -179.848 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 193' ' ' THR . . . . . . . . . . . . . 81.8 p -88.45 171.23 10.26 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.121 -179.914 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 3.7 mppt? -110.15 135.32 51.12 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.883 179.912 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 195' ' ' TYR . . . . . . . . . . . . . 40.9 m-85 -68.77 -47.89 65.07 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.875 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 196' ' ' CYS . . . . . . . . . . . . . 2.1 t -44.46 -62.39 1.2 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.924 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 46.7 t -65.76 98.38 0.39 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.879 -179.795 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 198' ' ' TYR . . . . . . . . . . . . . 74.6 t80 -91.51 96.26 10.39 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.889 -179.875 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 1.3 t -155.34 119.69 4.67 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.864 -179.868 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 200' ' ' GLY . . . . . 0.434 ' N ' ' HA ' ' A' ' 201' ' ' PRO . . . -71.7 -66.15 2.2 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.5 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 201' ' ' PRO . . . . . 0.434 ' HA ' ' N ' ' A' ' 200' ' ' GLY . 53.9 Cg_endo -69.8 -13.09 12.43 Favored 'Cis proline' 0 C--N 1.341 0.152 0 C-N-CA 122.649 -1.813 . . . . 0.0 112.36 0.044 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 202' ' ' SER . . . . . . . . . . . . . 17.3 t -65.54 109.15 2.25 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.829 -179.84 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 18.2 p -93.41 124.6 37.51 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.874 -179.826 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.27 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.49 -179.977 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.251 0 N-CA-C 112.48 -0.248 . . . . 0.0 112.48 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 74.9 m -138.58 126.74 22.77 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.919 0.39 . . . . 0.0 110.87 -179.719 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 93.4 p 44.98 38.81 3.22 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.881 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 103.56 -150.66 17.64 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.479 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 42.0 m -105.72 -60.34 1.64 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.857 0.36 . . . . 0.0 110.844 -179.733 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 29.0 p -173.4 171.8 3.89 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.848 -179.804 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -117.52 -179.28 17.49 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.458 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -50.52 161.36 0.33 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.824 0.345 . . . . 0.0 111.085 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 46.2 m -79.99 -49.36 11.94 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.867 -179.795 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 22.4 m -84.5 151.51 3.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.148 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 29.9 mtt85 -98.81 126.36 44.43 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.842 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 14.2 p -131.85 135.09 59.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.105 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 4.9 m -119.12 129.53 75.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.151 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 20.3 tp60 -164.54 153.92 13.49 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.914 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.597 ' O ' HD21 ' A' ' 190' ' ' LEU . 22.5 mmtm -102.52 -52.06 3.19 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.918 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 29.0 p-10 -86.24 49.58 1.82 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.863 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 11.5 tp -130.53 146.77 52.12 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.908 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.446 HG22 HD11 ' A' ' 173' ' ' ILE . 85.2 t -122.55 111.75 31.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.105 179.872 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.437 ' CE1' ' HB2' ' A' ' 158' ' ' SER . 42.1 t80 -98.46 113.34 25.3 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.889 179.991 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.434 HG21 ' CZ ' ' A' ' 132' ' ' PHE . 92.8 t -110.68 137.23 43.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.117 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 35.9 m -126.91 168.19 20.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.147 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 74.29 41.67 37.42 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.476 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 50.5 mt -103.54 130.84 51.02 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.797 0.332 . . . . 0.0 110.94 -179.951 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . 0.491 ' O ' ' N ' ' A' ' 120' ' ' LEU . 89.6 p -77.37 142.65 39.2 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.85 -179.934 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' GLN . . . . . 0.442 ' C ' ' O ' ' A' ' 117' ' ' SER . 55.0 mm-40 -34.85 -40.36 0.11 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.892 -179.938 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 25.0 mtm-85 -63.34 -47.26 82.93 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.871 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . 0.491 ' N ' ' O ' ' A' ' 117' ' ' SER . 20.7 mt -72.44 -29.44 63.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.936 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -65.46 82.99 0.06 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.099 179.81 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' ASP . . . . . 0.422 ' HB2' ' CG2' ' A' ' 125' ' ' VAL . 19.4 m-20 -149.0 143.84 17.46 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.599 0.714 . . . . 0.0 110.863 179.985 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 -44.26 2.19 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.682 2.255 . . . . 0.0 112.389 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 66.3 mm-40 -74.2 -38.61 63.54 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.886 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.586 ' O ' ' CD1' ' A' ' 131' ' ' TYR . 68.9 t -61.0 -49.5 84.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.103 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 92.8 mt -66.33 -43.36 86.36 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.943 179.936 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.478 ' HA ' ' CD1' ' A' ' 138' ' ' ILE . 31.1 tttm -61.64 -42.71 99.27 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.878 179.849 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . 0.424 ' C ' ' O ' ' A' ' 127' ' ' LYS . 21.4 mmt180 -35.61 143.28 0.26 Allowed Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.643 0.735 . . . . 0.0 110.826 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.75 -1.4 8.4 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.66 2.24 . . . . 0.0 112.34 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 10.2 mp0 -103.26 -0.98 29.57 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.884 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' TYR . . . . . 0.586 ' CD1' ' O ' ' A' ' 125' ' ' VAL . 47.0 m-85 -117.06 -74.15 0.62 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.913 -179.879 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.434 ' CZ ' HG21 ' A' ' 113' ' ' VAL . 46.5 m-85 -121.75 -17.85 7.28 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.91 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -72.08 -1.44 48.88 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.491 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 1.3 ptpp? -78.85 -19.67 51.46 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.78 0.324 . . . . 0.0 110.894 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 135' ' ' PHE . . . . . 0.419 ' CD2' ' HB1' ' A' ' 172' ' ' ALA . 58.2 m-85 -85.62 -38.17 18.72 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.856 -179.99 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -179.72 -174.52 45.74 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.511 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 45.9 mtpt -81.49 134.62 35.55 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.779 0.323 . . . . 0.0 110.889 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.478 ' CD1' ' HA ' ' A' ' 127' ' ' LYS . 65.1 mt -94.98 147.03 6.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.155 179.861 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 4.6 t60 -99.11 -43.61 6.59 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.891 179.901 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 26.5 ttpt -148.28 143.69 27.12 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.95 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . 0.459 HG22 HG21 ' A' ' 138' ' ' ILE . 41.3 t -127.23 121.17 56.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.208 179.862 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 72.4 t -125.71 145.27 33.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.153 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 29.1 mm -115.8 141.82 31.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.118 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 48.2 t30 -129.45 142.92 50.67 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.916 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 44.7 t-20 -129.13 136.6 50.42 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.831 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 44.3 t -68.06 105.49 2.06 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.829 -179.844 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 42.9 p -92.03 -52.29 4.79 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.168 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 47.2 t -65.98 111.52 3.38 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.835 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 47.6 m-85 -71.4 107.65 4.44 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.961 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -84.44 41.22 0.82 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.076 179.911 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 88.61 -19.57 36.02 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.496 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 2.7 m -100.67 143.22 31.1 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.798 0.332 . . . . 0.0 110.876 -179.74 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 14.7 mp0 -101.16 132.77 46.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.891 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 74.25 61.35 3.24 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.506 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 -173.56 0.74 Allowed 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.672 2.248 . . . . 0.0 112.357 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 69.6 m -107.94 155.01 20.79 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.868 -179.854 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -103.92 149.14 25.38 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.079 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . 0.437 ' HB2' ' CE1' ' A' ' 112' ' ' PHE . 53.1 p -117.21 171.59 7.85 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.89 -179.803 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -146.79 133.55 20.03 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.12 179.875 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 38.7 m-85 -104.48 113.75 27.53 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.905 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 98.7 t -109.13 123.93 65.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.129 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 40.4 m -98.02 123.88 42.24 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.134 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 9.8 m-85 -105.99 146.73 29.69 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.923 -179.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 86.9 mt -79.41 -36.24 17.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.133 179.883 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 31.9 mmm-85 -106.93 117.08 33.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.872 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 74.2 m -49.24 -51.11 35.39 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.846 -179.771 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 18.5 mm-40 -48.74 -51.02 31.11 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.897 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -54.26 -45.13 72.34 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.871 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -60.24 -62.61 1.74 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.094 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 50.6 mt -41.57 -66.38 0.35 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.9 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 79.2 mtp180 -48.37 -54.43 13.97 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.869 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . 0.591 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -43.51 -35.16 1.56 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.083 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 173' ' ' ILE . . . . . 0.541 HG23 ' HB3' ' A' ' 188' ' ' ALA . 63.6 mt -77.92 -40.46 26.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.183 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 88.2 mm-40 -61.36 -27.57 68.61 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.914 179.918 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 175' ' ' CYS . . . . . 0.477 ' O ' ' CG2' ' A' ' 179' ' ' VAL . 1.9 m -93.82 -42.1 9.29 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.882 -179.914 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 176' ' ' VAL . . . . . 0.591 HG23 ' O ' ' A' ' 172' ' ' ALA . 10.3 t -58.07 -36.27 56.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.14 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 177' ' ' ASN . . . . . 0.418 ' O ' HG23 ' A' ' 179' ' ' VAL . 12.3 t-20 -68.41 150.83 47.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.873 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 178' ' ' ASN . . . . . 0.411 ' CG ' ' O ' ' A' ' 178' ' ' ASN . 37.4 t30 57.66 42.84 23.25 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.854 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 179' ' ' VAL . . . . . 0.477 ' CG2' ' O ' ' A' ' 175' ' ' CYS . 62.0 t -128.68 135.03 63.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.142 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 90.3 t -98.97 106.38 18.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.129 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . 0.457 HG21 HD12 ' A' ' 186' ' ' LEU . 57.1 t -114.18 121.32 66.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.115 179.909 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 14.4 m-20 51.23 28.45 4.17 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.844 179.908 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 81.47 32.01 32.07 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.493 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 4.2 mpt_? -138.69 124.47 19.79 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.878 0.37 . . . . 0.0 110.878 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 19.4 m -76.65 93.28 3.6 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.122 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 186' ' ' LEU . . . . . 0.457 HD12 HG21 ' A' ' 181' ' ' VAL . 51.0 mt -62.01 125.98 25.76 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.875 179.962 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 9.5 tptm -122.86 112.28 17.68 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.922 179.788 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . 0.541 ' HB3' HG23 ' A' ' 173' ' ' ILE . . . -107.57 153.19 23.22 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.128 179.826 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 48.0 m -139.2 156.34 47.17 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.877 -179.765 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 190' ' ' LEU . . . . . 0.597 HD21 ' O ' ' A' ' 108' ' ' LYS . 1.5 tm? -120.2 102.28 8.4 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.913 179.968 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 55.2 27.85 47.7 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.494 179.87 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 192' ' ' THR . . . . . 0.416 HG21 ' HA ' ' A' ' 196' ' ' CYS . 51.3 p -138.06 138.57 38.91 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.848 0.356 . . . . 0.0 111.12 -179.829 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 193' ' ' THR . . . . . 0.524 HG23 ' HG3' ' A' ' 194' ' ' LYS . 8.5 t -119.41 -30.14 4.96 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.122 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 194' ' ' LYS . . . . . 0.524 ' HG3' HG23 ' A' ' 193' ' ' THR . 69.6 mttt -111.57 -72.18 0.73 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.912 179.866 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 195' ' ' TYR . . . . . . . . . . . . . 7.3 m-85 -108.64 131.83 54.5 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.904 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 196' ' ' CYS . . . . . 0.416 ' HA ' HG21 ' A' ' 192' ' ' THR . 26.5 p -63.31 177.19 0.67 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.901 179.964 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 1.8 m -159.29 167.89 27.8 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.827 -179.771 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 198' ' ' TYR . . . . . . . . . . . . . 36.3 p90 -161.21 156.95 24.96 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.944 -179.857 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 65.0 p -167.9 148.98 5.22 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.883 -179.83 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . -115.31 -162.73 13.67 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.466 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 201' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 132.91 23.64 Favored 'Cis proline' 0 C--N 1.341 0.173 0 C-N-CA 122.674 -1.803 . . . . 0.0 112.36 -0.013 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 202' ' ' SER . . . . . . . . . . . . . 13.0 t -106.39 75.76 1.1 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.819 -179.788 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 1.1 t -108.58 152.3 24.95 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.837 -179.833 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.274 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.487 179.979 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.324 0 N-CA-C 112.438 -0.265 . . . . 0.0 112.438 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 29.1 m -160.78 112.65 1.9 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.839 0.352 . . . . 0.0 110.915 -179.772 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 82.9 p -97.67 168.07 10.57 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.825 -179.759 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 152.65 118.93 0.77 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.505 -179.952 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 15.0 t -111.23 143.54 41.82 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.867 0.365 . . . . 0.0 110.847 -179.739 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 23.8 t -126.53 118.89 25.83 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.86 -179.81 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -123.17 -174.87 14.37 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.461 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -95.44 136.24 36.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.824 0.345 . . . . 0.0 111.058 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 51.4 m -150.73 166.76 29.43 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.826 -179.782 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 30.1 m -73.15 139.16 19.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.183 179.894 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 57.2 ttp180 -126.62 136.86 53.07 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.842 -179.926 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 11.0 t -122.6 155.58 27.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.15 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 0.517 HG13 ' O ' ' A' ' 106' ' ' VAL . 13.0 p -104.37 120.87 55.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.165 179.919 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 4.1 pt20 -173.82 120.88 0.31 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.954 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 35.4 pttt -91.85 41.35 1.07 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.92 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . 0.431 ' ND2' ' O ' ' A' ' 163' ' ' TYR . 26.1 t-20 -115.89 40.6 2.75 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.897 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 15.8 tp -143.94 142.06 30.55 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.938 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 99.1 t -122.47 110.97 28.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.13 179.833 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.408 ' CB ' HG21 ' A' ' 192' ' ' THR . 46.4 t80 -102.83 108.03 19.1 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.853 -179.937 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 86.0 t -105.2 134.46 46.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.155 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 34.0 m -124.42 167.04 18.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.08 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 78.58 49.21 6.77 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.541 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 28.8 mt -113.78 139.89 48.75 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.823 0.344 . . . . 0.0 110.91 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . 0.44 ' H ' HD12 ' A' ' 120' ' ' LEU . 36.0 t -73.83 146.44 44.16 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.872 -179.903 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 25.4 mt-30 -42.19 -29.93 0.27 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.94 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 56.2 ttt180 -88.41 -38.23 15.23 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.872 -179.913 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . 0.44 HD12 ' H ' ' A' ' 117' ' ' SER . 44.8 mt -65.18 -33.8 76.87 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.905 179.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . 0.424 ' HB1' HG23 ' A' ' 143' ' ' ILE . . . -70.16 83.08 0.52 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.151 179.802 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 21.7 m-20 -148.93 147.1 23.07 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.605 0.717 . . . . 0.0 110.86 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 -37.24 9.53 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.708 2.272 . . . . 0.0 112.36 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 14.9 pt-20 -77.29 -44.43 29.74 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.87 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 86.1 t -61.71 -39.93 85.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.158 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 91.2 mt -74.2 -39.31 63.23 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.933 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.63 ' HD2' HD12 ' A' ' 138' ' ' ILE . 2.0 mmmp? -64.64 -30.81 71.83 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.86 179.867 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 14.7 mmt180 -42.44 143.93 1.03 Allowed Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.591 0.71 . . . . 0.0 110.876 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 -4.19 13.51 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.66 2.24 . . . . 0.0 112.337 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 4.8 tt0 -99.98 1.07 42.23 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.895 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' TYR . . . . . . . . . . . . . 30.7 m-85 -121.0 -74.93 0.6 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.888 -179.831 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 58.0 m-85 -122.99 -18.14 6.5 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.867 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -55.59 -23.03 34.41 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.499 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 12.4 ptpt -90.83 -11.36 39.58 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.796 0.331 . . . . 0.0 110.858 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 135' ' ' PHE . . . . . . . . . . . . . 22.9 m-85 -80.42 -33.23 37.12 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.925 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 173.65 -166.25 38.45 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.444 -179.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 39.4 tptt -95.65 109.27 21.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.737 0.303 . . . . 0.0 110.911 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.63 HD12 ' HD2' ' A' ' 127' ' ' LYS . 86.2 mt -76.71 140.26 17.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.145 179.864 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 18.6 t60 -114.12 -51.07 2.79 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.9 179.871 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -127.28 135.63 50.84 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.868 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . 0.621 ' CG2' HG21 ' A' ' 138' ' ' ILE . 19.2 t -137.49 143.04 35.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.129 179.886 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 74.6 t -145.34 140.18 22.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.132 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . 0.424 HG23 ' HB1' ' A' ' 121' ' ' ALA . 24.6 mm -110.94 126.43 68.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.096 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 2.9 m120 -124.45 137.78 54.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.905 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 5.3 p30 -105.37 159.48 15.87 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.908 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 66.9 p -52.17 127.67 22.51 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.89 -179.84 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 22.4 p -99.14 -44.76 6.15 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.143 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 2.1 m -74.5 155.35 38.06 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.854 -179.852 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 79.7 m-85 -108.11 100.17 9.53 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.903 -179.878 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -85.81 -45.9 11.15 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.081 179.892 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 110.02 -20.01 26.91 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.519 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 48.3 m -67.06 142.53 57.12 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.826 0.346 . . . . 0.0 110.853 -179.735 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 2.1 mp0 -70.35 142.53 52.14 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.885 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 82.42 83.59 0.84 Allowed Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.447 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 152.68 69.35 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.688 2.259 . . . . 0.0 112.369 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 55.8 m -117.9 133.78 55.59 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.861 -179.815 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -112.85 149.71 32.73 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.091 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . 0.403 ' HB2' ' CE1' ' A' ' 112' ' ' PHE . 89.9 p -113.71 158.27 21.14 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.852 -179.803 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -141.08 128.52 21.21 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.102 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 35.9 m-85 -99.91 126.56 46.06 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.932 -179.871 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.6 HG22 HG13 ' A' ' 141' ' ' VAL . 96.6 t -129.09 137.59 56.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.101 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 96.0 m -108.31 134.42 51.16 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.162 180.0 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 163' ' ' TYR . . . . . 0.6 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 16.1 m-85 -111.8 129.51 56.11 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.937 -179.927 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 56.2 mt -61.46 -41.04 88.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.097 -0.502 . . . . 0.0 111.155 179.918 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 82.3 mtt-85 -91.66 113.78 26.14 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.895 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 23.2 t -52.16 -59.54 4.25 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.832 -179.751 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 54.1 tt0 -47.31 -49.19 24.56 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.898 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 4.9 t0 -52.48 -51.16 60.78 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.884 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 169' ' ' ALA . . . . . 0.6 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -54.2 -57.74 10.0 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.078 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 42.0 mt -43.56 -61.43 1.39 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.931 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 41.9 mtt-85 -54.6 -43.51 72.24 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.85 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . 0.608 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -54.39 -30.98 53.88 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.123 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 97.3 mt -82.54 -34.51 11.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.103 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 11.2 mm-40 -68.2 -27.82 66.72 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.911 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 175' ' ' CYS . . . . . 0.44 ' O ' ' CG2' ' A' ' 179' ' ' VAL . 2.0 m -93.75 -35.59 12.7 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.89 -179.954 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 176' ' ' VAL . . . . . 0.608 HG23 ' O ' ' A' ' 172' ' ' ALA . 10.5 t -66.48 -29.92 48.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.146 -179.974 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 4.3 t-20 -73.41 126.95 31.36 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.844 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 26.2 t-20 74.41 52.08 0.09 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.863 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 179' ' ' VAL . . . . . 0.446 HG12 HG23 ' A' ' 181' ' ' VAL . 69.5 t -130.83 132.78 63.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.138 179.905 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 86.6 t -92.54 107.44 19.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.182 179.885 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . 0.446 HG23 HG12 ' A' ' 179' ' ' VAL . 98.3 t -121.0 113.79 41.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.11 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 4.4 t70 58.78 26.51 14.82 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.905 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 81.33 26.67 51.16 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.508 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 3.1 mpt_? -136.27 123.48 21.77 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.932 0.396 . . . . 0.0 110.872 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 18.3 m -76.26 101.64 5.53 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.154 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 89.0 mt -78.18 125.21 29.03 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.957 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 38.1 mmtt -118.5 117.99 30.49 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.898 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . 0.547 ' HB2' HG11 ' A' ' 176' ' ' VAL . . . -106.9 140.72 39.27 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.105 179.81 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 59.3 m -145.03 162.88 35.86 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.853 -179.768 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 190' ' ' LEU . . . . . 0.704 HD12 ' O ' ' A' ' 190' ' ' LEU . 3.5 pp -130.24 153.31 48.74 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.927 180.0 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 79.74 28.39 51.21 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.525 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 192' ' ' THR . . . . . 0.408 HG21 ' CB ' ' A' ' 112' ' ' PHE . 3.0 t -106.18 134.05 49.92 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.862 0.363 . . . . 0.0 111.183 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 193' ' ' THR . . . . . . . . . . . . . 78.3 p -116.15 157.38 24.89 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.14 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 22.7 tptp -114.69 121.57 43.76 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.939 179.873 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 195' ' ' TYR . . . . . . . . . . . . . 31.0 m-85 -50.19 98.73 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.908 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 196' ' ' CYS . . . . . . . . . . . . . 29.6 p -103.17 128.8 50.0 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.934 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 23.3 t -143.89 142.38 30.76 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.839 -179.735 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 198' ' ' TYR . . . . . . . . . . . . . 11.1 p90 -154.4 173.42 16.24 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.92 -179.865 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 9.1 t -96.49 159.94 14.67 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.904 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . 60.92 -166.05 13.69 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.514 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 201' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.78 166.02 75.18 Favored 'Cis proline' 0 C--O 1.231 0.155 0 C-N-CA 122.689 -1.796 . . . . 0.0 112.372 0.067 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 202' ' ' SER . . . . . . . . . . . . . 2.5 m -50.06 154.12 1.22 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.828 -179.826 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 52.2 p -101.09 92.26 4.92 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.837 -179.832 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.289 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.465 179.977 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.327 0 N-CA-C 112.46 -0.256 . . . . 0.0 112.46 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 4.9 m -118.69 115.12 23.85 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.85 0.357 . . . . 0.0 110.879 -179.732 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 14.9 t -126.2 136.05 52.36 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.874 -179.826 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 92.33 65.21 1.11 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.517 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 44.5 t -65.79 145.66 55.7 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.855 0.359 . . . . 0.0 110.868 -179.722 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 59.7 p -88.87 174.11 8.14 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.857 -179.782 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -162.39 169.38 37.68 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.53 -180.0 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -49.89 166.26 0.07 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.793 0.33 . . . . 0.0 111.122 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 70.2 m -124.76 85.72 2.45 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.833 -179.762 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 14.7 p -82.76 148.84 4.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.136 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 13.6 ptp180 -103.48 96.35 6.68 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.825 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 42.6 t -97.28 139.01 20.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.129 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 7.2 p -110.19 142.79 21.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.181 179.905 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 16.7 mm-40 62.69 49.82 3.67 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.93 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 43.9 mtmt -70.86 99.13 1.69 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.931 179.92 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 1.8 p-10 -131.83 50.61 2.22 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.904 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 19.5 tp -142.71 112.7 7.02 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.876 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.731 HG22 HD11 ' A' ' 173' ' ' ILE . 71.2 t -114.38 124.05 70.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.161 179.804 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.52 ' CE1' ' HB2' ' A' ' 158' ' ' SER . 65.2 t80 -106.55 108.32 19.77 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.866 -179.919 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.431 HG22 ' HB2' ' A' ' 188' ' ' ALA . 40.2 t -110.7 132.18 59.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.1 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.549 HG12 ' HB3' ' A' ' 158' ' ' SER . 23.7 m -121.71 160.7 23.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.137 179.919 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 86.33 51.99 3.35 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.496 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 82.4 mt -116.17 134.44 54.92 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.808 0.337 . . . . 0.0 110.96 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 10.6 t -69.48 149.26 48.47 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.854 -179.92 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 1.4 pp0? -47.58 -31.9 4.92 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.96 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 17.0 ttt180 -84.47 -39.75 18.53 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.898 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 83.1 mt -66.68 -28.95 68.86 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.918 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . 0.483 ' HB1' ' CG2' ' A' ' 143' ' ' ILE . . . -70.69 85.18 0.64 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.105 179.81 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -148.11 144.29 18.69 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.596 0.712 . . . . 0.0 110.855 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.76 -49.45 0.56 Allowed 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.66 2.24 . . . . 0.0 112.357 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 26.0 mt-10 -66.68 -41.88 87.39 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.806 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.637 HG13 ' CE2' ' A' ' 131' ' ' TYR . 87.8 t -62.64 -42.97 98.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.129 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 89.1 mt -73.18 -42.59 62.56 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.948 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 4.7 mtmp? -61.43 -27.49 68.59 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.934 179.809 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 13.5 mtm180 -53.89 144.01 38.61 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.633 0.73 . . . . 0.0 110.892 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.81 1.89 4.06 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.691 2.261 . . . . 0.0 112.309 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 8.1 mp0 -101.67 -13.85 17.62 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.924 180.0 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 131' ' ' TYR . . . . . 0.637 ' CE2' HG13 ' A' ' 125' ' ' VAL . 52.6 m-85 -109.41 -71.17 0.77 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.899 -179.82 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.457 ' O ' ' N ' ' A' ' 134' ' ' LYS . 25.1 m-85 -122.14 -40.14 2.53 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.895 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . 0.404 ' C ' ' O ' ' A' ' 132' ' ' PHE . . . -38.17 -28.57 0.05 OUTLIER Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.709 -0.757 . . . . 0.0 112.48 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.457 ' N ' ' O ' ' A' ' 132' ' ' PHE . 8.8 ptmm? -52.89 -53.79 44.11 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.831 0.348 . . . . 0.0 110.873 -179.949 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 135' ' ' PHE . . . . . 0.41 ' CD1' ' HA ' ' A' ' 172' ' ' ALA . 70.3 m-85 -52.62 -40.22 62.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.909 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -177.66 178.62 48.4 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.476 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 28.2 mtpt -86.15 97.58 10.41 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.774 0.321 . . . . 0.0 110.915 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.428 HG21 ' CG2' ' A' ' 141' ' ' VAL . 71.7 mt -62.06 140.61 18.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.138 179.907 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 17.2 t-80 -97.34 -54.1 3.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.859 179.872 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 140' ' ' LYS . . . . . 0.614 ' HD3' HG23 ' A' ' 142' ' ' VAL . 1.2 tmmt? -126.79 152.1 47.38 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.922 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . 0.428 ' CG2' HG21 ' A' ' 138' ' ' ILE . 54.4 t -139.82 145.46 26.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.133 179.915 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.614 HG23 ' HD3' ' A' ' 140' ' ' LYS . 23.5 t -138.9 116.65 12.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.113 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . 0.483 ' CG2' ' HB1' ' A' ' 121' ' ' ALA . 7.2 mm -101.57 127.81 54.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.157 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 34.6 m-80 -126.71 106.66 9.53 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.903 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 6.6 p30 -126.83 157.18 39.96 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.89 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 3.3 t -55.82 170.62 0.27 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.817 -179.814 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 31.0 m -76.68 -55.27 5.65 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.148 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 21.9 t -113.92 119.87 38.74 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.884 -179.842 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 27.5 p90 -112.97 133.16 55.06 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.903 -179.861 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -103.41 -44.33 5.17 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.139 179.854 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 116.44 39.42 0.86 Allowed Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.493 -179.994 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 7.3 m -114.55 174.07 6.14 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.771 0.32 . . . . 0.0 110.902 -179.757 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 13.6 pt20 -82.77 133.52 35.14 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.889 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 134.94 -71.98 0.48 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.507 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 120.91 7.62 Favored 'Trans proline' 0 C--N 1.342 0.228 0 C-N-CA 122.696 2.264 . . . . 0.0 112.325 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 4.2 m -120.81 161.15 21.98 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.882 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -108.39 163.66 13.01 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.082 179.938 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . 0.549 ' HB3' HG12 ' A' ' 114' ' ' VAL . 34.8 p -138.57 156.05 47.83 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.826 -179.782 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -148.9 152.15 35.9 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.083 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 19.8 m-85 -111.94 121.59 45.44 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.906 -179.852 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 61.9 t -109.43 131.62 59.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.114 -0.493 . . . . 0.0 111.079 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 20.8 m -101.26 124.4 46.89 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.116 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 163' ' ' TYR . . . . . 0.646 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 9.5 m-85 -104.53 137.53 42.24 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.946 -179.911 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 68.4 mt -62.21 -49.21 84.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.123 179.934 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 34.0 mtt85 -104.11 127.35 51.69 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.889 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 75.6 m -53.65 -58.2 8.05 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.881 -179.779 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 66.0 mm-40 -43.7 -49.24 7.9 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.872 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -55.54 -49.44 72.64 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.887 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 169' ' ' ALA . . . . . 0.646 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -56.44 -56.03 26.28 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.054 179.989 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 39.5 mt -45.41 -63.3 0.98 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.918 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 46.3 mtp180 -53.75 -48.12 69.98 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.86 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . 0.787 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -48.36 -34.14 10.18 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.145 179.899 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 173' ' ' ILE . . . . . 0.731 HD11 HG22 ' A' ' 111' ' ' VAL . 67.3 mt -80.68 -37.26 16.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.147 179.999 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 42.5 mt-30 -63.48 -27.79 69.52 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.952 179.875 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 2.6 t -93.81 -36.73 12.12 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.889 -179.927 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 176' ' ' VAL . . . . . 0.787 HG23 ' O ' ' A' ' 172' ' ' ALA . 11.3 t -58.31 -42.46 83.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.133 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 22.6 t30 -65.94 141.68 58.14 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.855 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 7.3 t30 69.37 51.33 0.5 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.884 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 96.9 t -135.13 137.87 49.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.092 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 94.7 t -98.64 109.21 23.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.125 179.889 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 84.2 t -116.58 102.44 13.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.116 179.918 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 6.9 t70 58.29 35.96 25.28 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.87 179.907 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 78.61 26.22 59.35 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.484 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 30.0 mtt-85 -133.8 115.6 14.7 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.917 0.389 . . . . 0.0 110.839 -179.833 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 23.5 m -79.73 92.76 5.45 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.157 -179.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 73.3 mt -62.95 136.46 57.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.927 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 13.6 tptp -123.81 116.43 22.96 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.886 179.8 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . 0.431 ' HB2' HG22 ' A' ' 113' ' ' VAL . . . -112.47 140.13 47.47 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.093 179.807 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 74.5 m -140.15 157.94 44.83 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.858 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 190' ' ' LEU . . . . . 0.403 ' HB2' HD13 ' A' ' 173' ' ' ILE . 7.3 tt -131.75 122.66 26.22 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.901 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 109.7 28.51 4.22 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.5 179.909 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 192' ' ' THR . . . . . . . . . . . . . 39.1 p -122.01 116.11 23.71 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.859 0.361 . . . . 0.0 111.123 -179.869 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 193' ' ' THR . . . . . . . . . . . . . 74.3 p -108.62 142.25 39.35 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.128 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 12.9 tmtt? -106.14 -55.97 2.25 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.857 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 195' ' ' TYR . . . . . . . . . . . . . 27.7 t80 -169.81 128.67 0.94 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.929 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 196' ' ' CYS . . . . . . . . . . . . . 20.9 p -164.61 152.93 12.4 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.928 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 66.9 p -40.44 129.29 2.42 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.839 -179.716 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 198' ' ' TYR . . . . . . . . . . . . . 14.2 p90 -105.49 170.02 8.13 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.889 -179.866 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 22.9 t -140.51 158.55 43.83 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.844 -179.815 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 200' ' ' GLY . . . . . 0.484 ' N ' ' O ' ' A' ' 201' ' ' PRO . . . 77.14 80.32 0.65 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.482 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 201' ' ' PRO . . . . . 0.484 ' O ' ' N ' ' A' ' 200' ' ' GLY . 53.4 Cg_endo -69.8 171.55 53.29 Favored 'Cis proline' 0 C--O 1.231 0.163 0 C-N-CA 122.666 -1.806 . . . . 0.0 112.33 0.052 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 202' ' ' SER . . . . . . . . . . . . . 10.2 t -108.77 -48.14 3.35 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.873 -179.825 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 45.0 m -105.14 165.61 10.97 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.833 -179.791 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.317 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.482 -179.984 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.314 0 N-CA-C 112.486 -0.246 . . . . 0.0 112.486 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 6.6 m -98.46 101.91 13.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.894 0.378 . . . . 0.0 110.839 -179.72 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 35.9 p -138.97 148.16 43.13 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.835 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 122.86 52.86 0.21 Allowed Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.483 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.8 t 65.85 41.9 3.65 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.853 0.359 . . . . 0.0 110.828 -179.731 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 42.2 m -97.18 173.82 7.04 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.854 -179.866 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 166.03 -177.75 40.97 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.48 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.437 ' O ' ' C ' ' A' ' 102' ' ' SER . . . -78.81 137.31 37.65 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.853 0.359 . . . . 0.0 111.052 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . 0.437 ' C ' ' O ' ' A' ' 101' ' ' ALA . 5.2 t -35.27 -43.71 0.24 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.884 -179.824 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 99.7 t -73.06 131.63 34.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.145 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 11.9 mpt_? -78.2 124.25 27.85 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.877 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.498 HG13 ' HD2' ' A' ' 108' ' ' LYS . 2.6 p -129.13 132.87 66.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.141 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 9.8 p -118.68 153.8 20.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.116 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 18.8 mm100 62.31 52.52 3.07 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.949 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.498 ' HD2' HG13 ' A' ' 105' ' ' VAL . 3.1 mppt? -70.98 87.19 0.73 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.925 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . 0.409 ' CG ' ' O ' ' A' ' 109' ' ' ASN . 28.7 t-20 -102.66 42.62 1.13 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.884 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 23.3 tp -139.61 146.07 39.31 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.888 -179.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.53 HG22 HD11 ' A' ' 173' ' ' ILE . 45.1 t -133.07 107.7 11.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.107 179.828 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.562 ' CE1' ' HB2' ' A' ' 158' ' ' SER . 67.4 t80 -102.88 113.61 27.19 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.907 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 38.2 t -111.18 145.67 17.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.101 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.44 HG12 ' HB3' ' A' ' 158' ' ' SER . 23.1 m -130.97 170.59 19.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.1 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 79.15 51.12 5.47 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.481 179.906 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 23.5 mt -118.03 131.03 56.5 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.829 0.347 . . . . 0.0 110.922 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . 0.484 ' O ' ' N ' ' A' ' 119' ' ' ARG . 23.1 t -70.95 140.19 50.85 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.812 -179.868 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' GLN . . . . . 0.434 ' C ' ' O ' ' A' ' 117' ' ' SER . 9.5 tp-100 -35.54 -32.06 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.934 -179.979 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.484 ' N ' ' O ' ' A' ' 117' ' ' SER . 18.5 tpp180 -81.49 -47.12 13.56 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.856 -179.91 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . 0.453 ' N ' ' O ' ' A' ' 117' ' ' SER . 62.4 mt -61.83 -33.69 74.6 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.952 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -66.09 86.79 0.1 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.095 179.815 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' ASP . . . . . 0.508 ' O ' HD12 ' A' ' 126' ' ' LEU . 0.6 OUTLIER -148.07 144.03 18.38 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.622 0.725 . . . . 0.0 110.871 179.969 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . 0.446 ' HA ' HG11 ' A' ' 141' ' ' VAL . 53.3 Cg_endo -69.81 -50.28 0.47 Allowed 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.649 2.232 . . . . 0.0 112.313 -179.984 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 42.7 mt-10 -68.14 -45.68 72.91 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.881 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.415 ' O ' ' CD1' ' A' ' 131' ' ' TYR . 58.4 t -60.03 -39.39 80.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.135 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.508 HD12 ' O ' ' A' ' 122' ' ' ASP . 47.3 mt -74.63 -42.01 59.36 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.942 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.736 ' HA ' HD12 ' A' ' 138' ' ' ILE . 17.3 ttmt -59.48 -30.73 68.75 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.91 179.85 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 46.8 mtt180 -39.94 143.87 0.57 Allowed Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.583 0.706 . . . . 0.0 110.893 179.949 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 2.94 3.1 Favored 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.645 2.23 . . . . 0.0 112.319 -179.984 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -106.67 -30.09 9.2 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.879 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 131' ' ' TYR . . . . . 0.415 ' CD1' ' O ' ' A' ' 125' ' ' VAL . 43.4 m-85 -86.01 -75.05 0.39 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.933 -179.844 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 17.0 m-85 -115.32 -39.72 3.55 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.888 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -52.61 -20.55 7.81 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.488 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.446 ' HD2' ' CG ' ' A' ' 135' ' ' PHE . 0.0 OUTLIER -51.2 -40.96 59.86 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.791 0.329 . . . . 0.0 110.875 -179.964 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 135' ' ' PHE . . . . . 0.446 ' CG ' ' HD2' ' A' ' 134' ' ' LYS . 83.1 m-85 -66.26 -46.38 77.27 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.882 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -173.86 -159.87 21.13 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.506 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 17.0 tptm -91.15 116.23 28.65 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.799 0.333 . . . . 0.0 110.861 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.736 HD12 ' HA ' ' A' ' 127' ' ' LYS . 91.0 mt -73.03 141.89 15.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.081 179.899 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 71.4 t60 -96.15 -44.08 7.45 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.894 179.852 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 15.8 tttm -139.67 142.7 36.94 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.911 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . 0.713 HG22 HG21 ' A' ' 138' ' ' ILE . 39.2 t -134.59 110.55 13.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.143 179.864 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 64.9 t -116.06 137.98 48.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.11 179.949 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . 0.417 HD11 HD12 ' A' ' 126' ' ' LEU . 43.1 mm -111.82 134.7 53.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.094 179.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 34.0 m-20 -131.04 110.97 11.6 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.851 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 5.8 p30 -104.43 146.19 29.21 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.918 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 66.5 m -77.4 120.55 22.56 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.851 -179.824 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 62.8 p -92.19 -46.46 7.73 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.107 -179.91 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 17.8 t -67.49 150.51 48.78 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.868 -179.859 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . 0.406 ' O ' ' CD1' ' A' ' 149' ' ' TYR . 18.7 p90 -81.27 109.98 16.3 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.917 -179.882 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -77.85 -43.66 29.64 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.113 179.86 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 93.06 38.85 5.31 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.485 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 95.3 p -116.53 175.36 5.6 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.877 0.37 . . . . 0.0 110.822 -179.698 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 4.6 tm0? -70.04 80.61 0.49 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.942 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 90.86 145.96 15.53 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.525 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 157.36 60.59 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.682 2.255 . . . . 0.0 112.31 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 3.5 m -138.39 130.22 28.12 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.878 -179.877 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -117.41 164.47 14.82 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.125 179.898 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . 0.562 ' HB2' ' CE1' ' A' ' 112' ' ' PHE . 71.5 p -140.09 154.74 47.13 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.84 -179.779 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -139.08 152.14 47.29 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.082 179.893 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 160' ' ' TYR . . . . . 0.562 ' CZ ' ' CD1' ' A' ' 112' ' ' PHE . 8.5 m-85 -114.0 115.83 28.24 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.933 -179.837 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 29.9 t -110.35 142.61 22.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.134 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 18.7 m -120.44 115.86 24.31 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.119 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 163' ' ' TYR . . . . . 0.661 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 25.0 m-85 -90.32 135.08 33.9 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.933 -179.929 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 64.1 mt -57.73 -42.73 82.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.139 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 17.7 mmm180 -98.25 125.65 43.41 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.888 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 46.6 m -55.26 -62.87 1.38 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.855 -179.781 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 5.4 tp10 -41.89 -55.84 2.95 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.856 -179.906 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 5.9 m-20 -49.59 -45.65 48.21 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.863 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 169' ' ' ALA . . . . . 0.661 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -57.1 -61.78 2.22 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.135 179.959 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 53.7 mt -42.45 -61.74 1.14 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.957 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 59.1 mtp180 -55.7 -51.56 66.87 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.882 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . 0.558 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -42.2 -36.58 1.24 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.055 179.915 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 173' ' ' ILE . . . . . 0.601 HD12 HD23 ' A' ' 190' ' ' LEU . 95.2 mt -80.18 -39.1 18.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.257 -0.428 . . . . 0.0 111.177 179.969 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 30.6 mt-30 -62.07 -26.18 68.12 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.92 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 2.2 m -93.76 -38.21 11.4 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.854 -179.92 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 176' ' ' VAL . . . . . 0.663 ' CG1' ' HB2' ' A' ' 188' ' ' ALA . 10.2 t -63.61 -39.74 86.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.128 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 14.1 t30 -63.83 138.66 58.57 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.885 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 49.9 t30 67.74 48.19 1.07 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.913 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 87.0 t -130.1 130.14 65.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.172 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 98.1 t -89.75 109.06 20.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.111 179.965 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . 0.503 ' CG2' HD12 ' A' ' 186' ' ' LEU . 87.0 t -117.17 109.85 29.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.1 179.961 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 61.9 m-20 59.85 38.49 21.26 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.831 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 73.71 34.12 56.99 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.486 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 59.0 mtt-85 -143.02 123.25 13.75 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.887 0.375 . . . . 0.0 110.88 -179.867 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 37.7 m -80.39 93.61 6.01 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.153 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 186' ' ' LEU . . . . . 0.503 HD12 ' CG2' ' A' ' 181' ' ' VAL . 45.0 mt -66.07 147.0 54.02 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.876 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 13.9 tppt? -128.0 112.35 14.55 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.913 179.838 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . 0.663 ' HB2' ' CG1' ' A' ' 176' ' ' VAL . . . -102.93 129.24 49.58 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.09 179.853 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 19.4 m -161.58 145.11 12.55 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.838 -179.775 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 190' ' ' LEU . . . . . 0.601 HD23 HD12 ' A' ' 173' ' ' ILE . 4.3 pp -118.31 158.65 24.82 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.918 179.987 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 113.05 30.66 2.67 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.481 179.884 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 192' ' ' THR . . . . . . . . . . . . . 39.6 m -109.57 116.44 31.77 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.874 0.369 . . . . 0.0 111.168 -179.917 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 193' ' ' THR . . . . . . . . . . . . . 43.7 m -109.77 129.85 55.58 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.143 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 194' ' ' LYS . . . . . 0.43 ' O ' ' C ' ' A' ' 195' ' ' TYR . 54.5 tttt -84.19 42.48 0.88 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.864 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 195' ' ' TYR . . . . . 0.43 ' C ' ' O ' ' A' ' 194' ' ' LYS . 42.1 p90 35.66 43.45 0.17 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.948 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 196' ' ' CYS . . . . . . . . . . . . . 5.3 t -76.59 123.74 26.56 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.849 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 51.8 p -80.14 143.36 33.95 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.81 -179.746 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 198' ' ' TYR . . . . . 0.496 ' CD1' ' C ' ' A' ' 198' ' ' TYR . 2.9 p90 -175.03 167.51 3.52 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.94 -179.894 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 80.6 p -119.34 142.62 47.97 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.855 -179.853 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . 136.34 -162.83 25.14 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.487 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 201' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 163.64 81.22 Favored 'Cis proline' 0 C--O 1.231 0.161 0 C-N-CA 122.696 -1.793 . . . . 0.0 112.372 0.01 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 202' ' ' SER . . . . . . . . . . . . . 11.8 t -86.72 149.55 24.8 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.84 -179.829 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 13.4 t -40.99 129.43 2.72 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.855 -179.795 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.338 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.481 -179.973 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.335 0 N-CA-C 112.468 -0.253 . . . . 0.0 112.468 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 82.1 p -121.63 138.24 54.41 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.879 0.371 . . . . 0.0 110.841 -179.737 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 4.8 t -40.77 -52.3 3.0 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.85 -179.82 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 99.46 46.73 1.93 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.478 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 2.1 t -116.3 152.98 32.78 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.872 0.368 . . . . 0.0 110.854 -179.717 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 84.5 p -116.15 -44.81 2.88 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.853 -179.823 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 177.42 95.7 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.516 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -75.81 127.09 32.27 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.812 0.339 . . . . 0.0 111.085 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 78.2 p -138.54 129.02 26.12 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.865 -179.813 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 90.9 t -96.18 109.64 23.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.129 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 36.9 ttt-85 -125.11 107.41 10.76 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.854 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 84.3 t -115.52 130.06 70.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.117 179.954 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 8.3 p -74.12 153.75 6.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.133 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 62.2 mm-40 57.85 44.93 19.28 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.935 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 18.9 ptmt -76.7 47.69 0.52 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.917 179.942 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 1.1 p-10 -130.48 -37.11 1.41 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.918 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 8.7 tp -85.98 125.43 33.38 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.894 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.877 HG22 HD11 ' A' ' 173' ' ' ILE . 96.0 t -97.85 131.76 44.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.138 179.847 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.641 ' CD1' ' CE2' ' A' ' 160' ' ' TYR . 34.5 t80 -130.27 117.43 19.81 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.845 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 69.1 t -114.73 135.54 54.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.143 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.953 HG12 ' HB3' ' A' ' 158' ' ' SER . 35.2 m -124.2 168.57 16.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.123 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 81.93 47.15 6.35 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.508 179.999 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 38.0 mt -113.45 137.76 51.08 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.888 0.375 . . . . 0.0 110.931 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . 0.406 ' O ' ' N ' ' A' ' 120' ' ' LEU . 38.4 t -63.8 141.36 58.8 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.887 -179.915 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 37.0 tt0 -39.26 -37.71 0.45 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.939 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 33.8 tpt85 -79.33 -40.82 29.37 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.874 -179.914 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . 0.406 ' N ' ' O ' ' A' ' 117' ' ' SER . 35.8 mt -62.27 -35.88 80.34 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.931 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -66.24 82.99 0.09 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.108 179.787 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 13.1 m-20 -148.06 148.35 29.37 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.555 0.693 . . . . 0.0 110.895 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 -44.34 2.15 Favored 'Trans proline' 0 N--CA 1.465 -0.165 0 C-N-CA 122.711 2.274 . . . . 0.0 112.353 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -71.87 -39.64 69.5 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.901 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.587 ' O ' ' CD1' ' A' ' 131' ' ' TYR . 37.9 t -62.55 -45.32 99.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.133 -179.989 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.565 HD22 ' CE1' ' A' ' 132' ' ' PHE . 67.0 mt -74.43 -40.92 61.65 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.891 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.459 ' HA ' HD12 ' A' ' 138' ' ' ILE . 31.6 mttt -58.32 -31.83 67.92 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.904 179.828 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 15.8 mmt85 -44.24 143.5 1.9 Allowed Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.617 0.722 . . . . 0.0 110.888 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.69 -0.56 7.03 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.72 2.28 . . . . 0.0 112.375 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 25.6 mp0 -101.46 -26.99 13.38 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.892 -179.948 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 131' ' ' TYR . . . . . 0.587 ' CD1' ' O ' ' A' ' 125' ' ' VAL . 39.8 m-85 -88.76 -75.15 0.44 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.921 -179.852 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.565 ' CE1' HD22 ' A' ' 126' ' ' LEU . 10.8 m-85 -110.45 -46.17 3.44 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.872 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -47.7 -21.21 1.37 Allowed Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.501 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.509 ' HD2' ' CD1' ' A' ' 135' ' ' PHE . 0.0 OUTLIER -53.88 -34.99 61.05 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.79 0.329 . . . . 0.0 110.884 -179.995 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 135' ' ' PHE . . . . . 0.509 ' CD1' ' HD2' ' A' ' 134' ' ' LYS . 70.8 m-85 -71.1 -46.03 62.52 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.905 179.958 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -172.6 -127.93 1.01 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.504 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . 0.482 ' HG3' HD12 ' A' ' 164' ' ' ILE . 0.3 OUTLIER -117.02 138.8 51.34 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.797 0.332 . . . . 0.0 110.938 179.994 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.459 HD12 ' HA ' ' A' ' 127' ' ' LYS . 82.1 mt -100.03 139.77 20.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.13 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 52.2 t60 -91.04 -54.14 4.08 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.852 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 35.9 ttpt -144.68 144.24 31.13 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.938 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 46.8 t -123.6 145.82 29.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.12 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 59.1 t -136.08 134.77 50.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.095 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 37.1 mm -110.47 132.46 58.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.092 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 43.6 t-20 -126.78 124.14 39.0 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.877 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 16.7 t-20 -117.36 144.97 44.37 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.883 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 3.1 t -72.57 139.57 47.55 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.861 -179.839 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 23.9 m -128.22 -41.67 1.57 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.151 -179.923 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 59.7 p -114.02 114.51 26.24 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.915 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 8.4 p90 -119.91 137.6 53.93 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.93 -179.881 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -104.58 86.23 2.46 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.101 179.87 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 56.92 40.05 89.88 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.487 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 44.4 m -109.11 130.91 55.49 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.789 0.328 . . . . 0.0 110.858 -179.729 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 8.5 pt20 -107.25 82.87 1.73 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.924 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 165.08 83.37 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.458 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.73 99.93 0.78 Allowed 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.674 2.249 . . . . 0.0 112.371 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 83.3 p -117.2 141.77 47.87 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.917 -179.863 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -114.74 156.24 25.2 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.12 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . 0.953 ' HB3' HG12 ' A' ' 114' ' ' VAL . 22.0 p -128.37 174.12 9.59 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.859 -179.766 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -159.89 141.28 12.66 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.105 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 160' ' ' TYR . . . . . 0.641 ' CE2' ' CD1' ' A' ' 112' ' ' PHE . 35.5 m-85 -100.97 144.5 29.84 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.896 -179.848 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 80.2 t -132.19 135.49 58.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.156 179.879 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 38.2 m -112.42 118.92 36.51 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.161 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 163' ' ' TYR . . . . . 0.551 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 20.0 m-85 -102.44 143.89 31.6 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.953 -179.914 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . 0.482 HD12 ' HG3' ' A' ' 137' ' ' LYS . 60.6 mt -68.19 -45.52 82.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.162 179.897 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 19.5 mtm180 -97.71 118.24 33.8 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.881 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 41.9 t -51.53 -58.5 6.13 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.846 -179.782 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 16.5 tt0 -42.4 -53.03 4.41 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.9 -179.938 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -51.85 -51.27 57.9 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.833 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 169' ' ' ALA . . . . . 0.551 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -53.37 -63.27 1.2 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.077 179.989 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 39.5 mt -38.38 -57.83 1.08 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.905 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 171' ' ' ARG . . . . . 0.427 ' O ' ' N ' ' A' ' 174' ' ' GLN . 54.2 mtp180 -58.14 -57.97 10.5 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.873 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . 0.68 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -37.67 -35.81 0.15 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.132 179.873 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 173' ' ' ILE . . . . . 0.877 HD11 HG22 ' A' ' 111' ' ' VAL . 73.6 mt -82.47 -41.13 17.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.118 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 174' ' ' GLN . . . . . 0.427 ' N ' ' O ' ' A' ' 171' ' ' ARG . 15.0 mm100 -57.23 -28.28 62.76 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.895 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 3.4 t -93.77 -39.34 10.8 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.88 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 176' ' ' VAL . . . . . 0.68 HG23 ' O ' ' A' ' 172' ' ' ALA . 10.9 t -59.52 -48.51 87.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.132 -179.947 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 10.5 t-20 -59.08 139.12 57.2 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.893 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 4.7 t-20 70.25 45.91 0.63 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.876 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 179' ' ' VAL . . . . . 0.576 HG23 ' O ' ' A' ' 176' ' ' VAL . 84.3 t -125.18 137.72 56.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.138 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 95.6 t -96.51 98.57 7.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.155 179.922 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . 0.52 HG21 HD12 ' A' ' 186' ' ' LEU . 47.7 t -111.11 111.82 37.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.169 179.908 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 57.12 42.81 25.15 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.88 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 67.03 35.08 88.74 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.511 -179.89 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 81.9 mtt85 -143.03 136.43 28.38 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.876 0.369 . . . . 0.0 110.906 -179.889 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 23.1 m -92.22 92.19 8.09 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.129 -179.885 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 186' ' ' LEU . . . . . 0.52 HD12 HG21 ' A' ' 181' ' ' VAL . 44.8 mt -61.62 125.11 22.63 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.917 179.929 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 36.0 mmtt -103.09 114.01 27.95 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.862 179.848 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -111.35 132.52 54.35 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.109 179.837 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 16.8 m -149.81 145.28 26.51 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.843 -179.788 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 190' ' ' LEU . . . . . 0.491 ' HB3' HD13 ' A' ' 173' ' ' ILE . 1.3 pt? -123.81 151.1 43.73 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.932 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 73.44 27.25 68.11 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.518 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 192' ' ' THR . . . . . . . . . . . . . 9.8 m -127.46 140.53 52.09 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.872 0.368 . . . . 0.0 111.131 -179.864 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 193' ' ' THR . . . . . . . . . . . . . 13.1 t -107.4 -17.84 14.02 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.132 -179.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 30.2 mmtm -97.25 165.72 11.9 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.9 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 195' ' ' TYR . . . . . . . . . . . . . 57.7 m-85 -77.93 -51.02 11.06 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.938 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 196' ' ' CYS . . . . . . . . . . . . . 30.1 p -170.1 130.51 0.96 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.872 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 7.7 t -170.58 161.69 7.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.824 -179.795 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 198' ' ' TYR . . . . . . . . . . . . . 17.3 t80 -64.75 92.76 0.1 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.891 -179.846 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 76.0 p -56.96 146.04 28.23 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.876 -179.874 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 200' ' ' GLY . . . . . 0.405 ' HA3' ' C ' ' A' ' 201' ' ' PRO . . . 158.0 -69.25 0.27 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.507 -179.998 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 201' ' ' PRO . . . . . 0.405 ' C ' ' HA3' ' A' ' 200' ' ' GLY . 53.8 Cg_endo -69.7 -32.23 4.04 Favored 'Cis proline' 0 C--N 1.341 0.157 0 C-N-CA 122.686 -1.797 . . . . 0.0 112.342 -0.017 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 202' ' ' SER . . . . . . . . . . . . . 1.3 t -168.44 134.2 1.81 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.847 -179.807 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 82.9 p -130.69 124.01 30.62 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.852 -179.829 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.366 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.521 179.997 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.315 0 N-CA-C 112.514 -0.234 . . . . 0.0 112.514 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 50.3 m -152.19 135.49 15.91 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.893 0.378 . . . . 0.0 110.831 -179.758 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 99.5 p -154.65 154.73 33.44 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.878 -179.837 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 94.05 179.83 38.41 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.44 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 22.7 t -129.34 -59.3 1.1 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.854 0.359 . . . . 0.0 110.853 -179.709 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 6.4 t -72.78 105.31 4.29 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.872 -179.83 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -103.09 -166.03 25.83 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.52 -179.992 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -93.3 120.45 33.6 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.808 0.337 . . . . 0.0 111.103 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 74.7 m -73.27 80.48 1.33 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.904 -179.822 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 10.8 m -89.86 151.66 3.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.18 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 17.7 ptt180 -126.44 147.17 49.84 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.845 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 79.6 t -119.89 112.65 37.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.131 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 1.2 p -93.21 134.07 32.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.133 179.915 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 49.8 tt0 -159.85 139.22 11.12 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.902 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.437 ' HG3' HD21 ' A' ' 170' ' ' LEU . 20.3 pttm -97.68 59.91 1.52 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.923 179.963 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -128.43 -38.59 1.74 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.914 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 17.1 tp -88.16 143.03 27.29 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.93 179.932 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.687 HG22 HD11 ' A' ' 173' ' ' ILE . 87.9 t -115.6 132.62 64.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.152 179.86 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.568 ' CE2' ' CG1' ' A' ' 114' ' ' VAL . 50.3 t80 -128.65 106.68 9.12 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.871 -179.936 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.455 HG22 ' HB2' ' A' ' 188' ' ' ALA . 55.9 t -103.46 122.05 55.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.12 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.568 ' CG1' ' CE2' ' A' ' 112' ' ' PHE . 18.7 m -110.66 152.65 12.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.111 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 94.2 37.7 5.31 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.524 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . 0.419 ' O ' ' HB3' ' A' ' 157' ' ' ALA . 30.0 mt -101.64 134.38 44.86 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.834 0.35 . . . . 0.0 110.889 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . 0.437 ' O ' ' N ' ' A' ' 120' ' ' LEU . 24.4 t -68.71 141.33 55.33 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.874 -179.932 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 43.6 tt0 -42.27 -25.7 0.08 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.881 -179.926 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 6.3 tpm_? -89.83 -36.32 15.17 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.83 -179.914 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . 0.437 ' N ' ' O ' ' A' ' 117' ' ' SER . 32.2 mt -70.25 -32.25 70.01 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.879 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -70.19 84.67 0.55 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.117 179.77 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -146.31 146.71 28.64 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.588 0.709 . . . . 0.0 110.838 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 -46.23 1.28 Allowed 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.666 2.244 . . . . 0.0 112.333 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -70.64 -38.13 73.85 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.875 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.484 ' O ' ' CD1' ' A' ' 131' ' ' TYR . 87.3 t -65.76 -50.84 68.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.085 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.622 HD22 ' CE1' ' A' ' 132' ' ' PHE . 89.8 mt -68.41 -37.16 80.08 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.901 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.418 ' HA ' HD12 ' A' ' 138' ' ' ILE . 27.6 mttm -62.25 -37.46 85.53 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.863 179.874 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 2.5 mmp_? -43.29 143.88 1.32 Allowed Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.607 0.718 . . . . 0.0 110.839 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 -4.28 13.72 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.651 2.234 . . . . 0.0 112.338 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 1.3 tm-20 -94.18 -16.26 23.86 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.918 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 131' ' ' TYR . . . . . 0.484 ' CD1' ' O ' ' A' ' 125' ' ' VAL . 61.8 m-85 -102.53 -72.06 0.7 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.929 -179.857 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.622 ' CE1' HD22 ' A' ' 126' ' ' LEU . 61.1 m-85 -122.44 -39.6 2.55 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.862 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -41.24 -26.43 0.19 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.484 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.406 ' N ' ' O ' ' A' ' 132' ' ' PHE . 8.5 ptmm? -47.0 -39.13 11.94 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.808 0.337 . . . . 0.0 110.946 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 135' ' ' PHE . . . . . 0.54 ' CE1' ' HA ' ' A' ' 172' ' ' ALA . 66.0 m-85 -63.18 -45.6 91.01 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.87 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 173.58 -148.19 10.03 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.483 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 16.6 tttm -95.42 115.71 27.8 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.828 0.347 . . . . 0.0 110.93 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.548 HG21 ' CG2' ' A' ' 141' ' ' VAL . 86.2 mt -71.63 140.09 18.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.109 179.906 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 34.3 t-80 -82.12 -59.62 2.5 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.883 179.871 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 39.9 tptt -140.13 151.22 45.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.966 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . 0.548 ' CG2' HG21 ' A' ' 138' ' ' ILE . 88.3 t -136.97 122.42 26.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.133 179.933 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 43.7 t -125.9 120.23 56.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.132 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 18.2 mm -86.57 136.71 22.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.133 179.902 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 2.3 m-80 -128.48 134.35 48.7 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.897 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 88.5 m-20 -126.19 170.38 11.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.87 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 58.3 m -99.07 118.21 35.32 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.886 -179.863 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 10.7 t -118.47 40.8 3.13 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.128 -179.892 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 66.7 m -114.01 162.7 16.1 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.863 -179.849 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . 0.578 ' O ' ' CD2' ' A' ' 149' ' ' TYR . 46.5 p90 -115.98 95.65 5.21 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.933 -179.901 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -109.84 -42.35 4.27 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.113 179.882 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 108.83 39.94 1.65 Allowed Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.483 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 23.6 m -104.21 167.38 9.79 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.805 0.336 . . . . 0.0 110.881 -179.727 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 24.2 tp60 -106.23 141.44 37.57 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.921 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 49.02 82.62 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.482 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.73 170.54 16.3 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.687 2.258 . . . . 0.0 112.378 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 21.1 m -128.94 148.6 50.94 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.864 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . 0.419 ' HB3' ' O ' ' A' ' 116' ' ' LEU . . . -116.04 164.17 14.83 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.091 179.922 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . 0.4 ' HB2' ' CE1' ' A' ' 112' ' ' PHE . 51.1 p -139.58 158.68 43.71 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.882 -179.827 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -139.71 145.0 37.8 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.081 179.878 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 160' ' ' TYR . . . . . 0.471 ' CZ ' ' CD1' ' A' ' 112' ' ' PHE . 89.1 m-85 -104.73 125.95 51.32 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.918 -179.841 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 85.7 t -122.11 130.92 74.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.133 179.895 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 20.6 m -111.53 129.79 55.94 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.122 -179.908 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 163' ' ' TYR . . . . . 0.51 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 33.4 m-85 -105.27 160.0 15.44 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.918 -179.93 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 63.0 mt -84.51 -58.82 3.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.147 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 22.2 mmt180 -85.85 125.38 33.25 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.866 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 17.4 m -49.19 -60.55 2.7 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.878 -179.797 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . 0.47 ' HA ' HD12 ' A' ' 170' ' ' LEU . 29.1 tt0 -40.89 -54.91 2.61 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.91 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 7.4 t70 -49.68 -49.91 45.62 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.901 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 169' ' ' ALA . . . . . 0.51 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -57.67 -54.18 49.8 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.132 179.935 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . 0.47 HD12 ' HA ' ' A' ' 167' ' ' GLU . 35.8 mt -44.09 -60.96 1.64 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.883 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 85.5 mtt180 -58.84 -42.99 90.6 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.892 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . 0.659 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -49.42 -35.24 18.55 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.096 179.939 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 173' ' ' ILE . . . . . 0.687 HD11 HG22 ' A' ' 111' ' ' VAL . 82.6 mt -86.47 -40.7 14.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.153 179.97 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 77.3 mt-30 -62.39 -27.19 68.91 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.923 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 16.1 m -93.79 -42.21 9.25 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.941 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 176' ' ' VAL . . . . . 0.659 HG23 ' O ' ' A' ' 172' ' ' ALA . 9.9 t -59.05 -40.48 80.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.137 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 177' ' ' ASN . . . . . 0.435 ' C ' ' OD1' ' A' ' 177' ' ' ASN . 0.8 OUTLIER -66.49 145.18 55.93 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.916 179.982 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 19.1 t30 68.85 41.61 1.5 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.85 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 95.3 t -121.61 133.12 69.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.112 179.886 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 87.8 t -98.6 103.02 14.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.121 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 97.8 t -111.6 116.39 52.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.111 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER 47.4 43.09 15.13 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.911 179.947 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 71.22 31.29 66.41 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.464 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 32.0 mtp85 -137.09 109.42 7.33 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.883 0.373 . . . . 0.0 110.886 -179.884 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 29.7 m -71.78 92.35 1.21 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.163 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 62.7 mt -60.48 132.86 55.22 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.936 179.963 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -124.89 115.45 20.65 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.865 179.87 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . 0.455 ' HB2' HG22 ' A' ' 113' ' ' VAL . . . -107.25 144.06 34.6 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.135 179.801 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 2.4 t -146.58 168.57 20.93 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.869 -179.763 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 190' ' ' LEU . . . . . 0.771 ' N ' HD13 ' A' ' 190' ' ' LEU . 0.0 OUTLIER -125.79 161.46 27.33 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.94 179.995 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 68.18 30.72 73.89 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.494 179.901 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 192' ' ' THR . . . . . 0.4 HG21 ' CD2' ' A' ' 112' ' ' PHE . 29.0 m -88.71 130.2 35.38 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.849 0.356 . . . . 0.0 111.133 -179.827 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 193' ' ' THR . . . . . . . . . . . . . 30.2 m -117.6 131.71 56.63 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.123 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 28.4 pttt -107.86 -16.98 14.18 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.867 179.912 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 195' ' ' TYR . . . . . 0.419 ' O ' ' C ' ' A' ' 196' ' ' CYS . 35.9 t80 -133.14 119.49 20.0 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.906 -179.97 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 196' ' ' CYS . . . . . 0.419 ' C ' ' O ' ' A' ' 195' ' ' TYR . 26.8 p -37.05 130.19 0.84 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.893 179.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 10.7 t -96.77 128.1 43.4 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.828 -179.71 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 198' ' ' TYR . . . . . . . . . . . . . 3.2 p90 -125.29 129.16 49.45 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.906 -179.885 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 6.3 t -167.51 126.57 1.33 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.864 -179.808 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . 113.2 175.67 19.33 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.503 179.997 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 201' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.77 177.11 30.02 Favored 'Cis proline' 0 C--O 1.231 0.167 0 C-N-CA 122.682 -1.799 . . . . 0.0 112.347 0.086 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 202' ' ' SER . . . . . . . . . . . . . 19.7 m -120.41 88.98 3.04 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.876 -179.837 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 90.0 p -160.17 150.82 18.74 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.864 -179.812 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.362 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.538 -179.953 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.271 0 N-CA-C 112.479 -0.249 . . . . 0.0 112.479 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 4.9 t -121.32 117.55 27.27 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.851 0.357 . . . . 0.0 110.828 -179.728 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 30.9 t -39.4 -44.25 1.32 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.861 -179.826 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -127.0 87.35 0.34 Allowed Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.485 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 1.1 t -103.51 130.05 50.82 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.83 0.347 . . . . 0.0 110.866 -179.734 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 2.4 t -140.85 129.66 23.03 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.896 -179.853 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 131.17 -78.36 0.38 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.459 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -58.56 154.56 13.97 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.799 0.333 . . . . 0.0 111.117 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 4.0 m -136.71 121.94 19.2 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.831 -179.78 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 93.6 t -92.37 125.28 45.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.129 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 11.6 ptm180 -106.64 146.4 30.78 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.923 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 98.9 t -98.82 104.52 16.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.119 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 34.9 m -117.45 146.58 21.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.12 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 7.5 tt0 -37.15 138.23 0.3 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.937 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.425 ' HA ' HD11 ' A' ' 190' ' ' LEU . 8.8 mptt -97.96 48.83 1.01 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.91 179.914 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 3.3 t30 -90.03 -36.84 14.69 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.836 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 20.0 tp -90.82 127.78 36.48 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.875 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 90.7 t -118.51 123.35 71.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.114 179.856 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.437 ' CZ ' HG12 ' A' ' 114' ' ' VAL . 39.2 t80 -113.34 126.06 54.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.853 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.43 HG22 ' HB2' ' A' ' 188' ' ' ALA . 55.6 t -119.74 141.07 41.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.128 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.437 HG12 ' CZ ' ' A' ' 112' ' ' PHE . 19.8 m -119.73 171.76 7.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.134 179.889 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 73.75 53.56 7.2 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.514 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 29.7 mt -116.25 126.32 53.43 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.827 0.346 . . . . 0.0 110.9 -179.9 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 89.0 p -64.58 153.08 40.32 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.865 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 44.6 tt0 -52.6 -26.53 13.73 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.907 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -87.19 -43.29 12.34 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.88 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 51.9 mt -66.52 -21.16 66.17 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.964 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -71.68 82.99 0.87 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.123 179.755 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -148.98 144.01 17.65 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-O 121.63 0.729 . . . . 0.0 110.893 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -50.51 0.46 Allowed 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.728 2.285 . . . . 0.0 112.339 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 35.0 mt-10 -69.43 -45.39 69.27 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.859 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.592 ' O ' ' CD1' ' A' ' 131' ' ' TYR . 53.5 t -57.94 -42.33 82.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.156 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 77.0 mt -72.47 -44.73 61.91 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.87 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.544 ' HA ' HD12 ' A' ' 138' ' ' ILE . 12.0 ttpp -59.17 -35.13 72.99 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.881 179.853 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 38.4 mtt-85 -38.58 144.6 0.39 Allowed Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.567 0.699 . . . . 0.0 110.889 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.73 0.5 5.53 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.706 2.271 . . . . 0.0 112.329 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -104.98 -7.93 18.92 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.854 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 131' ' ' TYR . . . . . 0.592 ' CD1' ' O ' ' A' ' 125' ' ' VAL . 45.1 m-85 -111.47 -74.93 0.62 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.927 -179.861 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.435 ' O ' ' N ' ' A' ' 134' ' ' LYS . 14.2 m-85 -114.99 -36.34 4.46 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.886 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -42.56 -22.41 0.13 Allowed Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.486 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.435 ' N ' ' O ' ' A' ' 132' ' ' PHE . 5.3 mtpt -49.22 -59.5 3.62 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.813 0.34 . . . . 0.0 110.896 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 135' ' ' PHE . . . . . 0.57 ' CE1' ' HA ' ' A' ' 172' ' ' ALA . 82.2 m-85 -47.89 -42.55 27.18 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.889 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 173.84 -168.31 41.12 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.487 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 13.5 tttt -82.68 117.6 22.73 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.751 0.31 . . . . 0.0 110.901 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.544 HD12 ' HA ' ' A' ' 127' ' ' LYS . 68.5 mt -77.0 144.88 11.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.167 179.859 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 9.8 t-80 -88.89 -57.62 2.84 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.879 179.846 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 42.4 tttt -142.13 149.24 39.54 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.894 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . 0.508 ' CG2' HG21 ' A' ' 138' ' ' ILE . 59.7 t -133.67 140.74 45.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.144 179.855 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 84.3 t -134.66 129.79 52.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.154 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 51.9 mm -100.33 131.32 48.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.136 179.916 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 4.4 m-80 -128.67 117.45 21.21 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.881 179.961 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 3.0 p-10 -100.14 140.3 34.58 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.885 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 43.9 t -80.51 121.69 26.08 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.881 -179.862 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 90.3 m -83.17 -42.65 17.06 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.134 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 17.0 t -102.71 109.67 21.34 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.894 -179.877 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 3.3 p90 -105.35 154.19 20.62 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.918 -179.847 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -75.08 -46.9 31.6 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.129 179.877 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 96.64 39.41 4.16 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.451 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 19.2 m -106.64 -57.15 2.1 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.813 0.339 . . . . 0.0 110.866 -179.769 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 17.7 mp0 -104.02 -52.29 2.98 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.881 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 160.57 176.77 33.04 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.487 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 121.08 7.77 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.695 2.263 . . . . 0.0 112.335 -179.929 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 80.0 p -132.65 112.5 12.08 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.855 -179.844 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -91.3 168.56 11.49 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.081 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 7.2 m -130.63 168.14 17.61 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.872 -179.82 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -146.74 150.96 36.39 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.106 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 160' ' ' TYR . . . . . 0.424 ' CZ ' ' CD1' ' A' ' 112' ' ' PHE . 7.1 m-85 -116.48 123.01 46.42 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.949 -179.838 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 87.3 t -112.56 142.2 25.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.124 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 32.9 m -113.36 118.3 34.2 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.141 -179.926 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 24.4 m-85 -98.57 150.19 21.98 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.907 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 57.4 mt -88.94 -42.09 14.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.158 179.905 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 75.4 mtp180 -94.67 119.31 33.11 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.895 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 29.3 m -49.2 -60.09 3.11 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.859 -179.776 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 19.5 mt-10 -42.92 -53.02 4.91 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.899 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -49.84 -49.05 50.53 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.849 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -56.62 -58.73 6.82 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.119 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 56.2 mt -41.0 -59.65 1.4 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.863 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 54.0 mtp180 -59.99 -44.23 94.65 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.91 179.948 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . 0.613 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -47.96 -36.12 11.98 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.11 179.937 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 173' ' ' ILE . . . . . . . . . . . . . 64.7 mt -79.87 -42.67 22.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.085 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 40.3 mt-30 -65.26 -24.61 67.36 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.928 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 175' ' ' CYS . . . . . 0.494 ' O ' ' CG2' ' A' ' 179' ' ' VAL . 3.3 t -93.89 -38.94 10.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.849 -179.932 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 176' ' ' VAL . . . . . 0.613 HG23 ' O ' ' A' ' 172' ' ' ALA . 9.8 t -64.34 -26.97 41.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.139 -179.985 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 12.5 t30 -75.61 146.63 40.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.869 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 42.1 t30 59.89 41.43 17.85 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.887 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 179' ' ' VAL . . . . . 0.494 ' CG2' ' O ' ' A' ' 175' ' ' CYS . 85.9 t -121.12 135.96 59.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.133 179.917 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 99.7 t -104.15 122.98 57.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.147 179.895 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . 0.465 HG21 ' CD1' ' A' ' 186' ' ' LEU . 60.6 t -128.28 103.38 9.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.114 179.949 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 5.9 m-20 55.24 37.82 29.47 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.857 179.91 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 81.02 36.78 20.81 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.476 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -141.55 121.36 13.53 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.893 0.378 . . . . 0.0 110.866 -179.855 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 27.6 m -84.23 92.9 8.07 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.144 -179.891 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 186' ' ' LEU . . . . . 0.465 ' CD1' HG21 ' A' ' 181' ' ' VAL . 88.5 mt -69.59 120.74 15.83 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.893 179.991 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 14.8 mtmm -121.51 122.89 40.73 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.892 179.8 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . 0.43 ' HB2' HG22 ' A' ' 113' ' ' VAL . . . -107.7 146.18 32.43 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.104 179.834 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 53.2 m -139.05 169.52 17.64 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.862 -179.821 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 190' ' ' LEU . . . . . 0.433 ' HA ' HD22 ' A' ' 190' ' ' LEU . 0.7 OUTLIER -127.8 125.73 40.38 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.942 179.977 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 69.57 28.87 71.81 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.493 179.915 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 192' ' ' THR . . . . . . . . . . . . . 4.4 p -117.88 133.82 55.55 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.867 0.365 . . . . 0.0 111.128 -179.817 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 193' ' ' THR . . . . . . . . . . . . . 68.9 p -122.04 99.76 6.61 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.146 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 21.7 mmtt -99.91 86.0 3.19 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.909 179.908 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 195' ' ' TYR . . . . . . . . . . . . . 45.7 t80 -175.0 158.98 2.57 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.9 -179.925 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 196' ' ' CYS . . . . . . . . . . . . . 55.6 m -83.35 95.74 8.3 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.834 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 59.5 p -117.99 83.93 2.08 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.846 -179.757 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 198' ' ' TYR . . . . . 0.409 ' O ' ' CD1' ' A' ' 198' ' ' TYR . 10.9 p90 -103.67 104.48 14.52 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.906 -179.868 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 82.8 p -149.78 160.02 43.89 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.836 -179.865 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 200' ' ' GLY . . . . . 0.426 ' HA2' ' C ' ' A' ' 201' ' ' PRO . . . 88.99 172.07 46.06 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.494 -179.987 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 201' ' ' PRO . . . . . 0.426 ' C ' ' HA2' ' A' ' 200' ' ' GLY . 53.7 Cg_endo -69.8 165.13 77.57 Favored 'Cis proline' 0 C--N 1.341 0.162 0 C-N-CA 122.692 -1.795 . . . . 0.0 112.342 0.073 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 202' ' ' SER . . . . . . . . . . . . . 93.0 p -151.94 156.84 40.86 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.901 -179.855 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 17.6 t -98.11 149.89 22.03 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.818 -179.769 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.343 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.515 179.995 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.309 0 N-CA-C 112.496 -0.242 . . . . 0.0 112.496 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 8.6 t -169.84 115.78 0.54 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.89 0.376 . . . . 0.0 110.873 -179.7 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 50.9 m -104.69 122.37 45.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.861 -179.799 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -61.39 -115.1 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.519 -179.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 52.1 p -142.6 116.63 9.4 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.872 0.368 . . . . 0.0 110.866 -179.736 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 11.8 p -38.75 -39.66 0.53 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.87 -179.86 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 117.93 114.88 2.68 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.498 -179.957 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.622 ' O ' HG23 ' A' ' 103' ' ' VAL . . . -55.5 118.12 4.19 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.798 0.332 . . . . 0.0 111.126 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . 0.439 ' C ' ' O ' ' A' ' 101' ' ' ALA . 28.7 t 34.46 39.78 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.892 -179.734 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.622 HG23 ' O ' ' A' ' 101' ' ' ALA . 82.7 t -94.91 99.65 9.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.148 179.939 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -100.15 109.74 22.01 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.905 -179.987 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.752 HG21 ' HB ' ' A' ' 193' ' ' THR . 13.5 p -114.43 141.19 31.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.118 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 94.7 t -118.93 95.86 3.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.11 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.451 ' CD ' HD22 ' A' ' 110' ' ' LEU . 9.6 mt-30 -151.82 118.52 5.74 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.905 179.994 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 28.2 ttmt -103.8 -37.82 7.3 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.931 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 16.1 p30 -93.12 39.38 1.05 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.908 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . 0.451 HD22 ' CD ' ' A' ' 107' ' ' GLN . 26.2 tp -113.49 116.3 29.36 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.873 -179.999 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 99.5 t -106.48 109.68 28.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.213 179.775 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.483 ' CZ ' ' CG1' ' A' ' 114' ' ' VAL . 40.4 t80 -100.64 107.09 18.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.924 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 75.0 t -106.35 138.57 31.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.139 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.483 ' CG1' ' CZ ' ' A' ' 112' ' ' PHE . 31.0 m -122.68 160.79 24.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.101 179.913 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 81.54 53.21 3.89 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.491 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 32.9 mt -106.17 120.74 42.61 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.778 0.323 . . . . 0.0 110.938 -179.903 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . 0.42 ' O ' ' N ' ' A' ' 120' ' ' LEU . 26.3 t -64.65 142.82 58.29 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.883 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 118' ' ' GLN . . . . . 0.439 ' C ' ' CD ' ' A' ' 118' ' ' GLN . 0.7 OUTLIER -36.65 -43.71 0.43 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.917 -179.942 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 25.9 tpt180 -74.2 -42.32 59.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.852 -179.926 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . 0.42 ' N ' ' O ' ' A' ' 117' ' ' SER . 40.1 mt -61.49 -31.35 71.33 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.922 -179.987 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -68.5 83.37 0.27 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.134 179.801 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 73.1 m-20 -148.96 143.18 16.79 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.574 0.702 . . . . 0.0 110.899 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.86 -50.78 0.42 Allowed 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.67 2.247 . . . . 0.0 112.335 -179.925 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -65.46 -51.33 60.91 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.881 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.644 ' CG1' ' CZ ' ' A' ' 131' ' ' TYR . 64.3 t -54.02 -46.59 65.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.112 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.423 HD22 ' CE1' ' A' ' 132' ' ' PHE . 83.0 mt -66.99 -42.79 84.44 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.895 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.539 ' HA ' HD12 ' A' ' 138' ' ' ILE . 20.2 tttm -58.17 -40.46 81.51 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.884 179.845 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 34.6 mtp180 -38.24 143.29 0.43 Allowed Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.598 0.713 . . . . 0.0 110.872 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 1.53 4.37 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.626 2.217 . . . . 0.0 112.321 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 35.2 mm-40 -99.68 -27.99 13.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.848 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 131' ' ' TYR . . . . . 0.644 ' CZ ' ' CG1' ' A' ' 125' ' ' VAL . 55.7 m-85 -90.54 -68.27 0.8 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.92 -179.82 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.493 ' O ' ' N ' ' A' ' 134' ' ' LYS . 12.8 m-85 -116.95 -52.5 2.52 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.894 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . 0.402 ' C ' ' O ' ' A' ' 132' ' ' PHE . . . -37.8 -27.37 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.5 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.493 ' N ' ' O ' ' A' ' 132' ' ' PHE . 19.5 ptmt -43.04 -49.64 6.09 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.814 0.34 . . . . 0.0 110.851 -179.93 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 135' ' ' PHE . . . . . 0.469 ' CZ ' ' CG2' ' A' ' 176' ' ' VAL . 58.0 m-85 -63.3 -47.38 82.51 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.915 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -173.61 -172.26 38.85 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.755 -0.735 . . . . 0.0 112.477 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 22.8 mtmm -79.23 122.93 26.92 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.777 0.322 . . . . 0.0 110.872 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.539 HD12 ' HA ' ' A' ' 127' ' ' LYS . 87.7 mt -79.92 141.64 15.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.111 179.871 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 61.5 t-80 -91.02 -49.07 6.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.852 179.868 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 76.8 tttt -146.28 153.47 40.61 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.897 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 42.2 t -132.4 140.24 48.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.156 179.881 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 93.3 t -133.23 131.52 58.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.143 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 43.5 mm -111.67 121.99 65.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.138 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 11.1 t30 -114.49 118.69 34.5 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.89 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 28.5 m-80 -103.67 147.86 26.73 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.869 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 23.0 t -87.71 129.66 35.08 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.839 -179.861 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 147' ' ' THR . . . . . 0.445 HG23 ' N ' ' A' ' 148' ' ' SER . 10.1 t -109.12 -42.68 4.35 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.169 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . 0.445 ' N ' HG23 ' A' ' 147' ' ' THR . 25.3 t -67.61 123.35 20.23 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.844 -179.869 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 40.7 p90 -74.06 141.79 45.7 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.878 -179.872 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -102.65 -50.61 3.51 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.125 179.844 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 82.78 -19.75 10.97 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.489 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 66.9 m -111.18 -51.66 2.85 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.813 0.34 . . . . 0.0 110.848 -179.721 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . 0.412 ' O ' ' C ' ' A' ' 154' ' ' GLY . 37.4 mt-30 -107.23 112.46 25.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.878 -179.951 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . 0.412 ' C ' ' O ' ' A' ' 153' ' ' GLN . . . -37.18 146.12 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.467 -179.952 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.76 124.07 10.72 Favored 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.7 2.267 . . . . 0.0 112.342 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 90.0 p -126.99 122.78 35.49 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.817 -179.818 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -87.57 162.61 17.09 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.05 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 94.2 p -136.36 163.2 31.0 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.845 -179.813 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -146.76 148.77 32.29 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.067 179.917 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 160' ' ' TYR . . . . . 0.506 ' CZ ' ' HB3' ' A' ' 194' ' ' LYS . 11.0 m-85 -112.73 139.53 48.26 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.948 -179.873 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 71.4 t -130.3 121.43 51.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.16 179.896 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 87.2 m -99.52 129.0 45.66 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.13 -179.93 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 163' ' ' TYR . . . . . 0.554 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 52.7 m-85 -110.37 147.07 34.68 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.906 -179.88 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 53.1 mt -67.42 -60.62 2.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.123 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 46.9 mtp85 -82.43 112.99 19.88 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.893 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 74.0 m -52.45 -49.38 64.74 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.882 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 16.5 tt0 -44.5 -55.64 4.93 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.921 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 64.8 m-20 -55.84 -45.86 78.29 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.858 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 169' ' ' ALA . . . . . 0.554 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -58.48 -59.85 4.73 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.063 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 46.1 mt -42.65 -61.56 1.21 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.892 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 1.3 mpt_? -54.93 -50.38 68.99 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.835 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . 0.706 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -43.52 -36.73 2.15 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.091 179.933 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 173' ' ' ILE . . . . . 0.476 HG23 ' HB3' ' A' ' 188' ' ' ALA . 73.6 mt -78.77 -40.79 23.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.142 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 33.7 mt-30 -60.01 -30.22 69.0 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.915 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 1.8 m -93.8 -39.91 10.48 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.832 -179.895 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 176' ' ' VAL . . . . . 0.706 HG23 ' O ' ' A' ' 172' ' ' ALA . 10.6 t -59.56 -45.43 94.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.156 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 177' ' ' ASN . . . . . 0.448 ' OD1' ' N ' ' A' ' 178' ' ' ASN . 37.0 t30 -53.92 146.17 14.79 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.909 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 178' ' ' ASN . . . . . 0.448 ' N ' ' OD1' ' A' ' 177' ' ' ASN . 10.4 m120 57.83 47.26 15.61 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.891 -180.0 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 95.3 t -132.43 139.76 49.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.145 179.893 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 95.4 t -93.97 114.02 29.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.101 179.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 96.0 t -120.86 105.87 17.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.156 179.879 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 6.5 t0 65.62 35.32 7.13 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.878 179.928 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 81.19 -14.03 29.83 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.493 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 10.6 mpt_? -102.94 112.7 25.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.867 0.365 . . . . 0.0 110.863 -179.869 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 25.3 m -70.9 93.7 1.0 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.17 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 83.3 mt -70.97 149.5 46.61 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.947 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 13.5 ttpt -136.36 126.45 26.18 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.928 179.863 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . 0.476 ' HB3' HG23 ' A' ' 173' ' ' ILE . . . -112.38 141.91 45.54 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.139 179.801 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 8.5 t -139.86 165.56 26.99 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.868 -179.748 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 190' ' ' LEU . . . . . . . . . . . . . 38.1 tp -127.14 135.82 51.24 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.918 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 105.58 24.68 6.94 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.498 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 192' ' ' THR . . . . . 0.439 ' O ' HD21 ' A' ' 110' ' ' LEU . 34.3 p -128.35 119.31 24.81 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.854 0.359 . . . . 0.0 111.108 -179.815 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 193' ' ' THR . . . . . 0.752 ' HB ' HG21 ' A' ' 105' ' ' VAL . 1.9 t -107.38 128.4 54.44 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.144 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 194' ' ' LYS . . . . . 0.506 ' HB3' ' CZ ' ' A' ' 160' ' ' TYR . 22.8 pttt -63.6 153.12 36.88 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.916 179.912 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 195' ' ' TYR . . . . . . . . . . . . . 96.2 m-85 -86.67 88.47 7.67 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.894 -179.931 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 196' ' ' CYS . . . . . . . . . . . . . 43.0 t -100.44 152.33 20.49 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.864 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 29.8 t -134.22 140.36 46.43 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.901 -179.744 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 198' ' ' TYR . . . . . . . . . . . . . 8.4 p90 -148.53 164.89 32.85 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.91 -179.837 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 91.7 p -90.21 129.08 36.51 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.871 -179.865 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 200' ' ' GLY . . . . . 0.43 ' HA2' ' C ' ' A' ' 201' ' ' PRO . . . -131.11 171.94 20.85 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.52 180.0 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 201' ' ' PRO . . . . . 0.43 ' C ' ' HA2' ' A' ' 200' ' ' GLY . 53.3 Cg_endo -69.81 131.32 19.0 Favored 'Cis proline' 0 C--N 1.342 0.196 0 C-N-CA 122.647 -1.814 . . . . 0.0 112.337 0.12 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 202' ' ' SER . . . . . . . . . . . . . 77.3 p -77.95 87.79 4.13 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.876 -179.848 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 3.0 m 57.77 38.28 27.34 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.858 -179.845 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.358 0 C-N-CA 120.734 -0.745 . . . . 0.0 112.514 179.985 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.328 0 N-CA-C 112.482 -0.247 . . . . 0.0 112.482 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 12.2 m -38.15 107.72 0.07 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.875 0.369 . . . . 0.0 110.876 -179.778 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 24.6 m -154.92 170.23 22.2 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.873 -179.83 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 157.08 164.91 14.14 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.534 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 49.8 m -107.07 83.52 1.84 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.858 0.361 . . . . 0.0 110.898 -179.743 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 90.8 p -108.99 101.07 10.18 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.879 -179.824 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 124.03 105.21 1.66 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.493 -179.956 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -75.06 141.94 43.78 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.782 0.325 . . . . 0.0 111.12 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 17.4 m -150.63 171.76 16.61 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.866 -179.808 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 35.0 m -75.95 151.66 6.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.113 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 14.3 ptt180 -93.38 125.18 37.85 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.887 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 16.6 m -128.36 127.12 66.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.117 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 98.9 t -87.23 102.08 11.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.121 179.899 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 45.2 mt-30 -115.68 78.1 1.15 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.974 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.93 ' O ' HD11 ' A' ' 190' ' ' LEU . 36.1 pttt -74.7 -35.03 62.74 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.91 179.989 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 59.4 t-20 -86.81 38.55 0.8 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.901 179.939 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . 0.674 ' O ' HD12 ' A' ' 190' ' ' LEU . 41.4 tp -141.68 129.13 21.29 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.904 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.509 HG22 HD11 ' A' ' 173' ' ' ILE . 94.7 t -116.78 119.43 61.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.112 179.852 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.567 ' CE1' ' HB2' ' A' ' 158' ' ' SER . 48.2 t80 -113.67 109.64 18.91 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.861 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.687 HG22 ' HB2' ' A' ' 188' ' ' ALA . 68.1 t -106.32 146.5 12.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.121 179.932 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.444 HG12 ' HB3' ' A' ' 158' ' ' SER . 32.9 m -132.03 170.69 19.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.086 179.942 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 78.29 45.49 9.95 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.455 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 32.4 mt -117.91 136.79 53.24 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.877 0.37 . . . . 0.0 110.955 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . 0.483 ' O ' ' N ' ' A' ' 119' ' ' ARG . 15.3 p -82.33 140.51 33.51 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.862 -179.892 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 118' ' ' GLN . . . . . 0.424 ' C ' ' O ' ' A' ' 117' ' ' SER . 82.8 mm-40 -35.02 -33.02 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.878 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.483 ' N ' ' O ' ' A' ' 117' ' ' SER . 72.8 mtm-85 -68.85 -50.22 51.69 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.827 -179.869 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . 0.462 ' N ' ' O ' ' A' ' 117' ' ' SER . 36.0 mt -70.97 -38.96 72.77 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.927 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -60.14 83.48 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.116 179.823 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 122' ' ' ASP . . . . . 0.4 ' N ' ' O ' ' A' ' 120' ' ' LEU . 6.0 m-20 -147.18 145.82 23.37 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.623 0.725 . . . . 0.0 110.888 179.962 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.76 -40.02 5.82 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.736 2.291 . . . . 0.0 112.327 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . 0.433 ' HG3' ' N ' ' A' ' 125' ' ' VAL . 16.8 pt-20 -75.8 -50.23 15.79 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.883 -179.967 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.476 HG13 ' CE2' ' A' ' 131' ' ' TYR . 53.2 t -56.51 -41.38 72.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.101 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.454 HD22 ' CE1' ' A' ' 132' ' ' PHE . 71.5 mt -74.68 -37.22 62.73 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.893 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.679 ' HA ' HD12 ' A' ' 138' ' ' ILE . 35.2 mttm -65.39 -22.9 66.84 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.906 179.832 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 64.1 mtt180 -48.5 143.75 7.27 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.571 0.701 . . . . 0.0 110.908 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 1.35 4.5 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.708 2.272 . . . . 0.0 112.335 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 26.9 mp0 -103.95 -42.02 5.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.908 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 131' ' ' TYR . . . . . 0.476 ' CE2' HG13 ' A' ' 125' ' ' VAL . 37.5 m-85 -72.77 -75.14 0.15 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.932 -179.872 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.454 ' CE1' HD22 ' A' ' 126' ' ' LEU . 45.6 m-85 -116.35 -32.85 5.15 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.867 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -52.49 -15.28 2.81 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.514 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 16.8 ptmt -67.7 -42.83 81.38 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.79 0.329 . . . . 0.0 110.895 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 135' ' ' PHE . . . . . 0.555 ' CE1' ' HA ' ' A' ' 172' ' ' ALA . 29.3 m-85 -60.63 -45.69 93.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.888 179.939 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -179.24 167.54 37.7 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.518 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 8.0 tmtm? -61.03 131.91 52.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.732 0.301 . . . . 0.0 110.878 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.679 HD12 ' HA ' ' A' ' 127' ' ' LYS . 95.1 mt -93.0 142.28 13.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.111 179.876 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 38.4 t60 -104.9 -59.6 1.72 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.803 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 140' ' ' LYS . . . . . 0.413 ' HD3' ' CG2' ' A' ' 142' ' ' VAL . 1.0 OUTLIER -129.17 136.52 50.26 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.916 -179.977 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . 0.646 ' CG2' HG21 ' A' ' 138' ' ' ILE . 47.1 t -129.36 139.76 50.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.179 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.413 ' CG2' ' HD3' ' A' ' 140' ' ' LYS . 5.4 t -132.18 140.19 48.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.117 179.929 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 42.1 mm -114.48 121.42 66.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.159 179.926 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 7.5 m-80 -115.67 113.39 23.45 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.933 179.916 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 53.6 p30 -127.55 160.59 31.09 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.879 -179.974 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 2.7 t -63.52 117.43 6.74 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.844 -179.831 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 15.3 t -79.81 8.17 7.28 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.189 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 65.4 m -102.66 164.66 11.51 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.838 -179.81 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 17.2 m-85 -65.9 143.82 57.19 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.902 -179.883 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -52.26 156.9 1.54 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.09 179.873 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 112.29 36.85 1.56 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.519 -179.908 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 52.5 p -108.45 -178.93 3.73 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.818 0.342 . . . . 0.0 110.873 -179.736 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 58.1 mt-30 -79.54 79.92 5.97 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.888 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 79.07 83.41 0.64 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.498 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 81.35 0.83 Allowed 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.677 2.251 . . . . 0.0 112.336 -179.94 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 31.2 p -106.41 126.69 52.56 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.859 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -95.03 163.4 13.32 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.059 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . 0.567 ' HB2' ' CE1' ' A' ' 112' ' ' PHE . 58.9 p -134.46 164.83 26.58 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.813 -179.757 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -147.15 136.43 22.58 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.108 179.898 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 160' ' ' TYR . . . . . 0.479 ' CE2' ' CD1' ' A' ' 112' ' ' PHE . 11.9 m-85 -104.96 113.11 26.51 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.902 -179.812 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 50.0 t -108.16 139.48 30.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.132 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 54.3 m -106.56 126.58 52.45 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.146 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 163' ' ' TYR . . . . . 0.628 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 15.4 m-85 -109.02 127.79 54.4 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.947 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 64.8 mt -59.48 -52.18 63.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.145 179.889 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 33.4 mtp85 -84.98 110.36 18.84 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.834 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 166' ' ' SER . . . . . 0.416 ' O ' ' C ' ' A' ' 167' ' ' GLU . 68.5 m -49.73 -64.72 0.72 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.833 -179.808 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . 0.416 ' C ' ' O ' ' A' ' 166' ' ' SER . 15.3 mt-10 -37.29 -57.69 0.87 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.899 -179.961 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -51.22 -47.74 62.24 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.895 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 169' ' ' ALA . . . . . 0.628 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -54.77 -58.61 6.87 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.08 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 41.1 mt -46.21 -56.95 4.99 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.879 -179.924 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 6.6 mpt_? -55.19 -51.86 65.17 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.856 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . 0.555 ' HA ' ' CE1' ' A' ' 135' ' ' PHE . . . -47.52 -33.04 5.87 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.06 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 173' ' ' ILE . . . . . 0.509 HD11 HG22 ' A' ' 111' ' ' VAL . 56.9 mt -79.12 -34.38 16.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.124 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 44.7 mt-30 -70.69 -26.01 63.23 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.912 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 4.0 m -93.77 -36.11 12.44 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.932 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 176' ' ' VAL . . . . . 0.491 HG23 ' O ' ' A' ' 172' ' ' ALA . 9.8 t -67.94 -35.81 73.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.118 -179.976 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 58.4 t30 -62.97 145.26 55.73 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.921 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 35.5 t30 55.62 51.68 12.21 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.916 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 179' ' ' VAL . . . . . 0.47 HG12 HG23 ' A' ' 181' ' ' VAL . 76.7 t -125.89 142.37 42.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.104 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 91.3 t -104.24 105.12 17.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.128 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . 0.47 HG23 HG12 ' A' ' 179' ' ' VAL . 85.7 t -119.11 105.01 16.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.174 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 1.6 t70 60.01 41.23 17.73 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.901 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 71.28 24.09 77.35 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.524 -179.932 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 3.5 mmp_? -126.93 114.23 17.58 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.884 0.373 . . . . 0.0 110.875 -179.837 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 7.8 m -70.7 103.19 2.49 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.122 -179.89 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 31.1 mt -71.52 126.1 28.78 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.934 179.932 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -131.02 114.55 15.33 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.89 179.837 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . 0.687 ' HB2' HG22 ' A' ' 113' ' ' VAL . . . -118.54 137.62 53.1 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.046 179.862 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 7.3 t -125.89 166.78 16.26 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.875 -179.785 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 190' ' ' LEU . . . . . 0.93 HD11 ' O ' ' A' ' 108' ' ' LYS . 9.0 tp -131.8 143.41 50.19 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.897 -179.97 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 76.04 10.48 85.2 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.547 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 192' ' ' THR . . . . . . . . . . . . . 15.3 t -93.62 130.07 39.66 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.822 0.344 . . . . 0.0 111.175 -179.851 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 193' ' ' THR . . . . . . . . . . . . . 5.1 t -118.17 134.08 55.33 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.158 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 194' ' ' LYS . . . . . 0.436 ' O ' ' C ' ' A' ' 195' ' ' TYR . 0.1 OUTLIER -119.75 102.07 8.34 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.893 179.913 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 195' ' ' TYR . . . . . 0.436 ' C ' ' O ' ' A' ' 194' ' ' LYS . 5.6 t80 35.0 53.39 0.67 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.912 -179.997 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 196' ' ' CYS . . . . . . . . . . . . . 23.5 p -146.12 146.27 30.82 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.881 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 8.5 t -95.59 149.01 21.91 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.867 -179.782 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 198' ' ' TYR . . . . . . . . . . . . . 52.9 t80 -130.71 97.54 4.39 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.925 -179.907 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 1.7 t -89.22 124.89 34.79 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.82 -179.827 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . 122.77 -164.11 15.88 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.484 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 201' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.78 167.88 69.55 Favored 'Cis proline' 0 C--N 1.342 0.192 0 C-N-CA 122.68 -1.8 . . . . 0.0 112.323 0.089 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 202' ' ' SER . . . . . . . . . . . . . 14.1 p -119.28 90.8 3.4 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.835 -179.836 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 4.0 t -58.61 96.43 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.827 -179.816 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.291 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.497 179.992 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.315 0 N-CA-C 112.427 -0.269 . . . . 0.0 112.427 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 16.1 t -49.13 117.34 2.08 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.88 0.371 . . . . 0.0 110.781 -179.718 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 3.6 m 41.2 43.14 1.89 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.841 -179.865 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -118.94 69.88 0.33 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.475 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 26.3 p -149.42 147.36 28.17 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.868 0.366 . . . . 0.0 110.858 -179.783 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 30.6 m -89.25 170.9 10.19 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.833 -179.809 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -118.49 -45.33 0.48 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.692 -0.765 . . . . 0.0 112.503 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -46.79 147.65 1.24 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.766 0.317 . . . . 0.0 111.079 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 4.2 t -102.03 159.95 14.92 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.845 -179.799 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 90.4 t -65.4 99.04 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.114 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 14.4 tpp180 -112.24 138.77 48.46 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.887 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.558 HG13 ' O ' ' A' ' 105' ' ' VAL . 11.2 p -116.44 114.54 46.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.141 179.929 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 10.5 p -117.64 138.36 48.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.119 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 51.9 mt-30 -52.45 125.12 15.25 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.936 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 35.9 mtmm -89.36 42.72 1.1 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.887 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 11.6 p-10 -112.21 39.96 2.31 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.858 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 13.9 tp -135.16 123.12 22.62 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.931 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 1.088 HG22 HD11 ' A' ' 173' ' ' ILE . 77.9 t -103.44 108.02 23.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.103 179.867 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.451 ' CD1' ' CE1' ' A' ' 160' ' ' TYR . 47.2 t80 -106.56 113.86 27.63 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.875 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.579 HG22 ' HB2' ' A' ' 188' ' ' ALA . 32.7 t -112.61 137.94 43.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.163 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 23.1 m -121.36 166.22 16.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.125 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . 0.412 ' O ' HD23 ' A' ' 186' ' ' LEU . . . 73.38 55.69 6.01 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.493 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 32.3 mt -117.81 127.76 54.2 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.813 0.339 . . . . 0.0 110.894 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 11.8 m -63.78 136.01 57.1 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.846 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 118' ' ' GLN . . . . . 0.454 ' OE1' ' ND2' ' A' ' 145' ' ' ASN . 4.8 tp-100 -41.97 -27.28 0.12 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.884 -179.974 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 1.8 mpt_? -78.4 -48.27 15.85 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.901 -179.932 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 42.8 mt -66.22 -38.7 88.56 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.932 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -60.91 88.12 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.069 179.839 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 24.9 m-20 -148.65 149.54 31.21 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.635 0.731 . . . . 0.0 110.852 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.82 -43.39 2.64 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.675 2.25 . . . . 0.0 112.325 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 27.6 mt-10 -76.39 -41.86 46.44 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.857 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.723 HG13 ' CZ ' ' A' ' 131' ' ' TYR . 74.3 t -60.24 -48.06 89.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.127 -179.987 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 42.3 mt -70.26 -40.25 74.49 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.886 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.504 ' HA ' HD12 ' A' ' 138' ' ' ILE . 32.1 mttm -61.54 -35.89 79.04 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.864 179.854 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 48.7 mtt85 -43.9 143.41 1.74 Allowed Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.592 0.711 . . . . 0.0 110.875 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 -3.54 12.19 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.707 2.272 . . . . 0.0 112.362 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -94.96 -36.13 11.71 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.944 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 131' ' ' TYR . . . . . 0.723 ' CZ ' HG13 ' A' ' 125' ' ' VAL . 57.1 m-85 -80.21 -74.23 0.32 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.888 -179.841 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.487 ' O ' ' N ' ' A' ' 134' ' ' LYS . 14.6 m-85 -116.9 -44.84 2.79 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.915 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . 0.439 ' C ' ' O ' ' A' ' 132' ' ' PHE . . . -35.39 -31.06 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.515 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.487 ' N ' ' O ' ' A' ' 132' ' ' PHE . 16.6 ptmt -45.86 -48.77 15.89 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.812 0.339 . . . . 0.0 110.887 -179.995 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 135' ' ' PHE . . . . . 0.545 ' CD2' ' HA ' ' A' ' 172' ' ' ALA . 78.9 m-85 -61.69 -43.91 97.95 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.882 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -173.94 -174.54 40.91 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.491 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 29.5 mtmt -90.09 102.18 14.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.753 0.311 . . . . 0.0 110.845 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.504 HD12 ' HA ' ' A' ' 127' ' ' LYS . 58.1 mt -61.33 148.38 9.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.104 179.847 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 61.4 t60 -101.55 -57.55 2.06 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.875 179.837 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 40.2 tttm -123.17 143.8 49.77 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.904 179.916 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . 0.463 HG22 HG21 ' A' ' 138' ' ' ILE . 58.5 t -135.91 118.45 21.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.135 179.89 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 83.9 t -117.32 134.72 60.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.128 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 3.3 mm -106.46 125.39 62.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.129 179.923 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 4.4 m-80 -117.87 104.36 10.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.947 179.87 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 145' ' ' ASN . . . . . 0.454 ' ND2' ' OE1' ' A' ' 118' ' ' GLN . 35.4 m120 -85.73 138.2 32.27 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.893 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 25.9 t -45.35 149.98 0.49 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.885 -179.842 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 90.6 m -128.81 -56.35 1.2 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.138 -179.931 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 34.4 p -85.83 140.94 30.0 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.874 -179.866 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . 0.473 ' CG ' ' O ' ' A' ' 149' ' ' TYR . 3.7 p90 -100.81 122.84 44.1 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.906 -179.889 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -106.73 -56.51 2.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.093 179.879 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 94.76 39.72 4.57 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.501 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 20.0 m -102.17 -51.38 3.39 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.787 0.327 . . . . 0.0 110.831 -179.739 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 28.5 mm-40 -121.51 -44.11 2.37 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.895 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 145.28 -167.97 27.27 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.501 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.8 105.4 1.48 Allowed 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.681 2.254 . . . . 0.0 112.332 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 58.1 m -126.07 125.34 42.43 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.848 -179.807 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -106.5 165.32 11.36 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.064 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . 0.407 ' HB2' ' CE1' ' A' ' 112' ' ' PHE . 79.0 p -130.12 167.38 18.44 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.842 -179.767 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -155.68 136.21 13.29 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.137 179.9 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 160' ' ' TYR . . . . . 0.451 ' CE1' ' CD1' ' A' ' 112' ' ' PHE . 98.3 m-85 -99.4 133.14 44.15 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.926 -179.869 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.44 HG13 ' CG2' ' A' ' 138' ' ' ILE . 75.2 t -125.6 122.28 62.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.179 179.893 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 87.4 m -94.97 124.18 38.87 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.197 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 163' ' ' TYR . . . . . 0.494 ' CB ' ' HB2' ' A' ' 169' ' ' ALA . 14.0 m-85 -100.2 147.77 25.35 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.925 -179.897 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 52.0 mt -73.5 -41.74 56.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.154 179.871 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 13.3 mmm180 -105.18 133.41 49.99 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.862 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 71.5 m -63.05 -68.18 0.36 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.834 -179.722 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 4.9 tp10 -42.93 -58.45 2.4 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.884 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -47.16 -46.48 23.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.921 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 169' ' ' ALA . . . . . 0.494 ' HB2' ' CB ' ' A' ' 163' ' ' TYR . . . -58.98 -61.53 2.57 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.119 179.938 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 59.0 mt -39.21 -52.75 1.94 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.914 179.994 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 171' ' ' ARG . . . . . 0.431 ' O ' ' N ' ' A' ' 174' ' ' GLN . 86.1 mtt180 -59.44 -58.61 7.83 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.898 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . 0.545 ' HA ' ' CD2' ' A' ' 135' ' ' PHE . . . -41.02 -35.59 0.56 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.098 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 173' ' ' ILE . . . . . 1.088 HD11 HG22 ' A' ' 111' ' ' VAL . 58.5 mt -76.89 -37.58 27.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.074 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 174' ' ' GLN . . . . . 0.431 ' N ' ' O ' ' A' ' 171' ' ' ARG . 61.5 mt-30 -64.68 -21.42 66.73 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.883 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 3.9 m -93.83 -40.39 10.2 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.873 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 176' ' ' VAL . . . . . 0.479 ' O ' HG23 ' A' ' 179' ' ' VAL . 9.1 t -62.45 -38.36 81.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.115 -179.984 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 5.1 t-20 -60.71 140.36 57.55 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.887 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 15.6 t-20 65.2 50.74 1.75 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.91 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 179' ' ' VAL . . . . . 0.479 HG23 ' O ' ' A' ' 176' ' ' VAL . 71.1 t -124.78 142.04 42.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.061 179.946 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 83.3 t -96.25 110.68 25.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.16 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . 0.744 HG21 HD12 ' A' ' 186' ' ' LEU . 48.7 t -120.02 106.02 18.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.125 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 53.77 43.47 30.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.881 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 71.19 30.83 66.91 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.454 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 32.9 mtt-85 -138.24 122.71 18.41 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.882 0.372 . . . . 0.0 110.902 -179.874 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 17.7 m -82.47 96.91 8.15 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.143 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 186' ' ' LEU . . . . . 0.744 HD12 HG21 ' A' ' 181' ' ' VAL . 95.8 mt -74.45 132.71 42.16 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.937 179.928 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 47.8 mttt -117.87 132.22 56.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.941 179.8 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . 0.579 ' HB2' HG22 ' A' ' 113' ' ' VAL . . . -123.53 147.27 47.42 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.106 179.857 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 68.0 m -158.06 162.62 38.09 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.856 -179.806 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 190' ' ' LEU . . . . . . . . . . . . . 4.5 pp -129.77 156.33 44.49 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.894 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 93.82 29.66 9.67 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.507 179.867 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 192' ' ' THR . . . . . . . . . . . . . 13.5 t -105.01 149.5 25.73 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.846 0.355 . . . . 0.0 111.14 -179.84 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 193' ' ' THR . . . . . . . . . . . . . 7.3 t -112.9 141.02 47.2 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.152 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 194' ' ' LYS . . . . . . . . . . . . . 10.3 pttt -62.22 134.53 56.66 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.884 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 195' ' ' TYR . . . . . . . . . . . . . 9.4 m-85 -80.85 92.49 6.11 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.933 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 196' ' ' CYS . . . . . . . . . . . . . 1.8 t -120.86 151.42 39.67 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.883 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 1.9 t -64.69 108.66 1.78 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.851 -179.743 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 198' ' ' TYR . . . . . . . . . . . . . 19.5 p90 -107.98 133.77 51.83 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.893 -179.854 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 29.9 t -158.81 146.4 17.78 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.889 -179.862 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . 77.29 -165.32 53.06 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.492 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 201' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 153.52 92.95 Favored 'Cis proline' 0 C--O 1.232 0.194 0 C-N-CA 122.704 -1.79 . . . . 0.0 112.366 0.027 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 202' ' ' SER . . . . . . . . . . . . . 7.9 m -64.84 117.35 7.41 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.865 -179.835 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 78.0 p -103.24 116.93 33.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.846 -179.804 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.31 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.506 -179.988 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.343 0 N-CA-C 112.494 -0.242 . . . . 0.0 112.494 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 75.7 m -123.15 154.91 38.01 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.901 0.381 . . . . 0.0 110.861 -179.762 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 40.2 t -70.02 147.38 50.16 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.875 -179.858 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 141.65 101.36 0.43 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.473 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 19.4 m -100.87 150.49 22.77 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.874 0.368 . . . . 0.0 110.848 -179.752 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 93.2 p 37.35 42.2 0.3 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.924 -179.796 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 68.89 -142.99 39.11 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.494 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -94.39 148.6 22.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.804 0.335 . . . . 0.0 111.075 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 52.0 p -101.4 125.34 48.02 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.84 -179.798 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 34.9 m -120.35 131.01 73.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.147 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 76.0 mtm-85 -124.1 143.38 50.5 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.835 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 91.5 t -74.07 110.66 8.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.141 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 69.3 t -115.52 141.56 32.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.101 179.949 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 8.0 pt20 -65.66 145.14 56.41 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.952 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 20.4 mmtp -101.66 -15.06 17.15 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.89 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 9.5 m-20 -101.17 51.7 0.85 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.91 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . 0.506 ' O ' HD22 ' A' ' 190' ' ' LEU . 14.1 tp -135.28 105.03 6.1 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.877 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.593 HG22 HD11 ' A' ' 173' ' ' ILE . 41.4 t -95.49 104.22 15.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.15 179.815 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.579 ' CD1' ' CE2' ' A' ' 160' ' ' TYR . 39.5 t80 -94.08 122.36 36.51 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.848 -179.948 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.401 HG22 ' HB2' ' A' ' 188' ' ' ALA . 42.3 t -117.82 133.55 64.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.145 179.92 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.429 ' CG1' ' CE2' ' A' ' 112' ' ' PHE . 11.9 m -120.4 166.64 14.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.125 179.899 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 67.0 53.53 26.24 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.506 179.983 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 34.9 mt -105.98 146.57 29.89 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.844 0.354 . . . . 0.0 110.846 -179.86 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 29.2 m -77.35 153.98 33.24 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.801 -179.908 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 84.9 mm-40 -56.55 -44.9 81.37 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.892 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 10.6 ttt180 -74.38 -44.96 49.85 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.897 -179.925 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 66.2 mt -66.89 -24.84 66.16 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.932 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -76.06 83.71 2.93 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.11 179.773 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -148.3 150.34 34.32 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-O 121.62 0.724 . . . . 0.0 110.857 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.83 -50.62 0.44 Allowed 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.668 2.245 . . . . 0.0 112.319 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 7.0 mm-40 -65.35 -41.91 93.38 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.89 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.67 HG13 ' CZ ' ' A' ' 131' ' ' TYR . 85.9 t -61.79 -42.68 95.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.128 179.975 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.545 HD22 ' CE1' ' A' ' 132' ' ' PHE . 79.4 mt -74.33 -40.32 62.25 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.929 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.459 ' HA ' ' CD1' ' A' ' 138' ' ' ILE . 43.0 tttt -61.03 -31.25 70.89 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.873 179.837 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 72.6 mtt-85 -44.13 142.88 2.02 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.573 0.701 . . . . 0.0 110.873 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 0.8 5.14 Favored 'Trans proline' 0 C--N 1.341 0.136 0 C-N-CA 122.662 2.241 . . . . 0.0 112.375 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 5.0 tp10 -103.99 -36.01 7.9 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.915 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 131' ' ' TYR . . . . . 0.67 ' CZ ' HG13 ' A' ' 125' ' ' VAL . 38.8 m-85 -75.91 -75.02 0.2 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.962 -179.869 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.545 ' CE1' HD22 ' A' ' 126' ' ' LEU . 19.9 m-85 -114.86 -40.58 3.5 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.858 -179.996 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -52.23 -20.47 6.93 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.51 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.423 ' C ' ' HD3' ' A' ' 134' ' ' LYS . 0.0 OUTLIER -53.54 -31.65 47.27 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.86 0.362 . . . . 0.0 110.903 -179.999 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 135' ' ' PHE . . . . . 0.454 ' CE2' ' CG2' ' A' ' 176' ' ' VAL . 65.3 m-85 -73.21 -42.48 62.6 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.87 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -177.66 -163.41 29.41 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.47 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 16.9 mttp -79.58 142.14 35.95 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.774 0.321 . . . . 0.0 110.915 -179.966 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.558 HG21 HG22 ' A' ' 141' ' ' VAL . 82.6 mt -105.25 132.19 52.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.146 179.899 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 3.8 t-160 -85.97 -59.64 2.24 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.857 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 140' ' ' LYS . . . . . . . . . . . . . 73.6 tttt -132.72 146.1 51.58 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.936 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . 0.558 HG22 HG21 ' A' ' 138' ' ' ILE . 24.2 t -129.38 130.08 67.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.153 179.876 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 96.1 t -134.34 147.49 30.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.133 179.879 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 15.3 mm -118.05 150.44 20.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.133 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 39.9 t30 -129.02 106.47 8.9 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.889 179.902 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 3.0 p30 -119.8 142.07 48.93 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.896 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 79.9 p -56.81 128.58 37.39 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.885 -179.866 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 22.6 p -89.07 -35.98 16.02 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.143 -179.92 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 60.1 p -86.82 148.55 25.34 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.885 -179.911 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 98.1 m-85 -69.13 113.57 6.61 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.945 -179.912 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -88.77 -61.08 1.79 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.105 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 81.74 37.72 15.87 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.501 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 43.1 m -110.69 163.22 13.96 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.802 0.334 . . . . 0.0 110.873 -179.728 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 18.3 tt0 -79.81 102.55 9.15 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.919 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 84.05 83.13 0.96 Allowed Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.487 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.75 120.67 7.42 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.674 2.249 . . . . 0.0 112.336 -179.955 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 78.7 p -86.56 123.23 31.53 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.825 -179.831 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -112.28 164.81 12.79 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.082 179.911 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 14.8 m -133.16 164.55 26.8 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.87 -179.797 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -150.81 166.47 30.4 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.131 179.922 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 160' ' ' TYR . . . . . 0.579 ' CE2' ' CD1' ' A' ' 112' ' ' PHE . 11.6 m-85 -136.29 126.4 26.2 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.913 -179.821 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 67.0 t -126.72 146.13 33.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.09 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 82.2 m -108.35 134.16 51.55 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.192 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 163' ' ' TYR . . . . . 0.651 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 7.9 m-85 -111.96 120.75 42.95 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.924 -179.867 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 88.7 mt -49.75 -50.86 17.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.102 179.918 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 24.9 mtp85 -88.1 109.72 20.09 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.883 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 5.3 t -48.85 -59.3 3.69 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.855 -179.772 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 23.8 mt-10 -47.94 -46.29 31.94 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.89 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 6.5 t0 -56.13 -45.12 79.68 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.829 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 169' ' ' ALA . . . . . 0.651 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -55.75 -52.42 63.98 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.116 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 26.8 mt -51.38 -59.4 4.27 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.894 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 171' ' ' ARG . . . . . . . . . . . . . 74.3 mtp180 -55.09 -49.23 72.22 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.903 179.909 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . 0.638 ' O ' HG23 ' A' ' 176' ' ' VAL . . . -50.08 -33.16 17.61 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.066 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 173' ' ' ILE . . . . . 0.593 HD11 HG22 ' A' ' 111' ' ' VAL . 55.2 mt -76.65 -38.4 30.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.128 -179.996 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 10.3 mm100 -65.66 -30.54 71.25 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.884 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 175' ' ' CYS . . . . . 0.444 ' O ' ' CG2' ' A' ' 179' ' ' VAL . 3.0 t -93.72 -27.33 16.58 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.85 -179.94 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 176' ' ' VAL . . . . . 0.638 HG23 ' O ' ' A' ' 172' ' ' ALA . 10.4 t -77.9 -26.28 14.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.181 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -79.09 154.15 29.61 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.855 -179.972 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 178' ' ' ASN . . . . . 0.438 ' O ' ' CG ' ' A' ' 178' ' ' ASN . 32.5 t30 55.23 36.27 26.67 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.881 179.978 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 179' ' ' VAL . . . . . 0.444 ' CG2' ' O ' ' A' ' 175' ' ' CYS . 92.3 t -108.84 141.98 22.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.109 179.919 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 53.7 t -106.2 97.1 5.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.121 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . 0.48 HG12 ' OD2' ' A' ' 182' ' ' ASP . 40.0 t -102.41 118.34 49.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.143 179.941 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 182' ' ' ASP . . . . . 0.48 ' OD2' HG12 ' A' ' 181' ' ' VAL . 2.9 p30 47.26 31.65 1.84 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.851 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 86.02 20.7 54.87 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.453 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 5.5 tpm_? -118.21 133.97 55.43 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.904 0.383 . . . . 0.0 110.882 -179.857 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 17.3 m -90.76 95.13 9.99 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.164 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 71.1 mt -74.8 128.33 35.3 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.892 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 2.8 mmmp? -128.79 121.7 28.92 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.887 179.822 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . 0.401 ' HB2' HG22 ' A' ' 113' ' ' VAL . . . -119.4 156.52 29.98 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.087 179.859 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 8.5 t -147.76 165.28 31.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.857 -179.813 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 190' ' ' LEU . . . . . 0.789 HD13 ' N ' ' A' ' 191' ' ' GLY . 1.6 tm? -132.2 137.58 47.65 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.877 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 191' ' ' GLY . . . . . 0.789 ' N ' HD13 ' A' ' 190' ' ' LEU . . . 86.58 30.28 21.92 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.441 179.83 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 192' ' ' THR . . . . . 0.448 HG21 ' CB ' ' A' ' 112' ' ' PHE . 15.2 t -88.82 147.17 24.55 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.883 0.373 . . . . 0.0 111.103 -179.86 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 193' ' ' THR . . . . . . . . . . . . . 58.6 p -72.52 112.53 8.66 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.155 179.969 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 194' ' ' LYS . . . . . 0.414 ' HD2' ' C ' ' A' ' 194' ' ' LYS . 0.3 OUTLIER -99.92 104.73 16.39 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.954 179.881 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 195' ' ' TYR . . . . . . . . . . . . . 80.4 t80 -67.28 147.58 52.81 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.948 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 196' ' ' CYS . . . . . 0.4 ' HB3' ' NZ ' ' A' ' 194' ' ' LYS . 27.0 p -158.55 168.16 27.66 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.912 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 15.5 t -104.46 138.76 40.37 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.817 -179.718 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 198' ' ' TYR . . . . . . . . . . . . . 12.6 t80 -118.25 144.96 45.38 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.922 -179.868 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . 0.487 ' C ' ' HA ' ' A' ' 201' ' ' PRO . 1.2 t -127.46 -59.42 1.22 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.864 -179.856 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 200' ' ' GLY . . . . . 0.415 ' HA3' ' C ' ' A' ' 201' ' ' PRO . . . 124.98 -69.67 0.48 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.488 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 201' ' ' PRO . . . . . 0.487 ' HA ' ' C ' ' A' ' 199' ' ' SER . 53.5 Cg_endo -69.73 155.69 93.06 Favored 'Cis proline' 0 C--N 1.341 0.156 0 C-N-CA 122.68 -1.8 . . . . 0.0 112.34 0.022 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 202' ' ' SER . . . . . 0.424 ' N ' ' O ' ' A' ' 199' ' ' SER . 30.6 t -40.68 140.51 0.68 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.859 -179.859 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 1.1 t 38.42 45.39 0.83 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.866 -179.807 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.281 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.492 -179.999 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 N-CA-C 112.495 -0.242 . . . . 0.0 112.495 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 3.9 t -50.45 124.92 11.56 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.92 0.39 . . . . 0.0 110.855 -179.735 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 69.2 m -124.55 -49.08 1.78 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.88 -179.819 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 113.04 81.47 1.08 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.491 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 70.7 m -101.67 97.98 8.32 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.9 0.381 . . . . 0.0 110.828 -179.706 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 24.1 p -145.95 119.31 8.99 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.907 -179.888 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 152.04 158.25 8.33 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.46 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -103.05 144.44 31.29 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.772 0.32 . . . . 0.0 111.088 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 25.8 p -174.26 149.52 1.4 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.828 -179.827 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 96.3 t -120.58 113.67 40.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.146 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -124.68 146.95 48.86 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.895 -179.968 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 77.6 t -82.18 113.86 22.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.137 179.943 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 0.432 ' O ' HG13 ' A' ' 106' ' ' VAL . 14.9 p -100.0 126.85 53.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.097 179.911 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 67.0 mt-30 -132.97 157.88 44.06 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.916 179.976 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 30.0 pttt -96.76 35.11 1.57 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.908 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 34.3 p-10 -119.19 42.92 2.72 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.874 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . 0.776 HD22 ' HE3' ' A' ' 194' ' ' LYS . 9.4 tp -132.84 123.55 26.29 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.941 179.964 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.471 HG22 HD11 ' A' ' 173' ' ' ILE . 69.5 t -108.95 106.67 21.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.131 179.899 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.511 ' CZ ' ' CG1' ' A' ' 114' ' ' VAL . 61.4 t80 -99.83 117.42 34.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.864 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 21.2 t -116.56 135.67 56.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.107 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.511 ' CG1' ' CZ ' ' A' ' 112' ' ' PHE . 34.1 m -124.55 165.38 21.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.123 179.904 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 78.6 52.46 5.08 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.48 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 21.2 mt -109.16 133.67 52.72 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.85 0.357 . . . . 0.0 110.932 -179.917 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 40.2 t -66.53 147.83 52.74 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.853 -179.92 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.9 mt-30 -40.86 -47.3 2.91 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.917 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 39.3 mtp180 -71.47 -37.78 71.3 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.901 -179.922 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 51.7 mt -67.27 -26.7 66.68 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.943 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -74.01 83.81 1.76 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.098 179.763 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -148.99 142.99 16.56 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.592 0.711 . . . . 0.0 110.904 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.7 -49.26 0.59 Allowed 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.69 2.26 . . . . 0.0 112.359 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 51.4 mt-10 -69.48 -42.28 75.04 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.887 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.479 ' CG1' ' CZ ' ' A' ' 131' ' ' TYR . 60.3 t -59.16 -46.15 92.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.128 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 68.0 mt -69.81 -40.49 75.91 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.918 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.514 ' HA ' HD12 ' A' ' 138' ' ' ILE . 15.3 tttt -61.83 -27.88 69.09 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.937 179.809 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 13.8 mtp85 -45.24 143.6 2.52 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.632 0.729 . . . . 0.0 110.857 179.98 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 1.23 4.61 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.656 2.237 . . . . 0.0 112.347 -179.997 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 7.1 tp10 -105.51 -35.55 7.42 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.931 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 131' ' ' TYR . . . . . 0.479 ' CZ ' ' CG1' ' A' ' 125' ' ' VAL . 38.0 m-85 -77.46 -75.11 0.22 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.911 -179.857 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 13.2 m-85 -116.23 -34.68 4.58 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.902 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -49.99 -23.9 5.93 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.527 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.424 ' C ' ' HD3' ' A' ' 134' ' ' LYS . 0.0 OUTLIER -56.03 -34.07 65.51 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.788 0.328 . . . . 0.0 110.913 -179.959 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 135' ' ' PHE . . . . . 0.563 ' CE1' ' HA ' ' A' ' 172' ' ' ALA . 19.4 m-85 -69.89 -47.06 64.02 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.875 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -174.12 177.28 46.42 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.502 -179.947 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 5.8 mmmt -74.57 110.25 8.71 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.747 0.308 . . . . 0.0 110.893 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.607 HG21 HG22 ' A' ' 141' ' ' VAL . 56.8 mt -75.64 143.53 13.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.126 179.924 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 19.8 t-160 -99.2 -58.73 1.87 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.864 179.903 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 140' ' ' LYS . . . . . 0.725 ' HD3' HG23 ' A' ' 142' ' ' VAL . 0.2 OUTLIER -127.78 141.9 51.45 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.869 179.984 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . 0.607 HG22 HG21 ' A' ' 138' ' ' ILE . 3.9 t -130.94 139.86 50.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.114 179.887 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.725 HG23 ' HD3' ' A' ' 140' ' ' LYS . 69.5 t -135.45 139.84 45.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.132 179.93 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 16.7 mm -112.13 114.71 47.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.143 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 1.6 t30 -99.94 127.46 46.13 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.897 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 2.1 p-10 -107.15 152.69 23.71 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.872 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 7.4 t -81.41 133.6 35.43 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.868 -179.851 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 1.4 m -81.5 44.5 0.8 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.172 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 3.7 m -88.62 165.29 14.9 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.844 -179.829 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 61.7 m-85 -60.24 144.28 50.61 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.91 -179.884 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -64.74 133.45 52.09 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.145 179.838 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . 93.77 39.75 4.86 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.512 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 9.9 m -89.45 147.64 23.9 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.821 0.343 . . . . 0.0 110.842 -179.699 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 39.7 tt0 -82.19 94.74 7.34 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.92 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 69.32 69.29 1.42 Allowed Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.479 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 128.95 16.74 Favored 'Trans proline' 0 C--O 1.232 0.181 0 C-N-CA 122.678 2.252 . . . . 0.0 112.352 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 53.9 p -79.95 125.26 29.52 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.861 -179.826 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -122.32 152.59 39.96 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.109 179.907 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 87.5 p -124.89 176.43 6.63 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.894 -179.818 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 159' ' ' ALA . . . . . . . . . . . . . . . -160.7 162.06 32.45 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.125 179.891 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 160' ' ' TYR . . . . . 0.483 ' CE2' ' CD1' ' A' ' 112' ' ' PHE . 16.5 m-85 -125.61 127.56 46.53 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.921 -179.825 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.41 HG22 HG13 ' A' ' 141' ' ' VAL . 66.7 t -121.75 140.27 46.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.117 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 162' ' ' THR . . . . . . . . . . . . . 4.7 m -114.21 115.71 27.89 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.185 -179.997 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 163' ' ' TYR . . . . . 0.638 ' HB2' ' HB2' ' A' ' 169' ' ' ALA . 29.1 m-85 -90.47 134.2 34.51 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.928 -179.904 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 66.4 mt -59.36 -42.63 88.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.119 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 19.0 mtm-85 -99.57 112.04 24.31 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.877 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 2.7 t -48.86 -57.59 6.17 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.896 -179.822 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 32.7 tt0 -42.93 -52.46 5.15 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.88 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -52.34 -50.6 62.0 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.883 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 169' ' ' ALA . . . . . 0.638 ' HB2' ' HB2' ' A' ' 163' ' ' TYR . . . -54.77 -64.02 0.97 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.106 179.915 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . 0.401 ' C ' ' O ' ' A' ' 169' ' ' ALA . 55.9 mt -37.15 -58.54 0.79 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.888 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 171' ' ' ARG . . . . . 0.432 ' HB3' ' NH1' ' A' ' 171' ' ' ARG . 10.6 mtp-105 -60.61 -46.04 91.75 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.846 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . 0.563 ' HA ' ' CE1' ' A' ' 135' ' ' PHE . . . -47.38 -32.89 5.33 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.072 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 173' ' ' ILE . . . . . 0.471 HD11 HG22 ' A' ' 111' ' ' VAL . 96.9 mt -82.85 -40.08 16.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.155 179.963 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 174' ' ' GLN . . . . . . . . . . . . . 30.1 mt-30 -66.25 -23.28 66.38 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.893 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 175' ' ' CYS . . . . . . . . . . . . . 1.8 t -93.9 -37.09 11.89 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.86 -179.927 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 176' ' ' VAL . . . . . 0.428 HG23 ' CZ ' ' A' ' 135' ' ' PHE . 9.0 t -70.18 -48.43 61.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.149 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 7.5 t30 -43.76 124.82 3.85 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.95 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 178' ' ' ASN . . . . . . . . . . . . . 65.7 t30 70.62 52.03 0.32 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.898 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 179' ' ' VAL . . . . . . . . . . . . . 54.5 t -134.12 135.34 54.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.123 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 83.4 t -86.96 120.57 36.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.119 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . 0.705 HG21 HD12 ' A' ' 186' ' ' LEU . 85.0 t -124.7 116.54 47.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.1 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 34.3 t70 58.52 36.52 25.29 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.87 179.899 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 84.35 -20.17 15.17 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.456 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 43.0 ttm-85 -107.23 133.4 51.86 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.897 0.379 . . . . 0.0 110.861 -179.859 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 30.0 m -80.27 133.29 35.97 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.104 -179.884 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 186' ' ' LEU . . . . . 0.705 HD12 HG21 ' A' ' 181' ' ' VAL . 27.4 mt -101.06 147.42 26.24 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.949 179.924 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 187' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -121.29 131.98 54.52 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.903 179.839 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -129.5 143.54 50.88 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.075 179.843 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 5.5 t -138.7 167.54 21.76 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.866 -179.785 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 190' ' ' LEU . . . . . 0.753 HD13 ' N ' ' A' ' 191' ' ' GLY . 2.0 tm? -132.61 128.9 38.13 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.925 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 191' ' ' GLY . . . . . 0.753 ' N ' HD13 ' A' ' 190' ' ' LEU . . . 99.91 27.81 7.68 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.447 179.878 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 192' ' ' THR . . . . . . . . . . . . . 30.4 p -89.04 152.95 21.38 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.84 0.352 . . . . 0.0 111.145 -179.879 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 193' ' ' THR . . . . . . . . . . . . . 40.7 p -87.64 141.76 28.36 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.123 -179.979 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 194' ' ' LYS . . . . . 0.776 ' HE3' HD22 ' A' ' 110' ' ' LEU . 0.0 OUTLIER -102.09 178.0 4.73 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.901 179.875 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 195' ' ' TYR . . . . . . . . . . . . . 45.9 t80 -116.92 99.17 6.9 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.897 -179.895 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 196' ' ' CYS . . . . . . . . . . . . . 12.0 t -146.2 151.04 36.97 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.851 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 3.2 m -118.59 128.77 54.87 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.888 -179.755 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 198' ' ' TYR . . . . . . . . . . . . . 9.3 p90 -45.78 133.41 8.3 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.881 -179.863 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 20.0 m -142.42 158.42 43.72 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.814 -179.838 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 200' ' ' GLY . . . . . 0.417 ' HA3' ' C ' ' A' ' 201' ' ' PRO . . . -84.68 -69.77 1.36 Allowed Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.505 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 201' ' ' PRO . . . . . 0.417 ' C ' ' HA3' ' A' ' 200' ' ' GLY . 53.1 Cg_endo -69.82 -19.78 11.15 Favored 'Cis proline' 0 C--N 1.342 0.209 0 C-N-CA 122.662 -1.808 . . . . 0.0 112.346 0.11 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 202' ' ' SER . . . . . . . . . . . . . 6.6 m -134.64 152.93 52.13 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.862 -179.851 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 203' ' ' SER . . . . . . . . . . . . . 66.5 m -66.79 -62.02 1.66 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.818 -179.801 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 204' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.346 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.509 -179.988 . . . . . . . . 0 0 . 1 stop_ save_